data_6g4a_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6g4a _Structure_validation_residue.Date_analyzed 2019-04-05 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo . . . . . 0 N--CA 1.449 -1.129 0 N-CA-C 109.002 -1.191 . . . . 0.0 109.002 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -101.5 135.7 19.77 Favored Pre-proline 0 C--O 1.238 0.475 0 CA-C-O 115.816 -2.04 . . . . 0.0 113.868 -177.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -53.42 149.14 31.16 Favored 'Trans proline' 0 N--CA 1.44 -1.624 1 C-N-CA 132.061 8.507 . . . . 0.0 113.622 157.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.3 m -145.7 161.17 40.5 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 123.342 1.544 . . . . 0.0 107.45 -166.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.29 -44.04 89.23 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 108.825 -3.807 . . . . 0.0 114.601 -172.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . 0.288 68.1 mm-40 -64.88 -20.72 66.58 Favored 'General case' 0 N--CA 1.442 -0.83 0 C-N-CA 129.296 3.038 . . . . 0.0 112.763 167.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -121.28 16.52 11.45 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 130.499 3.52 . . . . 0.0 117.733 -163.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 t -142.84 135.05 27.36 Favored 'General case' 0 N--CA 1.445 -0.684 0 O-C-N 118.374 -2.704 . . . . 0.0 110.661 166.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . 0.356 49.6 m-85 -154.41 147.27 24.43 Favored 'General case' 0 N--CA 1.446 -0.673 0 C-N-CA 127.646 2.378 . . . . 0.0 107.415 -167.052 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -136.69 150.08 48.27 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 118.377 2.732 . . . . 0.0 118.377 -172.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -156.61 145.63 20.28 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 119.324 3.083 . . . . 0.0 119.324 -165.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.8 -170.33 21.22 Favored Glycine 0 C--N 1.341 0.833 0 C-N-CA 127.521 2.486 . . . . 0.0 115.578 174.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -58.18 -38.66 77.11 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 125.813 1.645 . . . . 0.0 110.256 -170.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -68.33 -1.84 23.4 Favored Glycine 0 CA--C 1.527 0.835 0 O-C-N 117.814 -3.054 . . . . 0.0 113.366 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.5 mt -120.27 21.75 11.61 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 122.095 2.948 . . . . 0.0 107.289 169.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.0 t -124.43 -50.85 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-O 116.309 -1.805 . . . . 0.0 112.669 165.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.4 pttt -155.63 136.3 13.42 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 122.419 2.372 . . . . 0.0 110.505 -165.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 46.2 t -144.73 141.03 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 CA-C-O 115.303 -2.284 . . . . 0.0 109.049 -170.284 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -137.43 -171.47 2.98 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 120.36 3.467 . . . . 0.0 120.36 -172.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 48.4 t0 -94.03 -57.55 2.5 Favored 'General case' 0 N--CA 1.447 -0.587 1 O-C-N 115.101 -4.75 . . . . 0.0 109.294 -162.188 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 66.6 m-80 -97.97 -2.8 39.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 118.841 2.904 . . . . 0.0 118.841 172.093 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -114.47 88.85 16.54 Favored Pre-proline 0 N--CA 1.445 -0.719 0 CA-C-O 122.58 1.181 . . . . 0.0 110.248 160.106 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -43.77 135.63 7.26 Favored 'Trans proline' 0 N--CA 1.445 -1.325 0 N-CA-C 116.997 1.884 . . . . 0.0 116.997 156.381 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.44 153.95 22.58 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.238 2.215 . . . . 0.0 113.418 -174.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -138.11 147.92 44.46 Favored 'General case' 0 N--CA 1.442 -0.851 0 C-N-CA 128.494 2.717 . . . . 0.0 112.626 -171.051 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -155.02 175.14 14.21 Favored 'General case' 0 CA--C 1.514 -0.429 0 C-N-CA 130.111 3.365 . . . . 0.0 112.868 166.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.402 ' CG2' ' HB ' ' A' ' 78' ' ' THR . 86.9 m -123.36 125.7 45.48 Favored 'General case' 0 C--N 1.344 0.364 0 N-CA-C 117.23 2.307 . . . . 0.0 117.23 -164.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . 0.273 2.3 mt -78.31 123.25 34.85 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.717 0 CA-C-O 114.001 -2.904 . . . . 0.0 115.791 167.59 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.312 22.7 p90 -111.05 91.96 3.86 Favored 'General case' 0 N--CA 1.433 -1.287 0 C-N-CA 129.843 3.257 . . . . 0.0 115.262 177.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -97.74 138.14 35.57 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 130.529 3.531 . . . . 0.0 114.379 -166.266 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.1 t -131.58 135.73 58.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 CA-C-N 112.078 -2.328 . . . . 0.0 107.948 170.126 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -61.55 -61.26 2.65 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 117.029 2.233 . . . . 0.0 117.029 166.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 21.1 p -164.03 -26.67 0.04 OUTLIER 'General case' 0 N--CA 1.443 -0.795 0 C-N-CA 130.354 3.462 . . . . 0.0 110.648 169.196 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 34.6 mtmm -76.4 19.22 0.26 Allowed 'General case' 0 CA--C 1.515 -0.386 0 O-C-N 127.006 2.691 . . . . 0.0 114.166 -163.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 62.6 -46.38 0.07 OUTLIER Glycine 0 C--N 1.347 1.19 0 C-N-CA 127.067 2.27 . . . . 0.0 118.049 177.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 57.9 t -52.27 140.34 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 CA-C-N 121.881 2.841 . . . . 0.0 112.398 159.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -32.44 153.05 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 117.351 2.352 . . . . 0.0 117.351 165.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 8.0 mmm180 -59.7 128.13 35.41 Favored 'General case' 0 N--CA 1.452 -0.355 0 O-C-N 118.01 -2.931 . . . . 0.0 113.408 173.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 59.9 p -88.82 1.53 55.12 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 127.806 2.442 . . . . 0.0 112.877 -169.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -163.82 156.74 18.1 Favored 'General case' 0 N--CA 1.448 -0.526 1 O-C-N 115.786 -4.321 . . . . 0.0 112.922 176.4 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.81 -173.92 30.63 Favored Glycine 0 N--CA 1.466 0.684 0 O-C-N 125.591 1.807 . . . . 0.0 108.98 -155.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.23 32.36 83.89 Favored Glycine 0 C--O 1.236 0.224 0 C-N-CA 127.672 2.558 . . . . 0.0 114.076 171.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -60.71 145.17 88.48 Favored Pre-proline 0 CA--C 1.514 -0.418 0 O-C-N 117.743 -3.21 . . . . 0.0 106.763 160.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -84.09 135.97 6.68 Favored 'Trans proline' 0 CA--C 1.509 -0.735 0 C-N-CA 124.734 3.623 . . . . 0.0 115.952 170.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -135.2 163.96 28.77 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 129.62 3.168 . . . . 0.0 111.2 -172.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.427 ' O ' ' HA ' ' A' ' 95' ' ' VAL 0.275 21.5 tt0 -145.64 141.56 28.25 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 127.919 2.488 . . . . 0.0 113.472 164.667 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 4.3 t -129.9 61.49 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 129.487 3.115 . . . . 0.0 105.335 -173.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -83.81 132.04 34.85 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 112.839 -1.982 . . . . 0.0 113.958 -175.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 61.3 mt -138.77 145.59 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 CA-C-O 124.34 2.019 . . . . 0.0 108.486 -158.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 24.3 m120 -113.18 129.69 56.44 Favored 'General case' 0 N--CA 1.45 -0.455 0 O-C-N 116.587 -3.821 . . . . 0.0 108.993 167.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.22 -172.61 41.79 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 126.205 1.86 . . . . 0.0 114.042 157.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo . . . . . 0 N--CA 1.455 -0.766 0 C-N-CA 122.94 2.427 . . . . 0.0 112.937 -178.984 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . 0.265 56.7 t . . . . . 0 N--CA 1.449 -0.523 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 2.3 t -127.8 151.57 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 O-C-N 120.904 -1.123 . . . . 0.0 108.477 -168.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -121.76 139.75 53.2 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 126.411 3.005 . . . . 0.0 110.816 153.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -87.16 125.84 34.41 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 112.172 -2.285 . . . . 0.0 106.716 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 30.3 mmtm -81.17 133.64 35.49 Favored 'General case' 0 N--CA 1.449 -0.481 0 O-C-N 118.848 -2.407 . . . . 0.0 111.285 -167.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 72.2 t -107.97 139.96 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.685 0 CA-C-O 126.072 2.844 . . . . 0.0 106.842 -168.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 28.4 m -144.5 127.18 16.15 Favored 'General case' 0 C--N 1.345 0.37 0 CA-C-N 111.606 -2.543 . . . . 0.0 109.611 173.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 62.3 t0 -63.05 129.67 41.35 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 125.459 1.503 . . . . 0.0 111.752 177.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 -82.84 -11.37 58.29 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 115.954 1.835 . . . . 0.0 115.954 173.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.39 2.5 m120 63.66 48.5 3.31 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.294 2.238 . . . . 0.0 116.181 -172.697 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 44.0 p-10 -156.75 8.35 0.2 Allowed 'General case' 0 C--N 1.345 0.388 0 CA-C-O 126.376 2.988 . . . . 0.0 117.726 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 95.16 17.52 36.97 Favored Glycine 0 CA--C 1.526 0.742 0 O-C-N 117.588 -3.195 . . . . 0.0 108.441 -178.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.402 ' HB ' ' CG2' ' A' ' 37' ' ' THR . 31.1 p -136.76 166.58 23.26 Favored 'General case' 0 C--N 1.331 -0.226 0 O-C-N 124.728 0.899 . . . . 0.0 111.947 173.41 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -137.28 121.61 18.14 Favored 'General case' 0 N--CA 1.441 -0.888 0 O-C-N 125.674 1.859 . . . . 0.0 108.359 -172.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -76.18 134.24 15.45 Favored Glycine 0 N--CA 1.466 0.636 0 CA-C-O 124.221 2.012 . . . . 0.0 113.399 163.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 89.7 t -117.29 146.48 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 C-N-CA 129.575 3.15 . . . . 0.0 113.329 171.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -134.36 141.6 43.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 O-C-N 125.816 1.947 . . . . 0.0 113.285 175.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -162.15 167.38 24.27 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 116.275 -1.821 . . . . 0.0 112.051 168.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 40.7 p30 -144.99 154.64 42.76 Favored 'General case' 0 C--N 1.348 0.535 0 C-N-CA 126.096 1.758 . . . . 0.0 109.02 -166.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -124.42 118.25 26.37 Favored Pre-proline 0 N--CA 1.446 -0.647 0 C-N-CA 128.03 2.532 . . . . 0.0 114.514 -166.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.263 45.7 Cg_endo -71.87 -14.51 29.61 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.608 2.205 . . . . 0.0 111.803 -175.716 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.9 m -137.77 132.74 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.853 0 C-N-CA 128.139 2.576 . . . . 0.0 114.242 -139.387 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -54.45 112.17 0.94 Allowed 'General case' 0 N--CA 1.447 -0.618 0 O-C-N 118.045 -2.909 . . . . 0.0 115.255 144.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 168.69 -145.5 9.58 Favored Glycine 0 CA--C 1.529 0.922 1 O-C-N 114.453 -5.154 . . . . 0.0 114.818 -173.422 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ASN . . . . . 0.603 HD22 ' HB3' ' A' ' 108' ' ' ASP . 5.4 t30 -145.49 133.39 21.26 Favored 'General case' 0 N--CA 1.448 -0.525 0 O-C-N 117.431 -3.394 . . . . 0.0 115.152 -176.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 17.7 m-85 -102.34 148.68 25.18 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 104.669 -2.345 . . . . 0.0 104.669 174.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -126.39 106.59 9.59 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 128.347 3.53 . . . . 0.0 112.51 -177.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 42.6 t -111.81 131.44 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 O-C-N 119.612 -1.93 . . . . 0.0 108.571 -158.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 -126.74 120.24 28.89 Favored 'General case' 0 CA--C 1.513 -0.473 0 C-N-CA 129.746 3.218 . . . . 0.0 110.158 174.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.427 ' HA ' ' O ' ' A' ' 56' ' ' GLU . 77.1 t -99.92 148.21 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 115.534 1.679 . . . . 0.0 115.534 170.467 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.7 p -150.41 148.83 29.24 Favored 'General case' 0 N--CA 1.445 -0.675 0 O-C-N 117.385 -3.322 . . . . 0.0 113.025 -177.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 8.0 mp -128.8 106.65 9.06 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 127.971 2.508 . . . . 0.0 110.184 -158.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? 51.56 44.32 29.17 Favored 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 126.212 1.805 . . . . 0.0 108.295 -160.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 58.59 26.56 59.99 Favored Glycine 0 N--CA 1.439 -1.103 0 N-CA-C 118.429 2.131 . . . . 0.0 118.429 -177.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 73.5 m-20 -122.06 143.53 39.12 Favored Pre-proline 0 CA--C 1.516 -0.362 0 C-N-CA 125.088 1.355 . . . . 0.0 108.887 174.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . 0.282 24.4 Cg_endo -82.88 175.83 8.25 Favored 'Trans proline' 0 N--CA 1.446 -1.293 0 CA-C-O 125.948 2.395 . . . . 0.0 108.318 -168.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 25.7 pt -149.7 -176.11 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 C-N-CA 127.961 2.505 . . . . 0.0 109.865 -167.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 41.1 mtpt -81.28 163.56 22.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 123.14 1.447 . . . . 0.0 113.314 -176.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.295 23.2 m120 58.39 54.49 5.57 Favored 'General case' 0 C--O 1.222 -0.386 0 N-CA-C 117.125 2.269 . . . . 0.0 117.125 168.115 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 9.7 mmt -164.3 146.98 7.39 Favored Pre-proline 0 CA--C 1.507 -0.686 0 C-N-CA 128.079 2.552 . . . . 0.0 105.449 -162.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -70.58 164.81 80.65 Favored 'Cis proline' 0 N--CA 1.445 -1.352 0 C-N-CA 130.836 1.598 . . . . 0.0 109.979 -5.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 31.4 pt -130.43 174.04 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 C-N-CA 126.202 1.801 . . . . 0.0 108.043 174.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . 0.603 ' HB3' HD22 ' A' ' 90' ' ' ASN . 6.4 m-20 -125.44 139.31 53.76 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 117.49 2.404 . . . . 0.0 117.49 -168.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 2.4 t -147.39 125.67 3.76 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-O 124.005 1.86 . . . . 0.0 114.323 -175.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . 0.271 46.1 pttt -66.44 129.04 38.51 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 127.057 2.143 . . . . 0.0 108.818 -173.121 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . 0.383 72.5 m -107.71 141.95 38.45 Favored 'General case' 0 N--CA 1.448 -0.531 0 O-C-N 126.72 2.512 . . . . 0.0 104.528 178.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 21.9 mt -144.52 143.65 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 O-C-N 117.281 -3.387 . . . . 0.0 111.977 173.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . 0.298 12.0 pt-20 -93.56 53.1 1.81 Allowed 'General case' 0 N--CA 1.449 -0.507 1 O-C-N 114.427 -5.171 . . . . 0.0 110.741 -157.05 . . . . . . . . 3 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 0.338 0 C-N-CA 128.453 2.93 . . . . 0.0 113.671 -176.289 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo . . . . . 0 N--CA 1.448 -1.185 0 CA-C-O 122.595 0.998 . . . . 0.0 110.556 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -99.55 161.65 23.81 Favored Pre-proline 0 N--CA 1.45 -0.432 0 N-CA-C 117.244 2.313 . . . . 0.0 117.244 -173.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -74.17 170.2 20.71 Favored 'Trans proline' 0 N--CA 1.445 -1.348 0 C-N-CA 123.927 3.084 . . . . 0.0 111.276 -178.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.5 t -152.22 173.99 14.31 Favored 'General case' 0 N--CA 1.452 -0.341 0 O-C-N 124.348 1.03 . . . . 0.0 111.716 174.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.83 -39.97 79.69 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-N 115.125 -0.943 . . . . 0.0 113.374 -170.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . 0.4 ' CD ' ' HZ1' ' A' ' 103' ' ' LYS . 72.5 mm-40 -53.0 -35.76 59.73 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 129.547 3.139 . . . . 0.0 113.596 168.186 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -120.5 19.76 11.94 Favored 'General case' 0 N--CA 1.438 -1.026 0 CA-C-N 111.928 -2.397 . . . . 0.0 111.76 -161.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.4 t -137.45 138.28 39.61 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 117.999 -2.938 . . . . 0.0 105.468 171.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -164.31 153.44 13.52 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 110.778 -2.919 . . . . 0.0 110.606 -170.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -140.11 150.0 43.76 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 119.621 3.193 . . . . 0.0 119.621 -171.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -157.47 134.31 10.04 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 127.563 2.345 . . . . 0.0 111.916 -165.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 148.46 166.5 12.91 Favored Glycine 0 C--N 1.336 0.56 0 C-N-CA 126.473 1.987 . . . . 0.0 112.292 176.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -65.34 -19.78 66.1 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 116.682 -1.628 . . . . 0.0 109.436 -169.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.29 0.3 3.84 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 124.58 3.355 . . . . 0.0 117.22 168.182 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . 0.27 56.9 mt -109.54 13.33 24.0 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 129.637 3.175 . . . . 0.0 111.854 167.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 t -131.52 -53.36 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 C-N-CA 130.69 3.596 . . . . 0.0 112.018 -178.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 46.7 pttt -161.85 125.64 3.2 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 -159.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.2 t -137.67 155.72 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 C-N-CA 129.303 3.041 . . . . 0.0 109.907 -177.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -131.78 -176.66 4.12 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-O 123.933 1.825 . . . . 0.0 111.856 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -88.05 -46.85 8.98 Favored 'General case' 0 N--CA 1.446 -0.629 0 O-C-N 119.489 -2.007 . . . . 0.0 109.462 -174.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -109.5 6.91 24.52 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-O 126.64 3.114 . . . . 0.0 117.304 176.555 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -122.46 100.36 41.67 Favored Pre-proline 0 N--CA 1.442 -0.858 1 O-C-N 116.202 -4.061 . . . . 0.0 101.784 167.162 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -62.42 157.62 45.03 Favored 'Trans proline' 0 N--CA 1.45 -1.031 0 C-N-CA 123.654 2.903 . . . . 0.0 113.595 166.123 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -123.89 153.03 41.71 Favored 'General case' 0 CA--C 1.511 -0.548 0 C-N-CA 127.136 2.175 . . . . 0.0 112.86 -176.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -127.4 155.42 43.67 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 124.067 0.947 . . . . 0.0 108.979 -175.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.445 ' CZ ' HG13 ' A' ' 81' ' ' VAL . 5.2 p90 -161.65 155.38 21.67 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -179.3 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 86.4 m -124.21 119.75 30.27 Favored 'General case' 0 N--CA 1.452 -0.342 0 O-C-N 119.014 -2.303 . . . . 0.0 109.593 -161.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . 0.263 17.2 mt -79.74 102.96 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 124.994 1.318 . . . . 0.0 111.533 164.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.371 40.5 p90 -83.24 124.76 30.88 Favored 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 126.49 1.916 . . . . 0.0 113.797 165.637 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -110.45 146.61 35.6 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 179.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 9.7 t -129.99 139.11 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 O-C-N 126.757 2.536 . . . . 0.0 106.431 160.228 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -66.76 -50.32 63.1 Favored 'General case' 0 N--CA 1.452 -0.336 0 O-C-N 117.779 -3.076 . . . . 0.0 111.881 178.364 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 64.3 p -148.98 -60.23 0.22 Allowed 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 115.947 -1.978 . . . . 0.0 111.359 -166.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 12.7 ttmt -134.61 101.29 4.9 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 122.149 2.249 . . . . 0.0 114.543 -178.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 77.45 -65.56 3.08 Favored Glycine 0 N--CA 1.451 -0.306 0 O-C-N 120.372 -1.455 . . . . 0.0 114.375 162.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 46.3 t -61.01 124.71 15.93 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 C-N-CA 128.891 2.876 . . . . 0.0 108.717 179.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -50.91 168.2 0.06 Allowed 'General case' 0 N--CA 1.449 -0.486 0 CA-C-O 124.471 2.081 . . . . 0.0 112.982 178.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -53.75 125.85 19.9 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 108.719 -3.855 . . . . 0.0 107.631 163.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 17.5 p -79.08 -18.33 53.57 Favored 'General case' 0 N--CA 1.453 -0.297 1 C-N-CA 131.757 4.023 . . . . 0.0 111.486 -173.05 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -151.86 169.35 22.48 Favored 'General case' 0 CA--C 1.517 -0.297 0 O-C-N 127.551 3.032 . . . . 0.0 107.965 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -102.58 -142.75 12.53 Favored Glycine 0 CA--C 1.525 0.671 0 C-N-CA 124.763 1.173 . . . . 0.0 115.001 -167.423 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 71.65 5.34 60.32 Favored Glycine 0 C--N 1.334 0.455 0 CA-C-O 117.234 -1.87 . . . . 0.0 116.751 165.489 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 38.1 m-20 -77.01 143.54 70.61 Favored Pre-proline 0 N--CA 1.45 -0.455 0 CA-C-O 115.435 -2.221 . . . . 0.0 115.981 -178.261 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -83.02 127.71 4.79 Favored 'Trans proline' 0 N--CA 1.449 -1.09 0 CA-C-N 125.151 2.875 . . . . 0.0 115.998 -176.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -138.25 161.48 36.77 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 114.133 -1.394 . . . . 0.0 111.428 -171.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -153.39 151.72 30.24 Favored 'General case' 0 N--CA 1.447 -0.62 0 O-C-N 120.547 -1.346 . . . . 0.0 113.22 172.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 53.5 t -133.35 99.73 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 C-N-CA 130.054 3.342 . . . . 0.0 104.335 -172.072 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -125.07 138.87 54.18 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 113.577 -1.647 . . . . 0.0 112.663 -170.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.4 mt -138.78 115.45 10.58 Favored 'Isoleucine or valine' 0 C--O 1.238 0.482 0 O-C-N 119.715 -1.866 . . . . 0.0 107.978 -147.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -88.64 138.62 31.26 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 118.823 -2.423 . . . . 0.0 107.011 173.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -141.83 173.33 23.64 Favored Glycine 0 CA--C 1.523 0.539 0 C-N-CA 129.359 3.361 . . . . 0.0 112.475 -166.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo . . . . . 0 N--CA 1.46 -0.484 1 C-N-CA 125.921 4.414 . . . . 0.0 117.454 170.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 4.5 t . . . . . 0 N--CA 1.451 -0.397 0 CA-C-O 126.064 2.84 . . . . 0.0 113.207 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 8.9 t -149.43 152.67 11.71 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 O-C-N 116.906 -3.621 . . . . 0.0 107.5 -176.185 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -131.21 138.24 49.29 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-O 123.413 1.578 . . . . 0.0 115.02 161.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -94.09 131.1 39.94 Favored 'General case' 0 N--CA 1.441 -0.917 1 C-N-CA 133.319 4.648 . . . . 0.0 112.585 -164.289 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.41 ' HE2' ' HB3' ' A' ' 70' ' ' LYS 0.258 28.5 ttpt -71.31 126.03 28.56 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 122.894 2.588 . . . . 0.0 112.506 -166.663 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 68.8 t -106.88 140.2 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 O-C-N 119.552 -1.968 . . . . 0.0 106.446 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 90.4 m -144.76 127.97 16.71 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-O 124.868 2.27 . . . . 0.0 113.933 178.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -69.26 128.31 36.14 Favored 'General case' 0 N--CA 1.456 -0.155 0 C-N-CA 127.35 2.26 . . . . 0.0 109.895 -174.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 55.8 m-20 -91.11 5.47 48.82 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 118.458 2.762 . . . . 0.0 118.458 174.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 1.8 m120 55.17 43.23 29.73 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 120.057 1.299 . . . . 0.0 112.423 174.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 35.3 p-10 -155.57 3.29 0.18 Allowed 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 128.052 2.541 . . . . 0.0 116.565 -174.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 98.95 4.2 56.79 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 118.515 -2.616 . . . . 0.0 112.33 -174.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 16.9 p -133.94 165.77 24.24 Favored 'General case' 0 CA--C 1.515 -0.387 0 N-CA-C 116.723 2.12 . . . . 0.0 116.723 177.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 45.2 m-85 -129.64 134.43 47.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.602 177.179 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -81.75 133.72 12.35 Favored Glycine 0 C--N 1.342 0.863 0 O-C-N 125.775 1.922 . . . . 0.0 108.325 172.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.445 HG13 ' CZ ' ' A' ' 36' ' ' PHE . 17.5 t -118.55 136.94 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 128.122 2.569 . . . . 0.0 109.433 175.454 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 p -134.84 135.05 53.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 CA-C-O 114.574 -2.631 . . . . 0.0 111.347 -178.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 80.2 t80 -156.17 144.39 19.85 Favored 'General case' 0 N--CA 1.445 -0.686 1 O-C-N 130.82 5.075 . . . . 0.0 113.084 -174.794 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.9 p30 -130.0 149.0 51.91 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 126.473 1.909 . . . . 0.0 107.999 -177.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -115.25 112.27 44.1 Favored Pre-proline 0 CA--C 1.511 -0.532 0 C-N-CA 125.731 1.612 . . . . 0.0 112.016 -171.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -71.41 -14.55 31.01 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 C-N-CA 124.032 3.155 . . . . 0.0 117.321 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.8 m -143.57 143.59 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 O-C-N 119.824 -1.797 . . . . 0.0 109.853 -174.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 -49.47 121.48 5.11 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 162.306 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -179.92 171.57 43.06 Favored Glycine 0 C--N 1.339 0.711 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.394 -175.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -98.86 133.22 43.46 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 128.886 2.874 . . . . 0.0 112.504 158.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 -126.94 150.03 49.54 Favored 'General case' 0 C--O 1.22 -0.464 0 N-CA-C 106.363 -1.717 . . . . 0.0 106.363 -173.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -119.18 111.28 18.04 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-N 114.214 -1.357 . . . . 0.0 114.632 -170.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.6 t -102.35 132.82 47.6 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.43 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 -166.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -122.6 128.09 50.24 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 131.169 3.788 . . . . 0.0 112.243 166.113 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 62.0 t -117.36 143.65 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 CA-C-N 114.481 -1.236 . . . . 0.0 109.682 -177.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.5 p -140.31 160.55 39.72 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 117.971 -1.014 . . . . 0.0 111.888 -171.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . 0.257 8.2 tt -135.65 94.08 3.04 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 103.152 -2.907 . . . . 0.0 103.152 -152.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 26.4 ttp-105 52.96 37.42 24.46 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 120.975 1.716 . . . . 0.0 112.019 -170.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 65.07 35.95 92.41 Favored Glycine 0 C--N 1.338 0.679 0 N-CA-C 116.65 1.42 . . . . 0.0 116.65 -176.26 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 71.3 m-80 -115.38 141.19 26.83 Favored Pre-proline 0 N--CA 1.447 -0.588 0 CA-C-O 117.353 -1.308 . . . . 0.0 110.009 166.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -71.69 165.98 30.86 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 CA-C-O 124.988 1.995 . . . . 0.0 112.095 166.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 11.6 pt -137.62 179.55 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 C-N-CA 127.234 2.214 . . . . 0.0 112.788 -173.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.4 ' HZ1' ' CD ' ' A' ' 16' ' ' GLU . 56.3 mtpt -74.71 165.91 24.45 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-O 115.529 -2.177 . . . . 0.0 111.025 -173.084 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.421 15.1 m120 66.93 -20.58 0.11 Allowed 'General case' 0 C--N 1.33 -0.268 0 O-C-N 125.59 1.806 . . . . 0.0 114.019 172.737 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 12.9 mmt -67.17 158.65 80.77 Favored Pre-proline 0 N--CA 1.446 -0.644 0 C-N-CA 127.268 2.227 . . . . 0.0 116.575 -178.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -73.51 159.68 97.06 Favored 'Cis proline' 0 N--CA 1.442 -1.517 0 O-C-N 125.089 2.099 . . . . 0.0 107.932 -20.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 8.2 pt -131.23 161.96 40.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 C-N-CA 126.828 2.051 . . . . 0.0 108.736 -174.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 69.8 m-20 -117.27 147.9 42.14 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 126.481 1.912 . . . . 0.0 111.28 -159.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 42.7 t -139.66 117.29 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 126.344 1.857 . . . . 0.0 111.889 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 65.4 tttt -81.9 136.14 35.35 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 115.524 1.675 . . . . 0.0 115.524 168.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 98.1 m -126.77 133.39 50.85 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 125.766 1.626 . . . . 0.0 107.622 -170.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 48.9 mm -121.82 141.78 40.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 O-C-N 120.156 -1.59 . . . . 0.0 107.65 177.272 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -82.75 41.23 0.72 Allowed 'General case' 0 N--CA 1.454 -0.246 1 O-C-N 114.941 -4.85 . . . . 0.0 116.548 -155.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.651 0 O-C-N 119.493 -2.004 . . . . 0.0 113.449 -175.685 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo . . . . . 0 N--CA 1.447 -1.255 0 N-CA-C 108.986 -1.198 . . . . 0.0 108.986 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -114.59 161.97 26.0 Favored Pre-proline 0 N--CA 1.447 -0.578 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_exo -52.06 166.78 0.59 Allowed 'Trans proline' 0 N--CA 1.444 -1.394 0 N-CA-C 115.806 1.425 . . . . 0.0 115.806 170.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.7 t -133.95 149.75 51.27 Favored 'General case' 0 N--CA 1.447 -0.59 0 O-C-N 120.306 -1.496 . . . . 0.0 107.971 160.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -47.99 -33.1 7.36 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 130.477 3.511 . . . . 0.0 111.406 164.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -67.43 -19.8 65.42 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 75.0 m-70 -141.32 14.91 2.21 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 117.321 2.341 . . . . 0.0 117.321 -159.25 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.1 t -141.49 126.31 18.11 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 176.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 65.4 m-85 -150.88 158.0 43.6 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 130.01 3.324 . . . . 0.0 108.882 -161.205 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -133.32 148.68 51.91 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 118.343 2.72 . . . . 0.0 118.343 -175.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -145.27 146.13 31.54 Favored 'General case' 0 C--O 1.221 -0.408 0 N-CA-C 119.917 3.302 . . . . 0.0 119.917 171.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.44 178.83 28.37 Favored Glycine 0 C--N 1.342 0.863 0 C-N-CA 125.457 1.503 . . . . 0.0 114.899 173.207 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -59.28 -32.33 69.92 Favored 'General case' 0 C--O 1.239 0.552 0 O-C-N 117.994 -3.063 . . . . 0.0 117.296 176.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.39 10.06 2.94 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 125.342 1.449 . . . . 0.0 115.795 170.187 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 89.6 mt -124.38 30.52 6.01 Favored 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 118.829 -2.571 . . . . 0.0 112.754 154.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 95.4 t -138.86 -63.05 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 O-C-N 120.111 -1.618 . . . . 0.0 109.683 175.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.292 37.2 pttt -144.65 131.83 20.57 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 123.122 2.692 . . . . 0.0 115.128 -173.111 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 t -130.78 146.76 33.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 1 O-C-N 129.176 4.048 . . . . 0.0 112.386 -174.366 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.466 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 3.9 m-85 -140.1 179.77 6.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 116.84 2.163 . . . . 0.0 116.84 177.137 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -82.36 -39.93 22.07 Favored 'General case' 0 C--O 1.235 0.341 0 O-C-N 116.818 -3.676 . . . . 0.0 113.538 -168.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 15.6 m-80 -105.81 3.42 28.72 Favored 'General case' 0 N--CA 1.449 -0.522 0 O-C-N 126.379 2.3 . . . . 0.0 112.907 178.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -128.77 89.64 48.49 Favored Pre-proline 0 N--CA 1.447 -0.599 0 O-C-N 121.693 -0.629 . . . . 0.0 110.731 175.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_endo -65.97 147.59 84.87 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 O-C-N 125.843 2.496 . . . . 0.0 110.576 -178.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.412 ' O ' ' HA ' ' A' ' 82' ' ' VAL . . . -108.21 164.77 12.01 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 126.426 1.89 . . . . 0.0 111.305 -177.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -140.34 146.0 37.89 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 115.616 -2.135 . . . . 0.0 112.748 -175.097 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 24.6 p90 -153.52 167.39 29.64 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 122.858 2.572 . . . . 0.0 107.49 171.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 94.7 m -127.46 115.6 19.14 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.262 1.425 . . . . 0.0 109.012 -156.005 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . 0.405 8.4 mt -67.06 96.91 0.29 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.22 0 C-N-CA 125.529 1.532 . . . . 0.0 112.044 162.717 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -83.49 112.43 19.96 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-O 125.086 2.374 . . . . 0.0 111.942 166.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -114.97 126.94 55.35 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 116.496 -3.878 . . . . 0.0 110.259 -167.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.453 HG21 ' HA ' ' A' ' 47' ' ' ALA . 54.4 t -127.62 149.43 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-O 123.967 1.841 . . . . 0.0 106.894 173.563 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -80.86 -37.57 29.67 Favored 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 117.162 2.282 . . . . 0.0 117.162 169.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 82.7 p -160.0 -69.94 0.07 Allowed 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 127.048 2.717 . . . . 0.0 116.907 -170.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 50.6 mttm -127.98 99.13 5.38 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 122.282 2.31 . . . . 0.0 113.253 -174.01 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 76.37 -75.32 1.6 Allowed Glycine 0 CA--C 1.525 0.661 0 CA-C-N 121.995 2.18 . . . . 0.0 114.915 159.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 65.5 t -46.66 129.03 2.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 126.624 1.97 . . . . 0.0 107.005 171.157 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.453 ' HA ' HG21 ' A' ' 41' ' ' VAL . . . -58.81 171.23 0.68 Allowed 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 116.661 2.097 . . . . 0.0 116.661 177.088 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.3 mmm180 -64.22 116.06 5.63 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 115.598 -2.144 . . . . 0.0 106.28 165.273 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.7 p -76.63 4.6 9.07 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 127.762 3.164 . . . . 0.0 116.604 -160.45 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -168.4 163.06 12.69 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-O 125.338 2.494 . . . . 0.0 108.314 -173.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -103.17 -169.5 25.98 Favored Glycine 0 CA--C 1.524 0.646 0 O-C-N 118.064 -2.898 . . . . 0.0 113.61 -150.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 62.24 22.08 62.67 Favored Glycine 0 C--N 1.335 0.475 0 CA-C-O 113.854 -3.748 . . . . 0.0 117.952 169.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -69.09 153.59 95.89 Favored Pre-proline 0 N--CA 1.452 -0.363 0 CA-C-N 124.15 3.975 . . . . 0.0 110.253 173.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -88.03 133.08 2.87 Favored 'Trans proline' 0 N--CA 1.447 -1.264 1 C-N-CA 127.091 5.194 . . . . 0.0 118.388 -172.366 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -148.8 167.12 26.47 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 113.174 -1.83 . . . . 0.0 110.37 -156.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -161.96 141.76 10.01 Favored 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 129.021 2.928 . . . . 0.0 107.241 174.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 20.2 t -132.14 96.04 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 C-N-CA 130.769 3.628 . . . . 0.0 103.917 -178.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -116.16 140.36 49.38 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 112.236 -2.257 . . . . 0.0 110.016 -168.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 58.5 mt -134.82 148.84 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 CA-C-N 113.754 -1.567 . . . . 0.0 110.041 -159.229 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 54.2 m-80 -126.67 151.5 47.99 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 104.693 -2.336 . . . . 0.0 104.693 165.05 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.0 -145.72 4.72 Favored Glycine 0 C--O 1.219 -0.819 0 N-CA-C 107.613 -2.195 . . . . 0.0 107.613 173.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo . . . . . 0 N--CA 1.45 -1.029 0 CA-C-O 124.496 1.79 . . . . 0.0 111.746 -172.316 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 99.0 t . . . . . 0 CA--C 1.514 -0.424 0 CA-C-O 123.295 1.521 . . . . 0.0 107.023 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 24.4 t -140.36 151.53 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.993 0 C-N-CA 125.21 1.404 . . . . 0.0 111.735 -168.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.256 8.3 p-10 -135.72 122.55 21.15 Favored 'General case' 0 C--N 1.326 -0.429 0 O-C-N 127.532 3.02 . . . . 0.0 109.791 167.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -74.75 151.08 39.19 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 128.586 2.754 . . . . 0.0 114.828 -178.173 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 66.3 tttt -93.73 98.75 11.31 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 114.369 -1.287 . . . . 0.0 111.376 -160.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.1 t -88.64 133.24 31.49 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.117 0 O-C-N 125.678 1.861 . . . . 0.0 106.451 -170.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 26.3 m -144.4 126.48 15.53 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 118.574 -1.25 . . . . 0.0 109.353 172.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -48.56 120.84 3.99 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 128.534 2.734 . . . . 0.0 118.283 166.589 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 -84.55 1.16 47.13 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 114.256 -2.783 . . . . 0.0 112.613 178.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 9.3 m120 61.29 24.24 14.37 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 117.556 2.428 . . . . 0.0 117.556 -177.267 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 19.8 p30 -134.55 -6.28 2.53 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 115.487 1.662 . . . . 0.0 115.487 -177.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 112.61 0.79 26.08 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 114.836 -3.202 . . . . 0.0 114.586 -166.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 66.0 p -131.74 160.46 35.47 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 120.407 2.103 . . . . 0.0 113.529 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -123.79 127.63 48.38 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 117.866 -3.021 . . . . 0.0 110.362 173.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -80.6 116.35 4.22 Favored Glycine 0 CA--C 1.526 0.755 0 C-N-CA 129.246 3.308 . . . . 0.0 106.103 171.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.7 t -102.14 125.34 56.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 117.194 2.294 . . . . 0.0 117.194 165.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.412 ' HA ' ' O ' ' A' ' 34' ' ' ALA . 87.6 t -125.79 145.79 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-N 121.906 2.139 . . . . 0.0 111.762 -173.666 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . 0.343 1.2 p90 -165.93 172.63 11.33 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 122.849 2.568 . . . . 0.0 114.524 179.513 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 19.8 p30 -135.33 169.48 17.41 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -177.037 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -132.88 109.64 13.02 Favored Pre-proline 0 N--CA 1.447 -0.604 0 N-CA-C 114.752 1.389 . . . . 0.0 114.752 179.184 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.288 68.8 Cg_endo -71.88 -2.63 11.78 Favored 'Trans proline' 0 N--CA 1.449 -1.14 0 C-N-CA 124.702 3.601 . . . . 0.0 111.366 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.8 m -138.66 144.71 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.634 0 CA-C-O 121.653 0.739 . . . . 0.0 111.961 -163.05 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -63.29 127.52 31.66 Favored 'General case' 0 N--CA 1.451 -0.423 0 O-C-N 119.361 -2.087 . . . . 0.0 109.956 153.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 167.39 -166.37 39.24 Favored Glycine 0 CA--C 1.521 0.444 0 CA-C-O 123.756 1.753 . . . . 0.0 116.289 -172.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 11.1 t30 -114.48 139.71 49.32 Favored 'General case' 0 C--O 1.22 -0.487 0 CA-C-N 111.295 -2.452 . . . . 0.0 111.908 164.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . 0.415 ' CD2' ' SG ' ' A' ' 111' ' ' CYS . 10.1 m-85 -98.57 152.04 20.01 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 127.518 3.532 . . . . 0.0 112.494 152.269 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -129.08 109.07 10.88 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 109.806 -3.361 . . . . 0.0 108.164 -174.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 87.0 t -101.32 129.08 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 113.155 -1.839 . . . . 0.0 108.403 -163.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -131.15 130.52 43.16 Favored 'General case' 0 N--CA 1.449 -0.509 0 O-C-N 126.445 2.341 . . . . 0.0 110.889 176.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 99.6 t -112.74 147.13 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.741 0 N-CA-C 114.67 1.359 . . . . 0.0 114.67 -177.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 31.4 p -142.89 162.54 35.19 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 120.792 1.633 . . . . 0.0 111.597 175.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 3.0 tt -144.51 101.26 3.66 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 -147.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 28.8 ttm-85 47.51 42.01 13.92 Favored 'General case' 0 N--CA 1.445 -0.684 0 O-C-N 124.625 1.203 . . . . 0.0 108.324 -163.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 85.48 2.75 87.11 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 128.791 3.091 . . . . 0.0 120.077 177.129 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.2 m-20 -115.58 147.84 39.72 Favored Pre-proline 0 CA--C 1.514 -0.425 0 C-N-CA 125.881 1.672 . . . . 0.0 113.243 -176.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -74.15 163.04 37.52 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 124.755 3.637 . . . . 0.0 111.138 -177.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 10.7 pt -140.82 175.09 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 126.219 1.807 . . . . 0.0 112.699 -165.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -82.28 164.08 21.39 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 120.832 1.651 . . . . 0.0 113.915 -170.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 29.7 m120 53.97 40.15 31.28 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 127.403 2.281 . . . . 0.0 116.772 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 8.7 mmt -126.25 168.96 12.71 Favored Pre-proline 0 N--CA 1.45 -0.462 0 C-N-CA 126.993 2.117 . . . . 0.0 107.376 -170.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -65.67 168.66 14.47 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 N-CA-C 117.453 2.059 . . . . 0.0 117.453 -33.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . 0.372 17.1 pt -138.54 140.05 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-O 122.71 1.243 . . . . 0.0 109.202 -168.631 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -107.93 139.16 42.97 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 117.526 2.417 . . . . 0.0 117.526 -168.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 66.1 t -146.53 114.88 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.762 0 O-C-N 119.783 -1.823 . . . . 0.0 109.395 -161.442 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 68.2 tttt -80.51 144.26 32.65 Favored 'General case' 0 CA--C 1.523 -0.093 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . 0.415 ' SG ' ' CD2' ' A' ' 91' ' ' TYR . 87.7 m -117.14 139.08 51.19 Favored 'General case' 0 N--CA 1.451 -0.42 2 O-C-N 131.991 5.807 . . . . 0.0 110.233 -179.984 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.466 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 90.9 mt -135.04 123.37 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-N 108.469 -3.969 . . . . 0.0 113.361 171.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . 0.3 7.5 pt-20 -76.23 39.97 0.2 Allowed 'General case' 0 N--CA 1.451 -0.395 0 O-C-N 116.947 -3.595 . . . . 0.0 115.332 -164.646 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.626 0 CA-C-N 121.457 1.935 . . . . 0.0 115.585 169.728 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo . . . . . 0 N--CA 1.439 -1.703 0 CA-C-O 119.391 -0.337 . . . . 0.0 111.313 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -111.53 136.83 21.03 Favored Pre-proline 0 C--O 1.239 0.538 0 C-N-CA 131.116 3.767 . . . . 0.0 114.187 -176.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . 0.252 23.3 Cg_exo -65.58 168.78 14.04 Favored 'Trans proline' 0 CA--C 1.514 -0.49 0 N-CA-C 117.498 2.076 . . . . 0.0 117.498 170.63 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.6 m -142.88 160.85 39.55 Favored 'General case' 0 N--CA 1.44 -0.958 0 CA-C-N 123.317 2.78 . . . . 0.0 110.937 -174.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.44 -48.43 81.68 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 113.597 -3.097 . . . . 0.0 113.861 174.638 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -52.64 -28.32 20.95 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 123.06 2.663 . . . . 0.0 106.773 173.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 74.4 m-70 -117.37 5.86 12.61 Favored 'General case' 0 C--O 1.218 -0.603 0 N-CA-C 116.525 2.046 . . . . 0.0 116.525 -156.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.8 t -135.14 121.86 20.88 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 116.816 2.154 . . . . 0.0 116.816 173.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 26.6 m-85 -153.31 155.19 36.02 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -161.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . 0.462 . . -132.01 147.92 52.48 Favored 'General case' 0 C--O 1.217 -0.61 0 N-CA-C 117.85 2.537 . . . . 0.0 117.85 -167.36 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -160.96 145.95 14.08 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 130.125 3.37 . . . . 0.0 108.736 -164.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.1 175.21 13.94 Favored Glycine 0 N--CA 1.446 -0.696 0 O-C-N 126.99 2.681 . . . . 0.0 117.505 -173.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -74.03 -30.21 62.31 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 112.652 -3.547 . . . . 0.0 113.715 -176.139 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -62.23 9.82 0.12 Allowed Glycine 0 CA--C 1.531 1.047 0 CA-C-N 124.945 3.52 . . . . 0.0 115.371 161.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 17.0 mt -113.9 19.85 16.25 Favored 'General case' 0 C--O 1.223 -0.312 0 CA-C-N 122.023 2.911 . . . . 0.0 109.799 167.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 1.7 t -137.97 -41.75 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 CA-C-O 115.313 -2.28 . . . . 0.0 110.312 174.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 42.4 mtmt -155.74 118.09 4.14 Favored 'General case' 0 C--N 1.328 -0.367 0 O-C-N 124.685 1.241 . . . . 0.0 114.096 -163.051 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 t -124.7 138.69 53.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 C-N-CA 130.853 3.661 . . . . 0.0 116.188 177.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -128.78 -169.82 2.15 Favored 'General case' 0 N--CA 1.452 -0.358 0 O-C-N 126.552 2.408 . . . . 0.0 115.434 -174.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 17.7 t0 -105.17 -33.29 8.31 Favored 'General case' 0 CA--C 1.511 -0.541 0 O-C-N 118.278 -2.764 . . . . 0.0 114.212 -167.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 53.8 m-80 -101.83 8.73 41.22 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 120.511 3.523 . . . . 0.0 120.511 162.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -137.57 96.15 10.95 Favored Pre-proline 0 N--CA 1.445 -0.676 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.263 178.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_exo -62.83 128.29 22.79 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 121.883 1.722 . . . . 0.0 111.7 171.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -92.35 156.41 17.26 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 123.05 1.405 . . . . 0.0 109.71 -177.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -133.97 149.77 51.25 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 -169.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -161.64 173.27 14.95 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.194 -2.521 . . . . 0.0 104.194 168.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 26.1 m -127.02 118.17 23.93 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 131.53 3.932 . . . . 0.0 114.811 -158.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 44.7 mm -76.19 96.31 1.32 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.483 0 C-N-CA 127.012 2.125 . . . . 0.0 106.213 173.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -81.83 99.87 9.26 Favored 'General case' 0 C--O 1.214 -0.8 0 O-C-N 119.114 -2.241 . . . . 0.0 114.87 171.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -100.12 137.14 38.97 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 117.807 2.521 . . . . 0.0 117.807 -167.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 71.7 t -134.94 156.45 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 C-N-CA 128.449 2.7 . . . . 0.0 113.858 169.612 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.7 p30 -76.71 -71.65 0.38 Allowed 'General case' 0 N--CA 1.448 -0.555 0 O-C-N 118.741 -2.474 . . . . 0.0 109.882 174.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 77.8 p -156.18 -39.67 0.08 Allowed 'General case' 0 C--O 1.238 0.481 1 C-N-CA 133.57 4.748 . . . . 0.0 106.86 -175.705 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 46.6 mtmt -87.65 28.43 1.0 Allowed 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 123.237 2.744 . . . . 0.0 110.755 -154.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 78.28 -41.56 2.05 Favored Glycine 0 N--CA 1.444 -0.807 0 O-C-N 118.27 -2.769 . . . . 0.0 115.675 169.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.6 t -71.21 145.11 12.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 126.178 1.791 . . . . 0.0 114.667 168.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -47.12 162.19 0.06 Allowed 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 114.306 -1.316 . . . . 0.0 113.882 177.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -64.82 113.04 3.54 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.369 174.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.5 p -89.11 4.86 47.04 Favored 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 131.232 3.813 . . . . 0.0 113.142 -163.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.9 p30 -152.49 172.69 16.17 Favored 'General case' 0 N--CA 1.446 -0.657 1 C-N-CA 133.697 4.799 . . . . 0.0 108.521 162.737 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -138.03 -175.64 14.03 Favored Glycine 0 N--CA 1.443 -0.844 0 O-C-N 118.322 -2.736 . . . . 0.0 109.797 -149.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.93 41.5 98.67 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 127.213 2.339 . . . . 0.0 111.503 -178.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -74.51 156.61 86.9 Favored Pre-proline 0 C--O 1.221 -0.405 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 167.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -87.83 135.64 3.49 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 CA-C-O 127.298 2.958 . . . . 0.0 113.632 174.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -147.49 151.94 37.22 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 117.994 -2.941 . . . . 0.0 110.436 -173.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -140.59 142.8 35.05 Favored 'General case' 0 N--CA 1.446 -0.643 0 O-C-N 118.94 -2.35 . . . . 0.0 109.924 178.649 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 19.9 t -129.58 81.79 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 C-N-CA 129.876 3.27 . . . . 0.0 106.047 178.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -94.65 131.9 39.95 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 113.142 -1.844 . . . . 0.0 114.793 176.249 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.7 mt -124.13 156.95 31.58 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.581 0 C-N-CA 125.782 1.633 . . . . 0.0 108.116 -163.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -115.28 132.85 56.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 115.508 -2.187 . . . . 0.0 114.426 144.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -80.52 -152.42 8.23 Favored Glycine 0 CA--C 1.532 1.118 0 O-C-N 125.709 1.881 . . . . 0.0 110.611 160.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_exo . . . . . 0 N--CA 1.442 -1.529 0 C-N-CA 124.773 3.648 . . . . 0.0 110.806 -170.294 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 96.4 t . . . . . 0 N--CA 1.453 -0.288 0 N-CA-C 115.422 1.638 . . . . 0.0 115.422 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 20.0 t -130.34 153.21 38.66 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.797 0 O-C-N 117.895 -3.003 . . . . 0.0 115.191 -173.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.2 p-10 -130.04 138.45 50.77 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 160.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -90.97 149.47 21.85 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-O 125.011 2.339 . . . . 0.0 111.926 177.11 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 52.6 mmtt -93.0 115.37 28.06 Favored 'General case' 0 N--CA 1.445 -0.681 0 O-C-N 118.612 -2.555 . . . . 0.0 108.62 -163.311 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 36.3 t -97.1 139.26 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 CA-C-N 114.051 -1.431 . . . . 0.0 109.813 -176.09 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 59.9 m -138.97 137.34 36.3 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 127.586 2.354 . . . . 0.0 113.056 174.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -73.05 128.68 36.19 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 126.132 1.773 . . . . 0.0 109.924 177.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 67.5 m-20 -90.16 -1.38 57.93 Favored 'General case' 0 C--O 1.221 -0.401 0 CA-C-O 115.722 -2.085 . . . . 0.0 115.3 175.034 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 1.7 m120 70.6 24.52 4.4 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 123.797 2.998 . . . . 0.0 111.553 167.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 38.0 p30 -139.27 -7.17 1.35 Allowed 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 121.582 3.919 . . . . 0.0 121.582 179.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 130.89 -13.2 5.56 Favored Glycine 0 C--O 1.242 0.628 0 CA-C-O 123.228 1.46 . . . . 0.0 112.967 -177.216 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.6 p -128.22 164.64 22.09 Favored 'General case' 0 C--O 1.24 0.586 0 C-N-CA 127.696 2.398 . . . . 0.0 113.472 -171.053 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 -128.49 147.76 50.7 Favored 'General case' 0 C--N 1.329 -0.291 0 O-C-N 125.308 1.63 . . . . 0.0 107.641 174.621 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -94.38 132.18 11.05 Favored Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 128.761 3.077 . . . . 0.0 111.183 173.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.9 t -128.07 138.62 54.17 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 CA-C-O 117.401 -1.285 . . . . 0.0 113.036 178.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.9 t -141.91 130.94 22.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 O-C-N 124.783 1.302 . . . . 0.0 112.695 -167.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -161.15 138.14 8.79 Favored 'General case' 0 CA--C 1.517 -0.313 0 CA-C-O 124.35 2.024 . . . . 0.0 111.859 -174.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.267 57.4 p-10 -109.88 160.9 15.98 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 129.227 3.011 . . . . 0.0 112.829 175.396 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -130.15 109.87 16.67 Favored Pre-proline 0 N--CA 1.443 -0.776 0 C-N-CA 126.508 1.923 . . . . 0.0 109.754 -167.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -70.5 -6.41 18.91 Favored 'Trans proline' 0 N--CA 1.445 -1.341 0 C-N-CA 122.072 1.848 . . . . 0.0 114.906 -179.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.5 m -149.68 147.14 16.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 O-C-N 118.126 -2.859 . . . . 0.0 114.737 -151.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 28.7 tt0 -62.95 102.95 0.4 Allowed 'General case' 0 C--O 1.241 0.607 0 CA-C-O 123.35 1.548 . . . . 0.0 108.848 167.071 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -177.91 -136.62 2.55 Favored Glycine 0 N--CA 1.434 -1.488 1 O-C-N 116.288 -4.007 . . . . 0.0 122.784 178.098 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 25.8 t30 -132.36 137.04 47.23 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 130.18 3.392 . . . . 0.0 110.552 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 13.6 m-85 -106.75 151.9 24.53 Favored 'General case' 0 N--CA 1.446 -0.671 0 O-C-N 124.502 1.126 . . . . 0.0 112.75 151.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -119.77 116.52 26.08 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 110.894 -2.866 . . . . 0.0 112.213 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 3.3 t -112.33 126.02 69.67 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.966 0 N-CA-C 115.507 1.669 . . . . 0.0 115.507 -162.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -136.53 118.96 15.76 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 115.452 -2.213 . . . . 0.0 110.312 -168.183 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 67.3 t -119.24 144.41 27.71 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.473 0 CA-C-N 120.515 1.507 . . . . 0.0 108.625 -174.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 33.0 p -135.36 153.06 51.96 Favored 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 127.086 2.154 . . . . 0.0 110.619 -177.274 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.5 mp -126.14 91.65 3.42 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-O 112.702 -3.523 . . . . 0.0 112.673 -161.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.1 ttm180 55.92 35.27 25.17 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 124.744 2.211 . . . . 0.0 110.307 -159.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 75.32 0.91 63.05 Favored Glycine 0 CA--C 1.533 1.195 0 O-C-N 117.793 -3.067 . . . . 0.0 117.918 -177.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 63.8 m-80 -78.51 134.14 62.33 Favored Pre-proline 0 N--CA 1.448 -0.539 0 O-C-N 120.525 -1.573 . . . . 0.0 112.013 168.434 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -87.76 178.52 3.22 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 123.904 3.07 . . . . 0.0 104.968 -177.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 19.2 pt -152.82 177.32 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 O-C-N 120.169 -1.582 . . . . 0.0 112.761 -172.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 13.3 ptmt -86.86 170.97 11.19 Favored 'General case' 0 N--CA 1.442 -0.874 0 C-N-CA 128.28 2.632 . . . . 0.0 117.91 -168.161 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 10.3 m120 53.43 32.89 14.76 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 129.512 3.125 . . . . 0.0 113.878 -177.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 2.9 ttm -146.34 145.54 24.3 Favored Pre-proline 0 C--O 1.246 0.897 0 O-C-N 116.69 -3.757 . . . . 0.0 111.486 -158.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . 0.3 10.1 Cg_endo -54.45 159.14 15.31 Favored 'Cis proline' 0 N--CA 1.443 -1.462 0 CA-C-N 125.002 2.822 . . . . 0.0 116.343 -13.625 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 13.4 pt -126.76 158.19 37.43 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 C-N-CA 130.38 3.472 . . . . 0.0 110.058 175.27 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -114.52 143.92 44.19 Favored 'General case' 0 CA--C 1.503 -0.833 0 N-CA-C 117.033 2.234 . . . . 0.0 117.033 -176.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 60.8 t -139.24 117.64 12.38 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 CA-C-O 117.087 -1.435 . . . . 0.0 110.318 -174.276 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . 0.25 32.6 ttpt -64.62 133.49 52.36 Favored 'General case' 0 N--CA 1.443 -0.797 0 C-N-CA 127.813 2.445 . . . . 0.0 113.66 -179.026 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 72.2 m -117.95 156.47 28.44 Favored 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 127.929 2.491 . . . . 0.0 112.492 -177.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 7.7 tt -155.27 156.64 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 114.776 1.399 . . . . 0.0 114.776 158.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . 0.316 5.0 pt-20 -62.51 43.44 0.01 OUTLIER 'General case' 0 N--CA 1.444 -0.769 0 C-N-CA 127.149 2.18 . . . . 0.0 116.879 173.372 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.676 0 N-CA-C 118.634 2.214 . . . . 0.0 118.634 179.939 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo . . . . . 0 N--CA 1.451 -0.98 0 N-CA-C 118.05 2.288 . . . . 0.0 118.05 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . 0.411 ' O ' ' HA ' ' A' ' 42' ' ' ASP . . . -93.21 147.53 33.95 Favored Pre-proline 0 N--CA 1.45 -0.467 0 O-C-N 125.645 1.84 . . . . 0.0 114.414 -178.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -57.43 154.15 37.16 Favored 'Trans proline' 0 N--CA 1.449 -1.145 1 C-N-CA 127.224 5.283 . . . . 0.0 114.584 152.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 34.2 t -140.28 176.57 8.66 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 121.765 2.075 . . . . 0.0 113.579 -178.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . 0.296 . . -65.88 -48.23 72.21 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 129.935 3.294 . . . . 0.0 115.959 -173.223 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.0 mp0 -54.71 -28.18 46.12 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 111.231 -2.713 . . . . 0.0 113.458 166.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 31.4 m-70 -133.2 7.48 3.94 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-O 125.518 2.58 . . . . 0.0 112.928 -148.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . 0.268 29.2 t -125.46 114.04 18.29 Favored 'General case' 0 N--CA 1.45 -0.468 0 O-C-N 116.35 -3.969 . . . . 0.0 107.478 169.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . 0.265 75.6 m-85 -130.62 160.98 32.61 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 129.192 2.997 . . . . 0.0 108.195 174.449 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -137.85 151.16 47.79 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 127.63 2.372 . . . . 0.0 115.344 -169.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -154.39 137.14 15.26 Favored 'General case' 0 N--CA 1.452 -0.363 1 O-C-N 116.023 -4.173 . . . . 0.0 114.787 -165.589 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.36 -175.09 19.76 Favored Glycine 0 C--O 1.222 -0.636 0 C-N-CA 126.412 1.958 . . . . 0.0 108.514 160.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.2 tt0 -68.6 -22.78 64.43 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-O 114.725 -2.559 . . . . 0.0 113.714 -158.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -56.25 -0.14 0.17 Allowed Glycine 0 N--CA 1.443 -0.841 0 CA-C-O 115.247 -2.974 . . . . 0.0 117.829 161.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 23.8 mt -121.72 24.27 9.8 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 127.658 2.383 . . . . 0.0 114.729 168.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.8 t -142.96 -47.03 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 CA-C-O 114.976 -2.44 . . . . 0.0 107.7 -172.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 28.4 ttmt -172.47 139.54 0.99 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 115.36 -2.257 . . . . 0.0 112.279 -177.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 34.2 t -144.97 142.45 22.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 115.168 -2.348 . . . . 0.0 113.938 -166.384 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.427 ' HB2' ' HB3' ' A' ' 32' ' ' ALA 0.278 1.2 m-85 -129.6 177.53 7.15 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 125.381 1.676 . . . . 0.0 114.413 -166.283 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -94.86 -37.89 10.99 Favored 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 116.515 2.043 . . . . 0.0 116.515 -178.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 55.9 m-80 -102.52 19.48 18.9 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 115.975 1.843 . . . . 0.0 115.975 165.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.427 ' HB3' ' HB2' ' A' ' 29' ' ' PHE . . . -139.3 92.72 10.42 Favored Pre-proline 0 N--CA 1.455 -0.19 0 C-N-CA 126.1 1.76 . . . . 0.0 106.57 171.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . 0.324 74.9 Cg_exo -43.71 119.84 2.04 Favored 'Trans proline' 0 N--CA 1.449 -1.134 1 C-N-CA 129.854 7.036 . . . . 0.0 112.019 148.309 . . . . . . . . 3 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.403 ' O ' ' HA ' ' A' ' 82' ' ' VAL . . . -96.81 150.81 20.3 Favored 'General case' 0 N--CA 1.45 -0.457 0 C-N-CA 128.504 2.722 . . . . 0.0 111.116 -178.477 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -121.54 137.73 54.61 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-O 115.119 -2.372 . . . . 0.0 114.363 -173.109 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -154.53 172.17 18.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 CA-C-N 125.202 3.637 . . . . 0.0 107.723 164.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 55.5 m -138.0 129.6 28.09 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-O 115.947 -1.977 . . . . 0.0 111.533 -157.044 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 16.1 mt -89.57 124.01 42.07 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 O-C-N 125.928 2.018 . . . . 0.0 107.114 171.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.277 39.2 p90 -99.26 115.95 30.32 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 128.471 2.709 . . . . 0.0 112.232 170.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -116.46 129.74 56.38 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-O 123.716 1.722 . . . . 0.0 110.112 -161.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.6 t -125.03 151.41 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 C-N-CA 126.934 2.094 . . . . 0.0 113.816 163.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.411 ' HA ' ' O ' ' A' ' 12' ' ' ALA . 8.9 p30 -77.05 -72.56 0.34 Allowed 'General case' 0 N--CA 1.443 -0.784 0 CA-C-O 125.193 2.425 . . . . 0.0 116.464 170.607 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 16.0 p -159.54 -28.24 0.07 Allowed 'General case' 0 CA--C 1.517 -0.293 1 C-N-CA 133.774 4.829 . . . . 0.0 112.239 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . 0.393 84.3 mttt -94.4 13.92 22.22 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 123.015 2.643 . . . . 0.0 115.89 -170.414 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 79.8 -33.72 2.13 Favored Glycine 0 CA--C 1.523 0.556 0 O-C-N 118.164 -2.835 . . . . 0.0 112.542 164.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 71.1 t -54.99 133.41 18.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 1 CA-C-N 125.402 4.601 . . . . 0.0 112.22 155.541 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.53 166.74 0.05 OUTLIER 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 117.399 2.37 . . . . 0.0 117.399 169.43 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 8.4 mmm180 -53.86 120.03 5.77 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 176.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 34.8 p -88.19 -4.82 58.67 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 125.077 1.351 . . . . 0.0 110.914 -160.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -165.19 160.47 18.59 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 127.83 2.452 . . . . 0.0 108.998 -169.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -106.59 -162.38 22.38 Favored Glycine 0 N--CA 1.444 -0.826 0 O-C-N 126.839 2.587 . . . . 0.0 116.641 -158.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 48.91 44.07 31.36 Favored Glycine 0 C--O 1.222 -0.616 0 C-N-CA 128.359 2.885 . . . . 0.0 113.957 174.764 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -78.02 141.06 62.6 Favored Pre-proline 0 N--CA 1.451 -0.395 0 O-C-N 119.347 -2.266 . . . . 0.0 109.538 159.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -90.92 132.24 1.57 Allowed 'Trans proline' 0 N--CA 1.442 -1.55 0 N-CA-C 121.234 3.513 . . . . 0.0 121.234 -171.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -136.68 149.72 48.08 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 113.053 0.76 . . . . 0.0 113.053 -151.083 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -134.4 145.23 48.73 Favored 'General case' 0 N--CA 1.442 -0.836 0 O-C-N 127.73 3.144 . . . . 0.0 106.457 168.265 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 40.6 t -126.46 99.47 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 102.598 -3.112 . . . . 0.0 102.598 163.46 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -109.57 137.0 48.04 Favored 'General case' 0 N--CA 1.442 -0.842 0 O-C-N 126.253 2.22 . . . . 0.0 113.662 -171.247 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 84.2 mt -140.21 148.33 22.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 114.996 1.48 . . . . 0.0 114.996 -157.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.6 m120 -122.26 144.4 49.01 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 127.257 2.223 . . . . 0.0 107.512 166.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -124.59 -163.92 11.79 Favored Glycine 0 C--N 1.337 0.632 0 C-N-CA 127.272 2.368 . . . . 0.0 109.302 161.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo . . . . . 0 N--CA 1.448 -1.147 1 C-N-CA 129.824 7.016 . . . . 0.0 116.322 178.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.8 t . . . . . 0 N--CA 1.448 -0.55 0 CA-C-O 122.272 1.034 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 55.8 t -132.6 155.57 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 N-CA-C 115.515 1.672 . . . . 0.0 115.515 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.254 6.4 p-10 -129.87 123.38 30.67 Favored 'General case' 0 N--CA 1.44 -0.944 1 CA-C-O 128.993 4.235 . . . . 0.0 108.7 168.582 . . . . . . . . 3 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.21 131.17 34.3 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-O 127.459 3.504 . . . . 0.0 110.486 -178.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 14.5 mptt -91.13 119.91 31.64 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 112.696 -2.047 . . . . 0.0 114.196 -166.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.0 t -100.29 144.92 11.8 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.371 0 C-N-CA 130.421 3.488 . . . . 0.0 112.098 -169.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . 0.26 42.3 m -154.3 136.87 15.11 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 127.233 3.397 . . . . 0.0 111.465 170.027 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.477 ' HA ' ' CD1' ' A' ' 79' ' ' TYR . 39.7 t0 -62.04 118.23 7.03 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 131.076 3.75 . . . . 0.0 109.164 179.101 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -80.04 -6.34 57.44 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-O 116.434 -1.746 . . . . 0.0 115.207 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.258 10.8 t-20 60.29 30.51 19.9 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 127.653 3.597 . . . . 0.0 114.693 -176.043 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 18.1 p30 -138.28 -1.18 1.95 Allowed 'General case' 0 C--O 1.238 0.46 0 O-C-N 117.084 -3.51 . . . . 0.0 119.116 174.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 104.92 1.51 42.31 Favored Glycine 0 CA--C 1.521 0.449 0 CA-C-O 116.482 -2.288 . . . . 0.0 118.44 -163.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 44.1 p -126.32 171.64 10.79 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 127.543 2.337 . . . . 0.0 111.635 177.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.477 ' CD1' ' HA ' ' A' ' 73' ' ' ASP . 46.3 m-85 -144.95 118.84 9.3 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-O 115.605 -2.141 . . . . 0.0 109.267 178.221 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.71 136.75 24.83 Favored Glycine 0 CA--C 1.524 0.629 1 C-N-CA 130.991 4.139 . . . . 0.0 111.239 175.302 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.0 t -135.29 126.63 45.76 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 CA-C-O 128.131 3.824 . . . . 0.0 107.85 -177.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.403 ' HA ' ' O ' ' A' ' 34' ' ' ALA . 3.7 p -122.11 132.15 71.62 Favored 'Isoleucine or valine' 0 C--O 1.236 0.37 0 O-C-N 118.772 -2.455 . . . . 0.0 114.021 178.149 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -158.15 168.65 26.47 Favored 'General case' 0 C--O 1.221 -0.414 0 N-CA-C 117.76 2.504 . . . . 0.0 117.76 173.084 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.427 31.9 p30 -133.7 151.82 51.73 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 123.673 1.701 . . . . 0.0 114.236 -173.187 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -119.92 118.41 31.74 Favored Pre-proline 0 N--CA 1.445 -0.682 0 O-C-N 119.867 -1.771 . . . . 0.0 109.204 -173.117 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.262 29.0 Cg_endo -83.01 4.71 6.91 Favored 'Trans proline' 0 N--CA 1.447 -1.232 1 C-N-CA 128.225 5.95 . . . . 0.0 108.756 -178.793 . . . . . . . . 3 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.9 m -132.05 138.55 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 N-CA-C 120.399 3.481 . . . . 0.0 120.399 -167.281 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -54.15 118.87 4.4 Favored 'General case' 0 N--CA 1.449 -0.512 0 O-C-N 120.157 -1.589 . . . . 0.0 107.246 137.252 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 159.96 -135.39 4.07 Favored Glycine 0 C--N 1.331 0.296 0 CA-C-N 120.334 1.425 . . . . 0.0 115.038 172.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 -141.36 138.87 33.35 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 127.579 2.351 . . . . 0.0 113.767 177.149 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 -99.61 149.12 23.6 Favored 'General case' 0 C--O 1.222 -0.376 0 C-N-CA 126.479 1.912 . . . . 0.0 112.52 168.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -137.1 114.99 11.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 103.713 -2.699 . . . . 0.0 103.713 -164.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.2 t -114.56 126.01 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 CA-C-N 111.186 -2.734 . . . . 0.0 109.71 -153.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.0 t30 -138.69 118.34 13.08 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 123.874 1.797 . . . . 0.0 106.651 -172.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 54.6 t -116.74 142.77 29.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 O-C-N 118.079 -2.888 . . . . 0.0 112.386 -178.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 16.1 p -150.1 151.83 33.8 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 117.175 2.287 . . . . 0.0 117.175 -169.314 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 11.2 mp -135.08 87.53 2.34 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 102.861 -3.015 . . . . 0.0 102.861 -137.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 18.6 ttm-85 59.41 25.01 13.68 Favored 'General case' 0 N--CA 1.45 -0.466 0 O-C-N 117.322 -3.361 . . . . 0.0 108.737 -158.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 81.51 6.28 89.3 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-O 116.906 -2.052 . . . . 0.0 116.504 -175.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -76.0 120.9 83.74 Favored Pre-proline 0 N--CA 1.445 -0.722 0 O-C-N 125.135 1.138 . . . . 0.0 111.776 162.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -81.9 174.21 10.42 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 CA-C-N 121.661 1.629 . . . . 0.0 110.275 178.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . 0.261 27.8 pt -138.99 174.32 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 O-C-N 125.921 2.013 . . . . 0.0 113.949 -164.311 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 18.7 ptpt -72.28 166.68 21.97 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 127.895 2.478 . . . . 0.0 113.067 172.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 25.9 m120 50.59 32.23 6.56 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 123.173 1.464 . . . . 0.0 107.71 -179.089 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 14.6 mmt -143.31 134.11 12.43 Favored Pre-proline 0 N--CA 1.448 -0.557 1 O-C-N 115.029 -4.794 . . . . 0.0 107.661 176.42 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -86.02 171.88 39.61 Favored 'Cis proline' 0 N--CA 1.449 -1.117 0 CA-C-N 121.563 1.594 . . . . 0.0 109.853 13.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 19.3 pt -144.33 164.69 13.78 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-O 115.055 -2.402 . . . . 0.0 115.272 -178.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -126.7 136.04 51.92 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 124.659 3.39 . . . . 0.0 113.61 -166.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 3.3 t -128.57 140.73 48.43 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 C-N-CA 129.151 2.98 . . . . 0.0 114.682 -173.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 13.2 tppt? -74.74 142.64 44.34 Favored 'General case' 0 N--CA 1.445 -0.722 0 O-C-N 123.588 0.555 . . . . 0.0 111.191 178.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 69.4 m -132.06 140.77 48.98 Favored 'General case' 0 N--CA 1.452 -0.331 0 N-CA-C 115.178 1.547 . . . . 0.0 115.178 177.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 10.4 tp -149.08 135.85 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 CA-C-O 117.33 -1.319 . . . . 0.0 112.421 170.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.45 39.59 0.88 Allowed 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 123.009 2.64 . . . . 0.0 116.176 -164.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.341 0.85 0 O-C-N 126.056 2.097 . . . . 0.0 113.468 162.486 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo . . . . . 0 N--CA 1.453 -0.912 0 N-CA-C 117.296 1.998 . . . . 0.0 117.296 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -97.17 143.07 25.5 Favored Pre-proline 0 CA--C 1.519 -0.221 0 N-CA-C 118.308 2.707 . . . . 0.0 118.308 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -71.43 143.18 42.43 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 124.182 3.254 . . . . 0.0 109.839 166.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.6 m -123.25 168.76 12.04 Favored 'General case' 0 CA--C 1.516 -0.344 0 O-C-N 127.321 2.888 . . . . 0.0 111.774 -165.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.02 -41.09 82.68 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 115.874 1.805 . . . . 0.0 115.874 -174.185 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 56.4 mp0 -68.2 -16.94 64.18 Favored 'General case' 0 C--O 1.22 -0.453 0 C-N-CA 127.39 2.276 . . . . 0.0 112.873 173.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 86.1 m-70 -127.7 13.29 6.92 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 120.91 -1.119 . . . . 0.0 110.898 -154.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 9.1 t -135.45 122.82 21.85 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-O 122.913 1.339 . . . . 0.0 111.391 169.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -152.39 154.79 36.3 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 128.792 2.837 . . . . 0.0 112.032 -172.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -138.51 162.42 34.55 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 120.066 1.303 . . . . 0.0 108.415 -164.01 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -146.76 132.0 18.45 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 127.316 2.247 . . . . 0.0 108.202 -170.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 139.17 -157.36 24.9 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 117.196 1.639 . . . . 0.0 117.196 145.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . 0.258 39.1 mt-10 -55.87 -41.72 74.82 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 119.375 3.102 . . . . 0.0 119.375 -175.642 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -67.7 2.82 5.66 Favored Glycine 0 CA--C 1.523 0.578 0 C-N-CA 127.829 2.633 . . . . 0.0 113.944 168.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . 0.334 20.9 mt -108.11 1.04 22.0 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 117.45 2.389 . . . . 0.0 117.45 155.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 72.9 t -119.8 -45.82 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 O-C-N 119.393 -2.067 . . . . 0.0 113.517 -174.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.262 31.5 ttmt -159.15 134.7 8.56 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 115.843 1.794 . . . . 0.0 115.843 175.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.7 t -135.65 139.62 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 106.715 -1.587 . . . . 0.0 106.715 -173.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.406 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 11.3 m-85 -121.25 176.64 5.52 Favored 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 128.964 2.906 . . . . 0.0 116.262 -169.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -80.25 -54.3 5.86 Favored 'General case' 0 N--CA 1.441 -0.894 0 O-C-N 120.011 -1.681 . . . . 0.0 113.058 178.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 -103.72 4.71 35.61 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 129.59 3.156 . . . . 0.0 114.478 177.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . 0.304 . . -110.39 84.07 3.63 Favored Pre-proline 0 N--CA 1.448 -0.537 0 CA-C-O 113.328 -3.225 . . . . 0.0 106.262 159.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -59.04 120.79 8.87 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 CA-C-N 123.816 2.399 . . . . 0.0 110.525 164.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -91.13 154.76 19.13 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 112.506 -2.133 . . . . 0.0 108.22 -175.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -120.36 165.98 14.16 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 109.712 -3.404 . . . . 0.0 112.49 175.364 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 10.7 p90 -162.16 173.5 14.22 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 128.566 2.746 . . . . 0.0 110.704 163.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 98.8 m -130.28 126.47 37.32 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 126.927 2.091 . . . . 0.0 115.652 -163.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 6.5 mt -92.34 105.14 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 C-N-CA 125.837 1.655 . . . . 0.0 108.018 178.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.26 1.3 p90 -72.59 132.12 43.35 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.348 1.459 . . . . 0.0 112.04 167.055 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -130.98 134.7 46.96 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 118.272 -2.767 . . . . 0.0 113.133 -170.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.2 t -131.45 150.82 34.63 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.396 0 CA-C-O 125.882 2.753 . . . . 0.0 103.78 169.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.0 p30 -69.73 -70.8 0.26 Allowed 'General case' 0 N--CA 1.443 -0.806 1 O-C-N 115.935 -4.228 . . . . 0.0 112.517 169.063 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 24.3 p -162.68 -9.82 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.418 1 C-N-CA 135.045 5.338 . . . . 0.0 114.707 -179.77 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 26.5 mtpp -122.18 34.54 5.14 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 122.393 2.36 . . . . 0.0 111.328 -163.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.82 -58.13 5.03 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 118.853 2.301 . . . . 0.0 118.853 160.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 62.1 t -57.85 132.33 22.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 O-C-N 126.271 1.806 . . . . 0.0 111.007 163.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -45.59 161.8 0.04 OUTLIER 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 125.276 2.465 . . . . 0.0 116.849 170.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 9.5 mmm180 -55.37 110.38 0.68 Allowed 'General case' 0 CA--C 1.518 -0.263 0 O-C-N 117.069 -3.519 . . . . 0.0 110.467 174.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.1 p -76.07 5.47 6.66 Favored 'General case' 0 N--CA 1.449 -0.519 1 C-N-CA 136.483 5.913 . . . . 0.0 117.092 -179.085 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -170.14 168.19 8.42 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 123.797 1.761 . . . . 0.0 107.85 169.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -123.86 -162.86 11.57 Favored Glycine 0 C--N 1.344 1.002 0 O-C-N 117.829 -3.044 . . . . 0.0 111.632 -146.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.66 21.21 74.65 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 122.059 3.584 . . . . 0.0 122.059 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 41.9 m-20 -73.39 152.79 90.04 Favored Pre-proline 0 C--O 1.223 -0.31 0 CA-C-N 118.59 1.195 . . . . 0.0 111.925 174.073 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -101.29 131.55 0.14 Allowed 'Trans proline' 0 N--CA 1.457 -0.66 0 CA-C-O 126.001 2.417 . . . . 0.0 112.313 -174.423 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -136.7 155.68 49.55 Favored 'General case' 0 N--CA 1.444 -0.769 0 CA-C-N 111.478 -2.601 . . . . 0.0 110.262 -172.4 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.432 ' O ' ' HA ' ' A' ' 95' ' ' VAL . 34.5 tt0 -139.39 141.43 37.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 125.203 2.43 . . . . 0.0 111.425 175.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 46.6 t -133.98 76.86 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.693 0 C-N-CA 128.195 2.598 . . . . 0.0 104.916 -175.553 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -99.04 141.44 31.79 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 125.872 2.749 . . . . 0.0 107.812 -170.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . 0.437 ' HA ' ' O ' ' A' ' 92' ' ' ASN . 54.5 mt -137.04 139.96 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-N 111.046 -2.797 . . . . 0.0 114.965 -159.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 12.2 m120 -124.59 117.09 23.54 Favored 'General case' 0 C--O 1.223 -0.312 0 C-N-CA 126.983 2.113 . . . . 0.0 106.471 176.02 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -78.98 -159.19 14.28 Favored Glycine 0 N--CA 1.445 -0.766 0 CA-C-O 114.571 -3.35 . . . . 0.0 115.845 161.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_endo . . . . . 0 N--CA 1.446 -1.298 1 C-N-CA 127.282 5.321 . . . . 0.0 110.63 162.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 51.8 t . . . . . 0 C--O 1.234 0.271 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 68.2 t -133.29 159.87 42.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 CA-C-N 113.162 -1.835 . . . . 0.0 109.456 -165.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.264 1.1 p30 -133.59 142.95 48.37 Favored 'General case' 0 N--CA 1.448 -0.55 0 O-C-N 120.24 -1.537 . . . . 0.0 109.875 157.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.3 147.08 24.96 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 125.519 1.762 . . . . 0.0 113.632 162.402 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -99.16 113.89 26.37 Favored 'General case' 0 CA--C 1.511 -0.525 0 C-N-CA 127.599 2.36 . . . . 0.0 108.36 -158.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.6 t -91.83 129.49 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 O-C-N 124.42 1.075 . . . . 0.0 111.079 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.7 m -136.87 140.67 42.54 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 102.34 -3.207 . . . . 0.0 102.34 -178.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 57.9 t0 -72.31 124.2 24.6 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 129.199 3.0 . . . . 0.0 107.603 -172.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -82.14 -1.5 49.06 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 116.343 -1.789 . . . . 0.0 115.331 169.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.395 1.5 m120 60.57 32.58 20.44 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-N 121.449 1.931 . . . . 0.0 115.691 176.748 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 25.7 p30 -144.5 6.1 1.25 Allowed 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 113.032 -1.894 . . . . 0.0 112.409 -172.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 89.8 7.27 68.84 Favored Glycine 0 C--N 1.333 0.414 0 CA-C-N 122.58 2.445 . . . . 0.0 115.653 -166.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.9 p -141.16 158.31 44.08 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 129.25 3.02 . . . . 0.0 114.208 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 23.2 m-85 -132.04 126.65 34.4 Favored 'General case' 0 N--CA 1.449 -0.501 0 O-C-N 120.215 -1.553 . . . . 0.0 107.478 -169.351 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -89.17 147.82 19.82 Favored Glycine 0 C--N 1.335 0.5 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.3 t -131.54 133.83 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 CA-C-N 110.235 -2.982 . . . . 0.0 114.088 -174.027 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 13.7 p -137.54 131.39 43.93 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 CA-C-N 120.781 1.628 . . . . 0.0 110.359 -169.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -161.86 151.67 16.58 Favored 'General case' 0 N--CA 1.452 -0.353 1 O-C-N 115.95 -4.219 . . . . 0.0 111.582 176.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 26.0 p30 -116.93 151.66 36.17 Favored 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 130.92 3.688 . . . . 0.0 111.182 -172.412 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . 0.312 . . -130.44 104.91 16.04 Favored Pre-proline 0 N--CA 1.441 -0.876 0 N-CA-C 118.87 2.915 . . . . 0.0 118.87 -170.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -93.21 24.44 0.45 Allowed 'Trans proline' 0 N--CA 1.45 -1.044 0 C-N-CA 124.488 3.459 . . . . 0.0 112.76 -174.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.5 m -140.04 134.87 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 117.145 2.276 . . . . 0.0 117.145 -179.148 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . 0.284 38.5 tt0 -56.43 105.15 0.18 Allowed 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.705 144.016 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 162.41 -139.99 6.28 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 117.97 -1.461 . . . . 0.0 110.876 176.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 85.0 m-20 -143.24 137.97 29.3 Favored 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 105.848 -1.908 . . . . 0.0 105.848 -170.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -90.04 145.91 24.73 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 111.435 -2.62 . . . . 0.0 113.143 156.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.437 ' O ' ' HA ' ' A' ' 59' ' ' ILE . 26.1 t-20 -113.0 116.97 30.78 Favored 'General case' 0 N--CA 1.442 -0.828 0 O-C-N 128.566 3.666 . . . . 0.0 112.232 172.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 43.5 t -111.91 131.18 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 CA-C-O 126.102 2.858 . . . . 0.0 113.105 -168.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 21.5 t-20 -131.96 131.68 42.83 Favored 'General case' 0 N--CA 1.445 -0.694 0 O-C-N 119.157 -2.214 . . . . 0.0 111.302 176.309 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.432 ' HA ' ' O ' ' A' ' 56' ' ' GLU . 57.7 t -118.52 129.95 74.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 O-C-N 124.159 0.912 . . . . 0.0 112.718 -174.44 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 46.9 p -139.6 153.19 47.31 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -172.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 3.2 mp -126.16 105.84 9.14 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 105.043 -2.206 . . . . 0.0 105.043 -142.149 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 44.4 ttm-85 46.93 42.22 11.95 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 125.997 2.808 . . . . 0.0 108.937 -153.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 57.93 14.22 16.16 Favored Glycine 0 CA--C 1.528 0.882 0 O-C-N 116.765 -3.71 . . . . 0.0 115.798 -177.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 76.8 m-20 -95.32 157.37 36.43 Favored Pre-proline 0 N--CA 1.449 -0.485 0 C-N-CA 117.6 -1.64 . . . . 0.0 115.325 168.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -79.91 168.38 19.18 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 CA-C-O 125.82 2.342 . . . . 0.0 111.836 -174.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 43.5 pt -147.02 -177.52 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-O 126.038 2.828 . . . . 0.0 113.733 -178.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 17.2 ptmt -84.71 168.51 15.17 Favored 'General case' 0 N--CA 1.446 -0.669 0 O-C-N 116.405 -3.934 . . . . 0.0 110.936 -176.337 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 17.4 m120 54.77 29.46 11.85 Favored 'General case' 0 N--CA 1.446 -0.674 0 O-C-N 120.386 -1.446 . . . . 0.0 114.536 175.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 11.1 mmt -143.18 150.55 52.66 Favored Pre-proline 0 CA--C 1.518 -0.28 0 CA-C-O 113.351 -3.214 . . . . 0.0 111.73 177.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.43 175.82 34.03 Favored 'Cis proline' 0 N--CA 1.446 -1.316 0 CA-C-N 123.809 2.396 . . . . 0.0 113.199 -0.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 14.0 pt -144.56 -176.04 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 170.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -135.12 148.52 49.81 Favored 'General case' 0 N--CA 1.45 -0.463 1 O-C-N 114.745 -4.972 . . . . 0.0 112.294 -172.862 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 99.5 t -143.66 128.81 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.909 0 N-CA-C 105.478 -2.045 . . . . 0.0 105.478 -171.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 69.5 tttt -70.63 132.19 45.07 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 112.669 -2.059 . . . . 0.0 112.221 -176.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 81.6 m -113.08 126.82 55.89 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.208 1.403 . . . . 0.0 109.548 -178.257 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.406 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 2.8 tp -135.36 132.14 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 O-C-N 119.86 -1.775 . . . . 0.0 108.897 155.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -72.75 55.23 0.38 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 130.377 3.471 . . . . 0.0 114.028 -163.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.452 0 C-N-CA 128.021 2.724 . . . . 0.0 115.692 176.338 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo . . . . . 0 N--CA 1.453 -0.907 0 CA-C-O 122.382 0.909 . . . . 0.0 111.586 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -82.08 134.12 49.98 Favored Pre-proline 0 N--CA 1.445 -0.686 0 C-N-CA 127.135 2.174 . . . . 0.0 113.725 175.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -63.86 158.8 45.05 Favored 'Trans proline' 0 N--CA 1.443 -1.476 1 C-N-CA 127.015 5.143 . . . . 0.0 111.394 172.584 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -135.97 155.97 49.46 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 125.283 1.433 . . . . 0.0 111.791 -163.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -75.33 -33.58 61.15 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 117.191 2.293 . . . . 0.0 117.191 -172.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -57.77 -14.39 5.75 Favored 'General case' 0 N--CA 1.44 -0.932 1 O-C-N 114.574 -5.079 . . . . 0.0 116.756 153.475 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 48.1 m-70 -135.14 18.64 3.43 Favored 'General case' 0 N--CA 1.444 -0.733 0 O-C-N 125.956 2.035 . . . . 0.0 114.679 -159.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.9 t -138.3 120.16 15.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 O-C-N 117.152 -3.468 . . . . 0.0 107.697 171.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . 0.442 ' O ' ' CD2' ' A' ' 39' ' ' PHE . 23.8 m-85 -153.78 150.64 28.68 Favored 'General case' 0 N--CA 1.455 -0.213 0 CA-C-O 114.441 -2.695 . . . . 0.0 111.569 -170.244 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.409 ' HB3' ' HA ' ' A' ' 38' ' ' ILE . . . -141.28 158.37 43.98 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 118.195 2.665 . . . . 0.0 118.195 -161.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -153.62 141.37 20.03 Favored 'General case' 0 CA--C 1.518 -0.269 0 C-N-CA 126.411 1.884 . . . . 0.0 112.356 -159.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 132.66 157.35 8.49 Favored Glycine 0 N--CA 1.447 -0.614 1 C-N-CA 130.874 4.083 . . . . 0.0 116.282 -174.272 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -63.46 -20.18 65.36 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 118.661 2.837 . . . . 0.0 118.661 -173.264 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.79 8.39 0.55 Allowed Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 128.821 3.105 . . . . 0.0 117.088 162.015 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 75.9 mt -108.75 10.25 26.8 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-O 116.294 -1.812 . . . . 0.0 109.747 160.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 91.7 t -139.47 -29.96 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 CA-C-N 121.959 2.163 . . . . 0.0 113.213 -174.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 26.9 ttmt -164.5 138.21 5.17 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 119.508 -1.995 . . . . 0.0 107.508 171.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 t -132.33 136.22 56.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.458 0 O-C-N 126.387 2.305 . . . . 0.0 109.699 -174.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -127.86 -172.24 2.63 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 122.148 2.249 . . . . 0.0 112.592 -163.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -88.01 -54.74 4.07 Favored 'General case' 0 N--CA 1.448 -0.569 0 O-C-N 117.832 -3.042 . . . . 0.0 115.928 177.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 69.0 m-80 -97.91 8.28 44.99 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 115.64 1.718 . . . . 0.0 115.64 174.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . 0.259 . . -126.27 80.96 68.0 Favored Pre-proline 0 CA--C 1.516 -0.334 0 C-N-CA 125.614 1.566 . . . . 0.0 111.468 174.325 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -61.61 123.63 13.08 Favored 'Trans proline' 0 N--CA 1.445 -1.334 0 CA-C-O 122.903 1.126 . . . . 0.0 111.649 176.257 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.63 150.72 23.71 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 112.689 -2.05 . . . . 0.0 111.483 -164.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -129.66 153.89 47.67 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 127.514 2.325 . . . . 0.0 114.536 -162.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -164.48 158.84 18.75 Favored 'General case' 0 N--CA 1.446 -0.66 0 O-C-N 121.09 -1.006 . . . . 0.0 111.491 172.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 7.2 m -129.56 115.11 16.93 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 113.36 -1.745 . . . . 0.0 110.529 -154.349 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.409 ' HA ' ' HB3' ' A' ' 20' ' ' ALA . 15.5 mt -82.2 98.77 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 O-C-N 128.553 3.658 . . . . 0.0 108.979 178.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.442 ' CD2' ' O ' ' A' ' 19' ' ' TYR 0.328 47.3 p90 -76.94 105.12 7.81 Favored 'General case' 0 N--CA 1.451 -0.424 0 O-C-N 118.339 -2.726 . . . . 0.0 113.327 170.915 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . 0.264 . . -90.03 134.27 34.34 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 127.339 2.256 . . . . 0.0 116.674 -176.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 46.3 t -133.27 143.34 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 C-N-CA 126.776 2.03 . . . . 0.0 106.673 160.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.09 -81.22 0.02 OUTLIER 'General case' 0 N--CA 1.443 -0.795 0 O-C-N 117.846 -3.034 . . . . 0.0 114.476 161.611 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 19.1 p -161.32 -41.12 0.04 OUTLIER 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 128.436 2.695 . . . . 0.0 111.393 -169.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -90.62 52.16 2.14 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 121.927 2.149 . . . . 0.0 113.254 -167.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 71.81 -66.2 1.12 Allowed Glycine 0 C--N 1.341 0.848 0 CA-C-O 118.249 -1.306 . . . . 0.0 115.782 174.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 70.8 t -56.38 129.51 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 O-C-N 125.54 1.377 . . . . 0.0 111.974 178.303 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -36.91 164.83 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 130.284 3.434 . . . . 0.0 116.192 163.378 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . 0.254 7.3 mmm180 -66.16 101.67 0.74 Allowed 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 114.611 1.337 . . . . 0.0 114.611 175.232 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 61.8 p -79.37 2.76 20.48 Favored 'General case' 0 N--CA 1.449 -0.515 1 C-N-CA 133.464 4.705 . . . . 0.0 114.741 178.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -155.83 -174.72 5.08 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 130.014 3.326 . . . . 0.0 113.721 158.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -154.04 -176.45 26.41 Favored Glycine 0 CA--C 1.521 0.425 0 CA-C-O 124.741 2.301 . . . . 0.0 115.797 -141.68 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.71 14.35 67.31 Favored Glycine 0 C--N 1.336 0.549 0 O-C-N 117.462 -3.375 . . . . 0.0 112.789 -170.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -60.69 123.55 74.95 Favored Pre-proline 0 N--CA 1.446 -0.672 0 CA-C-N 123.7 3.75 . . . . 0.0 106.98 175.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -83.85 153.77 13.17 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 CA-C-N 122.468 1.917 . . . . 0.0 116.294 -162.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -142.95 156.29 44.86 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-O 126.35 2.976 . . . . 0.0 110.14 -157.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -144.11 153.25 41.96 Favored 'General case' 0 N--CA 1.448 -0.53 0 O-C-N 118.671 -2.518 . . . . 0.0 109.989 161.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 92.0 t -133.81 108.54 11.86 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.96 0 C-N-CA 129.789 3.235 . . . . 0.0 104.052 169.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -117.12 133.87 55.47 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 126.833 2.053 . . . . 0.0 112.287 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . 0.275 3.4 mp -124.06 144.9 32.24 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 C-N-CA 125.848 1.659 . . . . 0.0 113.94 -167.405 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 53.0 m-80 -118.23 140.41 49.84 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 114.217 -2.802 . . . . 0.0 110.061 174.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.47 -169.51 14.31 Favored Glycine 0 CA--C 1.526 0.774 0 CA-C-N 121.558 1.981 . . . . 0.0 111.68 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . 0.304 19.2 Cg_endo . . . . . 0 N--CA 1.451 -1.027 0 N-CA-C 114.96 1.1 . . . . 0.0 114.96 -179.107 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 51.5 t . . . . . 0 N--CA 1.445 -0.718 0 N-CA-C 105.432 -2.062 . . . . 0.0 105.432 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 9.5 t -133.51 150.7 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.155 0 CA-C-N 113.193 -1.821 . . . . 0.0 106.843 -165.287 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.269 2.4 p30 -117.74 137.8 52.46 Favored 'General case' 0 N--CA 1.439 -0.985 0 O-C-N 118.979 -2.326 . . . . 0.0 112.717 148.492 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.21 158.97 22.09 Favored 'General case' 0 N--CA 1.444 -0.738 0 O-C-N 126.277 2.235 . . . . 0.0 112.439 -174.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 38.9 mmtm -90.33 103.13 15.84 Favored 'General case' 0 N--CA 1.447 -0.609 0 O-C-N 120.265 -1.522 . . . . 0.0 112.719 -172.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 54.9 t -71.27 135.48 27.9 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.662 172.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 54.6 m -123.91 137.87 54.56 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 124.735 1.214 . . . . 0.0 112.033 162.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 48.5 t0 -78.02 121.38 24.15 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 124.161 1.934 . . . . 0.0 111.94 169.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 -76.2 -7.5 54.98 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 112.228 -2.26 . . . . 0.0 115.088 -177.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 4.7 m120 59.85 25.95 15.1 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 129.655 3.182 . . . . 0.0 114.248 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 42.7 p30 -134.25 -6.84 2.63 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 129.194 2.998 . . . . 0.0 112.903 -175.257 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 103.29 15.6 22.96 Favored Glycine 0 C--N 1.336 0.555 1 C-N-CA 133.41 5.291 . . . . 0.0 114.288 -172.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 27.1 p -140.69 165.24 28.03 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 122.505 3.152 . . . . 0.0 108.791 177.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 67.4 m-85 -135.88 125.12 24.62 Favored 'General case' 0 N--CA 1.447 -0.579 0 N-CA-C 104.823 -2.288 . . . . 0.0 104.823 -166.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -96.68 129.95 10.08 Favored Glycine 0 C--N 1.336 0.575 0 C-N-CA 129.597 3.475 . . . . 0.0 107.165 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.8 t -108.68 128.21 64.58 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 1 CA-C-O 110.811 -4.423 . . . . 0.0 112.892 172.253 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.2 p -127.54 142.27 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 123.915 3.052 . . . . 0.0 115.666 172.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -165.03 160.43 18.93 Favored 'General case' 0 N--CA 1.449 -0.491 0 O-C-N 117.096 -3.502 . . . . 0.0 112.947 -173.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.465 42.5 p30 -137.77 148.32 45.45 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 128.437 2.695 . . . . 0.0 114.347 -168.685 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -125.28 113.08 26.01 Favored Pre-proline 0 N--CA 1.445 -0.708 0 C-N-CA 128.26 2.624 . . . . 0.0 112.025 -171.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.258 59.0 Cg_endo -76.04 12.91 1.37 Allowed 'Trans proline' 0 N--CA 1.441 -1.611 0 O-C-N 125.186 2.15 . . . . 0.0 113.359 177.778 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.8 m -140.62 141.28 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 115.579 1.696 . . . . 0.0 115.579 -151.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -63.96 114.17 3.94 Favored 'General case' 0 N--CA 1.447 -0.625 0 O-C-N 117.329 -3.357 . . . . 0.0 110.119 144.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 163.07 -155.43 26.77 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 125.317 2.621 . . . . 0.0 117.561 -169.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 5.0 t30 -135.81 121.88 20.14 Favored 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 127.278 2.231 . . . . 0.0 107.432 -167.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . 0.25 7.3 m-85 -87.48 143.09 27.39 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 123.298 0.639 . . . . 0.0 112.65 158.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -127.55 123.65 36.3 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 124.376 2.036 . . . . 0.0 107.999 -175.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . 0.344 3.3 t -109.46 135.14 49.31 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 N-CA-C 117.519 2.414 . . . . 0.0 117.519 -164.81 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -136.57 128.51 29.36 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 131.494 3.917 . . . . 0.0 108.373 179.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 58.2 t -118.12 152.59 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 CA-C-O 123.677 1.703 . . . . 0.0 108.374 -173.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.7 p -151.15 152.0 32.74 Favored 'General case' 0 N--CA 1.441 -0.915 0 O-C-N 120.411 -1.431 . . . . 0.0 112.952 -177.085 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 9.4 mp -137.3 94.9 2.99 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 104.351 -2.463 . . . . 0.0 104.351 -153.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . 0.277 25.3 ttm-85 49.2 43.8 22.87 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 112.571 -2.104 . . . . 0.0 110.691 -162.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 74.31 -13.29 4.85 Favored Glycine 0 CA--C 1.522 0.489 0 CA-C-O 114.681 -3.288 . . . . 0.0 116.132 -168.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 72.6 m-20 -74.25 126.83 88.68 Favored Pre-proline 0 N--CA 1.451 -0.398 0 CA-C-N 122.534 3.167 . . . . 0.0 119.072 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -74.29 172.11 16.7 Favored 'Trans proline' 0 N--CA 1.453 -0.885 1 C-N-CA 127.451 5.434 . . . . 0.0 106.863 -177.468 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 27.4 pt -143.87 177.61 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 O-C-N 118.346 -2.721 . . . . 0.0 107.705 -164.388 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 38.4 mttm -80.71 159.81 25.15 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 128.678 2.791 . . . . 0.0 111.191 -169.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 15.2 m120 54.2 43.89 29.93 Favored 'General case' 0 C--O 1.224 -0.285 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 176.25 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 6.9 mmt -138.55 139.52 24.91 Favored Pre-proline 0 N--CA 1.444 -0.728 0 C-N-CA 129.812 3.245 . . . . 0.0 107.956 -163.138 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -79.06 165.05 82.37 Favored 'Cis proline' 0 N--CA 1.447 -1.215 0 CA-C-N 122.78 2.029 . . . . 0.0 109.328 1.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . 0.276 2.2 pp -114.46 159.36 14.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 C-N-CA 125.366 1.466 . . . . 0.0 114.081 171.227 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -122.59 134.44 54.52 Favored 'General case' 0 N--CA 1.449 -0.502 0 O-C-N 118.588 -2.57 . . . . 0.0 111.899 -167.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 1.7 t -129.53 121.36 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-O 125.695 2.664 . . . . 0.0 112.615 -177.252 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -55.72 130.29 42.67 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 112.222 -2.263 . . . . 0.0 114.155 170.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 48.7 m -121.82 153.82 37.85 Favored 'General case' 0 N--CA 1.445 -0.699 0 O-C-N 123.994 0.809 . . . . 0.0 110.461 176.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 10.4 tp -150.52 138.06 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.773 0 C-N-CA 127.602 2.361 . . . . 0.0 113.486 165.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -68.84 43.29 0.04 OUTLIER 'General case' 0 N--CA 1.444 -0.768 1 CA-C-O 129.778 4.609 . . . . 0.0 115.584 -166.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.616 1 O-C-N 114.68 -5.013 . . . . 0.0 112.116 -175.359 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . 0.29 40.3 Cg_endo . . . . . 0 N--CA 1.453 -0.862 0 N-CA-C 118.429 2.434 . . . . 0.0 118.429 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -77.85 129.22 76.93 Favored Pre-proline 0 CA--C 1.516 -0.347 0 N-CA-C 118.433 2.753 . . . . 0.0 118.433 -178.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -62.81 150.6 87.73 Favored 'Trans proline' 0 N--CA 1.448 -1.162 1 C-N-CA 126.027 4.485 . . . . 0.0 110.775 169.84 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.8 t -129.64 152.13 49.49 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 117.159 2.281 . . . . 0.0 117.159 -170.03 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.33 -36.18 79.43 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 120.379 -1.451 . . . . 0.0 113.337 179.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 59.7 mm-40 -54.93 -31.01 59.95 Favored 'General case' 0 C--N 1.349 0.554 0 CA-C-N 124.32 3.236 . . . . 0.0 112.554 163.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 55.0 m-70 -125.23 19.37 8.25 Favored 'General case' 0 N--CA 1.445 -0.688 0 CA-C-O 125.627 2.632 . . . . 0.0 113.711 -154.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 7.1 t -147.38 122.69 10.28 Favored 'General case' 0 C--N 1.347 0.48 1 O-C-N 113.615 -5.678 . . . . 0.0 113.474 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 37.1 m-85 -160.36 151.13 18.7 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-O 116.185 -1.865 . . . . 0.0 110.235 -164.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -131.52 153.23 50.03 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-O 122.565 1.174 . . . . 0.0 109.78 -167.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -159.12 147.96 18.32 Favored 'General case' 0 N--CA 1.447 -0.609 0 C-N-CA 125.93 1.692 . . . . 0.0 110.348 -168.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.84 -179.87 16.02 Favored Glycine 0 C--N 1.338 0.666 0 C-N-CA 129.668 3.509 . . . . 0.0 117.339 175.097 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . 0.588 1.9 tt0 -62.23 -27.57 69.09 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 120.15 3.389 . . . . 0.0 120.15 -168.397 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -61.03 0.13 1.29 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 118.827 2.291 . . . . 0.0 118.827 160.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 49.2 mt -113.85 13.78 18.46 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.493 1.117 . . . . 0.0 111.463 168.205 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.9 t -129.47 -55.47 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 CA-C-O 115.839 -2.029 . . . . 0.0 113.334 178.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -150.16 128.25 11.94 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 116.638 -1.649 . . . . 0.0 111.777 -177.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 52.0 t -137.58 132.24 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 O-C-N 127.855 3.222 . . . . 0.0 113.255 -162.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 5.9 m-85 -126.63 -168.42 1.86 Allowed 'General case' 0 C--N 1.334 -0.065 0 CA-C-O 123.694 1.711 . . . . 0.0 112.453 -164.595 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -100.46 -56.32 2.38 Favored 'General case' 0 N--CA 1.449 -0.514 0 O-C-N 119.133 -2.229 . . . . 0.0 111.358 -166.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 40.0 m-80 -100.08 8.09 44.19 Favored 'General case' 0 N--CA 1.451 -0.403 0 O-C-N 119.027 -2.295 . . . . 0.0 111.678 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -121.22 93.14 48.81 Favored Pre-proline 0 N--CA 1.448 -0.57 0 O-C-N 119.423 -2.048 . . . . 0.0 108.197 167.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.11 128.02 22.87 Favored 'Trans proline' 0 N--CA 1.453 -0.901 1 C-N-CA 127.393 5.395 . . . . 0.0 113.465 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -92.47 152.47 19.66 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 128.257 2.623 . . . . 0.0 117.232 177.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.469 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 29.1 mt-10 -143.32 148.92 37.05 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 128.942 3.901 . . . . 0.0 110.265 -161.166 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 20.7 p90 -168.77 165.75 11.77 Favored 'General case' 0 CA--C 1.518 -0.284 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 -178.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 57.7 m -133.63 122.55 23.63 Favored 'General case' 0 N--CA 1.448 -0.548 0 O-C-N 127.887 3.242 . . . . 0.0 114.173 -155.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 4.0 mt -86.03 101.17 10.0 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-O 114.866 -2.493 . . . . 0.0 105.638 177.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 12.7 p90 -74.58 112.23 10.56 Favored 'General case' 0 N--CA 1.446 -0.634 0 O-C-N 124.917 1.386 . . . . 0.0 112.656 162.086 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . 0.252 . . -102.3 135.13 44.46 Favored 'General case' 0 C--O 1.222 -0.395 0 C-N-CA 126.151 1.78 . . . . 0.0 115.266 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.6 t -125.29 149.17 29.79 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 130.661 3.584 . . . . 0.0 108.961 162.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -74.96 -62.41 1.56 Allowed 'General case' 0 N--CA 1.441 -0.903 0 O-C-N 119.498 -2.001 . . . . 0.0 112.007 173.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 8.2 p -173.99 -25.83 0.01 OUTLIER 'General case' 0 C--O 1.218 -0.574 1 C-N-CA 133.158 4.583 . . . . 0.0 110.349 -173.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 71.4 mmtt -93.67 27.43 2.68 Favored 'General case' 0 N--CA 1.445 -0.691 0 O-C-N 118.529 -2.607 . . . . 0.0 112.311 -167.085 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 62.95 -32.3 0.07 OUTLIER Glycine 0 N--CA 1.444 -0.802 1 N-CA-C 123.404 4.122 . . . . 0.0 123.404 178.428 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 90.2 t -78.4 138.67 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.845 0 CA-C-N 119.196 1.498 . . . . 0.0 111.881 167.232 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -50.83 166.77 0.08 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.901 1.376 . . . . 0.0 113.397 -177.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 11.1 mmm180 -62.29 122.66 16.19 Favored 'General case' 0 C--O 1.22 -0.468 0 CA-C-N 121.947 2.158 . . . . 0.0 113.096 -172.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 72.9 p -100.38 13.49 34.28 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-O 126.756 3.17 . . . . 0.0 113.193 -161.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.8 p30 -159.66 175.14 13.55 Favored 'General case' 0 N--CA 1.45 -0.454 2 C-N-CA 131.861 4.064 . . . . 0.0 109.534 160.021 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -127.5 -178.34 15.28 Favored Glycine 0 C--N 1.343 0.94 0 N-CA-C 118.871 2.308 . . . . 0.0 118.871 -159.093 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.45 20.74 68.46 Favored Glycine 0 C--N 1.346 1.134 0 CA-C-O 114.094 -3.614 . . . . 0.0 110.597 172.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -70.21 145.94 94.11 Favored Pre-proline 0 N--CA 1.445 -0.695 0 CA-C-N 123.807 3.804 . . . . 0.0 112.858 170.357 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -76.08 119.26 5.27 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 N-CA-C 117.307 2.003 . . . . 0.0 117.307 -178.172 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -131.25 165.43 23.4 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-O 124.04 1.876 . . . . 0.0 115.891 168.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -160.64 147.06 15.25 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 113.51 -1.677 . . . . 0.0 110.233 -171.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 2.4 t -131.04 123.48 53.95 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.754 0 C-N-CA 127.984 2.514 . . . . 0.0 106.769 176.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -121.44 131.63 54.27 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 113.927 -1.488 . . . . 0.0 109.023 -170.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.6 mp -132.4 132.86 60.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 -163.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 24.8 m120 -113.78 129.73 56.54 Favored 'General case' 0 N--CA 1.442 -0.841 0 O-C-N 125.396 1.685 . . . . 0.0 108.287 151.451 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -96.75 -164.18 32.77 Favored Glycine 0 C--N 1.345 1.045 0 CA-C-O 123.379 1.544 . . . . 0.0 111.273 151.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . 0.282 84.2 Cg_endo . . . . . 0 N--CA 1.448 -1.171 0 C-N-CA 123.514 2.809 . . . . 0.0 118.379 176.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 87.1 t . . . . . 0 N--CA 1.45 -0.473 0 CA-C-O 116.662 -1.637 . . . . 0.0 107.61 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 87.9 t -135.54 143.84 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 125.922 1.689 . . . . 0.0 108.977 -173.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.319 35.5 t0 -129.52 125.99 37.58 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-O 115.337 -2.268 . . . . 0.0 110.435 175.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.25 162.23 19.24 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 125.453 1.72 . . . . 0.0 114.644 176.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -103.22 123.2 46.28 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 -177.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.5 t -100.68 137.05 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 O-C-N 128.595 3.684 . . . . 0.0 109.905 -175.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . 0.25 53.1 m -134.92 136.54 42.39 Favored 'General case' 0 N--CA 1.445 -0.676 0 O-C-N 117.912 -2.993 . . . . 0.0 109.371 -179.425 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 59.7 t0 -62.66 123.98 19.8 Favored 'General case' 0 N--CA 1.448 -0.559 0 O-C-N 120.497 -1.377 . . . . 0.0 112.004 164.255 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -84.83 -10.41 57.19 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-O 116.377 -1.773 . . . . 0.0 115.264 174.069 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.374 1.4 m120 74.21 36.95 0.63 Allowed 'General case' 0 C--O 1.219 -0.515 0 CA-C-O 115.988 -1.958 . . . . 0.0 113.768 172.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 20.0 p30 -154.58 -10.98 0.13 Allowed 'General case' 0 N--CA 1.449 -0.476 0 O-C-N 126.042 2.089 . . . . 0.0 114.676 -167.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 130.85 -25.72 4.13 Favored Glycine 0 CA--C 1.522 0.511 0 CA-C-N 122.852 2.569 . . . . 0.0 113.63 -158.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 2.8 p -136.81 171.77 14.0 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 118.252 2.686 . . . . 0.0 118.252 -157.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -135.94 113.61 10.98 Favored 'General case' 0 N--CA 1.433 -1.282 0 C-N-CA 126.032 1.733 . . . . 0.0 109.487 -172.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -86.16 146.48 21.13 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-O 124.146 1.97 . . . . 0.0 112.723 176.282 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.469 ' O ' ' HA ' ' A' ' 35' ' ' GLU . 41.0 t -136.4 130.0 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 C-N-CA 128.113 2.565 . . . . 0.0 109.032 -167.805 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 14.7 p -134.34 122.09 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.429 0 C-N-CA 125.836 1.654 . . . . 0.0 110.401 -168.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . 0.257 0.1 OUTLIER -154.44 175.38 13.65 Favored 'General case' 0 N--CA 1.447 -0.597 0 O-C-N 118.975 -2.328 . . . . 0.0 111.91 -177.4 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 5.2 p30 -151.76 162.96 40.17 Favored 'General case' 0 N--CA 1.448 -0.556 1 O-C-N 116.268 -4.02 . . . . 0.0 109.708 -174.107 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -134.46 110.89 11.53 Favored Pre-proline 0 N--CA 1.446 -0.637 1 C-N-CA 133.924 4.89 . . . . 0.0 113.103 -172.406 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -75.77 8.57 2.65 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 123.822 3.015 . . . . 0.0 114.132 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.5 m -134.03 138.15 50.83 Favored 'Isoleucine or valine' 0 C--O 1.238 0.46 0 C-N-CA 129.551 3.14 . . . . 0.0 115.855 -160.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 17.3 tt0 -59.81 109.31 0.9 Allowed 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 139.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 176.71 -157.21 22.34 Favored Glycine 0 C--N 1.344 0.975 0 CA-C-O 117.675 -1.625 . . . . 0.0 116.184 -173.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -133.12 139.21 46.98 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 127.623 2.369 . . . . 0.0 108.688 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -105.96 145.19 31.65 Favored 'General case' 0 N--CA 1.446 -0.642 0 O-C-N 119.747 -1.845 . . . . 0.0 110.627 161.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -126.55 116.96 21.87 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.843 -2.28 . . . . 0.0 104.843 -176.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 61.1 t -124.29 135.83 62.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 C-N-CA 125.417 1.487 . . . . 0.0 110.581 -149.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -136.32 133.68 37.13 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 105.447 -2.057 . . . . 0.0 105.447 -172.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 94.5 t -114.0 137.78 46.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 O-C-N 119.16 -2.212 . . . . 0.0 113.923 172.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 35.9 p -143.17 165.8 26.43 Favored 'General case' 0 CA--C 1.516 -0.349 0 O-C-N 120.614 -1.304 . . . . 0.0 113.609 -164.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . 0.26 7.4 tt -150.15 99.9 2.85 Favored 'General case' 0 C--N 1.344 0.368 0 N-CA-C 101.668 -3.456 . . . . 0.0 101.668 -146.767 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 8.7 ttm180 52.87 36.87 22.73 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 119.758 1.163 . . . . 0.0 111.471 -150.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.37 0.5 38.14 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-O 115.271 -2.96 . . . . 0.0 109.8 -178.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -94.81 142.93 25.35 Favored Pre-proline 0 N--CA 1.441 -0.877 0 CA-C-N 121.148 2.474 . . . . 0.0 109.868 -176.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -79.06 158.98 27.04 Favored 'Trans proline' 0 C--O 1.218 -0.499 0 CA-C-O 126.239 2.516 . . . . 0.0 113.459 -177.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 29.2 pt -142.92 -171.46 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 CA-C-N 109.386 -3.552 . . . . 0.0 113.32 -171.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -93.79 157.72 16.01 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 125.856 1.662 . . . . 0.0 112.341 -158.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.26 30.9 m120 50.19 34.1 8.15 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 129.793 3.237 . . . . 0.0 112.785 178.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 6.0 mmt -130.57 151.29 78.43 Favored Pre-proline 0 N--CA 1.444 -0.769 1 C-N-CA 134.551 5.141 . . . . 0.0 106.284 176.843 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -76.69 163.13 90.37 Favored 'Cis proline' 0 N--CA 1.45 -1.037 0 CA-C-N 126.432 3.333 . . . . 0.0 107.336 -2.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . 0.376 1.3 pp -127.04 167.54 21.66 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.409 0 N-CA-C 118.14 2.644 . . . . 0.0 118.14 163.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -106.57 142.13 36.72 Favored 'General case' 0 N--CA 1.449 -0.496 0 O-C-N 118.159 -2.838 . . . . 0.0 118.019 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 61.5 t -123.12 124.14 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 127.018 2.127 . . . . 0.0 109.977 -179.303 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -80.43 128.0 33.07 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-O 118.575 -0.726 . . . . 0.0 111.424 165.47 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 99.5 m -115.68 140.4 49.23 Favored 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 128.247 2.619 . . . . 0.0 112.819 -170.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 98.6 mt -133.85 145.73 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 CA-C-N 121.898 2.135 . . . . 0.0 106.795 177.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -82.19 48.1 1.22 Allowed 'General case' 0 N--CA 1.445 -0.698 0 O-C-N 116.76 -3.712 . . . . 0.0 113.692 -166.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.435 -1.391 0 O-C-N 120.575 -1.328 . . . . 0.0 116.111 174.493 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo . . . . . 0 N--CA 1.445 -1.348 0 N-CA-C 113.26 0.446 . . . . 0.0 113.26 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -119.17 138.41 26.25 Favored Pre-proline 0 CA--C 1.512 -0.491 0 C-N-CA 126.106 1.762 . . . . 0.0 110.474 -178.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_exo -65.47 169.49 12.54 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.155 1.903 . . . . 0.0 114.156 170.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -145.74 168.02 21.74 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 125.547 1.539 . . . . 0.0 113.131 -171.456 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.44 -43.78 72.62 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 117.593 2.442 . . . . 0.0 117.593 179.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 55.6 mm-40 -60.65 -20.42 60.79 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.5 1.52 . . . . 0.0 111.353 167.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 68.6 m-70 -126.48 18.54 7.5 Favored 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 129.322 3.049 . . . . 0.0 112.757 -158.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.9 t -141.56 126.3 18.02 Favored 'General case' 0 N--CA 1.444 -0.729 0 O-C-N 119.856 -1.777 . . . . 0.0 106.476 166.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -153.86 157.85 39.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 130.632 3.573 . . . . 0.0 110.679 -175.306 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -141.92 148.77 39.22 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 127.734 2.413 . . . . 0.0 116.718 -165.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -144.08 143.31 31.1 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 113.969 -1.469 . . . . 0.0 109.33 -171.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 138.98 173.4 12.98 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 118.625 2.21 . . . . 0.0 118.625 169.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -68.87 -24.82 64.38 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 120.202 -1.763 . . . . 0.0 111.973 -168.354 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.18 7.35 0.56 Allowed Glycine 0 C--N 1.339 0.697 0 C-N-CA 129.779 3.562 . . . . 0.0 116.954 171.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 96.6 mt -116.98 -2.59 11.72 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-O 114.185 -2.817 . . . . 0.0 110.221 172.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 t -129.8 -55.05 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 CA-C-N 122.832 2.56 . . . . 0.0 109.156 -168.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 23.8 pttt -145.36 120.62 10.21 Favored 'General case' 0 C--O 1.238 0.46 0 O-C-N 118.873 -2.392 . . . . 0.0 112.282 -172.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 93.9 t -125.85 139.54 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 119.348 -2.095 . . . . 0.0 105.466 -172.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.408 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 42.5 m-85 -127.79 -163.43 1.26 Allowed 'General case' 0 N--CA 1.447 -0.621 0 CA-C-O 115.099 -2.381 . . . . 0.0 110.215 -178.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -103.14 -50.52 3.47 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 120.803 1.638 . . . . 0.0 114.572 -170.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 19.1 m-80 -109.2 6.01 24.34 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 130.27 3.428 . . . . 0.0 111.028 -179.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -122.06 85.82 46.34 Favored Pre-proline 0 C--O 1.224 -0.252 0 C-N-CA 126.693 1.997 . . . . 0.0 111.73 165.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -55.93 146.56 67.62 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 C-N-CA 117.244 -1.37 . . . . 0.0 115.091 176.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -93.76 162.64 13.85 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 119.044 2.979 . . . . 0.0 119.044 170.3 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -136.85 147.77 46.71 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 117.612 2.449 . . . . 0.0 117.612 -174.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -157.98 160.81 37.92 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-N 122.182 2.265 . . . . 0.0 107.77 169.443 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 49.2 m -119.18 127.92 53.75 Favored 'General case' 0 N--CA 1.441 -0.909 0 CA-C-O 113.805 -2.997 . . . . 0.0 113.811 -166.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.0 mt -86.39 106.53 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 O-C-N 126.681 2.488 . . . . 0.0 105.548 179.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.474 55.5 p90 -85.34 114.25 22.27 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 117.874 2.546 . . . . 0.0 117.874 175.015 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -119.91 139.04 53.04 Favored 'General case' 0 CA--C 1.517 -0.325 0 CA-C-N 122.85 2.568 . . . . 0.0 113.106 -167.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 78.0 t -129.35 143.57 40.78 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 1 C-N-CA 132.236 4.214 . . . . 0.0 111.457 173.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -70.03 -82.93 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 126.941 3.258 . . . . 0.0 107.924 173.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 48.9 p -153.44 -21.3 0.14 Allowed 'General case' 0 C--N 1.328 -0.328 2 C-N-CA 134.773 5.229 . . . . 0.0 117.992 -179.394 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 18.4 mmtp -80.5 16.34 1.38 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 127.789 3.181 . . . . 0.0 116.33 -176.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.62 -56.65 5.03 Favored Glycine 0 C--N 1.345 1.034 0 N-CA-C 120.301 2.88 . . . . 0.0 120.301 -175.34 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 24.5 t -63.68 146.53 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 172.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.76 170.12 0.06 Allowed 'General case' 0 N--CA 1.438 -1.034 0 CA-C-O 121.589 0.709 . . . . 0.0 111.228 177.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.7 mmm180 -68.44 118.39 11.44 Favored 'General case' 0 C--N 1.351 0.659 0 O-C-N 118.261 -2.774 . . . . 0.0 113.564 -175.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 16.0 p -77.88 1.56 20.09 Favored 'General case' 0 N--CA 1.447 -0.591 1 C-N-CA 134.738 5.215 . . . . 0.0 117.733 -171.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 10.0 p30 -161.09 -174.5 4.39 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-N 111.171 -2.74 . . . . 0.0 104.801 163.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -144.2 -170.36 13.56 Favored Glycine 0 CA--C 1.524 0.641 0 C-N-CA 128.462 2.934 . . . . 0.0 117.321 -142.08 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 54.18 46.18 71.47 Favored Glycine 0 C--N 1.337 0.623 0 CA-C-O 123.629 1.683 . . . . 0.0 110.639 178.07 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -86.71 137.88 33.64 Favored Pre-proline 0 N--CA 1.45 -0.449 0 O-C-N 116.688 -3.831 . . . . 0.0 112.157 174.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -68.94 137.18 37.22 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.383 2.722 . . . . 0.0 113.756 -171.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -159.6 150.37 19.37 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 112.217 -2.265 . . . . 0.0 112.924 -165.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -152.34 134.92 15.32 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 118.106 -2.871 . . . . 0.0 113.977 -166.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 4.5 t -129.74 81.62 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 CA-C-N 113.325 -1.761 . . . . 0.0 113.643 -176.273 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -100.53 141.13 33.81 Favored 'General case' 0 CA--C 1.516 -0.354 0 O-C-N 126.023 2.077 . . . . 0.0 110.87 -174.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.5 mt -132.88 147.42 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 CA-C-O 125.01 2.338 . . . . 0.0 108.23 -163.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -116.5 118.83 33.73 Favored 'General case' 0 C--O 1.223 -0.33 0 O-C-N 119.3 -2.125 . . . . 0.0 109.166 166.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -111.31 -158.75 15.3 Favored Glycine 0 N--CA 1.442 -0.948 0 N-CA-C 121.797 3.479 . . . . 0.0 121.797 163.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo . . . . . 0 N--CA 1.434 -2.017 1 C-N-CA 125.834 4.356 . . . . 0.0 113.339 -177.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.44 -0.946 0 CA-C-O 118.009 -0.996 . . . . 0.0 112.757 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 72.8 t -132.63 145.34 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 CA-C-N 122.304 2.32 . . . . 0.0 106.465 -174.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -128.87 131.68 47.67 Favored 'General case' 0 N--CA 1.445 -0.69 0 O-C-N 119.122 -2.236 . . . . 0.0 110.332 172.186 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -102.63 137.37 40.95 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 126.476 1.91 . . . . 0.0 113.752 -165.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.271 37.1 ttpt -81.96 117.46 22.2 Favored 'General case' 0 C--O 1.218 -0.556 0 O-C-N 120.245 -1.535 . . . . 0.0 111.664 -160.05 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -88.48 131.6 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 175.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 67.2 m -131.84 125.96 33.09 Favored 'General case' 0 N--CA 1.452 -0.349 0 O-C-N 125.619 1.824 . . . . 0.0 110.934 172.321 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -66.29 118.52 10.09 Favored 'General case' 0 N--CA 1.44 -0.951 0 C-N-CA 128.153 2.581 . . . . 0.0 110.644 176.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.4 m-20 -79.63 -4.07 49.98 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 119.807 3.262 . . . . 0.0 119.807 175.653 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 68.56 25.66 6.6 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 131.595 3.958 . . . . 0.0 114.008 176.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 43.2 p30 -135.06 -4.69 2.41 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 114.053 -2.879 . . . . 0.0 110.946 -165.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 120.88 -14.34 9.71 Favored Glycine 0 C--N 1.337 0.624 0 C-N-CA 126.847 2.165 . . . . 0.0 111.223 -171.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 p -133.12 165.83 23.86 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 131.388 3.875 . . . . 0.0 113.56 -170.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 16.7 m-85 -131.57 137.57 48.51 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 128.704 2.802 . . . . 0.0 106.671 -174.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -92.21 139.41 14.67 Favored Glycine 0 C--O 1.226 -0.369 0 C-N-CA 128.159 2.79 . . . . 0.0 107.304 174.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 22.8 t -122.83 130.79 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-O 117.119 -1.419 . . . . 0.0 108.633 178.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.4 p -135.71 141.85 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 119.696 1.134 . . . . 0.0 112.527 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 7.5 p90 -161.11 169.61 22.05 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 115.902 1.816 . . . . 0.0 115.902 179.194 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 15.2 p30 -139.0 164.79 28.83 Favored 'General case' 0 N--CA 1.449 -0.508 0 O-C-N 118.756 -2.465 . . . . 0.0 117.532 177.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -123.53 112.57 29.35 Favored Pre-proline 0 N--CA 1.448 -0.568 0 O-C-N 125.305 1.628 . . . . 0.0 107.643 -174.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.336 14.9 Cg_endo -66.76 -8.52 21.56 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 N-CA-C 117.57 2.104 . . . . 0.0 117.57 170.382 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 28.4 m -148.08 134.51 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 O-C-N 120.369 -1.457 . . . . 0.0 110.606 -164.568 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -56.39 116.16 2.91 Favored 'General case' 0 N--CA 1.456 -0.169 0 O-C-N 126.195 2.185 . . . . 0.0 112.47 167.026 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 170.29 -166.7 39.89 Favored Glycine 0 CA--C 1.527 0.828 0 CA-C-O 122.306 0.948 . . . . 0.0 112.485 -172.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -106.42 137.75 43.84 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 114.37 1.248 . . . . 0.0 114.37 175.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -103.34 139.29 38.96 Favored 'General case' 0 N--CA 1.445 -0.713 0 C-N-CA 128.634 2.774 . . . . 0.0 110.418 168.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -114.53 119.55 37.21 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 117.164 2.283 . . . . 0.0 117.164 170.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . 0.275 65.2 t -118.1 133.64 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-N 112.795 -2.002 . . . . 0.0 111.863 -157.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -130.23 138.95 50.81 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 126.879 2.072 . . . . 0.0 109.087 171.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 85.8 t -114.79 126.48 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 C-N-CA 124.856 1.262 . . . . 0.0 113.312 168.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . 0.301 67.0 p -132.8 145.97 51.44 Favored 'General case' 0 N--CA 1.444 -0.767 0 O-C-N 125.423 1.702 . . . . 0.0 114.519 -168.561 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 8.4 tt -136.62 95.8 3.22 Favored 'General case' 0 N--CA 1.447 -0.58 1 O-C-N 116.182 -4.074 . . . . 0.0 107.796 -137.491 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . 0.316 51.4 ttt180 46.0 40.09 6.51 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 125.933 2.778 . . . . 0.0 115.858 -147.644 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 69.15 16.75 71.27 Favored Glycine 0 C--N 1.341 0.818 0 O-C-N 118.318 -2.739 . . . . 0.0 117.838 -175.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -106.57 153.51 40.56 Favored Pre-proline 0 N--CA 1.447 -0.6 0 O-C-N 116.508 -3.937 . . . . 0.0 111.678 165.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_endo -86.53 169.57 8.14 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 124.548 3.499 . . . . 0.0 114.166 -178.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 11.2 pt -130.8 -173.22 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-N 113.975 -1.466 . . . . 0.0 109.13 176.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 57.1 mttm -67.84 169.59 9.51 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 115.385 1.624 . . . . 0.0 115.385 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 33.3 m120 47.49 28.66 1.2 Allowed 'General case' 0 N--CA 1.447 -0.617 0 O-C-N 116.959 -3.588 . . . . 0.0 118.859 169.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 12.7 mmt -136.32 146.14 54.83 Favored Pre-proline 0 N--CA 1.444 -0.765 0 C-N-CA 129.128 2.971 . . . . 0.0 109.187 -177.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . 0.272 96.6 Cg_endo -68.07 169.24 55.87 Favored 'Cis proline' 0 N--CA 1.457 -0.63 0 CA-C-N 127.293 3.64 . . . . 0.0 116.232 -4.566 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 27.2 pt -146.77 161.25 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 O-C-N 126.9 2.625 . . . . 0.0 114.616 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -112.83 131.28 55.77 Favored 'General case' 0 N--CA 1.445 -0.71 0 C-N-CA 127.352 2.261 . . . . 0.0 112.875 -178.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 59.0 t -122.98 141.26 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 C-N-CA 126.681 1.992 . . . . 0.0 106.813 -175.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 39.8 mmtm -91.37 138.33 31.67 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 116.335 1.976 . . . . 0.0 116.335 176.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 21.8 m -115.96 126.51 53.95 Favored 'General case' 0 N--CA 1.441 -0.903 0 C-N-CA 129.504 3.122 . . . . 0.0 108.342 -174.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.408 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 15.2 mt -124.64 135.17 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 161.017 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -72.96 56.04 0.42 Allowed 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 118.699 2.851 . . . . 0.0 118.699 -176.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.4 0 O-C-N 117.388 -3.32 . . . . 0.0 117.14 165.975 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo . . . . . 0 N--CA 1.453 -0.887 0 CA-C-O 119.828 -0.155 . . . . 0.0 112.28 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -123.14 154.22 64.9 Favored Pre-proline 0 N--CA 1.446 -0.653 0 C-N-CA 128.059 2.543 . . . . 0.0 113.258 -166.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_exo -63.92 153.82 73.53 Favored 'Trans proline' 0 N--CA 1.444 -1.413 0 C-N-CA 124.162 3.241 . . . . 0.0 116.076 166.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 26.4 t -122.86 150.75 42.46 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.17 1.788 . . . . 0.0 106.259 178.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . 0.314 . . -51.19 -37.99 49.77 Favored 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 126.118 1.767 . . . . 0.0 114.632 163.067 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -58.61 -29.11 66.22 Favored 'General case' 0 N--CA 1.443 -0.809 0 C-N-CA 125.003 1.321 . . . . 0.0 110.192 170.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 86.6 m-70 -134.66 24.98 3.71 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 131.292 3.837 . . . . 0.0 112.556 -155.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 42.6 t -148.16 120.24 8.27 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 117.343 2.349 . . . . 0.0 117.343 166.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -146.48 142.49 28.15 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-O 113.482 -3.152 . . . . 0.0 113.832 -160.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -124.48 140.82 52.59 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 119.373 3.101 . . . . 0.0 119.373 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -136.44 147.57 47.3 Favored 'General case' 0 C--O 1.223 -0.317 0 CA-C-N 120.962 1.71 . . . . 0.0 112.19 -177.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.43 175.8 18.84 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 125.436 1.494 . . . . 0.0 114.575 167.403 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -55.93 -34.75 65.91 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-O 114.495 -2.669 . . . . 0.0 112.503 177.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -57.93 -3.0 1.02 Allowed Glycine 0 C--O 1.226 -0.355 0 CA-C-N 123.462 2.847 . . . . 0.0 116.138 165.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . 0.373 24.1 mt -109.29 29.26 7.7 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 120.544 2.172 . . . . 0.0 111.32 161.403 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 96.8 t -150.16 -42.0 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 CA-C-N 121.683 2.038 . . . . 0.0 114.584 -175.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.333 43.0 pttt -151.39 131.12 13.17 Favored 'General case' 0 C--N 1.326 -0.429 1 O-C-N 116.164 -4.085 . . . . 0.0 112.36 -179.425 . . . . . . . . 3 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 38.4 t -143.66 141.15 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 -166.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -136.08 172.31 13.19 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-N 120.181 1.355 . . . . 0.0 114.277 -169.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 46.8 t0 -78.55 -50.81 10.91 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-O 122.631 1.205 . . . . 0.0 112.519 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 70.4 m-80 -104.03 8.7 36.65 Favored 'General case' 0 N--CA 1.448 -0.545 0 O-C-N 118.427 -2.67 . . . . 0.0 111.636 -179.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -133.85 101.81 12.63 Favored Pre-proline 0 N--CA 1.447 -0.625 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 170.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -57.92 131.47 43.94 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 CA-C-O 125.552 2.23 . . . . 0.0 111.888 159.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -85.93 162.48 18.54 Favored 'General case' 0 N--CA 1.45 -0.459 0 O-C-N 117.008 -3.558 . . . . 0.0 113.539 165.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -133.22 154.6 50.51 Favored 'General case' 0 N--CA 1.448 -0.553 0 O-C-N 125.057 1.473 . . . . 0.0 110.508 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -157.48 171.45 20.34 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 117.662 -3.149 . . . . 0.0 105.403 167.176 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 91.1 m -133.35 130.47 38.86 Favored 'General case' 0 C--O 1.233 0.197 0 O-C-N 127.167 2.792 . . . . 0.0 113.737 -164.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.2 mt -84.77 104.06 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 123.929 0.892 . . . . 0.0 110.946 171.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 32.5 p90 -77.15 108.1 9.99 Favored 'General case' 0 N--CA 1.44 -0.973 0 N-CA-C 119.222 3.045 . . . . 0.0 119.222 163.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -117.78 150.22 39.49 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 121.288 1.858 . . . . 0.0 109.491 -163.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.2 t -137.79 159.19 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 105.718 -1.956 . . . . 0.0 105.718 174.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.0 p30 -78.36 -61.91 1.85 Allowed 'General case' 0 N--CA 1.452 -0.331 0 O-C-N 119.766 -1.834 . . . . 0.0 115.214 170.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 21.9 p -174.91 -35.63 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 131.64 3.976 . . . . 0.0 114.42 -161.034 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -107.69 40.92 1.61 Allowed 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 122.73 2.514 . . . . 0.0 112.665 -171.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 53.02 -25.39 0.01 OUTLIER Glycine 0 C--N 1.338 0.666 0 C-N-CA 130.129 3.728 . . . . 0.0 121.568 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.1 t -64.3 125.55 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 O-C-N 116.951 -3.676 . . . . 0.0 107.882 167.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -31.33 127.2 0.19 Allowed 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 117.36 2.356 . . . . 0.0 117.36 162.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 11.5 mmm180 -35.12 122.03 0.57 Allowed 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 118.672 2.841 . . . . 0.0 118.672 -177.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 8.5 p -78.79 -2.6 40.34 Favored 'General case' 0 N--CA 1.445 -0.696 0 C-N-CA 126.774 2.03 . . . . 0.0 111.576 -162.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.9 p30 -162.45 169.2 20.8 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 127.925 2.49 . . . . 0.0 109.199 178.055 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -123.91 -157.07 9.68 Favored Glycine 0 CA--C 1.522 0.502 0 C-N-CA 119.918 -1.134 . . . . 0.0 110.897 -160.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 61.01 41.05 99.31 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 178.286 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 58.4 m-20 -78.38 156.08 78.79 Favored Pre-proline 0 N--CA 1.448 -0.552 0 C-N-CA 126.982 2.113 . . . . 0.0 108.438 173.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -91.67 62.78 1.04 Allowed 'Trans proline' 0 N--CA 1.444 -1.395 0 C-N-CA 124.811 3.674 . . . . 0.0 117.284 -169.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -69.88 149.55 47.73 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 120.971 3.693 . . . . 0.0 120.971 173.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -150.49 128.36 11.74 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 127.22 2.208 . . . . 0.0 112.906 168.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 39.5 t -114.46 87.53 1.03 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.326 0 C-N-CA 129.99 3.316 . . . . 0.0 104.408 -174.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -104.66 142.29 34.94 Favored 'General case' 0 N--CA 1.444 -0.753 0 C-N-CA 127.14 2.176 . . . . 0.0 106.065 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 19.1 mt -130.86 155.38 41.87 Favored 'Isoleucine or valine' 0 C--O 1.238 0.463 0 C-N-CA 128.334 2.654 . . . . 0.0 113.492 -170.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 71.6 m-80 -125.01 126.25 45.14 Favored 'General case' 0 N--CA 1.446 -0.642 0 C-N-CA 131.426 3.89 . . . . 0.0 109.137 174.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -118.49 -177.87 16.92 Favored Glycine 0 CA--C 1.528 0.876 0 O-C-N 119.034 -2.291 . . . . 0.0 112.351 167.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo . . . . . 0 N--CA 1.441 -1.594 0 CA-C-N 118.741 1.27 . . . . 0.0 111.875 -174.739 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 26.2 t . . . . . 0 C--O 1.24 0.554 0 CA-C-O 122.063 0.935 . . . . 0.0 109.749 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 96.0 t -142.02 144.37 25.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 112.474 -2.148 . . . . 0.0 111.846 -177.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.301 3.6 p-10 -127.2 134.55 50.11 Favored 'General case' 0 N--CA 1.445 -0.695 0 O-C-N 117.953 -2.967 . . . . 0.0 111.285 168.199 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.75 155.57 19.49 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 126.927 3.251 . . . . 0.0 111.134 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.301 9.2 tmtt? -99.99 104.17 15.76 Favored 'General case' 0 N--CA 1.448 -0.553 1 O-C-N 113.235 -5.916 . . . . 0.0 111.216 -170.45 . . . . . . . . 3 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.0 t -76.38 138.64 20.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 O-C-N 127.17 2.794 . . . . 0.0 117.644 169.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 10.0 m -144.15 128.86 18.24 Favored 'General case' 0 C--O 1.237 0.443 0 O-C-N 126.725 2.516 . . . . 0.0 111.091 173.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -79.16 136.07 37.0 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 125.237 2.446 . . . . 0.0 110.226 -169.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . 0.266 8.0 m-20 -96.61 0.56 50.1 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 116.534 -3.854 . . . . 0.0 118.551 -175.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 6.5 m120 68.68 27.62 5.88 Favored 'General case' 0 C--O 1.215 -0.733 0 O-C-N 128.731 3.769 . . . . 0.0 114.512 176.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 26.7 p30 -134.66 -8.24 2.46 Favored 'General case' 0 N--CA 1.445 -0.706 0 CA-C-O 117.227 -1.368 . . . . 0.0 112.153 -176.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 109.02 5.88 30.41 Favored Glycine 0 C--N 1.35 1.313 0 CA-C-O 113.492 -3.949 . . . . 0.0 108.21 -170.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.7 p -130.09 158.07 40.64 Favored 'General case' 0 N--CA 1.442 -0.83 1 CA-C-N 126.491 5.146 . . . . 0.0 111.391 -175.065 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -135.93 113.01 10.42 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 120.633 1.561 . . . . 0.0 110.543 -174.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -63.33 136.91 42.63 Favored Glycine 0 N--CA 1.452 -0.268 0 N-CA-C 116.539 1.376 . . . . 0.0 116.539 167.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.9 t -131.64 134.41 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 126.713 2.005 . . . . 0.0 112.155 -178.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -132.5 141.56 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-N 122.912 2.596 . . . . 0.0 109.82 -175.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 1.8 p90 -166.32 170.81 12.73 Favored 'General case' 0 N--CA 1.446 -0.637 0 O-C-N 125.512 1.758 . . . . 0.0 115.185 170.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 27.2 p30 -142.41 141.87 32.3 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 129.077 2.951 . . . . 0.0 109.916 -158.01 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -112.91 125.61 29.57 Favored Pre-proline 0 C--N 1.344 0.365 0 CA-C-O 117.399 -1.286 . . . . 0.0 113.201 -176.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -84.01 -1.09 9.83 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 123.387 2.724 . . . . 0.0 112.54 178.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.4 m -128.24 148.93 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 O-C-N 118.783 -2.448 . . . . 0.0 113.532 -164.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -63.4 111.39 2.28 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-O 124.814 2.245 . . . . 0.0 109.235 139.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 169.26 -162.52 36.18 Favored Glycine 0 C--O 1.221 -0.657 0 O-C-N 118.583 -2.573 . . . . 0.0 118.015 -173.114 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 27.3 t30 -117.68 132.58 56.47 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 127.435 2.294 . . . . 0.0 111.83 177.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -90.73 153.28 20.39 Favored 'General case' 0 C--O 1.221 -0.416 0 O-C-N 118.423 -2.673 . . . . 0.0 113.086 158.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -128.37 113.28 15.39 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 113.186 -1.825 . . . . 0.0 113.699 176.05 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.6 t -115.07 120.37 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 CA-C-N 113.887 -1.506 . . . . 0.0 114.204 -154.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.6 t30 -129.65 111.16 12.41 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 126.301 1.84 . . . . 0.0 108.379 -167.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 84.2 t -98.03 134.89 34.66 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.525 0 C-N-CA 126.72 2.008 . . . . 0.0 109.971 177.047 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 17.0 p -144.01 157.42 44.34 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 126.497 3.046 . . . . 0.0 115.911 -173.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 49.3 tp -129.03 104.97 7.88 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 101.763 -3.421 . . . . 0.0 101.763 -149.039 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 67.6 ttp85 45.74 42.79 9.01 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 104.91 -2.256 . . . . 0.0 104.91 -162.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.63 -1.06 31.55 Favored Glycine 0 CA--C 1.52 0.378 0 N-CA-C 119.932 2.733 . . . . 0.0 119.932 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -85.96 148.76 48.92 Favored Pre-proline 0 N--CA 1.445 -0.677 0 C-N-CA 129.246 3.019 . . . . 0.0 112.225 174.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_endo -76.73 170.8 19.19 Favored 'Trans proline' 0 N--CA 1.444 -1.423 0 O-C-N 124.769 1.931 . . . . 0.0 112.383 -175.248 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . 0.284 4.3 pt -136.37 -163.15 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 C-N-CA 128.399 2.679 . . . . 0.0 112.438 -179.124 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 32.1 mttt -100.88 159.81 14.89 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 125.337 3.699 . . . . 0.0 109.19 -173.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 33.4 m120 54.31 31.51 14.48 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 128.36 2.664 . . . . 0.0 113.351 173.066 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' MET . . . . . . . . . . . . 0.263 7.2 mmt -132.49 150.37 75.68 Favored Pre-proline 0 N--CA 1.454 -0.248 0 O-C-N 118.082 -2.886 . . . . 0.0 105.594 -173.205 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -66.15 174.84 25.54 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 CA-C-N 125.47 2.989 . . . . 0.0 112.735 -5.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 12.4 pt -143.32 169.81 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 O-C-N 126.083 2.114 . . . . 0.0 109.1 170.323 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -125.7 141.39 52.04 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 122.482 2.401 . . . . 0.0 114.437 -167.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 58.5 t -132.81 120.57 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 123.337 0.655 . . . . 0.0 109.421 -170.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 62.5 mttm -65.67 132.21 48.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 126.94 2.096 . . . . 0.0 108.183 173.318 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 20.1 m -126.28 138.27 53.59 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 127.422 2.289 . . . . 0.0 115.885 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 83.7 mt -130.63 152.06 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 O-C-N 118.709 -2.494 . . . . 0.0 110.437 167.003 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -84.91 45.48 1.17 Allowed 'General case' 0 N--CA 1.453 -0.32 0 O-C-N 120.41 -1.431 . . . . 0.0 113.828 -165.29 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.93 0 N-CA-C 116.431 1.332 . . . . 0.0 116.431 -174.41 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.0 tpt . . . . . 0 N--CA 1.479 0.994 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 49.6 t-80 -78.15 -50.58 11.7 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 117.678 -1.609 . . . . 0.0 109.635 -177.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 8.9 t60 -78.66 114.13 17.31 Favored 'General case' 0 C--N 1.319 -0.726 0 O-C-N 117.304 -3.372 . . . . 0.0 107.151 175.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 85.8 t60 -159.46 140.99 13.04 Favored 'General case' 0 N--CA 1.446 -0.655 0 O-C-N 118.87 -2.394 . . . . 0.0 110.154 -175.221 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.4 m-70 -87.73 98.24 11.34 Favored 'General case' 0 N--CA 1.446 -0.664 0 O-C-N 119.689 -1.882 . . . . 0.0 115.696 167.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 15.5 t60 -81.73 -36.63 28.39 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 110.718 -2.946 . . . . 0.0 109.754 -178.174 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 47.0 t-80 -147.99 169.25 20.31 Favored 'General case' 0 N--CA 1.449 -0.495 0 O-C-N 118.373 -2.705 . . . . 0.0 111.692 -167.668 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -88.98 30.23 0.96 Allowed 'General case' 0 N--CA 1.438 -1.068 0 C-N-CA 127.45 2.3 . . . . 0.0 116.809 -178.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.6 p -140.65 160.2 40.55 Favored 'General case' 0 C--O 1.234 0.281 0 C-N-CA 126.109 1.764 . . . . 0.0 112.145 169.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 35.0 mtmt -143.86 133.17 11.5 Favored Pre-proline 0 N--CA 1.446 -0.63 1 CA-C-O 110.997 -4.335 . . . . 0.0 112.785 -171.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -71.79 168.55 23.48 Favored 'Trans proline' 0 N--CA 1.449 -1.129 0 O-C-N 126.05 2.605 . . . . 0.0 109.002 175.554 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -101.5 135.7 19.77 Favored Pre-proline 0 C--O 1.238 0.475 0 CA-C-O 115.816 -2.04 . . . . 0.0 113.868 -177.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -53.42 149.14 31.16 Favored 'Trans proline' 0 N--CA 1.44 -1.624 1 C-N-CA 132.061 8.507 . . . . 0.0 113.622 157.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.3 m -145.7 161.17 40.5 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 123.342 1.544 . . . . 0.0 107.45 -166.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.29 -44.04 89.23 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 108.825 -3.807 . . . . 0.0 114.601 -172.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . 0.288 68.1 mm-40 -64.88 -20.72 66.58 Favored 'General case' 0 N--CA 1.442 -0.83 0 C-N-CA 129.296 3.038 . . . . 0.0 112.763 167.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -121.28 16.52 11.45 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 130.499 3.52 . . . . 0.0 117.733 -163.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 t -142.84 135.05 27.36 Favored 'General case' 0 N--CA 1.445 -0.684 0 O-C-N 118.374 -2.704 . . . . 0.0 110.661 166.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . 0.356 49.6 m-85 -154.41 147.27 24.43 Favored 'General case' 0 N--CA 1.446 -0.673 0 C-N-CA 127.646 2.378 . . . . 0.0 107.415 -167.052 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -136.69 150.08 48.27 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 118.377 2.732 . . . . 0.0 118.377 -172.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -156.61 145.63 20.28 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 119.324 3.083 . . . . 0.0 119.324 -165.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.8 -170.33 21.22 Favored Glycine 0 C--N 1.341 0.833 0 C-N-CA 127.521 2.486 . . . . 0.0 115.578 174.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -58.18 -38.66 77.11 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 125.813 1.645 . . . . 0.0 110.256 -170.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -68.33 -1.84 23.4 Favored Glycine 0 CA--C 1.527 0.835 0 O-C-N 117.814 -3.054 . . . . 0.0 113.366 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.5 mt -120.27 21.75 11.61 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 122.095 2.948 . . . . 0.0 107.289 169.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.0 t -124.43 -50.85 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-O 116.309 -1.805 . . . . 0.0 112.669 165.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.4 pttt -155.63 136.3 13.42 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 122.419 2.372 . . . . 0.0 110.505 -165.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 46.2 t -144.73 141.03 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 CA-C-O 115.303 -2.284 . . . . 0.0 109.049 -170.284 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -137.43 -171.47 2.98 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 120.36 3.467 . . . . 0.0 120.36 -172.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 48.4 t0 -94.03 -57.55 2.5 Favored 'General case' 0 N--CA 1.447 -0.587 1 O-C-N 115.101 -4.75 . . . . 0.0 109.294 -162.188 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 66.6 m-80 -97.97 -2.8 39.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 118.841 2.904 . . . . 0.0 118.841 172.093 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -114.47 88.85 16.54 Favored Pre-proline 0 N--CA 1.445 -0.719 0 CA-C-O 122.58 1.181 . . . . 0.0 110.248 160.106 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -43.77 135.63 7.26 Favored 'Trans proline' 0 N--CA 1.445 -1.325 0 N-CA-C 116.997 1.884 . . . . 0.0 116.997 156.381 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.44 153.95 22.58 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.238 2.215 . . . . 0.0 113.418 -174.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -138.11 147.92 44.46 Favored 'General case' 0 N--CA 1.442 -0.851 0 C-N-CA 128.494 2.717 . . . . 0.0 112.626 -171.051 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -155.02 175.14 14.21 Favored 'General case' 0 CA--C 1.514 -0.429 0 C-N-CA 130.111 3.365 . . . . 0.0 112.868 166.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.402 ' CG2' ' HB ' ' A' ' 78' ' ' THR . 86.9 m -123.36 125.7 45.48 Favored 'General case' 0 C--N 1.344 0.364 0 N-CA-C 117.23 2.307 . . . . 0.0 117.23 -164.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . 0.273 2.3 mt -78.31 123.25 34.85 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.717 0 CA-C-O 114.001 -2.904 . . . . 0.0 115.791 167.59 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.312 22.7 p90 -111.05 91.96 3.86 Favored 'General case' 0 N--CA 1.433 -1.287 0 C-N-CA 129.843 3.257 . . . . 0.0 115.262 177.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -97.74 138.14 35.57 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 130.529 3.531 . . . . 0.0 114.379 -166.266 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.1 t -131.58 135.73 58.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 CA-C-N 112.078 -2.328 . . . . 0.0 107.948 170.126 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -61.55 -61.26 2.65 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 117.029 2.233 . . . . 0.0 117.029 166.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 21.1 p -164.03 -26.67 0.04 OUTLIER 'General case' 0 N--CA 1.443 -0.795 0 C-N-CA 130.354 3.462 . . . . 0.0 110.648 169.196 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 34.6 mtmm -76.4 19.22 0.26 Allowed 'General case' 0 CA--C 1.515 -0.386 0 O-C-N 127.006 2.691 . . . . 0.0 114.166 -163.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 62.6 -46.38 0.07 OUTLIER Glycine 0 C--N 1.347 1.19 0 C-N-CA 127.067 2.27 . . . . 0.0 118.049 177.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 57.9 t -52.27 140.34 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 CA-C-N 121.881 2.841 . . . . 0.0 112.398 159.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -32.44 153.05 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 117.351 2.352 . . . . 0.0 117.351 165.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 8.0 mmm180 -59.7 128.13 35.41 Favored 'General case' 0 N--CA 1.452 -0.355 0 O-C-N 118.01 -2.931 . . . . 0.0 113.408 173.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 59.9 p -88.82 1.53 55.12 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 127.806 2.442 . . . . 0.0 112.877 -169.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -163.82 156.74 18.1 Favored 'General case' 0 N--CA 1.448 -0.526 1 O-C-N 115.786 -4.321 . . . . 0.0 112.922 176.4 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.81 -173.92 30.63 Favored Glycine 0 N--CA 1.466 0.684 0 O-C-N 125.591 1.807 . . . . 0.0 108.98 -155.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.23 32.36 83.89 Favored Glycine 0 C--O 1.236 0.224 0 C-N-CA 127.672 2.558 . . . . 0.0 114.076 171.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -60.71 145.17 88.48 Favored Pre-proline 0 CA--C 1.514 -0.418 0 O-C-N 117.743 -3.21 . . . . 0.0 106.763 160.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -84.09 135.97 6.68 Favored 'Trans proline' 0 CA--C 1.509 -0.735 0 C-N-CA 124.734 3.623 . . . . 0.0 115.952 170.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -135.2 163.96 28.77 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 129.62 3.168 . . . . 0.0 111.2 -172.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.427 ' O ' ' HA ' ' A' ' 95' ' ' VAL 0.275 21.5 tt0 -145.64 141.56 28.25 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 127.919 2.488 . . . . 0.0 113.472 164.667 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 4.3 t -129.9 61.49 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 129.487 3.115 . . . . 0.0 105.335 -173.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -83.81 132.04 34.85 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 112.839 -1.982 . . . . 0.0 113.958 -175.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 61.3 mt -138.77 145.59 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 CA-C-O 124.34 2.019 . . . . 0.0 108.486 -158.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 24.3 m120 -113.18 129.69 56.44 Favored 'General case' 0 N--CA 1.45 -0.455 0 O-C-N 116.587 -3.821 . . . . 0.0 108.993 167.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.22 -172.61 41.79 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 126.205 1.86 . . . . 0.0 114.042 157.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -63.78 124.89 14.36 Favored 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 122.94 2.427 . . . . 0.0 112.937 -178.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 55.61 -114.17 0.83 Allowed 'General case' 0 N--CA 1.441 -0.898 0 O-C-N 125.301 1.625 . . . . 0.0 111.1 -178.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -78.45 3.74 62.04 Favored Glycine 0 C--N 1.332 0.332 0 CA-C-O 125.677 2.821 . . . . 0.0 113.829 -161.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 33.9 mt -89.64 72.38 7.77 Favored 'General case' 0 C--O 1.219 -0.504 1 O-C-N 115.788 -4.36 . . . . 0.0 114.57 -172.032 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . 0.265 56.7 t -88.45 112.28 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 109.42 -3.536 . . . . 0.0 107.924 179.433 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 2.3 t -127.8 151.57 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 O-C-N 120.904 -1.123 . . . . 0.0 108.477 -168.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -121.76 139.75 53.2 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 126.411 3.005 . . . . 0.0 110.816 153.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -87.16 125.84 34.41 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 112.172 -2.285 . . . . 0.0 106.716 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 30.3 mmtm -81.17 133.64 35.49 Favored 'General case' 0 N--CA 1.449 -0.481 0 O-C-N 118.848 -2.407 . . . . 0.0 111.285 -167.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 72.2 t -107.97 139.96 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.685 0 CA-C-O 126.072 2.844 . . . . 0.0 106.842 -168.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 28.4 m -144.5 127.18 16.15 Favored 'General case' 0 C--N 1.345 0.37 0 CA-C-N 111.606 -2.543 . . . . 0.0 109.611 173.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 62.3 t0 -63.05 129.67 41.35 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 125.459 1.503 . . . . 0.0 111.752 177.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 -82.84 -11.37 58.29 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 115.954 1.835 . . . . 0.0 115.954 173.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.39 2.5 m120 63.66 48.5 3.31 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.294 2.238 . . . . 0.0 116.181 -172.697 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 44.0 p-10 -156.75 8.35 0.2 Allowed 'General case' 0 C--N 1.345 0.388 0 CA-C-O 126.376 2.988 . . . . 0.0 117.726 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 95.16 17.52 36.97 Favored Glycine 0 CA--C 1.526 0.742 0 O-C-N 117.588 -3.195 . . . . 0.0 108.441 -178.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.402 ' HB ' ' CG2' ' A' ' 37' ' ' THR . 31.1 p -136.76 166.58 23.26 Favored 'General case' 0 C--N 1.331 -0.226 0 O-C-N 124.728 0.899 . . . . 0.0 111.947 173.41 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -137.28 121.61 18.14 Favored 'General case' 0 N--CA 1.441 -0.888 0 O-C-N 125.674 1.859 . . . . 0.0 108.359 -172.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -76.18 134.24 15.45 Favored Glycine 0 N--CA 1.466 0.636 0 CA-C-O 124.221 2.012 . . . . 0.0 113.399 163.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 89.7 t -117.29 146.48 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 C-N-CA 129.575 3.15 . . . . 0.0 113.329 171.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -134.36 141.6 43.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 O-C-N 125.816 1.947 . . . . 0.0 113.285 175.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -162.15 167.38 24.27 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 116.275 -1.821 . . . . 0.0 112.051 168.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 40.7 p30 -144.99 154.64 42.76 Favored 'General case' 0 C--N 1.348 0.535 0 C-N-CA 126.096 1.758 . . . . 0.0 109.02 -166.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -124.42 118.25 26.37 Favored Pre-proline 0 N--CA 1.446 -0.647 0 C-N-CA 128.03 2.532 . . . . 0.0 114.514 -166.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.263 45.7 Cg_endo -71.87 -14.51 29.61 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.608 2.205 . . . . 0.0 111.803 -175.716 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.9 m -137.77 132.74 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.853 0 C-N-CA 128.139 2.576 . . . . 0.0 114.242 -139.387 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -54.45 112.17 0.94 Allowed 'General case' 0 N--CA 1.447 -0.618 0 O-C-N 118.045 -2.909 . . . . 0.0 115.255 144.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 168.69 -145.5 9.58 Favored Glycine 0 CA--C 1.529 0.922 1 O-C-N 114.453 -5.154 . . . . 0.0 114.818 -173.422 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . 0.603 HD22 ' HB3' ' A' ' 108' ' ' ASP . 5.4 t30 -145.49 133.39 21.26 Favored 'General case' 0 N--CA 1.448 -0.525 0 O-C-N 117.431 -3.394 . . . . 0.0 115.152 -176.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 17.7 m-85 -102.34 148.68 25.18 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 104.669 -2.345 . . . . 0.0 104.669 174.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -126.39 106.59 9.59 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 128.347 3.53 . . . . 0.0 112.51 -177.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 42.6 t -111.81 131.44 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 O-C-N 119.612 -1.93 . . . . 0.0 108.571 -158.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 -126.74 120.24 28.89 Favored 'General case' 0 CA--C 1.513 -0.473 0 C-N-CA 129.746 3.218 . . . . 0.0 110.158 174.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.427 ' HA ' ' O ' ' A' ' 56' ' ' GLU . 77.1 t -99.92 148.21 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 115.534 1.679 . . . . 0.0 115.534 170.467 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.7 p -150.41 148.83 29.24 Favored 'General case' 0 N--CA 1.445 -0.675 0 O-C-N 117.385 -3.322 . . . . 0.0 113.025 -177.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 8.0 mp -128.8 106.65 9.06 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 127.971 2.508 . . . . 0.0 110.184 -158.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? 51.56 44.32 29.17 Favored 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 126.212 1.805 . . . . 0.0 108.295 -160.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 58.59 26.56 59.99 Favored Glycine 0 N--CA 1.439 -1.103 0 N-CA-C 118.429 2.131 . . . . 0.0 118.429 -177.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 73.5 m-20 -122.06 143.53 39.12 Favored Pre-proline 0 CA--C 1.516 -0.362 0 C-N-CA 125.088 1.355 . . . . 0.0 108.887 174.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . 0.282 24.4 Cg_endo -82.88 175.83 8.25 Favored 'Trans proline' 0 N--CA 1.446 -1.293 0 CA-C-O 125.948 2.395 . . . . 0.0 108.318 -168.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 25.7 pt -149.7 -176.11 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 C-N-CA 127.961 2.505 . . . . 0.0 109.865 -167.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 41.1 mtpt -81.28 163.56 22.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 123.14 1.447 . . . . 0.0 113.314 -176.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.295 23.2 m120 58.39 54.49 5.57 Favored 'General case' 0 C--O 1.222 -0.386 0 N-CA-C 117.125 2.269 . . . . 0.0 117.125 168.115 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 9.7 mmt -164.3 146.98 7.39 Favored Pre-proline 0 CA--C 1.507 -0.686 0 C-N-CA 128.079 2.552 . . . . 0.0 105.449 -162.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -70.58 164.81 80.65 Favored 'Cis proline' 0 N--CA 1.445 -1.352 0 C-N-CA 130.836 1.598 . . . . 0.0 109.979 -5.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 31.4 pt -130.43 174.04 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 C-N-CA 126.202 1.801 . . . . 0.0 108.043 174.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . 0.603 ' HB3' HD22 ' A' ' 90' ' ' ASN . 6.4 m-20 -125.44 139.31 53.76 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 117.49 2.404 . . . . 0.0 117.49 -168.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 2.4 t -147.39 125.67 3.76 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-O 124.005 1.86 . . . . 0.0 114.323 -175.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . 0.271 46.1 pttt -66.44 129.04 38.51 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 127.057 2.143 . . . . 0.0 108.818 -173.121 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . 0.383 72.5 m -107.71 141.95 38.45 Favored 'General case' 0 N--CA 1.448 -0.531 0 O-C-N 126.72 2.512 . . . . 0.0 104.528 178.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 21.9 mt -144.52 143.65 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 O-C-N 117.281 -3.387 . . . . 0.0 111.977 173.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . 0.298 12.0 pt-20 -93.56 53.1 1.81 Allowed 'General case' 0 N--CA 1.449 -0.507 1 O-C-N 114.427 -5.171 . . . . 0.0 110.741 -157.05 . . . . . . . . 3 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 0.338 0 C-N-CA 128.453 2.93 . . . . 0.0 113.671 -176.289 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.2 tpt . . . . . 0 N--CA 1.472 0.656 0 CA-C-O 123.44 1.591 . . . . 0.0 110.181 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 44.1 m80 -115.48 40.21 2.78 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 130.826 3.65 . . . . 0.0 113.827 177.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.6 m-70 -83.68 171.41 13.26 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 119.478 -2.013 . . . . 0.0 112.304 170.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 28.3 p80 -151.77 123.32 7.87 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 125.26 1.424 . . . . 0.0 112.935 176.061 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 9.7 m-70 -108.06 134.85 50.35 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 115.462 -2.209 . . . . 0.0 115.769 -168.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -135.85 -35.97 0.77 Allowed 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 116.31 1.967 . . . . 0.0 116.31 -166.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -140.44 155.17 46.8 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 103.201 -2.889 . . . . 0.0 103.201 -165.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -58.15 -61.94 2.19 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-N 115.523 -0.762 . . . . 0.0 112.981 176.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 71.6 m -52.33 152.49 3.4 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 126.581 1.953 . . . . 0.0 114.098 175.355 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 57.6 mttp -104.87 99.14 17.45 Favored Pre-proline 0 N--CA 1.447 -0.594 0 C-N-CA 127.724 2.409 . . . . 0.0 104.8 167.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -74.78 152.16 41.62 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 124.108 3.205 . . . . 0.0 110.556 169.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -99.55 161.65 23.81 Favored Pre-proline 0 N--CA 1.45 -0.432 0 N-CA-C 117.244 2.313 . . . . 0.0 117.244 -173.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -74.17 170.2 20.71 Favored 'Trans proline' 0 N--CA 1.445 -1.348 0 C-N-CA 123.927 3.084 . . . . 0.0 111.276 -178.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.5 t -152.22 173.99 14.31 Favored 'General case' 0 N--CA 1.452 -0.341 0 O-C-N 124.348 1.03 . . . . 0.0 111.716 174.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.83 -39.97 79.69 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-N 115.125 -0.943 . . . . 0.0 113.374 -170.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . 0.4 ' CD ' ' HZ1' ' A' ' 103' ' ' LYS . 72.5 mm-40 -53.0 -35.76 59.73 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 129.547 3.139 . . . . 0.0 113.596 168.186 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -120.5 19.76 11.94 Favored 'General case' 0 N--CA 1.438 -1.026 0 CA-C-N 111.928 -2.397 . . . . 0.0 111.76 -161.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.4 t -137.45 138.28 39.61 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 117.999 -2.938 . . . . 0.0 105.468 171.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -164.31 153.44 13.52 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 110.778 -2.919 . . . . 0.0 110.606 -170.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -140.11 150.0 43.76 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 119.621 3.193 . . . . 0.0 119.621 -171.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -157.47 134.31 10.04 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 127.563 2.345 . . . . 0.0 111.916 -165.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 148.46 166.5 12.91 Favored Glycine 0 C--N 1.336 0.56 0 C-N-CA 126.473 1.987 . . . . 0.0 112.292 176.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -65.34 -19.78 66.1 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 116.682 -1.628 . . . . 0.0 109.436 -169.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.29 0.3 3.84 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 124.58 3.355 . . . . 0.0 117.22 168.182 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . 0.27 56.9 mt -109.54 13.33 24.0 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 129.637 3.175 . . . . 0.0 111.854 167.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 t -131.52 -53.36 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 C-N-CA 130.69 3.596 . . . . 0.0 112.018 -178.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 46.7 pttt -161.85 125.64 3.2 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 -159.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.2 t -137.67 155.72 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 C-N-CA 129.303 3.041 . . . . 0.0 109.907 -177.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -131.78 -176.66 4.12 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-O 123.933 1.825 . . . . 0.0 111.856 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -88.05 -46.85 8.98 Favored 'General case' 0 N--CA 1.446 -0.629 0 O-C-N 119.489 -2.007 . . . . 0.0 109.462 -174.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -109.5 6.91 24.52 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-O 126.64 3.114 . . . . 0.0 117.304 176.555 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -122.46 100.36 41.67 Favored Pre-proline 0 N--CA 1.442 -0.858 1 O-C-N 116.202 -4.061 . . . . 0.0 101.784 167.162 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -62.42 157.62 45.03 Favored 'Trans proline' 0 N--CA 1.45 -1.031 0 C-N-CA 123.654 2.903 . . . . 0.0 113.595 166.123 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -123.89 153.03 41.71 Favored 'General case' 0 CA--C 1.511 -0.548 0 C-N-CA 127.136 2.175 . . . . 0.0 112.86 -176.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -127.4 155.42 43.67 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 124.067 0.947 . . . . 0.0 108.979 -175.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.445 ' CZ ' HG13 ' A' ' 81' ' ' VAL . 5.2 p90 -161.65 155.38 21.67 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -179.3 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 86.4 m -124.21 119.75 30.27 Favored 'General case' 0 N--CA 1.452 -0.342 0 O-C-N 119.014 -2.303 . . . . 0.0 109.593 -161.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . 0.263 17.2 mt -79.74 102.96 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 124.994 1.318 . . . . 0.0 111.533 164.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.371 40.5 p90 -83.24 124.76 30.88 Favored 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 126.49 1.916 . . . . 0.0 113.797 165.637 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -110.45 146.61 35.6 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 179.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 9.7 t -129.99 139.11 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 O-C-N 126.757 2.536 . . . . 0.0 106.431 160.228 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -66.76 -50.32 63.1 Favored 'General case' 0 N--CA 1.452 -0.336 0 O-C-N 117.779 -3.076 . . . . 0.0 111.881 178.364 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 64.3 p -148.98 -60.23 0.22 Allowed 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 115.947 -1.978 . . . . 0.0 111.359 -166.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 12.7 ttmt -134.61 101.29 4.9 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 122.149 2.249 . . . . 0.0 114.543 -178.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 77.45 -65.56 3.08 Favored Glycine 0 N--CA 1.451 -0.306 0 O-C-N 120.372 -1.455 . . . . 0.0 114.375 162.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 46.3 t -61.01 124.71 15.93 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 C-N-CA 128.891 2.876 . . . . 0.0 108.717 179.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -50.91 168.2 0.06 Allowed 'General case' 0 N--CA 1.449 -0.486 0 CA-C-O 124.471 2.081 . . . . 0.0 112.982 178.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -53.75 125.85 19.9 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 108.719 -3.855 . . . . 0.0 107.631 163.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 17.5 p -79.08 -18.33 53.57 Favored 'General case' 0 N--CA 1.453 -0.297 1 C-N-CA 131.757 4.023 . . . . 0.0 111.486 -173.05 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -151.86 169.35 22.48 Favored 'General case' 0 CA--C 1.517 -0.297 0 O-C-N 127.551 3.032 . . . . 0.0 107.965 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -102.58 -142.75 12.53 Favored Glycine 0 CA--C 1.525 0.671 0 C-N-CA 124.763 1.173 . . . . 0.0 115.001 -167.423 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 71.65 5.34 60.32 Favored Glycine 0 C--N 1.334 0.455 0 CA-C-O 117.234 -1.87 . . . . 0.0 116.751 165.489 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 38.1 m-20 -77.01 143.54 70.61 Favored Pre-proline 0 N--CA 1.45 -0.455 0 CA-C-O 115.435 -2.221 . . . . 0.0 115.981 -178.261 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -83.02 127.71 4.79 Favored 'Trans proline' 0 N--CA 1.449 -1.09 0 CA-C-N 125.151 2.875 . . . . 0.0 115.998 -176.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -138.25 161.48 36.77 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 114.133 -1.394 . . . . 0.0 111.428 -171.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -153.39 151.72 30.24 Favored 'General case' 0 N--CA 1.447 -0.62 0 O-C-N 120.547 -1.346 . . . . 0.0 113.22 172.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 53.5 t -133.35 99.73 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 C-N-CA 130.054 3.342 . . . . 0.0 104.335 -172.072 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -125.07 138.87 54.18 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 113.577 -1.647 . . . . 0.0 112.663 -170.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.4 mt -138.78 115.45 10.58 Favored 'Isoleucine or valine' 0 C--O 1.238 0.482 0 O-C-N 119.715 -1.866 . . . . 0.0 107.978 -147.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -88.64 138.62 31.26 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 118.823 -2.423 . . . . 0.0 107.011 173.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -141.83 173.33 23.64 Favored Glycine 0 CA--C 1.523 0.539 0 C-N-CA 129.359 3.361 . . . . 0.0 112.475 -166.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -49.07 145.91 13.3 Favored 'Trans proline' 0 N--CA 1.46 -0.484 1 C-N-CA 125.921 4.414 . . . . 0.0 117.454 170.629 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.261 30.0 m-20 67.63 7.6 5.76 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 112.498 -2.137 . . . . 0.0 112.871 -167.481 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 76.95 33.69 44.97 Favored Glycine 0 CA--C 1.523 0.585 0 O-C-N 117.813 -3.054 . . . . 0.0 110.837 175.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 67.6 mt -80.29 138.31 36.74 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 126.521 1.928 . . . . 0.0 114.863 173.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 4.5 t -103.27 145.36 12.58 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 CA-C-O 126.064 2.84 . . . . 0.0 113.207 166.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 8.9 t -149.43 152.67 11.71 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 O-C-N 116.906 -3.621 . . . . 0.0 107.5 -176.185 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -131.21 138.24 49.29 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-O 123.413 1.578 . . . . 0.0 115.02 161.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -94.09 131.1 39.94 Favored 'General case' 0 N--CA 1.441 -0.917 1 C-N-CA 133.319 4.648 . . . . 0.0 112.585 -164.289 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.41 ' HE2' ' HB3' ' A' ' 70' ' ' LYS 0.258 28.5 ttpt -71.31 126.03 28.56 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 122.894 2.588 . . . . 0.0 112.506 -166.663 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 68.8 t -106.88 140.2 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 O-C-N 119.552 -1.968 . . . . 0.0 106.446 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 90.4 m -144.76 127.97 16.71 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-O 124.868 2.27 . . . . 0.0 113.933 178.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -69.26 128.31 36.14 Favored 'General case' 0 N--CA 1.456 -0.155 0 C-N-CA 127.35 2.26 . . . . 0.0 109.895 -174.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 55.8 m-20 -91.11 5.47 48.82 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 118.458 2.762 . . . . 0.0 118.458 174.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 1.8 m120 55.17 43.23 29.73 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 120.057 1.299 . . . . 0.0 112.423 174.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 35.3 p-10 -155.57 3.29 0.18 Allowed 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 128.052 2.541 . . . . 0.0 116.565 -174.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 98.95 4.2 56.79 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 118.515 -2.616 . . . . 0.0 112.33 -174.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 16.9 p -133.94 165.77 24.24 Favored 'General case' 0 CA--C 1.515 -0.387 0 N-CA-C 116.723 2.12 . . . . 0.0 116.723 177.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 45.2 m-85 -129.64 134.43 47.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.602 177.179 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -81.75 133.72 12.35 Favored Glycine 0 C--N 1.342 0.863 0 O-C-N 125.775 1.922 . . . . 0.0 108.325 172.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.445 HG13 ' CZ ' ' A' ' 36' ' ' PHE . 17.5 t -118.55 136.94 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 128.122 2.569 . . . . 0.0 109.433 175.454 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 p -134.84 135.05 53.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 CA-C-O 114.574 -2.631 . . . . 0.0 111.347 -178.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 80.2 t80 -156.17 144.39 19.85 Favored 'General case' 0 N--CA 1.445 -0.686 1 O-C-N 130.82 5.075 . . . . 0.0 113.084 -174.794 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.9 p30 -130.0 149.0 51.91 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 126.473 1.909 . . . . 0.0 107.999 -177.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -115.25 112.27 44.1 Favored Pre-proline 0 CA--C 1.511 -0.532 0 C-N-CA 125.731 1.612 . . . . 0.0 112.016 -171.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -71.41 -14.55 31.01 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 C-N-CA 124.032 3.155 . . . . 0.0 117.321 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.8 m -143.57 143.59 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 O-C-N 119.824 -1.797 . . . . 0.0 109.853 -174.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 -49.47 121.48 5.11 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 162.306 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -179.92 171.57 43.06 Favored Glycine 0 C--N 1.339 0.711 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.394 -175.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -98.86 133.22 43.46 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 128.886 2.874 . . . . 0.0 112.504 158.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 -126.94 150.03 49.54 Favored 'General case' 0 C--O 1.22 -0.464 0 N-CA-C 106.363 -1.717 . . . . 0.0 106.363 -173.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -119.18 111.28 18.04 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-N 114.214 -1.357 . . . . 0.0 114.632 -170.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.6 t -102.35 132.82 47.6 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.43 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 -166.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -122.6 128.09 50.24 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 131.169 3.788 . . . . 0.0 112.243 166.113 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 62.0 t -117.36 143.65 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 CA-C-N 114.481 -1.236 . . . . 0.0 109.682 -177.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.5 p -140.31 160.55 39.72 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 117.971 -1.014 . . . . 0.0 111.888 -171.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . 0.257 8.2 tt -135.65 94.08 3.04 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 103.152 -2.907 . . . . 0.0 103.152 -152.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 26.4 ttp-105 52.96 37.42 24.46 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 120.975 1.716 . . . . 0.0 112.019 -170.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 65.07 35.95 92.41 Favored Glycine 0 C--N 1.338 0.679 0 N-CA-C 116.65 1.42 . . . . 0.0 116.65 -176.26 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 71.3 m-80 -115.38 141.19 26.83 Favored Pre-proline 0 N--CA 1.447 -0.588 0 CA-C-O 117.353 -1.308 . . . . 0.0 110.009 166.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -71.69 165.98 30.86 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 CA-C-O 124.988 1.995 . . . . 0.0 112.095 166.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 11.6 pt -137.62 179.55 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 C-N-CA 127.234 2.214 . . . . 0.0 112.788 -173.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.4 ' HZ1' ' CD ' ' A' ' 16' ' ' GLU . 56.3 mtpt -74.71 165.91 24.45 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-O 115.529 -2.177 . . . . 0.0 111.025 -173.084 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.421 15.1 m120 66.93 -20.58 0.11 Allowed 'General case' 0 C--N 1.33 -0.268 0 O-C-N 125.59 1.806 . . . . 0.0 114.019 172.737 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 12.9 mmt -67.17 158.65 80.77 Favored Pre-proline 0 N--CA 1.446 -0.644 0 C-N-CA 127.268 2.227 . . . . 0.0 116.575 -178.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -73.51 159.68 97.06 Favored 'Cis proline' 0 N--CA 1.442 -1.517 0 O-C-N 125.089 2.099 . . . . 0.0 107.932 -20.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 8.2 pt -131.23 161.96 40.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 C-N-CA 126.828 2.051 . . . . 0.0 108.736 -174.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 69.8 m-20 -117.27 147.9 42.14 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 126.481 1.912 . . . . 0.0 111.28 -159.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 42.7 t -139.66 117.29 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 126.344 1.857 . . . . 0.0 111.889 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 65.4 tttt -81.9 136.14 35.35 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 115.524 1.675 . . . . 0.0 115.524 168.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 98.1 m -126.77 133.39 50.85 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 125.766 1.626 . . . . 0.0 107.622 -170.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 48.9 mm -121.82 141.78 40.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 O-C-N 120.156 -1.59 . . . . 0.0 107.65 177.272 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -82.75 41.23 0.72 Allowed 'General case' 0 N--CA 1.454 -0.246 1 O-C-N 114.941 -4.85 . . . . 0.0 116.548 -155.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.651 0 O-C-N 119.493 -2.004 . . . . 0.0 113.449 -175.685 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.6 mmt . . . . . 0 N--CA 1.472 0.664 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 46.3 t60 -151.48 148.75 28.44 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 126.429 3.014 . . . . 0.0 114.461 -164.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 8.1 m-70 -48.37 134.33 15.09 Favored 'General case' 0 N--CA 1.445 -0.701 0 C-N-CA 128.592 2.757 . . . . 0.0 115.272 165.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 3.6 p-80 -135.49 62.38 1.63 Allowed 'General case' 0 C--O 1.234 0.284 0 C-N-CA 127.832 2.453 . . . . 0.0 109.933 -171.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.8 p80 -85.43 155.74 21.14 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 129.984 3.314 . . . . 0.0 107.331 170.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 61.8 m80 -137.43 -30.31 0.85 Allowed 'General case' 0 N--CA 1.445 -0.69 0 C-N-CA 128.863 2.865 . . . . 0.0 114.768 177.197 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 16.9 p80 -126.71 144.9 50.79 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 129.181 2.993 . . . . 0.0 113.861 179.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -66.31 -28.77 68.94 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 120.723 3.601 . . . . 0.0 120.723 -175.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.4 p -66.46 132.7 48.85 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 122.187 2.267 . . . . 0.0 114.974 166.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 55.5 pttt -124.21 144.28 45.09 Favored Pre-proline 0 N--CA 1.451 -0.409 0 C-N-CA 126.955 2.102 . . . . 0.0 111.721 -176.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -92.53 176.26 1.73 Allowed 'Trans proline' 0 N--CA 1.447 -1.255 0 C-N-CA 123.72 2.947 . . . . 0.0 108.986 168.633 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -114.59 161.97 26.0 Favored Pre-proline 0 N--CA 1.447 -0.578 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_exo -52.06 166.78 0.59 Allowed 'Trans proline' 0 N--CA 1.444 -1.394 0 N-CA-C 115.806 1.425 . . . . 0.0 115.806 170.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.7 t -133.95 149.75 51.27 Favored 'General case' 0 N--CA 1.447 -0.59 0 O-C-N 120.306 -1.496 . . . . 0.0 107.971 160.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -47.99 -33.1 7.36 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 130.477 3.511 . . . . 0.0 111.406 164.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -67.43 -19.8 65.42 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 75.0 m-70 -141.32 14.91 2.21 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 117.321 2.341 . . . . 0.0 117.321 -159.25 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.1 t -141.49 126.31 18.11 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 176.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 65.4 m-85 -150.88 158.0 43.6 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 130.01 3.324 . . . . 0.0 108.882 -161.205 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -133.32 148.68 51.91 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 118.343 2.72 . . . . 0.0 118.343 -175.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -145.27 146.13 31.54 Favored 'General case' 0 C--O 1.221 -0.408 0 N-CA-C 119.917 3.302 . . . . 0.0 119.917 171.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.44 178.83 28.37 Favored Glycine 0 C--N 1.342 0.863 0 C-N-CA 125.457 1.503 . . . . 0.0 114.899 173.207 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -59.28 -32.33 69.92 Favored 'General case' 0 C--O 1.239 0.552 0 O-C-N 117.994 -3.063 . . . . 0.0 117.296 176.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.39 10.06 2.94 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 125.342 1.449 . . . . 0.0 115.795 170.187 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 89.6 mt -124.38 30.52 6.01 Favored 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 118.829 -2.571 . . . . 0.0 112.754 154.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 95.4 t -138.86 -63.05 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 O-C-N 120.111 -1.618 . . . . 0.0 109.683 175.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.292 37.2 pttt -144.65 131.83 20.57 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 123.122 2.692 . . . . 0.0 115.128 -173.111 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 t -130.78 146.76 33.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 1 O-C-N 129.176 4.048 . . . . 0.0 112.386 -174.366 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.466 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 3.9 m-85 -140.1 179.77 6.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 116.84 2.163 . . . . 0.0 116.84 177.137 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -82.36 -39.93 22.07 Favored 'General case' 0 C--O 1.235 0.341 0 O-C-N 116.818 -3.676 . . . . 0.0 113.538 -168.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 15.6 m-80 -105.81 3.42 28.72 Favored 'General case' 0 N--CA 1.449 -0.522 0 O-C-N 126.379 2.3 . . . . 0.0 112.907 178.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -128.77 89.64 48.49 Favored Pre-proline 0 N--CA 1.447 -0.599 0 O-C-N 121.693 -0.629 . . . . 0.0 110.731 175.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_endo -65.97 147.59 84.87 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 O-C-N 125.843 2.496 . . . . 0.0 110.576 -178.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.412 ' O ' ' HA ' ' A' ' 82' ' ' VAL . . . -108.21 164.77 12.01 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 126.426 1.89 . . . . 0.0 111.305 -177.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -140.34 146.0 37.89 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 115.616 -2.135 . . . . 0.0 112.748 -175.097 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 24.6 p90 -153.52 167.39 29.64 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 122.858 2.572 . . . . 0.0 107.49 171.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 94.7 m -127.46 115.6 19.14 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.262 1.425 . . . . 0.0 109.012 -156.005 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . 0.405 8.4 mt -67.06 96.91 0.29 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.22 0 C-N-CA 125.529 1.532 . . . . 0.0 112.044 162.717 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -83.49 112.43 19.96 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-O 125.086 2.374 . . . . 0.0 111.942 166.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -114.97 126.94 55.35 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 116.496 -3.878 . . . . 0.0 110.259 -167.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.453 HG21 ' HA ' ' A' ' 47' ' ' ALA . 54.4 t -127.62 149.43 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-O 123.967 1.841 . . . . 0.0 106.894 173.563 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -80.86 -37.57 29.67 Favored 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 117.162 2.282 . . . . 0.0 117.162 169.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 82.7 p -160.0 -69.94 0.07 Allowed 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 127.048 2.717 . . . . 0.0 116.907 -170.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 50.6 mttm -127.98 99.13 5.38 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 122.282 2.31 . . . . 0.0 113.253 -174.01 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 76.37 -75.32 1.6 Allowed Glycine 0 CA--C 1.525 0.661 0 CA-C-N 121.995 2.18 . . . . 0.0 114.915 159.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 65.5 t -46.66 129.03 2.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 126.624 1.97 . . . . 0.0 107.005 171.157 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.453 ' HA ' HG21 ' A' ' 41' ' ' VAL . . . -58.81 171.23 0.68 Allowed 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 116.661 2.097 . . . . 0.0 116.661 177.088 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.3 mmm180 -64.22 116.06 5.63 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 115.598 -2.144 . . . . 0.0 106.28 165.273 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.7 p -76.63 4.6 9.07 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 127.762 3.164 . . . . 0.0 116.604 -160.45 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -168.4 163.06 12.69 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-O 125.338 2.494 . . . . 0.0 108.314 -173.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -103.17 -169.5 25.98 Favored Glycine 0 CA--C 1.524 0.646 0 O-C-N 118.064 -2.898 . . . . 0.0 113.61 -150.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 62.24 22.08 62.67 Favored Glycine 0 C--N 1.335 0.475 0 CA-C-O 113.854 -3.748 . . . . 0.0 117.952 169.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -69.09 153.59 95.89 Favored Pre-proline 0 N--CA 1.452 -0.363 0 CA-C-N 124.15 3.975 . . . . 0.0 110.253 173.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -88.03 133.08 2.87 Favored 'Trans proline' 0 N--CA 1.447 -1.264 1 C-N-CA 127.091 5.194 . . . . 0.0 118.388 -172.366 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -148.8 167.12 26.47 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 113.174 -1.83 . . . . 0.0 110.37 -156.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -161.96 141.76 10.01 Favored 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 129.021 2.928 . . . . 0.0 107.241 174.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 20.2 t -132.14 96.04 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 C-N-CA 130.769 3.628 . . . . 0.0 103.917 -178.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -116.16 140.36 49.38 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 112.236 -2.257 . . . . 0.0 110.016 -168.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 58.5 mt -134.82 148.84 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 CA-C-N 113.754 -1.567 . . . . 0.0 110.041 -159.229 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 54.2 m-80 -126.67 151.5 47.99 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 104.693 -2.336 . . . . 0.0 104.693 165.05 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.0 -145.72 4.72 Favored Glycine 0 C--O 1.219 -0.819 0 N-CA-C 107.613 -2.195 . . . . 0.0 107.613 173.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -75.02 133.65 16.82 Favored 'Trans proline' 0 N--CA 1.45 -1.029 0 CA-C-O 124.496 1.79 . . . . 0.0 111.746 -172.316 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.31 15.1 t70 48.74 -125.31 1.95 Allowed 'General case' 0 N--CA 1.45 -0.444 0 O-C-N 117.608 -3.182 . . . . 0.0 113.669 -172.068 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -80.93 4.76 68.62 Favored Glycine 0 CA--C 1.532 1.105 0 C-N-CA 127.021 2.248 . . . . 0.0 115.086 -170.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . 0.273 19.9 tp -72.93 104.34 4.04 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 114.792 1.404 . . . . 0.0 114.792 -177.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 99.0 t -116.3 135.01 57.91 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-O 123.295 1.521 . . . . 0.0 107.023 175.108 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 24.4 t -140.36 151.53 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.993 0 C-N-CA 125.21 1.404 . . . . 0.0 111.735 -168.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.256 8.3 p-10 -135.72 122.55 21.15 Favored 'General case' 0 C--N 1.326 -0.429 0 O-C-N 127.532 3.02 . . . . 0.0 109.791 167.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -74.75 151.08 39.19 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 128.586 2.754 . . . . 0.0 114.828 -178.173 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 66.3 tttt -93.73 98.75 11.31 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 114.369 -1.287 . . . . 0.0 111.376 -160.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.1 t -88.64 133.24 31.49 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.117 0 O-C-N 125.678 1.861 . . . . 0.0 106.451 -170.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 26.3 m -144.4 126.48 15.53 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 118.574 -1.25 . . . . 0.0 109.353 172.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -48.56 120.84 3.99 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 128.534 2.734 . . . . 0.0 118.283 166.589 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 -84.55 1.16 47.13 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 114.256 -2.783 . . . . 0.0 112.613 178.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 9.3 m120 61.29 24.24 14.37 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 117.556 2.428 . . . . 0.0 117.556 -177.267 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 19.8 p30 -134.55 -6.28 2.53 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 115.487 1.662 . . . . 0.0 115.487 -177.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 112.61 0.79 26.08 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 114.836 -3.202 . . . . 0.0 114.586 -166.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 66.0 p -131.74 160.46 35.47 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 120.407 2.103 . . . . 0.0 113.529 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -123.79 127.63 48.38 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 117.866 -3.021 . . . . 0.0 110.362 173.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -80.6 116.35 4.22 Favored Glycine 0 CA--C 1.526 0.755 0 C-N-CA 129.246 3.308 . . . . 0.0 106.103 171.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.7 t -102.14 125.34 56.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 117.194 2.294 . . . . 0.0 117.194 165.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.412 ' HA ' ' O ' ' A' ' 34' ' ' ALA . 87.6 t -125.79 145.79 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-N 121.906 2.139 . . . . 0.0 111.762 -173.666 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . 0.343 1.2 p90 -165.93 172.63 11.33 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 122.849 2.568 . . . . 0.0 114.524 179.513 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 19.8 p30 -135.33 169.48 17.41 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -177.037 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -132.88 109.64 13.02 Favored Pre-proline 0 N--CA 1.447 -0.604 0 N-CA-C 114.752 1.389 . . . . 0.0 114.752 179.184 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.288 68.8 Cg_endo -71.88 -2.63 11.78 Favored 'Trans proline' 0 N--CA 1.449 -1.14 0 C-N-CA 124.702 3.601 . . . . 0.0 111.366 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.8 m -138.66 144.71 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.634 0 CA-C-O 121.653 0.739 . . . . 0.0 111.961 -163.05 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -63.29 127.52 31.66 Favored 'General case' 0 N--CA 1.451 -0.423 0 O-C-N 119.361 -2.087 . . . . 0.0 109.956 153.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 167.39 -166.37 39.24 Favored Glycine 0 CA--C 1.521 0.444 0 CA-C-O 123.756 1.753 . . . . 0.0 116.289 -172.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 11.1 t30 -114.48 139.71 49.32 Favored 'General case' 0 C--O 1.22 -0.487 0 CA-C-N 111.295 -2.452 . . . . 0.0 111.908 164.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . 0.415 ' CD2' ' SG ' ' A' ' 111' ' ' CYS . 10.1 m-85 -98.57 152.04 20.01 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 127.518 3.532 . . . . 0.0 112.494 152.269 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -129.08 109.07 10.88 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 109.806 -3.361 . . . . 0.0 108.164 -174.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 87.0 t -101.32 129.08 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 113.155 -1.839 . . . . 0.0 108.403 -163.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -131.15 130.52 43.16 Favored 'General case' 0 N--CA 1.449 -0.509 0 O-C-N 126.445 2.341 . . . . 0.0 110.889 176.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 99.6 t -112.74 147.13 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.741 0 N-CA-C 114.67 1.359 . . . . 0.0 114.67 -177.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 31.4 p -142.89 162.54 35.19 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 120.792 1.633 . . . . 0.0 111.597 175.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 3.0 tt -144.51 101.26 3.66 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 -147.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 28.8 ttm-85 47.51 42.01 13.92 Favored 'General case' 0 N--CA 1.445 -0.684 0 O-C-N 124.625 1.203 . . . . 0.0 108.324 -163.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 85.48 2.75 87.11 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 128.791 3.091 . . . . 0.0 120.077 177.129 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.2 m-20 -115.58 147.84 39.72 Favored Pre-proline 0 CA--C 1.514 -0.425 0 C-N-CA 125.881 1.672 . . . . 0.0 113.243 -176.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -74.15 163.04 37.52 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 124.755 3.637 . . . . 0.0 111.138 -177.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 10.7 pt -140.82 175.09 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 126.219 1.807 . . . . 0.0 112.699 -165.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -82.28 164.08 21.39 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 120.832 1.651 . . . . 0.0 113.915 -170.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 29.7 m120 53.97 40.15 31.28 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 127.403 2.281 . . . . 0.0 116.772 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 8.7 mmt -126.25 168.96 12.71 Favored Pre-proline 0 N--CA 1.45 -0.462 0 C-N-CA 126.993 2.117 . . . . 0.0 107.376 -170.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -65.67 168.66 14.47 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 N-CA-C 117.453 2.059 . . . . 0.0 117.453 -33.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . 0.372 17.1 pt -138.54 140.05 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-O 122.71 1.243 . . . . 0.0 109.202 -168.631 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -107.93 139.16 42.97 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 117.526 2.417 . . . . 0.0 117.526 -168.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 66.1 t -146.53 114.88 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.762 0 O-C-N 119.783 -1.823 . . . . 0.0 109.395 -161.442 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 68.2 tttt -80.51 144.26 32.65 Favored 'General case' 0 CA--C 1.523 -0.093 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.415 ' SG ' ' CD2' ' A' ' 91' ' ' TYR . 87.7 m -117.14 139.08 51.19 Favored 'General case' 0 N--CA 1.451 -0.42 2 O-C-N 131.991 5.807 . . . . 0.0 110.233 -179.984 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.466 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 90.9 mt -135.04 123.37 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-N 108.469 -3.969 . . . . 0.0 113.361 171.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . 0.3 7.5 pt-20 -76.23 39.97 0.2 Allowed 'General case' 0 N--CA 1.451 -0.395 0 O-C-N 116.947 -3.595 . . . . 0.0 115.332 -164.646 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.626 0 CA-C-N 121.457 1.935 . . . . 0.0 115.585 169.728 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 tmt? . . . . . 0 CA--C 1.511 -0.553 0 CA-C-O 114.64 -2.6 . . . . 0.0 110.155 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 77.6 t60 -136.88 132.9 35.17 Favored 'General case' 0 C--N 1.34 0.185 0 CA-C-N 122.358 2.344 . . . . 0.0 106.355 175.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -80.15 113.27 18.2 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 126.273 2.939 . . . . 0.0 110.208 165.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 56.6 t-80 -157.99 129.17 6.57 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 112.196 -2.275 . . . . 0.0 116.255 177.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.4 m-70 -73.28 114.3 11.32 Favored 'General case' 0 N--CA 1.433 -1.314 0 O-C-N 118.981 -2.324 . . . . 0.0 114.964 178.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . 0.419 ' HD1' ' CD2' ' A' ' 7' ' ' HIS . 28.2 t-80 -80.08 -47.6 14.57 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-O 116.012 -1.946 . . . . 0.0 112.86 174.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.419 ' CD2' ' HD1' ' A' ' 6' ' ' HIS . 72.5 m-70 -122.51 173.87 7.4 Favored 'General case' 0 N--CA 1.453 -0.288 0 O-C-N 127.741 3.15 . . . . 0.0 115.031 177.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -68.1 -33.55 74.74 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 116.815 2.154 . . . . 0.0 116.815 158.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.2 p -68.54 149.36 49.3 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 115.772 1.767 . . . . 0.0 115.772 160.195 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 31.9 pttt -161.18 154.49 18.05 Favored Pre-proline 0 N--CA 1.443 -0.819 0 C-N-CA 126.772 2.029 . . . . 0.0 115.756 179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -69.3 168.6 20.48 Favored 'Trans proline' 0 N--CA 1.439 -1.703 0 C-N-CA 124.394 3.396 . . . . 0.0 111.313 176.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -111.53 136.83 21.03 Favored Pre-proline 0 C--O 1.239 0.538 0 C-N-CA 131.116 3.767 . . . . 0.0 114.187 -176.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . 0.252 23.3 Cg_exo -65.58 168.78 14.04 Favored 'Trans proline' 0 CA--C 1.514 -0.49 0 N-CA-C 117.498 2.076 . . . . 0.0 117.498 170.63 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.6 m -142.88 160.85 39.55 Favored 'General case' 0 N--CA 1.44 -0.958 0 CA-C-N 123.317 2.78 . . . . 0.0 110.937 -174.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.44 -48.43 81.68 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 113.597 -3.097 . . . . 0.0 113.861 174.638 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -52.64 -28.32 20.95 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 123.06 2.663 . . . . 0.0 106.773 173.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 74.4 m-70 -117.37 5.86 12.61 Favored 'General case' 0 C--O 1.218 -0.603 0 N-CA-C 116.525 2.046 . . . . 0.0 116.525 -156.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.8 t -135.14 121.86 20.88 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 116.816 2.154 . . . . 0.0 116.816 173.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 26.6 m-85 -153.31 155.19 36.02 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -161.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . 0.462 . . -132.01 147.92 52.48 Favored 'General case' 0 C--O 1.217 -0.61 0 N-CA-C 117.85 2.537 . . . . 0.0 117.85 -167.36 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -160.96 145.95 14.08 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 130.125 3.37 . . . . 0.0 108.736 -164.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.1 175.21 13.94 Favored Glycine 0 N--CA 1.446 -0.696 0 O-C-N 126.99 2.681 . . . . 0.0 117.505 -173.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -74.03 -30.21 62.31 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 112.652 -3.547 . . . . 0.0 113.715 -176.139 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -62.23 9.82 0.12 Allowed Glycine 0 CA--C 1.531 1.047 0 CA-C-N 124.945 3.52 . . . . 0.0 115.371 161.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 17.0 mt -113.9 19.85 16.25 Favored 'General case' 0 C--O 1.223 -0.312 0 CA-C-N 122.023 2.911 . . . . 0.0 109.799 167.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 1.7 t -137.97 -41.75 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 CA-C-O 115.313 -2.28 . . . . 0.0 110.312 174.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 42.4 mtmt -155.74 118.09 4.14 Favored 'General case' 0 C--N 1.328 -0.367 0 O-C-N 124.685 1.241 . . . . 0.0 114.096 -163.051 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 t -124.7 138.69 53.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 C-N-CA 130.853 3.661 . . . . 0.0 116.188 177.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -128.78 -169.82 2.15 Favored 'General case' 0 N--CA 1.452 -0.358 0 O-C-N 126.552 2.408 . . . . 0.0 115.434 -174.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 17.7 t0 -105.17 -33.29 8.31 Favored 'General case' 0 CA--C 1.511 -0.541 0 O-C-N 118.278 -2.764 . . . . 0.0 114.212 -167.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 53.8 m-80 -101.83 8.73 41.22 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 120.511 3.523 . . . . 0.0 120.511 162.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -137.57 96.15 10.95 Favored Pre-proline 0 N--CA 1.445 -0.676 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.263 178.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_exo -62.83 128.29 22.79 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 121.883 1.722 . . . . 0.0 111.7 171.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -92.35 156.41 17.26 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 123.05 1.405 . . . . 0.0 109.71 -177.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -133.97 149.77 51.25 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 -169.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -161.64 173.27 14.95 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.194 -2.521 . . . . 0.0 104.194 168.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 26.1 m -127.02 118.17 23.93 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 131.53 3.932 . . . . 0.0 114.811 -158.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 44.7 mm -76.19 96.31 1.32 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.483 0 C-N-CA 127.012 2.125 . . . . 0.0 106.213 173.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -81.83 99.87 9.26 Favored 'General case' 0 C--O 1.214 -0.8 0 O-C-N 119.114 -2.241 . . . . 0.0 114.87 171.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -100.12 137.14 38.97 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 117.807 2.521 . . . . 0.0 117.807 -167.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 71.7 t -134.94 156.45 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 C-N-CA 128.449 2.7 . . . . 0.0 113.858 169.612 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.7 p30 -76.71 -71.65 0.38 Allowed 'General case' 0 N--CA 1.448 -0.555 0 O-C-N 118.741 -2.474 . . . . 0.0 109.882 174.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 77.8 p -156.18 -39.67 0.08 Allowed 'General case' 0 C--O 1.238 0.481 1 C-N-CA 133.57 4.748 . . . . 0.0 106.86 -175.705 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 46.6 mtmt -87.65 28.43 1.0 Allowed 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 123.237 2.744 . . . . 0.0 110.755 -154.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 78.28 -41.56 2.05 Favored Glycine 0 N--CA 1.444 -0.807 0 O-C-N 118.27 -2.769 . . . . 0.0 115.675 169.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.6 t -71.21 145.11 12.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 126.178 1.791 . . . . 0.0 114.667 168.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -47.12 162.19 0.06 Allowed 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 114.306 -1.316 . . . . 0.0 113.882 177.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -64.82 113.04 3.54 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.369 174.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.5 p -89.11 4.86 47.04 Favored 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 131.232 3.813 . . . . 0.0 113.142 -163.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.9 p30 -152.49 172.69 16.17 Favored 'General case' 0 N--CA 1.446 -0.657 1 C-N-CA 133.697 4.799 . . . . 0.0 108.521 162.737 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -138.03 -175.64 14.03 Favored Glycine 0 N--CA 1.443 -0.844 0 O-C-N 118.322 -2.736 . . . . 0.0 109.797 -149.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.93 41.5 98.67 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 127.213 2.339 . . . . 0.0 111.503 -178.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -74.51 156.61 86.9 Favored Pre-proline 0 C--O 1.221 -0.405 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 167.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -87.83 135.64 3.49 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 CA-C-O 127.298 2.958 . . . . 0.0 113.632 174.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -147.49 151.94 37.22 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 117.994 -2.941 . . . . 0.0 110.436 -173.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -140.59 142.8 35.05 Favored 'General case' 0 N--CA 1.446 -0.643 0 O-C-N 118.94 -2.35 . . . . 0.0 109.924 178.649 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 19.9 t -129.58 81.79 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 C-N-CA 129.876 3.27 . . . . 0.0 106.047 178.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -94.65 131.9 39.95 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 113.142 -1.844 . . . . 0.0 114.793 176.249 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.7 mt -124.13 156.95 31.58 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.581 0 C-N-CA 125.782 1.633 . . . . 0.0 108.116 -163.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -115.28 132.85 56.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 115.508 -2.187 . . . . 0.0 114.426 144.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -80.52 -152.42 8.23 Favored Glycine 0 CA--C 1.532 1.118 0 O-C-N 125.709 1.881 . . . . 0.0 110.611 160.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_exo -82.66 122.69 3.57 Favored 'Trans proline' 0 N--CA 1.442 -1.529 0 C-N-CA 124.773 3.648 . . . . 0.0 110.806 -170.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 25.5 t0 30.15 -92.81 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.408 0 O-C-N 126.775 2.547 . . . . 0.0 112.632 -156.027 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.21 2.86 55.21 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 118.533 2.173 . . . . 0.0 118.533 -167.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . 0.264 53.4 tp -86.51 90.01 8.09 Favored 'General case' 0 C--O 1.238 0.455 0 O-C-N 119.646 -2.091 . . . . 0.0 109.02 -174.172 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 96.4 t -77.24 114.48 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 CA-C-N 110.856 -2.884 . . . . 0.0 115.422 169.11 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 20.0 t -130.34 153.21 38.66 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.797 0 O-C-N 117.895 -3.003 . . . . 0.0 115.191 -173.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.2 p-10 -130.04 138.45 50.77 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 160.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -90.97 149.47 21.85 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-O 125.011 2.339 . . . . 0.0 111.926 177.11 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 52.6 mmtt -93.0 115.37 28.06 Favored 'General case' 0 N--CA 1.445 -0.681 0 O-C-N 118.612 -2.555 . . . . 0.0 108.62 -163.311 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 36.3 t -97.1 139.26 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 CA-C-N 114.051 -1.431 . . . . 0.0 109.813 -176.09 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 59.9 m -138.97 137.34 36.3 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 127.586 2.354 . . . . 0.0 113.056 174.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -73.05 128.68 36.19 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 126.132 1.773 . . . . 0.0 109.924 177.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 67.5 m-20 -90.16 -1.38 57.93 Favored 'General case' 0 C--O 1.221 -0.401 0 CA-C-O 115.722 -2.085 . . . . 0.0 115.3 175.034 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 1.7 m120 70.6 24.52 4.4 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 123.797 2.998 . . . . 0.0 111.553 167.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 38.0 p30 -139.27 -7.17 1.35 Allowed 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 121.582 3.919 . . . . 0.0 121.582 179.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 130.89 -13.2 5.56 Favored Glycine 0 C--O 1.242 0.628 0 CA-C-O 123.228 1.46 . . . . 0.0 112.967 -177.216 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.6 p -128.22 164.64 22.09 Favored 'General case' 0 C--O 1.24 0.586 0 C-N-CA 127.696 2.398 . . . . 0.0 113.472 -171.053 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 -128.49 147.76 50.7 Favored 'General case' 0 C--N 1.329 -0.291 0 O-C-N 125.308 1.63 . . . . 0.0 107.641 174.621 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -94.38 132.18 11.05 Favored Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 128.761 3.077 . . . . 0.0 111.183 173.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.9 t -128.07 138.62 54.17 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 CA-C-O 117.401 -1.285 . . . . 0.0 113.036 178.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.9 t -141.91 130.94 22.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 O-C-N 124.783 1.302 . . . . 0.0 112.695 -167.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -161.15 138.14 8.79 Favored 'General case' 0 CA--C 1.517 -0.313 0 CA-C-O 124.35 2.024 . . . . 0.0 111.859 -174.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.267 57.4 p-10 -109.88 160.9 15.98 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 129.227 3.011 . . . . 0.0 112.829 175.396 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -130.15 109.87 16.67 Favored Pre-proline 0 N--CA 1.443 -0.776 0 C-N-CA 126.508 1.923 . . . . 0.0 109.754 -167.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -70.5 -6.41 18.91 Favored 'Trans proline' 0 N--CA 1.445 -1.341 0 C-N-CA 122.072 1.848 . . . . 0.0 114.906 -179.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.5 m -149.68 147.14 16.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 O-C-N 118.126 -2.859 . . . . 0.0 114.737 -151.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 28.7 tt0 -62.95 102.95 0.4 Allowed 'General case' 0 C--O 1.241 0.607 0 CA-C-O 123.35 1.548 . . . . 0.0 108.848 167.071 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -177.91 -136.62 2.55 Favored Glycine 0 N--CA 1.434 -1.488 1 O-C-N 116.288 -4.007 . . . . 0.0 122.784 178.098 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 25.8 t30 -132.36 137.04 47.23 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 130.18 3.392 . . . . 0.0 110.552 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 13.6 m-85 -106.75 151.9 24.53 Favored 'General case' 0 N--CA 1.446 -0.671 0 O-C-N 124.502 1.126 . . . . 0.0 112.75 151.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -119.77 116.52 26.08 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 110.894 -2.866 . . . . 0.0 112.213 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 3.3 t -112.33 126.02 69.67 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.966 0 N-CA-C 115.507 1.669 . . . . 0.0 115.507 -162.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -136.53 118.96 15.76 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 115.452 -2.213 . . . . 0.0 110.312 -168.183 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 67.3 t -119.24 144.41 27.71 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.473 0 CA-C-N 120.515 1.507 . . . . 0.0 108.625 -174.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 33.0 p -135.36 153.06 51.96 Favored 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 127.086 2.154 . . . . 0.0 110.619 -177.274 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.5 mp -126.14 91.65 3.42 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-O 112.702 -3.523 . . . . 0.0 112.673 -161.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.1 ttm180 55.92 35.27 25.17 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 124.744 2.211 . . . . 0.0 110.307 -159.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 75.32 0.91 63.05 Favored Glycine 0 CA--C 1.533 1.195 0 O-C-N 117.793 -3.067 . . . . 0.0 117.918 -177.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 63.8 m-80 -78.51 134.14 62.33 Favored Pre-proline 0 N--CA 1.448 -0.539 0 O-C-N 120.525 -1.573 . . . . 0.0 112.013 168.434 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -87.76 178.52 3.22 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 123.904 3.07 . . . . 0.0 104.968 -177.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 19.2 pt -152.82 177.32 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 O-C-N 120.169 -1.582 . . . . 0.0 112.761 -172.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 13.3 ptmt -86.86 170.97 11.19 Favored 'General case' 0 N--CA 1.442 -0.874 0 C-N-CA 128.28 2.632 . . . . 0.0 117.91 -168.161 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 10.3 m120 53.43 32.89 14.76 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 129.512 3.125 . . . . 0.0 113.878 -177.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 2.9 ttm -146.34 145.54 24.3 Favored Pre-proline 0 C--O 1.246 0.897 0 O-C-N 116.69 -3.757 . . . . 0.0 111.486 -158.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . 0.3 10.1 Cg_endo -54.45 159.14 15.31 Favored 'Cis proline' 0 N--CA 1.443 -1.462 0 CA-C-N 125.002 2.822 . . . . 0.0 116.343 -13.625 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 13.4 pt -126.76 158.19 37.43 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 C-N-CA 130.38 3.472 . . . . 0.0 110.058 175.27 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -114.52 143.92 44.19 Favored 'General case' 0 CA--C 1.503 -0.833 0 N-CA-C 117.033 2.234 . . . . 0.0 117.033 -176.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 60.8 t -139.24 117.64 12.38 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 CA-C-O 117.087 -1.435 . . . . 0.0 110.318 -174.276 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . 0.25 32.6 ttpt -64.62 133.49 52.36 Favored 'General case' 0 N--CA 1.443 -0.797 0 C-N-CA 127.813 2.445 . . . . 0.0 113.66 -179.026 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 72.2 m -117.95 156.47 28.44 Favored 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 127.929 2.491 . . . . 0.0 112.492 -177.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 7.7 tt -155.27 156.64 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 114.776 1.399 . . . . 0.0 114.776 158.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . 0.316 5.0 pt-20 -62.51 43.44 0.01 OUTLIER 'General case' 0 N--CA 1.444 -0.769 0 C-N-CA 127.149 2.18 . . . . 0.0 116.879 173.372 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.676 0 N-CA-C 118.634 2.214 . . . . 0.0 118.634 179.939 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.1 tmt? . . . . . 0 N--CA 1.474 0.756 0 CA-C-O 117.066 -1.445 . . . . 0.0 108.599 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 72.9 t60 -116.33 130.95 57.04 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-N 120.819 1.645 . . . . 0.0 112.262 -170.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 9.4 t60 -97.85 119.51 36.58 Favored 'General case' 0 C--N 1.333 -0.133 0 N-CA-C 105.908 -1.886 . . . . 0.0 105.908 174.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . 0.514 ' HD1' ' CG ' ' A' ' 6' ' ' HIS . 38.1 t-80 -160.44 135.58 7.88 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 127.325 2.25 . . . . 0.0 110.415 173.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.442 ' CE1' ' H ' ' A' ' 51' ' ' GLY . 92.1 m-70 -71.07 95.82 1.26 Allowed 'General case' 0 N--CA 1.453 -0.301 0 CA-C-O 125.946 2.784 . . . . 0.0 112.846 165.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . 0.514 ' CG ' ' HD1' ' A' ' 4' ' ' HIS . 69.7 m80 -85.35 -22.38 28.48 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 119.231 -2.168 . . . . 0.0 114.65 172.027 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 67.3 m80 -141.34 166.3 25.14 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -162.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -74.97 -54.18 7.66 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 115.116 1.524 . . . . 0.0 115.116 164.212 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 65.8 m -68.37 135.07 51.22 Favored 'General case' 0 N--CA 1.455 -0.206 0 O-C-N 118.04 -2.912 . . . . 0.0 113.234 171.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 28.8 mtmt -127.88 149.23 70.15 Favored Pre-proline 0 N--CA 1.45 -0.46 0 O-C-N 118.326 -2.734 . . . . 0.0 108.986 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -70.1 156.85 61.48 Favored 'Trans proline' 0 N--CA 1.451 -0.98 0 N-CA-C 118.05 2.288 . . . . 0.0 118.05 156.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.411 ' O ' ' HA ' ' A' ' 42' ' ' ASP . . . -93.21 147.53 33.95 Favored Pre-proline 0 N--CA 1.45 -0.467 0 O-C-N 125.645 1.84 . . . . 0.0 114.414 -178.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -57.43 154.15 37.16 Favored 'Trans proline' 0 N--CA 1.449 -1.145 1 C-N-CA 127.224 5.283 . . . . 0.0 114.584 152.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 34.2 t -140.28 176.57 8.66 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 121.765 2.075 . . . . 0.0 113.579 -178.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . 0.296 . . -65.88 -48.23 72.21 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 129.935 3.294 . . . . 0.0 115.959 -173.223 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.0 mp0 -54.71 -28.18 46.12 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 111.231 -2.713 . . . . 0.0 113.458 166.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 31.4 m-70 -133.2 7.48 3.94 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-O 125.518 2.58 . . . . 0.0 112.928 -148.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . 0.268 29.2 t -125.46 114.04 18.29 Favored 'General case' 0 N--CA 1.45 -0.468 0 O-C-N 116.35 -3.969 . . . . 0.0 107.478 169.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . 0.265 75.6 m-85 -130.62 160.98 32.61 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 129.192 2.997 . . . . 0.0 108.195 174.449 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -137.85 151.16 47.79 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 127.63 2.372 . . . . 0.0 115.344 -169.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -154.39 137.14 15.26 Favored 'General case' 0 N--CA 1.452 -0.363 1 O-C-N 116.023 -4.173 . . . . 0.0 114.787 -165.589 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.36 -175.09 19.76 Favored Glycine 0 C--O 1.222 -0.636 0 C-N-CA 126.412 1.958 . . . . 0.0 108.514 160.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.2 tt0 -68.6 -22.78 64.43 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-O 114.725 -2.559 . . . . 0.0 113.714 -158.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -56.25 -0.14 0.17 Allowed Glycine 0 N--CA 1.443 -0.841 0 CA-C-O 115.247 -2.974 . . . . 0.0 117.829 161.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 23.8 mt -121.72 24.27 9.8 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 127.658 2.383 . . . . 0.0 114.729 168.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.8 t -142.96 -47.03 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 CA-C-O 114.976 -2.44 . . . . 0.0 107.7 -172.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 28.4 ttmt -172.47 139.54 0.99 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 115.36 -2.257 . . . . 0.0 112.279 -177.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 34.2 t -144.97 142.45 22.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 115.168 -2.348 . . . . 0.0 113.938 -166.384 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.427 ' HB2' ' HB3' ' A' ' 32' ' ' ALA 0.278 1.2 m-85 -129.6 177.53 7.15 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 125.381 1.676 . . . . 0.0 114.413 -166.283 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -94.86 -37.89 10.99 Favored 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 116.515 2.043 . . . . 0.0 116.515 -178.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 55.9 m-80 -102.52 19.48 18.9 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 115.975 1.843 . . . . 0.0 115.975 165.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.427 ' HB3' ' HB2' ' A' ' 29' ' ' PHE . . . -139.3 92.72 10.42 Favored Pre-proline 0 N--CA 1.455 -0.19 0 C-N-CA 126.1 1.76 . . . . 0.0 106.57 171.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . 0.324 74.9 Cg_exo -43.71 119.84 2.04 Favored 'Trans proline' 0 N--CA 1.449 -1.134 1 C-N-CA 129.854 7.036 . . . . 0.0 112.019 148.309 . . . . . . . . 3 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.403 ' O ' ' HA ' ' A' ' 82' ' ' VAL . . . -96.81 150.81 20.3 Favored 'General case' 0 N--CA 1.45 -0.457 0 C-N-CA 128.504 2.722 . . . . 0.0 111.116 -178.477 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -121.54 137.73 54.61 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-O 115.119 -2.372 . . . . 0.0 114.363 -173.109 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -154.53 172.17 18.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 CA-C-N 125.202 3.637 . . . . 0.0 107.723 164.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 55.5 m -138.0 129.6 28.09 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-O 115.947 -1.977 . . . . 0.0 111.533 -157.044 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 16.1 mt -89.57 124.01 42.07 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 O-C-N 125.928 2.018 . . . . 0.0 107.114 171.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.277 39.2 p90 -99.26 115.95 30.32 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 128.471 2.709 . . . . 0.0 112.232 170.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -116.46 129.74 56.38 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-O 123.716 1.722 . . . . 0.0 110.112 -161.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.6 t -125.03 151.41 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 C-N-CA 126.934 2.094 . . . . 0.0 113.816 163.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.411 ' HA ' ' O ' ' A' ' 12' ' ' ALA . 8.9 p30 -77.05 -72.56 0.34 Allowed 'General case' 0 N--CA 1.443 -0.784 0 CA-C-O 125.193 2.425 . . . . 0.0 116.464 170.607 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 16.0 p -159.54 -28.24 0.07 Allowed 'General case' 0 CA--C 1.517 -0.293 1 C-N-CA 133.774 4.829 . . . . 0.0 112.239 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . 0.393 84.3 mttt -94.4 13.92 22.22 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 123.015 2.643 . . . . 0.0 115.89 -170.414 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 79.8 -33.72 2.13 Favored Glycine 0 CA--C 1.523 0.556 0 O-C-N 118.164 -2.835 . . . . 0.0 112.542 164.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 71.1 t -54.99 133.41 18.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 1 CA-C-N 125.402 4.601 . . . . 0.0 112.22 155.541 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.53 166.74 0.05 OUTLIER 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 117.399 2.37 . . . . 0.0 117.399 169.43 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 8.4 mmm180 -53.86 120.03 5.77 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 176.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 34.8 p -88.19 -4.82 58.67 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 125.077 1.351 . . . . 0.0 110.914 -160.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -165.19 160.47 18.59 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 127.83 2.452 . . . . 0.0 108.998 -169.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.442 ' H ' ' CE1' ' A' ' 5' ' ' HIS . . . -106.59 -162.38 22.38 Favored Glycine 0 N--CA 1.444 -0.826 0 O-C-N 126.839 2.587 . . . . 0.0 116.641 -158.253 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 48.91 44.07 31.36 Favored Glycine 0 C--O 1.222 -0.616 0 C-N-CA 128.359 2.885 . . . . 0.0 113.957 174.764 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -78.02 141.06 62.6 Favored Pre-proline 0 N--CA 1.451 -0.395 0 O-C-N 119.347 -2.266 . . . . 0.0 109.538 159.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -90.92 132.24 1.57 Allowed 'Trans proline' 0 N--CA 1.442 -1.55 0 N-CA-C 121.234 3.513 . . . . 0.0 121.234 -171.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -136.68 149.72 48.08 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 113.053 0.76 . . . . 0.0 113.053 -151.083 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -134.4 145.23 48.73 Favored 'General case' 0 N--CA 1.442 -0.836 0 O-C-N 127.73 3.144 . . . . 0.0 106.457 168.265 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 40.6 t -126.46 99.47 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 102.598 -3.112 . . . . 0.0 102.598 163.46 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -109.57 137.0 48.04 Favored 'General case' 0 N--CA 1.442 -0.842 0 O-C-N 126.253 2.22 . . . . 0.0 113.662 -171.247 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 84.2 mt -140.21 148.33 22.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 114.996 1.48 . . . . 0.0 114.996 -157.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.6 m120 -122.26 144.4 49.01 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 127.257 2.223 . . . . 0.0 107.512 166.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -124.59 -163.92 11.79 Favored Glycine 0 C--N 1.337 0.632 0 C-N-CA 127.272 2.368 . . . . 0.0 109.302 161.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -56.59 133.17 56.28 Favored 'Trans proline' 0 N--CA 1.448 -1.147 1 C-N-CA 129.824 7.016 . . . . 0.0 116.322 178.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.271 42.1 t0 58.14 -112.24 0.63 Allowed 'General case' 0 N--CA 1.443 -0.806 1 O-C-N 116.136 -4.102 . . . . 0.0 110.665 179.622 . . . . . . . . 3 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -91.9 -5.92 65.82 Favored Glycine 0 CA--C 1.518 0.239 0 O-C-N 119.358 -2.089 . . . . 0.0 116.761 -174.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 31.6 tp -67.69 100.97 0.96 Allowed 'General case' 0 N--CA 1.448 -0.547 0 O-C-N 117.442 -3.387 . . . . 0.0 114.144 -176.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.8 t -106.07 134.16 48.43 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 CA-C-N 110.867 -2.878 . . . . 0.0 110.422 169.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 55.8 t -132.6 155.57 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 N-CA-C 115.515 1.672 . . . . 0.0 115.515 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.254 6.4 p-10 -129.87 123.38 30.67 Favored 'General case' 0 N--CA 1.44 -0.944 1 CA-C-O 128.993 4.235 . . . . 0.0 108.7 168.582 . . . . . . . . 3 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.21 131.17 34.3 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-O 127.459 3.504 . . . . 0.0 110.486 -178.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 14.5 mptt -91.13 119.91 31.64 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 112.696 -2.047 . . . . 0.0 114.196 -166.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.0 t -100.29 144.92 11.8 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.371 0 C-N-CA 130.421 3.488 . . . . 0.0 112.098 -169.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . 0.26 42.3 m -154.3 136.87 15.11 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 127.233 3.397 . . . . 0.0 111.465 170.027 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.477 ' HA ' ' CD1' ' A' ' 79' ' ' TYR . 39.7 t0 -62.04 118.23 7.03 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 131.076 3.75 . . . . 0.0 109.164 179.101 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -80.04 -6.34 57.44 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-O 116.434 -1.746 . . . . 0.0 115.207 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.258 10.8 t-20 60.29 30.51 19.9 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 127.653 3.597 . . . . 0.0 114.693 -176.043 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 18.1 p30 -138.28 -1.18 1.95 Allowed 'General case' 0 C--O 1.238 0.46 0 O-C-N 117.084 -3.51 . . . . 0.0 119.116 174.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 104.92 1.51 42.31 Favored Glycine 0 CA--C 1.521 0.449 0 CA-C-O 116.482 -2.288 . . . . 0.0 118.44 -163.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 44.1 p -126.32 171.64 10.79 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 127.543 2.337 . . . . 0.0 111.635 177.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.477 ' CD1' ' HA ' ' A' ' 73' ' ' ASP . 46.3 m-85 -144.95 118.84 9.3 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-O 115.605 -2.141 . . . . 0.0 109.267 178.221 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.71 136.75 24.83 Favored Glycine 0 CA--C 1.524 0.629 1 C-N-CA 130.991 4.139 . . . . 0.0 111.239 175.302 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.0 t -135.29 126.63 45.76 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 CA-C-O 128.131 3.824 . . . . 0.0 107.85 -177.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.403 ' HA ' ' O ' ' A' ' 34' ' ' ALA . 3.7 p -122.11 132.15 71.62 Favored 'Isoleucine or valine' 0 C--O 1.236 0.37 0 O-C-N 118.772 -2.455 . . . . 0.0 114.021 178.149 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -158.15 168.65 26.47 Favored 'General case' 0 C--O 1.221 -0.414 0 N-CA-C 117.76 2.504 . . . . 0.0 117.76 173.084 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.427 31.9 p30 -133.7 151.82 51.73 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 123.673 1.701 . . . . 0.0 114.236 -173.187 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -119.92 118.41 31.74 Favored Pre-proline 0 N--CA 1.445 -0.682 0 O-C-N 119.867 -1.771 . . . . 0.0 109.204 -173.117 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.262 29.0 Cg_endo -83.01 4.71 6.91 Favored 'Trans proline' 0 N--CA 1.447 -1.232 1 C-N-CA 128.225 5.95 . . . . 0.0 108.756 -178.793 . . . . . . . . 3 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.9 m -132.05 138.55 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 N-CA-C 120.399 3.481 . . . . 0.0 120.399 -167.281 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -54.15 118.87 4.4 Favored 'General case' 0 N--CA 1.449 -0.512 0 O-C-N 120.157 -1.589 . . . . 0.0 107.246 137.252 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 159.96 -135.39 4.07 Favored Glycine 0 C--N 1.331 0.296 0 CA-C-N 120.334 1.425 . . . . 0.0 115.038 172.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 -141.36 138.87 33.35 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 127.579 2.351 . . . . 0.0 113.767 177.149 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 -99.61 149.12 23.6 Favored 'General case' 0 C--O 1.222 -0.376 0 C-N-CA 126.479 1.912 . . . . 0.0 112.52 168.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -137.1 114.99 11.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 103.713 -2.699 . . . . 0.0 103.713 -164.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.2 t -114.56 126.01 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 CA-C-N 111.186 -2.734 . . . . 0.0 109.71 -153.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.0 t30 -138.69 118.34 13.08 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 123.874 1.797 . . . . 0.0 106.651 -172.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 54.6 t -116.74 142.77 29.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 O-C-N 118.079 -2.888 . . . . 0.0 112.386 -178.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 16.1 p -150.1 151.83 33.8 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 117.175 2.287 . . . . 0.0 117.175 -169.314 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 11.2 mp -135.08 87.53 2.34 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 102.861 -3.015 . . . . 0.0 102.861 -137.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 18.6 ttm-85 59.41 25.01 13.68 Favored 'General case' 0 N--CA 1.45 -0.466 0 O-C-N 117.322 -3.361 . . . . 0.0 108.737 -158.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 81.51 6.28 89.3 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-O 116.906 -2.052 . . . . 0.0 116.504 -175.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -76.0 120.9 83.74 Favored Pre-proline 0 N--CA 1.445 -0.722 0 O-C-N 125.135 1.138 . . . . 0.0 111.776 162.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -81.9 174.21 10.42 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 CA-C-N 121.661 1.629 . . . . 0.0 110.275 178.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . 0.261 27.8 pt -138.99 174.32 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 O-C-N 125.921 2.013 . . . . 0.0 113.949 -164.311 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 18.7 ptpt -72.28 166.68 21.97 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 127.895 2.478 . . . . 0.0 113.067 172.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 25.9 m120 50.59 32.23 6.56 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 123.173 1.464 . . . . 0.0 107.71 -179.089 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 14.6 mmt -143.31 134.11 12.43 Favored Pre-proline 0 N--CA 1.448 -0.557 1 O-C-N 115.029 -4.794 . . . . 0.0 107.661 176.42 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -86.02 171.88 39.61 Favored 'Cis proline' 0 N--CA 1.449 -1.117 0 CA-C-N 121.563 1.594 . . . . 0.0 109.853 13.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 19.3 pt -144.33 164.69 13.78 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-O 115.055 -2.402 . . . . 0.0 115.272 -178.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -126.7 136.04 51.92 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 124.659 3.39 . . . . 0.0 113.61 -166.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 3.3 t -128.57 140.73 48.43 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 C-N-CA 129.151 2.98 . . . . 0.0 114.682 -173.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 13.2 tppt? -74.74 142.64 44.34 Favored 'General case' 0 N--CA 1.445 -0.722 0 O-C-N 123.588 0.555 . . . . 0.0 111.191 178.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 69.4 m -132.06 140.77 48.98 Favored 'General case' 0 N--CA 1.452 -0.331 0 N-CA-C 115.178 1.547 . . . . 0.0 115.178 177.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 10.4 tp -149.08 135.85 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 CA-C-O 117.33 -1.319 . . . . 0.0 112.421 170.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.45 39.59 0.88 Allowed 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 123.009 2.64 . . . . 0.0 116.176 -164.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.341 0.85 0 O-C-N 126.056 2.097 . . . . 0.0 113.468 162.486 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.1 tmm? . . . . . 0 N--CA 1.476 0.867 0 CA-C-O 117.476 -1.249 . . . . 0.0 110.514 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 78.3 t60 -93.87 98.66 11.21 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 117.581 -1.2 . . . . 0.0 111.528 -175.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 9.2 t60 -98.35 104.89 16.97 Favored 'General case' 0 N--CA 1.441 -0.896 0 CA-C-O 117.759 -1.115 . . . . 0.0 110.077 179.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 55.2 t60 -154.38 141.41 19.32 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-N 122.633 2.47 . . . . 0.0 109.747 -174.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 69.0 m-70 -79.17 106.5 11.25 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 117.993 -1.003 . . . . 0.0 112.064 -176.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 67.4 m80 -104.37 -47.78 4.02 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 124.51 1.124 . . . . 0.0 112.155 -176.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 54.2 m80 -94.25 159.48 15.11 Favored 'General case' 0 C--O 1.221 -0.438 0 C-N-CA 126.192 1.797 . . . . 0.0 113.241 -160.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -57.7 -45.03 86.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 116.37 -1.776 . . . . 0.0 113.939 172.292 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 69.0 m -129.94 154.92 46.86 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 122.797 2.544 . . . . 0.0 117.094 174.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 38.6 mtmt -95.88 146.86 32.06 Favored Pre-proline 0 N--CA 1.443 -0.803 0 O-C-N 118.617 -2.552 . . . . 0.0 111.309 -174.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -73.24 166.59 29.56 Favored 'Trans proline' 0 N--CA 1.453 -0.912 0 N-CA-C 117.296 1.998 . . . . 0.0 117.296 160.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -97.17 143.07 25.5 Favored Pre-proline 0 CA--C 1.519 -0.221 0 N-CA-C 118.308 2.707 . . . . 0.0 118.308 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -71.43 143.18 42.43 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 124.182 3.254 . . . . 0.0 109.839 166.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.6 m -123.25 168.76 12.04 Favored 'General case' 0 CA--C 1.516 -0.344 0 O-C-N 127.321 2.888 . . . . 0.0 111.774 -165.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.02 -41.09 82.68 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 115.874 1.805 . . . . 0.0 115.874 -174.185 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 56.4 mp0 -68.2 -16.94 64.18 Favored 'General case' 0 C--O 1.22 -0.453 0 C-N-CA 127.39 2.276 . . . . 0.0 112.873 173.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 86.1 m-70 -127.7 13.29 6.92 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 120.91 -1.119 . . . . 0.0 110.898 -154.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 9.1 t -135.45 122.82 21.85 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-O 122.913 1.339 . . . . 0.0 111.391 169.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -152.39 154.79 36.3 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 128.792 2.837 . . . . 0.0 112.032 -172.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -138.51 162.42 34.55 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 120.066 1.303 . . . . 0.0 108.415 -164.01 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -146.76 132.0 18.45 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 127.316 2.247 . . . . 0.0 108.202 -170.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 139.17 -157.36 24.9 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 117.196 1.639 . . . . 0.0 117.196 145.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . 0.258 39.1 mt-10 -55.87 -41.72 74.82 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 119.375 3.102 . . . . 0.0 119.375 -175.642 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -67.7 2.82 5.66 Favored Glycine 0 CA--C 1.523 0.578 0 C-N-CA 127.829 2.633 . . . . 0.0 113.944 168.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . 0.334 20.9 mt -108.11 1.04 22.0 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 117.45 2.389 . . . . 0.0 117.45 155.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 72.9 t -119.8 -45.82 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 O-C-N 119.393 -2.067 . . . . 0.0 113.517 -174.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.262 31.5 ttmt -159.15 134.7 8.56 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 115.843 1.794 . . . . 0.0 115.843 175.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.7 t -135.65 139.62 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 106.715 -1.587 . . . . 0.0 106.715 -173.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.406 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 11.3 m-85 -121.25 176.64 5.52 Favored 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 128.964 2.906 . . . . 0.0 116.262 -169.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -80.25 -54.3 5.86 Favored 'General case' 0 N--CA 1.441 -0.894 0 O-C-N 120.011 -1.681 . . . . 0.0 113.058 178.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 -103.72 4.71 35.61 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 129.59 3.156 . . . . 0.0 114.478 177.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . 0.304 . . -110.39 84.07 3.63 Favored Pre-proline 0 N--CA 1.448 -0.537 0 CA-C-O 113.328 -3.225 . . . . 0.0 106.262 159.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -59.04 120.79 8.87 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 CA-C-N 123.816 2.399 . . . . 0.0 110.525 164.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -91.13 154.76 19.13 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 112.506 -2.133 . . . . 0.0 108.22 -175.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -120.36 165.98 14.16 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 109.712 -3.404 . . . . 0.0 112.49 175.364 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 10.7 p90 -162.16 173.5 14.22 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 128.566 2.746 . . . . 0.0 110.704 163.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 98.8 m -130.28 126.47 37.32 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 126.927 2.091 . . . . 0.0 115.652 -163.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 6.5 mt -92.34 105.14 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 C-N-CA 125.837 1.655 . . . . 0.0 108.018 178.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.26 1.3 p90 -72.59 132.12 43.35 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.348 1.459 . . . . 0.0 112.04 167.055 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -130.98 134.7 46.96 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 118.272 -2.767 . . . . 0.0 113.133 -170.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.2 t -131.45 150.82 34.63 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.396 0 CA-C-O 125.882 2.753 . . . . 0.0 103.78 169.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.0 p30 -69.73 -70.8 0.26 Allowed 'General case' 0 N--CA 1.443 -0.806 1 O-C-N 115.935 -4.228 . . . . 0.0 112.517 169.063 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 24.3 p -162.68 -9.82 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.418 1 C-N-CA 135.045 5.338 . . . . 0.0 114.707 -179.77 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 26.5 mtpp -122.18 34.54 5.14 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 122.393 2.36 . . . . 0.0 111.328 -163.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.82 -58.13 5.03 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 118.853 2.301 . . . . 0.0 118.853 160.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 62.1 t -57.85 132.33 22.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 O-C-N 126.271 1.806 . . . . 0.0 111.007 163.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -45.59 161.8 0.04 OUTLIER 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 125.276 2.465 . . . . 0.0 116.849 170.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 9.5 mmm180 -55.37 110.38 0.68 Allowed 'General case' 0 CA--C 1.518 -0.263 0 O-C-N 117.069 -3.519 . . . . 0.0 110.467 174.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.1 p -76.07 5.47 6.66 Favored 'General case' 0 N--CA 1.449 -0.519 1 C-N-CA 136.483 5.913 . . . . 0.0 117.092 -179.085 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -170.14 168.19 8.42 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 123.797 1.761 . . . . 0.0 107.85 169.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -123.86 -162.86 11.57 Favored Glycine 0 C--N 1.344 1.002 0 O-C-N 117.829 -3.044 . . . . 0.0 111.632 -146.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.66 21.21 74.65 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 122.059 3.584 . . . . 0.0 122.059 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 41.9 m-20 -73.39 152.79 90.04 Favored Pre-proline 0 C--O 1.223 -0.31 0 CA-C-N 118.59 1.195 . . . . 0.0 111.925 174.073 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -101.29 131.55 0.14 Allowed 'Trans proline' 0 N--CA 1.457 -0.66 0 CA-C-O 126.001 2.417 . . . . 0.0 112.313 -174.423 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -136.7 155.68 49.55 Favored 'General case' 0 N--CA 1.444 -0.769 0 CA-C-N 111.478 -2.601 . . . . 0.0 110.262 -172.4 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.432 ' O ' ' HA ' ' A' ' 95' ' ' VAL . 34.5 tt0 -139.39 141.43 37.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 125.203 2.43 . . . . 0.0 111.425 175.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 46.6 t -133.98 76.86 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.693 0 C-N-CA 128.195 2.598 . . . . 0.0 104.916 -175.553 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -99.04 141.44 31.79 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 125.872 2.749 . . . . 0.0 107.812 -170.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.437 ' HA ' ' O ' ' A' ' 92' ' ' ASN . 54.5 mt -137.04 139.96 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-N 111.046 -2.797 . . . . 0.0 114.965 -159.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 12.2 m120 -124.59 117.09 23.54 Favored 'General case' 0 C--O 1.223 -0.312 0 C-N-CA 126.983 2.113 . . . . 0.0 106.471 176.02 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -78.98 -159.19 14.28 Favored Glycine 0 N--CA 1.445 -0.766 0 CA-C-O 114.571 -3.35 . . . . 0.0 115.845 161.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_endo -63.28 116.52 3.65 Favored 'Trans proline' 0 N--CA 1.446 -1.298 1 C-N-CA 127.282 5.321 . . . . 0.0 110.63 162.551 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 23.4 t70 51.46 -100.49 0.09 Allowed 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 117.051 2.241 . . . . 0.0 117.051 177.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -74.55 -6.63 77.25 Favored Glycine 0 N--CA 1.438 -1.194 0 O-C-N 121.157 -0.964 . . . . 0.0 115.363 -172.314 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . 0.328 14.6 tp -77.95 73.97 4.51 Favored 'General case' 0 N--CA 1.442 -0.837 0 O-C-N 118.975 -2.485 . . . . 0.0 114.615 -168.63 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 51.8 t -87.91 110.14 20.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 C-N-CA 127.599 2.36 . . . . 0.0 113.794 175.049 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 68.2 t -133.29 159.87 42.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 CA-C-N 113.162 -1.835 . . . . 0.0 109.456 -165.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.264 1.1 p30 -133.59 142.95 48.37 Favored 'General case' 0 N--CA 1.448 -0.55 0 O-C-N 120.24 -1.537 . . . . 0.0 109.875 157.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.3 147.08 24.96 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 125.519 1.762 . . . . 0.0 113.632 162.402 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -99.16 113.89 26.37 Favored 'General case' 0 CA--C 1.511 -0.525 0 C-N-CA 127.599 2.36 . . . . 0.0 108.36 -158.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.6 t -91.83 129.49 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 O-C-N 124.42 1.075 . . . . 0.0 111.079 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.7 m -136.87 140.67 42.54 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 102.34 -3.207 . . . . 0.0 102.34 -178.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 57.9 t0 -72.31 124.2 24.6 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 129.199 3.0 . . . . 0.0 107.603 -172.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -82.14 -1.5 49.06 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 116.343 -1.789 . . . . 0.0 115.331 169.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.395 1.5 m120 60.57 32.58 20.44 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-N 121.449 1.931 . . . . 0.0 115.691 176.748 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 25.7 p30 -144.5 6.1 1.25 Allowed 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 113.032 -1.894 . . . . 0.0 112.409 -172.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 89.8 7.27 68.84 Favored Glycine 0 C--N 1.333 0.414 0 CA-C-N 122.58 2.445 . . . . 0.0 115.653 -166.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.9 p -141.16 158.31 44.08 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 129.25 3.02 . . . . 0.0 114.208 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 23.2 m-85 -132.04 126.65 34.4 Favored 'General case' 0 N--CA 1.449 -0.501 0 O-C-N 120.215 -1.553 . . . . 0.0 107.478 -169.351 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -89.17 147.82 19.82 Favored Glycine 0 C--N 1.335 0.5 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.3 t -131.54 133.83 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 CA-C-N 110.235 -2.982 . . . . 0.0 114.088 -174.027 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 13.7 p -137.54 131.39 43.93 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 CA-C-N 120.781 1.628 . . . . 0.0 110.359 -169.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -161.86 151.67 16.58 Favored 'General case' 0 N--CA 1.452 -0.353 1 O-C-N 115.95 -4.219 . . . . 0.0 111.582 176.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 26.0 p30 -116.93 151.66 36.17 Favored 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 130.92 3.688 . . . . 0.0 111.182 -172.412 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . 0.312 . . -130.44 104.91 16.04 Favored Pre-proline 0 N--CA 1.441 -0.876 0 N-CA-C 118.87 2.915 . . . . 0.0 118.87 -170.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -93.21 24.44 0.45 Allowed 'Trans proline' 0 N--CA 1.45 -1.044 0 C-N-CA 124.488 3.459 . . . . 0.0 112.76 -174.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.5 m -140.04 134.87 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 117.145 2.276 . . . . 0.0 117.145 -179.148 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . 0.284 38.5 tt0 -56.43 105.15 0.18 Allowed 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.705 144.016 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 162.41 -139.99 6.28 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 117.97 -1.461 . . . . 0.0 110.876 176.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 85.0 m-20 -143.24 137.97 29.3 Favored 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 105.848 -1.908 . . . . 0.0 105.848 -170.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -90.04 145.91 24.73 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 111.435 -2.62 . . . . 0.0 113.143 156.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.437 ' O ' ' HA ' ' A' ' 59' ' ' ILE . 26.1 t-20 -113.0 116.97 30.78 Favored 'General case' 0 N--CA 1.442 -0.828 0 O-C-N 128.566 3.666 . . . . 0.0 112.232 172.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 43.5 t -111.91 131.18 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 CA-C-O 126.102 2.858 . . . . 0.0 113.105 -168.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 21.5 t-20 -131.96 131.68 42.83 Favored 'General case' 0 N--CA 1.445 -0.694 0 O-C-N 119.157 -2.214 . . . . 0.0 111.302 176.309 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.432 ' HA ' ' O ' ' A' ' 56' ' ' GLU . 57.7 t -118.52 129.95 74.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 O-C-N 124.159 0.912 . . . . 0.0 112.718 -174.44 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 46.9 p -139.6 153.19 47.31 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -172.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 3.2 mp -126.16 105.84 9.14 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 105.043 -2.206 . . . . 0.0 105.043 -142.149 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 44.4 ttm-85 46.93 42.22 11.95 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 125.997 2.808 . . . . 0.0 108.937 -153.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 57.93 14.22 16.16 Favored Glycine 0 CA--C 1.528 0.882 0 O-C-N 116.765 -3.71 . . . . 0.0 115.798 -177.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 76.8 m-20 -95.32 157.37 36.43 Favored Pre-proline 0 N--CA 1.449 -0.485 0 C-N-CA 117.6 -1.64 . . . . 0.0 115.325 168.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -79.91 168.38 19.18 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 CA-C-O 125.82 2.342 . . . . 0.0 111.836 -174.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 43.5 pt -147.02 -177.52 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-O 126.038 2.828 . . . . 0.0 113.733 -178.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 17.2 ptmt -84.71 168.51 15.17 Favored 'General case' 0 N--CA 1.446 -0.669 0 O-C-N 116.405 -3.934 . . . . 0.0 110.936 -176.337 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 17.4 m120 54.77 29.46 11.85 Favored 'General case' 0 N--CA 1.446 -0.674 0 O-C-N 120.386 -1.446 . . . . 0.0 114.536 175.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 11.1 mmt -143.18 150.55 52.66 Favored Pre-proline 0 CA--C 1.518 -0.28 0 CA-C-O 113.351 -3.214 . . . . 0.0 111.73 177.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.43 175.82 34.03 Favored 'Cis proline' 0 N--CA 1.446 -1.316 0 CA-C-N 123.809 2.396 . . . . 0.0 113.199 -0.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 14.0 pt -144.56 -176.04 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 170.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -135.12 148.52 49.81 Favored 'General case' 0 N--CA 1.45 -0.463 1 O-C-N 114.745 -4.972 . . . . 0.0 112.294 -172.862 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 99.5 t -143.66 128.81 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.909 0 N-CA-C 105.478 -2.045 . . . . 0.0 105.478 -171.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 69.5 tttt -70.63 132.19 45.07 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 112.669 -2.059 . . . . 0.0 112.221 -176.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 81.6 m -113.08 126.82 55.89 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.208 1.403 . . . . 0.0 109.548 -178.257 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.406 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 2.8 tp -135.36 132.14 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 O-C-N 119.86 -1.775 . . . . 0.0 108.897 155.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -72.75 55.23 0.38 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 130.377 3.471 . . . . 0.0 114.028 -163.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.452 0 C-N-CA 128.021 2.724 . . . . 0.0 115.692 176.338 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.9 tpt . . . . . 0 C--O 1.236 0.352 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 43.0 t-80 -163.14 140.23 7.53 Favored 'General case' 0 N--CA 1.443 -0.776 0 O-C-N 125.666 1.854 . . . . 0.0 112.419 173.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . 0.304 8.3 t60 -91.84 100.66 13.3 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 129.497 3.119 . . . . 0.0 112.209 -170.027 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 60.0 t-80 -147.25 150.63 35.21 Favored 'General case' 0 N--CA 1.445 -0.683 0 O-C-N 119.395 -2.066 . . . . 0.0 112.63 178.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -90.92 125.93 35.91 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-O 115.868 -2.015 . . . . 0.0 113.65 177.741 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 36.8 m80 -120.55 -26.97 5.23 Favored 'General case' 0 C--O 1.219 -0.533 0 C-N-CA 128.268 2.627 . . . . 0.0 112.36 -177.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 40.1 m80 -142.58 160.33 40.51 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-O 123.975 1.845 . . . . 0.0 112.89 -161.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -76.94 -22.68 52.91 Favored 'General case' 0 N--CA 1.454 -0.245 0 O-C-N 117.609 -3.182 . . . . 0.0 117.863 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 79.6 p -109.85 147.41 33.38 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 128.393 3.558 . . . . 0.0 117.032 170.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . 0.294 20.0 mtmt -125.73 151.8 71.37 Favored Pre-proline 0 N--CA 1.455 -0.197 0 CA-C-O 114.745 -2.55 . . . . 0.0 112.715 173.405 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -70.99 150.7 61.19 Favored 'Trans proline' 0 N--CA 1.453 -0.907 1 O-C-N 128.964 4.139 . . . . 0.0 111.586 165.14 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -82.08 134.12 49.98 Favored Pre-proline 0 N--CA 1.445 -0.686 0 C-N-CA 127.135 2.174 . . . . 0.0 113.725 175.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -63.86 158.8 45.05 Favored 'Trans proline' 0 N--CA 1.443 -1.476 1 C-N-CA 127.015 5.143 . . . . 0.0 111.394 172.584 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -135.97 155.97 49.46 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 125.283 1.433 . . . . 0.0 111.791 -163.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -75.33 -33.58 61.15 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 117.191 2.293 . . . . 0.0 117.191 -172.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -57.77 -14.39 5.75 Favored 'General case' 0 N--CA 1.44 -0.932 1 O-C-N 114.574 -5.079 . . . . 0.0 116.756 153.475 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 48.1 m-70 -135.14 18.64 3.43 Favored 'General case' 0 N--CA 1.444 -0.733 0 O-C-N 125.956 2.035 . . . . 0.0 114.679 -159.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.9 t -138.3 120.16 15.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 O-C-N 117.152 -3.468 . . . . 0.0 107.697 171.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . 0.442 ' O ' ' CD2' ' A' ' 39' ' ' PHE . 23.8 m-85 -153.78 150.64 28.68 Favored 'General case' 0 N--CA 1.455 -0.213 0 CA-C-O 114.441 -2.695 . . . . 0.0 111.569 -170.244 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.409 ' HB3' ' HA ' ' A' ' 38' ' ' ILE . . . -141.28 158.37 43.98 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 118.195 2.665 . . . . 0.0 118.195 -161.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -153.62 141.37 20.03 Favored 'General case' 0 CA--C 1.518 -0.269 0 C-N-CA 126.411 1.884 . . . . 0.0 112.356 -159.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 132.66 157.35 8.49 Favored Glycine 0 N--CA 1.447 -0.614 1 C-N-CA 130.874 4.083 . . . . 0.0 116.282 -174.272 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -63.46 -20.18 65.36 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 118.661 2.837 . . . . 0.0 118.661 -173.264 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.79 8.39 0.55 Allowed Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 128.821 3.105 . . . . 0.0 117.088 162.015 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 75.9 mt -108.75 10.25 26.8 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-O 116.294 -1.812 . . . . 0.0 109.747 160.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 91.7 t -139.47 -29.96 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 CA-C-N 121.959 2.163 . . . . 0.0 113.213 -174.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 26.9 ttmt -164.5 138.21 5.17 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 119.508 -1.995 . . . . 0.0 107.508 171.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 t -132.33 136.22 56.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.458 0 O-C-N 126.387 2.305 . . . . 0.0 109.699 -174.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -127.86 -172.24 2.63 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 122.148 2.249 . . . . 0.0 112.592 -163.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -88.01 -54.74 4.07 Favored 'General case' 0 N--CA 1.448 -0.569 0 O-C-N 117.832 -3.042 . . . . 0.0 115.928 177.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 69.0 m-80 -97.91 8.28 44.99 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 115.64 1.718 . . . . 0.0 115.64 174.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . 0.259 . . -126.27 80.96 68.0 Favored Pre-proline 0 CA--C 1.516 -0.334 0 C-N-CA 125.614 1.566 . . . . 0.0 111.468 174.325 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -61.61 123.63 13.08 Favored 'Trans proline' 0 N--CA 1.445 -1.334 0 CA-C-O 122.903 1.126 . . . . 0.0 111.649 176.257 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.63 150.72 23.71 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 112.689 -2.05 . . . . 0.0 111.483 -164.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -129.66 153.89 47.67 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 127.514 2.325 . . . . 0.0 114.536 -162.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -164.48 158.84 18.75 Favored 'General case' 0 N--CA 1.446 -0.66 0 O-C-N 121.09 -1.006 . . . . 0.0 111.491 172.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 7.2 m -129.56 115.11 16.93 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 113.36 -1.745 . . . . 0.0 110.529 -154.349 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.409 ' HA ' ' HB3' ' A' ' 20' ' ' ALA . 15.5 mt -82.2 98.77 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 O-C-N 128.553 3.658 . . . . 0.0 108.979 178.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.442 ' CD2' ' O ' ' A' ' 19' ' ' TYR 0.328 47.3 p90 -76.94 105.12 7.81 Favored 'General case' 0 N--CA 1.451 -0.424 0 O-C-N 118.339 -2.726 . . . . 0.0 113.327 170.915 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . 0.264 . . -90.03 134.27 34.34 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 127.339 2.256 . . . . 0.0 116.674 -176.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 46.3 t -133.27 143.34 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 C-N-CA 126.776 2.03 . . . . 0.0 106.673 160.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.09 -81.22 0.02 OUTLIER 'General case' 0 N--CA 1.443 -0.795 0 O-C-N 117.846 -3.034 . . . . 0.0 114.476 161.611 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 19.1 p -161.32 -41.12 0.04 OUTLIER 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 128.436 2.695 . . . . 0.0 111.393 -169.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -90.62 52.16 2.14 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 121.927 2.149 . . . . 0.0 113.254 -167.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 71.81 -66.2 1.12 Allowed Glycine 0 C--N 1.341 0.848 0 CA-C-O 118.249 -1.306 . . . . 0.0 115.782 174.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 70.8 t -56.38 129.51 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 O-C-N 125.54 1.377 . . . . 0.0 111.974 178.303 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -36.91 164.83 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 130.284 3.434 . . . . 0.0 116.192 163.378 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . 0.254 7.3 mmm180 -66.16 101.67 0.74 Allowed 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 114.611 1.337 . . . . 0.0 114.611 175.232 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 61.8 p -79.37 2.76 20.48 Favored 'General case' 0 N--CA 1.449 -0.515 1 C-N-CA 133.464 4.705 . . . . 0.0 114.741 178.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -155.83 -174.72 5.08 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 130.014 3.326 . . . . 0.0 113.721 158.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -154.04 -176.45 26.41 Favored Glycine 0 CA--C 1.521 0.425 0 CA-C-O 124.741 2.301 . . . . 0.0 115.797 -141.68 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.71 14.35 67.31 Favored Glycine 0 C--N 1.336 0.549 0 O-C-N 117.462 -3.375 . . . . 0.0 112.789 -170.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -60.69 123.55 74.95 Favored Pre-proline 0 N--CA 1.446 -0.672 0 CA-C-N 123.7 3.75 . . . . 0.0 106.98 175.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -83.85 153.77 13.17 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 CA-C-N 122.468 1.917 . . . . 0.0 116.294 -162.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -142.95 156.29 44.86 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-O 126.35 2.976 . . . . 0.0 110.14 -157.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -144.11 153.25 41.96 Favored 'General case' 0 N--CA 1.448 -0.53 0 O-C-N 118.671 -2.518 . . . . 0.0 109.989 161.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 92.0 t -133.81 108.54 11.86 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.96 0 C-N-CA 129.789 3.235 . . . . 0.0 104.052 169.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -117.12 133.87 55.47 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 126.833 2.053 . . . . 0.0 112.287 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . 0.275 3.4 mp -124.06 144.9 32.24 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 C-N-CA 125.848 1.659 . . . . 0.0 113.94 -167.405 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 53.0 m-80 -118.23 140.41 49.84 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 114.217 -2.802 . . . . 0.0 110.061 174.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.47 -169.51 14.31 Favored Glycine 0 CA--C 1.526 0.774 0 CA-C-N 121.558 1.981 . . . . 0.0 111.68 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . 0.304 19.2 Cg_endo -60.18 130.28 33.6 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 N-CA-C 114.96 1.1 . . . . 0.0 114.96 -179.107 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.27 8.7 t0 52.79 -109.29 0.46 Allowed 'General case' 0 N--CA 1.453 -0.287 0 CA-C-O 114.908 -2.472 . . . . 0.0 113.275 177.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.11 -10.12 77.58 Favored Glycine 0 CA--C 1.523 0.569 0 O-C-N 126.273 2.233 . . . . 0.0 115.341 -176.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 88.0 mt -71.87 100.97 2.53 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 124.161 0.984 . . . . 0.0 110.213 -170.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 51.5 t -133.56 126.57 51.93 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 O-C-N 119.347 -2.096 . . . . 0.0 105.432 164.228 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 9.5 t -133.51 150.7 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.155 0 CA-C-N 113.193 -1.821 . . . . 0.0 106.843 -165.287 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.269 2.4 p30 -117.74 137.8 52.46 Favored 'General case' 0 N--CA 1.439 -0.985 0 O-C-N 118.979 -2.326 . . . . 0.0 112.717 148.492 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.21 158.97 22.09 Favored 'General case' 0 N--CA 1.444 -0.738 0 O-C-N 126.277 2.235 . . . . 0.0 112.439 -174.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 38.9 mmtm -90.33 103.13 15.84 Favored 'General case' 0 N--CA 1.447 -0.609 0 O-C-N 120.265 -1.522 . . . . 0.0 112.719 -172.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 54.9 t -71.27 135.48 27.9 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.662 172.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 54.6 m -123.91 137.87 54.56 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 124.735 1.214 . . . . 0.0 112.033 162.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 48.5 t0 -78.02 121.38 24.15 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 124.161 1.934 . . . . 0.0 111.94 169.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 -76.2 -7.5 54.98 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 112.228 -2.26 . . . . 0.0 115.088 -177.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 4.7 m120 59.85 25.95 15.1 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 129.655 3.182 . . . . 0.0 114.248 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 42.7 p30 -134.25 -6.84 2.63 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 129.194 2.998 . . . . 0.0 112.903 -175.257 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 103.29 15.6 22.96 Favored Glycine 0 C--N 1.336 0.555 1 C-N-CA 133.41 5.291 . . . . 0.0 114.288 -172.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 27.1 p -140.69 165.24 28.03 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 122.505 3.152 . . . . 0.0 108.791 177.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 67.4 m-85 -135.88 125.12 24.62 Favored 'General case' 0 N--CA 1.447 -0.579 0 N-CA-C 104.823 -2.288 . . . . 0.0 104.823 -166.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -96.68 129.95 10.08 Favored Glycine 0 C--N 1.336 0.575 0 C-N-CA 129.597 3.475 . . . . 0.0 107.165 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.8 t -108.68 128.21 64.58 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 1 CA-C-O 110.811 -4.423 . . . . 0.0 112.892 172.253 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.2 p -127.54 142.27 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 123.915 3.052 . . . . 0.0 115.666 172.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -165.03 160.43 18.93 Favored 'General case' 0 N--CA 1.449 -0.491 0 O-C-N 117.096 -3.502 . . . . 0.0 112.947 -173.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.465 42.5 p30 -137.77 148.32 45.45 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 128.437 2.695 . . . . 0.0 114.347 -168.685 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -125.28 113.08 26.01 Favored Pre-proline 0 N--CA 1.445 -0.708 0 C-N-CA 128.26 2.624 . . . . 0.0 112.025 -171.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.258 59.0 Cg_endo -76.04 12.91 1.37 Allowed 'Trans proline' 0 N--CA 1.441 -1.611 0 O-C-N 125.186 2.15 . . . . 0.0 113.359 177.778 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.8 m -140.62 141.28 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 115.579 1.696 . . . . 0.0 115.579 -151.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -63.96 114.17 3.94 Favored 'General case' 0 N--CA 1.447 -0.625 0 O-C-N 117.329 -3.357 . . . . 0.0 110.119 144.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 163.07 -155.43 26.77 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 125.317 2.621 . . . . 0.0 117.561 -169.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 5.0 t30 -135.81 121.88 20.14 Favored 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 127.278 2.231 . . . . 0.0 107.432 -167.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . 0.25 7.3 m-85 -87.48 143.09 27.39 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 123.298 0.639 . . . . 0.0 112.65 158.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -127.55 123.65 36.3 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 124.376 2.036 . . . . 0.0 107.999 -175.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . 0.344 3.3 t -109.46 135.14 49.31 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 N-CA-C 117.519 2.414 . . . . 0.0 117.519 -164.81 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -136.57 128.51 29.36 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 131.494 3.917 . . . . 0.0 108.373 179.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 58.2 t -118.12 152.59 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 CA-C-O 123.677 1.703 . . . . 0.0 108.374 -173.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.7 p -151.15 152.0 32.74 Favored 'General case' 0 N--CA 1.441 -0.915 0 O-C-N 120.411 -1.431 . . . . 0.0 112.952 -177.085 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 9.4 mp -137.3 94.9 2.99 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 104.351 -2.463 . . . . 0.0 104.351 -153.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . 0.277 25.3 ttm-85 49.2 43.8 22.87 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 112.571 -2.104 . . . . 0.0 110.691 -162.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 74.31 -13.29 4.85 Favored Glycine 0 CA--C 1.522 0.489 0 CA-C-O 114.681 -3.288 . . . . 0.0 116.132 -168.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 72.6 m-20 -74.25 126.83 88.68 Favored Pre-proline 0 N--CA 1.451 -0.398 0 CA-C-N 122.534 3.167 . . . . 0.0 119.072 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -74.29 172.11 16.7 Favored 'Trans proline' 0 N--CA 1.453 -0.885 1 C-N-CA 127.451 5.434 . . . . 0.0 106.863 -177.468 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 27.4 pt -143.87 177.61 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 O-C-N 118.346 -2.721 . . . . 0.0 107.705 -164.388 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 38.4 mttm -80.71 159.81 25.15 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 128.678 2.791 . . . . 0.0 111.191 -169.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 15.2 m120 54.2 43.89 29.93 Favored 'General case' 0 C--O 1.224 -0.285 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 176.25 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 6.9 mmt -138.55 139.52 24.91 Favored Pre-proline 0 N--CA 1.444 -0.728 0 C-N-CA 129.812 3.245 . . . . 0.0 107.956 -163.138 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -79.06 165.05 82.37 Favored 'Cis proline' 0 N--CA 1.447 -1.215 0 CA-C-N 122.78 2.029 . . . . 0.0 109.328 1.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . 0.276 2.2 pp -114.46 159.36 14.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 C-N-CA 125.366 1.466 . . . . 0.0 114.081 171.227 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -122.59 134.44 54.52 Favored 'General case' 0 N--CA 1.449 -0.502 0 O-C-N 118.588 -2.57 . . . . 0.0 111.899 -167.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 1.7 t -129.53 121.36 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-O 125.695 2.664 . . . . 0.0 112.615 -177.252 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -55.72 130.29 42.67 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 112.222 -2.263 . . . . 0.0 114.155 170.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 48.7 m -121.82 153.82 37.85 Favored 'General case' 0 N--CA 1.445 -0.699 0 O-C-N 123.994 0.809 . . . . 0.0 110.461 176.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 10.4 tp -150.52 138.06 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.773 0 C-N-CA 127.602 2.361 . . . . 0.0 113.486 165.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -68.84 43.29 0.04 OUTLIER 'General case' 0 N--CA 1.444 -0.768 1 CA-C-O 129.778 4.609 . . . . 0.0 115.584 -166.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.616 1 O-C-N 114.68 -5.013 . . . . 0.0 112.116 -175.359 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 42.2 tpp . . . . . 0 N--CA 1.473 0.683 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -79.05 -19.48 51.28 Favored 'General case' 0 N--CA 1.44 -0.932 0 CA-C-O 117.113 -1.423 . . . . 0.0 111.758 -177.68 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 8.8 t60 -79.23 106.98 11.65 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 122.086 2.221 . . . . 0.0 108.132 -174.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 9.7 t-160 -161.37 109.86 1.53 Allowed 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 123.513 1.625 . . . . 0.0 108.42 -167.323 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.466 ' CE1' ' H ' ' A' ' 51' ' ' GLY 0.279 81.0 m-70 -60.77 127.41 31.51 Favored 'General case' 0 C--N 1.329 -0.288 0 O-C-N 120.764 -1.21 . . . . 0.0 113.995 172.906 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 15.6 t60 -139.73 -10.95 1.18 Allowed 'General case' 0 N--CA 1.452 -0.327 0 O-C-N 118.972 -2.33 . . . . 0.0 107.9 -175.268 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . 0.252 32.4 m170 -147.78 168.19 22.78 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.702 -164.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -69.5 -45.02 69.89 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 117.377 -1.297 . . . . 0.0 113.054 163.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.7 m -103.33 144.33 31.5 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 119.702 1.137 . . . . 0.0 111.396 -166.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 49.9 mtmt -127.99 161.63 54.72 Favored Pre-proline 0 N--CA 1.454 -0.266 0 C-N-CA 125.024 1.33 . . . . 0.0 113.236 -177.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . 0.29 40.3 Cg_endo -83.1 147.13 12.95 Favored 'Trans proline' 0 N--CA 1.453 -0.862 1 C-N-CA 126.729 4.953 . . . . 0.0 118.429 166.666 . . . . . . . . 3 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -77.85 129.22 76.93 Favored Pre-proline 0 CA--C 1.516 -0.347 0 N-CA-C 118.433 2.753 . . . . 0.0 118.433 -178.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -62.81 150.6 87.73 Favored 'Trans proline' 0 N--CA 1.448 -1.162 1 C-N-CA 126.027 4.485 . . . . 0.0 110.775 169.84 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.8 t -129.64 152.13 49.49 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 117.159 2.281 . . . . 0.0 117.159 -170.03 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.33 -36.18 79.43 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 120.379 -1.451 . . . . 0.0 113.337 179.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 59.7 mm-40 -54.93 -31.01 59.95 Favored 'General case' 0 C--N 1.349 0.554 0 CA-C-N 124.32 3.236 . . . . 0.0 112.554 163.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 55.0 m-70 -125.23 19.37 8.25 Favored 'General case' 0 N--CA 1.445 -0.688 0 CA-C-O 125.627 2.632 . . . . 0.0 113.711 -154.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 7.1 t -147.38 122.69 10.28 Favored 'General case' 0 C--N 1.347 0.48 1 O-C-N 113.615 -5.678 . . . . 0.0 113.474 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 37.1 m-85 -160.36 151.13 18.7 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-O 116.185 -1.865 . . . . 0.0 110.235 -164.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -131.52 153.23 50.03 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-O 122.565 1.174 . . . . 0.0 109.78 -167.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -159.12 147.96 18.32 Favored 'General case' 0 N--CA 1.447 -0.609 0 C-N-CA 125.93 1.692 . . . . 0.0 110.348 -168.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.84 -179.87 16.02 Favored Glycine 0 C--N 1.338 0.666 0 C-N-CA 129.668 3.509 . . . . 0.0 117.339 175.097 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . 0.588 1.9 tt0 -62.23 -27.57 69.09 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 120.15 3.389 . . . . 0.0 120.15 -168.397 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -61.03 0.13 1.29 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 118.827 2.291 . . . . 0.0 118.827 160.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 49.2 mt -113.85 13.78 18.46 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.493 1.117 . . . . 0.0 111.463 168.205 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.9 t -129.47 -55.47 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 CA-C-O 115.839 -2.029 . . . . 0.0 113.334 178.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -150.16 128.25 11.94 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 116.638 -1.649 . . . . 0.0 111.777 -177.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 52.0 t -137.58 132.24 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 O-C-N 127.855 3.222 . . . . 0.0 113.255 -162.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 5.9 m-85 -126.63 -168.42 1.86 Allowed 'General case' 0 C--N 1.334 -0.065 0 CA-C-O 123.694 1.711 . . . . 0.0 112.453 -164.595 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -100.46 -56.32 2.38 Favored 'General case' 0 N--CA 1.449 -0.514 0 O-C-N 119.133 -2.229 . . . . 0.0 111.358 -166.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 40.0 m-80 -100.08 8.09 44.19 Favored 'General case' 0 N--CA 1.451 -0.403 0 O-C-N 119.027 -2.295 . . . . 0.0 111.678 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -121.22 93.14 48.81 Favored Pre-proline 0 N--CA 1.448 -0.57 0 O-C-N 119.423 -2.048 . . . . 0.0 108.197 167.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.11 128.02 22.87 Favored 'Trans proline' 0 N--CA 1.453 -0.901 1 C-N-CA 127.393 5.395 . . . . 0.0 113.465 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -92.47 152.47 19.66 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 128.257 2.623 . . . . 0.0 117.232 177.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.469 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 29.1 mt-10 -143.32 148.92 37.05 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 128.942 3.901 . . . . 0.0 110.265 -161.166 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 20.7 p90 -168.77 165.75 11.77 Favored 'General case' 0 CA--C 1.518 -0.284 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 -178.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 57.7 m -133.63 122.55 23.63 Favored 'General case' 0 N--CA 1.448 -0.548 0 O-C-N 127.887 3.242 . . . . 0.0 114.173 -155.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 4.0 mt -86.03 101.17 10.0 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-O 114.866 -2.493 . . . . 0.0 105.638 177.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 12.7 p90 -74.58 112.23 10.56 Favored 'General case' 0 N--CA 1.446 -0.634 0 O-C-N 124.917 1.386 . . . . 0.0 112.656 162.086 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . 0.252 . . -102.3 135.13 44.46 Favored 'General case' 0 C--O 1.222 -0.395 0 C-N-CA 126.151 1.78 . . . . 0.0 115.266 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.6 t -125.29 149.17 29.79 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 130.661 3.584 . . . . 0.0 108.961 162.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -74.96 -62.41 1.56 Allowed 'General case' 0 N--CA 1.441 -0.903 0 O-C-N 119.498 -2.001 . . . . 0.0 112.007 173.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 8.2 p -173.99 -25.83 0.01 OUTLIER 'General case' 0 C--O 1.218 -0.574 1 C-N-CA 133.158 4.583 . . . . 0.0 110.349 -173.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 71.4 mmtt -93.67 27.43 2.68 Favored 'General case' 0 N--CA 1.445 -0.691 0 O-C-N 118.529 -2.607 . . . . 0.0 112.311 -167.085 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 62.95 -32.3 0.07 OUTLIER Glycine 0 N--CA 1.444 -0.802 1 N-CA-C 123.404 4.122 . . . . 0.0 123.404 178.428 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 90.2 t -78.4 138.67 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.845 0 CA-C-N 119.196 1.498 . . . . 0.0 111.881 167.232 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -50.83 166.77 0.08 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.901 1.376 . . . . 0.0 113.397 -177.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 11.1 mmm180 -62.29 122.66 16.19 Favored 'General case' 0 C--O 1.22 -0.468 0 CA-C-N 121.947 2.158 . . . . 0.0 113.096 -172.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 72.9 p -100.38 13.49 34.28 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-O 126.756 3.17 . . . . 0.0 113.193 -161.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.8 p30 -159.66 175.14 13.55 Favored 'General case' 0 N--CA 1.45 -0.454 2 C-N-CA 131.861 4.064 . . . . 0.0 109.534 160.021 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.466 ' H ' ' CE1' ' A' ' 5' ' ' HIS . . . -127.5 -178.34 15.28 Favored Glycine 0 C--N 1.343 0.94 0 N-CA-C 118.871 2.308 . . . . 0.0 118.871 -159.093 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.45 20.74 68.46 Favored Glycine 0 C--N 1.346 1.134 0 CA-C-O 114.094 -3.614 . . . . 0.0 110.597 172.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -70.21 145.94 94.11 Favored Pre-proline 0 N--CA 1.445 -0.695 0 CA-C-N 123.807 3.804 . . . . 0.0 112.858 170.357 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -76.08 119.26 5.27 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 N-CA-C 117.307 2.003 . . . . 0.0 117.307 -178.172 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -131.25 165.43 23.4 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-O 124.04 1.876 . . . . 0.0 115.891 168.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -160.64 147.06 15.25 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 113.51 -1.677 . . . . 0.0 110.233 -171.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 2.4 t -131.04 123.48 53.95 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.754 0 C-N-CA 127.984 2.514 . . . . 0.0 106.769 176.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -121.44 131.63 54.27 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 113.927 -1.488 . . . . 0.0 109.023 -170.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.6 mp -132.4 132.86 60.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 -163.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 24.8 m120 -113.78 129.73 56.54 Favored 'General case' 0 N--CA 1.442 -0.841 0 O-C-N 125.396 1.685 . . . . 0.0 108.287 151.451 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -96.75 -164.18 32.77 Favored Glycine 0 C--N 1.345 1.045 0 CA-C-O 123.379 1.544 . . . . 0.0 111.273 151.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . 0.282 84.2 Cg_endo -64.28 124.05 12.78 Favored 'Trans proline' 0 N--CA 1.448 -1.171 0 C-N-CA 123.514 2.809 . . . . 0.0 118.379 176.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 38.13 -101.93 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.533 1 C-N-CA 132.217 4.207 . . . . 0.0 115.298 -174.425 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -53.36 -23.29 18.06 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 125.459 1.504 . . . . 0.0 113.988 -172.258 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . 0.311 95.5 mt -76.54 64.38 2.2 Favored 'General case' 0 N--CA 1.44 -0.933 0 C-N-CA 130.182 3.393 . . . . 0.0 118.316 -179.076 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 87.1 t -72.08 128.02 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 CA-C-N 113.515 -1.675 . . . . 0.0 107.61 151.172 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 87.9 t -135.54 143.84 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 125.922 1.689 . . . . 0.0 108.977 -173.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.319 35.5 t0 -129.52 125.99 37.58 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-O 115.337 -2.268 . . . . 0.0 110.435 175.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.25 162.23 19.24 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 125.453 1.72 . . . . 0.0 114.644 176.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -103.22 123.2 46.28 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 -177.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.5 t -100.68 137.05 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 O-C-N 128.595 3.684 . . . . 0.0 109.905 -175.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . 0.25 53.1 m -134.92 136.54 42.39 Favored 'General case' 0 N--CA 1.445 -0.676 0 O-C-N 117.912 -2.993 . . . . 0.0 109.371 -179.425 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 59.7 t0 -62.66 123.98 19.8 Favored 'General case' 0 N--CA 1.448 -0.559 0 O-C-N 120.497 -1.377 . . . . 0.0 112.004 164.255 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -84.83 -10.41 57.19 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-O 116.377 -1.773 . . . . 0.0 115.264 174.069 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.374 1.4 m120 74.21 36.95 0.63 Allowed 'General case' 0 C--O 1.219 -0.515 0 CA-C-O 115.988 -1.958 . . . . 0.0 113.768 172.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 20.0 p30 -154.58 -10.98 0.13 Allowed 'General case' 0 N--CA 1.449 -0.476 0 O-C-N 126.042 2.089 . . . . 0.0 114.676 -167.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 130.85 -25.72 4.13 Favored Glycine 0 CA--C 1.522 0.511 0 CA-C-N 122.852 2.569 . . . . 0.0 113.63 -158.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 2.8 p -136.81 171.77 14.0 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 118.252 2.686 . . . . 0.0 118.252 -157.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -135.94 113.61 10.98 Favored 'General case' 0 N--CA 1.433 -1.282 0 C-N-CA 126.032 1.733 . . . . 0.0 109.487 -172.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -86.16 146.48 21.13 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-O 124.146 1.97 . . . . 0.0 112.723 176.282 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.469 ' O ' ' HA ' ' A' ' 35' ' ' GLU . 41.0 t -136.4 130.0 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 C-N-CA 128.113 2.565 . . . . 0.0 109.032 -167.805 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 14.7 p -134.34 122.09 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.429 0 C-N-CA 125.836 1.654 . . . . 0.0 110.401 -168.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . 0.257 0.1 OUTLIER -154.44 175.38 13.65 Favored 'General case' 0 N--CA 1.447 -0.597 0 O-C-N 118.975 -2.328 . . . . 0.0 111.91 -177.4 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 5.2 p30 -151.76 162.96 40.17 Favored 'General case' 0 N--CA 1.448 -0.556 1 O-C-N 116.268 -4.02 . . . . 0.0 109.708 -174.107 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -134.46 110.89 11.53 Favored Pre-proline 0 N--CA 1.446 -0.637 1 C-N-CA 133.924 4.89 . . . . 0.0 113.103 -172.406 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -75.77 8.57 2.65 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 123.822 3.015 . . . . 0.0 114.132 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.5 m -134.03 138.15 50.83 Favored 'Isoleucine or valine' 0 C--O 1.238 0.46 0 C-N-CA 129.551 3.14 . . . . 0.0 115.855 -160.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 17.3 tt0 -59.81 109.31 0.9 Allowed 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 139.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 176.71 -157.21 22.34 Favored Glycine 0 C--N 1.344 0.975 0 CA-C-O 117.675 -1.625 . . . . 0.0 116.184 -173.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -133.12 139.21 46.98 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 127.623 2.369 . . . . 0.0 108.688 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -105.96 145.19 31.65 Favored 'General case' 0 N--CA 1.446 -0.642 0 O-C-N 119.747 -1.845 . . . . 0.0 110.627 161.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -126.55 116.96 21.87 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.843 -2.28 . . . . 0.0 104.843 -176.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 61.1 t -124.29 135.83 62.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 C-N-CA 125.417 1.487 . . . . 0.0 110.581 -149.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -136.32 133.68 37.13 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 105.447 -2.057 . . . . 0.0 105.447 -172.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 94.5 t -114.0 137.78 46.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 O-C-N 119.16 -2.212 . . . . 0.0 113.923 172.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 35.9 p -143.17 165.8 26.43 Favored 'General case' 0 CA--C 1.516 -0.349 0 O-C-N 120.614 -1.304 . . . . 0.0 113.609 -164.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . 0.26 7.4 tt -150.15 99.9 2.85 Favored 'General case' 0 C--N 1.344 0.368 0 N-CA-C 101.668 -3.456 . . . . 0.0 101.668 -146.767 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 8.7 ttm180 52.87 36.87 22.73 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 119.758 1.163 . . . . 0.0 111.471 -150.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.37 0.5 38.14 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-O 115.271 -2.96 . . . . 0.0 109.8 -178.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -94.81 142.93 25.35 Favored Pre-proline 0 N--CA 1.441 -0.877 0 CA-C-N 121.148 2.474 . . . . 0.0 109.868 -176.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -79.06 158.98 27.04 Favored 'Trans proline' 0 C--O 1.218 -0.499 0 CA-C-O 126.239 2.516 . . . . 0.0 113.459 -177.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 29.2 pt -142.92 -171.46 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 CA-C-N 109.386 -3.552 . . . . 0.0 113.32 -171.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -93.79 157.72 16.01 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 125.856 1.662 . . . . 0.0 112.341 -158.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.26 30.9 m120 50.19 34.1 8.15 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 129.793 3.237 . . . . 0.0 112.785 178.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 6.0 mmt -130.57 151.29 78.43 Favored Pre-proline 0 N--CA 1.444 -0.769 1 C-N-CA 134.551 5.141 . . . . 0.0 106.284 176.843 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -76.69 163.13 90.37 Favored 'Cis proline' 0 N--CA 1.45 -1.037 0 CA-C-N 126.432 3.333 . . . . 0.0 107.336 -2.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . 0.376 1.3 pp -127.04 167.54 21.66 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.409 0 N-CA-C 118.14 2.644 . . . . 0.0 118.14 163.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -106.57 142.13 36.72 Favored 'General case' 0 N--CA 1.449 -0.496 0 O-C-N 118.159 -2.838 . . . . 0.0 118.019 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 61.5 t -123.12 124.14 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 127.018 2.127 . . . . 0.0 109.977 -179.303 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -80.43 128.0 33.07 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-O 118.575 -0.726 . . . . 0.0 111.424 165.47 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 99.5 m -115.68 140.4 49.23 Favored 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 128.247 2.619 . . . . 0.0 112.819 -170.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 98.6 mt -133.85 145.73 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 CA-C-N 121.898 2.135 . . . . 0.0 106.795 177.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -82.19 48.1 1.22 Allowed 'General case' 0 N--CA 1.445 -0.698 0 O-C-N 116.76 -3.712 . . . . 0.0 113.692 -166.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.435 -1.391 0 O-C-N 120.575 -1.328 . . . . 0.0 116.111 174.493 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 17.2 tpt . . . . . 0 CA--C 1.531 0.226 0 CA-C-O 120.733 0.301 . . . . 0.0 111.208 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 91.9 m-70 -117.4 2.17 12.44 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 118.248 2.685 . . . . 0.0 118.248 -176.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -74.48 119.41 18.64 Favored 'General case' 0 N--CA 1.431 -1.376 0 O-C-N 118.964 -2.335 . . . . 0.0 115.502 -174.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 28.1 t-80 -166.12 123.88 1.45 Allowed 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 113.506 0.928 . . . . 0.0 113.506 -176.196 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 9.9 m-70 -82.56 131.64 35.21 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-O 118.016 -0.993 . . . . 0.0 112.921 -172.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 -142.49 -31.68 0.52 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 124.236 3.198 . . . . 0.0 112.555 -170.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 32.8 m170 -130.94 155.4 46.85 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 125.869 1.668 . . . . 0.0 114.193 -173.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.72 -48.43 54.6 Favored 'General case' 0 N--CA 1.442 -0.863 0 O-C-N 119.332 -2.105 . . . . 0.0 112.924 178.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 66.8 p -68.67 137.13 53.92 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 122.257 2.299 . . . . 0.0 113.301 166.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 32.3 mtmt -127.85 156.1 76.42 Favored Pre-proline 0 N--CA 1.448 -0.57 0 CA-C-O 115.983 -1.96 . . . . 0.0 114.564 176.09 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo -57.37 164.07 7.5 Favored 'Trans proline' 0 N--CA 1.445 -1.348 0 C-N-CA 124.582 3.521 . . . . 0.0 113.26 160.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -119.17 138.41 26.25 Favored Pre-proline 0 CA--C 1.512 -0.491 0 C-N-CA 126.106 1.762 . . . . 0.0 110.474 -178.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_exo -65.47 169.49 12.54 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.155 1.903 . . . . 0.0 114.156 170.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -145.74 168.02 21.74 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 125.547 1.539 . . . . 0.0 113.131 -171.456 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.44 -43.78 72.62 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 117.593 2.442 . . . . 0.0 117.593 179.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 55.6 mm-40 -60.65 -20.42 60.79 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.5 1.52 . . . . 0.0 111.353 167.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 68.6 m-70 -126.48 18.54 7.5 Favored 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 129.322 3.049 . . . . 0.0 112.757 -158.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.9 t -141.56 126.3 18.02 Favored 'General case' 0 N--CA 1.444 -0.729 0 O-C-N 119.856 -1.777 . . . . 0.0 106.476 166.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -153.86 157.85 39.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 130.632 3.573 . . . . 0.0 110.679 -175.306 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -141.92 148.77 39.22 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 127.734 2.413 . . . . 0.0 116.718 -165.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -144.08 143.31 31.1 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 113.969 -1.469 . . . . 0.0 109.33 -171.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 138.98 173.4 12.98 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 118.625 2.21 . . . . 0.0 118.625 169.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -68.87 -24.82 64.38 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 120.202 -1.763 . . . . 0.0 111.973 -168.354 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.18 7.35 0.56 Allowed Glycine 0 C--N 1.339 0.697 0 C-N-CA 129.779 3.562 . . . . 0.0 116.954 171.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 96.6 mt -116.98 -2.59 11.72 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-O 114.185 -2.817 . . . . 0.0 110.221 172.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 t -129.8 -55.05 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 CA-C-N 122.832 2.56 . . . . 0.0 109.156 -168.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 23.8 pttt -145.36 120.62 10.21 Favored 'General case' 0 C--O 1.238 0.46 0 O-C-N 118.873 -2.392 . . . . 0.0 112.282 -172.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 93.9 t -125.85 139.54 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 119.348 -2.095 . . . . 0.0 105.466 -172.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.408 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 42.5 m-85 -127.79 -163.43 1.26 Allowed 'General case' 0 N--CA 1.447 -0.621 0 CA-C-O 115.099 -2.381 . . . . 0.0 110.215 -178.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -103.14 -50.52 3.47 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 120.803 1.638 . . . . 0.0 114.572 -170.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 19.1 m-80 -109.2 6.01 24.34 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 130.27 3.428 . . . . 0.0 111.028 -179.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -122.06 85.82 46.34 Favored Pre-proline 0 C--O 1.224 -0.252 0 C-N-CA 126.693 1.997 . . . . 0.0 111.73 165.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -55.93 146.56 67.62 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 C-N-CA 117.244 -1.37 . . . . 0.0 115.091 176.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -93.76 162.64 13.85 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 119.044 2.979 . . . . 0.0 119.044 170.3 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -136.85 147.77 46.71 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 117.612 2.449 . . . . 0.0 117.612 -174.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -157.98 160.81 37.92 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-N 122.182 2.265 . . . . 0.0 107.77 169.443 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 49.2 m -119.18 127.92 53.75 Favored 'General case' 0 N--CA 1.441 -0.909 0 CA-C-O 113.805 -2.997 . . . . 0.0 113.811 -166.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.0 mt -86.39 106.53 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 O-C-N 126.681 2.488 . . . . 0.0 105.548 179.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.474 55.5 p90 -85.34 114.25 22.27 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 117.874 2.546 . . . . 0.0 117.874 175.015 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -119.91 139.04 53.04 Favored 'General case' 0 CA--C 1.517 -0.325 0 CA-C-N 122.85 2.568 . . . . 0.0 113.106 -167.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 78.0 t -129.35 143.57 40.78 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 1 C-N-CA 132.236 4.214 . . . . 0.0 111.457 173.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -70.03 -82.93 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 126.941 3.258 . . . . 0.0 107.924 173.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 48.9 p -153.44 -21.3 0.14 Allowed 'General case' 0 C--N 1.328 -0.328 2 C-N-CA 134.773 5.229 . . . . 0.0 117.992 -179.394 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 18.4 mmtp -80.5 16.34 1.38 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 127.789 3.181 . . . . 0.0 116.33 -176.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.62 -56.65 5.03 Favored Glycine 0 C--N 1.345 1.034 0 N-CA-C 120.301 2.88 . . . . 0.0 120.301 -175.34 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 24.5 t -63.68 146.53 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 172.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.76 170.12 0.06 Allowed 'General case' 0 N--CA 1.438 -1.034 0 CA-C-O 121.589 0.709 . . . . 0.0 111.228 177.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.7 mmm180 -68.44 118.39 11.44 Favored 'General case' 0 C--N 1.351 0.659 0 O-C-N 118.261 -2.774 . . . . 0.0 113.564 -175.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 16.0 p -77.88 1.56 20.09 Favored 'General case' 0 N--CA 1.447 -0.591 1 C-N-CA 134.738 5.215 . . . . 0.0 117.733 -171.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 10.0 p30 -161.09 -174.5 4.39 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-N 111.171 -2.74 . . . . 0.0 104.801 163.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -144.2 -170.36 13.56 Favored Glycine 0 CA--C 1.524 0.641 0 C-N-CA 128.462 2.934 . . . . 0.0 117.321 -142.08 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 54.18 46.18 71.47 Favored Glycine 0 C--N 1.337 0.623 0 CA-C-O 123.629 1.683 . . . . 0.0 110.639 178.07 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -86.71 137.88 33.64 Favored Pre-proline 0 N--CA 1.45 -0.449 0 O-C-N 116.688 -3.831 . . . . 0.0 112.157 174.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -68.94 137.18 37.22 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.383 2.722 . . . . 0.0 113.756 -171.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -159.6 150.37 19.37 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 112.217 -2.265 . . . . 0.0 112.924 -165.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -152.34 134.92 15.32 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 118.106 -2.871 . . . . 0.0 113.977 -166.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 4.5 t -129.74 81.62 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 CA-C-N 113.325 -1.761 . . . . 0.0 113.643 -176.273 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -100.53 141.13 33.81 Favored 'General case' 0 CA--C 1.516 -0.354 0 O-C-N 126.023 2.077 . . . . 0.0 110.87 -174.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.5 mt -132.88 147.42 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 CA-C-O 125.01 2.338 . . . . 0.0 108.23 -163.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -116.5 118.83 33.73 Favored 'General case' 0 C--O 1.223 -0.33 0 O-C-N 119.3 -2.125 . . . . 0.0 109.166 166.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -111.31 -158.75 15.3 Favored Glycine 0 N--CA 1.442 -0.948 0 N-CA-C 121.797 3.479 . . . . 0.0 121.797 163.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo -68.52 141.34 50.35 Favored 'Trans proline' 0 N--CA 1.434 -2.017 1 C-N-CA 125.834 4.356 . . . . 0.0 113.339 -177.213 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.368 60.3 m-20 55.79 -125.33 2.06 Favored 'General case' 0 N--CA 1.446 -0.673 0 C-N-CA 126.834 2.054 . . . . 0.0 111.138 -176.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -82.6 8.61 61.55 Favored Glycine 0 CA--C 1.53 1.003 1 O-C-N 114.502 -5.124 . . . . 0.0 119.728 179.144 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.6 mt -76.57 75.96 3.27 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-N 117.882 0.841 . . . . 0.0 110.162 -176.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 1.4 m -58.04 123.31 9.51 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 O-C-N 120.186 -1.571 . . . . 0.0 112.757 134.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 72.8 t -132.63 145.34 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 CA-C-N 122.304 2.32 . . . . 0.0 106.465 -174.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -128.87 131.68 47.67 Favored 'General case' 0 N--CA 1.445 -0.69 0 O-C-N 119.122 -2.236 . . . . 0.0 110.332 172.186 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -102.63 137.37 40.95 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 126.476 1.91 . . . . 0.0 113.752 -165.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.271 37.1 ttpt -81.96 117.46 22.2 Favored 'General case' 0 C--O 1.218 -0.556 0 O-C-N 120.245 -1.535 . . . . 0.0 111.664 -160.05 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -88.48 131.6 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 175.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 67.2 m -131.84 125.96 33.09 Favored 'General case' 0 N--CA 1.452 -0.349 0 O-C-N 125.619 1.824 . . . . 0.0 110.934 172.321 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -66.29 118.52 10.09 Favored 'General case' 0 N--CA 1.44 -0.951 0 C-N-CA 128.153 2.581 . . . . 0.0 110.644 176.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.4 m-20 -79.63 -4.07 49.98 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 119.807 3.262 . . . . 0.0 119.807 175.653 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 68.56 25.66 6.6 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 131.595 3.958 . . . . 0.0 114.008 176.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 43.2 p30 -135.06 -4.69 2.41 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 114.053 -2.879 . . . . 0.0 110.946 -165.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 120.88 -14.34 9.71 Favored Glycine 0 C--N 1.337 0.624 0 C-N-CA 126.847 2.165 . . . . 0.0 111.223 -171.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 p -133.12 165.83 23.86 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 131.388 3.875 . . . . 0.0 113.56 -170.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 16.7 m-85 -131.57 137.57 48.51 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 128.704 2.802 . . . . 0.0 106.671 -174.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -92.21 139.41 14.67 Favored Glycine 0 C--O 1.226 -0.369 0 C-N-CA 128.159 2.79 . . . . 0.0 107.304 174.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 22.8 t -122.83 130.79 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-O 117.119 -1.419 . . . . 0.0 108.633 178.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.4 p -135.71 141.85 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 119.696 1.134 . . . . 0.0 112.527 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 7.5 p90 -161.11 169.61 22.05 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 115.902 1.816 . . . . 0.0 115.902 179.194 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 15.2 p30 -139.0 164.79 28.83 Favored 'General case' 0 N--CA 1.449 -0.508 0 O-C-N 118.756 -2.465 . . . . 0.0 117.532 177.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -123.53 112.57 29.35 Favored Pre-proline 0 N--CA 1.448 -0.568 0 O-C-N 125.305 1.628 . . . . 0.0 107.643 -174.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.336 14.9 Cg_endo -66.76 -8.52 21.56 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 N-CA-C 117.57 2.104 . . . . 0.0 117.57 170.382 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 28.4 m -148.08 134.51 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 O-C-N 120.369 -1.457 . . . . 0.0 110.606 -164.568 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -56.39 116.16 2.91 Favored 'General case' 0 N--CA 1.456 -0.169 0 O-C-N 126.195 2.185 . . . . 0.0 112.47 167.026 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 170.29 -166.7 39.89 Favored Glycine 0 CA--C 1.527 0.828 0 CA-C-O 122.306 0.948 . . . . 0.0 112.485 -172.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -106.42 137.75 43.84 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 114.37 1.248 . . . . 0.0 114.37 175.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -103.34 139.29 38.96 Favored 'General case' 0 N--CA 1.445 -0.713 0 C-N-CA 128.634 2.774 . . . . 0.0 110.418 168.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -114.53 119.55 37.21 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 117.164 2.283 . . . . 0.0 117.164 170.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . 0.275 65.2 t -118.1 133.64 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-N 112.795 -2.002 . . . . 0.0 111.863 -157.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -130.23 138.95 50.81 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 126.879 2.072 . . . . 0.0 109.087 171.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 85.8 t -114.79 126.48 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 C-N-CA 124.856 1.262 . . . . 0.0 113.312 168.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . 0.301 67.0 p -132.8 145.97 51.44 Favored 'General case' 0 N--CA 1.444 -0.767 0 O-C-N 125.423 1.702 . . . . 0.0 114.519 -168.561 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 8.4 tt -136.62 95.8 3.22 Favored 'General case' 0 N--CA 1.447 -0.58 1 O-C-N 116.182 -4.074 . . . . 0.0 107.796 -137.491 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . 0.316 51.4 ttt180 46.0 40.09 6.51 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 125.933 2.778 . . . . 0.0 115.858 -147.644 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 69.15 16.75 71.27 Favored Glycine 0 C--N 1.341 0.818 0 O-C-N 118.318 -2.739 . . . . 0.0 117.838 -175.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -106.57 153.51 40.56 Favored Pre-proline 0 N--CA 1.447 -0.6 0 O-C-N 116.508 -3.937 . . . . 0.0 111.678 165.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_endo -86.53 169.57 8.14 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 124.548 3.499 . . . . 0.0 114.166 -178.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 11.2 pt -130.8 -173.22 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-N 113.975 -1.466 . . . . 0.0 109.13 176.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 57.1 mttm -67.84 169.59 9.51 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 115.385 1.624 . . . . 0.0 115.385 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 33.3 m120 47.49 28.66 1.2 Allowed 'General case' 0 N--CA 1.447 -0.617 0 O-C-N 116.959 -3.588 . . . . 0.0 118.859 169.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 12.7 mmt -136.32 146.14 54.83 Favored Pre-proline 0 N--CA 1.444 -0.765 0 C-N-CA 129.128 2.971 . . . . 0.0 109.187 -177.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . 0.272 96.6 Cg_endo -68.07 169.24 55.87 Favored 'Cis proline' 0 N--CA 1.457 -0.63 0 CA-C-N 127.293 3.64 . . . . 0.0 116.232 -4.566 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 27.2 pt -146.77 161.25 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 O-C-N 126.9 2.625 . . . . 0.0 114.616 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -112.83 131.28 55.77 Favored 'General case' 0 N--CA 1.445 -0.71 0 C-N-CA 127.352 2.261 . . . . 0.0 112.875 -178.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 59.0 t -122.98 141.26 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 C-N-CA 126.681 1.992 . . . . 0.0 106.813 -175.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 39.8 mmtm -91.37 138.33 31.67 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 116.335 1.976 . . . . 0.0 116.335 176.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 21.8 m -115.96 126.51 53.95 Favored 'General case' 0 N--CA 1.441 -0.903 0 C-N-CA 129.504 3.122 . . . . 0.0 108.342 -174.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.408 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 15.2 mt -124.64 135.17 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 161.017 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -72.96 56.04 0.42 Allowed 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 118.699 2.851 . . . . 0.0 118.699 -176.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.4 0 O-C-N 117.388 -3.32 . . . . 0.0 117.14 165.975 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 41.3 tpp . . . . . 0 CA--C 1.514 -0.428 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 68.5 m-70 -87.36 4.43 43.05 Favored 'General case' 0 CA--C 1.508 -0.636 0 C-N-CA 125.913 1.685 . . . . 0.0 112.059 173.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 5.3 t60 -88.22 124.43 33.84 Favored 'General case' 0 N--CA 1.445 -0.687 0 O-C-N 116.674 -3.766 . . . . 0.0 113.336 175.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . 0.267 11.5 t60 -172.13 130.95 0.62 Allowed 'General case' 0 N--CA 1.442 -0.861 0 C-N-CA 128.548 2.739 . . . . 0.0 115.177 -168.059 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 77.3 m-70 -95.68 88.12 4.9 Favored 'General case' 0 N--CA 1.438 -1.044 1 C-N-CA 131.747 4.019 . . . . 0.0 107.413 -179.032 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 3.2 t-80 -125.04 0.72 7.93 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 126.52 1.928 . . . . 0.0 115.272 -179.151 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -137.23 153.93 50.27 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-O 114.853 -2.499 . . . . 0.0 108.704 -172.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -90.17 -27.69 19.41 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 124.194 3.179 . . . . 0.0 117.614 177.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 11.3 m -85.12 149.63 25.4 Favored 'General case' 0 C--O 1.245 0.84 0 C-N-CA 129.411 3.085 . . . . 0.0 113.394 165.463 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 54.3 mtmt -119.36 152.09 52.16 Favored Pre-proline 0 N--CA 1.448 -0.555 0 N-CA-C 117.446 2.387 . . . . 0.0 117.446 170.22 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -70.85 164.76 34.47 Favored 'Trans proline' 0 N--CA 1.453 -0.887 0 CA-C-N 121.261 1.486 . . . . 0.0 112.28 146.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -123.14 154.22 64.9 Favored Pre-proline 0 N--CA 1.446 -0.653 0 C-N-CA 128.059 2.543 . . . . 0.0 113.258 -166.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_exo -63.92 153.82 73.53 Favored 'Trans proline' 0 N--CA 1.444 -1.413 0 C-N-CA 124.162 3.241 . . . . 0.0 116.076 166.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 26.4 t -122.86 150.75 42.46 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.17 1.788 . . . . 0.0 106.259 178.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . 0.314 . . -51.19 -37.99 49.77 Favored 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 126.118 1.767 . . . . 0.0 114.632 163.067 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -58.61 -29.11 66.22 Favored 'General case' 0 N--CA 1.443 -0.809 0 C-N-CA 125.003 1.321 . . . . 0.0 110.192 170.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 86.6 m-70 -134.66 24.98 3.71 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 131.292 3.837 . . . . 0.0 112.556 -155.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 42.6 t -148.16 120.24 8.27 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 117.343 2.349 . . . . 0.0 117.343 166.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -146.48 142.49 28.15 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-O 113.482 -3.152 . . . . 0.0 113.832 -160.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -124.48 140.82 52.59 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 119.373 3.101 . . . . 0.0 119.373 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -136.44 147.57 47.3 Favored 'General case' 0 C--O 1.223 -0.317 0 CA-C-N 120.962 1.71 . . . . 0.0 112.19 -177.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.43 175.8 18.84 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 125.436 1.494 . . . . 0.0 114.575 167.403 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -55.93 -34.75 65.91 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-O 114.495 -2.669 . . . . 0.0 112.503 177.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -57.93 -3.0 1.02 Allowed Glycine 0 C--O 1.226 -0.355 0 CA-C-N 123.462 2.847 . . . . 0.0 116.138 165.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . 0.373 24.1 mt -109.29 29.26 7.7 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 120.544 2.172 . . . . 0.0 111.32 161.403 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 96.8 t -150.16 -42.0 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 CA-C-N 121.683 2.038 . . . . 0.0 114.584 -175.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.333 43.0 pttt -151.39 131.12 13.17 Favored 'General case' 0 C--N 1.326 -0.429 1 O-C-N 116.164 -4.085 . . . . 0.0 112.36 -179.425 . . . . . . . . 3 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 38.4 t -143.66 141.15 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 -166.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -136.08 172.31 13.19 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-N 120.181 1.355 . . . . 0.0 114.277 -169.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 46.8 t0 -78.55 -50.81 10.91 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-O 122.631 1.205 . . . . 0.0 112.519 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 70.4 m-80 -104.03 8.7 36.65 Favored 'General case' 0 N--CA 1.448 -0.545 0 O-C-N 118.427 -2.67 . . . . 0.0 111.636 -179.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -133.85 101.81 12.63 Favored Pre-proline 0 N--CA 1.447 -0.625 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 170.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -57.92 131.47 43.94 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 CA-C-O 125.552 2.23 . . . . 0.0 111.888 159.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -85.93 162.48 18.54 Favored 'General case' 0 N--CA 1.45 -0.459 0 O-C-N 117.008 -3.558 . . . . 0.0 113.539 165.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -133.22 154.6 50.51 Favored 'General case' 0 N--CA 1.448 -0.553 0 O-C-N 125.057 1.473 . . . . 0.0 110.508 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -157.48 171.45 20.34 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 117.662 -3.149 . . . . 0.0 105.403 167.176 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 91.1 m -133.35 130.47 38.86 Favored 'General case' 0 C--O 1.233 0.197 0 O-C-N 127.167 2.792 . . . . 0.0 113.737 -164.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.2 mt -84.77 104.06 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 123.929 0.892 . . . . 0.0 110.946 171.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 32.5 p90 -77.15 108.1 9.99 Favored 'General case' 0 N--CA 1.44 -0.973 0 N-CA-C 119.222 3.045 . . . . 0.0 119.222 163.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -117.78 150.22 39.49 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 121.288 1.858 . . . . 0.0 109.491 -163.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.2 t -137.79 159.19 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 105.718 -1.956 . . . . 0.0 105.718 174.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.0 p30 -78.36 -61.91 1.85 Allowed 'General case' 0 N--CA 1.452 -0.331 0 O-C-N 119.766 -1.834 . . . . 0.0 115.214 170.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 21.9 p -174.91 -35.63 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 131.64 3.976 . . . . 0.0 114.42 -161.034 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -107.69 40.92 1.61 Allowed 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 122.73 2.514 . . . . 0.0 112.665 -171.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 53.02 -25.39 0.01 OUTLIER Glycine 0 C--N 1.338 0.666 0 C-N-CA 130.129 3.728 . . . . 0.0 121.568 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.1 t -64.3 125.55 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 O-C-N 116.951 -3.676 . . . . 0.0 107.882 167.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -31.33 127.2 0.19 Allowed 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 117.36 2.356 . . . . 0.0 117.36 162.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 11.5 mmm180 -35.12 122.03 0.57 Allowed 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 118.672 2.841 . . . . 0.0 118.672 -177.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 8.5 p -78.79 -2.6 40.34 Favored 'General case' 0 N--CA 1.445 -0.696 0 C-N-CA 126.774 2.03 . . . . 0.0 111.576 -162.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.9 p30 -162.45 169.2 20.8 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 127.925 2.49 . . . . 0.0 109.199 178.055 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -123.91 -157.07 9.68 Favored Glycine 0 CA--C 1.522 0.502 0 C-N-CA 119.918 -1.134 . . . . 0.0 110.897 -160.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 61.01 41.05 99.31 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 178.286 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 58.4 m-20 -78.38 156.08 78.79 Favored Pre-proline 0 N--CA 1.448 -0.552 0 C-N-CA 126.982 2.113 . . . . 0.0 108.438 173.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -91.67 62.78 1.04 Allowed 'Trans proline' 0 N--CA 1.444 -1.395 0 C-N-CA 124.811 3.674 . . . . 0.0 117.284 -169.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -69.88 149.55 47.73 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 120.971 3.693 . . . . 0.0 120.971 173.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -150.49 128.36 11.74 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 127.22 2.208 . . . . 0.0 112.906 168.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 39.5 t -114.46 87.53 1.03 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.326 0 C-N-CA 129.99 3.316 . . . . 0.0 104.408 -174.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -104.66 142.29 34.94 Favored 'General case' 0 N--CA 1.444 -0.753 0 C-N-CA 127.14 2.176 . . . . 0.0 106.065 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 19.1 mt -130.86 155.38 41.87 Favored 'Isoleucine or valine' 0 C--O 1.238 0.463 0 C-N-CA 128.334 2.654 . . . . 0.0 113.492 -170.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 71.6 m-80 -125.01 126.25 45.14 Favored 'General case' 0 N--CA 1.446 -0.642 0 C-N-CA 131.426 3.89 . . . . 0.0 109.137 174.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -118.49 -177.87 16.92 Favored Glycine 0 CA--C 1.528 0.876 0 O-C-N 119.034 -2.291 . . . . 0.0 112.351 167.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo -56.26 125.49 19.24 Favored 'Trans proline' 0 N--CA 1.441 -1.594 0 CA-C-N 118.741 1.27 . . . . 0.0 111.875 -174.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 58.0 m-20 63.26 -118.61 0.53 Allowed 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 126.17 1.788 . . . . 0.0 110.905 173.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.92 -7.89 76.75 Favored Glycine 0 N--CA 1.441 -0.981 0 O-C-N 126.357 2.286 . . . . 0.0 114.468 -166.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 93.2 mt -76.02 77.74 2.88 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 127.472 3.511 . . . . 0.0 119.058 176.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 26.2 t -64.0 131.65 29.69 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 CA-C-N 112.589 -2.096 . . . . 0.0 109.749 143.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 96.0 t -142.02 144.37 25.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 112.474 -2.148 . . . . 0.0 111.846 -177.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.301 3.6 p-10 -127.2 134.55 50.11 Favored 'General case' 0 N--CA 1.445 -0.695 0 O-C-N 117.953 -2.967 . . . . 0.0 111.285 168.199 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.75 155.57 19.49 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 126.927 3.251 . . . . 0.0 111.134 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.301 9.2 tmtt? -99.99 104.17 15.76 Favored 'General case' 0 N--CA 1.448 -0.553 1 O-C-N 113.235 -5.916 . . . . 0.0 111.216 -170.45 . . . . . . . . 3 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.0 t -76.38 138.64 20.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 O-C-N 127.17 2.794 . . . . 0.0 117.644 169.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 10.0 m -144.15 128.86 18.24 Favored 'General case' 0 C--O 1.237 0.443 0 O-C-N 126.725 2.516 . . . . 0.0 111.091 173.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -79.16 136.07 37.0 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 125.237 2.446 . . . . 0.0 110.226 -169.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . 0.266 8.0 m-20 -96.61 0.56 50.1 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 116.534 -3.854 . . . . 0.0 118.551 -175.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 6.5 m120 68.68 27.62 5.88 Favored 'General case' 0 C--O 1.215 -0.733 0 O-C-N 128.731 3.769 . . . . 0.0 114.512 176.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 26.7 p30 -134.66 -8.24 2.46 Favored 'General case' 0 N--CA 1.445 -0.706 0 CA-C-O 117.227 -1.368 . . . . 0.0 112.153 -176.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 109.02 5.88 30.41 Favored Glycine 0 C--N 1.35 1.313 0 CA-C-O 113.492 -3.949 . . . . 0.0 108.21 -170.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.7 p -130.09 158.07 40.64 Favored 'General case' 0 N--CA 1.442 -0.83 1 CA-C-N 126.491 5.146 . . . . 0.0 111.391 -175.065 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -135.93 113.01 10.42 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 120.633 1.561 . . . . 0.0 110.543 -174.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -63.33 136.91 42.63 Favored Glycine 0 N--CA 1.452 -0.268 0 N-CA-C 116.539 1.376 . . . . 0.0 116.539 167.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.9 t -131.64 134.41 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 126.713 2.005 . . . . 0.0 112.155 -178.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -132.5 141.56 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-N 122.912 2.596 . . . . 0.0 109.82 -175.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 1.8 p90 -166.32 170.81 12.73 Favored 'General case' 0 N--CA 1.446 -0.637 0 O-C-N 125.512 1.758 . . . . 0.0 115.185 170.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 27.2 p30 -142.41 141.87 32.3 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 129.077 2.951 . . . . 0.0 109.916 -158.01 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -112.91 125.61 29.57 Favored Pre-proline 0 C--N 1.344 0.365 0 CA-C-O 117.399 -1.286 . . . . 0.0 113.201 -176.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -84.01 -1.09 9.83 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 123.387 2.724 . . . . 0.0 112.54 178.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.4 m -128.24 148.93 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 O-C-N 118.783 -2.448 . . . . 0.0 113.532 -164.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -63.4 111.39 2.28 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-O 124.814 2.245 . . . . 0.0 109.235 139.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 169.26 -162.52 36.18 Favored Glycine 0 C--O 1.221 -0.657 0 O-C-N 118.583 -2.573 . . . . 0.0 118.015 -173.114 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 27.3 t30 -117.68 132.58 56.47 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 127.435 2.294 . . . . 0.0 111.83 177.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -90.73 153.28 20.39 Favored 'General case' 0 C--O 1.221 -0.416 0 O-C-N 118.423 -2.673 . . . . 0.0 113.086 158.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -128.37 113.28 15.39 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 113.186 -1.825 . . . . 0.0 113.699 176.05 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.6 t -115.07 120.37 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 CA-C-N 113.887 -1.506 . . . . 0.0 114.204 -154.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.6 t30 -129.65 111.16 12.41 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 126.301 1.84 . . . . 0.0 108.379 -167.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 84.2 t -98.03 134.89 34.66 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.525 0 C-N-CA 126.72 2.008 . . . . 0.0 109.971 177.047 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 17.0 p -144.01 157.42 44.34 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 126.497 3.046 . . . . 0.0 115.911 -173.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 49.3 tp -129.03 104.97 7.88 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 101.763 -3.421 . . . . 0.0 101.763 -149.039 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 67.6 ttp85 45.74 42.79 9.01 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 104.91 -2.256 . . . . 0.0 104.91 -162.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.63 -1.06 31.55 Favored Glycine 0 CA--C 1.52 0.378 0 N-CA-C 119.932 2.733 . . . . 0.0 119.932 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -85.96 148.76 48.92 Favored Pre-proline 0 N--CA 1.445 -0.677 0 C-N-CA 129.246 3.019 . . . . 0.0 112.225 174.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_endo -76.73 170.8 19.19 Favored 'Trans proline' 0 N--CA 1.444 -1.423 0 O-C-N 124.769 1.931 . . . . 0.0 112.383 -175.248 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . 0.284 4.3 pt -136.37 -163.15 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 C-N-CA 128.399 2.679 . . . . 0.0 112.438 -179.124 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 32.1 mttt -100.88 159.81 14.89 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 125.337 3.699 . . . . 0.0 109.19 -173.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 33.4 m120 54.31 31.51 14.48 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 128.36 2.664 . . . . 0.0 113.351 173.066 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' MET . . . . . . . . . . . . 0.263 7.2 mmt -132.49 150.37 75.68 Favored Pre-proline 0 N--CA 1.454 -0.248 0 O-C-N 118.082 -2.886 . . . . 0.0 105.594 -173.205 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -66.15 174.84 25.54 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 CA-C-N 125.47 2.989 . . . . 0.0 112.735 -5.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 12.4 pt -143.32 169.81 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 O-C-N 126.083 2.114 . . . . 0.0 109.1 170.323 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -125.7 141.39 52.04 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 122.482 2.401 . . . . 0.0 114.437 -167.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 58.5 t -132.81 120.57 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 123.337 0.655 . . . . 0.0 109.421 -170.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 62.5 mttm -65.67 132.21 48.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 126.94 2.096 . . . . 0.0 108.183 173.318 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 20.1 m -126.28 138.27 53.59 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 127.422 2.289 . . . . 0.0 115.885 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 83.7 mt -130.63 152.06 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 O-C-N 118.709 -2.494 . . . . 0.0 110.437 167.003 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -84.91 45.48 1.17 Allowed 'General case' 0 N--CA 1.453 -0.32 0 O-C-N 120.41 -1.431 . . . . 0.0 113.828 -165.29 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.93 0 N-CA-C 116.431 1.332 . . . . 0.0 116.431 -174.41 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo . . . . . 0 N--CA 1.449 -1.129 0 N-CA-C 109.002 -1.191 . . . . 0.0 109.002 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -101.5 135.7 19.77 Favored Pre-proline 0 C--O 1.238 0.475 0 CA-C-O 115.816 -2.04 . . . . 0.0 113.868 -177.591 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -53.42 149.14 31.16 Favored 'Trans proline' 0 N--CA 1.44 -1.624 1 C-N-CA 132.061 8.507 . . . . 0.0 113.622 157.196 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.3 m -145.7 161.17 40.5 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 123.342 1.544 . . . . 0.0 107.45 -166.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.29 -44.04 89.23 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 108.825 -3.807 . . . . 0.0 114.601 -172.036 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . 0.288 68.1 mm-40 -64.88 -20.72 66.58 Favored 'General case' 0 N--CA 1.442 -0.83 0 C-N-CA 129.296 3.038 . . . . 0.0 112.763 167.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 34.2 m170 -121.28 16.52 11.45 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 130.499 3.52 . . . . 0.0 117.733 -163.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 t -142.84 135.05 27.36 Favored 'General case' 0 N--CA 1.445 -0.684 0 O-C-N 118.374 -2.704 . . . . 0.0 110.661 166.147 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . 0.356 49.6 m-85 -154.41 147.27 24.43 Favored 'General case' 0 N--CA 1.446 -0.673 0 C-N-CA 127.646 2.378 . . . . 0.0 107.415 -167.052 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -136.69 150.08 48.27 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 118.377 2.732 . . . . 0.0 118.377 -172.319 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -156.61 145.63 20.28 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 119.324 3.083 . . . . 0.0 119.324 -165.557 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.8 -170.33 21.22 Favored Glycine 0 C--N 1.341 0.833 0 C-N-CA 127.521 2.486 . . . . 0.0 115.578 174.414 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -58.18 -38.66 77.11 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 125.813 1.645 . . . . 0.0 110.256 -170.542 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -68.33 -1.84 23.4 Favored Glycine 0 CA--C 1.527 0.835 0 O-C-N 117.814 -3.054 . . . . 0.0 113.366 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.5 mt -120.27 21.75 11.61 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 122.095 2.948 . . . . 0.0 107.289 169.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.0 t -124.43 -50.85 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-O 116.309 -1.805 . . . . 0.0 112.669 165.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.4 pttt -155.63 136.3 13.42 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 122.419 2.372 . . . . 0.0 110.505 -165.903 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 46.2 t -144.73 141.03 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 CA-C-O 115.303 -2.284 . . . . 0.0 109.049 -170.284 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -137.43 -171.47 2.98 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 120.36 3.467 . . . . 0.0 120.36 -172.603 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 48.4 t0 -94.03 -57.55 2.5 Favored 'General case' 0 N--CA 1.447 -0.587 1 O-C-N 115.101 -4.75 . . . . 0.0 109.294 -162.188 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 66.6 m-80 -97.97 -2.8 39.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 118.841 2.904 . . . . 0.0 118.841 172.093 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -114.47 88.85 16.54 Favored Pre-proline 0 N--CA 1.445 -0.719 0 CA-C-O 122.58 1.181 . . . . 0.0 110.248 160.106 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -43.77 135.63 7.26 Favored 'Trans proline' 0 N--CA 1.445 -1.325 0 N-CA-C 116.997 1.884 . . . . 0.0 116.997 156.381 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.44 153.95 22.58 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.238 2.215 . . . . 0.0 113.418 -174.287 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -138.11 147.92 44.46 Favored 'General case' 0 N--CA 1.442 -0.851 0 C-N-CA 128.494 2.717 . . . . 0.0 112.626 -171.051 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -155.02 175.14 14.21 Favored 'General case' 0 CA--C 1.514 -0.429 0 C-N-CA 130.111 3.365 . . . . 0.0 112.868 166.403 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.415 ' CG2' ' HB ' ' A' ' 78' ' ' THR . 86.9 m -123.36 125.7 45.48 Favored 'General case' 0 C--N 1.344 0.364 0 N-CA-C 117.23 2.307 . . . . 0.0 117.23 -164.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . 0.273 2.3 mt -78.31 123.25 34.85 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.717 0 CA-C-O 114.001 -2.904 . . . . 0.0 115.791 167.59 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.312 22.7 p90 -111.05 91.96 3.86 Favored 'General case' 0 N--CA 1.433 -1.287 0 C-N-CA 129.843 3.257 . . . . 0.0 115.262 177.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -97.74 138.14 35.57 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 130.529 3.531 . . . . 0.0 114.379 -166.266 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.1 t -131.58 135.73 58.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 CA-C-N 112.078 -2.328 . . . . 0.0 107.948 170.126 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -61.55 -61.26 2.65 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 117.029 2.233 . . . . 0.0 117.029 166.838 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 21.1 p -164.03 -26.67 0.04 OUTLIER 'General case' 0 N--CA 1.443 -0.795 0 C-N-CA 130.354 3.462 . . . . 0.0 110.648 169.196 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 34.6 mtmm -76.4 19.22 0.26 Allowed 'General case' 0 CA--C 1.515 -0.386 0 O-C-N 127.006 2.691 . . . . 0.0 114.166 -163.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 62.6 -46.38 0.07 OUTLIER Glycine 0 C--N 1.347 1.19 0 C-N-CA 127.067 2.27 . . . . 0.0 118.049 177.549 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 57.9 t -52.27 140.34 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 CA-C-N 121.881 2.841 . . . . 0.0 112.398 159.136 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -32.44 153.05 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 117.351 2.352 . . . . 0.0 117.351 165.249 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 8.0 mmm180 -59.7 128.13 35.41 Favored 'General case' 0 N--CA 1.452 -0.355 0 O-C-N 118.01 -2.931 . . . . 0.0 113.408 173.556 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 59.9 p -88.82 1.53 55.12 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 127.806 2.442 . . . . 0.0 112.877 -169.34 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -163.82 156.74 18.1 Favored 'General case' 0 N--CA 1.448 -0.526 1 O-C-N 115.786 -4.321 . . . . 0.0 112.922 176.4 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.81 -173.92 30.63 Favored Glycine 0 N--CA 1.466 0.684 0 O-C-N 125.591 1.807 . . . . 0.0 108.98 -155.386 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.23 32.36 83.89 Favored Glycine 0 C--O 1.236 0.224 0 C-N-CA 127.672 2.558 . . . . 0.0 114.076 171.297 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -60.71 145.17 88.48 Favored Pre-proline 0 CA--C 1.514 -0.418 0 O-C-N 117.743 -3.21 . . . . 0.0 106.763 160.103 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -84.09 135.97 6.68 Favored 'Trans proline' 0 CA--C 1.509 -0.735 0 C-N-CA 124.734 3.623 . . . . 0.0 115.952 170.304 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -135.2 163.96 28.77 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 129.62 3.168 . . . . 0.0 111.2 -172.669 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.439 ' O ' ' HA ' ' A' ' 95' ' ' VAL 0.275 21.5 tt0 -145.64 141.56 28.25 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 127.919 2.488 . . . . 0.0 113.472 164.667 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 4.3 t -129.9 61.49 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 129.487 3.115 . . . . 0.0 105.335 -173.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -83.81 132.04 34.85 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 112.839 -1.982 . . . . 0.0 113.958 -175.779 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.437 HD13 ' CE2' ' A' ' 83' ' ' TYR . 61.3 mt -138.77 145.59 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 CA-C-O 124.34 2.019 . . . . 0.0 108.486 -158.277 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.9 m-80 -113.18 129.69 56.44 Favored 'General case' 0 N--CA 1.45 -0.455 0 O-C-N 116.587 -3.821 . . . . 0.0 108.993 167.206 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.22 -172.61 41.79 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 126.205 1.86 . . . . 0.0 114.042 157.403 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo . . . . . 0 N--CA 1.455 -0.766 0 C-N-CA 122.94 2.427 . . . . 0.0 112.937 -178.984 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . 0.265 56.7 t . . . . . 0 N--CA 1.449 -0.523 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 2.3 t -127.8 151.57 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 O-C-N 120.904 -1.123 . . . . 0.0 108.477 -168.136 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -121.76 139.75 53.2 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 126.411 3.005 . . . . 0.0 110.816 153.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -87.16 125.84 34.41 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 112.172 -2.285 . . . . 0.0 106.716 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 30.3 mmtm -81.17 133.64 35.49 Favored 'General case' 0 N--CA 1.449 -0.481 0 O-C-N 118.848 -2.407 . . . . 0.0 111.285 -167.794 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 72.2 t -107.97 139.96 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.685 0 CA-C-O 126.072 2.844 . . . . 0.0 106.842 -168.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 28.4 m -144.5 127.18 16.15 Favored 'General case' 0 C--N 1.345 0.37 0 CA-C-N 111.606 -2.543 . . . . 0.0 109.611 173.362 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 62.3 t0 -63.05 129.67 41.35 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 125.459 1.503 . . . . 0.0 111.752 177.279 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 -82.84 -11.37 58.29 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 115.954 1.835 . . . . 0.0 115.954 173.787 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.39 2.5 m120 63.66 48.5 3.31 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.294 2.238 . . . . 0.0 116.181 -172.697 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 44.0 p-10 -156.75 8.35 0.2 Allowed 'General case' 0 C--N 1.345 0.388 0 CA-C-O 126.376 2.988 . . . . 0.0 117.726 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 95.16 17.52 36.97 Favored Glycine 0 CA--C 1.526 0.742 0 O-C-N 117.588 -3.195 . . . . 0.0 108.441 -178.353 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.415 ' HB ' ' CG2' ' A' ' 37' ' ' THR . 31.1 p -136.76 166.58 23.26 Favored 'General case' 0 C--N 1.331 -0.226 0 O-C-N 124.728 0.899 . . . . 0.0 111.947 173.41 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -137.28 121.61 18.14 Favored 'General case' 0 N--CA 1.441 -0.888 0 O-C-N 125.674 1.859 . . . . 0.0 108.359 -172.752 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -76.18 134.24 15.45 Favored Glycine 0 N--CA 1.466 0.636 0 CA-C-O 124.221 2.012 . . . . 0.0 113.399 163.804 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 89.7 t -117.29 146.48 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 C-N-CA 129.575 3.15 . . . . 0.0 113.329 171.223 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -134.36 141.6 43.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 O-C-N 125.816 1.947 . . . . 0.0 113.285 175.885 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.437 ' CE2' HD13 ' A' ' 59' ' ' ILE . 1.3 p90 -162.15 167.38 24.27 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 116.275 -1.821 . . . . 0.0 112.051 168.841 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 40.7 p30 -144.99 154.64 42.76 Favored 'General case' 0 C--N 1.348 0.535 0 C-N-CA 126.096 1.758 . . . . 0.0 109.02 -166.517 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -124.42 118.25 26.37 Favored Pre-proline 0 N--CA 1.446 -0.647 0 C-N-CA 128.03 2.532 . . . . 0.0 114.514 -166.099 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.263 45.7 Cg_endo -71.87 -14.51 29.61 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.608 2.205 . . . . 0.0 111.803 -175.716 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.9 m -137.77 132.74 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.853 0 C-N-CA 128.139 2.576 . . . . 0.0 114.242 -139.387 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -54.45 112.17 0.94 Allowed 'General case' 0 N--CA 1.447 -0.618 0 O-C-N 118.045 -2.909 . . . . 0.0 115.255 144.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 168.69 -145.5 9.58 Favored Glycine 0 CA--C 1.529 0.922 1 O-C-N 114.453 -5.154 . . . . 0.0 114.818 -173.422 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -145.49 133.39 21.26 Favored 'General case' 0 N--CA 1.448 -0.525 0 O-C-N 117.431 -3.394 . . . . 0.0 115.152 -176.62 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 17.7 m-85 -102.34 148.68 25.18 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 104.669 -2.345 . . . . 0.0 104.669 174.138 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -126.39 106.59 9.59 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 128.347 3.53 . . . . 0.0 112.51 -177.81 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 42.6 t -111.81 131.44 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 O-C-N 119.612 -1.93 . . . . 0.0 108.571 -158.662 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 -126.74 120.24 28.89 Favored 'General case' 0 CA--C 1.513 -0.473 0 C-N-CA 129.746 3.218 . . . . 0.0 110.158 174.777 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.439 ' HA ' ' O ' ' A' ' 56' ' ' GLU . 77.1 t -99.92 148.21 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 115.534 1.679 . . . . 0.0 115.534 170.467 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.48 HG22 ' HA ' ' A' ' 101' ' ' PRO . 4.7 p -150.41 148.83 29.24 Favored 'General case' 0 N--CA 1.445 -0.675 0 O-C-N 117.385 -3.322 . . . . 0.0 113.025 -177.818 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.449 HD13 HG21 ' A' ' 102' ' ' ILE . 8.0 mp -128.8 106.65 9.06 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 127.971 2.508 . . . . 0.0 110.184 -158.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? 51.56 44.32 29.17 Favored 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 126.212 1.805 . . . . 0.0 108.295 -160.58 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 58.59 26.56 59.99 Favored Glycine 0 N--CA 1.439 -1.103 0 N-CA-C 118.429 2.131 . . . . 0.0 118.429 -177.146 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 73.5 m-20 -122.06 143.53 39.12 Favored Pre-proline 0 CA--C 1.516 -0.362 0 C-N-CA 125.088 1.355 . . . . 0.0 108.887 174.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.48 ' HA ' HG22 ' A' ' 96' ' ' THR 0.282 24.4 Cg_endo -82.88 175.83 8.25 Favored 'Trans proline' 0 N--CA 1.446 -1.293 0 CA-C-O 125.948 2.395 . . . . 0.0 108.318 -168.63 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.449 HG21 HD13 ' A' ' 97' ' ' LEU . 25.7 pt -149.7 -176.11 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 C-N-CA 127.961 2.505 . . . . 0.0 109.865 -167.575 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 41.1 mtpt -81.28 163.56 22.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 123.14 1.447 . . . . 0.0 113.314 -176.477 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.295 23.2 m120 58.39 54.49 5.57 Favored 'General case' 0 C--O 1.222 -0.386 0 N-CA-C 117.125 2.269 . . . . 0.0 117.125 168.115 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 9.7 mmt -164.3 146.98 7.39 Favored Pre-proline 0 CA--C 1.507 -0.686 0 C-N-CA 128.079 2.552 . . . . 0.0 105.449 -162.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -70.58 164.81 80.65 Favored 'Cis proline' 0 N--CA 1.445 -1.352 0 C-N-CA 130.836 1.598 . . . . 0.0 109.979 -5.79 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' ILE . . . . . 0.404 HD13 HG21 ' A' ' 107' ' ' ILE . 31.4 pt -130.43 174.04 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 C-N-CA 126.202 1.801 . . . . 0.0 108.043 174.336 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -125.44 139.31 53.76 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 117.49 2.404 . . . . 0.0 117.49 -168.314 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 2.4 t -147.39 125.67 3.76 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-O 124.005 1.86 . . . . 0.0 114.323 -175.646 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . 0.271 46.1 pttt -66.44 129.04 38.51 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 127.057 2.143 . . . . 0.0 108.818 -173.121 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . 0.383 72.5 m -107.71 141.95 38.45 Favored 'General case' 0 N--CA 1.448 -0.531 0 O-C-N 126.72 2.512 . . . . 0.0 104.528 178.668 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 21.9 mt -144.52 143.65 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 O-C-N 117.281 -3.387 . . . . 0.0 111.977 173.203 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . 0.298 12.0 pt-20 -93.56 53.1 1.81 Allowed 'General case' 0 N--CA 1.449 -0.507 1 O-C-N 114.427 -5.171 . . . . 0.0 110.741 -157.05 . . . . . . . . 3 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 0.338 0 C-N-CA 128.453 2.93 . . . . 0.0 113.671 -176.289 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo . . . . . 0 N--CA 1.448 -1.185 0 CA-C-O 122.595 0.998 . . . . 0.0 110.556 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -99.55 161.65 23.81 Favored Pre-proline 0 N--CA 1.45 -0.432 0 N-CA-C 117.244 2.313 . . . . 0.0 117.244 -173.734 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -74.17 170.2 20.71 Favored 'Trans proline' 0 N--CA 1.445 -1.348 0 C-N-CA 123.927 3.084 . . . . 0.0 111.276 -178.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.5 t -152.22 173.99 14.31 Favored 'General case' 0 N--CA 1.452 -0.341 0 O-C-N 124.348 1.03 . . . . 0.0 111.716 174.221 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.83 -39.97 79.69 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-N 115.125 -0.943 . . . . 0.0 113.374 -170.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 72.5 mm-40 -53.0 -35.76 59.73 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 129.547 3.139 . . . . 0.0 113.596 168.186 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 17.2 m170 -120.5 19.76 11.94 Favored 'General case' 0 N--CA 1.438 -1.026 0 CA-C-N 111.928 -2.397 . . . . 0.0 111.76 -161.546 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.4 t -137.45 138.28 39.61 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 117.999 -2.938 . . . . 0.0 105.468 171.804 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -164.31 153.44 13.52 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 110.778 -2.919 . . . . 0.0 110.606 -170.215 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.462 ' HB2' ' HA ' ' A' ' 38' ' ' ILE . . . -140.11 150.0 43.76 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 119.621 3.193 . . . . 0.0 119.621 -171.662 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -157.47 134.31 10.04 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 127.563 2.345 . . . . 0.0 111.916 -165.347 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 148.46 166.5 12.91 Favored Glycine 0 C--N 1.336 0.56 0 C-N-CA 126.473 1.987 . . . . 0.0 112.292 176.47 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -65.34 -19.78 66.1 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 116.682 -1.628 . . . . 0.0 109.436 -169.149 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.536 ' HA3' ' CD2' ' A' ' 36' ' ' PHE . . . -64.29 0.3 3.84 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 124.58 3.355 . . . . 0.0 117.22 168.182 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . 0.27 56.9 mt -109.54 13.33 24.0 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 129.637 3.175 . . . . 0.0 111.854 167.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 t -131.52 -53.36 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 C-N-CA 130.69 3.596 . . . . 0.0 112.018 -178.584 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 46.7 pttt -161.85 125.64 3.2 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 -159.367 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.2 t -137.67 155.72 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 C-N-CA 129.303 3.041 . . . . 0.0 109.907 -177.62 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -131.78 -176.66 4.12 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-O 123.933 1.825 . . . . 0.0 111.856 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -88.05 -46.85 8.98 Favored 'General case' 0 N--CA 1.446 -0.629 0 O-C-N 119.489 -2.007 . . . . 0.0 109.462 -174.642 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -109.5 6.91 24.52 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-O 126.64 3.114 . . . . 0.0 117.304 176.555 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -122.46 100.36 41.67 Favored Pre-proline 0 N--CA 1.442 -0.858 1 O-C-N 116.202 -4.061 . . . . 0.0 101.784 167.162 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -62.42 157.62 45.03 Favored 'Trans proline' 0 N--CA 1.45 -1.031 0 C-N-CA 123.654 2.903 . . . . 0.0 113.595 166.123 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -123.89 153.03 41.71 Favored 'General case' 0 CA--C 1.511 -0.548 0 C-N-CA 127.136 2.175 . . . . 0.0 112.86 -176.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.496 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 33.6 mt-10 -127.4 155.42 43.67 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 124.067 0.947 . . . . 0.0 108.979 -175.655 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.536 ' CD2' ' HA3' ' A' ' 24' ' ' GLY . 5.2 p90 -161.65 155.38 21.67 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -179.3 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 86.4 m -124.21 119.75 30.27 Favored 'General case' 0 N--CA 1.452 -0.342 0 O-C-N 119.014 -2.303 . . . . 0.0 109.593 -161.55 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.462 ' HA ' ' HB2' ' A' ' 20' ' ' ALA 0.263 17.2 mt -79.74 102.96 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 124.994 1.318 . . . . 0.0 111.533 164.897 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.371 40.5 p90 -83.24 124.76 30.88 Favored 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 126.49 1.916 . . . . 0.0 113.797 165.637 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -110.45 146.61 35.6 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 179.701 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 9.7 t -129.99 139.11 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 O-C-N 126.757 2.536 . . . . 0.0 106.431 160.228 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -66.76 -50.32 63.1 Favored 'General case' 0 N--CA 1.452 -0.336 0 O-C-N 117.779 -3.076 . . . . 0.0 111.881 178.364 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 64.3 p -148.98 -60.23 0.22 Allowed 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 115.947 -1.978 . . . . 0.0 111.359 -166.804 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 12.7 ttmt -134.61 101.29 4.9 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 122.149 2.249 . . . . 0.0 114.543 -178.508 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 77.45 -65.56 3.08 Favored Glycine 0 N--CA 1.451 -0.306 0 O-C-N 120.372 -1.455 . . . . 0.0 114.375 162.814 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 46.3 t -61.01 124.71 15.93 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 C-N-CA 128.891 2.876 . . . . 0.0 108.717 179.413 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -50.91 168.2 0.06 Allowed 'General case' 0 N--CA 1.449 -0.486 0 CA-C-O 124.471 2.081 . . . . 0.0 112.982 178.702 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -53.75 125.85 19.9 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 108.719 -3.855 . . . . 0.0 107.631 163.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 17.5 p -79.08 -18.33 53.57 Favored 'General case' 0 N--CA 1.453 -0.297 1 C-N-CA 131.757 4.023 . . . . 0.0 111.486 -173.05 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -151.86 169.35 22.48 Favored 'General case' 0 CA--C 1.517 -0.297 0 O-C-N 127.551 3.032 . . . . 0.0 107.965 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -102.58 -142.75 12.53 Favored Glycine 0 CA--C 1.525 0.671 0 C-N-CA 124.763 1.173 . . . . 0.0 115.001 -167.423 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 71.65 5.34 60.32 Favored Glycine 0 C--N 1.334 0.455 0 CA-C-O 117.234 -1.87 . . . . 0.0 116.751 165.489 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 38.1 m-20 -77.01 143.54 70.61 Favored Pre-proline 0 N--CA 1.45 -0.455 0 CA-C-O 115.435 -2.221 . . . . 0.0 115.981 -178.261 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -83.02 127.71 4.79 Favored 'Trans proline' 0 N--CA 1.449 -1.09 0 CA-C-N 125.151 2.875 . . . . 0.0 115.998 -176.702 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -138.25 161.48 36.77 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 114.133 -1.394 . . . . 0.0 111.428 -171.885 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -153.39 151.72 30.24 Favored 'General case' 0 N--CA 1.447 -0.62 0 O-C-N 120.547 -1.346 . . . . 0.0 113.22 172.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 53.5 t -133.35 99.73 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 C-N-CA 130.054 3.342 . . . . 0.0 104.335 -172.072 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -125.07 138.87 54.18 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 113.577 -1.647 . . . . 0.0 112.663 -170.432 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.4 mt -138.78 115.45 10.58 Favored 'Isoleucine or valine' 0 C--O 1.238 0.482 0 O-C-N 119.715 -1.866 . . . . 0.0 107.978 -147.048 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -88.64 138.62 31.26 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 118.823 -2.423 . . . . 0.0 107.011 173.433 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -141.83 173.33 23.64 Favored Glycine 0 CA--C 1.523 0.539 0 C-N-CA 129.359 3.361 . . . . 0.0 112.475 -166.321 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo . . . . . 0 N--CA 1.46 -0.484 1 C-N-CA 125.921 4.414 . . . . 0.0 117.454 170.629 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 4.5 t . . . . . 0 N--CA 1.451 -0.397 0 CA-C-O 126.064 2.84 . . . . 0.0 113.207 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 8.9 t -149.43 152.67 11.71 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 O-C-N 116.906 -3.621 . . . . 0.0 107.5 -176.185 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -131.21 138.24 49.29 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-O 123.413 1.578 . . . . 0.0 115.02 161.828 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -94.09 131.1 39.94 Favored 'General case' 0 N--CA 1.441 -0.917 1 C-N-CA 133.319 4.648 . . . . 0.0 112.585 -164.289 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.408 ' HE2' ' HB3' ' A' ' 70' ' ' LYS 0.258 28.5 ttpt -71.31 126.03 28.56 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 122.894 2.588 . . . . 0.0 112.506 -166.663 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.442 HG22 HG22 ' A' ' 81' ' ' VAL . 68.8 t -106.88 140.2 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 O-C-N 119.552 -1.968 . . . . 0.0 106.446 -179.409 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 90.4 m -144.76 127.97 16.71 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-O 124.868 2.27 . . . . 0.0 113.933 178.536 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -69.26 128.31 36.14 Favored 'General case' 0 N--CA 1.456 -0.155 0 C-N-CA 127.35 2.26 . . . . 0.0 109.895 -174.626 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 55.8 m-20 -91.11 5.47 48.82 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 118.458 2.762 . . . . 0.0 118.458 174.527 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 15.3 m-20 55.17 43.23 29.73 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 120.057 1.299 . . . . 0.0 112.423 174.656 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 35.3 p-10 -155.57 3.29 0.18 Allowed 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 128.052 2.541 . . . . 0.0 116.565 -174.695 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 98.95 4.2 56.79 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 118.515 -2.616 . . . . 0.0 112.33 -174.633 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 16.9 p -133.94 165.77 24.24 Favored 'General case' 0 CA--C 1.515 -0.387 0 N-CA-C 116.723 2.12 . . . . 0.0 116.723 177.429 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 45.2 m-85 -129.64 134.43 47.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.602 177.179 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -81.75 133.72 12.35 Favored Glycine 0 C--N 1.342 0.863 0 O-C-N 125.775 1.922 . . . . 0.0 108.325 172.361 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 35' ' ' GLU . 17.5 t -118.55 136.94 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 128.122 2.569 . . . . 0.0 109.433 175.454 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 p -134.84 135.05 53.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 CA-C-O 114.574 -2.631 . . . . 0.0 111.347 -178.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 80.2 t80 -156.17 144.39 19.85 Favored 'General case' 0 N--CA 1.445 -0.686 1 O-C-N 130.82 5.075 . . . . 0.0 113.084 -174.794 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.9 p30 -130.0 149.0 51.91 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 126.473 1.909 . . . . 0.0 107.999 -177.708 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -115.25 112.27 44.1 Favored Pre-proline 0 CA--C 1.511 -0.532 0 C-N-CA 125.731 1.612 . . . . 0.0 112.016 -171.71 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -71.41 -14.55 31.01 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 C-N-CA 124.032 3.155 . . . . 0.0 117.321 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.8 m -143.57 143.59 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 O-C-N 119.824 -1.797 . . . . 0.0 109.853 -174.783 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 -49.47 121.48 5.11 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 162.306 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -179.92 171.57 43.06 Favored Glycine 0 C--N 1.339 0.711 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.394 -175.659 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -98.86 133.22 43.46 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 128.886 2.874 . . . . 0.0 112.504 158.705 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 -126.94 150.03 49.54 Favored 'General case' 0 C--O 1.22 -0.464 0 N-CA-C 106.363 -1.717 . . . . 0.0 106.363 -173.513 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -119.18 111.28 18.04 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-N 114.214 -1.357 . . . . 0.0 114.632 -170.852 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.6 t -102.35 132.82 47.6 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.43 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 -166.575 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -122.6 128.09 50.24 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 131.169 3.788 . . . . 0.0 112.243 166.113 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 62.0 t -117.36 143.65 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 CA-C-N 114.481 -1.236 . . . . 0.0 109.682 -177.34 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.5 p -140.31 160.55 39.72 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 117.971 -1.014 . . . . 0.0 111.888 -171.502 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . 0.257 8.2 tt -135.65 94.08 3.04 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 103.152 -2.907 . . . . 0.0 103.152 -152.808 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 26.4 ttp-105 52.96 37.42 24.46 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 120.975 1.716 . . . . 0.0 112.019 -170.563 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 65.07 35.95 92.41 Favored Glycine 0 C--N 1.338 0.679 0 N-CA-C 116.65 1.42 . . . . 0.0 116.65 -176.26 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 71.3 m-80 -115.38 141.19 26.83 Favored Pre-proline 0 N--CA 1.447 -0.588 0 CA-C-O 117.353 -1.308 . . . . 0.0 110.009 166.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -71.69 165.98 30.86 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 CA-C-O 124.988 1.995 . . . . 0.0 112.095 166.134 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 11.6 pt -137.62 179.55 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 C-N-CA 127.234 2.214 . . . . 0.0 112.788 -173.055 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.403 ' C ' ' H ' ' A' ' 105' ' ' MET . 56.3 mtpt -74.71 165.91 24.45 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-O 115.529 -2.177 . . . . 0.0 111.025 -173.084 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.421 15.1 m120 66.93 -20.58 0.11 Allowed 'General case' 0 C--N 1.33 -0.268 0 O-C-N 125.59 1.806 . . . . 0.0 114.019 172.737 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' MET . . . . . 0.403 ' H ' ' C ' ' A' ' 103' ' ' LYS . 12.9 mmt -67.17 158.65 80.77 Favored Pre-proline 0 N--CA 1.446 -0.644 0 C-N-CA 127.268 2.227 . . . . 0.0 116.575 -178.669 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -73.51 159.68 97.06 Favored 'Cis proline' 0 N--CA 1.442 -1.517 0 O-C-N 125.089 2.099 . . . . 0.0 107.932 -20.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 8.2 pt -131.23 161.96 40.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 C-N-CA 126.828 2.051 . . . . 0.0 108.736 -174.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 69.8 m-20 -117.27 147.9 42.14 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 126.481 1.912 . . . . 0.0 111.28 -159.49 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 42.7 t -139.66 117.29 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 126.344 1.857 . . . . 0.0 111.889 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 65.4 tttt -81.9 136.14 35.35 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 115.524 1.675 . . . . 0.0 115.524 168.613 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 98.1 m -126.77 133.39 50.85 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 125.766 1.626 . . . . 0.0 107.622 -170.834 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 48.9 mm -121.82 141.78 40.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 O-C-N 120.156 -1.59 . . . . 0.0 107.65 177.272 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -82.75 41.23 0.72 Allowed 'General case' 0 N--CA 1.454 -0.246 1 O-C-N 114.941 -4.85 . . . . 0.0 116.548 -155.865 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.651 0 O-C-N 119.493 -2.004 . . . . 0.0 113.449 -175.685 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo . . . . . 0 N--CA 1.447 -1.255 0 N-CA-C 108.986 -1.198 . . . . 0.0 108.986 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -114.59 161.97 26.0 Favored Pre-proline 0 N--CA 1.447 -0.578 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_exo -52.06 166.78 0.59 Allowed 'Trans proline' 0 N--CA 1.444 -1.394 0 N-CA-C 115.806 1.425 . . . . 0.0 115.806 170.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.7 t -133.95 149.75 51.27 Favored 'General case' 0 N--CA 1.447 -0.59 0 O-C-N 120.306 -1.496 . . . . 0.0 107.971 160.493 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -47.99 -33.1 7.36 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 130.477 3.511 . . . . 0.0 111.406 164.707 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -67.43 -19.8 65.42 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 75.0 m-70 -141.32 14.91 2.21 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 117.321 2.341 . . . . 0.0 117.321 -159.25 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.1 t -141.49 126.31 18.11 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 176.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 65.4 m-85 -150.88 158.0 43.6 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 130.01 3.324 . . . . 0.0 108.882 -161.205 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -133.32 148.68 51.91 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 118.343 2.72 . . . . 0.0 118.343 -175.567 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -145.27 146.13 31.54 Favored 'General case' 0 C--O 1.221 -0.408 0 N-CA-C 119.917 3.302 . . . . 0.0 119.917 171.138 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.44 178.83 28.37 Favored Glycine 0 C--N 1.342 0.863 0 C-N-CA 125.457 1.503 . . . . 0.0 114.899 173.207 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -59.28 -32.33 69.92 Favored 'General case' 0 C--O 1.239 0.552 0 O-C-N 117.994 -3.063 . . . . 0.0 117.296 176.401 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.39 10.06 2.94 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 125.342 1.449 . . . . 0.0 115.795 170.187 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.424 ' HG ' ' CG ' ' A' ' 36' ' ' PHE . 89.6 mt -124.38 30.52 6.01 Favored 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 118.829 -2.571 . . . . 0.0 112.754 154.716 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 95.4 t -138.86 -63.05 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 O-C-N 120.111 -1.618 . . . . 0.0 109.683 175.277 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.292 37.2 pttt -144.65 131.83 20.57 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 123.122 2.692 . . . . 0.0 115.128 -173.111 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 t -130.78 146.76 33.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 1 O-C-N 129.176 4.048 . . . . 0.0 112.386 -174.366 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.492 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 3.9 m-85 -140.1 179.77 6.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 116.84 2.163 . . . . 0.0 116.84 177.137 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -82.36 -39.93 22.07 Favored 'General case' 0 C--O 1.235 0.341 0 O-C-N 116.818 -3.676 . . . . 0.0 113.538 -168.686 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 15.6 m-80 -105.81 3.42 28.72 Favored 'General case' 0 N--CA 1.449 -0.522 0 O-C-N 126.379 2.3 . . . . 0.0 112.907 178.323 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -128.77 89.64 48.49 Favored Pre-proline 0 N--CA 1.447 -0.599 0 O-C-N 121.693 -0.629 . . . . 0.0 110.731 175.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_endo -65.97 147.59 84.87 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 O-C-N 125.843 2.496 . . . . 0.0 110.576 -178.692 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.21 164.77 12.01 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 126.426 1.89 . . . . 0.0 111.305 -177.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.405 ' HG2' HG22 ' A' ' 82' ' ' VAL . 19.3 mt-10 -140.34 146.0 37.89 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 115.616 -2.135 . . . . 0.0 112.748 -175.097 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.424 ' CG ' ' HG ' ' A' ' 25' ' ' LEU . 24.6 p90 -153.52 167.39 29.64 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 122.858 2.572 . . . . 0.0 107.49 171.638 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 94.7 m -127.46 115.6 19.14 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.262 1.425 . . . . 0.0 109.012 -156.005 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . 0.405 8.4 mt -67.06 96.91 0.29 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.22 0 C-N-CA 125.529 1.532 . . . . 0.0 112.044 162.717 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -83.49 112.43 19.96 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-O 125.086 2.374 . . . . 0.0 111.942 166.321 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -114.97 126.94 55.35 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 116.496 -3.878 . . . . 0.0 110.259 -167.402 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.416 HG22 ' HA ' ' A' ' 47' ' ' ALA . 54.4 t -127.62 149.43 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-O 123.967 1.841 . . . . 0.0 106.894 173.563 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -80.86 -37.57 29.67 Favored 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 117.162 2.282 . . . . 0.0 117.162 169.584 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 82.7 p -160.0 -69.94 0.07 Allowed 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 127.048 2.717 . . . . 0.0 116.907 -170.452 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 50.6 mttm -127.98 99.13 5.38 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 122.282 2.31 . . . . 0.0 113.253 -174.01 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 76.37 -75.32 1.6 Allowed Glycine 0 CA--C 1.525 0.661 0 CA-C-N 121.995 2.18 . . . . 0.0 114.915 159.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 65.5 t -46.66 129.03 2.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 126.624 1.97 . . . . 0.0 107.005 171.157 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.416 ' HA ' HG22 ' A' ' 41' ' ' VAL . . . -58.81 171.23 0.68 Allowed 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 116.661 2.097 . . . . 0.0 116.661 177.088 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.3 mmm180 -64.22 116.06 5.63 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 115.598 -2.144 . . . . 0.0 106.28 165.273 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.7 p -76.63 4.6 9.07 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 127.762 3.164 . . . . 0.0 116.604 -160.45 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -168.4 163.06 12.69 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-O 125.338 2.494 . . . . 0.0 108.314 -173.697 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -103.17 -169.5 25.98 Favored Glycine 0 CA--C 1.524 0.646 0 O-C-N 118.064 -2.898 . . . . 0.0 113.61 -150.845 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 62.24 22.08 62.67 Favored Glycine 0 C--N 1.335 0.475 0 CA-C-O 113.854 -3.748 . . . . 0.0 117.952 169.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -69.09 153.59 95.89 Favored Pre-proline 0 N--CA 1.452 -0.363 0 CA-C-N 124.15 3.975 . . . . 0.0 110.253 173.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -88.03 133.08 2.87 Favored 'Trans proline' 0 N--CA 1.447 -1.264 1 C-N-CA 127.091 5.194 . . . . 0.0 118.388 -172.366 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -148.8 167.12 26.47 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 113.174 -1.83 . . . . 0.0 110.37 -156.656 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -161.96 141.76 10.01 Favored 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 129.021 2.928 . . . . 0.0 107.241 174.319 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 20.2 t -132.14 96.04 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 C-N-CA 130.769 3.628 . . . . 0.0 103.917 -178.652 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -116.16 140.36 49.38 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 112.236 -2.257 . . . . 0.0 110.016 -168.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 58.5 mt -134.82 148.84 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 CA-C-N 113.754 -1.567 . . . . 0.0 110.041 -159.229 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 54.2 m-80 -126.67 151.5 47.99 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 104.693 -2.336 . . . . 0.0 104.693 165.05 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.0 -145.72 4.72 Favored Glycine 0 C--O 1.219 -0.819 0 N-CA-C 107.613 -2.195 . . . . 0.0 107.613 173.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo . . . . . 0 N--CA 1.45 -1.029 0 CA-C-O 124.496 1.79 . . . . 0.0 111.746 -172.316 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 99.0 t . . . . . 0 CA--C 1.514 -0.424 0 CA-C-O 123.295 1.521 . . . . 0.0 107.023 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 24.4 t -140.36 151.53 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.993 0 C-N-CA 125.21 1.404 . . . . 0.0 111.735 -168.753 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.256 8.3 p-10 -135.72 122.55 21.15 Favored 'General case' 0 C--N 1.326 -0.429 0 O-C-N 127.532 3.02 . . . . 0.0 109.791 167.834 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -74.75 151.08 39.19 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 128.586 2.754 . . . . 0.0 114.828 -178.173 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 66.3 tttt -93.73 98.75 11.31 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 114.369 -1.287 . . . . 0.0 111.376 -160.598 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.1 t -88.64 133.24 31.49 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.117 0 O-C-N 125.678 1.861 . . . . 0.0 106.451 -170.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 26.3 m -144.4 126.48 15.53 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 118.574 -1.25 . . . . 0.0 109.353 172.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -48.56 120.84 3.99 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 128.534 2.734 . . . . 0.0 118.283 166.589 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 -84.55 1.16 47.13 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 114.256 -2.783 . . . . 0.0 112.613 178.747 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 9.3 m120 61.29 24.24 14.37 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 117.556 2.428 . . . . 0.0 117.556 -177.267 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 19.8 p30 -134.55 -6.28 2.53 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 115.487 1.662 . . . . 0.0 115.487 -177.584 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 112.61 0.79 26.08 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 114.836 -3.202 . . . . 0.0 114.586 -166.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 66.0 p -131.74 160.46 35.47 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 120.407 2.103 . . . . 0.0 113.529 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -123.79 127.63 48.38 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 117.866 -3.021 . . . . 0.0 110.362 173.746 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -80.6 116.35 4.22 Favored Glycine 0 CA--C 1.526 0.755 0 C-N-CA 129.246 3.308 . . . . 0.0 106.103 171.777 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.7 t -102.14 125.34 56.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 117.194 2.294 . . . . 0.0 117.194 165.338 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.405 HG22 ' HG2' ' A' ' 35' ' ' GLU . 87.6 t -125.79 145.79 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-N 121.906 2.139 . . . . 0.0 111.762 -173.666 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . 0.343 1.2 p90 -165.93 172.63 11.33 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 122.849 2.568 . . . . 0.0 114.524 179.513 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 19.8 p30 -135.33 169.48 17.41 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -177.037 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -132.88 109.64 13.02 Favored Pre-proline 0 N--CA 1.447 -0.604 0 N-CA-C 114.752 1.389 . . . . 0.0 114.752 179.184 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.288 68.8 Cg_endo -71.88 -2.63 11.78 Favored 'Trans proline' 0 N--CA 1.449 -1.14 0 C-N-CA 124.702 3.601 . . . . 0.0 111.366 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.8 m -138.66 144.71 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.634 0 CA-C-O 121.653 0.739 . . . . 0.0 111.961 -163.05 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -63.29 127.52 31.66 Favored 'General case' 0 N--CA 1.451 -0.423 0 O-C-N 119.361 -2.087 . . . . 0.0 109.956 153.019 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 167.39 -166.37 39.24 Favored Glycine 0 CA--C 1.521 0.444 0 CA-C-O 123.756 1.753 . . . . 0.0 116.289 -172.788 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 11.1 t30 -114.48 139.71 49.32 Favored 'General case' 0 C--O 1.22 -0.487 0 CA-C-N 111.295 -2.452 . . . . 0.0 111.908 164.234 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' TYR . . . . . 0.415 ' CD2' ' SG ' ' A' ' 111' ' ' CYS . 10.1 m-85 -98.57 152.04 20.01 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 127.518 3.532 . . . . 0.0 112.494 152.269 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -129.08 109.07 10.88 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 109.806 -3.361 . . . . 0.0 108.164 -174.567 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 87.0 t -101.32 129.08 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 113.155 -1.839 . . . . 0.0 108.403 -163.738 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -131.15 130.52 43.16 Favored 'General case' 0 N--CA 1.449 -0.509 0 O-C-N 126.445 2.341 . . . . 0.0 110.889 176.385 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 99.6 t -112.74 147.13 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.741 0 N-CA-C 114.67 1.359 . . . . 0.0 114.67 -177.332 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 31.4 p -142.89 162.54 35.19 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 120.792 1.633 . . . . 0.0 111.597 175.721 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 3.0 tt -144.51 101.26 3.66 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 -147.777 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 28.8 ttm-85 47.51 42.01 13.92 Favored 'General case' 0 N--CA 1.445 -0.684 0 O-C-N 124.625 1.203 . . . . 0.0 108.324 -163.689 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 85.48 2.75 87.11 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 128.791 3.091 . . . . 0.0 120.077 177.129 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.409 ' HA ' ' HD3' ' A' ' 101' ' ' PRO . 84.2 m-20 -115.58 147.84 39.72 Favored Pre-proline 0 CA--C 1.514 -0.425 0 C-N-CA 125.881 1.672 . . . . 0.0 113.243 -176.73 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 100' ' ' ASN . 58.4 Cg_endo -74.15 163.04 37.52 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 124.755 3.637 . . . . 0.0 111.138 -177.485 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 10.7 pt -140.82 175.09 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 126.219 1.807 . . . . 0.0 112.699 -165.55 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -82.28 164.08 21.39 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 120.832 1.651 . . . . 0.0 113.915 -170.331 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 29.7 m120 53.97 40.15 31.28 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 127.403 2.281 . . . . 0.0 116.772 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 8.7 mmt -126.25 168.96 12.71 Favored Pre-proline 0 N--CA 1.45 -0.462 0 C-N-CA 126.993 2.117 . . . . 0.0 107.376 -170.538 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -65.67 168.66 14.47 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 N-CA-C 117.453 2.059 . . . . 0.0 117.453 -33.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . 0.372 17.1 pt -138.54 140.05 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-O 122.71 1.243 . . . . 0.0 109.202 -168.631 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -107.93 139.16 42.97 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 117.526 2.417 . . . . 0.0 117.526 -168.553 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 66.1 t -146.53 114.88 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.762 0 O-C-N 119.783 -1.823 . . . . 0.0 109.395 -161.442 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 68.2 tttt -80.51 144.26 32.65 Favored 'General case' 0 CA--C 1.523 -0.093 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' CYS . . . . . 0.415 ' SG ' ' CD2' ' A' ' 91' ' ' TYR . 87.7 m -117.14 139.08 51.19 Favored 'General case' 0 N--CA 1.451 -0.42 2 O-C-N 131.991 5.807 . . . . 0.0 110.233 -179.984 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.492 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 90.9 mt -135.04 123.37 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-N 108.469 -3.969 . . . . 0.0 113.361 171.617 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' GLU . . . . . 0.413 ' HG2' ' H ' ' A' ' 113' ' ' GLU 0.3 7.5 pt-20 -76.23 39.97 0.2 Allowed 'General case' 0 N--CA 1.451 -0.395 0 O-C-N 116.947 -3.595 . . . . 0.0 115.332 -164.646 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.626 0 CA-C-N 121.457 1.935 . . . . 0.0 115.585 169.728 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo . . . . . 0 N--CA 1.439 -1.703 0 CA-C-O 119.391 -0.337 . . . . 0.0 111.313 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -111.53 136.83 21.03 Favored Pre-proline 0 C--O 1.239 0.538 0 C-N-CA 131.116 3.767 . . . . 0.0 114.187 -176.332 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . 0.252 23.3 Cg_exo -65.58 168.78 14.04 Favored 'Trans proline' 0 CA--C 1.514 -0.49 0 N-CA-C 117.498 2.076 . . . . 0.0 117.498 170.63 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.6 m -142.88 160.85 39.55 Favored 'General case' 0 N--CA 1.44 -0.958 0 CA-C-N 123.317 2.78 . . . . 0.0 110.937 -174.623 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.44 -48.43 81.68 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 113.597 -3.097 . . . . 0.0 113.861 174.638 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -52.64 -28.32 20.95 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 123.06 2.663 . . . . 0.0 106.773 173.005 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 26.2 m170 -117.37 5.86 12.61 Favored 'General case' 0 C--O 1.218 -0.603 0 N-CA-C 116.525 2.046 . . . . 0.0 116.525 -156.658 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.8 t -135.14 121.86 20.88 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 116.816 2.154 . . . . 0.0 116.816 173.795 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 26.6 m-85 -153.31 155.19 36.02 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -161.109 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . 0.462 . . -132.01 147.92 52.48 Favored 'General case' 0 C--O 1.217 -0.61 0 N-CA-C 117.85 2.537 . . . . 0.0 117.85 -167.36 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -160.96 145.95 14.08 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 130.125 3.37 . . . . 0.0 108.736 -164.486 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.1 175.21 13.94 Favored Glycine 0 N--CA 1.446 -0.696 0 O-C-N 126.99 2.681 . . . . 0.0 117.505 -173.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -74.03 -30.21 62.31 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 112.652 -3.547 . . . . 0.0 113.715 -176.139 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -62.23 9.82 0.12 Allowed Glycine 0 CA--C 1.531 1.047 0 CA-C-N 124.945 3.52 . . . . 0.0 115.371 161.66 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 17.0 mt -113.9 19.85 16.25 Favored 'General case' 0 C--O 1.223 -0.312 0 CA-C-N 122.023 2.911 . . . . 0.0 109.799 167.692 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 1.7 t -137.97 -41.75 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 CA-C-O 115.313 -2.28 . . . . 0.0 110.312 174.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 42.4 mtmt -155.74 118.09 4.14 Favored 'General case' 0 C--N 1.328 -0.367 0 O-C-N 124.685 1.241 . . . . 0.0 114.096 -163.051 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 t -124.7 138.69 53.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 C-N-CA 130.853 3.661 . . . . 0.0 116.188 177.772 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 27.3 m-85 -128.78 -169.82 2.15 Favored 'General case' 0 N--CA 1.452 -0.358 0 O-C-N 126.552 2.408 . . . . 0.0 115.434 -174.755 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 17.7 t0 -105.17 -33.29 8.31 Favored 'General case' 0 CA--C 1.511 -0.541 0 O-C-N 118.278 -2.764 . . . . 0.0 114.212 -167.471 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 53.8 m-80 -101.83 8.73 41.22 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 120.511 3.523 . . . . 0.0 120.511 162.096 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -137.57 96.15 10.95 Favored Pre-proline 0 N--CA 1.445 -0.676 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.263 178.822 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_exo -62.83 128.29 22.79 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 121.883 1.722 . . . . 0.0 111.7 171.759 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -92.35 156.41 17.26 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 123.05 1.405 . . . . 0.0 109.71 -177.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -133.97 149.77 51.25 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 -169.454 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -161.64 173.27 14.95 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.194 -2.521 . . . . 0.0 104.194 168.376 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 26.1 m -127.02 118.17 23.93 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 131.53 3.932 . . . . 0.0 114.811 -158.268 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.415 ' HB ' ' HB2' ' A' ' 79' ' ' TYR . 44.7 mm -76.19 96.31 1.32 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.483 0 C-N-CA 127.012 2.125 . . . . 0.0 106.213 173.571 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -81.83 99.87 9.26 Favored 'General case' 0 C--O 1.214 -0.8 0 O-C-N 119.114 -2.241 . . . . 0.0 114.87 171.164 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -100.12 137.14 38.97 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 117.807 2.521 . . . . 0.0 117.807 -167.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 71.7 t -134.94 156.45 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 C-N-CA 128.449 2.7 . . . . 0.0 113.858 169.612 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.7 p30 -76.71 -71.65 0.38 Allowed 'General case' 0 N--CA 1.448 -0.555 0 O-C-N 118.741 -2.474 . . . . 0.0 109.882 174.859 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 77.8 p -156.18 -39.67 0.08 Allowed 'General case' 0 C--O 1.238 0.481 1 C-N-CA 133.57 4.748 . . . . 0.0 106.86 -175.705 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 46.6 mtmt -87.65 28.43 1.0 Allowed 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 123.237 2.744 . . . . 0.0 110.755 -154.342 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 78.28 -41.56 2.05 Favored Glycine 0 N--CA 1.444 -0.807 0 O-C-N 118.27 -2.769 . . . . 0.0 115.675 169.606 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.6 t -71.21 145.11 12.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 126.178 1.791 . . . . 0.0 114.667 168.687 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -47.12 162.19 0.06 Allowed 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 114.306 -1.316 . . . . 0.0 113.882 177.827 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -64.82 113.04 3.54 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.369 174.608 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.5 p -89.11 4.86 47.04 Favored 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 131.232 3.813 . . . . 0.0 113.142 -163.832 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.9 p30 -152.49 172.69 16.17 Favored 'General case' 0 N--CA 1.446 -0.657 1 C-N-CA 133.697 4.799 . . . . 0.0 108.521 162.737 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -138.03 -175.64 14.03 Favored Glycine 0 N--CA 1.443 -0.844 0 O-C-N 118.322 -2.736 . . . . 0.0 109.797 -149.523 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.93 41.5 98.67 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 127.213 2.339 . . . . 0.0 111.503 -178.619 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -74.51 156.61 86.9 Favored Pre-proline 0 C--O 1.221 -0.405 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 167.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -87.83 135.64 3.49 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 CA-C-O 127.298 2.958 . . . . 0.0 113.632 174.349 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -147.49 151.94 37.22 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 117.994 -2.941 . . . . 0.0 110.436 -173.875 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -140.59 142.8 35.05 Favored 'General case' 0 N--CA 1.446 -0.643 0 O-C-N 118.94 -2.35 . . . . 0.0 109.924 178.649 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.522 HG22 HG22 ' A' ' 95' ' ' VAL . 19.9 t -129.58 81.79 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 C-N-CA 129.876 3.27 . . . . 0.0 106.047 178.787 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -94.65 131.9 39.95 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 113.142 -1.844 . . . . 0.0 114.793 176.249 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.7 mt -124.13 156.95 31.58 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.581 0 C-N-CA 125.782 1.633 . . . . 0.0 108.116 -163.781 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -115.28 132.85 56.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 115.508 -2.187 . . . . 0.0 114.426 144.698 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -80.52 -152.42 8.23 Favored Glycine 0 CA--C 1.532 1.118 0 O-C-N 125.709 1.881 . . . . 0.0 110.611 160.781 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_exo . . . . . 0 N--CA 1.442 -1.529 0 C-N-CA 124.773 3.648 . . . . 0.0 110.806 -170.294 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 96.4 t . . . . . 0 N--CA 1.453 -0.288 0 N-CA-C 115.422 1.638 . . . . 0.0 115.422 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 20.0 t -130.34 153.21 38.66 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.797 0 O-C-N 117.895 -3.003 . . . . 0.0 115.191 -173.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.2 p-10 -130.04 138.45 50.77 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 160.636 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -90.97 149.47 21.85 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-O 125.011 2.339 . . . . 0.0 111.926 177.11 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 52.6 mmtt -93.0 115.37 28.06 Favored 'General case' 0 N--CA 1.445 -0.681 0 O-C-N 118.612 -2.555 . . . . 0.0 108.62 -163.311 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 36.3 t -97.1 139.26 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 CA-C-N 114.051 -1.431 . . . . 0.0 109.813 -176.09 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 59.9 m -138.97 137.34 36.3 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 127.586 2.354 . . . . 0.0 113.056 174.25 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -73.05 128.68 36.19 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 126.132 1.773 . . . . 0.0 109.924 177.294 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 67.5 m-20 -90.16 -1.38 57.93 Favored 'General case' 0 C--O 1.221 -0.401 0 CA-C-O 115.722 -2.085 . . . . 0.0 115.3 175.034 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 1.7 m120 70.6 24.52 4.4 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 123.797 2.998 . . . . 0.0 111.553 167.632 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 38.0 p30 -139.27 -7.17 1.35 Allowed 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 121.582 3.919 . . . . 0.0 121.582 179.149 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 130.89 -13.2 5.56 Favored Glycine 0 C--O 1.242 0.628 0 CA-C-O 123.228 1.46 . . . . 0.0 112.967 -177.216 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.6 p -128.22 164.64 22.09 Favored 'General case' 0 C--O 1.24 0.586 0 C-N-CA 127.696 2.398 . . . . 0.0 113.472 -171.053 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.415 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 11.7 m-85 -128.49 147.76 50.7 Favored 'General case' 0 C--N 1.329 -0.291 0 O-C-N 125.308 1.63 . . . . 0.0 107.641 174.621 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -94.38 132.18 11.05 Favored Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 128.761 3.077 . . . . 0.0 111.183 173.201 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.9 t -128.07 138.62 54.17 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 CA-C-O 117.401 -1.285 . . . . 0.0 113.036 178.773 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.9 t -141.91 130.94 22.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 O-C-N 124.783 1.302 . . . . 0.0 112.695 -167.555 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -161.15 138.14 8.79 Favored 'General case' 0 CA--C 1.517 -0.313 0 CA-C-O 124.35 2.024 . . . . 0.0 111.859 -174.436 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.267 57.4 p-10 -109.88 160.9 15.98 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 129.227 3.011 . . . . 0.0 112.829 175.396 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -130.15 109.87 16.67 Favored Pre-proline 0 N--CA 1.443 -0.776 0 C-N-CA 126.508 1.923 . . . . 0.0 109.754 -167.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -70.5 -6.41 18.91 Favored 'Trans proline' 0 N--CA 1.445 -1.341 0 C-N-CA 122.072 1.848 . . . . 0.0 114.906 -179.31 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.5 m -149.68 147.14 16.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 O-C-N 118.126 -2.859 . . . . 0.0 114.737 -151.673 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 112' ' ' ILE . 28.7 tt0 -62.95 102.95 0.4 Allowed 'General case' 0 C--O 1.241 0.607 0 CA-C-O 123.35 1.548 . . . . 0.0 108.848 167.071 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -177.91 -136.62 2.55 Favored Glycine 0 N--CA 1.434 -1.488 1 O-C-N 116.288 -4.007 . . . . 0.0 122.784 178.098 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 25.8 t30 -132.36 137.04 47.23 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 130.18 3.392 . . . . 0.0 110.552 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 13.6 m-85 -106.75 151.9 24.53 Favored 'General case' 0 N--CA 1.446 -0.671 0 O-C-N 124.502 1.126 . . . . 0.0 112.75 151.744 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -119.77 116.52 26.08 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 110.894 -2.866 . . . . 0.0 112.213 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 3.3 t -112.33 126.02 69.67 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.966 0 N-CA-C 115.507 1.669 . . . . 0.0 115.507 -162.442 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -136.53 118.96 15.76 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 115.452 -2.213 . . . . 0.0 110.312 -168.183 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.522 HG22 HG22 ' A' ' 57' ' ' VAL . 67.3 t -119.24 144.41 27.71 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.473 0 CA-C-N 120.515 1.507 . . . . 0.0 108.625 -174.453 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 33.0 p -135.36 153.06 51.96 Favored 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 127.086 2.154 . . . . 0.0 110.619 -177.274 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.5 mp -126.14 91.65 3.42 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-O 112.702 -3.523 . . . . 0.0 112.673 -161.262 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.1 ttm180 55.92 35.27 25.17 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 124.744 2.211 . . . . 0.0 110.307 -159.239 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 75.32 0.91 63.05 Favored Glycine 0 CA--C 1.533 1.195 0 O-C-N 117.793 -3.067 . . . . 0.0 117.918 -177.441 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 63.8 m-80 -78.51 134.14 62.33 Favored Pre-proline 0 N--CA 1.448 -0.539 0 O-C-N 120.525 -1.573 . . . . 0.0 112.013 168.434 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -87.76 178.52 3.22 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 123.904 3.07 . . . . 0.0 104.968 -177.456 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 19.2 pt -152.82 177.32 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 O-C-N 120.169 -1.582 . . . . 0.0 112.761 -172.424 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 13.3 ptmt -86.86 170.97 11.19 Favored 'General case' 0 N--CA 1.442 -0.874 0 C-N-CA 128.28 2.632 . . . . 0.0 117.91 -168.161 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 10.3 m120 53.43 32.89 14.76 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 129.512 3.125 . . . . 0.0 113.878 -177.74 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' MET . . . . . 0.571 ' HG3' ' HA ' ' A' ' 106' ' ' PRO . 2.9 ttm -146.34 145.54 24.3 Favored Pre-proline 0 C--O 1.246 0.897 0 O-C-N 116.69 -3.757 . . . . 0.0 111.486 -158.501 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.571 ' HA ' ' HG3' ' A' ' 105' ' ' MET 0.3 10.1 Cg_endo -54.45 159.14 15.31 Favored 'Cis proline' 0 N--CA 1.443 -1.462 0 CA-C-N 125.002 2.822 . . . . 0.0 116.343 -13.625 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 13.4 pt -126.76 158.19 37.43 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 C-N-CA 130.38 3.472 . . . . 0.0 110.058 175.27 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -114.52 143.92 44.19 Favored 'General case' 0 CA--C 1.503 -0.833 0 N-CA-C 117.033 2.234 . . . . 0.0 117.033 -176.477 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 60.8 t -139.24 117.64 12.38 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 CA-C-O 117.087 -1.435 . . . . 0.0 110.318 -174.276 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . 0.25 32.6 ttpt -64.62 133.49 52.36 Favored 'General case' 0 N--CA 1.443 -0.797 0 C-N-CA 127.813 2.445 . . . . 0.0 113.66 -179.026 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 72.2 m -117.95 156.47 28.44 Favored 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 127.929 2.491 . . . . 0.0 112.492 -177.781 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 7.7 tt -155.27 156.64 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 114.776 1.399 . . . . 0.0 114.776 158.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . 0.316 5.0 pt-20 -62.51 43.44 0.01 OUTLIER 'General case' 0 N--CA 1.444 -0.769 0 C-N-CA 127.149 2.18 . . . . 0.0 116.879 173.372 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.676 0 N-CA-C 118.634 2.214 . . . . 0.0 118.634 179.939 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo . . . . . 0 N--CA 1.451 -0.98 0 N-CA-C 118.05 2.288 . . . . 0.0 118.05 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -93.21 147.53 33.95 Favored Pre-proline 0 N--CA 1.45 -0.467 0 O-C-N 125.645 1.84 . . . . 0.0 114.414 -178.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -57.43 154.15 37.16 Favored 'Trans proline' 0 N--CA 1.449 -1.145 1 C-N-CA 127.224 5.283 . . . . 0.0 114.584 152.654 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 34.2 t -140.28 176.57 8.66 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 121.765 2.075 . . . . 0.0 113.579 -178.12 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . 0.296 . . -65.88 -48.23 72.21 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 129.935 3.294 . . . . 0.0 115.959 -173.223 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.0 mp0 -54.71 -28.18 46.12 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 111.231 -2.713 . . . . 0.0 113.458 166.218 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 31.4 m-70 -133.2 7.48 3.94 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-O 125.518 2.58 . . . . 0.0 112.928 -148.003 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . 0.268 29.2 t -125.46 114.04 18.29 Favored 'General case' 0 N--CA 1.45 -0.468 0 O-C-N 116.35 -3.969 . . . . 0.0 107.478 169.871 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . 0.265 75.6 m-85 -130.62 160.98 32.61 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 129.192 2.997 . . . . 0.0 108.195 174.449 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -137.85 151.16 47.79 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 127.63 2.372 . . . . 0.0 115.344 -169.112 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -154.39 137.14 15.26 Favored 'General case' 0 N--CA 1.452 -0.363 1 O-C-N 116.023 -4.173 . . . . 0.0 114.787 -165.589 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.36 -175.09 19.76 Favored Glycine 0 C--O 1.222 -0.636 0 C-N-CA 126.412 1.958 . . . . 0.0 108.514 160.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.2 tt0 -68.6 -22.78 64.43 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-O 114.725 -2.559 . . . . 0.0 113.714 -158.629 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -56.25 -0.14 0.17 Allowed Glycine 0 N--CA 1.443 -0.841 0 CA-C-O 115.247 -2.974 . . . . 0.0 117.829 161.731 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 23.8 mt -121.72 24.27 9.8 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 127.658 2.383 . . . . 0.0 114.729 168.111 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.8 t -142.96 -47.03 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 CA-C-O 114.976 -2.44 . . . . 0.0 107.7 -172.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 28.4 ttmt -172.47 139.54 0.99 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 115.36 -2.257 . . . . 0.0 112.279 -177.826 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 34.2 t -144.97 142.45 22.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 115.168 -2.348 . . . . 0.0 113.938 -166.384 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.427 ' HB2' ' HB3' ' A' ' 32' ' ' ALA 0.278 1.2 m-85 -129.6 177.53 7.15 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 125.381 1.676 . . . . 0.0 114.413 -166.283 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -94.86 -37.89 10.99 Favored 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 116.515 2.043 . . . . 0.0 116.515 -178.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 55.9 m-80 -102.52 19.48 18.9 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 115.975 1.843 . . . . 0.0 115.975 165.336 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.427 ' HB3' ' HB2' ' A' ' 29' ' ' PHE . . . -139.3 92.72 10.42 Favored Pre-proline 0 N--CA 1.455 -0.19 0 C-N-CA 126.1 1.76 . . . . 0.0 106.57 171.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . 0.324 74.9 Cg_exo -43.71 119.84 2.04 Favored 'Trans proline' 0 N--CA 1.449 -1.134 1 C-N-CA 129.854 7.036 . . . . 0.0 112.019 148.309 . . . . . . . . 3 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.418 ' O ' ' HA ' ' A' ' 82' ' ' VAL . . . -96.81 150.81 20.3 Favored 'General case' 0 N--CA 1.45 -0.457 0 C-N-CA 128.504 2.722 . . . . 0.0 111.116 -178.477 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -121.54 137.73 54.61 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-O 115.119 -2.372 . . . . 0.0 114.363 -173.109 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -154.53 172.17 18.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 CA-C-N 125.202 3.637 . . . . 0.0 107.723 164.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 55.5 m -138.0 129.6 28.09 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-O 115.947 -1.977 . . . . 0.0 111.533 -157.044 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 16.1 mt -89.57 124.01 42.07 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 O-C-N 125.928 2.018 . . . . 0.0 107.114 171.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.277 39.2 p90 -99.26 115.95 30.32 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 128.471 2.709 . . . . 0.0 112.232 170.291 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -116.46 129.74 56.38 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-O 123.716 1.722 . . . . 0.0 110.112 -161.401 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.6 t -125.03 151.41 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 C-N-CA 126.934 2.094 . . . . 0.0 113.816 163.456 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.9 p30 -77.05 -72.56 0.34 Allowed 'General case' 0 N--CA 1.443 -0.784 0 CA-C-O 125.193 2.425 . . . . 0.0 116.464 170.607 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 16.0 p -159.54 -28.24 0.07 Allowed 'General case' 0 CA--C 1.517 -0.293 1 C-N-CA 133.774 4.829 . . . . 0.0 112.239 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . 0.393 84.3 mttt -94.4 13.92 22.22 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 123.015 2.643 . . . . 0.0 115.89 -170.414 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 79.8 -33.72 2.13 Favored Glycine 0 CA--C 1.523 0.556 0 O-C-N 118.164 -2.835 . . . . 0.0 112.542 164.891 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 71.1 t -54.99 133.41 18.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 1 CA-C-N 125.402 4.601 . . . . 0.0 112.22 155.541 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.53 166.74 0.05 OUTLIER 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 117.399 2.37 . . . . 0.0 117.399 169.43 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 8.4 mmm180 -53.86 120.03 5.77 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 176.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 34.8 p -88.19 -4.82 58.67 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 125.077 1.351 . . . . 0.0 110.914 -160.775 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -165.19 160.47 18.59 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 127.83 2.452 . . . . 0.0 108.998 -169.772 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -106.59 -162.38 22.38 Favored Glycine 0 N--CA 1.444 -0.826 0 O-C-N 126.839 2.587 . . . . 0.0 116.641 -158.253 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 48.91 44.07 31.36 Favored Glycine 0 C--O 1.222 -0.616 0 C-N-CA 128.359 2.885 . . . . 0.0 113.957 174.764 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -78.02 141.06 62.6 Favored Pre-proline 0 N--CA 1.451 -0.395 0 O-C-N 119.347 -2.266 . . . . 0.0 109.538 159.111 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -90.92 132.24 1.57 Allowed 'Trans proline' 0 N--CA 1.442 -1.55 0 N-CA-C 121.234 3.513 . . . . 0.0 121.234 -171.675 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -136.68 149.72 48.08 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 113.053 0.76 . . . . 0.0 113.053 -151.083 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -134.4 145.23 48.73 Favored 'General case' 0 N--CA 1.442 -0.836 0 O-C-N 127.73 3.144 . . . . 0.0 106.457 168.265 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 40.6 t -126.46 99.47 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 102.598 -3.112 . . . . 0.0 102.598 163.46 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -109.57 137.0 48.04 Favored 'General case' 0 N--CA 1.442 -0.842 0 O-C-N 126.253 2.22 . . . . 0.0 113.662 -171.247 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 84.2 mt -140.21 148.33 22.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 114.996 1.48 . . . . 0.0 114.996 -157.103 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.6 m120 -122.26 144.4 49.01 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 127.257 2.223 . . . . 0.0 107.512 166.579 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -124.59 -163.92 11.79 Favored Glycine 0 C--N 1.337 0.632 0 C-N-CA 127.272 2.368 . . . . 0.0 109.302 161.822 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo . . . . . 0 N--CA 1.448 -1.147 1 C-N-CA 129.824 7.016 . . . . 0.0 116.322 178.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.8 t . . . . . 0 N--CA 1.448 -0.55 0 CA-C-O 122.272 1.034 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 55.8 t -132.6 155.57 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 N-CA-C 115.515 1.672 . . . . 0.0 115.515 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.254 6.4 p-10 -129.87 123.38 30.67 Favored 'General case' 0 N--CA 1.44 -0.944 1 CA-C-O 128.993 4.235 . . . . 0.0 108.7 168.582 . . . . . . . . 3 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.21 131.17 34.3 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-O 127.459 3.504 . . . . 0.0 110.486 -178.213 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 14.5 mptt -91.13 119.91 31.64 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 112.696 -2.047 . . . . 0.0 114.196 -166.735 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.0 t -100.29 144.92 11.8 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.371 0 C-N-CA 130.421 3.488 . . . . 0.0 112.098 -169.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . 0.26 42.3 m -154.3 136.87 15.11 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 127.233 3.397 . . . . 0.0 111.465 170.027 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.436 ' HA ' ' CD1' ' A' ' 79' ' ' TYR . 39.7 t0 -62.04 118.23 7.03 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 131.076 3.75 . . . . 0.0 109.164 179.101 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -80.04 -6.34 57.44 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-O 116.434 -1.746 . . . . 0.0 115.207 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.258 10.8 t-20 60.29 30.51 19.9 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 127.653 3.597 . . . . 0.0 114.693 -176.043 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 18.1 p30 -138.28 -1.18 1.95 Allowed 'General case' 0 C--O 1.238 0.46 0 O-C-N 117.084 -3.51 . . . . 0.0 119.116 174.513 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 104.92 1.51 42.31 Favored Glycine 0 CA--C 1.521 0.449 0 CA-C-O 116.482 -2.288 . . . . 0.0 118.44 -163.286 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 44.1 p -126.32 171.64 10.79 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 127.543 2.337 . . . . 0.0 111.635 177.642 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.436 ' CD1' ' HA ' ' A' ' 73' ' ' ASP . 46.3 m-85 -144.95 118.84 9.3 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-O 115.605 -2.141 . . . . 0.0 109.267 178.221 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.71 136.75 24.83 Favored Glycine 0 CA--C 1.524 0.629 1 C-N-CA 130.991 4.139 . . . . 0.0 111.239 175.302 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.0 t -135.29 126.63 45.76 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 CA-C-O 128.131 3.824 . . . . 0.0 107.85 -177.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.418 ' HA ' ' O ' ' A' ' 34' ' ' ALA . 3.7 p -122.11 132.15 71.62 Favored 'Isoleucine or valine' 0 C--O 1.236 0.37 0 O-C-N 118.772 -2.455 . . . . 0.0 114.021 178.149 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -158.15 168.65 26.47 Favored 'General case' 0 C--O 1.221 -0.414 0 N-CA-C 117.76 2.504 . . . . 0.0 117.76 173.084 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.427 31.9 p30 -133.7 151.82 51.73 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 123.673 1.701 . . . . 0.0 114.236 -173.187 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -119.92 118.41 31.74 Favored Pre-proline 0 N--CA 1.445 -0.682 0 O-C-N 119.867 -1.771 . . . . 0.0 109.204 -173.117 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.262 29.0 Cg_endo -83.01 4.71 6.91 Favored 'Trans proline' 0 N--CA 1.447 -1.232 1 C-N-CA 128.225 5.95 . . . . 0.0 108.756 -178.793 . . . . . . . . 3 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.9 m -132.05 138.55 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 N-CA-C 120.399 3.481 . . . . 0.0 120.399 -167.281 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -54.15 118.87 4.4 Favored 'General case' 0 N--CA 1.449 -0.512 0 O-C-N 120.157 -1.589 . . . . 0.0 107.246 137.252 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 159.96 -135.39 4.07 Favored Glycine 0 C--N 1.331 0.296 0 CA-C-N 120.334 1.425 . . . . 0.0 115.038 172.485 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 -141.36 138.87 33.35 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 127.579 2.351 . . . . 0.0 113.767 177.149 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 -99.61 149.12 23.6 Favored 'General case' 0 C--O 1.222 -0.376 0 C-N-CA 126.479 1.912 . . . . 0.0 112.52 168.198 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -137.1 114.99 11.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 103.713 -2.699 . . . . 0.0 103.713 -164.459 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.2 t -114.56 126.01 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 CA-C-N 111.186 -2.734 . . . . 0.0 109.71 -153.619 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.0 t30 -138.69 118.34 13.08 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 123.874 1.797 . . . . 0.0 106.651 -172.422 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 54.6 t -116.74 142.77 29.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 O-C-N 118.079 -2.888 . . . . 0.0 112.386 -178.381 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.4 ' C ' HD12 ' A' ' 97' ' ' LEU . 16.1 p -150.1 151.83 33.8 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 117.175 2.287 . . . . 0.0 117.175 -169.314 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.4 HD12 ' C ' ' A' ' 96' ' ' THR . 11.2 mp -135.08 87.53 2.34 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 102.861 -3.015 . . . . 0.0 102.861 -137.843 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 18.6 ttm-85 59.41 25.01 13.68 Favored 'General case' 0 N--CA 1.45 -0.466 0 O-C-N 117.322 -3.361 . . . . 0.0 108.737 -158.81 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 81.51 6.28 89.3 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-O 116.906 -2.052 . . . . 0.0 116.504 -175.448 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -76.0 120.9 83.74 Favored Pre-proline 0 N--CA 1.445 -0.722 0 O-C-N 125.135 1.138 . . . . 0.0 111.776 162.701 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -81.9 174.21 10.42 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 CA-C-N 121.661 1.629 . . . . 0.0 110.275 178.484 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . 0.261 27.8 pt -138.99 174.32 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 O-C-N 125.921 2.013 . . . . 0.0 113.949 -164.311 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 18.7 ptpt -72.28 166.68 21.97 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 127.895 2.478 . . . . 0.0 113.067 172.045 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 25.9 m120 50.59 32.23 6.56 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 123.173 1.464 . . . . 0.0 107.71 -179.089 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 14.6 mmt -143.31 134.11 12.43 Favored Pre-proline 0 N--CA 1.448 -0.557 1 O-C-N 115.029 -4.794 . . . . 0.0 107.661 176.42 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -86.02 171.88 39.61 Favored 'Cis proline' 0 N--CA 1.449 -1.117 0 CA-C-N 121.563 1.594 . . . . 0.0 109.853 13.633 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' ILE . . . . . 0.442 HG21 HD13 ' A' ' 107' ' ' ILE . 19.3 pt -144.33 164.69 13.78 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-O 115.055 -2.402 . . . . 0.0 115.272 -178.864 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -126.7 136.04 51.92 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 124.659 3.39 . . . . 0.0 113.61 -166.66 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 3.3 t -128.57 140.73 48.43 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 C-N-CA 129.151 2.98 . . . . 0.0 114.682 -173.545 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 13.2 tppt? -74.74 142.64 44.34 Favored 'General case' 0 N--CA 1.445 -0.722 0 O-C-N 123.588 0.555 . . . . 0.0 111.191 178.188 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 69.4 m -132.06 140.77 48.98 Favored 'General case' 0 N--CA 1.452 -0.331 0 N-CA-C 115.178 1.547 . . . . 0.0 115.178 177.577 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.416 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 10.4 tp -149.08 135.85 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 CA-C-O 117.33 -1.319 . . . . 0.0 112.421 170.685 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.45 39.59 0.88 Allowed 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 123.009 2.64 . . . . 0.0 116.176 -164.706 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.341 0.85 0 O-C-N 126.056 2.097 . . . . 0.0 113.468 162.486 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo . . . . . 0 N--CA 1.453 -0.912 0 N-CA-C 117.296 1.998 . . . . 0.0 117.296 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -97.17 143.07 25.5 Favored Pre-proline 0 CA--C 1.519 -0.221 0 N-CA-C 118.308 2.707 . . . . 0.0 118.308 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -71.43 143.18 42.43 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 124.182 3.254 . . . . 0.0 109.839 166.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.6 m -123.25 168.76 12.04 Favored 'General case' 0 CA--C 1.516 -0.344 0 O-C-N 127.321 2.888 . . . . 0.0 111.774 -165.2 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.02 -41.09 82.68 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 115.874 1.805 . . . . 0.0 115.874 -174.185 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 56.4 mp0 -68.2 -16.94 64.18 Favored 'General case' 0 C--O 1.22 -0.453 0 C-N-CA 127.39 2.276 . . . . 0.0 112.873 173.416 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 86.1 m-70 -127.7 13.29 6.92 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 120.91 -1.119 . . . . 0.0 110.898 -154.455 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 9.1 t -135.45 122.82 21.85 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-O 122.913 1.339 . . . . 0.0 111.391 169.373 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.443 ' HB2' ' CE1' ' A' ' 39' ' ' PHE . 60.8 m-85 -152.39 154.79 36.3 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 128.792 2.837 . . . . 0.0 112.032 -172.874 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -138.51 162.42 34.55 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 120.066 1.303 . . . . 0.0 108.415 -164.01 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -146.76 132.0 18.45 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 127.316 2.247 . . . . 0.0 108.202 -170.857 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 139.17 -157.36 24.9 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 117.196 1.639 . . . . 0.0 117.196 145.091 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . 0.258 39.1 mt-10 -55.87 -41.72 74.82 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 119.375 3.102 . . . . 0.0 119.375 -175.642 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -67.7 2.82 5.66 Favored Glycine 0 CA--C 1.523 0.578 0 C-N-CA 127.829 2.633 . . . . 0.0 113.944 168.617 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.499 HD21 ' CE1' ' A' ' 36' ' ' PHE 0.334 20.9 mt -108.11 1.04 22.0 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 117.45 2.389 . . . . 0.0 117.45 155.988 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 72.9 t -119.8 -45.82 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 O-C-N 119.393 -2.067 . . . . 0.0 113.517 -174.749 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.262 31.5 ttmt -159.15 134.7 8.56 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 115.843 1.794 . . . . 0.0 115.843 175.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.7 t -135.65 139.62 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 106.715 -1.587 . . . . 0.0 106.715 -173.204 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 -121.25 176.64 5.52 Favored 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 128.964 2.906 . . . . 0.0 116.262 -169.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -80.25 -54.3 5.86 Favored 'General case' 0 N--CA 1.441 -0.894 0 O-C-N 120.011 -1.681 . . . . 0.0 113.058 178.634 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 -103.72 4.71 35.61 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 129.59 3.156 . . . . 0.0 114.478 177.155 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . 0.304 . . -110.39 84.07 3.63 Favored Pre-proline 0 N--CA 1.448 -0.537 0 CA-C-O 113.328 -3.225 . . . . 0.0 106.262 159.843 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -59.04 120.79 8.87 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 CA-C-N 123.816 2.399 . . . . 0.0 110.525 164.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -91.13 154.76 19.13 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 112.506 -2.133 . . . . 0.0 108.22 -175.322 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.437 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 45.8 mt-10 -120.36 165.98 14.16 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 109.712 -3.404 . . . . 0.0 112.49 175.364 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.499 ' CE1' HD21 ' A' ' 25' ' ' LEU . 10.7 p90 -162.16 173.5 14.22 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 128.566 2.746 . . . . 0.0 110.704 163.812 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 98.8 m -130.28 126.47 37.32 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 126.927 2.091 . . . . 0.0 115.652 -163.436 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 6.5 mt -92.34 105.14 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 C-N-CA 125.837 1.655 . . . . 0.0 108.018 178.289 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.443 ' CE1' ' HB2' ' A' ' 19' ' ' TYR 0.26 1.3 p90 -72.59 132.12 43.35 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.348 1.459 . . . . 0.0 112.04 167.055 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -130.98 134.7 46.96 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 118.272 -2.767 . . . . 0.0 113.133 -170.762 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.417 HG22 ' HA ' ' A' ' 47' ' ' ALA . 5.2 t -131.45 150.82 34.63 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.396 0 CA-C-O 125.882 2.753 . . . . 0.0 103.78 169.734 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.0 p30 -69.73 -70.8 0.26 Allowed 'General case' 0 N--CA 1.443 -0.806 1 O-C-N 115.935 -4.228 . . . . 0.0 112.517 169.063 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 24.3 p -162.68 -9.82 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.418 1 C-N-CA 135.045 5.338 . . . . 0.0 114.707 -179.77 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 26.5 mtpp -122.18 34.54 5.14 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 122.393 2.36 . . . . 0.0 111.328 -163.036 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.82 -58.13 5.03 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 118.853 2.301 . . . . 0.0 118.853 160.739 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 62.1 t -57.85 132.33 22.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 O-C-N 126.271 1.806 . . . . 0.0 111.007 163.714 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.417 ' HA ' HG22 ' A' ' 41' ' ' VAL . . . -45.59 161.8 0.04 OUTLIER 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 125.276 2.465 . . . . 0.0 116.849 170.624 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 9.5 mmm180 -55.37 110.38 0.68 Allowed 'General case' 0 CA--C 1.518 -0.263 0 O-C-N 117.069 -3.519 . . . . 0.0 110.467 174.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.1 p -76.07 5.47 6.66 Favored 'General case' 0 N--CA 1.449 -0.519 1 C-N-CA 136.483 5.913 . . . . 0.0 117.092 -179.085 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -170.14 168.19 8.42 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 123.797 1.761 . . . . 0.0 107.85 169.582 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -123.86 -162.86 11.57 Favored Glycine 0 C--N 1.344 1.002 0 O-C-N 117.829 -3.044 . . . . 0.0 111.632 -146.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.66 21.21 74.65 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 122.059 3.584 . . . . 0.0 122.059 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 41.9 m-20 -73.39 152.79 90.04 Favored Pre-proline 0 C--O 1.223 -0.31 0 CA-C-N 118.59 1.195 . . . . 0.0 111.925 174.073 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -101.29 131.55 0.14 Allowed 'Trans proline' 0 N--CA 1.457 -0.66 0 CA-C-O 126.001 2.417 . . . . 0.0 112.313 -174.423 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -136.7 155.68 49.55 Favored 'General case' 0 N--CA 1.444 -0.769 0 CA-C-N 111.478 -2.601 . . . . 0.0 110.262 -172.4 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.405 ' O ' ' HA ' ' A' ' 95' ' ' VAL . 34.5 tt0 -139.39 141.43 37.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 125.203 2.43 . . . . 0.0 111.425 175.875 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 46.6 t -133.98 76.86 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.693 0 C-N-CA 128.195 2.598 . . . . 0.0 104.916 -175.553 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -99.04 141.44 31.79 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 125.872 2.749 . . . . 0.0 107.812 -170.729 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.426 ' HA ' ' O ' ' A' ' 92' ' ' ASN . 54.5 mt -137.04 139.96 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-N 111.046 -2.797 . . . . 0.0 114.965 -159.928 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 12.2 m120 -124.59 117.09 23.54 Favored 'General case' 0 C--O 1.223 -0.312 0 C-N-CA 126.983 2.113 . . . . 0.0 106.471 176.02 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -78.98 -159.19 14.28 Favored Glycine 0 N--CA 1.445 -0.766 0 CA-C-O 114.571 -3.35 . . . . 0.0 115.845 161.499 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_endo . . . . . 0 N--CA 1.446 -1.298 1 C-N-CA 127.282 5.321 . . . . 0.0 110.63 162.551 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 51.8 t . . . . . 0 C--O 1.234 0.271 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 68.2 t -133.29 159.87 42.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 CA-C-N 113.162 -1.835 . . . . 0.0 109.456 -165.408 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.264 1.1 p30 -133.59 142.95 48.37 Favored 'General case' 0 N--CA 1.448 -0.55 0 O-C-N 120.24 -1.537 . . . . 0.0 109.875 157.868 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.3 147.08 24.96 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 125.519 1.762 . . . . 0.0 113.632 162.402 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -99.16 113.89 26.37 Favored 'General case' 0 CA--C 1.511 -0.525 0 C-N-CA 127.599 2.36 . . . . 0.0 108.36 -158.279 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.6 t -91.83 129.49 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 O-C-N 124.42 1.075 . . . . 0.0 111.079 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.7 m -136.87 140.67 42.54 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 102.34 -3.207 . . . . 0.0 102.34 -178.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 57.9 t0 -72.31 124.2 24.6 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 129.199 3.0 . . . . 0.0 107.603 -172.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -82.14 -1.5 49.06 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 116.343 -1.789 . . . . 0.0 115.331 169.119 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.395 1.5 m120 60.57 32.58 20.44 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-N 121.449 1.931 . . . . 0.0 115.691 176.748 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 25.7 p30 -144.5 6.1 1.25 Allowed 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 113.032 -1.894 . . . . 0.0 112.409 -172.324 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 89.8 7.27 68.84 Favored Glycine 0 C--N 1.333 0.414 0 CA-C-N 122.58 2.445 . . . . 0.0 115.653 -166.158 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.9 p -141.16 158.31 44.08 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 129.25 3.02 . . . . 0.0 114.208 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 23.2 m-85 -132.04 126.65 34.4 Favored 'General case' 0 N--CA 1.449 -0.501 0 O-C-N 120.215 -1.553 . . . . 0.0 107.478 -169.351 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -89.17 147.82 19.82 Favored Glycine 0 C--N 1.335 0.5 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 35' ' ' GLU . 2.3 t -131.54 133.83 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 CA-C-N 110.235 -2.982 . . . . 0.0 114.088 -174.027 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 13.7 p -137.54 131.39 43.93 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 CA-C-N 120.781 1.628 . . . . 0.0 110.359 -169.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -161.86 151.67 16.58 Favored 'General case' 0 N--CA 1.452 -0.353 1 O-C-N 115.95 -4.219 . . . . 0.0 111.582 176.753 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 26.0 p30 -116.93 151.66 36.17 Favored 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 130.92 3.688 . . . . 0.0 111.182 -172.412 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . 0.312 . . -130.44 104.91 16.04 Favored Pre-proline 0 N--CA 1.441 -0.876 0 N-CA-C 118.87 2.915 . . . . 0.0 118.87 -170.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -93.21 24.44 0.45 Allowed 'Trans proline' 0 N--CA 1.45 -1.044 0 C-N-CA 124.488 3.459 . . . . 0.0 112.76 -174.122 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.5 m -140.04 134.87 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 117.145 2.276 . . . . 0.0 117.145 -179.148 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . 0.284 38.5 tt0 -56.43 105.15 0.18 Allowed 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.705 144.016 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 162.41 -139.99 6.28 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 117.97 -1.461 . . . . 0.0 110.876 176.506 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 85.0 m-20 -143.24 137.97 29.3 Favored 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 105.848 -1.908 . . . . 0.0 105.848 -170.816 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -90.04 145.91 24.73 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 111.435 -2.62 . . . . 0.0 113.143 156.439 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.426 ' O ' ' HA ' ' A' ' 59' ' ' ILE . 26.1 t-20 -113.0 116.97 30.78 Favored 'General case' 0 N--CA 1.442 -0.828 0 O-C-N 128.566 3.666 . . . . 0.0 112.232 172.694 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 43.5 t -111.91 131.18 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 CA-C-O 126.102 2.858 . . . . 0.0 113.105 -168.448 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 21.5 t-20 -131.96 131.68 42.83 Favored 'General case' 0 N--CA 1.445 -0.694 0 O-C-N 119.157 -2.214 . . . . 0.0 111.302 176.309 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 56' ' ' GLU . 57.7 t -118.52 129.95 74.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 O-C-N 124.159 0.912 . . . . 0.0 112.718 -174.44 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.418 ' HB ' ' O ' ' A' ' 100' ' ' ASN . 46.9 p -139.6 153.19 47.31 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -172.594 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 3.2 mp -126.16 105.84 9.14 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 105.043 -2.206 . . . . 0.0 105.043 -142.149 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 44.4 ttm-85 46.93 42.22 11.95 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 125.997 2.808 . . . . 0.0 108.937 -153.169 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 57.93 14.22 16.16 Favored Glycine 0 CA--C 1.528 0.882 0 O-C-N 116.765 -3.71 . . . . 0.0 115.798 -177.785 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.418 ' O ' ' HB ' ' A' ' 96' ' ' THR . 76.8 m-20 -95.32 157.37 36.43 Favored Pre-proline 0 N--CA 1.449 -0.485 0 C-N-CA 117.6 -1.64 . . . . 0.0 115.325 168.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -79.91 168.38 19.18 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 CA-C-O 125.82 2.342 . . . . 0.0 111.836 -174.914 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 43.5 pt -147.02 -177.52 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-O 126.038 2.828 . . . . 0.0 113.733 -178.158 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 17.2 ptmt -84.71 168.51 15.17 Favored 'General case' 0 N--CA 1.446 -0.669 0 O-C-N 116.405 -3.934 . . . . 0.0 110.936 -176.337 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 17.4 m120 54.77 29.46 11.85 Favored 'General case' 0 N--CA 1.446 -0.674 0 O-C-N 120.386 -1.446 . . . . 0.0 114.536 175.555 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 11.1 mmt -143.18 150.55 52.66 Favored Pre-proline 0 CA--C 1.518 -0.28 0 CA-C-O 113.351 -3.214 . . . . 0.0 111.73 177.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.43 175.82 34.03 Favored 'Cis proline' 0 N--CA 1.446 -1.316 0 CA-C-N 123.809 2.396 . . . . 0.0 113.199 -0.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 14.0 pt -144.56 -176.04 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 170.272 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -135.12 148.52 49.81 Favored 'General case' 0 N--CA 1.45 -0.463 1 O-C-N 114.745 -4.972 . . . . 0.0 112.294 -172.862 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 99.5 t -143.66 128.81 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.909 0 N-CA-C 105.478 -2.045 . . . . 0.0 105.478 -171.838 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 69.5 tttt -70.63 132.19 45.07 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 112.669 -2.059 . . . . 0.0 112.221 -176.868 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 81.6 m -113.08 126.82 55.89 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.208 1.403 . . . . 0.0 109.548 -178.257 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.8 tp -135.36 132.14 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 O-C-N 119.86 -1.775 . . . . 0.0 108.897 155.405 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -72.75 55.23 0.38 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 130.377 3.471 . . . . 0.0 114.028 -163.036 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.452 0 C-N-CA 128.021 2.724 . . . . 0.0 115.692 176.338 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo . . . . . 0 N--CA 1.453 -0.907 0 CA-C-O 122.382 0.909 . . . . 0.0 111.586 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.406 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . . . -82.08 134.12 49.98 Favored Pre-proline 0 N--CA 1.445 -0.686 0 C-N-CA 127.135 2.174 . . . . 0.0 113.725 175.707 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 12' ' ' ALA . 24.1 Cg_exo -63.86 158.8 45.05 Favored 'Trans proline' 0 N--CA 1.443 -1.476 1 C-N-CA 127.015 5.143 . . . . 0.0 111.394 172.584 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -135.97 155.97 49.46 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 125.283 1.433 . . . . 0.0 111.791 -163.734 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -75.33 -33.58 61.15 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 117.191 2.293 . . . . 0.0 117.191 -172.654 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -57.77 -14.39 5.75 Favored 'General case' 0 N--CA 1.44 -0.932 1 O-C-N 114.574 -5.079 . . . . 0.0 116.756 153.475 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 48.1 m-70 -135.14 18.64 3.43 Favored 'General case' 0 N--CA 1.444 -0.733 0 O-C-N 125.956 2.035 . . . . 0.0 114.679 -159.643 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.9 t -138.3 120.16 15.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 O-C-N 117.152 -3.468 . . . . 0.0 107.697 171.655 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.442 ' O ' ' CD2' ' A' ' 39' ' ' PHE . 23.8 m-85 -153.78 150.64 28.68 Favored 'General case' 0 N--CA 1.455 -0.213 0 CA-C-O 114.441 -2.695 . . . . 0.0 111.569 -170.244 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.515 ' HB2' ' HA ' ' A' ' 38' ' ' ILE . . . -141.28 158.37 43.98 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 118.195 2.665 . . . . 0.0 118.195 -161.147 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -153.62 141.37 20.03 Favored 'General case' 0 CA--C 1.518 -0.269 0 C-N-CA 126.411 1.884 . . . . 0.0 112.356 -159.586 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 132.66 157.35 8.49 Favored Glycine 0 N--CA 1.447 -0.614 1 C-N-CA 130.874 4.083 . . . . 0.0 116.282 -174.272 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -63.46 -20.18 65.36 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 118.661 2.837 . . . . 0.0 118.661 -173.264 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.79 8.39 0.55 Allowed Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 128.821 3.105 . . . . 0.0 117.088 162.015 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 75.9 mt -108.75 10.25 26.8 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-O 116.294 -1.812 . . . . 0.0 109.747 160.317 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 91.7 t -139.47 -29.96 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 CA-C-N 121.959 2.163 . . . . 0.0 113.213 -174.487 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 26.9 ttmt -164.5 138.21 5.17 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 119.508 -1.995 . . . . 0.0 107.508 171.691 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 t -132.33 136.22 56.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.458 0 O-C-N 126.387 2.305 . . . . 0.0 109.699 -174.895 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.434 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 66.9 m-85 -127.86 -172.24 2.63 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 122.148 2.249 . . . . 0.0 112.592 -163.824 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -88.01 -54.74 4.07 Favored 'General case' 0 N--CA 1.448 -0.569 0 O-C-N 117.832 -3.042 . . . . 0.0 115.928 177.931 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 69.0 m-80 -97.91 8.28 44.99 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 115.64 1.718 . . . . 0.0 115.64 174.5 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . 0.259 . . -126.27 80.96 68.0 Favored Pre-proline 0 CA--C 1.516 -0.334 0 C-N-CA 125.614 1.566 . . . . 0.0 111.468 174.325 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -61.61 123.63 13.08 Favored 'Trans proline' 0 N--CA 1.445 -1.334 0 CA-C-O 122.903 1.126 . . . . 0.0 111.649 176.257 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.63 150.72 23.71 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 112.689 -2.05 . . . . 0.0 111.483 -164.433 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -129.66 153.89 47.67 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 127.514 2.325 . . . . 0.0 114.536 -162.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -164.48 158.84 18.75 Favored 'General case' 0 N--CA 1.446 -0.66 0 O-C-N 121.09 -1.006 . . . . 0.0 111.491 172.346 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 7.2 m -129.56 115.11 16.93 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 113.36 -1.745 . . . . 0.0 110.529 -154.349 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.515 ' HA ' ' HB2' ' A' ' 20' ' ' ALA . 15.5 mt -82.2 98.77 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 O-C-N 128.553 3.658 . . . . 0.0 108.979 178.779 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.442 ' CD2' ' O ' ' A' ' 19' ' ' TYR 0.328 47.3 p90 -76.94 105.12 7.81 Favored 'General case' 0 N--CA 1.451 -0.424 0 O-C-N 118.339 -2.726 . . . . 0.0 113.327 170.915 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . 0.264 . . -90.03 134.27 34.34 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 127.339 2.256 . . . . 0.0 116.674 -176.936 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 46.3 t -133.27 143.34 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 C-N-CA 126.776 2.03 . . . . 0.0 106.673 160.234 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.09 -81.22 0.02 OUTLIER 'General case' 0 N--CA 1.443 -0.795 0 O-C-N 117.846 -3.034 . . . . 0.0 114.476 161.611 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 19.1 p -161.32 -41.12 0.04 OUTLIER 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 128.436 2.695 . . . . 0.0 111.393 -169.875 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -90.62 52.16 2.14 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 121.927 2.149 . . . . 0.0 113.254 -167.708 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 71.81 -66.2 1.12 Allowed Glycine 0 C--N 1.341 0.848 0 CA-C-O 118.249 -1.306 . . . . 0.0 115.782 174.628 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 70.8 t -56.38 129.51 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 O-C-N 125.54 1.377 . . . . 0.0 111.974 178.303 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -36.91 164.83 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 130.284 3.434 . . . . 0.0 116.192 163.378 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . 0.254 7.3 mmm180 -66.16 101.67 0.74 Allowed 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 114.611 1.337 . . . . 0.0 114.611 175.232 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 61.8 p -79.37 2.76 20.48 Favored 'General case' 0 N--CA 1.449 -0.515 1 C-N-CA 133.464 4.705 . . . . 0.0 114.741 178.854 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -155.83 -174.72 5.08 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 130.014 3.326 . . . . 0.0 113.721 158.541 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -154.04 -176.45 26.41 Favored Glycine 0 CA--C 1.521 0.425 0 CA-C-O 124.741 2.301 . . . . 0.0 115.797 -141.68 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.71 14.35 67.31 Favored Glycine 0 C--N 1.336 0.549 0 O-C-N 117.462 -3.375 . . . . 0.0 112.789 -170.591 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -60.69 123.55 74.95 Favored Pre-proline 0 N--CA 1.446 -0.672 0 CA-C-N 123.7 3.75 . . . . 0.0 106.98 175.73 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -83.85 153.77 13.17 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 CA-C-N 122.468 1.917 . . . . 0.0 116.294 -162.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -142.95 156.29 44.86 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-O 126.35 2.976 . . . . 0.0 110.14 -157.738 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -144.11 153.25 41.96 Favored 'General case' 0 N--CA 1.448 -0.53 0 O-C-N 118.671 -2.518 . . . . 0.0 109.989 161.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.413 HG22 HG22 ' A' ' 95' ' ' VAL . 92.0 t -133.81 108.54 11.86 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.96 0 C-N-CA 129.789 3.235 . . . . 0.0 104.052 169.545 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -117.12 133.87 55.47 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 126.833 2.053 . . . . 0.0 112.287 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . 0.275 3.4 mp -124.06 144.9 32.24 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 C-N-CA 125.848 1.659 . . . . 0.0 113.94 -167.405 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 53.0 m-80 -118.23 140.41 49.84 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 114.217 -2.802 . . . . 0.0 110.061 174.809 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.47 -169.51 14.31 Favored Glycine 0 CA--C 1.526 0.774 0 CA-C-N 121.558 1.981 . . . . 0.0 111.68 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . 0.304 19.2 Cg_endo . . . . . 0 N--CA 1.451 -1.027 0 N-CA-C 114.96 1.1 . . . . 0.0 114.96 -179.107 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 51.5 t . . . . . 0 N--CA 1.445 -0.718 0 N-CA-C 105.432 -2.062 . . . . 0.0 105.432 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 9.5 t -133.51 150.7 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.155 0 CA-C-N 113.193 -1.821 . . . . 0.0 106.843 -165.287 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.269 2.4 p30 -117.74 137.8 52.46 Favored 'General case' 0 N--CA 1.439 -0.985 0 O-C-N 118.979 -2.326 . . . . 0.0 112.717 148.492 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.21 158.97 22.09 Favored 'General case' 0 N--CA 1.444 -0.738 0 O-C-N 126.277 2.235 . . . . 0.0 112.439 -174.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 38.9 mmtm -90.33 103.13 15.84 Favored 'General case' 0 N--CA 1.447 -0.609 0 O-C-N 120.265 -1.522 . . . . 0.0 112.719 -172.852 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 54.9 t -71.27 135.48 27.9 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.662 172.63 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 54.6 m -123.91 137.87 54.56 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 124.735 1.214 . . . . 0.0 112.033 162.667 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 48.5 t0 -78.02 121.38 24.15 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 124.161 1.934 . . . . 0.0 111.94 169.255 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 -76.2 -7.5 54.98 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 112.228 -2.26 . . . . 0.0 115.088 -177.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 4.7 m120 59.85 25.95 15.1 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 129.655 3.182 . . . . 0.0 114.248 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 42.7 p30 -134.25 -6.84 2.63 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 129.194 2.998 . . . . 0.0 112.903 -175.257 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 103.29 15.6 22.96 Favored Glycine 0 C--N 1.336 0.555 1 C-N-CA 133.41 5.291 . . . . 0.0 114.288 -172.769 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 27.1 p -140.69 165.24 28.03 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 122.505 3.152 . . . . 0.0 108.791 177.669 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 67.4 m-85 -135.88 125.12 24.62 Favored 'General case' 0 N--CA 1.447 -0.579 0 N-CA-C 104.823 -2.288 . . . . 0.0 104.823 -166.2 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -96.68 129.95 10.08 Favored Glycine 0 C--N 1.336 0.575 0 C-N-CA 129.597 3.475 . . . . 0.0 107.165 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.8 t -108.68 128.21 64.58 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 1 CA-C-O 110.811 -4.423 . . . . 0.0 112.892 172.253 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.2 p -127.54 142.27 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 123.915 3.052 . . . . 0.0 115.666 172.832 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -165.03 160.43 18.93 Favored 'General case' 0 N--CA 1.449 -0.491 0 O-C-N 117.096 -3.502 . . . . 0.0 112.947 -173.42 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.465 42.5 p30 -137.77 148.32 45.45 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 128.437 2.695 . . . . 0.0 114.347 -168.685 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -125.28 113.08 26.01 Favored Pre-proline 0 N--CA 1.445 -0.708 0 C-N-CA 128.26 2.624 . . . . 0.0 112.025 -171.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.258 59.0 Cg_endo -76.04 12.91 1.37 Allowed 'Trans proline' 0 N--CA 1.441 -1.611 0 O-C-N 125.186 2.15 . . . . 0.0 113.359 177.778 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.8 m -140.62 141.28 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 115.579 1.696 . . . . 0.0 115.579 -151.469 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -63.96 114.17 3.94 Favored 'General case' 0 N--CA 1.447 -0.625 0 O-C-N 117.329 -3.357 . . . . 0.0 110.119 144.407 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 163.07 -155.43 26.77 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 125.317 2.621 . . . . 0.0 117.561 -169.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 5.0 t30 -135.81 121.88 20.14 Favored 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 127.278 2.231 . . . . 0.0 107.432 -167.74 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . 0.25 7.3 m-85 -87.48 143.09 27.39 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 123.298 0.639 . . . . 0.0 112.65 158.854 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -127.55 123.65 36.3 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 124.376 2.036 . . . . 0.0 107.999 -175.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . 0.344 3.3 t -109.46 135.14 49.31 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 N-CA-C 117.519 2.414 . . . . 0.0 117.519 -164.81 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -136.57 128.51 29.36 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 131.494 3.917 . . . . 0.0 108.373 179.424 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.413 HG22 HG22 ' A' ' 57' ' ' VAL . 58.2 t -118.12 152.59 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 CA-C-O 123.677 1.703 . . . . 0.0 108.374 -173.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.7 p -151.15 152.0 32.74 Favored 'General case' 0 N--CA 1.441 -0.915 0 O-C-N 120.411 -1.431 . . . . 0.0 112.952 -177.085 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 9.4 mp -137.3 94.9 2.99 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 104.351 -2.463 . . . . 0.0 104.351 -153.676 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . 0.277 25.3 ttm-85 49.2 43.8 22.87 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 112.571 -2.104 . . . . 0.0 110.691 -162.726 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 74.31 -13.29 4.85 Favored Glycine 0 CA--C 1.522 0.489 0 CA-C-O 114.681 -3.288 . . . . 0.0 116.132 -168.731 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 72.6 m-20 -74.25 126.83 88.68 Favored Pre-proline 0 N--CA 1.451 -0.398 0 CA-C-N 122.534 3.167 . . . . 0.0 119.072 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.457 ' C ' HG23 ' A' ' 102' ' ' ILE . 61.4 Cg_endo -74.29 172.11 16.7 Favored 'Trans proline' 0 N--CA 1.453 -0.885 1 C-N-CA 127.451 5.434 . . . . 0.0 106.863 -177.468 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.572 HG13 ' HG3' ' A' ' 105' ' ' MET . 27.4 pt -143.87 177.61 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 O-C-N 118.346 -2.721 . . . . 0.0 107.705 -164.388 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 38.4 mttm -80.71 159.81 25.15 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 128.678 2.791 . . . . 0.0 111.191 -169.259 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 15.2 m120 54.2 43.89 29.93 Favored 'General case' 0 C--O 1.224 -0.285 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 176.25 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' MET . . . . . 0.572 ' HG3' HG13 ' A' ' 102' ' ' ILE . 6.9 mmt -138.55 139.52 24.91 Favored Pre-proline 0 N--CA 1.444 -0.728 0 C-N-CA 129.812 3.245 . . . . 0.0 107.956 -163.138 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -79.06 165.05 82.37 Favored 'Cis proline' 0 N--CA 1.447 -1.215 0 CA-C-N 122.78 2.029 . . . . 0.0 109.328 1.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . 0.276 2.2 pp -114.46 159.36 14.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 C-N-CA 125.366 1.466 . . . . 0.0 114.081 171.227 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -122.59 134.44 54.52 Favored 'General case' 0 N--CA 1.449 -0.502 0 O-C-N 118.588 -2.57 . . . . 0.0 111.899 -167.758 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 1.7 t -129.53 121.36 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-O 125.695 2.664 . . . . 0.0 112.615 -177.252 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -55.72 130.29 42.67 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 112.222 -2.263 . . . . 0.0 114.155 170.812 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 48.7 m -121.82 153.82 37.85 Favored 'General case' 0 N--CA 1.445 -0.699 0 O-C-N 123.994 0.809 . . . . 0.0 110.461 176.448 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.434 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 10.4 tp -150.52 138.06 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.773 0 C-N-CA 127.602 2.361 . . . . 0.0 113.486 165.367 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -68.84 43.29 0.04 OUTLIER 'General case' 0 N--CA 1.444 -0.768 1 CA-C-O 129.778 4.609 . . . . 0.0 115.584 -166.655 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.616 1 O-C-N 114.68 -5.013 . . . . 0.0 112.116 -175.359 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . 0.29 40.3 Cg_endo . . . . . 0 N--CA 1.453 -0.862 0 N-CA-C 118.429 2.434 . . . . 0.0 118.429 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.479 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . . . -77.85 129.22 76.93 Favored Pre-proline 0 CA--C 1.516 -0.347 0 N-CA-C 118.433 2.753 . . . . 0.0 118.433 -178.136 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.479 ' HD3' ' HA ' ' A' ' 12' ' ' ALA . 65.8 Cg_exo -62.81 150.6 87.73 Favored 'Trans proline' 0 N--CA 1.448 -1.162 1 C-N-CA 126.027 4.485 . . . . 0.0 110.775 169.84 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.8 t -129.64 152.13 49.49 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 117.159 2.281 . . . . 0.0 117.159 -170.03 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.33 -36.18 79.43 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 120.379 -1.451 . . . . 0.0 113.337 179.571 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 59.7 mm-40 -54.93 -31.01 59.95 Favored 'General case' 0 C--N 1.349 0.554 0 CA-C-N 124.32 3.236 . . . . 0.0 112.554 163.116 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 39.6 m80 -125.23 19.37 8.25 Favored 'General case' 0 N--CA 1.445 -0.688 0 CA-C-O 125.627 2.632 . . . . 0.0 113.711 -154.153 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 7.1 t -147.38 122.69 10.28 Favored 'General case' 0 C--N 1.347 0.48 1 O-C-N 113.615 -5.678 . . . . 0.0 113.474 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 37.1 m-85 -160.36 151.13 18.7 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-O 116.185 -1.865 . . . . 0.0 110.235 -164.722 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.408 ' HA ' ' O ' ' A' ' 37' ' ' THR . . . -131.52 153.23 50.03 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-O 122.565 1.174 . . . . 0.0 109.78 -167.859 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -159.12 147.96 18.32 Favored 'General case' 0 N--CA 1.447 -0.609 0 C-N-CA 125.93 1.692 . . . . 0.0 110.348 -168.582 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.84 -179.87 16.02 Favored Glycine 0 C--N 1.338 0.666 0 C-N-CA 129.668 3.509 . . . . 0.0 117.339 175.097 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . 0.588 1.9 tt0 -62.23 -27.57 69.09 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 120.15 3.389 . . . . 0.0 120.15 -168.397 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.406 ' HA2' ' HB1' ' A' ' 34' ' ' ALA . . . -61.03 0.13 1.29 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 118.827 2.291 . . . . 0.0 118.827 160.794 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 49.2 mt -113.85 13.78 18.46 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.493 1.117 . . . . 0.0 111.463 168.205 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.9 t -129.47 -55.47 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 CA-C-O 115.839 -2.029 . . . . 0.0 113.334 178.32 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -150.16 128.25 11.94 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 116.638 -1.649 . . . . 0.0 111.777 -177.274 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 52.0 t -137.58 132.24 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 O-C-N 127.855 3.222 . . . . 0.0 113.255 -162.057 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.467 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 5.9 m-85 -126.63 -168.42 1.86 Allowed 'General case' 0 C--N 1.334 -0.065 0 CA-C-O 123.694 1.711 . . . . 0.0 112.453 -164.595 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -100.46 -56.32 2.38 Favored 'General case' 0 N--CA 1.449 -0.514 0 O-C-N 119.133 -2.229 . . . . 0.0 111.358 -166.821 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 40.0 m-80 -100.08 8.09 44.19 Favored 'General case' 0 N--CA 1.451 -0.403 0 O-C-N 119.027 -2.295 . . . . 0.0 111.678 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -121.22 93.14 48.81 Favored Pre-proline 0 N--CA 1.448 -0.57 0 O-C-N 119.423 -2.048 . . . . 0.0 108.197 167.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.11 128.02 22.87 Favored 'Trans proline' 0 N--CA 1.453 -0.901 1 C-N-CA 127.393 5.395 . . . . 0.0 113.465 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.406 ' HB1' ' HA2' ' A' ' 24' ' ' GLY . . . -92.47 152.47 19.66 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 128.257 2.623 . . . . 0.0 117.232 177.409 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 29.1 mt-10 -143.32 148.92 37.05 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 128.942 3.901 . . . . 0.0 110.265 -161.166 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 20.7 p90 -168.77 165.75 11.77 Favored 'General case' 0 CA--C 1.518 -0.284 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 -178.86 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 20' ' ' ALA . 57.7 m -133.63 122.55 23.63 Favored 'General case' 0 N--CA 1.448 -0.548 0 O-C-N 127.887 3.242 . . . . 0.0 114.173 -155.262 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.4 ' HB ' ' HB2' ' A' ' 79' ' ' TYR . 4.0 mt -86.03 101.17 10.0 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-O 114.866 -2.493 . . . . 0.0 105.638 177.695 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.484 ' HA ' HG22 ' A' ' 78' ' ' THR . 12.7 p90 -74.58 112.23 10.56 Favored 'General case' 0 N--CA 1.446 -0.634 0 O-C-N 124.917 1.386 . . . . 0.0 112.656 162.086 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . 0.252 . . -102.3 135.13 44.46 Favored 'General case' 0 C--O 1.222 -0.395 0 C-N-CA 126.151 1.78 . . . . 0.0 115.266 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.6 t -125.29 149.17 29.79 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 130.661 3.584 . . . . 0.0 108.961 162.574 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -74.96 -62.41 1.56 Allowed 'General case' 0 N--CA 1.441 -0.903 0 O-C-N 119.498 -2.001 . . . . 0.0 112.007 173.505 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 8.2 p -173.99 -25.83 0.01 OUTLIER 'General case' 0 C--O 1.218 -0.574 1 C-N-CA 133.158 4.583 . . . . 0.0 110.349 -173.857 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 71.4 mmtt -93.67 27.43 2.68 Favored 'General case' 0 N--CA 1.445 -0.691 0 O-C-N 118.529 -2.607 . . . . 0.0 112.311 -167.085 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 62.95 -32.3 0.07 OUTLIER Glycine 0 N--CA 1.444 -0.802 1 N-CA-C 123.404 4.122 . . . . 0.0 123.404 178.428 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 90.2 t -78.4 138.67 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.845 0 CA-C-N 119.196 1.498 . . . . 0.0 111.881 167.232 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -50.83 166.77 0.08 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.901 1.376 . . . . 0.0 113.397 -177.666 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 11.1 mmm180 -62.29 122.66 16.19 Favored 'General case' 0 C--O 1.22 -0.468 0 CA-C-N 121.947 2.158 . . . . 0.0 113.096 -172.601 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 72.9 p -100.38 13.49 34.28 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-O 126.756 3.17 . . . . 0.0 113.193 -161.711 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.8 p30 -159.66 175.14 13.55 Favored 'General case' 0 N--CA 1.45 -0.454 2 C-N-CA 131.861 4.064 . . . . 0.0 109.534 160.021 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -127.5 -178.34 15.28 Favored Glycine 0 C--N 1.343 0.94 0 N-CA-C 118.871 2.308 . . . . 0.0 118.871 -159.093 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.45 20.74 68.46 Favored Glycine 0 C--N 1.346 1.134 0 CA-C-O 114.094 -3.614 . . . . 0.0 110.597 172.349 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -70.21 145.94 94.11 Favored Pre-proline 0 N--CA 1.445 -0.695 0 CA-C-N 123.807 3.804 . . . . 0.0 112.858 170.357 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -76.08 119.26 5.27 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 N-CA-C 117.307 2.003 . . . . 0.0 117.307 -178.172 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -131.25 165.43 23.4 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-O 124.04 1.876 . . . . 0.0 115.891 168.641 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -160.64 147.06 15.25 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 113.51 -1.677 . . . . 0.0 110.233 -171.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 2.4 t -131.04 123.48 53.95 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.754 0 C-N-CA 127.984 2.514 . . . . 0.0 106.769 176.725 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -121.44 131.63 54.27 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 113.927 -1.488 . . . . 0.0 109.023 -170.195 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.6 mp -132.4 132.86 60.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 -163.125 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 24.8 m120 -113.78 129.73 56.54 Favored 'General case' 0 N--CA 1.442 -0.841 0 O-C-N 125.396 1.685 . . . . 0.0 108.287 151.451 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -96.75 -164.18 32.77 Favored Glycine 0 C--N 1.345 1.045 0 CA-C-O 123.379 1.544 . . . . 0.0 111.273 151.524 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . 0.282 84.2 Cg_endo . . . . . 0 N--CA 1.448 -1.171 0 C-N-CA 123.514 2.809 . . . . 0.0 118.379 176.889 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 87.1 t . . . . . 0 N--CA 1.45 -0.473 0 CA-C-O 116.662 -1.637 . . . . 0.0 107.61 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 87.9 t -135.54 143.84 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 125.922 1.689 . . . . 0.0 108.977 -173.502 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.319 35.5 t0 -129.52 125.99 37.58 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-O 115.337 -2.268 . . . . 0.0 110.435 175.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.25 162.23 19.24 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 125.453 1.72 . . . . 0.0 114.644 176.262 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -103.22 123.2 46.28 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 -177.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.5 t -100.68 137.05 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 O-C-N 128.595 3.684 . . . . 0.0 109.905 -175.743 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . 0.25 53.1 m -134.92 136.54 42.39 Favored 'General case' 0 N--CA 1.445 -0.676 0 O-C-N 117.912 -2.993 . . . . 0.0 109.371 -179.425 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 59.7 t0 -62.66 123.98 19.8 Favored 'General case' 0 N--CA 1.448 -0.559 0 O-C-N 120.497 -1.377 . . . . 0.0 112.004 164.255 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -84.83 -10.41 57.19 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-O 116.377 -1.773 . . . . 0.0 115.264 174.069 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.374 1.4 m120 74.21 36.95 0.63 Allowed 'General case' 0 C--O 1.219 -0.515 0 CA-C-O 115.988 -1.958 . . . . 0.0 113.768 172.913 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 20.0 p30 -154.58 -10.98 0.13 Allowed 'General case' 0 N--CA 1.449 -0.476 0 O-C-N 126.042 2.089 . . . . 0.0 114.676 -167.87 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 130.85 -25.72 4.13 Favored Glycine 0 CA--C 1.522 0.511 0 CA-C-N 122.852 2.569 . . . . 0.0 113.63 -158.153 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.484 HG22 ' HA ' ' A' ' 39' ' ' PHE . 2.8 p -136.81 171.77 14.0 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 118.252 2.686 . . . . 0.0 118.252 -157.361 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.4 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 34.6 m-85 -135.94 113.61 10.98 Favored 'General case' 0 N--CA 1.433 -1.282 0 C-N-CA 126.032 1.733 . . . . 0.0 109.487 -172.035 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -86.16 146.48 21.13 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-O 124.146 1.97 . . . . 0.0 112.723 176.282 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 35' ' ' GLU . 41.0 t -136.4 130.0 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 C-N-CA 128.113 2.565 . . . . 0.0 109.032 -167.805 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 14.7 p -134.34 122.09 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.429 0 C-N-CA 125.836 1.654 . . . . 0.0 110.401 -168.021 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.435 ' HE2' ' CD2' ' A' ' 91' ' ' TYR 0.257 0.1 OUTLIER -154.44 175.38 13.65 Favored 'General case' 0 N--CA 1.447 -0.597 0 O-C-N 118.975 -2.328 . . . . 0.0 111.91 -177.4 . . . . . . . . 4 4 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 5.2 p30 -151.76 162.96 40.17 Favored 'General case' 0 N--CA 1.448 -0.556 1 O-C-N 116.268 -4.02 . . . . 0.0 109.708 -174.107 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.62 ' HB2' ' CE2' ' A' ' 91' ' ' TYR . . . -134.46 110.89 11.53 Favored Pre-proline 0 N--CA 1.446 -0.637 1 C-N-CA 133.924 4.89 . . . . 0.0 113.103 -172.406 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -75.77 8.57 2.65 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 123.822 3.015 . . . . 0.0 114.132 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.5 m -134.03 138.15 50.83 Favored 'Isoleucine or valine' 0 C--O 1.238 0.46 0 C-N-CA 129.551 3.14 . . . . 0.0 115.855 -160.436 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 17.3 tt0 -59.81 109.31 0.9 Allowed 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 139.866 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 176.71 -157.21 22.34 Favored Glycine 0 C--N 1.344 0.975 0 CA-C-O 117.675 -1.625 . . . . 0.0 116.184 -173.436 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -133.12 139.21 46.98 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 127.623 2.369 . . . . 0.0 108.688 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' TYR . . . . . 0.62 ' CE2' ' HB2' ' A' ' 85' ' ' ALA . 3.0 m-30 -105.96 145.19 31.65 Favored 'General case' 0 N--CA 1.446 -0.642 0 O-C-N 119.747 -1.845 . . . . 0.0 110.627 161.855 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -126.55 116.96 21.87 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.843 -2.28 . . . . 0.0 104.843 -176.238 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 61.1 t -124.29 135.83 62.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 C-N-CA 125.417 1.487 . . . . 0.0 110.581 -149.629 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -136.32 133.68 37.13 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 105.447 -2.057 . . . . 0.0 105.447 -172.382 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 94.5 t -114.0 137.78 46.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 O-C-N 119.16 -2.212 . . . . 0.0 113.923 172.625 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 35.9 p -143.17 165.8 26.43 Favored 'General case' 0 CA--C 1.516 -0.349 0 O-C-N 120.614 -1.304 . . . . 0.0 113.609 -164.142 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . 0.26 7.4 tt -150.15 99.9 2.85 Favored 'General case' 0 C--N 1.344 0.368 0 N-CA-C 101.668 -3.456 . . . . 0.0 101.668 -146.767 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 8.7 ttm180 52.87 36.87 22.73 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 119.758 1.163 . . . . 0.0 111.471 -150.878 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.37 0.5 38.14 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-O 115.271 -2.96 . . . . 0.0 109.8 -178.473 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -94.81 142.93 25.35 Favored Pre-proline 0 N--CA 1.441 -0.877 0 CA-C-N 121.148 2.474 . . . . 0.0 109.868 -176.419 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -79.06 158.98 27.04 Favored 'Trans proline' 0 C--O 1.218 -0.499 0 CA-C-O 126.239 2.516 . . . . 0.0 113.459 -177.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 29.2 pt -142.92 -171.46 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 CA-C-N 109.386 -3.552 . . . . 0.0 113.32 -171.035 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -93.79 157.72 16.01 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 125.856 1.662 . . . . 0.0 112.341 -158.757 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.26 30.9 m120 50.19 34.1 8.15 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 129.793 3.237 . . . . 0.0 112.785 178.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 6.0 mmt -130.57 151.29 78.43 Favored Pre-proline 0 N--CA 1.444 -0.769 1 C-N-CA 134.551 5.141 . . . . 0.0 106.284 176.843 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -76.69 163.13 90.37 Favored 'Cis proline' 0 N--CA 1.45 -1.037 0 CA-C-N 126.432 3.333 . . . . 0.0 107.336 -2.457 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' ILE . . . . . 0.536 HD12 ' C ' ' A' ' 107' ' ' ILE 0.376 1.3 pp -127.04 167.54 21.66 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.409 0 N-CA-C 118.14 2.644 . . . . 0.0 118.14 163.743 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -106.57 142.13 36.72 Favored 'General case' 0 N--CA 1.449 -0.496 0 O-C-N 118.159 -2.838 . . . . 0.0 118.019 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 61.5 t -123.12 124.14 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 127.018 2.127 . . . . 0.0 109.977 -179.303 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -80.43 128.0 33.07 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-O 118.575 -0.726 . . . . 0.0 111.424 165.47 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 99.5 m -115.68 140.4 49.23 Favored 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 128.247 2.619 . . . . 0.0 112.819 -170.528 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.467 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 98.6 mt -133.85 145.73 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 CA-C-N 121.898 2.135 . . . . 0.0 106.795 177.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -82.19 48.1 1.22 Allowed 'General case' 0 N--CA 1.445 -0.698 0 O-C-N 116.76 -3.712 . . . . 0.0 113.692 -166.28 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.435 -1.391 0 O-C-N 120.575 -1.328 . . . . 0.0 116.111 174.493 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo . . . . . 0 N--CA 1.445 -1.348 0 N-CA-C 113.26 0.446 . . . . 0.0 113.26 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -119.17 138.41 26.25 Favored Pre-proline 0 CA--C 1.512 -0.491 0 C-N-CA 126.106 1.762 . . . . 0.0 110.474 -178.197 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_exo -65.47 169.49 12.54 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.155 1.903 . . . . 0.0 114.156 170.233 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -145.74 168.02 21.74 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 125.547 1.539 . . . . 0.0 113.131 -171.456 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.44 -43.78 72.62 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 117.593 2.442 . . . . 0.0 117.593 179.32 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 55.6 mm-40 -60.65 -20.42 60.79 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.5 1.52 . . . . 0.0 111.353 167.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' HIS . . . . . 0.444 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . 68.6 m-70 -126.48 18.54 7.5 Favored 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 129.322 3.049 . . . . 0.0 112.757 -158.682 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.9 t -141.56 126.3 18.02 Favored 'General case' 0 N--CA 1.444 -0.729 0 O-C-N 119.856 -1.777 . . . . 0.0 106.476 166.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -153.86 157.85 39.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 130.632 3.573 . . . . 0.0 110.679 -175.306 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -141.92 148.77 39.22 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 127.734 2.413 . . . . 0.0 116.718 -165.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -144.08 143.31 31.1 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 113.969 -1.469 . . . . 0.0 109.33 -171.496 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 138.98 173.4 12.98 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 118.625 2.21 . . . . 0.0 118.625 169.846 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -68.87 -24.82 64.38 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 120.202 -1.763 . . . . 0.0 111.973 -168.354 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.18 7.35 0.56 Allowed Glycine 0 C--N 1.339 0.697 0 C-N-CA 129.779 3.562 . . . . 0.0 116.954 171.884 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 96.6 mt -116.98 -2.59 11.72 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-O 114.185 -2.817 . . . . 0.0 110.221 172.669 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 t -129.8 -55.05 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 CA-C-N 122.832 2.56 . . . . 0.0 109.156 -168.682 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 23.8 pttt -145.36 120.62 10.21 Favored 'General case' 0 C--O 1.238 0.46 0 O-C-N 118.873 -2.392 . . . . 0.0 112.282 -172.539 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 93.9 t -125.85 139.54 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 119.348 -2.095 . . . . 0.0 105.466 -172.734 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.443 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 42.5 m-85 -127.79 -163.43 1.26 Allowed 'General case' 0 N--CA 1.447 -0.621 0 CA-C-O 115.099 -2.381 . . . . 0.0 110.215 -178.582 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -103.14 -50.52 3.47 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 120.803 1.638 . . . . 0.0 114.572 -170.072 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 19.1 m-80 -109.2 6.01 24.34 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 130.27 3.428 . . . . 0.0 111.028 -179.156 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -122.06 85.82 46.34 Favored Pre-proline 0 C--O 1.224 -0.252 0 C-N-CA 126.693 1.997 . . . . 0.0 111.73 165.263 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -55.93 146.56 67.62 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 C-N-CA 117.244 -1.37 . . . . 0.0 115.091 176.573 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -93.76 162.64 13.85 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 119.044 2.979 . . . . 0.0 119.044 170.3 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -136.85 147.77 46.71 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 117.612 2.449 . . . . 0.0 117.612 -174.247 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -157.98 160.81 37.92 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-N 122.182 2.265 . . . . 0.0 107.77 169.443 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 49.2 m -119.18 127.92 53.75 Favored 'General case' 0 N--CA 1.441 -0.909 0 CA-C-O 113.805 -2.997 . . . . 0.0 113.811 -166.559 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.0 mt -86.39 106.53 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 O-C-N 126.681 2.488 . . . . 0.0 105.548 179.335 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.474 55.5 p90 -85.34 114.25 22.27 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 117.874 2.546 . . . . 0.0 117.874 175.015 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -119.91 139.04 53.04 Favored 'General case' 0 CA--C 1.517 -0.325 0 CA-C-N 122.85 2.568 . . . . 0.0 113.106 -167.803 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.444 ' HB ' ' HB3' ' A' ' 17' ' ' HIS . 78.0 t -129.35 143.57 40.78 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 1 C-N-CA 132.236 4.214 . . . . 0.0 111.457 173.414 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -70.03 -82.93 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 126.941 3.258 . . . . 0.0 107.924 173.45 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 48.9 p -153.44 -21.3 0.14 Allowed 'General case' 0 C--N 1.328 -0.328 2 C-N-CA 134.773 5.229 . . . . 0.0 117.992 -179.394 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 18.4 mmtp -80.5 16.34 1.38 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 127.789 3.181 . . . . 0.0 116.33 -176.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.62 -56.65 5.03 Favored Glycine 0 C--N 1.345 1.034 0 N-CA-C 120.301 2.88 . . . . 0.0 120.301 -175.34 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 24.5 t -63.68 146.53 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 172.846 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.76 170.12 0.06 Allowed 'General case' 0 N--CA 1.438 -1.034 0 CA-C-O 121.589 0.709 . . . . 0.0 111.228 177.486 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.7 mmm180 -68.44 118.39 11.44 Favored 'General case' 0 C--N 1.351 0.659 0 O-C-N 118.261 -2.774 . . . . 0.0 113.564 -175.849 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 16.0 p -77.88 1.56 20.09 Favored 'General case' 0 N--CA 1.447 -0.591 1 C-N-CA 134.738 5.215 . . . . 0.0 117.733 -171.684 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 10.0 p30 -161.09 -174.5 4.39 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-N 111.171 -2.74 . . . . 0.0 104.801 163.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -144.2 -170.36 13.56 Favored Glycine 0 CA--C 1.524 0.641 0 C-N-CA 128.462 2.934 . . . . 0.0 117.321 -142.08 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 54.18 46.18 71.47 Favored Glycine 0 C--N 1.337 0.623 0 CA-C-O 123.629 1.683 . . . . 0.0 110.639 178.07 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -86.71 137.88 33.64 Favored Pre-proline 0 N--CA 1.45 -0.449 0 O-C-N 116.688 -3.831 . . . . 0.0 112.157 174.488 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -68.94 137.18 37.22 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.383 2.722 . . . . 0.0 113.756 -171.496 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -159.6 150.37 19.37 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 112.217 -2.265 . . . . 0.0 112.924 -165.696 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -152.34 134.92 15.32 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 118.106 -2.871 . . . . 0.0 113.977 -166.7 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 4.5 t -129.74 81.62 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 CA-C-N 113.325 -1.761 . . . . 0.0 113.643 -176.273 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -100.53 141.13 33.81 Favored 'General case' 0 CA--C 1.516 -0.354 0 O-C-N 126.023 2.077 . . . . 0.0 110.87 -174.696 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.5 mt -132.88 147.42 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 CA-C-O 125.01 2.338 . . . . 0.0 108.23 -163.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -116.5 118.83 33.73 Favored 'General case' 0 C--O 1.223 -0.33 0 O-C-N 119.3 -2.125 . . . . 0.0 109.166 166.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -111.31 -158.75 15.3 Favored Glycine 0 N--CA 1.442 -0.948 0 N-CA-C 121.797 3.479 . . . . 0.0 121.797 163.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo . . . . . 0 N--CA 1.434 -2.017 1 C-N-CA 125.834 4.356 . . . . 0.0 113.339 -177.213 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.44 -0.946 0 CA-C-O 118.009 -0.996 . . . . 0.0 112.757 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 72.8 t -132.63 145.34 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 CA-C-N 122.304 2.32 . . . . 0.0 106.465 -174.069 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -128.87 131.68 47.67 Favored 'General case' 0 N--CA 1.445 -0.69 0 O-C-N 119.122 -2.236 . . . . 0.0 110.332 172.186 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -102.63 137.37 40.95 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 126.476 1.91 . . . . 0.0 113.752 -165.156 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.271 37.1 ttpt -81.96 117.46 22.2 Favored 'General case' 0 C--O 1.218 -0.556 0 O-C-N 120.245 -1.535 . . . . 0.0 111.664 -160.05 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -88.48 131.6 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 175.222 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 67.2 m -131.84 125.96 33.09 Favored 'General case' 0 N--CA 1.452 -0.349 0 O-C-N 125.619 1.824 . . . . 0.0 110.934 172.321 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -66.29 118.52 10.09 Favored 'General case' 0 N--CA 1.44 -0.951 0 C-N-CA 128.153 2.581 . . . . 0.0 110.644 176.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.4 m-20 -79.63 -4.07 49.98 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 119.807 3.262 . . . . 0.0 119.807 175.653 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 68.56 25.66 6.6 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 131.595 3.958 . . . . 0.0 114.008 176.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 43.2 p30 -135.06 -4.69 2.41 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 114.053 -2.879 . . . . 0.0 110.946 -165.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 120.88 -14.34 9.71 Favored Glycine 0 C--N 1.337 0.624 0 C-N-CA 126.847 2.165 . . . . 0.0 111.223 -171.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 p -133.12 165.83 23.86 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 131.388 3.875 . . . . 0.0 113.56 -170.282 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 16.7 m-85 -131.57 137.57 48.51 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 128.704 2.802 . . . . 0.0 106.671 -174.409 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -92.21 139.41 14.67 Favored Glycine 0 C--O 1.226 -0.369 0 C-N-CA 128.159 2.79 . . . . 0.0 107.304 174.339 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 22.8 t -122.83 130.79 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-O 117.119 -1.419 . . . . 0.0 108.633 178.693 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.4 p -135.71 141.85 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 119.696 1.134 . . . . 0.0 112.527 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 7.5 p90 -161.11 169.61 22.05 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 115.902 1.816 . . . . 0.0 115.902 179.194 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 15.2 p30 -139.0 164.79 28.83 Favored 'General case' 0 N--CA 1.449 -0.508 0 O-C-N 118.756 -2.465 . . . . 0.0 117.532 177.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -123.53 112.57 29.35 Favored Pre-proline 0 N--CA 1.448 -0.568 0 O-C-N 125.305 1.628 . . . . 0.0 107.643 -174.797 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.336 14.9 Cg_endo -66.76 -8.52 21.56 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 N-CA-C 117.57 2.104 . . . . 0.0 117.57 170.382 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 28.4 m -148.08 134.51 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 O-C-N 120.369 -1.457 . . . . 0.0 110.606 -164.568 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -56.39 116.16 2.91 Favored 'General case' 0 N--CA 1.456 -0.169 0 O-C-N 126.195 2.185 . . . . 0.0 112.47 167.026 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 170.29 -166.7 39.89 Favored Glycine 0 CA--C 1.527 0.828 0 CA-C-O 122.306 0.948 . . . . 0.0 112.485 -172.053 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -106.42 137.75 43.84 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 114.37 1.248 . . . . 0.0 114.37 175.434 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -103.34 139.29 38.96 Favored 'General case' 0 N--CA 1.445 -0.713 0 C-N-CA 128.634 2.774 . . . . 0.0 110.418 168.791 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -114.53 119.55 37.21 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 117.164 2.283 . . . . 0.0 117.164 170.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . 0.275 65.2 t -118.1 133.64 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-N 112.795 -2.002 . . . . 0.0 111.863 -157.885 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -130.23 138.95 50.81 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 126.879 2.072 . . . . 0.0 109.087 171.894 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 85.8 t -114.79 126.48 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 C-N-CA 124.856 1.262 . . . . 0.0 113.312 168.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . 0.301 67.0 p -132.8 145.97 51.44 Favored 'General case' 0 N--CA 1.444 -0.767 0 O-C-N 125.423 1.702 . . . . 0.0 114.519 -168.561 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 8.4 tt -136.62 95.8 3.22 Favored 'General case' 0 N--CA 1.447 -0.58 1 O-C-N 116.182 -4.074 . . . . 0.0 107.796 -137.491 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . 0.316 51.4 ttt180 46.0 40.09 6.51 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 125.933 2.778 . . . . 0.0 115.858 -147.644 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 69.15 16.75 71.27 Favored Glycine 0 C--N 1.341 0.818 0 O-C-N 118.318 -2.739 . . . . 0.0 117.838 -175.528 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -106.57 153.51 40.56 Favored Pre-proline 0 N--CA 1.447 -0.6 0 O-C-N 116.508 -3.937 . . . . 0.0 111.678 165.878 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_endo -86.53 169.57 8.14 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 124.548 3.499 . . . . 0.0 114.166 -178.694 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.406 ' HB ' ' H ' ' A' ' 103' ' ' LYS . 11.2 pt -130.8 -173.22 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-N 113.975 -1.466 . . . . 0.0 109.13 176.218 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.406 ' H ' ' HB ' ' A' ' 102' ' ' ILE . 57.1 mttm -67.84 169.59 9.51 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 115.385 1.624 . . . . 0.0 115.385 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 33.3 m120 47.49 28.66 1.2 Allowed 'General case' 0 N--CA 1.447 -0.617 0 O-C-N 116.959 -3.588 . . . . 0.0 118.859 169.738 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 12.7 mmt -136.32 146.14 54.83 Favored Pre-proline 0 N--CA 1.444 -0.765 0 C-N-CA 129.128 2.971 . . . . 0.0 109.187 -177.93 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . 0.272 96.6 Cg_endo -68.07 169.24 55.87 Favored 'Cis proline' 0 N--CA 1.457 -0.63 0 CA-C-N 127.293 3.64 . . . . 0.0 116.232 -4.566 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 27.2 pt -146.77 161.25 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 O-C-N 126.9 2.625 . . . . 0.0 114.616 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -112.83 131.28 55.77 Favored 'General case' 0 N--CA 1.445 -0.71 0 C-N-CA 127.352 2.261 . . . . 0.0 112.875 -178.439 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 59.0 t -122.98 141.26 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 C-N-CA 126.681 1.992 . . . . 0.0 106.813 -175.74 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 39.8 mmtm -91.37 138.33 31.67 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 116.335 1.976 . . . . 0.0 116.335 176.797 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 21.8 m -115.96 126.51 53.95 Favored 'General case' 0 N--CA 1.441 -0.903 0 C-N-CA 129.504 3.122 . . . . 0.0 108.342 -174.864 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.443 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 15.2 mt -124.64 135.17 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 161.017 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -72.96 56.04 0.42 Allowed 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 118.699 2.851 . . . . 0.0 118.699 -176.554 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.4 0 O-C-N 117.388 -3.32 . . . . 0.0 117.14 165.975 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo . . . . . 0 N--CA 1.453 -0.887 0 CA-C-O 119.828 -0.155 . . . . 0.0 112.28 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -123.14 154.22 64.9 Favored Pre-proline 0 N--CA 1.446 -0.653 0 C-N-CA 128.059 2.543 . . . . 0.0 113.258 -166.434 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_exo -63.92 153.82 73.53 Favored 'Trans proline' 0 N--CA 1.444 -1.413 0 C-N-CA 124.162 3.241 . . . . 0.0 116.076 166.364 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.463 ' HB3' ' HB2' ' A' ' 17' ' ' HIS . 26.4 t -122.86 150.75 42.46 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.17 1.788 . . . . 0.0 106.259 178.23 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . 0.314 . . -51.19 -37.99 49.77 Favored 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 126.118 1.767 . . . . 0.0 114.632 163.067 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -58.61 -29.11 66.22 Favored 'General case' 0 N--CA 1.443 -0.809 0 C-N-CA 125.003 1.321 . . . . 0.0 110.192 170.624 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' HIS . . . . . 0.463 ' HB2' ' HB3' ' A' ' 14' ' ' SER . 86.6 m-70 -134.66 24.98 3.71 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 131.292 3.837 . . . . 0.0 112.556 -155.181 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 42.6 t -148.16 120.24 8.27 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 117.343 2.349 . . . . 0.0 117.343 166.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -146.48 142.49 28.15 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-O 113.482 -3.152 . . . . 0.0 113.832 -160.816 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -124.48 140.82 52.59 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 119.373 3.101 . . . . 0.0 119.373 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -136.44 147.57 47.3 Favored 'General case' 0 C--O 1.223 -0.317 0 CA-C-N 120.962 1.71 . . . . 0.0 112.19 -177.203 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.43 175.8 18.84 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 125.436 1.494 . . . . 0.0 114.575 167.403 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -55.93 -34.75 65.91 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-O 114.495 -2.669 . . . . 0.0 112.503 177.711 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -57.93 -3.0 1.02 Allowed Glycine 0 C--O 1.226 -0.355 0 CA-C-N 123.462 2.847 . . . . 0.0 116.138 165.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . 0.373 24.1 mt -109.29 29.26 7.7 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 120.544 2.172 . . . . 0.0 111.32 161.403 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 96.8 t -150.16 -42.0 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 CA-C-N 121.683 2.038 . . . . 0.0 114.584 -175.854 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.333 43.0 pttt -151.39 131.12 13.17 Favored 'General case' 0 C--N 1.326 -0.429 1 O-C-N 116.164 -4.085 . . . . 0.0 112.36 -179.425 . . . . . . . . 3 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 38.4 t -143.66 141.15 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 -166.729 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -136.08 172.31 13.19 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-N 120.181 1.355 . . . . 0.0 114.277 -169.471 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 46.8 t0 -78.55 -50.81 10.91 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-O 122.631 1.205 . . . . 0.0 112.519 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 70.4 m-80 -104.03 8.7 36.65 Favored 'General case' 0 N--CA 1.448 -0.545 0 O-C-N 118.427 -2.67 . . . . 0.0 111.636 -179.223 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -133.85 101.81 12.63 Favored Pre-proline 0 N--CA 1.447 -0.625 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 170.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -57.92 131.47 43.94 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 CA-C-O 125.552 2.23 . . . . 0.0 111.888 159.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -85.93 162.48 18.54 Favored 'General case' 0 N--CA 1.45 -0.459 0 O-C-N 117.008 -3.558 . . . . 0.0 113.539 165.582 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -133.22 154.6 50.51 Favored 'General case' 0 N--CA 1.448 -0.553 0 O-C-N 125.057 1.473 . . . . 0.0 110.508 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -157.48 171.45 20.34 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 117.662 -3.149 . . . . 0.0 105.403 167.176 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 91.1 m -133.35 130.47 38.86 Favored 'General case' 0 C--O 1.233 0.197 0 O-C-N 127.167 2.792 . . . . 0.0 113.737 -164.365 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.2 mt -84.77 104.06 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 123.929 0.892 . . . . 0.0 110.946 171.552 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 32.5 p90 -77.15 108.1 9.99 Favored 'General case' 0 N--CA 1.44 -0.973 0 N-CA-C 119.222 3.045 . . . . 0.0 119.222 163.457 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -117.78 150.22 39.49 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 121.288 1.858 . . . . 0.0 109.491 -163.145 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.2 t -137.79 159.19 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 105.718 -1.956 . . . . 0.0 105.718 174.713 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.0 p30 -78.36 -61.91 1.85 Allowed 'General case' 0 N--CA 1.452 -0.331 0 O-C-N 119.766 -1.834 . . . . 0.0 115.214 170.259 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 21.9 p -174.91 -35.63 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 131.64 3.976 . . . . 0.0 114.42 -161.034 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -107.69 40.92 1.61 Allowed 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 122.73 2.514 . . . . 0.0 112.665 -171.755 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 53.02 -25.39 0.01 OUTLIER Glycine 0 C--N 1.338 0.666 0 C-N-CA 130.129 3.728 . . . . 0.0 121.568 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.1 t -64.3 125.55 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 O-C-N 116.951 -3.676 . . . . 0.0 107.882 167.149 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -31.33 127.2 0.19 Allowed 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 117.36 2.356 . . . . 0.0 117.36 162.828 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 11.5 mmm180 -35.12 122.03 0.57 Allowed 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 118.672 2.841 . . . . 0.0 118.672 -177.296 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 8.5 p -78.79 -2.6 40.34 Favored 'General case' 0 N--CA 1.445 -0.696 0 C-N-CA 126.774 2.03 . . . . 0.0 111.576 -162.781 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.9 p30 -162.45 169.2 20.8 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 127.925 2.49 . . . . 0.0 109.199 178.055 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -123.91 -157.07 9.68 Favored Glycine 0 CA--C 1.522 0.502 0 C-N-CA 119.918 -1.134 . . . . 0.0 110.897 -160.873 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 61.01 41.05 99.31 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 178.286 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 58.4 m-20 -78.38 156.08 78.79 Favored Pre-proline 0 N--CA 1.448 -0.552 0 C-N-CA 126.982 2.113 . . . . 0.0 108.438 173.773 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -91.67 62.78 1.04 Allowed 'Trans proline' 0 N--CA 1.444 -1.395 0 C-N-CA 124.811 3.674 . . . . 0.0 117.284 -169.229 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -69.88 149.55 47.73 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 120.971 3.693 . . . . 0.0 120.971 173.471 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -150.49 128.36 11.74 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 127.22 2.208 . . . . 0.0 112.906 168.283 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.583 HG22 HG22 ' A' ' 95' ' ' VAL . 39.5 t -114.46 87.53 1.03 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.326 0 C-N-CA 129.99 3.316 . . . . 0.0 104.408 -174.606 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -104.66 142.29 34.94 Favored 'General case' 0 N--CA 1.444 -0.753 0 C-N-CA 127.14 2.176 . . . . 0.0 106.065 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 19.1 mt -130.86 155.38 41.87 Favored 'Isoleucine or valine' 0 C--O 1.238 0.463 0 C-N-CA 128.334 2.654 . . . . 0.0 113.492 -170.468 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 71.6 m-80 -125.01 126.25 45.14 Favored 'General case' 0 N--CA 1.446 -0.642 0 C-N-CA 131.426 3.89 . . . . 0.0 109.137 174.249 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -118.49 -177.87 16.92 Favored Glycine 0 CA--C 1.528 0.876 0 O-C-N 119.034 -2.291 . . . . 0.0 112.351 167.799 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo . . . . . 0 N--CA 1.441 -1.594 0 CA-C-N 118.741 1.27 . . . . 0.0 111.875 -174.739 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 26.2 t . . . . . 0 C--O 1.24 0.554 0 CA-C-O 122.063 0.935 . . . . 0.0 109.749 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 96.0 t -142.02 144.37 25.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 112.474 -2.148 . . . . 0.0 111.846 -177.272 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.301 3.6 p-10 -127.2 134.55 50.11 Favored 'General case' 0 N--CA 1.445 -0.695 0 O-C-N 117.953 -2.967 . . . . 0.0 111.285 168.199 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.75 155.57 19.49 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 126.927 3.251 . . . . 0.0 111.134 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.301 9.2 tmtt? -99.99 104.17 15.76 Favored 'General case' 0 N--CA 1.448 -0.553 1 O-C-N 113.235 -5.916 . . . . 0.0 111.216 -170.45 . . . . . . . . 3 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.0 t -76.38 138.64 20.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 O-C-N 127.17 2.794 . . . . 0.0 117.644 169.824 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 10.0 m -144.15 128.86 18.24 Favored 'General case' 0 C--O 1.237 0.443 0 O-C-N 126.725 2.516 . . . . 0.0 111.091 173.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -79.16 136.07 37.0 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 125.237 2.446 . . . . 0.0 110.226 -169.835 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . 0.266 8.0 m-20 -96.61 0.56 50.1 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 116.534 -3.854 . . . . 0.0 118.551 -175.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 6.5 m120 68.68 27.62 5.88 Favored 'General case' 0 C--O 1.215 -0.733 0 O-C-N 128.731 3.769 . . . . 0.0 114.512 176.041 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 26.7 p30 -134.66 -8.24 2.46 Favored 'General case' 0 N--CA 1.445 -0.706 0 CA-C-O 117.227 -1.368 . . . . 0.0 112.153 -176.096 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 109.02 5.88 30.41 Favored Glycine 0 C--N 1.35 1.313 0 CA-C-O 113.492 -3.949 . . . . 0.0 108.21 -170.141 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.7 p -130.09 158.07 40.64 Favored 'General case' 0 N--CA 1.442 -0.83 1 CA-C-N 126.491 5.146 . . . . 0.0 111.391 -175.065 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -135.93 113.01 10.42 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 120.633 1.561 . . . . 0.0 110.543 -174.38 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -63.33 136.91 42.63 Favored Glycine 0 N--CA 1.452 -0.268 0 N-CA-C 116.539 1.376 . . . . 0.0 116.539 167.246 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.9 t -131.64 134.41 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 126.713 2.005 . . . . 0.0 112.155 -178.795 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -132.5 141.56 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-N 122.912 2.596 . . . . 0.0 109.82 -175.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 1.8 p90 -166.32 170.81 12.73 Favored 'General case' 0 N--CA 1.446 -0.637 0 O-C-N 125.512 1.758 . . . . 0.0 115.185 170.729 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 27.2 p30 -142.41 141.87 32.3 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 129.077 2.951 . . . . 0.0 109.916 -158.01 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -112.91 125.61 29.57 Favored Pre-proline 0 C--N 1.344 0.365 0 CA-C-O 117.399 -1.286 . . . . 0.0 113.201 -176.467 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -84.01 -1.09 9.83 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 123.387 2.724 . . . . 0.0 112.54 178.147 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.4 m -128.24 148.93 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 O-C-N 118.783 -2.448 . . . . 0.0 113.532 -164.289 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -63.4 111.39 2.28 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-O 124.814 2.245 . . . . 0.0 109.235 139.433 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 169.26 -162.52 36.18 Favored Glycine 0 C--O 1.221 -0.657 0 O-C-N 118.583 -2.573 . . . . 0.0 118.015 -173.114 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 27.3 t30 -117.68 132.58 56.47 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 127.435 2.294 . . . . 0.0 111.83 177.429 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -90.73 153.28 20.39 Favored 'General case' 0 C--O 1.221 -0.416 0 O-C-N 118.423 -2.673 . . . . 0.0 113.086 158.872 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -128.37 113.28 15.39 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 113.186 -1.825 . . . . 0.0 113.699 176.05 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.6 t -115.07 120.37 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 CA-C-N 113.887 -1.506 . . . . 0.0 114.204 -154.757 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.6 t30 -129.65 111.16 12.41 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 126.301 1.84 . . . . 0.0 108.379 -167.726 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.583 HG22 HG22 ' A' ' 57' ' ' VAL . 84.2 t -98.03 134.89 34.66 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.525 0 C-N-CA 126.72 2.008 . . . . 0.0 109.971 177.047 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 17.0 p -144.01 157.42 44.34 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 126.497 3.046 . . . . 0.0 115.911 -173.57 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 49.3 tp -129.03 104.97 7.88 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 101.763 -3.421 . . . . 0.0 101.763 -149.039 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 67.6 ttp85 45.74 42.79 9.01 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 104.91 -2.256 . . . . 0.0 104.91 -162.308 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.63 -1.06 31.55 Favored Glycine 0 CA--C 1.52 0.378 0 N-CA-C 119.932 2.733 . . . . 0.0 119.932 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -85.96 148.76 48.92 Favored Pre-proline 0 N--CA 1.445 -0.677 0 C-N-CA 129.246 3.019 . . . . 0.0 112.225 174.622 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_endo -76.73 170.8 19.19 Favored 'Trans proline' 0 N--CA 1.444 -1.423 0 O-C-N 124.769 1.931 . . . . 0.0 112.383 -175.248 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . 0.284 4.3 pt -136.37 -163.15 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 C-N-CA 128.399 2.679 . . . . 0.0 112.438 -179.124 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 32.1 mttt -100.88 159.81 14.89 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 125.337 3.699 . . . . 0.0 109.19 -173.582 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 33.4 m120 54.31 31.51 14.48 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 128.36 2.664 . . . . 0.0 113.351 173.066 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' MET . . . . . . . . . . . . 0.263 7.2 mmt -132.49 150.37 75.68 Favored Pre-proline 0 N--CA 1.454 -0.248 0 O-C-N 118.082 -2.886 . . . . 0.0 105.594 -173.205 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -66.15 174.84 25.54 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 CA-C-N 125.47 2.989 . . . . 0.0 112.735 -5.701 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 12.4 pt -143.32 169.81 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 O-C-N 126.083 2.114 . . . . 0.0 109.1 170.323 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -125.7 141.39 52.04 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 122.482 2.401 . . . . 0.0 114.437 -167.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 58.5 t -132.81 120.57 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 123.337 0.655 . . . . 0.0 109.421 -170.297 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 62.5 mttm -65.67 132.21 48.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 126.94 2.096 . . . . 0.0 108.183 173.318 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 20.1 m -126.28 138.27 53.59 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 127.422 2.289 . . . . 0.0 115.885 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 83.7 mt -130.63 152.06 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 O-C-N 118.709 -2.494 . . . . 0.0 110.437 167.003 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -84.91 45.48 1.17 Allowed 'General case' 0 N--CA 1.453 -0.32 0 O-C-N 120.41 -1.431 . . . . 0.0 113.828 -165.29 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.93 0 N-CA-C 116.431 1.332 . . . . 0.0 116.431 -174.41 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.0 tpt . . . . . 0 N--CA 1.479 0.994 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' HIS . . . . . 0.404 ' CE1' HG22 ' A' ' 49' ' ' THR . 49.6 t-80 -78.15 -50.58 11.7 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 117.678 -1.609 . . . . 0.0 109.635 -177.066 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.438 ' CE1' ' HA ' ' A' ' 75' ' ' ASN . 16.9 t-80 -78.66 114.13 17.31 Favored 'General case' 0 C--N 1.319 -0.726 0 O-C-N 117.304 -3.372 . . . . 0.0 107.151 175.707 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 85.8 t60 -159.46 140.99 13.04 Favored 'General case' 0 N--CA 1.446 -0.655 0 O-C-N 118.87 -2.394 . . . . 0.0 110.154 -175.221 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.4 m-70 -87.73 98.24 11.34 Favored 'General case' 0 N--CA 1.446 -0.664 0 O-C-N 119.689 -1.882 . . . . 0.0 115.696 167.277 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 15.5 t60 -81.73 -36.63 28.39 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 110.718 -2.946 . . . . 0.0 109.754 -178.174 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 47.0 t-80 -147.99 169.25 20.31 Favored 'General case' 0 N--CA 1.449 -0.495 0 O-C-N 118.373 -2.705 . . . . 0.0 111.692 -167.668 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -88.98 30.23 0.96 Allowed 'General case' 0 N--CA 1.438 -1.068 0 C-N-CA 127.45 2.3 . . . . 0.0 116.809 -178.222 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.6 p -140.65 160.2 40.55 Favored 'General case' 0 C--O 1.234 0.281 0 C-N-CA 126.109 1.764 . . . . 0.0 112.145 169.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 35.0 mtmt -143.86 133.17 11.5 Favored Pre-proline 0 N--CA 1.446 -0.63 1 CA-C-O 110.997 -4.335 . . . . 0.0 112.785 -171.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -71.79 168.55 23.48 Favored 'Trans proline' 0 N--CA 1.449 -1.129 0 O-C-N 126.05 2.605 . . . . 0.0 109.002 175.554 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -101.5 135.7 19.77 Favored Pre-proline 0 C--O 1.238 0.475 0 CA-C-O 115.816 -2.04 . . . . 0.0 113.868 -177.591 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -53.42 149.14 31.16 Favored 'Trans proline' 0 N--CA 1.44 -1.624 1 C-N-CA 132.061 8.507 . . . . 0.0 113.622 157.196 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.3 m -145.7 161.17 40.5 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 123.342 1.544 . . . . 0.0 107.45 -166.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.29 -44.04 89.23 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 108.825 -3.807 . . . . 0.0 114.601 -172.036 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . 0.288 68.1 mm-40 -64.88 -20.72 66.58 Favored 'General case' 0 N--CA 1.442 -0.83 0 C-N-CA 129.296 3.038 . . . . 0.0 112.763 167.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 34.2 m170 -121.28 16.52 11.45 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 130.499 3.52 . . . . 0.0 117.733 -163.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 t -142.84 135.05 27.36 Favored 'General case' 0 N--CA 1.445 -0.684 0 O-C-N 118.374 -2.704 . . . . 0.0 110.661 166.147 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . 0.356 49.6 m-85 -154.41 147.27 24.43 Favored 'General case' 0 N--CA 1.446 -0.673 0 C-N-CA 127.646 2.378 . . . . 0.0 107.415 -167.052 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -136.69 150.08 48.27 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 118.377 2.732 . . . . 0.0 118.377 -172.319 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -156.61 145.63 20.28 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 119.324 3.083 . . . . 0.0 119.324 -165.557 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.8 -170.33 21.22 Favored Glycine 0 C--N 1.341 0.833 0 C-N-CA 127.521 2.486 . . . . 0.0 115.578 174.414 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -58.18 -38.66 77.11 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 125.813 1.645 . . . . 0.0 110.256 -170.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -68.33 -1.84 23.4 Favored Glycine 0 CA--C 1.527 0.835 0 O-C-N 117.814 -3.054 . . . . 0.0 113.366 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.5 mt -120.27 21.75 11.61 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 122.095 2.948 . . . . 0.0 107.289 169.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.0 t -124.43 -50.85 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-O 116.309 -1.805 . . . . 0.0 112.669 165.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.4 pttt -155.63 136.3 13.42 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 122.419 2.372 . . . . 0.0 110.505 -165.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 46.2 t -144.73 141.03 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 CA-C-O 115.303 -2.284 . . . . 0.0 109.049 -170.284 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -137.43 -171.47 2.98 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 120.36 3.467 . . . . 0.0 120.36 -172.603 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 48.4 t0 -94.03 -57.55 2.5 Favored 'General case' 0 N--CA 1.447 -0.587 1 O-C-N 115.101 -4.75 . . . . 0.0 109.294 -162.188 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 66.6 m-80 -97.97 -2.8 39.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 118.841 2.904 . . . . 0.0 118.841 172.093 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -114.47 88.85 16.54 Favored Pre-proline 0 N--CA 1.445 -0.719 0 CA-C-O 122.58 1.181 . . . . 0.0 110.248 160.106 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -43.77 135.63 7.26 Favored 'Trans proline' 0 N--CA 1.445 -1.325 0 N-CA-C 116.997 1.884 . . . . 0.0 116.997 156.381 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.44 153.95 22.58 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.238 2.215 . . . . 0.0 113.418 -174.287 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -138.11 147.92 44.46 Favored 'General case' 0 N--CA 1.442 -0.851 0 C-N-CA 128.494 2.717 . . . . 0.0 112.626 -171.051 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -155.02 175.14 14.21 Favored 'General case' 0 CA--C 1.514 -0.429 0 C-N-CA 130.111 3.365 . . . . 0.0 112.868 166.403 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.415 ' CG2' ' HB ' ' A' ' 78' ' ' THR . 86.9 m -123.36 125.7 45.48 Favored 'General case' 0 C--N 1.344 0.364 0 N-CA-C 117.23 2.307 . . . . 0.0 117.23 -164.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . 0.273 2.3 mt -78.31 123.25 34.85 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.717 0 CA-C-O 114.001 -2.904 . . . . 0.0 115.791 167.59 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.312 22.7 p90 -111.05 91.96 3.86 Favored 'General case' 0 N--CA 1.433 -1.287 0 C-N-CA 129.843 3.257 . . . . 0.0 115.262 177.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -97.74 138.14 35.57 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 130.529 3.531 . . . . 0.0 114.379 -166.266 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.1 t -131.58 135.73 58.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 CA-C-N 112.078 -2.328 . . . . 0.0 107.948 170.126 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -61.55 -61.26 2.65 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 117.029 2.233 . . . . 0.0 117.029 166.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 21.1 p -164.03 -26.67 0.04 OUTLIER 'General case' 0 N--CA 1.443 -0.795 0 C-N-CA 130.354 3.462 . . . . 0.0 110.648 169.196 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 34.6 mtmm -76.4 19.22 0.26 Allowed 'General case' 0 CA--C 1.515 -0.386 0 O-C-N 127.006 2.691 . . . . 0.0 114.166 -163.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 62.6 -46.38 0.07 OUTLIER Glycine 0 C--N 1.347 1.19 0 C-N-CA 127.067 2.27 . . . . 0.0 118.049 177.549 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 57.9 t -52.27 140.34 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 CA-C-N 121.881 2.841 . . . . 0.0 112.398 159.136 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -32.44 153.05 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 117.351 2.352 . . . . 0.0 117.351 165.249 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 8.0 mmm180 -59.7 128.13 35.41 Favored 'General case' 0 N--CA 1.452 -0.355 0 O-C-N 118.01 -2.931 . . . . 0.0 113.408 173.556 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.404 HG22 ' CE1' ' A' ' 2' ' ' HIS . 59.9 p -88.82 1.53 55.12 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 127.806 2.442 . . . . 0.0 112.877 -169.34 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -163.82 156.74 18.1 Favored 'General case' 0 N--CA 1.448 -0.526 1 O-C-N 115.786 -4.321 . . . . 0.0 112.922 176.4 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.81 -173.92 30.63 Favored Glycine 0 N--CA 1.466 0.684 0 O-C-N 125.591 1.807 . . . . 0.0 108.98 -155.386 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.23 32.36 83.89 Favored Glycine 0 C--O 1.236 0.224 0 C-N-CA 127.672 2.558 . . . . 0.0 114.076 171.297 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -60.71 145.17 88.48 Favored Pre-proline 0 CA--C 1.514 -0.418 0 O-C-N 117.743 -3.21 . . . . 0.0 106.763 160.103 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -84.09 135.97 6.68 Favored 'Trans proline' 0 CA--C 1.509 -0.735 0 C-N-CA 124.734 3.623 . . . . 0.0 115.952 170.304 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -135.2 163.96 28.77 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 129.62 3.168 . . . . 0.0 111.2 -172.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.439 ' O ' ' HA ' ' A' ' 95' ' ' VAL 0.275 21.5 tt0 -145.64 141.56 28.25 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 127.919 2.488 . . . . 0.0 113.472 164.667 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 4.3 t -129.9 61.49 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 129.487 3.115 . . . . 0.0 105.335 -173.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -83.81 132.04 34.85 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 112.839 -1.982 . . . . 0.0 113.958 -175.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.437 HD13 ' CE2' ' A' ' 83' ' ' TYR . 61.3 mt -138.77 145.59 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 CA-C-O 124.34 2.019 . . . . 0.0 108.486 -158.277 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.9 m-80 -113.18 129.69 56.44 Favored 'General case' 0 N--CA 1.45 -0.455 0 O-C-N 116.587 -3.821 . . . . 0.0 108.993 167.206 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.22 -172.61 41.79 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 126.205 1.86 . . . . 0.0 114.042 157.403 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -63.78 124.89 14.36 Favored 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 122.94 2.427 . . . . 0.0 112.937 -178.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 55.61 -114.17 0.83 Allowed 'General case' 0 N--CA 1.441 -0.898 0 O-C-N 125.301 1.625 . . . . 0.0 111.1 -178.073 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -78.45 3.74 62.04 Favored Glycine 0 C--N 1.332 0.332 0 CA-C-O 125.677 2.821 . . . . 0.0 113.829 -161.705 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 33.9 mt -89.64 72.38 7.77 Favored 'General case' 0 C--O 1.219 -0.504 1 O-C-N 115.788 -4.36 . . . . 0.0 114.57 -172.032 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . 0.265 56.7 t -88.45 112.28 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 109.42 -3.536 . . . . 0.0 107.924 179.433 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 2.3 t -127.8 151.57 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 O-C-N 120.904 -1.123 . . . . 0.0 108.477 -168.136 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -121.76 139.75 53.2 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 126.411 3.005 . . . . 0.0 110.816 153.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -87.16 125.84 34.41 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 112.172 -2.285 . . . . 0.0 106.716 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 30.3 mmtm -81.17 133.64 35.49 Favored 'General case' 0 N--CA 1.449 -0.481 0 O-C-N 118.848 -2.407 . . . . 0.0 111.285 -167.794 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 72.2 t -107.97 139.96 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.685 0 CA-C-O 126.072 2.844 . . . . 0.0 106.842 -168.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 28.4 m -144.5 127.18 16.15 Favored 'General case' 0 C--N 1.345 0.37 0 CA-C-N 111.606 -2.543 . . . . 0.0 109.611 173.362 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 62.3 t0 -63.05 129.67 41.35 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 125.459 1.503 . . . . 0.0 111.752 177.279 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 -82.84 -11.37 58.29 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 115.954 1.835 . . . . 0.0 115.954 173.787 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ASN . . . . . 0.438 ' HA ' ' CE1' ' A' ' 3' ' ' HIS 0.39 2.5 m120 63.66 48.5 3.31 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.294 2.238 . . . . 0.0 116.181 -172.697 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 44.0 p-10 -156.75 8.35 0.2 Allowed 'General case' 0 C--N 1.345 0.388 0 CA-C-O 126.376 2.988 . . . . 0.0 117.726 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 95.16 17.52 36.97 Favored Glycine 0 CA--C 1.526 0.742 0 O-C-N 117.588 -3.195 . . . . 0.0 108.441 -178.353 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.415 ' HB ' ' CG2' ' A' ' 37' ' ' THR . 31.1 p -136.76 166.58 23.26 Favored 'General case' 0 C--N 1.331 -0.226 0 O-C-N 124.728 0.899 . . . . 0.0 111.947 173.41 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -137.28 121.61 18.14 Favored 'General case' 0 N--CA 1.441 -0.888 0 O-C-N 125.674 1.859 . . . . 0.0 108.359 -172.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -76.18 134.24 15.45 Favored Glycine 0 N--CA 1.466 0.636 0 CA-C-O 124.221 2.012 . . . . 0.0 113.399 163.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 89.7 t -117.29 146.48 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 C-N-CA 129.575 3.15 . . . . 0.0 113.329 171.223 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -134.36 141.6 43.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 O-C-N 125.816 1.947 . . . . 0.0 113.285 175.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.437 ' CE2' HD13 ' A' ' 59' ' ' ILE . 1.3 p90 -162.15 167.38 24.27 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 116.275 -1.821 . . . . 0.0 112.051 168.841 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 40.7 p30 -144.99 154.64 42.76 Favored 'General case' 0 C--N 1.348 0.535 0 C-N-CA 126.096 1.758 . . . . 0.0 109.02 -166.517 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -124.42 118.25 26.37 Favored Pre-proline 0 N--CA 1.446 -0.647 0 C-N-CA 128.03 2.532 . . . . 0.0 114.514 -166.099 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.263 45.7 Cg_endo -71.87 -14.51 29.61 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.608 2.205 . . . . 0.0 111.803 -175.716 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.9 m -137.77 132.74 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.853 0 C-N-CA 128.139 2.576 . . . . 0.0 114.242 -139.387 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -54.45 112.17 0.94 Allowed 'General case' 0 N--CA 1.447 -0.618 0 O-C-N 118.045 -2.909 . . . . 0.0 115.255 144.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 168.69 -145.5 9.58 Favored Glycine 0 CA--C 1.529 0.922 1 O-C-N 114.453 -5.154 . . . . 0.0 114.818 -173.422 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -145.49 133.39 21.26 Favored 'General case' 0 N--CA 1.448 -0.525 0 O-C-N 117.431 -3.394 . . . . 0.0 115.152 -176.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 17.7 m-85 -102.34 148.68 25.18 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 104.669 -2.345 . . . . 0.0 104.669 174.138 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -126.39 106.59 9.59 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 128.347 3.53 . . . . 0.0 112.51 -177.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 42.6 t -111.81 131.44 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 O-C-N 119.612 -1.93 . . . . 0.0 108.571 -158.662 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 -126.74 120.24 28.89 Favored 'General case' 0 CA--C 1.513 -0.473 0 C-N-CA 129.746 3.218 . . . . 0.0 110.158 174.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.439 ' HA ' ' O ' ' A' ' 56' ' ' GLU . 77.1 t -99.92 148.21 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 115.534 1.679 . . . . 0.0 115.534 170.467 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.48 HG22 ' HA ' ' A' ' 101' ' ' PRO . 4.7 p -150.41 148.83 29.24 Favored 'General case' 0 N--CA 1.445 -0.675 0 O-C-N 117.385 -3.322 . . . . 0.0 113.025 -177.818 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.449 HD13 HG21 ' A' ' 102' ' ' ILE . 8.0 mp -128.8 106.65 9.06 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 127.971 2.508 . . . . 0.0 110.184 -158.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? 51.56 44.32 29.17 Favored 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 126.212 1.805 . . . . 0.0 108.295 -160.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 58.59 26.56 59.99 Favored Glycine 0 N--CA 1.439 -1.103 0 N-CA-C 118.429 2.131 . . . . 0.0 118.429 -177.146 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 73.5 m-20 -122.06 143.53 39.12 Favored Pre-proline 0 CA--C 1.516 -0.362 0 C-N-CA 125.088 1.355 . . . . 0.0 108.887 174.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.48 ' HA ' HG22 ' A' ' 96' ' ' THR 0.282 24.4 Cg_endo -82.88 175.83 8.25 Favored 'Trans proline' 0 N--CA 1.446 -1.293 0 CA-C-O 125.948 2.395 . . . . 0.0 108.318 -168.63 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.449 HG21 HD13 ' A' ' 97' ' ' LEU . 25.7 pt -149.7 -176.11 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 C-N-CA 127.961 2.505 . . . . 0.0 109.865 -167.575 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 41.1 mtpt -81.28 163.56 22.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 123.14 1.447 . . . . 0.0 113.314 -176.477 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.295 23.2 m120 58.39 54.49 5.57 Favored 'General case' 0 C--O 1.222 -0.386 0 N-CA-C 117.125 2.269 . . . . 0.0 117.125 168.115 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 9.7 mmt -164.3 146.98 7.39 Favored Pre-proline 0 CA--C 1.507 -0.686 0 C-N-CA 128.079 2.552 . . . . 0.0 105.449 -162.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -70.58 164.81 80.65 Favored 'Cis proline' 0 N--CA 1.445 -1.352 0 C-N-CA 130.836 1.598 . . . . 0.0 109.979 -5.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' ILE . . . . . 0.404 HD13 HG21 ' A' ' 107' ' ' ILE . 31.4 pt -130.43 174.04 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 C-N-CA 126.202 1.801 . . . . 0.0 108.043 174.336 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -125.44 139.31 53.76 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 117.49 2.404 . . . . 0.0 117.49 -168.314 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 2.4 t -147.39 125.67 3.76 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-O 124.005 1.86 . . . . 0.0 114.323 -175.646 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . 0.271 46.1 pttt -66.44 129.04 38.51 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 127.057 2.143 . . . . 0.0 108.818 -173.121 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . 0.383 72.5 m -107.71 141.95 38.45 Favored 'General case' 0 N--CA 1.448 -0.531 0 O-C-N 126.72 2.512 . . . . 0.0 104.528 178.668 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 21.9 mt -144.52 143.65 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 O-C-N 117.281 -3.387 . . . . 0.0 111.977 173.203 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . 0.298 12.0 pt-20 -93.56 53.1 1.81 Allowed 'General case' 0 N--CA 1.449 -0.507 1 O-C-N 114.427 -5.171 . . . . 0.0 110.741 -157.05 . . . . . . . . 3 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 0.338 0 C-N-CA 128.453 2.93 . . . . 0.0 113.671 -176.289 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.2 tpt . . . . . 0 N--CA 1.472 0.656 0 CA-C-O 123.44 1.591 . . . . 0.0 110.181 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 44.1 m80 -115.48 40.21 2.78 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 130.826 3.65 . . . . 0.0 113.827 177.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.6 m-70 -83.68 171.41 13.26 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 119.478 -2.013 . . . . 0.0 112.304 170.77 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 28.3 p80 -151.77 123.32 7.87 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 125.26 1.424 . . . . 0.0 112.935 176.061 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 9.7 m-70 -108.06 134.85 50.35 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 115.462 -2.209 . . . . 0.0 115.769 -168.434 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -135.85 -35.97 0.77 Allowed 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 116.31 1.967 . . . . 0.0 116.31 -166.482 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -140.44 155.17 46.8 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 103.201 -2.889 . . . . 0.0 103.201 -165.019 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -58.15 -61.94 2.19 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-N 115.523 -0.762 . . . . 0.0 112.981 176.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 71.6 m -52.33 152.49 3.4 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 126.581 1.953 . . . . 0.0 114.098 175.355 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 57.6 mttp -104.87 99.14 17.45 Favored Pre-proline 0 N--CA 1.447 -0.594 0 C-N-CA 127.724 2.409 . . . . 0.0 104.8 167.443 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -74.78 152.16 41.62 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 124.108 3.205 . . . . 0.0 110.556 169.563 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -99.55 161.65 23.81 Favored Pre-proline 0 N--CA 1.45 -0.432 0 N-CA-C 117.244 2.313 . . . . 0.0 117.244 -173.734 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -74.17 170.2 20.71 Favored 'Trans proline' 0 N--CA 1.445 -1.348 0 C-N-CA 123.927 3.084 . . . . 0.0 111.276 -178.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.5 t -152.22 173.99 14.31 Favored 'General case' 0 N--CA 1.452 -0.341 0 O-C-N 124.348 1.03 . . . . 0.0 111.716 174.221 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.83 -39.97 79.69 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-N 115.125 -0.943 . . . . 0.0 113.374 -170.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 72.5 mm-40 -53.0 -35.76 59.73 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 129.547 3.139 . . . . 0.0 113.596 168.186 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 17.2 m170 -120.5 19.76 11.94 Favored 'General case' 0 N--CA 1.438 -1.026 0 CA-C-N 111.928 -2.397 . . . . 0.0 111.76 -161.546 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.4 t -137.45 138.28 39.61 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 117.999 -2.938 . . . . 0.0 105.468 171.804 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -164.31 153.44 13.52 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 110.778 -2.919 . . . . 0.0 110.606 -170.215 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.462 ' HB2' ' HA ' ' A' ' 38' ' ' ILE . . . -140.11 150.0 43.76 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 119.621 3.193 . . . . 0.0 119.621 -171.662 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -157.47 134.31 10.04 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 127.563 2.345 . . . . 0.0 111.916 -165.347 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 148.46 166.5 12.91 Favored Glycine 0 C--N 1.336 0.56 0 C-N-CA 126.473 1.987 . . . . 0.0 112.292 176.47 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -65.34 -19.78 66.1 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 116.682 -1.628 . . . . 0.0 109.436 -169.149 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.536 ' HA3' ' CD2' ' A' ' 36' ' ' PHE . . . -64.29 0.3 3.84 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 124.58 3.355 . . . . 0.0 117.22 168.182 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . 0.27 56.9 mt -109.54 13.33 24.0 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 129.637 3.175 . . . . 0.0 111.854 167.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 t -131.52 -53.36 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 C-N-CA 130.69 3.596 . . . . 0.0 112.018 -178.584 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 46.7 pttt -161.85 125.64 3.2 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 -159.367 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.2 t -137.67 155.72 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 C-N-CA 129.303 3.041 . . . . 0.0 109.907 -177.62 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -131.78 -176.66 4.12 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-O 123.933 1.825 . . . . 0.0 111.856 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -88.05 -46.85 8.98 Favored 'General case' 0 N--CA 1.446 -0.629 0 O-C-N 119.489 -2.007 . . . . 0.0 109.462 -174.642 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -109.5 6.91 24.52 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-O 126.64 3.114 . . . . 0.0 117.304 176.555 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -122.46 100.36 41.67 Favored Pre-proline 0 N--CA 1.442 -0.858 1 O-C-N 116.202 -4.061 . . . . 0.0 101.784 167.162 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -62.42 157.62 45.03 Favored 'Trans proline' 0 N--CA 1.45 -1.031 0 C-N-CA 123.654 2.903 . . . . 0.0 113.595 166.123 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -123.89 153.03 41.71 Favored 'General case' 0 CA--C 1.511 -0.548 0 C-N-CA 127.136 2.175 . . . . 0.0 112.86 -176.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.496 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 33.6 mt-10 -127.4 155.42 43.67 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 124.067 0.947 . . . . 0.0 108.979 -175.655 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.536 ' CD2' ' HA3' ' A' ' 24' ' ' GLY . 5.2 p90 -161.65 155.38 21.67 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -179.3 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 86.4 m -124.21 119.75 30.27 Favored 'General case' 0 N--CA 1.452 -0.342 0 O-C-N 119.014 -2.303 . . . . 0.0 109.593 -161.55 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.462 ' HA ' ' HB2' ' A' ' 20' ' ' ALA 0.263 17.2 mt -79.74 102.96 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 124.994 1.318 . . . . 0.0 111.533 164.897 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.371 40.5 p90 -83.24 124.76 30.88 Favored 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 126.49 1.916 . . . . 0.0 113.797 165.637 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -110.45 146.61 35.6 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 179.701 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 9.7 t -129.99 139.11 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 O-C-N 126.757 2.536 . . . . 0.0 106.431 160.228 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -66.76 -50.32 63.1 Favored 'General case' 0 N--CA 1.452 -0.336 0 O-C-N 117.779 -3.076 . . . . 0.0 111.881 178.364 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 64.3 p -148.98 -60.23 0.22 Allowed 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 115.947 -1.978 . . . . 0.0 111.359 -166.804 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 12.7 ttmt -134.61 101.29 4.9 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 122.149 2.249 . . . . 0.0 114.543 -178.508 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 77.45 -65.56 3.08 Favored Glycine 0 N--CA 1.451 -0.306 0 O-C-N 120.372 -1.455 . . . . 0.0 114.375 162.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 46.3 t -61.01 124.71 15.93 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 C-N-CA 128.891 2.876 . . . . 0.0 108.717 179.413 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -50.91 168.2 0.06 Allowed 'General case' 0 N--CA 1.449 -0.486 0 CA-C-O 124.471 2.081 . . . . 0.0 112.982 178.702 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -53.75 125.85 19.9 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 108.719 -3.855 . . . . 0.0 107.631 163.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 17.5 p -79.08 -18.33 53.57 Favored 'General case' 0 N--CA 1.453 -0.297 1 C-N-CA 131.757 4.023 . . . . 0.0 111.486 -173.05 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -151.86 169.35 22.48 Favored 'General case' 0 CA--C 1.517 -0.297 0 O-C-N 127.551 3.032 . . . . 0.0 107.965 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -102.58 -142.75 12.53 Favored Glycine 0 CA--C 1.525 0.671 0 C-N-CA 124.763 1.173 . . . . 0.0 115.001 -167.423 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 71.65 5.34 60.32 Favored Glycine 0 C--N 1.334 0.455 0 CA-C-O 117.234 -1.87 . . . . 0.0 116.751 165.489 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 38.1 m-20 -77.01 143.54 70.61 Favored Pre-proline 0 N--CA 1.45 -0.455 0 CA-C-O 115.435 -2.221 . . . . 0.0 115.981 -178.261 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -83.02 127.71 4.79 Favored 'Trans proline' 0 N--CA 1.449 -1.09 0 CA-C-N 125.151 2.875 . . . . 0.0 115.998 -176.702 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -138.25 161.48 36.77 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 114.133 -1.394 . . . . 0.0 111.428 -171.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -153.39 151.72 30.24 Favored 'General case' 0 N--CA 1.447 -0.62 0 O-C-N 120.547 -1.346 . . . . 0.0 113.22 172.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 53.5 t -133.35 99.73 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 C-N-CA 130.054 3.342 . . . . 0.0 104.335 -172.072 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -125.07 138.87 54.18 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 113.577 -1.647 . . . . 0.0 112.663 -170.432 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.4 mt -138.78 115.45 10.58 Favored 'Isoleucine or valine' 0 C--O 1.238 0.482 0 O-C-N 119.715 -1.866 . . . . 0.0 107.978 -147.048 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -88.64 138.62 31.26 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 118.823 -2.423 . . . . 0.0 107.011 173.433 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -141.83 173.33 23.64 Favored Glycine 0 CA--C 1.523 0.539 0 C-N-CA 129.359 3.361 . . . . 0.0 112.475 -166.321 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -49.07 145.91 13.3 Favored 'Trans proline' 0 N--CA 1.46 -0.484 1 C-N-CA 125.921 4.414 . . . . 0.0 117.454 170.629 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.261 30.0 m-20 67.63 7.6 5.76 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 112.498 -2.137 . . . . 0.0 112.871 -167.481 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 76.95 33.69 44.97 Favored Glycine 0 CA--C 1.523 0.585 0 O-C-N 117.813 -3.054 . . . . 0.0 110.837 175.738 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 67.6 mt -80.29 138.31 36.74 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 126.521 1.928 . . . . 0.0 114.863 173.655 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 4.5 t -103.27 145.36 12.58 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 CA-C-O 126.064 2.84 . . . . 0.0 113.207 166.058 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 8.9 t -149.43 152.67 11.71 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 O-C-N 116.906 -3.621 . . . . 0.0 107.5 -176.185 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -131.21 138.24 49.29 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-O 123.413 1.578 . . . . 0.0 115.02 161.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -94.09 131.1 39.94 Favored 'General case' 0 N--CA 1.441 -0.917 1 C-N-CA 133.319 4.648 . . . . 0.0 112.585 -164.289 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.408 ' HE2' ' HB3' ' A' ' 70' ' ' LYS 0.258 28.5 ttpt -71.31 126.03 28.56 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 122.894 2.588 . . . . 0.0 112.506 -166.663 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.442 HG22 HG22 ' A' ' 81' ' ' VAL . 68.8 t -106.88 140.2 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 O-C-N 119.552 -1.968 . . . . 0.0 106.446 -179.409 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 90.4 m -144.76 127.97 16.71 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-O 124.868 2.27 . . . . 0.0 113.933 178.536 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -69.26 128.31 36.14 Favored 'General case' 0 N--CA 1.456 -0.155 0 C-N-CA 127.35 2.26 . . . . 0.0 109.895 -174.626 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 55.8 m-20 -91.11 5.47 48.82 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 118.458 2.762 . . . . 0.0 118.458 174.527 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 15.3 m-20 55.17 43.23 29.73 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 120.057 1.299 . . . . 0.0 112.423 174.656 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 35.3 p-10 -155.57 3.29 0.18 Allowed 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 128.052 2.541 . . . . 0.0 116.565 -174.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 98.95 4.2 56.79 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 118.515 -2.616 . . . . 0.0 112.33 -174.633 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 16.9 p -133.94 165.77 24.24 Favored 'General case' 0 CA--C 1.515 -0.387 0 N-CA-C 116.723 2.12 . . . . 0.0 116.723 177.429 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 45.2 m-85 -129.64 134.43 47.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.602 177.179 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -81.75 133.72 12.35 Favored Glycine 0 C--N 1.342 0.863 0 O-C-N 125.775 1.922 . . . . 0.0 108.325 172.361 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 35' ' ' GLU . 17.5 t -118.55 136.94 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 128.122 2.569 . . . . 0.0 109.433 175.454 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 p -134.84 135.05 53.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 CA-C-O 114.574 -2.631 . . . . 0.0 111.347 -178.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 80.2 t80 -156.17 144.39 19.85 Favored 'General case' 0 N--CA 1.445 -0.686 1 O-C-N 130.82 5.075 . . . . 0.0 113.084 -174.794 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.9 p30 -130.0 149.0 51.91 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 126.473 1.909 . . . . 0.0 107.999 -177.708 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -115.25 112.27 44.1 Favored Pre-proline 0 CA--C 1.511 -0.532 0 C-N-CA 125.731 1.612 . . . . 0.0 112.016 -171.71 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -71.41 -14.55 31.01 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 C-N-CA 124.032 3.155 . . . . 0.0 117.321 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.8 m -143.57 143.59 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 O-C-N 119.824 -1.797 . . . . 0.0 109.853 -174.783 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 -49.47 121.48 5.11 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 162.306 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -179.92 171.57 43.06 Favored Glycine 0 C--N 1.339 0.711 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.394 -175.659 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -98.86 133.22 43.46 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 128.886 2.874 . . . . 0.0 112.504 158.705 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 -126.94 150.03 49.54 Favored 'General case' 0 C--O 1.22 -0.464 0 N-CA-C 106.363 -1.717 . . . . 0.0 106.363 -173.513 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -119.18 111.28 18.04 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-N 114.214 -1.357 . . . . 0.0 114.632 -170.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.6 t -102.35 132.82 47.6 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.43 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 -166.575 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -122.6 128.09 50.24 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 131.169 3.788 . . . . 0.0 112.243 166.113 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 62.0 t -117.36 143.65 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 CA-C-N 114.481 -1.236 . . . . 0.0 109.682 -177.34 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.5 p -140.31 160.55 39.72 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 117.971 -1.014 . . . . 0.0 111.888 -171.502 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . 0.257 8.2 tt -135.65 94.08 3.04 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 103.152 -2.907 . . . . 0.0 103.152 -152.808 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 26.4 ttp-105 52.96 37.42 24.46 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 120.975 1.716 . . . . 0.0 112.019 -170.563 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 65.07 35.95 92.41 Favored Glycine 0 C--N 1.338 0.679 0 N-CA-C 116.65 1.42 . . . . 0.0 116.65 -176.26 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 71.3 m-80 -115.38 141.19 26.83 Favored Pre-proline 0 N--CA 1.447 -0.588 0 CA-C-O 117.353 -1.308 . . . . 0.0 110.009 166.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -71.69 165.98 30.86 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 CA-C-O 124.988 1.995 . . . . 0.0 112.095 166.134 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 11.6 pt -137.62 179.55 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 C-N-CA 127.234 2.214 . . . . 0.0 112.788 -173.055 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.403 ' C ' ' H ' ' A' ' 105' ' ' MET . 56.3 mtpt -74.71 165.91 24.45 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-O 115.529 -2.177 . . . . 0.0 111.025 -173.084 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.421 15.1 m120 66.93 -20.58 0.11 Allowed 'General case' 0 C--N 1.33 -0.268 0 O-C-N 125.59 1.806 . . . . 0.0 114.019 172.737 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' MET . . . . . 0.403 ' H ' ' C ' ' A' ' 103' ' ' LYS . 12.9 mmt -67.17 158.65 80.77 Favored Pre-proline 0 N--CA 1.446 -0.644 0 C-N-CA 127.268 2.227 . . . . 0.0 116.575 -178.669 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -73.51 159.68 97.06 Favored 'Cis proline' 0 N--CA 1.442 -1.517 0 O-C-N 125.089 2.099 . . . . 0.0 107.932 -20.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 8.2 pt -131.23 161.96 40.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 C-N-CA 126.828 2.051 . . . . 0.0 108.736 -174.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 69.8 m-20 -117.27 147.9 42.14 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 126.481 1.912 . . . . 0.0 111.28 -159.49 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 42.7 t -139.66 117.29 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 126.344 1.857 . . . . 0.0 111.889 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 65.4 tttt -81.9 136.14 35.35 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 115.524 1.675 . . . . 0.0 115.524 168.613 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 98.1 m -126.77 133.39 50.85 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 125.766 1.626 . . . . 0.0 107.622 -170.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 48.9 mm -121.82 141.78 40.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 O-C-N 120.156 -1.59 . . . . 0.0 107.65 177.272 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -82.75 41.23 0.72 Allowed 'General case' 0 N--CA 1.454 -0.246 1 O-C-N 114.941 -4.85 . . . . 0.0 116.548 -155.865 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.651 0 O-C-N 119.493 -2.004 . . . . 0.0 113.449 -175.685 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.6 mmt . . . . . 0 N--CA 1.472 0.664 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 46.3 t60 -151.48 148.75 28.44 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 126.429 3.014 . . . . 0.0 114.461 -164.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 8.1 m-70 -48.37 134.33 15.09 Favored 'General case' 0 N--CA 1.445 -0.701 0 C-N-CA 128.592 2.757 . . . . 0.0 115.272 165.544 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' HIS . . . . . 0.487 ' CD2' HG22 ' A' ' 49' ' ' THR . 3.6 p-80 -135.49 62.38 1.63 Allowed 'General case' 0 C--O 1.234 0.284 0 C-N-CA 127.832 2.453 . . . . 0.0 109.933 -171.632 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.8 p80 -85.43 155.74 21.14 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 129.984 3.314 . . . . 0.0 107.331 170.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 61.8 m80 -137.43 -30.31 0.85 Allowed 'General case' 0 N--CA 1.445 -0.69 0 C-N-CA 128.863 2.865 . . . . 0.0 114.768 177.197 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 16.9 p80 -126.71 144.9 50.79 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 129.181 2.993 . . . . 0.0 113.861 179.105 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -66.31 -28.77 68.94 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 120.723 3.601 . . . . 0.0 120.723 -175.511 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.4 p -66.46 132.7 48.85 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 122.187 2.267 . . . . 0.0 114.974 166.7 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 55.5 pttt -124.21 144.28 45.09 Favored Pre-proline 0 N--CA 1.451 -0.409 0 C-N-CA 126.955 2.102 . . . . 0.0 111.721 -176.577 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -92.53 176.26 1.73 Allowed 'Trans proline' 0 N--CA 1.447 -1.255 0 C-N-CA 123.72 2.947 . . . . 0.0 108.986 168.633 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -114.59 161.97 26.0 Favored Pre-proline 0 N--CA 1.447 -0.578 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_exo -52.06 166.78 0.59 Allowed 'Trans proline' 0 N--CA 1.444 -1.394 0 N-CA-C 115.806 1.425 . . . . 0.0 115.806 170.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.7 t -133.95 149.75 51.27 Favored 'General case' 0 N--CA 1.447 -0.59 0 O-C-N 120.306 -1.496 . . . . 0.0 107.971 160.493 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -47.99 -33.1 7.36 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 130.477 3.511 . . . . 0.0 111.406 164.707 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -67.43 -19.8 65.42 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 75.0 m-70 -141.32 14.91 2.21 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 117.321 2.341 . . . . 0.0 117.321 -159.25 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.1 t -141.49 126.31 18.11 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 176.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 65.4 m-85 -150.88 158.0 43.6 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 130.01 3.324 . . . . 0.0 108.882 -161.205 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -133.32 148.68 51.91 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 118.343 2.72 . . . . 0.0 118.343 -175.567 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -145.27 146.13 31.54 Favored 'General case' 0 C--O 1.221 -0.408 0 N-CA-C 119.917 3.302 . . . . 0.0 119.917 171.138 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.44 178.83 28.37 Favored Glycine 0 C--N 1.342 0.863 0 C-N-CA 125.457 1.503 . . . . 0.0 114.899 173.207 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -59.28 -32.33 69.92 Favored 'General case' 0 C--O 1.239 0.552 0 O-C-N 117.994 -3.063 . . . . 0.0 117.296 176.401 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.39 10.06 2.94 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 125.342 1.449 . . . . 0.0 115.795 170.187 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.424 ' HG ' ' CG ' ' A' ' 36' ' ' PHE . 89.6 mt -124.38 30.52 6.01 Favored 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 118.829 -2.571 . . . . 0.0 112.754 154.716 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 95.4 t -138.86 -63.05 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 O-C-N 120.111 -1.618 . . . . 0.0 109.683 175.277 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.292 37.2 pttt -144.65 131.83 20.57 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 123.122 2.692 . . . . 0.0 115.128 -173.111 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 t -130.78 146.76 33.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 1 O-C-N 129.176 4.048 . . . . 0.0 112.386 -174.366 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.492 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 3.9 m-85 -140.1 179.77 6.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 116.84 2.163 . . . . 0.0 116.84 177.137 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -82.36 -39.93 22.07 Favored 'General case' 0 C--O 1.235 0.341 0 O-C-N 116.818 -3.676 . . . . 0.0 113.538 -168.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 15.6 m-80 -105.81 3.42 28.72 Favored 'General case' 0 N--CA 1.449 -0.522 0 O-C-N 126.379 2.3 . . . . 0.0 112.907 178.323 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -128.77 89.64 48.49 Favored Pre-proline 0 N--CA 1.447 -0.599 0 O-C-N 121.693 -0.629 . . . . 0.0 110.731 175.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_endo -65.97 147.59 84.87 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 O-C-N 125.843 2.496 . . . . 0.0 110.576 -178.692 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.21 164.77 12.01 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 126.426 1.89 . . . . 0.0 111.305 -177.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.405 ' HG2' HG22 ' A' ' 82' ' ' VAL . 19.3 mt-10 -140.34 146.0 37.89 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 115.616 -2.135 . . . . 0.0 112.748 -175.097 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.424 ' CG ' ' HG ' ' A' ' 25' ' ' LEU . 24.6 p90 -153.52 167.39 29.64 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 122.858 2.572 . . . . 0.0 107.49 171.638 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 94.7 m -127.46 115.6 19.14 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.262 1.425 . . . . 0.0 109.012 -156.005 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . 0.405 8.4 mt -67.06 96.91 0.29 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.22 0 C-N-CA 125.529 1.532 . . . . 0.0 112.044 162.717 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -83.49 112.43 19.96 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-O 125.086 2.374 . . . . 0.0 111.942 166.321 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -114.97 126.94 55.35 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 116.496 -3.878 . . . . 0.0 110.259 -167.402 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.416 HG22 ' HA ' ' A' ' 47' ' ' ALA . 54.4 t -127.62 149.43 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-O 123.967 1.841 . . . . 0.0 106.894 173.563 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -80.86 -37.57 29.67 Favored 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 117.162 2.282 . . . . 0.0 117.162 169.584 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 82.7 p -160.0 -69.94 0.07 Allowed 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 127.048 2.717 . . . . 0.0 116.907 -170.452 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 50.6 mttm -127.98 99.13 5.38 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 122.282 2.31 . . . . 0.0 113.253 -174.01 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 76.37 -75.32 1.6 Allowed Glycine 0 CA--C 1.525 0.661 0 CA-C-N 121.995 2.18 . . . . 0.0 114.915 159.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 65.5 t -46.66 129.03 2.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 126.624 1.97 . . . . 0.0 107.005 171.157 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.416 ' HA ' HG22 ' A' ' 41' ' ' VAL . . . -58.81 171.23 0.68 Allowed 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 116.661 2.097 . . . . 0.0 116.661 177.088 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.3 mmm180 -64.22 116.06 5.63 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 115.598 -2.144 . . . . 0.0 106.28 165.273 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.487 HG22 ' CD2' ' A' ' 4' ' ' HIS . 23.7 p -76.63 4.6 9.07 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 127.762 3.164 . . . . 0.0 116.604 -160.45 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -168.4 163.06 12.69 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-O 125.338 2.494 . . . . 0.0 108.314 -173.697 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -103.17 -169.5 25.98 Favored Glycine 0 CA--C 1.524 0.646 0 O-C-N 118.064 -2.898 . . . . 0.0 113.61 -150.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 62.24 22.08 62.67 Favored Glycine 0 C--N 1.335 0.475 0 CA-C-O 113.854 -3.748 . . . . 0.0 117.952 169.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -69.09 153.59 95.89 Favored Pre-proline 0 N--CA 1.452 -0.363 0 CA-C-N 124.15 3.975 . . . . 0.0 110.253 173.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -88.03 133.08 2.87 Favored 'Trans proline' 0 N--CA 1.447 -1.264 1 C-N-CA 127.091 5.194 . . . . 0.0 118.388 -172.366 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -148.8 167.12 26.47 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 113.174 -1.83 . . . . 0.0 110.37 -156.656 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -161.96 141.76 10.01 Favored 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 129.021 2.928 . . . . 0.0 107.241 174.319 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 20.2 t -132.14 96.04 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 C-N-CA 130.769 3.628 . . . . 0.0 103.917 -178.652 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -116.16 140.36 49.38 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 112.236 -2.257 . . . . 0.0 110.016 -168.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 58.5 mt -134.82 148.84 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 CA-C-N 113.754 -1.567 . . . . 0.0 110.041 -159.229 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 54.2 m-80 -126.67 151.5 47.99 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 104.693 -2.336 . . . . 0.0 104.693 165.05 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.0 -145.72 4.72 Favored Glycine 0 C--O 1.219 -0.819 0 N-CA-C 107.613 -2.195 . . . . 0.0 107.613 173.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -75.02 133.65 16.82 Favored 'Trans proline' 0 N--CA 1.45 -1.029 0 CA-C-O 124.496 1.79 . . . . 0.0 111.746 -172.316 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.31 15.1 t70 48.74 -125.31 1.95 Allowed 'General case' 0 N--CA 1.45 -0.444 0 O-C-N 117.608 -3.182 . . . . 0.0 113.669 -172.068 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -80.93 4.76 68.62 Favored Glycine 0 CA--C 1.532 1.105 0 C-N-CA 127.021 2.248 . . . . 0.0 115.086 -170.465 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . 0.273 19.9 tp -72.93 104.34 4.04 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 114.792 1.404 . . . . 0.0 114.792 -177.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 99.0 t -116.3 135.01 57.91 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-O 123.295 1.521 . . . . 0.0 107.023 175.108 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 24.4 t -140.36 151.53 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.993 0 C-N-CA 125.21 1.404 . . . . 0.0 111.735 -168.753 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.256 8.3 p-10 -135.72 122.55 21.15 Favored 'General case' 0 C--N 1.326 -0.429 0 O-C-N 127.532 3.02 . . . . 0.0 109.791 167.834 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -74.75 151.08 39.19 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 128.586 2.754 . . . . 0.0 114.828 -178.173 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 66.3 tttt -93.73 98.75 11.31 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 114.369 -1.287 . . . . 0.0 111.376 -160.598 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.1 t -88.64 133.24 31.49 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.117 0 O-C-N 125.678 1.861 . . . . 0.0 106.451 -170.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 26.3 m -144.4 126.48 15.53 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 118.574 -1.25 . . . . 0.0 109.353 172.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -48.56 120.84 3.99 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 128.534 2.734 . . . . 0.0 118.283 166.589 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 -84.55 1.16 47.13 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 114.256 -2.783 . . . . 0.0 112.613 178.747 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 9.3 m120 61.29 24.24 14.37 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 117.556 2.428 . . . . 0.0 117.556 -177.267 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 19.8 p30 -134.55 -6.28 2.53 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 115.487 1.662 . . . . 0.0 115.487 -177.584 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 112.61 0.79 26.08 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 114.836 -3.202 . . . . 0.0 114.586 -166.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 66.0 p -131.74 160.46 35.47 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 120.407 2.103 . . . . 0.0 113.529 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -123.79 127.63 48.38 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 117.866 -3.021 . . . . 0.0 110.362 173.746 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -80.6 116.35 4.22 Favored Glycine 0 CA--C 1.526 0.755 0 C-N-CA 129.246 3.308 . . . . 0.0 106.103 171.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.7 t -102.14 125.34 56.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 117.194 2.294 . . . . 0.0 117.194 165.338 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.405 HG22 ' HG2' ' A' ' 35' ' ' GLU . 87.6 t -125.79 145.79 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-N 121.906 2.139 . . . . 0.0 111.762 -173.666 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . 0.343 1.2 p90 -165.93 172.63 11.33 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 122.849 2.568 . . . . 0.0 114.524 179.513 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 19.8 p30 -135.33 169.48 17.41 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -177.037 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -132.88 109.64 13.02 Favored Pre-proline 0 N--CA 1.447 -0.604 0 N-CA-C 114.752 1.389 . . . . 0.0 114.752 179.184 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.288 68.8 Cg_endo -71.88 -2.63 11.78 Favored 'Trans proline' 0 N--CA 1.449 -1.14 0 C-N-CA 124.702 3.601 . . . . 0.0 111.366 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.8 m -138.66 144.71 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.634 0 CA-C-O 121.653 0.739 . . . . 0.0 111.961 -163.05 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -63.29 127.52 31.66 Favored 'General case' 0 N--CA 1.451 -0.423 0 O-C-N 119.361 -2.087 . . . . 0.0 109.956 153.019 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 167.39 -166.37 39.24 Favored Glycine 0 CA--C 1.521 0.444 0 CA-C-O 123.756 1.753 . . . . 0.0 116.289 -172.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 11.1 t30 -114.48 139.71 49.32 Favored 'General case' 0 C--O 1.22 -0.487 0 CA-C-N 111.295 -2.452 . . . . 0.0 111.908 164.234 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' TYR . . . . . 0.415 ' CD2' ' SG ' ' A' ' 111' ' ' CYS . 10.1 m-85 -98.57 152.04 20.01 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 127.518 3.532 . . . . 0.0 112.494 152.269 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -129.08 109.07 10.88 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 109.806 -3.361 . . . . 0.0 108.164 -174.567 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 87.0 t -101.32 129.08 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 113.155 -1.839 . . . . 0.0 108.403 -163.738 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -131.15 130.52 43.16 Favored 'General case' 0 N--CA 1.449 -0.509 0 O-C-N 126.445 2.341 . . . . 0.0 110.889 176.385 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 99.6 t -112.74 147.13 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.741 0 N-CA-C 114.67 1.359 . . . . 0.0 114.67 -177.332 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 31.4 p -142.89 162.54 35.19 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 120.792 1.633 . . . . 0.0 111.597 175.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 3.0 tt -144.51 101.26 3.66 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 -147.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 28.8 ttm-85 47.51 42.01 13.92 Favored 'General case' 0 N--CA 1.445 -0.684 0 O-C-N 124.625 1.203 . . . . 0.0 108.324 -163.689 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 85.48 2.75 87.11 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 128.791 3.091 . . . . 0.0 120.077 177.129 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.409 ' HA ' ' HD3' ' A' ' 101' ' ' PRO . 84.2 m-20 -115.58 147.84 39.72 Favored Pre-proline 0 CA--C 1.514 -0.425 0 C-N-CA 125.881 1.672 . . . . 0.0 113.243 -176.73 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 100' ' ' ASN . 58.4 Cg_endo -74.15 163.04 37.52 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 124.755 3.637 . . . . 0.0 111.138 -177.485 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 10.7 pt -140.82 175.09 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 126.219 1.807 . . . . 0.0 112.699 -165.55 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -82.28 164.08 21.39 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 120.832 1.651 . . . . 0.0 113.915 -170.331 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 29.7 m120 53.97 40.15 31.28 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 127.403 2.281 . . . . 0.0 116.772 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 8.7 mmt -126.25 168.96 12.71 Favored Pre-proline 0 N--CA 1.45 -0.462 0 C-N-CA 126.993 2.117 . . . . 0.0 107.376 -170.538 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -65.67 168.66 14.47 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 N-CA-C 117.453 2.059 . . . . 0.0 117.453 -33.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . 0.372 17.1 pt -138.54 140.05 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-O 122.71 1.243 . . . . 0.0 109.202 -168.631 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -107.93 139.16 42.97 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 117.526 2.417 . . . . 0.0 117.526 -168.553 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 66.1 t -146.53 114.88 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.762 0 O-C-N 119.783 -1.823 . . . . 0.0 109.395 -161.442 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 68.2 tttt -80.51 144.26 32.65 Favored 'General case' 0 CA--C 1.523 -0.093 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.415 ' SG ' ' CD2' ' A' ' 91' ' ' TYR . 87.7 m -117.14 139.08 51.19 Favored 'General case' 0 N--CA 1.451 -0.42 2 O-C-N 131.991 5.807 . . . . 0.0 110.233 -179.984 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.492 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 90.9 mt -135.04 123.37 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-N 108.469 -3.969 . . . . 0.0 113.361 171.617 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' GLU . . . . . 0.413 ' HG2' ' H ' ' A' ' 113' ' ' GLU 0.3 7.5 pt-20 -76.23 39.97 0.2 Allowed 'General case' 0 N--CA 1.451 -0.395 0 O-C-N 116.947 -3.595 . . . . 0.0 115.332 -164.646 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.626 0 CA-C-N 121.457 1.935 . . . . 0.0 115.585 169.728 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 tmt? . . . . . 0 CA--C 1.511 -0.553 0 CA-C-O 114.64 -2.6 . . . . 0.0 110.155 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 77.6 t60 -136.88 132.9 35.17 Favored 'General case' 0 C--N 1.34 0.185 0 CA-C-N 122.358 2.344 . . . . 0.0 106.355 175.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -80.15 113.27 18.2 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 126.273 2.939 . . . . 0.0 110.208 165.454 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 56.6 t-80 -157.99 129.17 6.57 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 112.196 -2.275 . . . . 0.0 116.255 177.562 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.4 m-70 -73.28 114.3 11.32 Favored 'General case' 0 N--CA 1.433 -1.314 0 O-C-N 118.981 -2.324 . . . . 0.0 114.964 178.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 28.2 t-80 -80.08 -47.6 14.57 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-O 116.012 -1.946 . . . . 0.0 112.86 174.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 72.5 m-70 -122.51 173.87 7.4 Favored 'General case' 0 N--CA 1.453 -0.288 0 O-C-N 127.741 3.15 . . . . 0.0 115.031 177.655 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -68.1 -33.55 74.74 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 116.815 2.154 . . . . 0.0 116.815 158.484 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.2 p -68.54 149.36 49.3 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 115.772 1.767 . . . . 0.0 115.772 160.195 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 31.9 pttt -161.18 154.49 18.05 Favored Pre-proline 0 N--CA 1.443 -0.819 0 C-N-CA 126.772 2.029 . . . . 0.0 115.756 179.694 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -69.3 168.6 20.48 Favored 'Trans proline' 0 N--CA 1.439 -1.703 0 C-N-CA 124.394 3.396 . . . . 0.0 111.313 176.239 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -111.53 136.83 21.03 Favored Pre-proline 0 C--O 1.239 0.538 0 C-N-CA 131.116 3.767 . . . . 0.0 114.187 -176.332 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . 0.252 23.3 Cg_exo -65.58 168.78 14.04 Favored 'Trans proline' 0 CA--C 1.514 -0.49 0 N-CA-C 117.498 2.076 . . . . 0.0 117.498 170.63 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.6 m -142.88 160.85 39.55 Favored 'General case' 0 N--CA 1.44 -0.958 0 CA-C-N 123.317 2.78 . . . . 0.0 110.937 -174.623 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.44 -48.43 81.68 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 113.597 -3.097 . . . . 0.0 113.861 174.638 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -52.64 -28.32 20.95 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 123.06 2.663 . . . . 0.0 106.773 173.005 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 26.2 m170 -117.37 5.86 12.61 Favored 'General case' 0 C--O 1.218 -0.603 0 N-CA-C 116.525 2.046 . . . . 0.0 116.525 -156.658 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.8 t -135.14 121.86 20.88 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 116.816 2.154 . . . . 0.0 116.816 173.795 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 26.6 m-85 -153.31 155.19 36.02 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -161.109 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . 0.462 . . -132.01 147.92 52.48 Favored 'General case' 0 C--O 1.217 -0.61 0 N-CA-C 117.85 2.537 . . . . 0.0 117.85 -167.36 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -160.96 145.95 14.08 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 130.125 3.37 . . . . 0.0 108.736 -164.486 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.1 175.21 13.94 Favored Glycine 0 N--CA 1.446 -0.696 0 O-C-N 126.99 2.681 . . . . 0.0 117.505 -173.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -74.03 -30.21 62.31 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 112.652 -3.547 . . . . 0.0 113.715 -176.139 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -62.23 9.82 0.12 Allowed Glycine 0 CA--C 1.531 1.047 0 CA-C-N 124.945 3.52 . . . . 0.0 115.371 161.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 17.0 mt -113.9 19.85 16.25 Favored 'General case' 0 C--O 1.223 -0.312 0 CA-C-N 122.023 2.911 . . . . 0.0 109.799 167.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 1.7 t -137.97 -41.75 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 CA-C-O 115.313 -2.28 . . . . 0.0 110.312 174.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 42.4 mtmt -155.74 118.09 4.14 Favored 'General case' 0 C--N 1.328 -0.367 0 O-C-N 124.685 1.241 . . . . 0.0 114.096 -163.051 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 t -124.7 138.69 53.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 C-N-CA 130.853 3.661 . . . . 0.0 116.188 177.772 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 27.3 m-85 -128.78 -169.82 2.15 Favored 'General case' 0 N--CA 1.452 -0.358 0 O-C-N 126.552 2.408 . . . . 0.0 115.434 -174.755 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 17.7 t0 -105.17 -33.29 8.31 Favored 'General case' 0 CA--C 1.511 -0.541 0 O-C-N 118.278 -2.764 . . . . 0.0 114.212 -167.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 53.8 m-80 -101.83 8.73 41.22 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 120.511 3.523 . . . . 0.0 120.511 162.096 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -137.57 96.15 10.95 Favored Pre-proline 0 N--CA 1.445 -0.676 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.263 178.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_exo -62.83 128.29 22.79 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 121.883 1.722 . . . . 0.0 111.7 171.759 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -92.35 156.41 17.26 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 123.05 1.405 . . . . 0.0 109.71 -177.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -133.97 149.77 51.25 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 -169.454 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -161.64 173.27 14.95 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.194 -2.521 . . . . 0.0 104.194 168.376 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 26.1 m -127.02 118.17 23.93 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 131.53 3.932 . . . . 0.0 114.811 -158.268 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.415 ' HB ' ' HB2' ' A' ' 79' ' ' TYR . 44.7 mm -76.19 96.31 1.32 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.483 0 C-N-CA 127.012 2.125 . . . . 0.0 106.213 173.571 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -81.83 99.87 9.26 Favored 'General case' 0 C--O 1.214 -0.8 0 O-C-N 119.114 -2.241 . . . . 0.0 114.87 171.164 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -100.12 137.14 38.97 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 117.807 2.521 . . . . 0.0 117.807 -167.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 71.7 t -134.94 156.45 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 C-N-CA 128.449 2.7 . . . . 0.0 113.858 169.612 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.7 p30 -76.71 -71.65 0.38 Allowed 'General case' 0 N--CA 1.448 -0.555 0 O-C-N 118.741 -2.474 . . . . 0.0 109.882 174.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 77.8 p -156.18 -39.67 0.08 Allowed 'General case' 0 C--O 1.238 0.481 1 C-N-CA 133.57 4.748 . . . . 0.0 106.86 -175.705 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 46.6 mtmt -87.65 28.43 1.0 Allowed 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 123.237 2.744 . . . . 0.0 110.755 -154.342 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 78.28 -41.56 2.05 Favored Glycine 0 N--CA 1.444 -0.807 0 O-C-N 118.27 -2.769 . . . . 0.0 115.675 169.606 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.6 t -71.21 145.11 12.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 126.178 1.791 . . . . 0.0 114.667 168.687 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -47.12 162.19 0.06 Allowed 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 114.306 -1.316 . . . . 0.0 113.882 177.827 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -64.82 113.04 3.54 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.369 174.608 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.5 p -89.11 4.86 47.04 Favored 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 131.232 3.813 . . . . 0.0 113.142 -163.832 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.9 p30 -152.49 172.69 16.17 Favored 'General case' 0 N--CA 1.446 -0.657 1 C-N-CA 133.697 4.799 . . . . 0.0 108.521 162.737 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -138.03 -175.64 14.03 Favored Glycine 0 N--CA 1.443 -0.844 0 O-C-N 118.322 -2.736 . . . . 0.0 109.797 -149.523 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.93 41.5 98.67 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 127.213 2.339 . . . . 0.0 111.503 -178.619 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -74.51 156.61 86.9 Favored Pre-proline 0 C--O 1.221 -0.405 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 167.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -87.83 135.64 3.49 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 CA-C-O 127.298 2.958 . . . . 0.0 113.632 174.349 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -147.49 151.94 37.22 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 117.994 -2.941 . . . . 0.0 110.436 -173.875 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -140.59 142.8 35.05 Favored 'General case' 0 N--CA 1.446 -0.643 0 O-C-N 118.94 -2.35 . . . . 0.0 109.924 178.649 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.522 HG22 HG22 ' A' ' 95' ' ' VAL . 19.9 t -129.58 81.79 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 C-N-CA 129.876 3.27 . . . . 0.0 106.047 178.787 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -94.65 131.9 39.95 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 113.142 -1.844 . . . . 0.0 114.793 176.249 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.7 mt -124.13 156.95 31.58 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.581 0 C-N-CA 125.782 1.633 . . . . 0.0 108.116 -163.781 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -115.28 132.85 56.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 115.508 -2.187 . . . . 0.0 114.426 144.698 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -80.52 -152.42 8.23 Favored Glycine 0 CA--C 1.532 1.118 0 O-C-N 125.709 1.881 . . . . 0.0 110.611 160.781 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_exo -82.66 122.69 3.57 Favored 'Trans proline' 0 N--CA 1.442 -1.529 0 C-N-CA 124.773 3.648 . . . . 0.0 110.806 -170.294 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 25.5 t0 30.15 -92.81 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.408 0 O-C-N 126.775 2.547 . . . . 0.0 112.632 -156.027 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.21 2.86 55.21 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 118.533 2.173 . . . . 0.0 118.533 -167.085 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . 0.264 53.4 tp -86.51 90.01 8.09 Favored 'General case' 0 C--O 1.238 0.455 0 O-C-N 119.646 -2.091 . . . . 0.0 109.02 -174.172 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 96.4 t -77.24 114.48 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 CA-C-N 110.856 -2.884 . . . . 0.0 115.422 169.11 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 20.0 t -130.34 153.21 38.66 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.797 0 O-C-N 117.895 -3.003 . . . . 0.0 115.191 -173.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.2 p-10 -130.04 138.45 50.77 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 160.636 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -90.97 149.47 21.85 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-O 125.011 2.339 . . . . 0.0 111.926 177.11 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 52.6 mmtt -93.0 115.37 28.06 Favored 'General case' 0 N--CA 1.445 -0.681 0 O-C-N 118.612 -2.555 . . . . 0.0 108.62 -163.311 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 36.3 t -97.1 139.26 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 CA-C-N 114.051 -1.431 . . . . 0.0 109.813 -176.09 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 59.9 m -138.97 137.34 36.3 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 127.586 2.354 . . . . 0.0 113.056 174.25 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -73.05 128.68 36.19 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 126.132 1.773 . . . . 0.0 109.924 177.294 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 67.5 m-20 -90.16 -1.38 57.93 Favored 'General case' 0 C--O 1.221 -0.401 0 CA-C-O 115.722 -2.085 . . . . 0.0 115.3 175.034 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 1.7 m120 70.6 24.52 4.4 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 123.797 2.998 . . . . 0.0 111.553 167.632 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 38.0 p30 -139.27 -7.17 1.35 Allowed 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 121.582 3.919 . . . . 0.0 121.582 179.149 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 130.89 -13.2 5.56 Favored Glycine 0 C--O 1.242 0.628 0 CA-C-O 123.228 1.46 . . . . 0.0 112.967 -177.216 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.6 p -128.22 164.64 22.09 Favored 'General case' 0 C--O 1.24 0.586 0 C-N-CA 127.696 2.398 . . . . 0.0 113.472 -171.053 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.415 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 11.7 m-85 -128.49 147.76 50.7 Favored 'General case' 0 C--N 1.329 -0.291 0 O-C-N 125.308 1.63 . . . . 0.0 107.641 174.621 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -94.38 132.18 11.05 Favored Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 128.761 3.077 . . . . 0.0 111.183 173.201 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.9 t -128.07 138.62 54.17 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 CA-C-O 117.401 -1.285 . . . . 0.0 113.036 178.773 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.9 t -141.91 130.94 22.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 O-C-N 124.783 1.302 . . . . 0.0 112.695 -167.555 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -161.15 138.14 8.79 Favored 'General case' 0 CA--C 1.517 -0.313 0 CA-C-O 124.35 2.024 . . . . 0.0 111.859 -174.436 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.267 57.4 p-10 -109.88 160.9 15.98 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 129.227 3.011 . . . . 0.0 112.829 175.396 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -130.15 109.87 16.67 Favored Pre-proline 0 N--CA 1.443 -0.776 0 C-N-CA 126.508 1.923 . . . . 0.0 109.754 -167.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -70.5 -6.41 18.91 Favored 'Trans proline' 0 N--CA 1.445 -1.341 0 C-N-CA 122.072 1.848 . . . . 0.0 114.906 -179.31 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.5 m -149.68 147.14 16.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 O-C-N 118.126 -2.859 . . . . 0.0 114.737 -151.673 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 112' ' ' ILE . 28.7 tt0 -62.95 102.95 0.4 Allowed 'General case' 0 C--O 1.241 0.607 0 CA-C-O 123.35 1.548 . . . . 0.0 108.848 167.071 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -177.91 -136.62 2.55 Favored Glycine 0 N--CA 1.434 -1.488 1 O-C-N 116.288 -4.007 . . . . 0.0 122.784 178.098 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 25.8 t30 -132.36 137.04 47.23 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 130.18 3.392 . . . . 0.0 110.552 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 13.6 m-85 -106.75 151.9 24.53 Favored 'General case' 0 N--CA 1.446 -0.671 0 O-C-N 124.502 1.126 . . . . 0.0 112.75 151.744 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -119.77 116.52 26.08 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 110.894 -2.866 . . . . 0.0 112.213 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 3.3 t -112.33 126.02 69.67 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.966 0 N-CA-C 115.507 1.669 . . . . 0.0 115.507 -162.442 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -136.53 118.96 15.76 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 115.452 -2.213 . . . . 0.0 110.312 -168.183 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.522 HG22 HG22 ' A' ' 57' ' ' VAL . 67.3 t -119.24 144.41 27.71 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.473 0 CA-C-N 120.515 1.507 . . . . 0.0 108.625 -174.453 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 33.0 p -135.36 153.06 51.96 Favored 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 127.086 2.154 . . . . 0.0 110.619 -177.274 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.5 mp -126.14 91.65 3.42 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-O 112.702 -3.523 . . . . 0.0 112.673 -161.262 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.1 ttm180 55.92 35.27 25.17 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 124.744 2.211 . . . . 0.0 110.307 -159.239 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 75.32 0.91 63.05 Favored Glycine 0 CA--C 1.533 1.195 0 O-C-N 117.793 -3.067 . . . . 0.0 117.918 -177.441 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 63.8 m-80 -78.51 134.14 62.33 Favored Pre-proline 0 N--CA 1.448 -0.539 0 O-C-N 120.525 -1.573 . . . . 0.0 112.013 168.434 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -87.76 178.52 3.22 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 123.904 3.07 . . . . 0.0 104.968 -177.456 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 19.2 pt -152.82 177.32 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 O-C-N 120.169 -1.582 . . . . 0.0 112.761 -172.424 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 13.3 ptmt -86.86 170.97 11.19 Favored 'General case' 0 N--CA 1.442 -0.874 0 C-N-CA 128.28 2.632 . . . . 0.0 117.91 -168.161 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 10.3 m120 53.43 32.89 14.76 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 129.512 3.125 . . . . 0.0 113.878 -177.74 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' MET . . . . . 0.571 ' HG3' ' HA ' ' A' ' 106' ' ' PRO . 2.9 ttm -146.34 145.54 24.3 Favored Pre-proline 0 C--O 1.246 0.897 0 O-C-N 116.69 -3.757 . . . . 0.0 111.486 -158.501 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.571 ' HA ' ' HG3' ' A' ' 105' ' ' MET 0.3 10.1 Cg_endo -54.45 159.14 15.31 Favored 'Cis proline' 0 N--CA 1.443 -1.462 0 CA-C-N 125.002 2.822 . . . . 0.0 116.343 -13.625 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 13.4 pt -126.76 158.19 37.43 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 C-N-CA 130.38 3.472 . . . . 0.0 110.058 175.27 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -114.52 143.92 44.19 Favored 'General case' 0 CA--C 1.503 -0.833 0 N-CA-C 117.033 2.234 . . . . 0.0 117.033 -176.477 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 60.8 t -139.24 117.64 12.38 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 CA-C-O 117.087 -1.435 . . . . 0.0 110.318 -174.276 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . 0.25 32.6 ttpt -64.62 133.49 52.36 Favored 'General case' 0 N--CA 1.443 -0.797 0 C-N-CA 127.813 2.445 . . . . 0.0 113.66 -179.026 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 72.2 m -117.95 156.47 28.44 Favored 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 127.929 2.491 . . . . 0.0 112.492 -177.781 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 7.7 tt -155.27 156.64 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 114.776 1.399 . . . . 0.0 114.776 158.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . 0.316 5.0 pt-20 -62.51 43.44 0.01 OUTLIER 'General case' 0 N--CA 1.444 -0.769 0 C-N-CA 127.149 2.18 . . . . 0.0 116.879 173.372 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.676 0 N-CA-C 118.634 2.214 . . . . 0.0 118.634 179.939 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.1 tmt? . . . . . 0 N--CA 1.474 0.756 0 CA-C-O 117.066 -1.445 . . . . 0.0 108.599 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 72.9 t60 -116.33 130.95 57.04 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-N 120.819 1.645 . . . . 0.0 112.262 -170.739 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 9.4 t60 -97.85 119.51 36.58 Favored 'General case' 0 C--N 1.333 -0.133 0 N-CA-C 105.908 -1.886 . . . . 0.0 105.908 174.549 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 38.1 t-80 -160.44 135.58 7.88 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 127.325 2.25 . . . . 0.0 110.415 173.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 80.8 m80 -71.07 95.82 1.26 Allowed 'General case' 0 N--CA 1.453 -0.301 0 CA-C-O 125.946 2.784 . . . . 0.0 112.846 165.635 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 69.7 m80 -85.35 -22.38 28.48 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 119.231 -2.168 . . . . 0.0 114.65 172.027 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 67.3 m80 -141.34 166.3 25.14 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -162.434 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -74.97 -54.18 7.66 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 115.116 1.524 . . . . 0.0 115.116 164.212 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 65.8 m -68.37 135.07 51.22 Favored 'General case' 0 N--CA 1.455 -0.206 0 O-C-N 118.04 -2.912 . . . . 0.0 113.234 171.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LYS . . . . . 0.429 ' HB2' ' HE3' ' A' ' 10' ' ' LYS . 28.8 mtmt -127.88 149.23 70.15 Favored Pre-proline 0 N--CA 1.45 -0.46 0 O-C-N 118.326 -2.734 . . . . 0.0 108.986 179.657 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -70.1 156.85 61.48 Favored 'Trans proline' 0 N--CA 1.451 -0.98 0 N-CA-C 118.05 2.288 . . . . 0.0 118.05 156.371 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -93.21 147.53 33.95 Favored Pre-proline 0 N--CA 1.45 -0.467 0 O-C-N 125.645 1.84 . . . . 0.0 114.414 -178.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -57.43 154.15 37.16 Favored 'Trans proline' 0 N--CA 1.449 -1.145 1 C-N-CA 127.224 5.283 . . . . 0.0 114.584 152.654 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 34.2 t -140.28 176.57 8.66 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 121.765 2.075 . . . . 0.0 113.579 -178.12 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . 0.296 . . -65.88 -48.23 72.21 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 129.935 3.294 . . . . 0.0 115.959 -173.223 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.0 mp0 -54.71 -28.18 46.12 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 111.231 -2.713 . . . . 0.0 113.458 166.218 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 31.4 m-70 -133.2 7.48 3.94 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-O 125.518 2.58 . . . . 0.0 112.928 -148.003 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . 0.268 29.2 t -125.46 114.04 18.29 Favored 'General case' 0 N--CA 1.45 -0.468 0 O-C-N 116.35 -3.969 . . . . 0.0 107.478 169.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . 0.265 75.6 m-85 -130.62 160.98 32.61 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 129.192 2.997 . . . . 0.0 108.195 174.449 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -137.85 151.16 47.79 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 127.63 2.372 . . . . 0.0 115.344 -169.112 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -154.39 137.14 15.26 Favored 'General case' 0 N--CA 1.452 -0.363 1 O-C-N 116.023 -4.173 . . . . 0.0 114.787 -165.589 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.36 -175.09 19.76 Favored Glycine 0 C--O 1.222 -0.636 0 C-N-CA 126.412 1.958 . . . . 0.0 108.514 160.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.2 tt0 -68.6 -22.78 64.43 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-O 114.725 -2.559 . . . . 0.0 113.714 -158.629 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -56.25 -0.14 0.17 Allowed Glycine 0 N--CA 1.443 -0.841 0 CA-C-O 115.247 -2.974 . . . . 0.0 117.829 161.731 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 23.8 mt -121.72 24.27 9.8 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 127.658 2.383 . . . . 0.0 114.729 168.111 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.8 t -142.96 -47.03 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 CA-C-O 114.976 -2.44 . . . . 0.0 107.7 -172.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 28.4 ttmt -172.47 139.54 0.99 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 115.36 -2.257 . . . . 0.0 112.279 -177.826 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 34.2 t -144.97 142.45 22.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 115.168 -2.348 . . . . 0.0 113.938 -166.384 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.427 ' HB2' ' HB3' ' A' ' 32' ' ' ALA 0.278 1.2 m-85 -129.6 177.53 7.15 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 125.381 1.676 . . . . 0.0 114.413 -166.283 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -94.86 -37.89 10.99 Favored 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 116.515 2.043 . . . . 0.0 116.515 -178.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 55.9 m-80 -102.52 19.48 18.9 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 115.975 1.843 . . . . 0.0 115.975 165.336 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.427 ' HB3' ' HB2' ' A' ' 29' ' ' PHE . . . -139.3 92.72 10.42 Favored Pre-proline 0 N--CA 1.455 -0.19 0 C-N-CA 126.1 1.76 . . . . 0.0 106.57 171.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . 0.324 74.9 Cg_exo -43.71 119.84 2.04 Favored 'Trans proline' 0 N--CA 1.449 -1.134 1 C-N-CA 129.854 7.036 . . . . 0.0 112.019 148.309 . . . . . . . . 3 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.418 ' O ' ' HA ' ' A' ' 82' ' ' VAL . . . -96.81 150.81 20.3 Favored 'General case' 0 N--CA 1.45 -0.457 0 C-N-CA 128.504 2.722 . . . . 0.0 111.116 -178.477 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -121.54 137.73 54.61 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-O 115.119 -2.372 . . . . 0.0 114.363 -173.109 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -154.53 172.17 18.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 CA-C-N 125.202 3.637 . . . . 0.0 107.723 164.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 55.5 m -138.0 129.6 28.09 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-O 115.947 -1.977 . . . . 0.0 111.533 -157.044 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 16.1 mt -89.57 124.01 42.07 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 O-C-N 125.928 2.018 . . . . 0.0 107.114 171.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.277 39.2 p90 -99.26 115.95 30.32 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 128.471 2.709 . . . . 0.0 112.232 170.291 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -116.46 129.74 56.38 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-O 123.716 1.722 . . . . 0.0 110.112 -161.401 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.6 t -125.03 151.41 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 C-N-CA 126.934 2.094 . . . . 0.0 113.816 163.456 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.9 p30 -77.05 -72.56 0.34 Allowed 'General case' 0 N--CA 1.443 -0.784 0 CA-C-O 125.193 2.425 . . . . 0.0 116.464 170.607 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 16.0 p -159.54 -28.24 0.07 Allowed 'General case' 0 CA--C 1.517 -0.293 1 C-N-CA 133.774 4.829 . . . . 0.0 112.239 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . 0.393 84.3 mttt -94.4 13.92 22.22 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 123.015 2.643 . . . . 0.0 115.89 -170.414 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 79.8 -33.72 2.13 Favored Glycine 0 CA--C 1.523 0.556 0 O-C-N 118.164 -2.835 . . . . 0.0 112.542 164.891 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 71.1 t -54.99 133.41 18.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 1 CA-C-N 125.402 4.601 . . . . 0.0 112.22 155.541 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.53 166.74 0.05 OUTLIER 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 117.399 2.37 . . . . 0.0 117.399 169.43 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 8.4 mmm180 -53.86 120.03 5.77 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 176.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 34.8 p -88.19 -4.82 58.67 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 125.077 1.351 . . . . 0.0 110.914 -160.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -165.19 160.47 18.59 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 127.83 2.452 . . . . 0.0 108.998 -169.772 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -106.59 -162.38 22.38 Favored Glycine 0 N--CA 1.444 -0.826 0 O-C-N 126.839 2.587 . . . . 0.0 116.641 -158.253 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 48.91 44.07 31.36 Favored Glycine 0 C--O 1.222 -0.616 0 C-N-CA 128.359 2.885 . . . . 0.0 113.957 174.764 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -78.02 141.06 62.6 Favored Pre-proline 0 N--CA 1.451 -0.395 0 O-C-N 119.347 -2.266 . . . . 0.0 109.538 159.111 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -90.92 132.24 1.57 Allowed 'Trans proline' 0 N--CA 1.442 -1.55 0 N-CA-C 121.234 3.513 . . . . 0.0 121.234 -171.675 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -136.68 149.72 48.08 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 113.053 0.76 . . . . 0.0 113.053 -151.083 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -134.4 145.23 48.73 Favored 'General case' 0 N--CA 1.442 -0.836 0 O-C-N 127.73 3.144 . . . . 0.0 106.457 168.265 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 40.6 t -126.46 99.47 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 102.598 -3.112 . . . . 0.0 102.598 163.46 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -109.57 137.0 48.04 Favored 'General case' 0 N--CA 1.442 -0.842 0 O-C-N 126.253 2.22 . . . . 0.0 113.662 -171.247 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 84.2 mt -140.21 148.33 22.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 114.996 1.48 . . . . 0.0 114.996 -157.103 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.6 m120 -122.26 144.4 49.01 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 127.257 2.223 . . . . 0.0 107.512 166.579 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -124.59 -163.92 11.79 Favored Glycine 0 C--N 1.337 0.632 0 C-N-CA 127.272 2.368 . . . . 0.0 109.302 161.822 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -56.59 133.17 56.28 Favored 'Trans proline' 0 N--CA 1.448 -1.147 1 C-N-CA 129.824 7.016 . . . . 0.0 116.322 178.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.271 42.1 t0 58.14 -112.24 0.63 Allowed 'General case' 0 N--CA 1.443 -0.806 1 O-C-N 116.136 -4.102 . . . . 0.0 110.665 179.622 . . . . . . . . 3 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -91.9 -5.92 65.82 Favored Glycine 0 CA--C 1.518 0.239 0 O-C-N 119.358 -2.089 . . . . 0.0 116.761 -174.734 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 31.6 tp -67.69 100.97 0.96 Allowed 'General case' 0 N--CA 1.448 -0.547 0 O-C-N 117.442 -3.387 . . . . 0.0 114.144 -176.621 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.8 t -106.07 134.16 48.43 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 CA-C-N 110.867 -2.878 . . . . 0.0 110.422 169.817 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 55.8 t -132.6 155.57 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 N-CA-C 115.515 1.672 . . . . 0.0 115.515 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.254 6.4 p-10 -129.87 123.38 30.67 Favored 'General case' 0 N--CA 1.44 -0.944 1 CA-C-O 128.993 4.235 . . . . 0.0 108.7 168.582 . . . . . . . . 3 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.21 131.17 34.3 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-O 127.459 3.504 . . . . 0.0 110.486 -178.213 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 14.5 mptt -91.13 119.91 31.64 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 112.696 -2.047 . . . . 0.0 114.196 -166.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.0 t -100.29 144.92 11.8 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.371 0 C-N-CA 130.421 3.488 . . . . 0.0 112.098 -169.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . 0.26 42.3 m -154.3 136.87 15.11 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 127.233 3.397 . . . . 0.0 111.465 170.027 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.436 ' HA ' ' CD1' ' A' ' 79' ' ' TYR . 39.7 t0 -62.04 118.23 7.03 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 131.076 3.75 . . . . 0.0 109.164 179.101 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -80.04 -6.34 57.44 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-O 116.434 -1.746 . . . . 0.0 115.207 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.258 10.8 t-20 60.29 30.51 19.9 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 127.653 3.597 . . . . 0.0 114.693 -176.043 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 18.1 p30 -138.28 -1.18 1.95 Allowed 'General case' 0 C--O 1.238 0.46 0 O-C-N 117.084 -3.51 . . . . 0.0 119.116 174.513 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 104.92 1.51 42.31 Favored Glycine 0 CA--C 1.521 0.449 0 CA-C-O 116.482 -2.288 . . . . 0.0 118.44 -163.286 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 44.1 p -126.32 171.64 10.79 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 127.543 2.337 . . . . 0.0 111.635 177.642 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.436 ' CD1' ' HA ' ' A' ' 73' ' ' ASP . 46.3 m-85 -144.95 118.84 9.3 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-O 115.605 -2.141 . . . . 0.0 109.267 178.221 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.71 136.75 24.83 Favored Glycine 0 CA--C 1.524 0.629 1 C-N-CA 130.991 4.139 . . . . 0.0 111.239 175.302 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.0 t -135.29 126.63 45.76 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 CA-C-O 128.131 3.824 . . . . 0.0 107.85 -177.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.418 ' HA ' ' O ' ' A' ' 34' ' ' ALA . 3.7 p -122.11 132.15 71.62 Favored 'Isoleucine or valine' 0 C--O 1.236 0.37 0 O-C-N 118.772 -2.455 . . . . 0.0 114.021 178.149 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -158.15 168.65 26.47 Favored 'General case' 0 C--O 1.221 -0.414 0 N-CA-C 117.76 2.504 . . . . 0.0 117.76 173.084 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.427 31.9 p30 -133.7 151.82 51.73 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 123.673 1.701 . . . . 0.0 114.236 -173.187 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -119.92 118.41 31.74 Favored Pre-proline 0 N--CA 1.445 -0.682 0 O-C-N 119.867 -1.771 . . . . 0.0 109.204 -173.117 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.262 29.0 Cg_endo -83.01 4.71 6.91 Favored 'Trans proline' 0 N--CA 1.447 -1.232 1 C-N-CA 128.225 5.95 . . . . 0.0 108.756 -178.793 . . . . . . . . 3 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.9 m -132.05 138.55 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 N-CA-C 120.399 3.481 . . . . 0.0 120.399 -167.281 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -54.15 118.87 4.4 Favored 'General case' 0 N--CA 1.449 -0.512 0 O-C-N 120.157 -1.589 . . . . 0.0 107.246 137.252 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 159.96 -135.39 4.07 Favored Glycine 0 C--N 1.331 0.296 0 CA-C-N 120.334 1.425 . . . . 0.0 115.038 172.485 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 -141.36 138.87 33.35 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 127.579 2.351 . . . . 0.0 113.767 177.149 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 -99.61 149.12 23.6 Favored 'General case' 0 C--O 1.222 -0.376 0 C-N-CA 126.479 1.912 . . . . 0.0 112.52 168.198 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -137.1 114.99 11.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 103.713 -2.699 . . . . 0.0 103.713 -164.459 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.2 t -114.56 126.01 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 CA-C-N 111.186 -2.734 . . . . 0.0 109.71 -153.619 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.0 t30 -138.69 118.34 13.08 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 123.874 1.797 . . . . 0.0 106.651 -172.422 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 54.6 t -116.74 142.77 29.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 O-C-N 118.079 -2.888 . . . . 0.0 112.386 -178.381 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.4 ' C ' HD12 ' A' ' 97' ' ' LEU . 16.1 p -150.1 151.83 33.8 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 117.175 2.287 . . . . 0.0 117.175 -169.314 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.4 HD12 ' C ' ' A' ' 96' ' ' THR . 11.2 mp -135.08 87.53 2.34 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 102.861 -3.015 . . . . 0.0 102.861 -137.843 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 18.6 ttm-85 59.41 25.01 13.68 Favored 'General case' 0 N--CA 1.45 -0.466 0 O-C-N 117.322 -3.361 . . . . 0.0 108.737 -158.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 81.51 6.28 89.3 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-O 116.906 -2.052 . . . . 0.0 116.504 -175.448 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -76.0 120.9 83.74 Favored Pre-proline 0 N--CA 1.445 -0.722 0 O-C-N 125.135 1.138 . . . . 0.0 111.776 162.701 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -81.9 174.21 10.42 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 CA-C-N 121.661 1.629 . . . . 0.0 110.275 178.484 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . 0.261 27.8 pt -138.99 174.32 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 O-C-N 125.921 2.013 . . . . 0.0 113.949 -164.311 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 18.7 ptpt -72.28 166.68 21.97 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 127.895 2.478 . . . . 0.0 113.067 172.045 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 25.9 m120 50.59 32.23 6.56 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 123.173 1.464 . . . . 0.0 107.71 -179.089 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 14.6 mmt -143.31 134.11 12.43 Favored Pre-proline 0 N--CA 1.448 -0.557 1 O-C-N 115.029 -4.794 . . . . 0.0 107.661 176.42 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -86.02 171.88 39.61 Favored 'Cis proline' 0 N--CA 1.449 -1.117 0 CA-C-N 121.563 1.594 . . . . 0.0 109.853 13.633 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' ILE . . . . . 0.442 HG21 HD13 ' A' ' 107' ' ' ILE . 19.3 pt -144.33 164.69 13.78 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-O 115.055 -2.402 . . . . 0.0 115.272 -178.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -126.7 136.04 51.92 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 124.659 3.39 . . . . 0.0 113.61 -166.66 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 3.3 t -128.57 140.73 48.43 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 C-N-CA 129.151 2.98 . . . . 0.0 114.682 -173.545 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 13.2 tppt? -74.74 142.64 44.34 Favored 'General case' 0 N--CA 1.445 -0.722 0 O-C-N 123.588 0.555 . . . . 0.0 111.191 178.188 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 69.4 m -132.06 140.77 48.98 Favored 'General case' 0 N--CA 1.452 -0.331 0 N-CA-C 115.178 1.547 . . . . 0.0 115.178 177.577 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.416 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 10.4 tp -149.08 135.85 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 CA-C-O 117.33 -1.319 . . . . 0.0 112.421 170.685 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.45 39.59 0.88 Allowed 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 123.009 2.64 . . . . 0.0 116.176 -164.706 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.341 0.85 0 O-C-N 126.056 2.097 . . . . 0.0 113.468 162.486 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.1 tmm? . . . . . 0 N--CA 1.476 0.867 0 CA-C-O 117.476 -1.249 . . . . 0.0 110.514 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 78.3 t60 -93.87 98.66 11.21 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 117.581 -1.2 . . . . 0.0 111.528 -175.74 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 9.2 t60 -98.35 104.89 16.97 Favored 'General case' 0 N--CA 1.441 -0.896 0 CA-C-O 117.759 -1.115 . . . . 0.0 110.077 179.146 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 55.2 t60 -154.38 141.41 19.32 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-N 122.633 2.47 . . . . 0.0 109.747 -174.458 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.4 ' CE1' ' HB2' ' A' ' 50' ' ' ASP . 69.0 m-70 -79.17 106.5 11.25 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 117.993 -1.003 . . . . 0.0 112.064 -176.703 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 67.4 m80 -104.37 -47.78 4.02 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 124.51 1.124 . . . . 0.0 112.155 -176.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 54.2 m80 -94.25 159.48 15.11 Favored 'General case' 0 C--O 1.221 -0.438 0 C-N-CA 126.192 1.797 . . . . 0.0 113.241 -160.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -57.7 -45.03 86.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 116.37 -1.776 . . . . 0.0 113.939 172.292 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 69.0 m -129.94 154.92 46.86 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 122.797 2.544 . . . . 0.0 117.094 174.139 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 38.6 mtmt -95.88 146.86 32.06 Favored Pre-proline 0 N--CA 1.443 -0.803 0 O-C-N 118.617 -2.552 . . . . 0.0 111.309 -174.519 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -73.24 166.59 29.56 Favored 'Trans proline' 0 N--CA 1.453 -0.912 0 N-CA-C 117.296 1.998 . . . . 0.0 117.296 160.597 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -97.17 143.07 25.5 Favored Pre-proline 0 CA--C 1.519 -0.221 0 N-CA-C 118.308 2.707 . . . . 0.0 118.308 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -71.43 143.18 42.43 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 124.182 3.254 . . . . 0.0 109.839 166.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.6 m -123.25 168.76 12.04 Favored 'General case' 0 CA--C 1.516 -0.344 0 O-C-N 127.321 2.888 . . . . 0.0 111.774 -165.2 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.02 -41.09 82.68 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 115.874 1.805 . . . . 0.0 115.874 -174.185 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 56.4 mp0 -68.2 -16.94 64.18 Favored 'General case' 0 C--O 1.22 -0.453 0 C-N-CA 127.39 2.276 . . . . 0.0 112.873 173.416 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 86.1 m-70 -127.7 13.29 6.92 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 120.91 -1.119 . . . . 0.0 110.898 -154.455 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 9.1 t -135.45 122.82 21.85 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-O 122.913 1.339 . . . . 0.0 111.391 169.373 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.443 ' HB2' ' CE1' ' A' ' 39' ' ' PHE . 60.8 m-85 -152.39 154.79 36.3 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 128.792 2.837 . . . . 0.0 112.032 -172.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -138.51 162.42 34.55 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 120.066 1.303 . . . . 0.0 108.415 -164.01 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -146.76 132.0 18.45 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 127.316 2.247 . . . . 0.0 108.202 -170.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 139.17 -157.36 24.9 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 117.196 1.639 . . . . 0.0 117.196 145.091 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . 0.258 39.1 mt-10 -55.87 -41.72 74.82 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 119.375 3.102 . . . . 0.0 119.375 -175.642 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -67.7 2.82 5.66 Favored Glycine 0 CA--C 1.523 0.578 0 C-N-CA 127.829 2.633 . . . . 0.0 113.944 168.617 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.499 HD21 ' CE1' ' A' ' 36' ' ' PHE 0.334 20.9 mt -108.11 1.04 22.0 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 117.45 2.389 . . . . 0.0 117.45 155.988 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 72.9 t -119.8 -45.82 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 O-C-N 119.393 -2.067 . . . . 0.0 113.517 -174.749 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.262 31.5 ttmt -159.15 134.7 8.56 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 115.843 1.794 . . . . 0.0 115.843 175.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.7 t -135.65 139.62 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 106.715 -1.587 . . . . 0.0 106.715 -173.204 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 -121.25 176.64 5.52 Favored 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 128.964 2.906 . . . . 0.0 116.262 -169.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -80.25 -54.3 5.86 Favored 'General case' 0 N--CA 1.441 -0.894 0 O-C-N 120.011 -1.681 . . . . 0.0 113.058 178.634 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 -103.72 4.71 35.61 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 129.59 3.156 . . . . 0.0 114.478 177.155 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . 0.304 . . -110.39 84.07 3.63 Favored Pre-proline 0 N--CA 1.448 -0.537 0 CA-C-O 113.328 -3.225 . . . . 0.0 106.262 159.843 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -59.04 120.79 8.87 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 CA-C-N 123.816 2.399 . . . . 0.0 110.525 164.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -91.13 154.76 19.13 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 112.506 -2.133 . . . . 0.0 108.22 -175.322 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.437 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 45.8 mt-10 -120.36 165.98 14.16 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 109.712 -3.404 . . . . 0.0 112.49 175.364 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.499 ' CE1' HD21 ' A' ' 25' ' ' LEU . 10.7 p90 -162.16 173.5 14.22 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 128.566 2.746 . . . . 0.0 110.704 163.812 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 98.8 m -130.28 126.47 37.32 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 126.927 2.091 . . . . 0.0 115.652 -163.436 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 6.5 mt -92.34 105.14 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 C-N-CA 125.837 1.655 . . . . 0.0 108.018 178.289 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.443 ' CE1' ' HB2' ' A' ' 19' ' ' TYR 0.26 1.3 p90 -72.59 132.12 43.35 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.348 1.459 . . . . 0.0 112.04 167.055 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -130.98 134.7 46.96 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 118.272 -2.767 . . . . 0.0 113.133 -170.762 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.417 HG22 ' HA ' ' A' ' 47' ' ' ALA . 5.2 t -131.45 150.82 34.63 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.396 0 CA-C-O 125.882 2.753 . . . . 0.0 103.78 169.734 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.0 p30 -69.73 -70.8 0.26 Allowed 'General case' 0 N--CA 1.443 -0.806 1 O-C-N 115.935 -4.228 . . . . 0.0 112.517 169.063 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 24.3 p -162.68 -9.82 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.418 1 C-N-CA 135.045 5.338 . . . . 0.0 114.707 -179.77 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 26.5 mtpp -122.18 34.54 5.14 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 122.393 2.36 . . . . 0.0 111.328 -163.036 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.82 -58.13 5.03 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 118.853 2.301 . . . . 0.0 118.853 160.739 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 62.1 t -57.85 132.33 22.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 O-C-N 126.271 1.806 . . . . 0.0 111.007 163.714 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.417 ' HA ' HG22 ' A' ' 41' ' ' VAL . . . -45.59 161.8 0.04 OUTLIER 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 125.276 2.465 . . . . 0.0 116.849 170.624 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 9.5 mmm180 -55.37 110.38 0.68 Allowed 'General case' 0 CA--C 1.518 -0.263 0 O-C-N 117.069 -3.519 . . . . 0.0 110.467 174.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.1 p -76.07 5.47 6.66 Favored 'General case' 0 N--CA 1.449 -0.519 1 C-N-CA 136.483 5.913 . . . . 0.0 117.092 -179.085 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.4 ' HB2' ' CE1' ' A' ' 5' ' ' HIS . 1.2 p30 -170.14 168.19 8.42 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 123.797 1.761 . . . . 0.0 107.85 169.582 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -123.86 -162.86 11.57 Favored Glycine 0 C--N 1.344 1.002 0 O-C-N 117.829 -3.044 . . . . 0.0 111.632 -146.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.66 21.21 74.65 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 122.059 3.584 . . . . 0.0 122.059 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 41.9 m-20 -73.39 152.79 90.04 Favored Pre-proline 0 C--O 1.223 -0.31 0 CA-C-N 118.59 1.195 . . . . 0.0 111.925 174.073 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -101.29 131.55 0.14 Allowed 'Trans proline' 0 N--CA 1.457 -0.66 0 CA-C-O 126.001 2.417 . . . . 0.0 112.313 -174.423 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -136.7 155.68 49.55 Favored 'General case' 0 N--CA 1.444 -0.769 0 CA-C-N 111.478 -2.601 . . . . 0.0 110.262 -172.4 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.405 ' O ' ' HA ' ' A' ' 95' ' ' VAL . 34.5 tt0 -139.39 141.43 37.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 125.203 2.43 . . . . 0.0 111.425 175.875 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 46.6 t -133.98 76.86 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.693 0 C-N-CA 128.195 2.598 . . . . 0.0 104.916 -175.553 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -99.04 141.44 31.79 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 125.872 2.749 . . . . 0.0 107.812 -170.729 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.426 ' HA ' ' O ' ' A' ' 92' ' ' ASN . 54.5 mt -137.04 139.96 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-N 111.046 -2.797 . . . . 0.0 114.965 -159.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 12.2 m120 -124.59 117.09 23.54 Favored 'General case' 0 C--O 1.223 -0.312 0 C-N-CA 126.983 2.113 . . . . 0.0 106.471 176.02 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.44 ' HA3' ' HB3' ' A' ' 65' ' ' LEU . . . -78.98 -159.19 14.28 Favored Glycine 0 N--CA 1.445 -0.766 0 CA-C-O 114.571 -3.35 . . . . 0.0 115.845 161.499 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_endo -63.28 116.52 3.65 Favored 'Trans proline' 0 N--CA 1.446 -1.298 1 C-N-CA 127.282 5.321 . . . . 0.0 110.63 162.551 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 23.4 t70 51.46 -100.49 0.09 Allowed 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 117.051 2.241 . . . . 0.0 117.051 177.521 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -74.55 -6.63 77.25 Favored Glycine 0 N--CA 1.438 -1.194 0 O-C-N 121.157 -0.964 . . . . 0.0 115.363 -172.314 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.44 ' HB3' ' HA3' ' A' ' 61' ' ' GLY 0.328 14.6 tp -77.95 73.97 4.51 Favored 'General case' 0 N--CA 1.442 -0.837 0 O-C-N 118.975 -2.485 . . . . 0.0 114.615 -168.63 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 51.8 t -87.91 110.14 20.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 C-N-CA 127.599 2.36 . . . . 0.0 113.794 175.049 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 68.2 t -133.29 159.87 42.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 CA-C-N 113.162 -1.835 . . . . 0.0 109.456 -165.408 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.264 1.1 p30 -133.59 142.95 48.37 Favored 'General case' 0 N--CA 1.448 -0.55 0 O-C-N 120.24 -1.537 . . . . 0.0 109.875 157.868 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.3 147.08 24.96 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 125.519 1.762 . . . . 0.0 113.632 162.402 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -99.16 113.89 26.37 Favored 'General case' 0 CA--C 1.511 -0.525 0 C-N-CA 127.599 2.36 . . . . 0.0 108.36 -158.279 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.6 t -91.83 129.49 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 O-C-N 124.42 1.075 . . . . 0.0 111.079 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.7 m -136.87 140.67 42.54 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 102.34 -3.207 . . . . 0.0 102.34 -178.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 57.9 t0 -72.31 124.2 24.6 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 129.199 3.0 . . . . 0.0 107.603 -172.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -82.14 -1.5 49.06 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 116.343 -1.789 . . . . 0.0 115.331 169.119 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.395 1.5 m120 60.57 32.58 20.44 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-N 121.449 1.931 . . . . 0.0 115.691 176.748 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 25.7 p30 -144.5 6.1 1.25 Allowed 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 113.032 -1.894 . . . . 0.0 112.409 -172.324 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 89.8 7.27 68.84 Favored Glycine 0 C--N 1.333 0.414 0 CA-C-N 122.58 2.445 . . . . 0.0 115.653 -166.158 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.9 p -141.16 158.31 44.08 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 129.25 3.02 . . . . 0.0 114.208 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 23.2 m-85 -132.04 126.65 34.4 Favored 'General case' 0 N--CA 1.449 -0.501 0 O-C-N 120.215 -1.553 . . . . 0.0 107.478 -169.351 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -89.17 147.82 19.82 Favored Glycine 0 C--N 1.335 0.5 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 35' ' ' GLU . 2.3 t -131.54 133.83 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 CA-C-N 110.235 -2.982 . . . . 0.0 114.088 -174.027 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 13.7 p -137.54 131.39 43.93 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 CA-C-N 120.781 1.628 . . . . 0.0 110.359 -169.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -161.86 151.67 16.58 Favored 'General case' 0 N--CA 1.452 -0.353 1 O-C-N 115.95 -4.219 . . . . 0.0 111.582 176.753 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 26.0 p30 -116.93 151.66 36.17 Favored 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 130.92 3.688 . . . . 0.0 111.182 -172.412 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . 0.312 . . -130.44 104.91 16.04 Favored Pre-proline 0 N--CA 1.441 -0.876 0 N-CA-C 118.87 2.915 . . . . 0.0 118.87 -170.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -93.21 24.44 0.45 Allowed 'Trans proline' 0 N--CA 1.45 -1.044 0 C-N-CA 124.488 3.459 . . . . 0.0 112.76 -174.122 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.5 m -140.04 134.87 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 117.145 2.276 . . . . 0.0 117.145 -179.148 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . 0.284 38.5 tt0 -56.43 105.15 0.18 Allowed 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.705 144.016 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 162.41 -139.99 6.28 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 117.97 -1.461 . . . . 0.0 110.876 176.506 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 85.0 m-20 -143.24 137.97 29.3 Favored 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 105.848 -1.908 . . . . 0.0 105.848 -170.816 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -90.04 145.91 24.73 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 111.435 -2.62 . . . . 0.0 113.143 156.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.426 ' O ' ' HA ' ' A' ' 59' ' ' ILE . 26.1 t-20 -113.0 116.97 30.78 Favored 'General case' 0 N--CA 1.442 -0.828 0 O-C-N 128.566 3.666 . . . . 0.0 112.232 172.694 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 43.5 t -111.91 131.18 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 CA-C-O 126.102 2.858 . . . . 0.0 113.105 -168.448 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 21.5 t-20 -131.96 131.68 42.83 Favored 'General case' 0 N--CA 1.445 -0.694 0 O-C-N 119.157 -2.214 . . . . 0.0 111.302 176.309 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 56' ' ' GLU . 57.7 t -118.52 129.95 74.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 O-C-N 124.159 0.912 . . . . 0.0 112.718 -174.44 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.418 ' HB ' ' O ' ' A' ' 100' ' ' ASN . 46.9 p -139.6 153.19 47.31 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -172.594 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 3.2 mp -126.16 105.84 9.14 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 105.043 -2.206 . . . . 0.0 105.043 -142.149 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 44.4 ttm-85 46.93 42.22 11.95 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 125.997 2.808 . . . . 0.0 108.937 -153.169 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 57.93 14.22 16.16 Favored Glycine 0 CA--C 1.528 0.882 0 O-C-N 116.765 -3.71 . . . . 0.0 115.798 -177.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.418 ' O ' ' HB ' ' A' ' 96' ' ' THR . 76.8 m-20 -95.32 157.37 36.43 Favored Pre-proline 0 N--CA 1.449 -0.485 0 C-N-CA 117.6 -1.64 . . . . 0.0 115.325 168.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -79.91 168.38 19.18 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 CA-C-O 125.82 2.342 . . . . 0.0 111.836 -174.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 43.5 pt -147.02 -177.52 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-O 126.038 2.828 . . . . 0.0 113.733 -178.158 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 17.2 ptmt -84.71 168.51 15.17 Favored 'General case' 0 N--CA 1.446 -0.669 0 O-C-N 116.405 -3.934 . . . . 0.0 110.936 -176.337 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 17.4 m120 54.77 29.46 11.85 Favored 'General case' 0 N--CA 1.446 -0.674 0 O-C-N 120.386 -1.446 . . . . 0.0 114.536 175.555 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 11.1 mmt -143.18 150.55 52.66 Favored Pre-proline 0 CA--C 1.518 -0.28 0 CA-C-O 113.351 -3.214 . . . . 0.0 111.73 177.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.43 175.82 34.03 Favored 'Cis proline' 0 N--CA 1.446 -1.316 0 CA-C-N 123.809 2.396 . . . . 0.0 113.199 -0.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 14.0 pt -144.56 -176.04 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 170.272 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -135.12 148.52 49.81 Favored 'General case' 0 N--CA 1.45 -0.463 1 O-C-N 114.745 -4.972 . . . . 0.0 112.294 -172.862 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 99.5 t -143.66 128.81 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.909 0 N-CA-C 105.478 -2.045 . . . . 0.0 105.478 -171.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 69.5 tttt -70.63 132.19 45.07 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 112.669 -2.059 . . . . 0.0 112.221 -176.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 81.6 m -113.08 126.82 55.89 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.208 1.403 . . . . 0.0 109.548 -178.257 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.8 tp -135.36 132.14 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 O-C-N 119.86 -1.775 . . . . 0.0 108.897 155.405 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -72.75 55.23 0.38 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 130.377 3.471 . . . . 0.0 114.028 -163.036 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.452 0 C-N-CA 128.021 2.724 . . . . 0.0 115.692 176.338 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.9 tpt . . . . . 0 C--O 1.236 0.352 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 43.0 t-80 -163.14 140.23 7.53 Favored 'General case' 0 N--CA 1.443 -0.776 0 O-C-N 125.666 1.854 . . . . 0.0 112.419 173.657 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . 0.304 8.3 t60 -91.84 100.66 13.3 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 129.497 3.119 . . . . 0.0 112.209 -170.027 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 60.0 t-80 -147.25 150.63 35.21 Favored 'General case' 0 N--CA 1.445 -0.683 0 O-C-N 119.395 -2.066 . . . . 0.0 112.63 178.77 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -90.92 125.93 35.91 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-O 115.868 -2.015 . . . . 0.0 113.65 177.741 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 36.8 m80 -120.55 -26.97 5.23 Favored 'General case' 0 C--O 1.219 -0.533 0 C-N-CA 128.268 2.627 . . . . 0.0 112.36 -177.601 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 40.1 m80 -142.58 160.33 40.51 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-O 123.975 1.845 . . . . 0.0 112.89 -161.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -76.94 -22.68 52.91 Favored 'General case' 0 N--CA 1.454 -0.245 0 O-C-N 117.609 -3.182 . . . . 0.0 117.863 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 79.6 p -109.85 147.41 33.38 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 128.393 3.558 . . . . 0.0 117.032 170.458 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . 0.294 20.0 mtmt -125.73 151.8 71.37 Favored Pre-proline 0 N--CA 1.455 -0.197 0 CA-C-O 114.745 -2.55 . . . . 0.0 112.715 173.405 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -70.99 150.7 61.19 Favored 'Trans proline' 0 N--CA 1.453 -0.907 1 O-C-N 128.964 4.139 . . . . 0.0 111.586 165.14 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.406 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . . . -82.08 134.12 49.98 Favored Pre-proline 0 N--CA 1.445 -0.686 0 C-N-CA 127.135 2.174 . . . . 0.0 113.725 175.707 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 12' ' ' ALA . 24.1 Cg_exo -63.86 158.8 45.05 Favored 'Trans proline' 0 N--CA 1.443 -1.476 1 C-N-CA 127.015 5.143 . . . . 0.0 111.394 172.584 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -135.97 155.97 49.46 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 125.283 1.433 . . . . 0.0 111.791 -163.734 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -75.33 -33.58 61.15 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 117.191 2.293 . . . . 0.0 117.191 -172.654 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -57.77 -14.39 5.75 Favored 'General case' 0 N--CA 1.44 -0.932 1 O-C-N 114.574 -5.079 . . . . 0.0 116.756 153.475 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 48.1 m-70 -135.14 18.64 3.43 Favored 'General case' 0 N--CA 1.444 -0.733 0 O-C-N 125.956 2.035 . . . . 0.0 114.679 -159.643 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.9 t -138.3 120.16 15.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 O-C-N 117.152 -3.468 . . . . 0.0 107.697 171.655 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.442 ' O ' ' CD2' ' A' ' 39' ' ' PHE . 23.8 m-85 -153.78 150.64 28.68 Favored 'General case' 0 N--CA 1.455 -0.213 0 CA-C-O 114.441 -2.695 . . . . 0.0 111.569 -170.244 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.515 ' HB2' ' HA ' ' A' ' 38' ' ' ILE . . . -141.28 158.37 43.98 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 118.195 2.665 . . . . 0.0 118.195 -161.147 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -153.62 141.37 20.03 Favored 'General case' 0 CA--C 1.518 -0.269 0 C-N-CA 126.411 1.884 . . . . 0.0 112.356 -159.586 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 132.66 157.35 8.49 Favored Glycine 0 N--CA 1.447 -0.614 1 C-N-CA 130.874 4.083 . . . . 0.0 116.282 -174.272 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -63.46 -20.18 65.36 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 118.661 2.837 . . . . 0.0 118.661 -173.264 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.79 8.39 0.55 Allowed Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 128.821 3.105 . . . . 0.0 117.088 162.015 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 75.9 mt -108.75 10.25 26.8 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-O 116.294 -1.812 . . . . 0.0 109.747 160.317 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 91.7 t -139.47 -29.96 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 CA-C-N 121.959 2.163 . . . . 0.0 113.213 -174.487 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 26.9 ttmt -164.5 138.21 5.17 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 119.508 -1.995 . . . . 0.0 107.508 171.691 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 t -132.33 136.22 56.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.458 0 O-C-N 126.387 2.305 . . . . 0.0 109.699 -174.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.434 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 66.9 m-85 -127.86 -172.24 2.63 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 122.148 2.249 . . . . 0.0 112.592 -163.824 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -88.01 -54.74 4.07 Favored 'General case' 0 N--CA 1.448 -0.569 0 O-C-N 117.832 -3.042 . . . . 0.0 115.928 177.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 69.0 m-80 -97.91 8.28 44.99 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 115.64 1.718 . . . . 0.0 115.64 174.5 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . 0.259 . . -126.27 80.96 68.0 Favored Pre-proline 0 CA--C 1.516 -0.334 0 C-N-CA 125.614 1.566 . . . . 0.0 111.468 174.325 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -61.61 123.63 13.08 Favored 'Trans proline' 0 N--CA 1.445 -1.334 0 CA-C-O 122.903 1.126 . . . . 0.0 111.649 176.257 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.63 150.72 23.71 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 112.689 -2.05 . . . . 0.0 111.483 -164.433 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -129.66 153.89 47.67 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 127.514 2.325 . . . . 0.0 114.536 -162.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -164.48 158.84 18.75 Favored 'General case' 0 N--CA 1.446 -0.66 0 O-C-N 121.09 -1.006 . . . . 0.0 111.491 172.346 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 7.2 m -129.56 115.11 16.93 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 113.36 -1.745 . . . . 0.0 110.529 -154.349 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.515 ' HA ' ' HB2' ' A' ' 20' ' ' ALA . 15.5 mt -82.2 98.77 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 O-C-N 128.553 3.658 . . . . 0.0 108.979 178.779 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.442 ' CD2' ' O ' ' A' ' 19' ' ' TYR 0.328 47.3 p90 -76.94 105.12 7.81 Favored 'General case' 0 N--CA 1.451 -0.424 0 O-C-N 118.339 -2.726 . . . . 0.0 113.327 170.915 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . 0.264 . . -90.03 134.27 34.34 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 127.339 2.256 . . . . 0.0 116.674 -176.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 46.3 t -133.27 143.34 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 C-N-CA 126.776 2.03 . . . . 0.0 106.673 160.234 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.09 -81.22 0.02 OUTLIER 'General case' 0 N--CA 1.443 -0.795 0 O-C-N 117.846 -3.034 . . . . 0.0 114.476 161.611 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 19.1 p -161.32 -41.12 0.04 OUTLIER 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 128.436 2.695 . . . . 0.0 111.393 -169.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -90.62 52.16 2.14 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 121.927 2.149 . . . . 0.0 113.254 -167.708 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 71.81 -66.2 1.12 Allowed Glycine 0 C--N 1.341 0.848 0 CA-C-O 118.249 -1.306 . . . . 0.0 115.782 174.628 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 70.8 t -56.38 129.51 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 O-C-N 125.54 1.377 . . . . 0.0 111.974 178.303 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -36.91 164.83 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 130.284 3.434 . . . . 0.0 116.192 163.378 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . 0.254 7.3 mmm180 -66.16 101.67 0.74 Allowed 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 114.611 1.337 . . . . 0.0 114.611 175.232 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 61.8 p -79.37 2.76 20.48 Favored 'General case' 0 N--CA 1.449 -0.515 1 C-N-CA 133.464 4.705 . . . . 0.0 114.741 178.854 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -155.83 -174.72 5.08 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 130.014 3.326 . . . . 0.0 113.721 158.541 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -154.04 -176.45 26.41 Favored Glycine 0 CA--C 1.521 0.425 0 CA-C-O 124.741 2.301 . . . . 0.0 115.797 -141.68 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.71 14.35 67.31 Favored Glycine 0 C--N 1.336 0.549 0 O-C-N 117.462 -3.375 . . . . 0.0 112.789 -170.591 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -60.69 123.55 74.95 Favored Pre-proline 0 N--CA 1.446 -0.672 0 CA-C-N 123.7 3.75 . . . . 0.0 106.98 175.73 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -83.85 153.77 13.17 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 CA-C-N 122.468 1.917 . . . . 0.0 116.294 -162.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -142.95 156.29 44.86 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-O 126.35 2.976 . . . . 0.0 110.14 -157.738 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -144.11 153.25 41.96 Favored 'General case' 0 N--CA 1.448 -0.53 0 O-C-N 118.671 -2.518 . . . . 0.0 109.989 161.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.413 HG22 HG22 ' A' ' 95' ' ' VAL . 92.0 t -133.81 108.54 11.86 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.96 0 C-N-CA 129.789 3.235 . . . . 0.0 104.052 169.545 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -117.12 133.87 55.47 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 126.833 2.053 . . . . 0.0 112.287 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . 0.275 3.4 mp -124.06 144.9 32.24 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 C-N-CA 125.848 1.659 . . . . 0.0 113.94 -167.405 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 53.0 m-80 -118.23 140.41 49.84 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 114.217 -2.802 . . . . 0.0 110.061 174.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.47 -169.51 14.31 Favored Glycine 0 CA--C 1.526 0.774 0 CA-C-N 121.558 1.981 . . . . 0.0 111.68 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . 0.304 19.2 Cg_endo -60.18 130.28 33.6 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 N-CA-C 114.96 1.1 . . . . 0.0 114.96 -179.107 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.27 8.7 t0 52.79 -109.29 0.46 Allowed 'General case' 0 N--CA 1.453 -0.287 0 CA-C-O 114.908 -2.472 . . . . 0.0 113.275 177.777 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.11 -10.12 77.58 Favored Glycine 0 CA--C 1.523 0.569 0 O-C-N 126.273 2.233 . . . . 0.0 115.341 -176.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 88.0 mt -71.87 100.97 2.53 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 124.161 0.984 . . . . 0.0 110.213 -170.078 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 51.5 t -133.56 126.57 51.93 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 O-C-N 119.347 -2.096 . . . . 0.0 105.432 164.228 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 9.5 t -133.51 150.7 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.155 0 CA-C-N 113.193 -1.821 . . . . 0.0 106.843 -165.287 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.269 2.4 p30 -117.74 137.8 52.46 Favored 'General case' 0 N--CA 1.439 -0.985 0 O-C-N 118.979 -2.326 . . . . 0.0 112.717 148.492 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.21 158.97 22.09 Favored 'General case' 0 N--CA 1.444 -0.738 0 O-C-N 126.277 2.235 . . . . 0.0 112.439 -174.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 38.9 mmtm -90.33 103.13 15.84 Favored 'General case' 0 N--CA 1.447 -0.609 0 O-C-N 120.265 -1.522 . . . . 0.0 112.719 -172.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 54.9 t -71.27 135.48 27.9 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.662 172.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 54.6 m -123.91 137.87 54.56 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 124.735 1.214 . . . . 0.0 112.033 162.667 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 48.5 t0 -78.02 121.38 24.15 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 124.161 1.934 . . . . 0.0 111.94 169.255 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 -76.2 -7.5 54.98 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 112.228 -2.26 . . . . 0.0 115.088 -177.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 4.7 m120 59.85 25.95 15.1 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 129.655 3.182 . . . . 0.0 114.248 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 42.7 p30 -134.25 -6.84 2.63 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 129.194 2.998 . . . . 0.0 112.903 -175.257 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 103.29 15.6 22.96 Favored Glycine 0 C--N 1.336 0.555 1 C-N-CA 133.41 5.291 . . . . 0.0 114.288 -172.769 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 27.1 p -140.69 165.24 28.03 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 122.505 3.152 . . . . 0.0 108.791 177.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 67.4 m-85 -135.88 125.12 24.62 Favored 'General case' 0 N--CA 1.447 -0.579 0 N-CA-C 104.823 -2.288 . . . . 0.0 104.823 -166.2 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -96.68 129.95 10.08 Favored Glycine 0 C--N 1.336 0.575 0 C-N-CA 129.597 3.475 . . . . 0.0 107.165 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.8 t -108.68 128.21 64.58 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 1 CA-C-O 110.811 -4.423 . . . . 0.0 112.892 172.253 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.2 p -127.54 142.27 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 123.915 3.052 . . . . 0.0 115.666 172.832 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -165.03 160.43 18.93 Favored 'General case' 0 N--CA 1.449 -0.491 0 O-C-N 117.096 -3.502 . . . . 0.0 112.947 -173.42 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.465 42.5 p30 -137.77 148.32 45.45 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 128.437 2.695 . . . . 0.0 114.347 -168.685 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -125.28 113.08 26.01 Favored Pre-proline 0 N--CA 1.445 -0.708 0 C-N-CA 128.26 2.624 . . . . 0.0 112.025 -171.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.258 59.0 Cg_endo -76.04 12.91 1.37 Allowed 'Trans proline' 0 N--CA 1.441 -1.611 0 O-C-N 125.186 2.15 . . . . 0.0 113.359 177.778 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.8 m -140.62 141.28 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 115.579 1.696 . . . . 0.0 115.579 -151.469 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -63.96 114.17 3.94 Favored 'General case' 0 N--CA 1.447 -0.625 0 O-C-N 117.329 -3.357 . . . . 0.0 110.119 144.407 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 163.07 -155.43 26.77 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 125.317 2.621 . . . . 0.0 117.561 -169.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 5.0 t30 -135.81 121.88 20.14 Favored 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 127.278 2.231 . . . . 0.0 107.432 -167.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . 0.25 7.3 m-85 -87.48 143.09 27.39 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 123.298 0.639 . . . . 0.0 112.65 158.854 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -127.55 123.65 36.3 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 124.376 2.036 . . . . 0.0 107.999 -175.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . 0.344 3.3 t -109.46 135.14 49.31 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 N-CA-C 117.519 2.414 . . . . 0.0 117.519 -164.81 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -136.57 128.51 29.36 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 131.494 3.917 . . . . 0.0 108.373 179.424 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.413 HG22 HG22 ' A' ' 57' ' ' VAL . 58.2 t -118.12 152.59 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 CA-C-O 123.677 1.703 . . . . 0.0 108.374 -173.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.7 p -151.15 152.0 32.74 Favored 'General case' 0 N--CA 1.441 -0.915 0 O-C-N 120.411 -1.431 . . . . 0.0 112.952 -177.085 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 9.4 mp -137.3 94.9 2.99 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 104.351 -2.463 . . . . 0.0 104.351 -153.676 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . 0.277 25.3 ttm-85 49.2 43.8 22.87 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 112.571 -2.104 . . . . 0.0 110.691 -162.726 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 74.31 -13.29 4.85 Favored Glycine 0 CA--C 1.522 0.489 0 CA-C-O 114.681 -3.288 . . . . 0.0 116.132 -168.731 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 72.6 m-20 -74.25 126.83 88.68 Favored Pre-proline 0 N--CA 1.451 -0.398 0 CA-C-N 122.534 3.167 . . . . 0.0 119.072 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.457 ' C ' HG23 ' A' ' 102' ' ' ILE . 61.4 Cg_endo -74.29 172.11 16.7 Favored 'Trans proline' 0 N--CA 1.453 -0.885 1 C-N-CA 127.451 5.434 . . . . 0.0 106.863 -177.468 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.572 HG13 ' HG3' ' A' ' 105' ' ' MET . 27.4 pt -143.87 177.61 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 O-C-N 118.346 -2.721 . . . . 0.0 107.705 -164.388 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 38.4 mttm -80.71 159.81 25.15 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 128.678 2.791 . . . . 0.0 111.191 -169.259 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 15.2 m120 54.2 43.89 29.93 Favored 'General case' 0 C--O 1.224 -0.285 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 176.25 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' MET . . . . . 0.572 ' HG3' HG13 ' A' ' 102' ' ' ILE . 6.9 mmt -138.55 139.52 24.91 Favored Pre-proline 0 N--CA 1.444 -0.728 0 C-N-CA 129.812 3.245 . . . . 0.0 107.956 -163.138 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -79.06 165.05 82.37 Favored 'Cis proline' 0 N--CA 1.447 -1.215 0 CA-C-N 122.78 2.029 . . . . 0.0 109.328 1.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . 0.276 2.2 pp -114.46 159.36 14.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 C-N-CA 125.366 1.466 . . . . 0.0 114.081 171.227 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -122.59 134.44 54.52 Favored 'General case' 0 N--CA 1.449 -0.502 0 O-C-N 118.588 -2.57 . . . . 0.0 111.899 -167.758 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 1.7 t -129.53 121.36 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-O 125.695 2.664 . . . . 0.0 112.615 -177.252 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -55.72 130.29 42.67 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 112.222 -2.263 . . . . 0.0 114.155 170.812 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 48.7 m -121.82 153.82 37.85 Favored 'General case' 0 N--CA 1.445 -0.699 0 O-C-N 123.994 0.809 . . . . 0.0 110.461 176.448 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.434 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 10.4 tp -150.52 138.06 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.773 0 C-N-CA 127.602 2.361 . . . . 0.0 113.486 165.367 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -68.84 43.29 0.04 OUTLIER 'General case' 0 N--CA 1.444 -0.768 1 CA-C-O 129.778 4.609 . . . . 0.0 115.584 -166.655 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.616 1 O-C-N 114.68 -5.013 . . . . 0.0 112.116 -175.359 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 42.2 tpp . . . . . 0 N--CA 1.473 0.683 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -79.05 -19.48 51.28 Favored 'General case' 0 N--CA 1.44 -0.932 0 CA-C-O 117.113 -1.423 . . . . 0.0 111.758 -177.68 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 8.8 t60 -79.23 106.98 11.65 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 122.086 2.221 . . . . 0.0 108.132 -174.239 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 9.7 t-160 -161.37 109.86 1.53 Allowed 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 123.513 1.625 . . . . 0.0 108.42 -167.323 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.436 ' CE1' ' H ' ' A' ' 51' ' ' GLY 0.279 74.6 m80 -60.77 127.41 31.51 Favored 'General case' 0 C--N 1.329 -0.288 0 O-C-N 120.764 -1.21 . . . . 0.0 113.995 172.906 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 15.6 t60 -139.73 -10.95 1.18 Allowed 'General case' 0 N--CA 1.452 -0.327 0 O-C-N 118.972 -2.33 . . . . 0.0 107.9 -175.268 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . 0.252 32.4 m170 -147.78 168.19 22.78 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.702 -164.86 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -69.5 -45.02 69.89 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 117.377 -1.297 . . . . 0.0 113.054 163.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.7 m -103.33 144.33 31.5 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 119.702 1.137 . . . . 0.0 111.396 -166.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 49.9 mtmt -127.99 161.63 54.72 Favored Pre-proline 0 N--CA 1.454 -0.266 0 C-N-CA 125.024 1.33 . . . . 0.0 113.236 -177.498 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . 0.29 40.3 Cg_endo -83.1 147.13 12.95 Favored 'Trans proline' 0 N--CA 1.453 -0.862 1 C-N-CA 126.729 4.953 . . . . 0.0 118.429 166.666 . . . . . . . . 3 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.479 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . . . -77.85 129.22 76.93 Favored Pre-proline 0 CA--C 1.516 -0.347 0 N-CA-C 118.433 2.753 . . . . 0.0 118.433 -178.136 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.479 ' HD3' ' HA ' ' A' ' 12' ' ' ALA . 65.8 Cg_exo -62.81 150.6 87.73 Favored 'Trans proline' 0 N--CA 1.448 -1.162 1 C-N-CA 126.027 4.485 . . . . 0.0 110.775 169.84 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.8 t -129.64 152.13 49.49 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 117.159 2.281 . . . . 0.0 117.159 -170.03 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.33 -36.18 79.43 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 120.379 -1.451 . . . . 0.0 113.337 179.571 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 59.7 mm-40 -54.93 -31.01 59.95 Favored 'General case' 0 C--N 1.349 0.554 0 CA-C-N 124.32 3.236 . . . . 0.0 112.554 163.116 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 39.6 m80 -125.23 19.37 8.25 Favored 'General case' 0 N--CA 1.445 -0.688 0 CA-C-O 125.627 2.632 . . . . 0.0 113.711 -154.153 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 7.1 t -147.38 122.69 10.28 Favored 'General case' 0 C--N 1.347 0.48 1 O-C-N 113.615 -5.678 . . . . 0.0 113.474 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 37.1 m-85 -160.36 151.13 18.7 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-O 116.185 -1.865 . . . . 0.0 110.235 -164.722 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.408 ' HA ' ' O ' ' A' ' 37' ' ' THR . . . -131.52 153.23 50.03 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-O 122.565 1.174 . . . . 0.0 109.78 -167.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -159.12 147.96 18.32 Favored 'General case' 0 N--CA 1.447 -0.609 0 C-N-CA 125.93 1.692 . . . . 0.0 110.348 -168.582 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.84 -179.87 16.02 Favored Glycine 0 C--N 1.338 0.666 0 C-N-CA 129.668 3.509 . . . . 0.0 117.339 175.097 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . 0.588 1.9 tt0 -62.23 -27.57 69.09 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 120.15 3.389 . . . . 0.0 120.15 -168.397 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.406 ' HA2' ' HB1' ' A' ' 34' ' ' ALA . . . -61.03 0.13 1.29 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 118.827 2.291 . . . . 0.0 118.827 160.794 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 49.2 mt -113.85 13.78 18.46 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.493 1.117 . . . . 0.0 111.463 168.205 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.9 t -129.47 -55.47 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 CA-C-O 115.839 -2.029 . . . . 0.0 113.334 178.32 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -150.16 128.25 11.94 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 116.638 -1.649 . . . . 0.0 111.777 -177.274 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 52.0 t -137.58 132.24 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 O-C-N 127.855 3.222 . . . . 0.0 113.255 -162.057 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.467 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 5.9 m-85 -126.63 -168.42 1.86 Allowed 'General case' 0 C--N 1.334 -0.065 0 CA-C-O 123.694 1.711 . . . . 0.0 112.453 -164.595 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -100.46 -56.32 2.38 Favored 'General case' 0 N--CA 1.449 -0.514 0 O-C-N 119.133 -2.229 . . . . 0.0 111.358 -166.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 40.0 m-80 -100.08 8.09 44.19 Favored 'General case' 0 N--CA 1.451 -0.403 0 O-C-N 119.027 -2.295 . . . . 0.0 111.678 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -121.22 93.14 48.81 Favored Pre-proline 0 N--CA 1.448 -0.57 0 O-C-N 119.423 -2.048 . . . . 0.0 108.197 167.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.11 128.02 22.87 Favored 'Trans proline' 0 N--CA 1.453 -0.901 1 C-N-CA 127.393 5.395 . . . . 0.0 113.465 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.406 ' HB1' ' HA2' ' A' ' 24' ' ' GLY . . . -92.47 152.47 19.66 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 128.257 2.623 . . . . 0.0 117.232 177.409 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 29.1 mt-10 -143.32 148.92 37.05 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 128.942 3.901 . . . . 0.0 110.265 -161.166 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 20.7 p90 -168.77 165.75 11.77 Favored 'General case' 0 CA--C 1.518 -0.284 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 -178.86 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 20' ' ' ALA . 57.7 m -133.63 122.55 23.63 Favored 'General case' 0 N--CA 1.448 -0.548 0 O-C-N 127.887 3.242 . . . . 0.0 114.173 -155.262 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.4 ' HB ' ' HB2' ' A' ' 79' ' ' TYR . 4.0 mt -86.03 101.17 10.0 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-O 114.866 -2.493 . . . . 0.0 105.638 177.695 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.484 ' HA ' HG22 ' A' ' 78' ' ' THR . 12.7 p90 -74.58 112.23 10.56 Favored 'General case' 0 N--CA 1.446 -0.634 0 O-C-N 124.917 1.386 . . . . 0.0 112.656 162.086 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . 0.252 . . -102.3 135.13 44.46 Favored 'General case' 0 C--O 1.222 -0.395 0 C-N-CA 126.151 1.78 . . . . 0.0 115.266 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.6 t -125.29 149.17 29.79 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 130.661 3.584 . . . . 0.0 108.961 162.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -74.96 -62.41 1.56 Allowed 'General case' 0 N--CA 1.441 -0.903 0 O-C-N 119.498 -2.001 . . . . 0.0 112.007 173.505 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 8.2 p -173.99 -25.83 0.01 OUTLIER 'General case' 0 C--O 1.218 -0.574 1 C-N-CA 133.158 4.583 . . . . 0.0 110.349 -173.857 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 71.4 mmtt -93.67 27.43 2.68 Favored 'General case' 0 N--CA 1.445 -0.691 0 O-C-N 118.529 -2.607 . . . . 0.0 112.311 -167.085 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 62.95 -32.3 0.07 OUTLIER Glycine 0 N--CA 1.444 -0.802 1 N-CA-C 123.404 4.122 . . . . 0.0 123.404 178.428 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 90.2 t -78.4 138.67 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.845 0 CA-C-N 119.196 1.498 . . . . 0.0 111.881 167.232 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -50.83 166.77 0.08 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.901 1.376 . . . . 0.0 113.397 -177.666 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 11.1 mmm180 -62.29 122.66 16.19 Favored 'General case' 0 C--O 1.22 -0.468 0 CA-C-N 121.947 2.158 . . . . 0.0 113.096 -172.601 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 72.9 p -100.38 13.49 34.28 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-O 126.756 3.17 . . . . 0.0 113.193 -161.711 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.8 p30 -159.66 175.14 13.55 Favored 'General case' 0 N--CA 1.45 -0.454 2 C-N-CA 131.861 4.064 . . . . 0.0 109.534 160.021 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.436 ' H ' ' CE1' ' A' ' 5' ' ' HIS . . . -127.5 -178.34 15.28 Favored Glycine 0 C--N 1.343 0.94 0 N-CA-C 118.871 2.308 . . . . 0.0 118.871 -159.093 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.45 20.74 68.46 Favored Glycine 0 C--N 1.346 1.134 0 CA-C-O 114.094 -3.614 . . . . 0.0 110.597 172.349 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -70.21 145.94 94.11 Favored Pre-proline 0 N--CA 1.445 -0.695 0 CA-C-N 123.807 3.804 . . . . 0.0 112.858 170.357 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -76.08 119.26 5.27 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 N-CA-C 117.307 2.003 . . . . 0.0 117.307 -178.172 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -131.25 165.43 23.4 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-O 124.04 1.876 . . . . 0.0 115.891 168.641 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -160.64 147.06 15.25 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 113.51 -1.677 . . . . 0.0 110.233 -171.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 2.4 t -131.04 123.48 53.95 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.754 0 C-N-CA 127.984 2.514 . . . . 0.0 106.769 176.725 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -121.44 131.63 54.27 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 113.927 -1.488 . . . . 0.0 109.023 -170.195 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.6 mp -132.4 132.86 60.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 -163.125 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 24.8 m120 -113.78 129.73 56.54 Favored 'General case' 0 N--CA 1.442 -0.841 0 O-C-N 125.396 1.685 . . . . 0.0 108.287 151.451 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -96.75 -164.18 32.77 Favored Glycine 0 C--N 1.345 1.045 0 CA-C-O 123.379 1.544 . . . . 0.0 111.273 151.524 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . 0.282 84.2 Cg_endo -64.28 124.05 12.78 Favored 'Trans proline' 0 N--CA 1.448 -1.171 0 C-N-CA 123.514 2.809 . . . . 0.0 118.379 176.889 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 38.13 -101.93 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.533 1 C-N-CA 132.217 4.207 . . . . 0.0 115.298 -174.425 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -53.36 -23.29 18.06 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 125.459 1.504 . . . . 0.0 113.988 -172.258 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . 0.311 95.5 mt -76.54 64.38 2.2 Favored 'General case' 0 N--CA 1.44 -0.933 0 C-N-CA 130.182 3.393 . . . . 0.0 118.316 -179.076 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 87.1 t -72.08 128.02 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 CA-C-N 113.515 -1.675 . . . . 0.0 107.61 151.172 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 87.9 t -135.54 143.84 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 125.922 1.689 . . . . 0.0 108.977 -173.502 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.319 35.5 t0 -129.52 125.99 37.58 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-O 115.337 -2.268 . . . . 0.0 110.435 175.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.25 162.23 19.24 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 125.453 1.72 . . . . 0.0 114.644 176.262 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -103.22 123.2 46.28 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 -177.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.5 t -100.68 137.05 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 O-C-N 128.595 3.684 . . . . 0.0 109.905 -175.743 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . 0.25 53.1 m -134.92 136.54 42.39 Favored 'General case' 0 N--CA 1.445 -0.676 0 O-C-N 117.912 -2.993 . . . . 0.0 109.371 -179.425 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 59.7 t0 -62.66 123.98 19.8 Favored 'General case' 0 N--CA 1.448 -0.559 0 O-C-N 120.497 -1.377 . . . . 0.0 112.004 164.255 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -84.83 -10.41 57.19 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-O 116.377 -1.773 . . . . 0.0 115.264 174.069 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.374 1.4 m120 74.21 36.95 0.63 Allowed 'General case' 0 C--O 1.219 -0.515 0 CA-C-O 115.988 -1.958 . . . . 0.0 113.768 172.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 20.0 p30 -154.58 -10.98 0.13 Allowed 'General case' 0 N--CA 1.449 -0.476 0 O-C-N 126.042 2.089 . . . . 0.0 114.676 -167.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 130.85 -25.72 4.13 Favored Glycine 0 CA--C 1.522 0.511 0 CA-C-N 122.852 2.569 . . . . 0.0 113.63 -158.153 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.484 HG22 ' HA ' ' A' ' 39' ' ' PHE . 2.8 p -136.81 171.77 14.0 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 118.252 2.686 . . . . 0.0 118.252 -157.361 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.4 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 34.6 m-85 -135.94 113.61 10.98 Favored 'General case' 0 N--CA 1.433 -1.282 0 C-N-CA 126.032 1.733 . . . . 0.0 109.487 -172.035 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -86.16 146.48 21.13 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-O 124.146 1.97 . . . . 0.0 112.723 176.282 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 35' ' ' GLU . 41.0 t -136.4 130.0 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 C-N-CA 128.113 2.565 . . . . 0.0 109.032 -167.805 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 14.7 p -134.34 122.09 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.429 0 C-N-CA 125.836 1.654 . . . . 0.0 110.401 -168.021 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.435 ' HE2' ' CD2' ' A' ' 91' ' ' TYR 0.257 0.1 OUTLIER -154.44 175.38 13.65 Favored 'General case' 0 N--CA 1.447 -0.597 0 O-C-N 118.975 -2.328 . . . . 0.0 111.91 -177.4 . . . . . . . . 4 4 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 5.2 p30 -151.76 162.96 40.17 Favored 'General case' 0 N--CA 1.448 -0.556 1 O-C-N 116.268 -4.02 . . . . 0.0 109.708 -174.107 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.62 ' HB2' ' CE2' ' A' ' 91' ' ' TYR . . . -134.46 110.89 11.53 Favored Pre-proline 0 N--CA 1.446 -0.637 1 C-N-CA 133.924 4.89 . . . . 0.0 113.103 -172.406 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -75.77 8.57 2.65 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 123.822 3.015 . . . . 0.0 114.132 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.5 m -134.03 138.15 50.83 Favored 'Isoleucine or valine' 0 C--O 1.238 0.46 0 C-N-CA 129.551 3.14 . . . . 0.0 115.855 -160.436 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 17.3 tt0 -59.81 109.31 0.9 Allowed 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 139.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 176.71 -157.21 22.34 Favored Glycine 0 C--N 1.344 0.975 0 CA-C-O 117.675 -1.625 . . . . 0.0 116.184 -173.436 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -133.12 139.21 46.98 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 127.623 2.369 . . . . 0.0 108.688 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' TYR . . . . . 0.62 ' CE2' ' HB2' ' A' ' 85' ' ' ALA . 3.0 m-30 -105.96 145.19 31.65 Favored 'General case' 0 N--CA 1.446 -0.642 0 O-C-N 119.747 -1.845 . . . . 0.0 110.627 161.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -126.55 116.96 21.87 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.843 -2.28 . . . . 0.0 104.843 -176.238 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 61.1 t -124.29 135.83 62.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 C-N-CA 125.417 1.487 . . . . 0.0 110.581 -149.629 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -136.32 133.68 37.13 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 105.447 -2.057 . . . . 0.0 105.447 -172.382 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 94.5 t -114.0 137.78 46.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 O-C-N 119.16 -2.212 . . . . 0.0 113.923 172.625 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 35.9 p -143.17 165.8 26.43 Favored 'General case' 0 CA--C 1.516 -0.349 0 O-C-N 120.614 -1.304 . . . . 0.0 113.609 -164.142 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . 0.26 7.4 tt -150.15 99.9 2.85 Favored 'General case' 0 C--N 1.344 0.368 0 N-CA-C 101.668 -3.456 . . . . 0.0 101.668 -146.767 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 8.7 ttm180 52.87 36.87 22.73 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 119.758 1.163 . . . . 0.0 111.471 -150.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.37 0.5 38.14 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-O 115.271 -2.96 . . . . 0.0 109.8 -178.473 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -94.81 142.93 25.35 Favored Pre-proline 0 N--CA 1.441 -0.877 0 CA-C-N 121.148 2.474 . . . . 0.0 109.868 -176.419 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -79.06 158.98 27.04 Favored 'Trans proline' 0 C--O 1.218 -0.499 0 CA-C-O 126.239 2.516 . . . . 0.0 113.459 -177.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 29.2 pt -142.92 -171.46 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 CA-C-N 109.386 -3.552 . . . . 0.0 113.32 -171.035 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -93.79 157.72 16.01 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 125.856 1.662 . . . . 0.0 112.341 -158.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.26 30.9 m120 50.19 34.1 8.15 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 129.793 3.237 . . . . 0.0 112.785 178.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 6.0 mmt -130.57 151.29 78.43 Favored Pre-proline 0 N--CA 1.444 -0.769 1 C-N-CA 134.551 5.141 . . . . 0.0 106.284 176.843 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -76.69 163.13 90.37 Favored 'Cis proline' 0 N--CA 1.45 -1.037 0 CA-C-N 126.432 3.333 . . . . 0.0 107.336 -2.457 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' ILE . . . . . 0.536 HD12 ' C ' ' A' ' 107' ' ' ILE 0.376 1.3 pp -127.04 167.54 21.66 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.409 0 N-CA-C 118.14 2.644 . . . . 0.0 118.14 163.743 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -106.57 142.13 36.72 Favored 'General case' 0 N--CA 1.449 -0.496 0 O-C-N 118.159 -2.838 . . . . 0.0 118.019 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 61.5 t -123.12 124.14 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 127.018 2.127 . . . . 0.0 109.977 -179.303 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -80.43 128.0 33.07 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-O 118.575 -0.726 . . . . 0.0 111.424 165.47 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 99.5 m -115.68 140.4 49.23 Favored 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 128.247 2.619 . . . . 0.0 112.819 -170.528 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.467 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 98.6 mt -133.85 145.73 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 CA-C-N 121.898 2.135 . . . . 0.0 106.795 177.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -82.19 48.1 1.22 Allowed 'General case' 0 N--CA 1.445 -0.698 0 O-C-N 116.76 -3.712 . . . . 0.0 113.692 -166.28 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.435 -1.391 0 O-C-N 120.575 -1.328 . . . . 0.0 116.111 174.493 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 17.2 tpt . . . . . 0 CA--C 1.531 0.226 0 CA-C-O 120.733 0.301 . . . . 0.0 111.208 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 91.9 m-70 -117.4 2.17 12.44 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 118.248 2.685 . . . . 0.0 118.248 -176.26 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -74.48 119.41 18.64 Favored 'General case' 0 N--CA 1.431 -1.376 0 O-C-N 118.964 -2.335 . . . . 0.0 115.502 -174.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 28.1 t-80 -166.12 123.88 1.45 Allowed 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 113.506 0.928 . . . . 0.0 113.506 -176.196 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 9.9 m-70 -82.56 131.64 35.21 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-O 118.016 -0.993 . . . . 0.0 112.921 -172.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 -142.49 -31.68 0.52 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 124.236 3.198 . . . . 0.0 112.555 -170.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 32.8 m170 -130.94 155.4 46.85 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 125.869 1.668 . . . . 0.0 114.193 -173.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.72 -48.43 54.6 Favored 'General case' 0 N--CA 1.442 -0.863 0 O-C-N 119.332 -2.105 . . . . 0.0 112.924 178.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 66.8 p -68.67 137.13 53.92 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 122.257 2.299 . . . . 0.0 113.301 166.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 32.3 mtmt -127.85 156.1 76.42 Favored Pre-proline 0 N--CA 1.448 -0.57 0 CA-C-O 115.983 -1.96 . . . . 0.0 114.564 176.09 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo -57.37 164.07 7.5 Favored 'Trans proline' 0 N--CA 1.445 -1.348 0 C-N-CA 124.582 3.521 . . . . 0.0 113.26 160.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -119.17 138.41 26.25 Favored Pre-proline 0 CA--C 1.512 -0.491 0 C-N-CA 126.106 1.762 . . . . 0.0 110.474 -178.197 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_exo -65.47 169.49 12.54 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.155 1.903 . . . . 0.0 114.156 170.233 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -145.74 168.02 21.74 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 125.547 1.539 . . . . 0.0 113.131 -171.456 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.44 -43.78 72.62 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 117.593 2.442 . . . . 0.0 117.593 179.32 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 55.6 mm-40 -60.65 -20.42 60.79 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.5 1.52 . . . . 0.0 111.353 167.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' HIS . . . . . 0.444 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . 68.6 m-70 -126.48 18.54 7.5 Favored 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 129.322 3.049 . . . . 0.0 112.757 -158.682 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.9 t -141.56 126.3 18.02 Favored 'General case' 0 N--CA 1.444 -0.729 0 O-C-N 119.856 -1.777 . . . . 0.0 106.476 166.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -153.86 157.85 39.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 130.632 3.573 . . . . 0.0 110.679 -175.306 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -141.92 148.77 39.22 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 127.734 2.413 . . . . 0.0 116.718 -165.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -144.08 143.31 31.1 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 113.969 -1.469 . . . . 0.0 109.33 -171.496 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 138.98 173.4 12.98 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 118.625 2.21 . . . . 0.0 118.625 169.846 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -68.87 -24.82 64.38 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 120.202 -1.763 . . . . 0.0 111.973 -168.354 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.18 7.35 0.56 Allowed Glycine 0 C--N 1.339 0.697 0 C-N-CA 129.779 3.562 . . . . 0.0 116.954 171.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 96.6 mt -116.98 -2.59 11.72 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-O 114.185 -2.817 . . . . 0.0 110.221 172.669 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 t -129.8 -55.05 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 CA-C-N 122.832 2.56 . . . . 0.0 109.156 -168.682 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 23.8 pttt -145.36 120.62 10.21 Favored 'General case' 0 C--O 1.238 0.46 0 O-C-N 118.873 -2.392 . . . . 0.0 112.282 -172.539 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 93.9 t -125.85 139.54 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 119.348 -2.095 . . . . 0.0 105.466 -172.734 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.443 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 42.5 m-85 -127.79 -163.43 1.26 Allowed 'General case' 0 N--CA 1.447 -0.621 0 CA-C-O 115.099 -2.381 . . . . 0.0 110.215 -178.582 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -103.14 -50.52 3.47 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 120.803 1.638 . . . . 0.0 114.572 -170.072 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 19.1 m-80 -109.2 6.01 24.34 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 130.27 3.428 . . . . 0.0 111.028 -179.156 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -122.06 85.82 46.34 Favored Pre-proline 0 C--O 1.224 -0.252 0 C-N-CA 126.693 1.997 . . . . 0.0 111.73 165.263 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -55.93 146.56 67.62 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 C-N-CA 117.244 -1.37 . . . . 0.0 115.091 176.573 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -93.76 162.64 13.85 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 119.044 2.979 . . . . 0.0 119.044 170.3 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -136.85 147.77 46.71 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 117.612 2.449 . . . . 0.0 117.612 -174.247 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -157.98 160.81 37.92 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-N 122.182 2.265 . . . . 0.0 107.77 169.443 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 49.2 m -119.18 127.92 53.75 Favored 'General case' 0 N--CA 1.441 -0.909 0 CA-C-O 113.805 -2.997 . . . . 0.0 113.811 -166.559 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.0 mt -86.39 106.53 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 O-C-N 126.681 2.488 . . . . 0.0 105.548 179.335 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.474 55.5 p90 -85.34 114.25 22.27 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 117.874 2.546 . . . . 0.0 117.874 175.015 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -119.91 139.04 53.04 Favored 'General case' 0 CA--C 1.517 -0.325 0 CA-C-N 122.85 2.568 . . . . 0.0 113.106 -167.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.444 ' HB ' ' HB3' ' A' ' 17' ' ' HIS . 78.0 t -129.35 143.57 40.78 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 1 C-N-CA 132.236 4.214 . . . . 0.0 111.457 173.414 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -70.03 -82.93 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 126.941 3.258 . . . . 0.0 107.924 173.45 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 48.9 p -153.44 -21.3 0.14 Allowed 'General case' 0 C--N 1.328 -0.328 2 C-N-CA 134.773 5.229 . . . . 0.0 117.992 -179.394 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 18.4 mmtp -80.5 16.34 1.38 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 127.789 3.181 . . . . 0.0 116.33 -176.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.62 -56.65 5.03 Favored Glycine 0 C--N 1.345 1.034 0 N-CA-C 120.301 2.88 . . . . 0.0 120.301 -175.34 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 24.5 t -63.68 146.53 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 172.846 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.76 170.12 0.06 Allowed 'General case' 0 N--CA 1.438 -1.034 0 CA-C-O 121.589 0.709 . . . . 0.0 111.228 177.486 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.7 mmm180 -68.44 118.39 11.44 Favored 'General case' 0 C--N 1.351 0.659 0 O-C-N 118.261 -2.774 . . . . 0.0 113.564 -175.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 16.0 p -77.88 1.56 20.09 Favored 'General case' 0 N--CA 1.447 -0.591 1 C-N-CA 134.738 5.215 . . . . 0.0 117.733 -171.684 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 10.0 p30 -161.09 -174.5 4.39 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-N 111.171 -2.74 . . . . 0.0 104.801 163.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -144.2 -170.36 13.56 Favored Glycine 0 CA--C 1.524 0.641 0 C-N-CA 128.462 2.934 . . . . 0.0 117.321 -142.08 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 54.18 46.18 71.47 Favored Glycine 0 C--N 1.337 0.623 0 CA-C-O 123.629 1.683 . . . . 0.0 110.639 178.07 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -86.71 137.88 33.64 Favored Pre-proline 0 N--CA 1.45 -0.449 0 O-C-N 116.688 -3.831 . . . . 0.0 112.157 174.488 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -68.94 137.18 37.22 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.383 2.722 . . . . 0.0 113.756 -171.496 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -159.6 150.37 19.37 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 112.217 -2.265 . . . . 0.0 112.924 -165.696 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -152.34 134.92 15.32 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 118.106 -2.871 . . . . 0.0 113.977 -166.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 4.5 t -129.74 81.62 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 CA-C-N 113.325 -1.761 . . . . 0.0 113.643 -176.273 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -100.53 141.13 33.81 Favored 'General case' 0 CA--C 1.516 -0.354 0 O-C-N 126.023 2.077 . . . . 0.0 110.87 -174.696 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.5 mt -132.88 147.42 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 CA-C-O 125.01 2.338 . . . . 0.0 108.23 -163.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -116.5 118.83 33.73 Favored 'General case' 0 C--O 1.223 -0.33 0 O-C-N 119.3 -2.125 . . . . 0.0 109.166 166.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -111.31 -158.75 15.3 Favored Glycine 0 N--CA 1.442 -0.948 0 N-CA-C 121.797 3.479 . . . . 0.0 121.797 163.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo -68.52 141.34 50.35 Favored 'Trans proline' 0 N--CA 1.434 -2.017 1 C-N-CA 125.834 4.356 . . . . 0.0 113.339 -177.213 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.368 60.3 m-20 55.79 -125.33 2.06 Favored 'General case' 0 N--CA 1.446 -0.673 0 C-N-CA 126.834 2.054 . . . . 0.0 111.138 -176.831 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -82.6 8.61 61.55 Favored Glycine 0 CA--C 1.53 1.003 1 O-C-N 114.502 -5.124 . . . . 0.0 119.728 179.144 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.6 mt -76.57 75.96 3.27 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-N 117.882 0.841 . . . . 0.0 110.162 -176.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 1.4 m -58.04 123.31 9.51 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 O-C-N 120.186 -1.571 . . . . 0.0 112.757 134.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 72.8 t -132.63 145.34 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 CA-C-N 122.304 2.32 . . . . 0.0 106.465 -174.069 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -128.87 131.68 47.67 Favored 'General case' 0 N--CA 1.445 -0.69 0 O-C-N 119.122 -2.236 . . . . 0.0 110.332 172.186 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -102.63 137.37 40.95 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 126.476 1.91 . . . . 0.0 113.752 -165.156 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.271 37.1 ttpt -81.96 117.46 22.2 Favored 'General case' 0 C--O 1.218 -0.556 0 O-C-N 120.245 -1.535 . . . . 0.0 111.664 -160.05 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -88.48 131.6 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 175.222 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 67.2 m -131.84 125.96 33.09 Favored 'General case' 0 N--CA 1.452 -0.349 0 O-C-N 125.619 1.824 . . . . 0.0 110.934 172.321 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -66.29 118.52 10.09 Favored 'General case' 0 N--CA 1.44 -0.951 0 C-N-CA 128.153 2.581 . . . . 0.0 110.644 176.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.4 m-20 -79.63 -4.07 49.98 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 119.807 3.262 . . . . 0.0 119.807 175.653 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 68.56 25.66 6.6 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 131.595 3.958 . . . . 0.0 114.008 176.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 43.2 p30 -135.06 -4.69 2.41 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 114.053 -2.879 . . . . 0.0 110.946 -165.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 120.88 -14.34 9.71 Favored Glycine 0 C--N 1.337 0.624 0 C-N-CA 126.847 2.165 . . . . 0.0 111.223 -171.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 p -133.12 165.83 23.86 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 131.388 3.875 . . . . 0.0 113.56 -170.282 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 16.7 m-85 -131.57 137.57 48.51 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 128.704 2.802 . . . . 0.0 106.671 -174.409 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -92.21 139.41 14.67 Favored Glycine 0 C--O 1.226 -0.369 0 C-N-CA 128.159 2.79 . . . . 0.0 107.304 174.339 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 22.8 t -122.83 130.79 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-O 117.119 -1.419 . . . . 0.0 108.633 178.693 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.4 p -135.71 141.85 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 119.696 1.134 . . . . 0.0 112.527 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 7.5 p90 -161.11 169.61 22.05 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 115.902 1.816 . . . . 0.0 115.902 179.194 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 15.2 p30 -139.0 164.79 28.83 Favored 'General case' 0 N--CA 1.449 -0.508 0 O-C-N 118.756 -2.465 . . . . 0.0 117.532 177.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -123.53 112.57 29.35 Favored Pre-proline 0 N--CA 1.448 -0.568 0 O-C-N 125.305 1.628 . . . . 0.0 107.643 -174.797 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.336 14.9 Cg_endo -66.76 -8.52 21.56 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 N-CA-C 117.57 2.104 . . . . 0.0 117.57 170.382 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 28.4 m -148.08 134.51 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 O-C-N 120.369 -1.457 . . . . 0.0 110.606 -164.568 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -56.39 116.16 2.91 Favored 'General case' 0 N--CA 1.456 -0.169 0 O-C-N 126.195 2.185 . . . . 0.0 112.47 167.026 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 170.29 -166.7 39.89 Favored Glycine 0 CA--C 1.527 0.828 0 CA-C-O 122.306 0.948 . . . . 0.0 112.485 -172.053 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -106.42 137.75 43.84 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 114.37 1.248 . . . . 0.0 114.37 175.434 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -103.34 139.29 38.96 Favored 'General case' 0 N--CA 1.445 -0.713 0 C-N-CA 128.634 2.774 . . . . 0.0 110.418 168.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -114.53 119.55 37.21 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 117.164 2.283 . . . . 0.0 117.164 170.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . 0.275 65.2 t -118.1 133.64 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-N 112.795 -2.002 . . . . 0.0 111.863 -157.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -130.23 138.95 50.81 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 126.879 2.072 . . . . 0.0 109.087 171.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 85.8 t -114.79 126.48 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 C-N-CA 124.856 1.262 . . . . 0.0 113.312 168.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . 0.301 67.0 p -132.8 145.97 51.44 Favored 'General case' 0 N--CA 1.444 -0.767 0 O-C-N 125.423 1.702 . . . . 0.0 114.519 -168.561 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 8.4 tt -136.62 95.8 3.22 Favored 'General case' 0 N--CA 1.447 -0.58 1 O-C-N 116.182 -4.074 . . . . 0.0 107.796 -137.491 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . 0.316 51.4 ttt180 46.0 40.09 6.51 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 125.933 2.778 . . . . 0.0 115.858 -147.644 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 69.15 16.75 71.27 Favored Glycine 0 C--N 1.341 0.818 0 O-C-N 118.318 -2.739 . . . . 0.0 117.838 -175.528 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -106.57 153.51 40.56 Favored Pre-proline 0 N--CA 1.447 -0.6 0 O-C-N 116.508 -3.937 . . . . 0.0 111.678 165.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_endo -86.53 169.57 8.14 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 124.548 3.499 . . . . 0.0 114.166 -178.694 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.406 ' HB ' ' H ' ' A' ' 103' ' ' LYS . 11.2 pt -130.8 -173.22 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-N 113.975 -1.466 . . . . 0.0 109.13 176.218 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.406 ' H ' ' HB ' ' A' ' 102' ' ' ILE . 57.1 mttm -67.84 169.59 9.51 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 115.385 1.624 . . . . 0.0 115.385 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 33.3 m120 47.49 28.66 1.2 Allowed 'General case' 0 N--CA 1.447 -0.617 0 O-C-N 116.959 -3.588 . . . . 0.0 118.859 169.738 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 12.7 mmt -136.32 146.14 54.83 Favored Pre-proline 0 N--CA 1.444 -0.765 0 C-N-CA 129.128 2.971 . . . . 0.0 109.187 -177.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . 0.272 96.6 Cg_endo -68.07 169.24 55.87 Favored 'Cis proline' 0 N--CA 1.457 -0.63 0 CA-C-N 127.293 3.64 . . . . 0.0 116.232 -4.566 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 27.2 pt -146.77 161.25 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 O-C-N 126.9 2.625 . . . . 0.0 114.616 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -112.83 131.28 55.77 Favored 'General case' 0 N--CA 1.445 -0.71 0 C-N-CA 127.352 2.261 . . . . 0.0 112.875 -178.439 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 59.0 t -122.98 141.26 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 C-N-CA 126.681 1.992 . . . . 0.0 106.813 -175.74 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 39.8 mmtm -91.37 138.33 31.67 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 116.335 1.976 . . . . 0.0 116.335 176.797 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 21.8 m -115.96 126.51 53.95 Favored 'General case' 0 N--CA 1.441 -0.903 0 C-N-CA 129.504 3.122 . . . . 0.0 108.342 -174.864 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.443 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 15.2 mt -124.64 135.17 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 161.017 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -72.96 56.04 0.42 Allowed 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 118.699 2.851 . . . . 0.0 118.699 -176.554 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.4 0 O-C-N 117.388 -3.32 . . . . 0.0 117.14 165.975 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 41.3 tpp . . . . . 0 CA--C 1.514 -0.428 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 68.5 m-70 -87.36 4.43 43.05 Favored 'General case' 0 CA--C 1.508 -0.636 0 C-N-CA 125.913 1.685 . . . . 0.0 112.059 173.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 5.3 t60 -88.22 124.43 33.84 Favored 'General case' 0 N--CA 1.445 -0.687 0 O-C-N 116.674 -3.766 . . . . 0.0 113.336 175.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . 0.267 11.5 t60 -172.13 130.95 0.62 Allowed 'General case' 0 N--CA 1.442 -0.861 0 C-N-CA 128.548 2.739 . . . . 0.0 115.177 -168.059 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 77.3 m-70 -95.68 88.12 4.9 Favored 'General case' 0 N--CA 1.438 -1.044 1 C-N-CA 131.747 4.019 . . . . 0.0 107.413 -179.032 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 3.2 t-80 -125.04 0.72 7.93 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 126.52 1.928 . . . . 0.0 115.272 -179.151 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -137.23 153.93 50.27 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-O 114.853 -2.499 . . . . 0.0 108.704 -172.489 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -90.17 -27.69 19.41 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 124.194 3.179 . . . . 0.0 117.614 177.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 11.3 m -85.12 149.63 25.4 Favored 'General case' 0 C--O 1.245 0.84 0 C-N-CA 129.411 3.085 . . . . 0.0 113.394 165.463 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 54.3 mtmt -119.36 152.09 52.16 Favored Pre-proline 0 N--CA 1.448 -0.555 0 N-CA-C 117.446 2.387 . . . . 0.0 117.446 170.22 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -70.85 164.76 34.47 Favored 'Trans proline' 0 N--CA 1.453 -0.887 0 CA-C-N 121.261 1.486 . . . . 0.0 112.28 146.217 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -123.14 154.22 64.9 Favored Pre-proline 0 N--CA 1.446 -0.653 0 C-N-CA 128.059 2.543 . . . . 0.0 113.258 -166.434 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_exo -63.92 153.82 73.53 Favored 'Trans proline' 0 N--CA 1.444 -1.413 0 C-N-CA 124.162 3.241 . . . . 0.0 116.076 166.364 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.463 ' HB3' ' HB2' ' A' ' 17' ' ' HIS . 26.4 t -122.86 150.75 42.46 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.17 1.788 . . . . 0.0 106.259 178.23 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . 0.314 . . -51.19 -37.99 49.77 Favored 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 126.118 1.767 . . . . 0.0 114.632 163.067 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -58.61 -29.11 66.22 Favored 'General case' 0 N--CA 1.443 -0.809 0 C-N-CA 125.003 1.321 . . . . 0.0 110.192 170.624 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' HIS . . . . . 0.463 ' HB2' ' HB3' ' A' ' 14' ' ' SER . 86.6 m-70 -134.66 24.98 3.71 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 131.292 3.837 . . . . 0.0 112.556 -155.181 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 42.6 t -148.16 120.24 8.27 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 117.343 2.349 . . . . 0.0 117.343 166.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -146.48 142.49 28.15 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-O 113.482 -3.152 . . . . 0.0 113.832 -160.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -124.48 140.82 52.59 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 119.373 3.101 . . . . 0.0 119.373 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -136.44 147.57 47.3 Favored 'General case' 0 C--O 1.223 -0.317 0 CA-C-N 120.962 1.71 . . . . 0.0 112.19 -177.203 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.43 175.8 18.84 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 125.436 1.494 . . . . 0.0 114.575 167.403 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -55.93 -34.75 65.91 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-O 114.495 -2.669 . . . . 0.0 112.503 177.711 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -57.93 -3.0 1.02 Allowed Glycine 0 C--O 1.226 -0.355 0 CA-C-N 123.462 2.847 . . . . 0.0 116.138 165.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . 0.373 24.1 mt -109.29 29.26 7.7 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 120.544 2.172 . . . . 0.0 111.32 161.403 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 96.8 t -150.16 -42.0 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 CA-C-N 121.683 2.038 . . . . 0.0 114.584 -175.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.333 43.0 pttt -151.39 131.12 13.17 Favored 'General case' 0 C--N 1.326 -0.429 1 O-C-N 116.164 -4.085 . . . . 0.0 112.36 -179.425 . . . . . . . . 3 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 38.4 t -143.66 141.15 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 -166.729 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -136.08 172.31 13.19 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-N 120.181 1.355 . . . . 0.0 114.277 -169.471 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 46.8 t0 -78.55 -50.81 10.91 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-O 122.631 1.205 . . . . 0.0 112.519 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 70.4 m-80 -104.03 8.7 36.65 Favored 'General case' 0 N--CA 1.448 -0.545 0 O-C-N 118.427 -2.67 . . . . 0.0 111.636 -179.223 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -133.85 101.81 12.63 Favored Pre-proline 0 N--CA 1.447 -0.625 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 170.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -57.92 131.47 43.94 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 CA-C-O 125.552 2.23 . . . . 0.0 111.888 159.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -85.93 162.48 18.54 Favored 'General case' 0 N--CA 1.45 -0.459 0 O-C-N 117.008 -3.558 . . . . 0.0 113.539 165.582 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -133.22 154.6 50.51 Favored 'General case' 0 N--CA 1.448 -0.553 0 O-C-N 125.057 1.473 . . . . 0.0 110.508 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -157.48 171.45 20.34 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 117.662 -3.149 . . . . 0.0 105.403 167.176 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 91.1 m -133.35 130.47 38.86 Favored 'General case' 0 C--O 1.233 0.197 0 O-C-N 127.167 2.792 . . . . 0.0 113.737 -164.365 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.2 mt -84.77 104.06 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 123.929 0.892 . . . . 0.0 110.946 171.552 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 32.5 p90 -77.15 108.1 9.99 Favored 'General case' 0 N--CA 1.44 -0.973 0 N-CA-C 119.222 3.045 . . . . 0.0 119.222 163.457 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -117.78 150.22 39.49 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 121.288 1.858 . . . . 0.0 109.491 -163.145 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.2 t -137.79 159.19 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 105.718 -1.956 . . . . 0.0 105.718 174.713 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.0 p30 -78.36 -61.91 1.85 Allowed 'General case' 0 N--CA 1.452 -0.331 0 O-C-N 119.766 -1.834 . . . . 0.0 115.214 170.259 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 21.9 p -174.91 -35.63 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 131.64 3.976 . . . . 0.0 114.42 -161.034 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -107.69 40.92 1.61 Allowed 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 122.73 2.514 . . . . 0.0 112.665 -171.755 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 53.02 -25.39 0.01 OUTLIER Glycine 0 C--N 1.338 0.666 0 C-N-CA 130.129 3.728 . . . . 0.0 121.568 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.1 t -64.3 125.55 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 O-C-N 116.951 -3.676 . . . . 0.0 107.882 167.149 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -31.33 127.2 0.19 Allowed 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 117.36 2.356 . . . . 0.0 117.36 162.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 11.5 mmm180 -35.12 122.03 0.57 Allowed 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 118.672 2.841 . . . . 0.0 118.672 -177.296 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 8.5 p -78.79 -2.6 40.34 Favored 'General case' 0 N--CA 1.445 -0.696 0 C-N-CA 126.774 2.03 . . . . 0.0 111.576 -162.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.9 p30 -162.45 169.2 20.8 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 127.925 2.49 . . . . 0.0 109.199 178.055 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -123.91 -157.07 9.68 Favored Glycine 0 CA--C 1.522 0.502 0 C-N-CA 119.918 -1.134 . . . . 0.0 110.897 -160.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 61.01 41.05 99.31 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 178.286 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 58.4 m-20 -78.38 156.08 78.79 Favored Pre-proline 0 N--CA 1.448 -0.552 0 C-N-CA 126.982 2.113 . . . . 0.0 108.438 173.773 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -91.67 62.78 1.04 Allowed 'Trans proline' 0 N--CA 1.444 -1.395 0 C-N-CA 124.811 3.674 . . . . 0.0 117.284 -169.229 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -69.88 149.55 47.73 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 120.971 3.693 . . . . 0.0 120.971 173.471 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -150.49 128.36 11.74 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 127.22 2.208 . . . . 0.0 112.906 168.283 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.583 HG22 HG22 ' A' ' 95' ' ' VAL . 39.5 t -114.46 87.53 1.03 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.326 0 C-N-CA 129.99 3.316 . . . . 0.0 104.408 -174.606 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -104.66 142.29 34.94 Favored 'General case' 0 N--CA 1.444 -0.753 0 C-N-CA 127.14 2.176 . . . . 0.0 106.065 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 19.1 mt -130.86 155.38 41.87 Favored 'Isoleucine or valine' 0 C--O 1.238 0.463 0 C-N-CA 128.334 2.654 . . . . 0.0 113.492 -170.468 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 71.6 m-80 -125.01 126.25 45.14 Favored 'General case' 0 N--CA 1.446 -0.642 0 C-N-CA 131.426 3.89 . . . . 0.0 109.137 174.249 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -118.49 -177.87 16.92 Favored Glycine 0 CA--C 1.528 0.876 0 O-C-N 119.034 -2.291 . . . . 0.0 112.351 167.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo -56.26 125.49 19.24 Favored 'Trans proline' 0 N--CA 1.441 -1.594 0 CA-C-N 118.741 1.27 . . . . 0.0 111.875 -174.739 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 58.0 m-20 63.26 -118.61 0.53 Allowed 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 126.17 1.788 . . . . 0.0 110.905 173.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.92 -7.89 76.75 Favored Glycine 0 N--CA 1.441 -0.981 0 O-C-N 126.357 2.286 . . . . 0.0 114.468 -166.203 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 93.2 mt -76.02 77.74 2.88 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 127.472 3.511 . . . . 0.0 119.058 176.284 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 26.2 t -64.0 131.65 29.69 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 CA-C-N 112.589 -2.096 . . . . 0.0 109.749 143.147 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 96.0 t -142.02 144.37 25.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 112.474 -2.148 . . . . 0.0 111.846 -177.272 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.301 3.6 p-10 -127.2 134.55 50.11 Favored 'General case' 0 N--CA 1.445 -0.695 0 O-C-N 117.953 -2.967 . . . . 0.0 111.285 168.199 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.75 155.57 19.49 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 126.927 3.251 . . . . 0.0 111.134 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.301 9.2 tmtt? -99.99 104.17 15.76 Favored 'General case' 0 N--CA 1.448 -0.553 1 O-C-N 113.235 -5.916 . . . . 0.0 111.216 -170.45 . . . . . . . . 3 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.0 t -76.38 138.64 20.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 O-C-N 127.17 2.794 . . . . 0.0 117.644 169.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 10.0 m -144.15 128.86 18.24 Favored 'General case' 0 C--O 1.237 0.443 0 O-C-N 126.725 2.516 . . . . 0.0 111.091 173.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -79.16 136.07 37.0 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 125.237 2.446 . . . . 0.0 110.226 -169.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . 0.266 8.0 m-20 -96.61 0.56 50.1 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 116.534 -3.854 . . . . 0.0 118.551 -175.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 6.5 m120 68.68 27.62 5.88 Favored 'General case' 0 C--O 1.215 -0.733 0 O-C-N 128.731 3.769 . . . . 0.0 114.512 176.041 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 26.7 p30 -134.66 -8.24 2.46 Favored 'General case' 0 N--CA 1.445 -0.706 0 CA-C-O 117.227 -1.368 . . . . 0.0 112.153 -176.096 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 109.02 5.88 30.41 Favored Glycine 0 C--N 1.35 1.313 0 CA-C-O 113.492 -3.949 . . . . 0.0 108.21 -170.141 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.7 p -130.09 158.07 40.64 Favored 'General case' 0 N--CA 1.442 -0.83 1 CA-C-N 126.491 5.146 . . . . 0.0 111.391 -175.065 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -135.93 113.01 10.42 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 120.633 1.561 . . . . 0.0 110.543 -174.38 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -63.33 136.91 42.63 Favored Glycine 0 N--CA 1.452 -0.268 0 N-CA-C 116.539 1.376 . . . . 0.0 116.539 167.246 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.9 t -131.64 134.41 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 126.713 2.005 . . . . 0.0 112.155 -178.795 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -132.5 141.56 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-N 122.912 2.596 . . . . 0.0 109.82 -175.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 1.8 p90 -166.32 170.81 12.73 Favored 'General case' 0 N--CA 1.446 -0.637 0 O-C-N 125.512 1.758 . . . . 0.0 115.185 170.729 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 27.2 p30 -142.41 141.87 32.3 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 129.077 2.951 . . . . 0.0 109.916 -158.01 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -112.91 125.61 29.57 Favored Pre-proline 0 C--N 1.344 0.365 0 CA-C-O 117.399 -1.286 . . . . 0.0 113.201 -176.467 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -84.01 -1.09 9.83 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 123.387 2.724 . . . . 0.0 112.54 178.147 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.4 m -128.24 148.93 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 O-C-N 118.783 -2.448 . . . . 0.0 113.532 -164.289 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -63.4 111.39 2.28 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-O 124.814 2.245 . . . . 0.0 109.235 139.433 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 169.26 -162.52 36.18 Favored Glycine 0 C--O 1.221 -0.657 0 O-C-N 118.583 -2.573 . . . . 0.0 118.015 -173.114 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 27.3 t30 -117.68 132.58 56.47 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 127.435 2.294 . . . . 0.0 111.83 177.429 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -90.73 153.28 20.39 Favored 'General case' 0 C--O 1.221 -0.416 0 O-C-N 118.423 -2.673 . . . . 0.0 113.086 158.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -128.37 113.28 15.39 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 113.186 -1.825 . . . . 0.0 113.699 176.05 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.6 t -115.07 120.37 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 CA-C-N 113.887 -1.506 . . . . 0.0 114.204 -154.757 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.6 t30 -129.65 111.16 12.41 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 126.301 1.84 . . . . 0.0 108.379 -167.726 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.583 HG22 HG22 ' A' ' 57' ' ' VAL . 84.2 t -98.03 134.89 34.66 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.525 0 C-N-CA 126.72 2.008 . . . . 0.0 109.971 177.047 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 17.0 p -144.01 157.42 44.34 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 126.497 3.046 . . . . 0.0 115.911 -173.57 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 49.3 tp -129.03 104.97 7.88 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 101.763 -3.421 . . . . 0.0 101.763 -149.039 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 67.6 ttp85 45.74 42.79 9.01 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 104.91 -2.256 . . . . 0.0 104.91 -162.308 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.63 -1.06 31.55 Favored Glycine 0 CA--C 1.52 0.378 0 N-CA-C 119.932 2.733 . . . . 0.0 119.932 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -85.96 148.76 48.92 Favored Pre-proline 0 N--CA 1.445 -0.677 0 C-N-CA 129.246 3.019 . . . . 0.0 112.225 174.622 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_endo -76.73 170.8 19.19 Favored 'Trans proline' 0 N--CA 1.444 -1.423 0 O-C-N 124.769 1.931 . . . . 0.0 112.383 -175.248 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . 0.284 4.3 pt -136.37 -163.15 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 C-N-CA 128.399 2.679 . . . . 0.0 112.438 -179.124 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 32.1 mttt -100.88 159.81 14.89 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 125.337 3.699 . . . . 0.0 109.19 -173.582 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 33.4 m120 54.31 31.51 14.48 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 128.36 2.664 . . . . 0.0 113.351 173.066 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' MET . . . . . . . . . . . . 0.263 7.2 mmt -132.49 150.37 75.68 Favored Pre-proline 0 N--CA 1.454 -0.248 0 O-C-N 118.082 -2.886 . . . . 0.0 105.594 -173.205 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -66.15 174.84 25.54 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 CA-C-N 125.47 2.989 . . . . 0.0 112.735 -5.701 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 12.4 pt -143.32 169.81 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 O-C-N 126.083 2.114 . . . . 0.0 109.1 170.323 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -125.7 141.39 52.04 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 122.482 2.401 . . . . 0.0 114.437 -167.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 58.5 t -132.81 120.57 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 123.337 0.655 . . . . 0.0 109.421 -170.297 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 62.5 mttm -65.67 132.21 48.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 126.94 2.096 . . . . 0.0 108.183 173.318 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 20.1 m -126.28 138.27 53.59 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 127.422 2.289 . . . . 0.0 115.885 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 83.7 mt -130.63 152.06 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 O-C-N 118.709 -2.494 . . . . 0.0 110.437 167.003 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -84.91 45.48 1.17 Allowed 'General case' 0 N--CA 1.453 -0.32 0 O-C-N 120.41 -1.431 . . . . 0.0 113.828 -165.29 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.93 0 N-CA-C 116.431 1.332 . . . . 0.0 116.431 -174.41 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo . . . . . 0 N--CA 1.449 -1.129 0 N-CA-C 109.002 -1.191 . . . . 0.0 109.002 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -101.5 135.7 19.77 Favored Pre-proline 0 C--O 1.238 0.475 0 CA-C-O 115.816 -2.04 . . . . 0.0 113.868 -177.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -53.42 149.14 31.16 Favored 'Trans proline' 0 N--CA 1.44 -1.624 1 C-N-CA 132.061 8.507 . . . . 0.0 113.622 157.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.3 m -145.7 161.17 40.5 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 123.342 1.544 . . . . 0.0 107.45 -166.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.29 -44.04 89.23 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 108.825 -3.807 . . . . 0.0 114.601 -172.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . 0.288 68.1 mm-40 -64.88 -20.72 66.58 Favored 'General case' 0 N--CA 1.442 -0.83 0 C-N-CA 129.296 3.038 . . . . 0.0 112.763 167.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -121.28 16.52 11.45 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 130.499 3.52 . . . . 0.0 117.733 -163.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 t -142.84 135.05 27.36 Favored 'General case' 0 N--CA 1.445 -0.684 0 O-C-N 118.374 -2.704 . . . . 0.0 110.661 166.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . 0.356 49.6 m-85 -154.41 147.27 24.43 Favored 'General case' 0 N--CA 1.446 -0.673 0 C-N-CA 127.646 2.378 . . . . 0.0 107.415 -167.052 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -136.69 150.08 48.27 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 118.377 2.732 . . . . 0.0 118.377 -172.319 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -156.61 145.63 20.28 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 119.324 3.083 . . . . 0.0 119.324 -165.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.8 -170.33 21.22 Favored Glycine 0 C--N 1.341 0.833 0 C-N-CA 127.521 2.486 . . . . 0.0 115.578 174.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -58.18 -38.66 77.11 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 125.813 1.645 . . . . 0.0 110.256 -170.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -68.33 -1.84 23.4 Favored Glycine 0 CA--C 1.527 0.835 0 O-C-N 117.814 -3.054 . . . . 0.0 113.366 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.5 mt -120.27 21.75 11.61 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 122.095 2.948 . . . . 0.0 107.289 169.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.0 t -124.43 -50.85 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-O 116.309 -1.805 . . . . 0.0 112.669 165.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.4 pttt -155.63 136.3 13.42 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 122.419 2.372 . . . . 0.0 110.505 -165.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 46.2 t -144.73 141.03 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 CA-C-O 115.303 -2.284 . . . . 0.0 109.049 -170.284 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -137.43 -171.47 2.98 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 120.36 3.467 . . . . 0.0 120.36 -172.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 48.4 t0 -94.03 -57.55 2.5 Favored 'General case' 0 N--CA 1.447 -0.587 1 O-C-N 115.101 -4.75 . . . . 0.0 109.294 -162.188 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 66.6 m-80 -97.97 -2.8 39.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 118.841 2.904 . . . . 0.0 118.841 172.093 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -114.47 88.85 16.54 Favored Pre-proline 0 N--CA 1.445 -0.719 0 CA-C-O 122.58 1.181 . . . . 0.0 110.248 160.106 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -43.77 135.63 7.26 Favored 'Trans proline' 0 N--CA 1.445 -1.325 0 N-CA-C 116.997 1.884 . . . . 0.0 116.997 156.381 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.44 153.95 22.58 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.238 2.215 . . . . 0.0 113.418 -174.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -138.11 147.92 44.46 Favored 'General case' 0 N--CA 1.442 -0.851 0 C-N-CA 128.494 2.717 . . . . 0.0 112.626 -171.051 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -155.02 175.14 14.21 Favored 'General case' 0 CA--C 1.514 -0.429 0 C-N-CA 130.111 3.365 . . . . 0.0 112.868 166.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.415 ' CG2' ' HB ' ' A' ' 78' ' ' THR . 86.9 m -123.36 125.7 45.48 Favored 'General case' 0 C--N 1.344 0.364 0 N-CA-C 117.23 2.307 . . . . 0.0 117.23 -164.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . 0.273 2.3 mt -78.31 123.25 34.85 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.717 0 CA-C-O 114.001 -2.904 . . . . 0.0 115.791 167.59 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.312 22.7 p90 -111.05 91.96 3.86 Favored 'General case' 0 N--CA 1.433 -1.287 0 C-N-CA 129.843 3.257 . . . . 0.0 115.262 177.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -97.74 138.14 35.57 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 130.529 3.531 . . . . 0.0 114.379 -166.266 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.1 t -131.58 135.73 58.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 CA-C-N 112.078 -2.328 . . . . 0.0 107.948 170.126 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -61.55 -61.26 2.65 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 117.029 2.233 . . . . 0.0 117.029 166.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 21.1 p -164.03 -26.67 0.04 OUTLIER 'General case' 0 N--CA 1.443 -0.795 0 C-N-CA 130.354 3.462 . . . . 0.0 110.648 169.196 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 34.6 mtmm -76.4 19.22 0.26 Allowed 'General case' 0 CA--C 1.515 -0.386 0 O-C-N 127.006 2.691 . . . . 0.0 114.166 -163.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 62.6 -46.38 0.07 OUTLIER Glycine 0 C--N 1.347 1.19 0 C-N-CA 127.067 2.27 . . . . 0.0 118.049 177.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 57.9 t -52.27 140.34 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 CA-C-N 121.881 2.841 . . . . 0.0 112.398 159.136 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -32.44 153.05 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 117.351 2.352 . . . . 0.0 117.351 165.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 8.0 mmm180 -59.7 128.13 35.41 Favored 'General case' 0 N--CA 1.452 -0.355 0 O-C-N 118.01 -2.931 . . . . 0.0 113.408 173.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 59.9 p -88.82 1.53 55.12 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 127.806 2.442 . . . . 0.0 112.877 -169.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -163.82 156.74 18.1 Favored 'General case' 0 N--CA 1.448 -0.526 1 O-C-N 115.786 -4.321 . . . . 0.0 112.922 176.4 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.81 -173.92 30.63 Favored Glycine 0 N--CA 1.466 0.684 0 O-C-N 125.591 1.807 . . . . 0.0 108.98 -155.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.23 32.36 83.89 Favored Glycine 0 C--O 1.236 0.224 0 C-N-CA 127.672 2.558 . . . . 0.0 114.076 171.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -60.71 145.17 88.48 Favored Pre-proline 0 CA--C 1.514 -0.418 0 O-C-N 117.743 -3.21 . . . . 0.0 106.763 160.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -84.09 135.97 6.68 Favored 'Trans proline' 0 CA--C 1.509 -0.735 0 C-N-CA 124.734 3.623 . . . . 0.0 115.952 170.304 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -135.2 163.96 28.77 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 129.62 3.168 . . . . 0.0 111.2 -172.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.439 ' O ' ' HA ' ' A' ' 95' ' ' VAL 0.275 21.5 tt0 -145.64 141.56 28.25 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 127.919 2.488 . . . . 0.0 113.472 164.667 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 4.3 t -129.9 61.49 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 129.487 3.115 . . . . 0.0 105.335 -173.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -83.81 132.04 34.85 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 112.839 -1.982 . . . . 0.0 113.958 -175.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.437 HD13 ' CE2' ' A' ' 83' ' ' TYR . 61.3 mt -138.77 145.59 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 CA-C-O 124.34 2.019 . . . . 0.0 108.486 -158.277 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 24.3 m120 -113.18 129.69 56.44 Favored 'General case' 0 N--CA 1.45 -0.455 0 O-C-N 116.587 -3.821 . . . . 0.0 108.993 167.206 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.22 -172.61 41.79 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 126.205 1.86 . . . . 0.0 114.042 157.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo . . . . . 0 N--CA 1.455 -0.766 0 C-N-CA 122.94 2.427 . . . . 0.0 112.937 -178.984 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . 0.265 56.7 t . . . . . 0 N--CA 1.449 -0.523 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 2.3 t -127.8 151.57 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 O-C-N 120.904 -1.123 . . . . 0.0 108.477 -168.136 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -121.76 139.75 53.2 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 126.411 3.005 . . . . 0.0 110.816 153.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -87.16 125.84 34.41 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 112.172 -2.285 . . . . 0.0 106.716 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 30.3 mmtm -81.17 133.64 35.49 Favored 'General case' 0 N--CA 1.449 -0.481 0 O-C-N 118.848 -2.407 . . . . 0.0 111.285 -167.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 72.2 t -107.97 139.96 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.685 0 CA-C-O 126.072 2.844 . . . . 0.0 106.842 -168.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 28.4 m -144.5 127.18 16.15 Favored 'General case' 0 C--N 1.345 0.37 0 CA-C-N 111.606 -2.543 . . . . 0.0 109.611 173.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 62.3 t0 -63.05 129.67 41.35 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 125.459 1.503 . . . . 0.0 111.752 177.279 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 -82.84 -11.37 58.29 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 115.954 1.835 . . . . 0.0 115.954 173.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.39 2.5 m120 63.66 48.5 3.31 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.294 2.238 . . . . 0.0 116.181 -172.697 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 44.0 p-10 -156.75 8.35 0.2 Allowed 'General case' 0 C--N 1.345 0.388 0 CA-C-O 126.376 2.988 . . . . 0.0 117.726 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 95.16 17.52 36.97 Favored Glycine 0 CA--C 1.526 0.742 0 O-C-N 117.588 -3.195 . . . . 0.0 108.441 -178.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.415 ' HB ' ' CG2' ' A' ' 37' ' ' THR . 31.1 p -136.76 166.58 23.26 Favored 'General case' 0 C--N 1.331 -0.226 0 O-C-N 124.728 0.899 . . . . 0.0 111.947 173.41 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -137.28 121.61 18.14 Favored 'General case' 0 N--CA 1.441 -0.888 0 O-C-N 125.674 1.859 . . . . 0.0 108.359 -172.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -76.18 134.24 15.45 Favored Glycine 0 N--CA 1.466 0.636 0 CA-C-O 124.221 2.012 . . . . 0.0 113.399 163.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 89.7 t -117.29 146.48 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 C-N-CA 129.575 3.15 . . . . 0.0 113.329 171.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -134.36 141.6 43.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 O-C-N 125.816 1.947 . . . . 0.0 113.285 175.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.437 ' CE2' HD13 ' A' ' 59' ' ' ILE . 1.3 p90 -162.15 167.38 24.27 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 116.275 -1.821 . . . . 0.0 112.051 168.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 40.7 p30 -144.99 154.64 42.76 Favored 'General case' 0 C--N 1.348 0.535 0 C-N-CA 126.096 1.758 . . . . 0.0 109.02 -166.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -124.42 118.25 26.37 Favored Pre-proline 0 N--CA 1.446 -0.647 0 C-N-CA 128.03 2.532 . . . . 0.0 114.514 -166.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.263 45.7 Cg_endo -71.87 -14.51 29.61 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.608 2.205 . . . . 0.0 111.803 -175.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.9 m -137.77 132.74 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.853 0 C-N-CA 128.139 2.576 . . . . 0.0 114.242 -139.387 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -54.45 112.17 0.94 Allowed 'General case' 0 N--CA 1.447 -0.618 0 O-C-N 118.045 -2.909 . . . . 0.0 115.255 144.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 168.69 -145.5 9.58 Favored Glycine 0 CA--C 1.529 0.922 1 O-C-N 114.453 -5.154 . . . . 0.0 114.818 -173.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ASN . . . . . 0.559 HD21 ' HB3' ' A' ' 108' ' ' ASP . 5.4 t30 -145.49 133.39 21.26 Favored 'General case' 0 N--CA 1.448 -0.525 0 O-C-N 117.431 -3.394 . . . . 0.0 115.152 -176.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 17.7 m-85 -102.34 148.68 25.18 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 104.669 -2.345 . . . . 0.0 104.669 174.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -126.39 106.59 9.59 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 128.347 3.53 . . . . 0.0 112.51 -177.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 42.6 t -111.81 131.44 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 O-C-N 119.612 -1.93 . . . . 0.0 108.571 -158.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 -126.74 120.24 28.89 Favored 'General case' 0 CA--C 1.513 -0.473 0 C-N-CA 129.746 3.218 . . . . 0.0 110.158 174.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.439 ' HA ' ' O ' ' A' ' 56' ' ' GLU . 77.1 t -99.92 148.21 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 115.534 1.679 . . . . 0.0 115.534 170.467 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.48 HG22 ' HA ' ' A' ' 101' ' ' PRO . 4.7 p -150.41 148.83 29.24 Favored 'General case' 0 N--CA 1.445 -0.675 0 O-C-N 117.385 -3.322 . . . . 0.0 113.025 -177.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.449 HD13 HG21 ' A' ' 102' ' ' ILE . 8.0 mp -128.8 106.65 9.06 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 127.971 2.508 . . . . 0.0 110.184 -158.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? 51.56 44.32 29.17 Favored 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 126.212 1.805 . . . . 0.0 108.295 -160.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 58.59 26.56 59.99 Favored Glycine 0 N--CA 1.439 -1.103 0 N-CA-C 118.429 2.131 . . . . 0.0 118.429 -177.146 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 73.5 m-20 -122.06 143.53 39.12 Favored Pre-proline 0 CA--C 1.516 -0.362 0 C-N-CA 125.088 1.355 . . . . 0.0 108.887 174.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.48 ' HA ' HG22 ' A' ' 96' ' ' THR 0.282 24.4 Cg_endo -82.88 175.83 8.25 Favored 'Trans proline' 0 N--CA 1.446 -1.293 0 CA-C-O 125.948 2.395 . . . . 0.0 108.318 -168.63 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.449 HG21 HD13 ' A' ' 97' ' ' LEU . 25.7 pt -149.7 -176.11 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 C-N-CA 127.961 2.505 . . . . 0.0 109.865 -167.575 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 41.1 mtpt -81.28 163.56 22.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 123.14 1.447 . . . . 0.0 113.314 -176.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.295 23.2 m120 58.39 54.49 5.57 Favored 'General case' 0 C--O 1.222 -0.386 0 N-CA-C 117.125 2.269 . . . . 0.0 117.125 168.115 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 9.7 mmt -164.3 146.98 7.39 Favored Pre-proline 0 CA--C 1.507 -0.686 0 C-N-CA 128.079 2.552 . . . . 0.0 105.449 -162.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -70.58 164.81 80.65 Favored 'Cis proline' 0 N--CA 1.445 -1.352 0 C-N-CA 130.836 1.598 . . . . 0.0 109.979 -5.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . 0.404 HD13 HG21 ' A' ' 107' ' ' ILE . 31.4 pt -130.43 174.04 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 C-N-CA 126.202 1.801 . . . . 0.0 108.043 174.336 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . 0.559 ' HB3' HD21 ' A' ' 90' ' ' ASN . 6.4 m-20 -125.44 139.31 53.76 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 117.49 2.404 . . . . 0.0 117.49 -168.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 2.4 t -147.39 125.67 3.76 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-O 124.005 1.86 . . . . 0.0 114.323 -175.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . 0.271 46.1 pttt -66.44 129.04 38.51 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 127.057 2.143 . . . . 0.0 108.818 -173.121 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . 0.383 72.5 m -107.71 141.95 38.45 Favored 'General case' 0 N--CA 1.448 -0.531 0 O-C-N 126.72 2.512 . . . . 0.0 104.528 178.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 21.9 mt -144.52 143.65 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 O-C-N 117.281 -3.387 . . . . 0.0 111.977 173.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . 0.298 12.0 pt-20 -93.56 53.1 1.81 Allowed 'General case' 0 N--CA 1.449 -0.507 1 O-C-N 114.427 -5.171 . . . . 0.0 110.741 -157.05 . . . . . . . . 3 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 0.338 0 C-N-CA 128.453 2.93 . . . . 0.0 113.671 -176.289 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo . . . . . 0 N--CA 1.448 -1.185 0 CA-C-O 122.595 0.998 . . . . 0.0 110.556 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -99.55 161.65 23.81 Favored Pre-proline 0 N--CA 1.45 -0.432 0 N-CA-C 117.244 2.313 . . . . 0.0 117.244 -173.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -74.17 170.2 20.71 Favored 'Trans proline' 0 N--CA 1.445 -1.348 0 C-N-CA 123.927 3.084 . . . . 0.0 111.276 -178.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.5 t -152.22 173.99 14.31 Favored 'General case' 0 N--CA 1.452 -0.341 0 O-C-N 124.348 1.03 . . . . 0.0 111.716 174.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.83 -39.97 79.69 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-N 115.125 -0.943 . . . . 0.0 113.374 -170.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 72.5 mm-40 -53.0 -35.76 59.73 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 129.547 3.139 . . . . 0.0 113.596 168.186 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -120.5 19.76 11.94 Favored 'General case' 0 N--CA 1.438 -1.026 0 CA-C-N 111.928 -2.397 . . . . 0.0 111.76 -161.546 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.4 t -137.45 138.28 39.61 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 117.999 -2.938 . . . . 0.0 105.468 171.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -164.31 153.44 13.52 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 110.778 -2.919 . . . . 0.0 110.606 -170.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.462 ' HB2' ' HA ' ' A' ' 38' ' ' ILE . . . -140.11 150.0 43.76 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 119.621 3.193 . . . . 0.0 119.621 -171.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -157.47 134.31 10.04 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 127.563 2.345 . . . . 0.0 111.916 -165.347 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 148.46 166.5 12.91 Favored Glycine 0 C--N 1.336 0.56 0 C-N-CA 126.473 1.987 . . . . 0.0 112.292 176.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -65.34 -19.78 66.1 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 116.682 -1.628 . . . . 0.0 109.436 -169.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.536 ' HA3' ' CD2' ' A' ' 36' ' ' PHE . . . -64.29 0.3 3.84 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 124.58 3.355 . . . . 0.0 117.22 168.182 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . 0.27 56.9 mt -109.54 13.33 24.0 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 129.637 3.175 . . . . 0.0 111.854 167.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 t -131.52 -53.36 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 C-N-CA 130.69 3.596 . . . . 0.0 112.018 -178.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 46.7 pttt -161.85 125.64 3.2 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 -159.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.2 t -137.67 155.72 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 C-N-CA 129.303 3.041 . . . . 0.0 109.907 -177.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -131.78 -176.66 4.12 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-O 123.933 1.825 . . . . 0.0 111.856 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -88.05 -46.85 8.98 Favored 'General case' 0 N--CA 1.446 -0.629 0 O-C-N 119.489 -2.007 . . . . 0.0 109.462 -174.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -109.5 6.91 24.52 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-O 126.64 3.114 . . . . 0.0 117.304 176.555 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -122.46 100.36 41.67 Favored Pre-proline 0 N--CA 1.442 -0.858 1 O-C-N 116.202 -4.061 . . . . 0.0 101.784 167.162 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -62.42 157.62 45.03 Favored 'Trans proline' 0 N--CA 1.45 -1.031 0 C-N-CA 123.654 2.903 . . . . 0.0 113.595 166.123 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -123.89 153.03 41.71 Favored 'General case' 0 CA--C 1.511 -0.548 0 C-N-CA 127.136 2.175 . . . . 0.0 112.86 -176.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.496 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 33.6 mt-10 -127.4 155.42 43.67 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 124.067 0.947 . . . . 0.0 108.979 -175.655 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.536 ' CD2' ' HA3' ' A' ' 24' ' ' GLY . 5.2 p90 -161.65 155.38 21.67 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -179.3 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 86.4 m -124.21 119.75 30.27 Favored 'General case' 0 N--CA 1.452 -0.342 0 O-C-N 119.014 -2.303 . . . . 0.0 109.593 -161.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.462 ' HA ' ' HB2' ' A' ' 20' ' ' ALA 0.263 17.2 mt -79.74 102.96 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 124.994 1.318 . . . . 0.0 111.533 164.897 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.371 40.5 p90 -83.24 124.76 30.88 Favored 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 126.49 1.916 . . . . 0.0 113.797 165.637 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -110.45 146.61 35.6 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 179.701 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 9.7 t -129.99 139.11 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 O-C-N 126.757 2.536 . . . . 0.0 106.431 160.228 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -66.76 -50.32 63.1 Favored 'General case' 0 N--CA 1.452 -0.336 0 O-C-N 117.779 -3.076 . . . . 0.0 111.881 178.364 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 64.3 p -148.98 -60.23 0.22 Allowed 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 115.947 -1.978 . . . . 0.0 111.359 -166.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 12.7 ttmt -134.61 101.29 4.9 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 122.149 2.249 . . . . 0.0 114.543 -178.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 77.45 -65.56 3.08 Favored Glycine 0 N--CA 1.451 -0.306 0 O-C-N 120.372 -1.455 . . . . 0.0 114.375 162.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 46.3 t -61.01 124.71 15.93 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 C-N-CA 128.891 2.876 . . . . 0.0 108.717 179.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -50.91 168.2 0.06 Allowed 'General case' 0 N--CA 1.449 -0.486 0 CA-C-O 124.471 2.081 . . . . 0.0 112.982 178.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -53.75 125.85 19.9 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 108.719 -3.855 . . . . 0.0 107.631 163.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 17.5 p -79.08 -18.33 53.57 Favored 'General case' 0 N--CA 1.453 -0.297 1 C-N-CA 131.757 4.023 . . . . 0.0 111.486 -173.05 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -151.86 169.35 22.48 Favored 'General case' 0 CA--C 1.517 -0.297 0 O-C-N 127.551 3.032 . . . . 0.0 107.965 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -102.58 -142.75 12.53 Favored Glycine 0 CA--C 1.525 0.671 0 C-N-CA 124.763 1.173 . . . . 0.0 115.001 -167.423 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 71.65 5.34 60.32 Favored Glycine 0 C--N 1.334 0.455 0 CA-C-O 117.234 -1.87 . . . . 0.0 116.751 165.489 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 38.1 m-20 -77.01 143.54 70.61 Favored Pre-proline 0 N--CA 1.45 -0.455 0 CA-C-O 115.435 -2.221 . . . . 0.0 115.981 -178.261 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -83.02 127.71 4.79 Favored 'Trans proline' 0 N--CA 1.449 -1.09 0 CA-C-N 125.151 2.875 . . . . 0.0 115.998 -176.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -138.25 161.48 36.77 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 114.133 -1.394 . . . . 0.0 111.428 -171.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -153.39 151.72 30.24 Favored 'General case' 0 N--CA 1.447 -0.62 0 O-C-N 120.547 -1.346 . . . . 0.0 113.22 172.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 53.5 t -133.35 99.73 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 C-N-CA 130.054 3.342 . . . . 0.0 104.335 -172.072 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -125.07 138.87 54.18 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 113.577 -1.647 . . . . 0.0 112.663 -170.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.4 mt -138.78 115.45 10.58 Favored 'Isoleucine or valine' 0 C--O 1.238 0.482 0 O-C-N 119.715 -1.866 . . . . 0.0 107.978 -147.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -88.64 138.62 31.26 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 118.823 -2.423 . . . . 0.0 107.011 173.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -141.83 173.33 23.64 Favored Glycine 0 CA--C 1.523 0.539 0 C-N-CA 129.359 3.361 . . . . 0.0 112.475 -166.321 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo . . . . . 0 N--CA 1.46 -0.484 1 C-N-CA 125.921 4.414 . . . . 0.0 117.454 170.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 4.5 t . . . . . 0 N--CA 1.451 -0.397 0 CA-C-O 126.064 2.84 . . . . 0.0 113.207 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 8.9 t -149.43 152.67 11.71 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 O-C-N 116.906 -3.621 . . . . 0.0 107.5 -176.185 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -131.21 138.24 49.29 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-O 123.413 1.578 . . . . 0.0 115.02 161.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -94.09 131.1 39.94 Favored 'General case' 0 N--CA 1.441 -0.917 1 C-N-CA 133.319 4.648 . . . . 0.0 112.585 -164.289 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.408 ' HE2' ' HB3' ' A' ' 70' ' ' LYS 0.258 28.5 ttpt -71.31 126.03 28.56 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 122.894 2.588 . . . . 0.0 112.506 -166.663 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.442 HG22 HG22 ' A' ' 81' ' ' VAL . 68.8 t -106.88 140.2 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 O-C-N 119.552 -1.968 . . . . 0.0 106.446 -179.409 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 90.4 m -144.76 127.97 16.71 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-O 124.868 2.27 . . . . 0.0 113.933 178.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -69.26 128.31 36.14 Favored 'General case' 0 N--CA 1.456 -0.155 0 C-N-CA 127.35 2.26 . . . . 0.0 109.895 -174.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 55.8 m-20 -91.11 5.47 48.82 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 118.458 2.762 . . . . 0.0 118.458 174.527 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 1.8 m120 55.17 43.23 29.73 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 120.057 1.299 . . . . 0.0 112.423 174.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 35.3 p-10 -155.57 3.29 0.18 Allowed 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 128.052 2.541 . . . . 0.0 116.565 -174.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 98.95 4.2 56.79 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 118.515 -2.616 . . . . 0.0 112.33 -174.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 16.9 p -133.94 165.77 24.24 Favored 'General case' 0 CA--C 1.515 -0.387 0 N-CA-C 116.723 2.12 . . . . 0.0 116.723 177.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 45.2 m-85 -129.64 134.43 47.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.602 177.179 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -81.75 133.72 12.35 Favored Glycine 0 C--N 1.342 0.863 0 O-C-N 125.775 1.922 . . . . 0.0 108.325 172.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 35' ' ' GLU . 17.5 t -118.55 136.94 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 128.122 2.569 . . . . 0.0 109.433 175.454 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 p -134.84 135.05 53.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 CA-C-O 114.574 -2.631 . . . . 0.0 111.347 -178.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 80.2 t80 -156.17 144.39 19.85 Favored 'General case' 0 N--CA 1.445 -0.686 1 O-C-N 130.82 5.075 . . . . 0.0 113.084 -174.794 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.9 p30 -130.0 149.0 51.91 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 126.473 1.909 . . . . 0.0 107.999 -177.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -115.25 112.27 44.1 Favored Pre-proline 0 CA--C 1.511 -0.532 0 C-N-CA 125.731 1.612 . . . . 0.0 112.016 -171.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -71.41 -14.55 31.01 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 C-N-CA 124.032 3.155 . . . . 0.0 117.321 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.8 m -143.57 143.59 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 O-C-N 119.824 -1.797 . . . . 0.0 109.853 -174.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 -49.47 121.48 5.11 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 162.306 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -179.92 171.57 43.06 Favored Glycine 0 C--N 1.339 0.711 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.394 -175.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -98.86 133.22 43.46 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 128.886 2.874 . . . . 0.0 112.504 158.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 -126.94 150.03 49.54 Favored 'General case' 0 C--O 1.22 -0.464 0 N-CA-C 106.363 -1.717 . . . . 0.0 106.363 -173.513 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -119.18 111.28 18.04 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-N 114.214 -1.357 . . . . 0.0 114.632 -170.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.6 t -102.35 132.82 47.6 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.43 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 -166.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -122.6 128.09 50.24 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 131.169 3.788 . . . . 0.0 112.243 166.113 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 62.0 t -117.36 143.65 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 CA-C-N 114.481 -1.236 . . . . 0.0 109.682 -177.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.5 p -140.31 160.55 39.72 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 117.971 -1.014 . . . . 0.0 111.888 -171.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . 0.257 8.2 tt -135.65 94.08 3.04 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 103.152 -2.907 . . . . 0.0 103.152 -152.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 26.4 ttp-105 52.96 37.42 24.46 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 120.975 1.716 . . . . 0.0 112.019 -170.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 65.07 35.95 92.41 Favored Glycine 0 C--N 1.338 0.679 0 N-CA-C 116.65 1.42 . . . . 0.0 116.65 -176.26 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 71.3 m-80 -115.38 141.19 26.83 Favored Pre-proline 0 N--CA 1.447 -0.588 0 CA-C-O 117.353 -1.308 . . . . 0.0 110.009 166.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -71.69 165.98 30.86 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 CA-C-O 124.988 1.995 . . . . 0.0 112.095 166.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 11.6 pt -137.62 179.55 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 C-N-CA 127.234 2.214 . . . . 0.0 112.788 -173.055 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.403 ' C ' ' H ' ' A' ' 105' ' ' MET . 56.3 mtpt -74.71 165.91 24.45 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-O 115.529 -2.177 . . . . 0.0 111.025 -173.084 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.421 15.1 m120 66.93 -20.58 0.11 Allowed 'General case' 0 C--N 1.33 -0.268 0 O-C-N 125.59 1.806 . . . . 0.0 114.019 172.737 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' MET . . . . . 0.403 ' H ' ' C ' ' A' ' 103' ' ' LYS . 12.9 mmt -67.17 158.65 80.77 Favored Pre-proline 0 N--CA 1.446 -0.644 0 C-N-CA 127.268 2.227 . . . . 0.0 116.575 -178.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -73.51 159.68 97.06 Favored 'Cis proline' 0 N--CA 1.442 -1.517 0 O-C-N 125.089 2.099 . . . . 0.0 107.932 -20.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 8.2 pt -131.23 161.96 40.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 C-N-CA 126.828 2.051 . . . . 0.0 108.736 -174.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 69.8 m-20 -117.27 147.9 42.14 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 126.481 1.912 . . . . 0.0 111.28 -159.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 42.7 t -139.66 117.29 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 126.344 1.857 . . . . 0.0 111.889 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 65.4 tttt -81.9 136.14 35.35 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 115.524 1.675 . . . . 0.0 115.524 168.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 98.1 m -126.77 133.39 50.85 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 125.766 1.626 . . . . 0.0 107.622 -170.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 48.9 mm -121.82 141.78 40.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 O-C-N 120.156 -1.59 . . . . 0.0 107.65 177.272 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -82.75 41.23 0.72 Allowed 'General case' 0 N--CA 1.454 -0.246 1 O-C-N 114.941 -4.85 . . . . 0.0 116.548 -155.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.651 0 O-C-N 119.493 -2.004 . . . . 0.0 113.449 -175.685 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo . . . . . 0 N--CA 1.447 -1.255 0 N-CA-C 108.986 -1.198 . . . . 0.0 108.986 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -114.59 161.97 26.0 Favored Pre-proline 0 N--CA 1.447 -0.578 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_exo -52.06 166.78 0.59 Allowed 'Trans proline' 0 N--CA 1.444 -1.394 0 N-CA-C 115.806 1.425 . . . . 0.0 115.806 170.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.7 t -133.95 149.75 51.27 Favored 'General case' 0 N--CA 1.447 -0.59 0 O-C-N 120.306 -1.496 . . . . 0.0 107.971 160.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -47.99 -33.1 7.36 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 130.477 3.511 . . . . 0.0 111.406 164.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -67.43 -19.8 65.42 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 75.0 m-70 -141.32 14.91 2.21 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 117.321 2.341 . . . . 0.0 117.321 -159.25 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.1 t -141.49 126.31 18.11 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 176.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 65.4 m-85 -150.88 158.0 43.6 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 130.01 3.324 . . . . 0.0 108.882 -161.205 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -133.32 148.68 51.91 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 118.343 2.72 . . . . 0.0 118.343 -175.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -145.27 146.13 31.54 Favored 'General case' 0 C--O 1.221 -0.408 0 N-CA-C 119.917 3.302 . . . . 0.0 119.917 171.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.44 178.83 28.37 Favored Glycine 0 C--N 1.342 0.863 0 C-N-CA 125.457 1.503 . . . . 0.0 114.899 173.207 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -59.28 -32.33 69.92 Favored 'General case' 0 C--O 1.239 0.552 0 O-C-N 117.994 -3.063 . . . . 0.0 117.296 176.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.39 10.06 2.94 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 125.342 1.449 . . . . 0.0 115.795 170.187 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.424 ' HG ' ' CG ' ' A' ' 36' ' ' PHE . 89.6 mt -124.38 30.52 6.01 Favored 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 118.829 -2.571 . . . . 0.0 112.754 154.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 95.4 t -138.86 -63.05 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 O-C-N 120.111 -1.618 . . . . 0.0 109.683 175.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.292 37.2 pttt -144.65 131.83 20.57 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 123.122 2.692 . . . . 0.0 115.128 -173.111 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 t -130.78 146.76 33.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 1 O-C-N 129.176 4.048 . . . . 0.0 112.386 -174.366 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.492 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 3.9 m-85 -140.1 179.77 6.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 116.84 2.163 . . . . 0.0 116.84 177.137 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -82.36 -39.93 22.07 Favored 'General case' 0 C--O 1.235 0.341 0 O-C-N 116.818 -3.676 . . . . 0.0 113.538 -168.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 15.6 m-80 -105.81 3.42 28.72 Favored 'General case' 0 N--CA 1.449 -0.522 0 O-C-N 126.379 2.3 . . . . 0.0 112.907 178.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -128.77 89.64 48.49 Favored Pre-proline 0 N--CA 1.447 -0.599 0 O-C-N 121.693 -0.629 . . . . 0.0 110.731 175.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_endo -65.97 147.59 84.87 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 O-C-N 125.843 2.496 . . . . 0.0 110.576 -178.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.21 164.77 12.01 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 126.426 1.89 . . . . 0.0 111.305 -177.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.405 ' HG2' HG22 ' A' ' 82' ' ' VAL . 19.3 mt-10 -140.34 146.0 37.89 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 115.616 -2.135 . . . . 0.0 112.748 -175.097 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.424 ' CG ' ' HG ' ' A' ' 25' ' ' LEU . 24.6 p90 -153.52 167.39 29.64 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 122.858 2.572 . . . . 0.0 107.49 171.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 94.7 m -127.46 115.6 19.14 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.262 1.425 . . . . 0.0 109.012 -156.005 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . 0.405 8.4 mt -67.06 96.91 0.29 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.22 0 C-N-CA 125.529 1.532 . . . . 0.0 112.044 162.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -83.49 112.43 19.96 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-O 125.086 2.374 . . . . 0.0 111.942 166.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -114.97 126.94 55.35 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 116.496 -3.878 . . . . 0.0 110.259 -167.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.416 HG22 ' HA ' ' A' ' 47' ' ' ALA . 54.4 t -127.62 149.43 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-O 123.967 1.841 . . . . 0.0 106.894 173.563 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -80.86 -37.57 29.67 Favored 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 117.162 2.282 . . . . 0.0 117.162 169.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 82.7 p -160.0 -69.94 0.07 Allowed 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 127.048 2.717 . . . . 0.0 116.907 -170.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 50.6 mttm -127.98 99.13 5.38 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 122.282 2.31 . . . . 0.0 113.253 -174.01 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 76.37 -75.32 1.6 Allowed Glycine 0 CA--C 1.525 0.661 0 CA-C-N 121.995 2.18 . . . . 0.0 114.915 159.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 65.5 t -46.66 129.03 2.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 126.624 1.97 . . . . 0.0 107.005 171.157 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.416 ' HA ' HG22 ' A' ' 41' ' ' VAL . . . -58.81 171.23 0.68 Allowed 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 116.661 2.097 . . . . 0.0 116.661 177.088 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.3 mmm180 -64.22 116.06 5.63 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 115.598 -2.144 . . . . 0.0 106.28 165.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.7 p -76.63 4.6 9.07 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 127.762 3.164 . . . . 0.0 116.604 -160.45 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -168.4 163.06 12.69 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-O 125.338 2.494 . . . . 0.0 108.314 -173.697 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -103.17 -169.5 25.98 Favored Glycine 0 CA--C 1.524 0.646 0 O-C-N 118.064 -2.898 . . . . 0.0 113.61 -150.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 62.24 22.08 62.67 Favored Glycine 0 C--N 1.335 0.475 0 CA-C-O 113.854 -3.748 . . . . 0.0 117.952 169.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -69.09 153.59 95.89 Favored Pre-proline 0 N--CA 1.452 -0.363 0 CA-C-N 124.15 3.975 . . . . 0.0 110.253 173.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -88.03 133.08 2.87 Favored 'Trans proline' 0 N--CA 1.447 -1.264 1 C-N-CA 127.091 5.194 . . . . 0.0 118.388 -172.366 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -148.8 167.12 26.47 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 113.174 -1.83 . . . . 0.0 110.37 -156.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -161.96 141.76 10.01 Favored 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 129.021 2.928 . . . . 0.0 107.241 174.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 20.2 t -132.14 96.04 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 C-N-CA 130.769 3.628 . . . . 0.0 103.917 -178.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -116.16 140.36 49.38 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 112.236 -2.257 . . . . 0.0 110.016 -168.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 58.5 mt -134.82 148.84 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 CA-C-N 113.754 -1.567 . . . . 0.0 110.041 -159.229 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 54.2 m-80 -126.67 151.5 47.99 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 104.693 -2.336 . . . . 0.0 104.693 165.05 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.0 -145.72 4.72 Favored Glycine 0 C--O 1.219 -0.819 0 N-CA-C 107.613 -2.195 . . . . 0.0 107.613 173.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo . . . . . 0 N--CA 1.45 -1.029 0 CA-C-O 124.496 1.79 . . . . 0.0 111.746 -172.316 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 99.0 t . . . . . 0 CA--C 1.514 -0.424 0 CA-C-O 123.295 1.521 . . . . 0.0 107.023 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 24.4 t -140.36 151.53 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.993 0 C-N-CA 125.21 1.404 . . . . 0.0 111.735 -168.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.256 8.3 p-10 -135.72 122.55 21.15 Favored 'General case' 0 C--N 1.326 -0.429 0 O-C-N 127.532 3.02 . . . . 0.0 109.791 167.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -74.75 151.08 39.19 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 128.586 2.754 . . . . 0.0 114.828 -178.173 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 66.3 tttt -93.73 98.75 11.31 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 114.369 -1.287 . . . . 0.0 111.376 -160.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.1 t -88.64 133.24 31.49 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.117 0 O-C-N 125.678 1.861 . . . . 0.0 106.451 -170.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 26.3 m -144.4 126.48 15.53 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 118.574 -1.25 . . . . 0.0 109.353 172.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -48.56 120.84 3.99 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 128.534 2.734 . . . . 0.0 118.283 166.589 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 -84.55 1.16 47.13 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 114.256 -2.783 . . . . 0.0 112.613 178.747 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 9.3 m120 61.29 24.24 14.37 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 117.556 2.428 . . . . 0.0 117.556 -177.267 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 19.8 p30 -134.55 -6.28 2.53 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 115.487 1.662 . . . . 0.0 115.487 -177.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 112.61 0.79 26.08 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 114.836 -3.202 . . . . 0.0 114.586 -166.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 66.0 p -131.74 160.46 35.47 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 120.407 2.103 . . . . 0.0 113.529 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -123.79 127.63 48.38 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 117.866 -3.021 . . . . 0.0 110.362 173.746 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -80.6 116.35 4.22 Favored Glycine 0 CA--C 1.526 0.755 0 C-N-CA 129.246 3.308 . . . . 0.0 106.103 171.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.7 t -102.14 125.34 56.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 117.194 2.294 . . . . 0.0 117.194 165.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.405 HG22 ' HG2' ' A' ' 35' ' ' GLU . 87.6 t -125.79 145.79 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-N 121.906 2.139 . . . . 0.0 111.762 -173.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . 0.343 1.2 p90 -165.93 172.63 11.33 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 122.849 2.568 . . . . 0.0 114.524 179.513 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 19.8 p30 -135.33 169.48 17.41 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -177.037 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -132.88 109.64 13.02 Favored Pre-proline 0 N--CA 1.447 -0.604 0 N-CA-C 114.752 1.389 . . . . 0.0 114.752 179.184 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.288 68.8 Cg_endo -71.88 -2.63 11.78 Favored 'Trans proline' 0 N--CA 1.449 -1.14 0 C-N-CA 124.702 3.601 . . . . 0.0 111.366 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.8 m -138.66 144.71 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.634 0 CA-C-O 121.653 0.739 . . . . 0.0 111.961 -163.05 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -63.29 127.52 31.66 Favored 'General case' 0 N--CA 1.451 -0.423 0 O-C-N 119.361 -2.087 . . . . 0.0 109.956 153.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 167.39 -166.37 39.24 Favored Glycine 0 CA--C 1.521 0.444 0 CA-C-O 123.756 1.753 . . . . 0.0 116.289 -172.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 11.1 t30 -114.48 139.71 49.32 Favored 'General case' 0 C--O 1.22 -0.487 0 CA-C-N 111.295 -2.452 . . . . 0.0 111.908 164.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . 0.415 ' CD2' ' SG ' ' A' ' 111' ' ' CYS . 10.1 m-85 -98.57 152.04 20.01 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 127.518 3.532 . . . . 0.0 112.494 152.269 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -129.08 109.07 10.88 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 109.806 -3.361 . . . . 0.0 108.164 -174.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 87.0 t -101.32 129.08 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 113.155 -1.839 . . . . 0.0 108.403 -163.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -131.15 130.52 43.16 Favored 'General case' 0 N--CA 1.449 -0.509 0 O-C-N 126.445 2.341 . . . . 0.0 110.889 176.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 99.6 t -112.74 147.13 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.741 0 N-CA-C 114.67 1.359 . . . . 0.0 114.67 -177.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 31.4 p -142.89 162.54 35.19 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 120.792 1.633 . . . . 0.0 111.597 175.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 3.0 tt -144.51 101.26 3.66 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 -147.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 28.8 ttm-85 47.51 42.01 13.92 Favored 'General case' 0 N--CA 1.445 -0.684 0 O-C-N 124.625 1.203 . . . . 0.0 108.324 -163.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 85.48 2.75 87.11 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 128.791 3.091 . . . . 0.0 120.077 177.129 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.409 ' HA ' ' HD3' ' A' ' 101' ' ' PRO . 84.2 m-20 -115.58 147.84 39.72 Favored Pre-proline 0 CA--C 1.514 -0.425 0 C-N-CA 125.881 1.672 . . . . 0.0 113.243 -176.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 100' ' ' ASN . 58.4 Cg_endo -74.15 163.04 37.52 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 124.755 3.637 . . . . 0.0 111.138 -177.485 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 10.7 pt -140.82 175.09 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 126.219 1.807 . . . . 0.0 112.699 -165.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -82.28 164.08 21.39 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 120.832 1.651 . . . . 0.0 113.915 -170.331 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 29.7 m120 53.97 40.15 31.28 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 127.403 2.281 . . . . 0.0 116.772 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 8.7 mmt -126.25 168.96 12.71 Favored Pre-proline 0 N--CA 1.45 -0.462 0 C-N-CA 126.993 2.117 . . . . 0.0 107.376 -170.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -65.67 168.66 14.47 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 N-CA-C 117.453 2.059 . . . . 0.0 117.453 -33.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . 0.372 17.1 pt -138.54 140.05 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-O 122.71 1.243 . . . . 0.0 109.202 -168.631 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -107.93 139.16 42.97 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 117.526 2.417 . . . . 0.0 117.526 -168.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 66.1 t -146.53 114.88 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.762 0 O-C-N 119.783 -1.823 . . . . 0.0 109.395 -161.442 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 68.2 tttt -80.51 144.26 32.65 Favored 'General case' 0 CA--C 1.523 -0.093 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . 0.415 ' SG ' ' CD2' ' A' ' 91' ' ' TYR . 87.7 m -117.14 139.08 51.19 Favored 'General case' 0 N--CA 1.451 -0.42 2 O-C-N 131.991 5.807 . . . . 0.0 110.233 -179.984 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.492 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 90.9 mt -135.04 123.37 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-N 108.469 -3.969 . . . . 0.0 113.361 171.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . 0.413 ' HG2' ' H ' ' A' ' 113' ' ' GLU 0.3 7.5 pt-20 -76.23 39.97 0.2 Allowed 'General case' 0 N--CA 1.451 -0.395 0 O-C-N 116.947 -3.595 . . . . 0.0 115.332 -164.646 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.626 0 CA-C-N 121.457 1.935 . . . . 0.0 115.585 169.728 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo . . . . . 0 N--CA 1.439 -1.703 0 CA-C-O 119.391 -0.337 . . . . 0.0 111.313 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -111.53 136.83 21.03 Favored Pre-proline 0 C--O 1.239 0.538 0 C-N-CA 131.116 3.767 . . . . 0.0 114.187 -176.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . 0.252 23.3 Cg_exo -65.58 168.78 14.04 Favored 'Trans proline' 0 CA--C 1.514 -0.49 0 N-CA-C 117.498 2.076 . . . . 0.0 117.498 170.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.6 m -142.88 160.85 39.55 Favored 'General case' 0 N--CA 1.44 -0.958 0 CA-C-N 123.317 2.78 . . . . 0.0 110.937 -174.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.44 -48.43 81.68 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 113.597 -3.097 . . . . 0.0 113.861 174.638 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -52.64 -28.32 20.95 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 123.06 2.663 . . . . 0.0 106.773 173.005 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 74.4 m-70 -117.37 5.86 12.61 Favored 'General case' 0 C--O 1.218 -0.603 0 N-CA-C 116.525 2.046 . . . . 0.0 116.525 -156.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.8 t -135.14 121.86 20.88 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 116.816 2.154 . . . . 0.0 116.816 173.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 26.6 m-85 -153.31 155.19 36.02 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -161.109 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . 0.462 . . -132.01 147.92 52.48 Favored 'General case' 0 C--O 1.217 -0.61 0 N-CA-C 117.85 2.537 . . . . 0.0 117.85 -167.36 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -160.96 145.95 14.08 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 130.125 3.37 . . . . 0.0 108.736 -164.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.1 175.21 13.94 Favored Glycine 0 N--CA 1.446 -0.696 0 O-C-N 126.99 2.681 . . . . 0.0 117.505 -173.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -74.03 -30.21 62.31 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 112.652 -3.547 . . . . 0.0 113.715 -176.139 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -62.23 9.82 0.12 Allowed Glycine 0 CA--C 1.531 1.047 0 CA-C-N 124.945 3.52 . . . . 0.0 115.371 161.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 17.0 mt -113.9 19.85 16.25 Favored 'General case' 0 C--O 1.223 -0.312 0 CA-C-N 122.023 2.911 . . . . 0.0 109.799 167.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 1.7 t -137.97 -41.75 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 CA-C-O 115.313 -2.28 . . . . 0.0 110.312 174.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 42.4 mtmt -155.74 118.09 4.14 Favored 'General case' 0 C--N 1.328 -0.367 0 O-C-N 124.685 1.241 . . . . 0.0 114.096 -163.051 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 t -124.7 138.69 53.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 C-N-CA 130.853 3.661 . . . . 0.0 116.188 177.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 27.3 m-85 -128.78 -169.82 2.15 Favored 'General case' 0 N--CA 1.452 -0.358 0 O-C-N 126.552 2.408 . . . . 0.0 115.434 -174.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 17.7 t0 -105.17 -33.29 8.31 Favored 'General case' 0 CA--C 1.511 -0.541 0 O-C-N 118.278 -2.764 . . . . 0.0 114.212 -167.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 53.8 m-80 -101.83 8.73 41.22 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 120.511 3.523 . . . . 0.0 120.511 162.096 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -137.57 96.15 10.95 Favored Pre-proline 0 N--CA 1.445 -0.676 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.263 178.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_exo -62.83 128.29 22.79 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 121.883 1.722 . . . . 0.0 111.7 171.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -92.35 156.41 17.26 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 123.05 1.405 . . . . 0.0 109.71 -177.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -133.97 149.77 51.25 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 -169.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -161.64 173.27 14.95 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.194 -2.521 . . . . 0.0 104.194 168.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 26.1 m -127.02 118.17 23.93 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 131.53 3.932 . . . . 0.0 114.811 -158.268 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.415 ' HB ' ' HB2' ' A' ' 79' ' ' TYR . 44.7 mm -76.19 96.31 1.32 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.483 0 C-N-CA 127.012 2.125 . . . . 0.0 106.213 173.571 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -81.83 99.87 9.26 Favored 'General case' 0 C--O 1.214 -0.8 0 O-C-N 119.114 -2.241 . . . . 0.0 114.87 171.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -100.12 137.14 38.97 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 117.807 2.521 . . . . 0.0 117.807 -167.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 71.7 t -134.94 156.45 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 C-N-CA 128.449 2.7 . . . . 0.0 113.858 169.612 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.7 p30 -76.71 -71.65 0.38 Allowed 'General case' 0 N--CA 1.448 -0.555 0 O-C-N 118.741 -2.474 . . . . 0.0 109.882 174.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 77.8 p -156.18 -39.67 0.08 Allowed 'General case' 0 C--O 1.238 0.481 1 C-N-CA 133.57 4.748 . . . . 0.0 106.86 -175.705 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 46.6 mtmt -87.65 28.43 1.0 Allowed 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 123.237 2.744 . . . . 0.0 110.755 -154.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 78.28 -41.56 2.05 Favored Glycine 0 N--CA 1.444 -0.807 0 O-C-N 118.27 -2.769 . . . . 0.0 115.675 169.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.6 t -71.21 145.11 12.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 126.178 1.791 . . . . 0.0 114.667 168.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -47.12 162.19 0.06 Allowed 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 114.306 -1.316 . . . . 0.0 113.882 177.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -64.82 113.04 3.54 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.369 174.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.5 p -89.11 4.86 47.04 Favored 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 131.232 3.813 . . . . 0.0 113.142 -163.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.9 p30 -152.49 172.69 16.17 Favored 'General case' 0 N--CA 1.446 -0.657 1 C-N-CA 133.697 4.799 . . . . 0.0 108.521 162.737 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -138.03 -175.64 14.03 Favored Glycine 0 N--CA 1.443 -0.844 0 O-C-N 118.322 -2.736 . . . . 0.0 109.797 -149.523 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.93 41.5 98.67 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 127.213 2.339 . . . . 0.0 111.503 -178.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -74.51 156.61 86.9 Favored Pre-proline 0 C--O 1.221 -0.405 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 167.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -87.83 135.64 3.49 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 CA-C-O 127.298 2.958 . . . . 0.0 113.632 174.349 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -147.49 151.94 37.22 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 117.994 -2.941 . . . . 0.0 110.436 -173.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -140.59 142.8 35.05 Favored 'General case' 0 N--CA 1.446 -0.643 0 O-C-N 118.94 -2.35 . . . . 0.0 109.924 178.649 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.522 HG22 HG22 ' A' ' 95' ' ' VAL . 19.9 t -129.58 81.79 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 C-N-CA 129.876 3.27 . . . . 0.0 106.047 178.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -94.65 131.9 39.95 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 113.142 -1.844 . . . . 0.0 114.793 176.249 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.7 mt -124.13 156.95 31.58 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.581 0 C-N-CA 125.782 1.633 . . . . 0.0 108.116 -163.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -115.28 132.85 56.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 115.508 -2.187 . . . . 0.0 114.426 144.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -80.52 -152.42 8.23 Favored Glycine 0 CA--C 1.532 1.118 0 O-C-N 125.709 1.881 . . . . 0.0 110.611 160.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_exo . . . . . 0 N--CA 1.442 -1.529 0 C-N-CA 124.773 3.648 . . . . 0.0 110.806 -170.294 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 96.4 t . . . . . 0 N--CA 1.453 -0.288 0 N-CA-C 115.422 1.638 . . . . 0.0 115.422 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 20.0 t -130.34 153.21 38.66 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.797 0 O-C-N 117.895 -3.003 . . . . 0.0 115.191 -173.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.2 p-10 -130.04 138.45 50.77 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 160.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -90.97 149.47 21.85 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-O 125.011 2.339 . . . . 0.0 111.926 177.11 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 52.6 mmtt -93.0 115.37 28.06 Favored 'General case' 0 N--CA 1.445 -0.681 0 O-C-N 118.612 -2.555 . . . . 0.0 108.62 -163.311 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 36.3 t -97.1 139.26 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 CA-C-N 114.051 -1.431 . . . . 0.0 109.813 -176.09 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 59.9 m -138.97 137.34 36.3 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 127.586 2.354 . . . . 0.0 113.056 174.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -73.05 128.68 36.19 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 126.132 1.773 . . . . 0.0 109.924 177.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 67.5 m-20 -90.16 -1.38 57.93 Favored 'General case' 0 C--O 1.221 -0.401 0 CA-C-O 115.722 -2.085 . . . . 0.0 115.3 175.034 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 1.7 m120 70.6 24.52 4.4 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 123.797 2.998 . . . . 0.0 111.553 167.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 38.0 p30 -139.27 -7.17 1.35 Allowed 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 121.582 3.919 . . . . 0.0 121.582 179.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 130.89 -13.2 5.56 Favored Glycine 0 C--O 1.242 0.628 0 CA-C-O 123.228 1.46 . . . . 0.0 112.967 -177.216 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.6 p -128.22 164.64 22.09 Favored 'General case' 0 C--O 1.24 0.586 0 C-N-CA 127.696 2.398 . . . . 0.0 113.472 -171.053 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.415 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 11.7 m-85 -128.49 147.76 50.7 Favored 'General case' 0 C--N 1.329 -0.291 0 O-C-N 125.308 1.63 . . . . 0.0 107.641 174.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -94.38 132.18 11.05 Favored Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 128.761 3.077 . . . . 0.0 111.183 173.201 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.9 t -128.07 138.62 54.17 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 CA-C-O 117.401 -1.285 . . . . 0.0 113.036 178.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.9 t -141.91 130.94 22.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 O-C-N 124.783 1.302 . . . . 0.0 112.695 -167.555 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -161.15 138.14 8.79 Favored 'General case' 0 CA--C 1.517 -0.313 0 CA-C-O 124.35 2.024 . . . . 0.0 111.859 -174.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.267 57.4 p-10 -109.88 160.9 15.98 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 129.227 3.011 . . . . 0.0 112.829 175.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -130.15 109.87 16.67 Favored Pre-proline 0 N--CA 1.443 -0.776 0 C-N-CA 126.508 1.923 . . . . 0.0 109.754 -167.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -70.5 -6.41 18.91 Favored 'Trans proline' 0 N--CA 1.445 -1.341 0 C-N-CA 122.072 1.848 . . . . 0.0 114.906 -179.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.5 m -149.68 147.14 16.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 O-C-N 118.126 -2.859 . . . . 0.0 114.737 -151.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 112' ' ' ILE . 28.7 tt0 -62.95 102.95 0.4 Allowed 'General case' 0 C--O 1.241 0.607 0 CA-C-O 123.35 1.548 . . . . 0.0 108.848 167.071 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -177.91 -136.62 2.55 Favored Glycine 0 N--CA 1.434 -1.488 1 O-C-N 116.288 -4.007 . . . . 0.0 122.784 178.098 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 25.8 t30 -132.36 137.04 47.23 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 130.18 3.392 . . . . 0.0 110.552 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 13.6 m-85 -106.75 151.9 24.53 Favored 'General case' 0 N--CA 1.446 -0.671 0 O-C-N 124.502 1.126 . . . . 0.0 112.75 151.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -119.77 116.52 26.08 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 110.894 -2.866 . . . . 0.0 112.213 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 3.3 t -112.33 126.02 69.67 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.966 0 N-CA-C 115.507 1.669 . . . . 0.0 115.507 -162.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -136.53 118.96 15.76 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 115.452 -2.213 . . . . 0.0 110.312 -168.183 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.522 HG22 HG22 ' A' ' 57' ' ' VAL . 67.3 t -119.24 144.41 27.71 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.473 0 CA-C-N 120.515 1.507 . . . . 0.0 108.625 -174.453 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 33.0 p -135.36 153.06 51.96 Favored 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 127.086 2.154 . . . . 0.0 110.619 -177.274 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.5 mp -126.14 91.65 3.42 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-O 112.702 -3.523 . . . . 0.0 112.673 -161.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.1 ttm180 55.92 35.27 25.17 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 124.744 2.211 . . . . 0.0 110.307 -159.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 75.32 0.91 63.05 Favored Glycine 0 CA--C 1.533 1.195 0 O-C-N 117.793 -3.067 . . . . 0.0 117.918 -177.441 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 63.8 m-80 -78.51 134.14 62.33 Favored Pre-proline 0 N--CA 1.448 -0.539 0 O-C-N 120.525 -1.573 . . . . 0.0 112.013 168.434 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -87.76 178.52 3.22 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 123.904 3.07 . . . . 0.0 104.968 -177.456 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 19.2 pt -152.82 177.32 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 O-C-N 120.169 -1.582 . . . . 0.0 112.761 -172.424 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 13.3 ptmt -86.86 170.97 11.19 Favored 'General case' 0 N--CA 1.442 -0.874 0 C-N-CA 128.28 2.632 . . . . 0.0 117.91 -168.161 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 10.3 m120 53.43 32.89 14.76 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 129.512 3.125 . . . . 0.0 113.878 -177.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' MET . . . . . 0.571 ' HG3' ' HA ' ' A' ' 106' ' ' PRO . 2.9 ttm -146.34 145.54 24.3 Favored Pre-proline 0 C--O 1.246 0.897 0 O-C-N 116.69 -3.757 . . . . 0.0 111.486 -158.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.571 ' HA ' ' HG3' ' A' ' 105' ' ' MET 0.3 10.1 Cg_endo -54.45 159.14 15.31 Favored 'Cis proline' 0 N--CA 1.443 -1.462 0 CA-C-N 125.002 2.822 . . . . 0.0 116.343 -13.625 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 13.4 pt -126.76 158.19 37.43 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 C-N-CA 130.38 3.472 . . . . 0.0 110.058 175.27 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -114.52 143.92 44.19 Favored 'General case' 0 CA--C 1.503 -0.833 0 N-CA-C 117.033 2.234 . . . . 0.0 117.033 -176.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 60.8 t -139.24 117.64 12.38 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 CA-C-O 117.087 -1.435 . . . . 0.0 110.318 -174.276 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . 0.25 32.6 ttpt -64.62 133.49 52.36 Favored 'General case' 0 N--CA 1.443 -0.797 0 C-N-CA 127.813 2.445 . . . . 0.0 113.66 -179.026 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 72.2 m -117.95 156.47 28.44 Favored 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 127.929 2.491 . . . . 0.0 112.492 -177.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 7.7 tt -155.27 156.64 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 114.776 1.399 . . . . 0.0 114.776 158.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . 0.316 5.0 pt-20 -62.51 43.44 0.01 OUTLIER 'General case' 0 N--CA 1.444 -0.769 0 C-N-CA 127.149 2.18 . . . . 0.0 116.879 173.372 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.676 0 N-CA-C 118.634 2.214 . . . . 0.0 118.634 179.939 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo . . . . . 0 N--CA 1.451 -0.98 0 N-CA-C 118.05 2.288 . . . . 0.0 118.05 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -93.21 147.53 33.95 Favored Pre-proline 0 N--CA 1.45 -0.467 0 O-C-N 125.645 1.84 . . . . 0.0 114.414 -178.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -57.43 154.15 37.16 Favored 'Trans proline' 0 N--CA 1.449 -1.145 1 C-N-CA 127.224 5.283 . . . . 0.0 114.584 152.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 34.2 t -140.28 176.57 8.66 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 121.765 2.075 . . . . 0.0 113.579 -178.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . 0.296 . . -65.88 -48.23 72.21 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 129.935 3.294 . . . . 0.0 115.959 -173.223 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.0 mp0 -54.71 -28.18 46.12 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 111.231 -2.713 . . . . 0.0 113.458 166.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 31.4 m-70 -133.2 7.48 3.94 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-O 125.518 2.58 . . . . 0.0 112.928 -148.003 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . 0.268 29.2 t -125.46 114.04 18.29 Favored 'General case' 0 N--CA 1.45 -0.468 0 O-C-N 116.35 -3.969 . . . . 0.0 107.478 169.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . 0.265 75.6 m-85 -130.62 160.98 32.61 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 129.192 2.997 . . . . 0.0 108.195 174.449 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -137.85 151.16 47.79 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 127.63 2.372 . . . . 0.0 115.344 -169.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -154.39 137.14 15.26 Favored 'General case' 0 N--CA 1.452 -0.363 1 O-C-N 116.023 -4.173 . . . . 0.0 114.787 -165.589 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.36 -175.09 19.76 Favored Glycine 0 C--O 1.222 -0.636 0 C-N-CA 126.412 1.958 . . . . 0.0 108.514 160.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.2 tt0 -68.6 -22.78 64.43 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-O 114.725 -2.559 . . . . 0.0 113.714 -158.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -56.25 -0.14 0.17 Allowed Glycine 0 N--CA 1.443 -0.841 0 CA-C-O 115.247 -2.974 . . . . 0.0 117.829 161.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 23.8 mt -121.72 24.27 9.8 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 127.658 2.383 . . . . 0.0 114.729 168.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.8 t -142.96 -47.03 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 CA-C-O 114.976 -2.44 . . . . 0.0 107.7 -172.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 28.4 ttmt -172.47 139.54 0.99 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 115.36 -2.257 . . . . 0.0 112.279 -177.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 34.2 t -144.97 142.45 22.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 115.168 -2.348 . . . . 0.0 113.938 -166.384 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.427 ' HB2' ' HB3' ' A' ' 32' ' ' ALA 0.278 1.2 m-85 -129.6 177.53 7.15 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 125.381 1.676 . . . . 0.0 114.413 -166.283 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -94.86 -37.89 10.99 Favored 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 116.515 2.043 . . . . 0.0 116.515 -178.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 55.9 m-80 -102.52 19.48 18.9 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 115.975 1.843 . . . . 0.0 115.975 165.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.427 ' HB3' ' HB2' ' A' ' 29' ' ' PHE . . . -139.3 92.72 10.42 Favored Pre-proline 0 N--CA 1.455 -0.19 0 C-N-CA 126.1 1.76 . . . . 0.0 106.57 171.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . 0.324 74.9 Cg_exo -43.71 119.84 2.04 Favored 'Trans proline' 0 N--CA 1.449 -1.134 1 C-N-CA 129.854 7.036 . . . . 0.0 112.019 148.309 . . . . . . . . 3 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.418 ' O ' ' HA ' ' A' ' 82' ' ' VAL . . . -96.81 150.81 20.3 Favored 'General case' 0 N--CA 1.45 -0.457 0 C-N-CA 128.504 2.722 . . . . 0.0 111.116 -178.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -121.54 137.73 54.61 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-O 115.119 -2.372 . . . . 0.0 114.363 -173.109 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -154.53 172.17 18.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 CA-C-N 125.202 3.637 . . . . 0.0 107.723 164.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 55.5 m -138.0 129.6 28.09 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-O 115.947 -1.977 . . . . 0.0 111.533 -157.044 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 16.1 mt -89.57 124.01 42.07 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 O-C-N 125.928 2.018 . . . . 0.0 107.114 171.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.277 39.2 p90 -99.26 115.95 30.32 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 128.471 2.709 . . . . 0.0 112.232 170.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -116.46 129.74 56.38 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-O 123.716 1.722 . . . . 0.0 110.112 -161.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.6 t -125.03 151.41 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 C-N-CA 126.934 2.094 . . . . 0.0 113.816 163.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.9 p30 -77.05 -72.56 0.34 Allowed 'General case' 0 N--CA 1.443 -0.784 0 CA-C-O 125.193 2.425 . . . . 0.0 116.464 170.607 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 16.0 p -159.54 -28.24 0.07 Allowed 'General case' 0 CA--C 1.517 -0.293 1 C-N-CA 133.774 4.829 . . . . 0.0 112.239 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . 0.393 84.3 mttt -94.4 13.92 22.22 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 123.015 2.643 . . . . 0.0 115.89 -170.414 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 79.8 -33.72 2.13 Favored Glycine 0 CA--C 1.523 0.556 0 O-C-N 118.164 -2.835 . . . . 0.0 112.542 164.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 71.1 t -54.99 133.41 18.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 1 CA-C-N 125.402 4.601 . . . . 0.0 112.22 155.541 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.53 166.74 0.05 OUTLIER 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 117.399 2.37 . . . . 0.0 117.399 169.43 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 8.4 mmm180 -53.86 120.03 5.77 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 176.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 34.8 p -88.19 -4.82 58.67 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 125.077 1.351 . . . . 0.0 110.914 -160.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -165.19 160.47 18.59 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 127.83 2.452 . . . . 0.0 108.998 -169.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -106.59 -162.38 22.38 Favored Glycine 0 N--CA 1.444 -0.826 0 O-C-N 126.839 2.587 . . . . 0.0 116.641 -158.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 48.91 44.07 31.36 Favored Glycine 0 C--O 1.222 -0.616 0 C-N-CA 128.359 2.885 . . . . 0.0 113.957 174.764 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -78.02 141.06 62.6 Favored Pre-proline 0 N--CA 1.451 -0.395 0 O-C-N 119.347 -2.266 . . . . 0.0 109.538 159.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -90.92 132.24 1.57 Allowed 'Trans proline' 0 N--CA 1.442 -1.55 0 N-CA-C 121.234 3.513 . . . . 0.0 121.234 -171.675 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -136.68 149.72 48.08 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 113.053 0.76 . . . . 0.0 113.053 -151.083 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -134.4 145.23 48.73 Favored 'General case' 0 N--CA 1.442 -0.836 0 O-C-N 127.73 3.144 . . . . 0.0 106.457 168.265 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 40.6 t -126.46 99.47 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 102.598 -3.112 . . . . 0.0 102.598 163.46 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -109.57 137.0 48.04 Favored 'General case' 0 N--CA 1.442 -0.842 0 O-C-N 126.253 2.22 . . . . 0.0 113.662 -171.247 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 84.2 mt -140.21 148.33 22.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 114.996 1.48 . . . . 0.0 114.996 -157.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.6 m120 -122.26 144.4 49.01 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 127.257 2.223 . . . . 0.0 107.512 166.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -124.59 -163.92 11.79 Favored Glycine 0 C--N 1.337 0.632 0 C-N-CA 127.272 2.368 . . . . 0.0 109.302 161.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo . . . . . 0 N--CA 1.448 -1.147 1 C-N-CA 129.824 7.016 . . . . 0.0 116.322 178.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.8 t . . . . . 0 N--CA 1.448 -0.55 0 CA-C-O 122.272 1.034 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 55.8 t -132.6 155.57 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 N-CA-C 115.515 1.672 . . . . 0.0 115.515 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.254 6.4 p-10 -129.87 123.38 30.67 Favored 'General case' 0 N--CA 1.44 -0.944 1 CA-C-O 128.993 4.235 . . . . 0.0 108.7 168.582 . . . . . . . . 3 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.21 131.17 34.3 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-O 127.459 3.504 . . . . 0.0 110.486 -178.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 14.5 mptt -91.13 119.91 31.64 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 112.696 -2.047 . . . . 0.0 114.196 -166.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.0 t -100.29 144.92 11.8 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.371 0 C-N-CA 130.421 3.488 . . . . 0.0 112.098 -169.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . 0.26 42.3 m -154.3 136.87 15.11 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 127.233 3.397 . . . . 0.0 111.465 170.027 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.436 ' HA ' ' CD1' ' A' ' 79' ' ' TYR . 39.7 t0 -62.04 118.23 7.03 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 131.076 3.75 . . . . 0.0 109.164 179.101 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -80.04 -6.34 57.44 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-O 116.434 -1.746 . . . . 0.0 115.207 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.258 10.8 t-20 60.29 30.51 19.9 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 127.653 3.597 . . . . 0.0 114.693 -176.043 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 18.1 p30 -138.28 -1.18 1.95 Allowed 'General case' 0 C--O 1.238 0.46 0 O-C-N 117.084 -3.51 . . . . 0.0 119.116 174.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 104.92 1.51 42.31 Favored Glycine 0 CA--C 1.521 0.449 0 CA-C-O 116.482 -2.288 . . . . 0.0 118.44 -163.286 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 44.1 p -126.32 171.64 10.79 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 127.543 2.337 . . . . 0.0 111.635 177.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.436 ' CD1' ' HA ' ' A' ' 73' ' ' ASP . 46.3 m-85 -144.95 118.84 9.3 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-O 115.605 -2.141 . . . . 0.0 109.267 178.221 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.71 136.75 24.83 Favored Glycine 0 CA--C 1.524 0.629 1 C-N-CA 130.991 4.139 . . . . 0.0 111.239 175.302 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.0 t -135.29 126.63 45.76 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 CA-C-O 128.131 3.824 . . . . 0.0 107.85 -177.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.418 ' HA ' ' O ' ' A' ' 34' ' ' ALA . 3.7 p -122.11 132.15 71.62 Favored 'Isoleucine or valine' 0 C--O 1.236 0.37 0 O-C-N 118.772 -2.455 . . . . 0.0 114.021 178.149 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -158.15 168.65 26.47 Favored 'General case' 0 C--O 1.221 -0.414 0 N-CA-C 117.76 2.504 . . . . 0.0 117.76 173.084 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.427 31.9 p30 -133.7 151.82 51.73 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 123.673 1.701 . . . . 0.0 114.236 -173.187 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -119.92 118.41 31.74 Favored Pre-proline 0 N--CA 1.445 -0.682 0 O-C-N 119.867 -1.771 . . . . 0.0 109.204 -173.117 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.262 29.0 Cg_endo -83.01 4.71 6.91 Favored 'Trans proline' 0 N--CA 1.447 -1.232 1 C-N-CA 128.225 5.95 . . . . 0.0 108.756 -178.793 . . . . . . . . 3 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.9 m -132.05 138.55 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 N-CA-C 120.399 3.481 . . . . 0.0 120.399 -167.281 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -54.15 118.87 4.4 Favored 'General case' 0 N--CA 1.449 -0.512 0 O-C-N 120.157 -1.589 . . . . 0.0 107.246 137.252 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 159.96 -135.39 4.07 Favored Glycine 0 C--N 1.331 0.296 0 CA-C-N 120.334 1.425 . . . . 0.0 115.038 172.485 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 -141.36 138.87 33.35 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 127.579 2.351 . . . . 0.0 113.767 177.149 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 -99.61 149.12 23.6 Favored 'General case' 0 C--O 1.222 -0.376 0 C-N-CA 126.479 1.912 . . . . 0.0 112.52 168.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -137.1 114.99 11.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 103.713 -2.699 . . . . 0.0 103.713 -164.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.2 t -114.56 126.01 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 CA-C-N 111.186 -2.734 . . . . 0.0 109.71 -153.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.0 t30 -138.69 118.34 13.08 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 123.874 1.797 . . . . 0.0 106.651 -172.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 54.6 t -116.74 142.77 29.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 O-C-N 118.079 -2.888 . . . . 0.0 112.386 -178.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.4 ' C ' HD12 ' A' ' 97' ' ' LEU . 16.1 p -150.1 151.83 33.8 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 117.175 2.287 . . . . 0.0 117.175 -169.314 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.4 HD12 ' C ' ' A' ' 96' ' ' THR . 11.2 mp -135.08 87.53 2.34 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 102.861 -3.015 . . . . 0.0 102.861 -137.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 18.6 ttm-85 59.41 25.01 13.68 Favored 'General case' 0 N--CA 1.45 -0.466 0 O-C-N 117.322 -3.361 . . . . 0.0 108.737 -158.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 81.51 6.28 89.3 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-O 116.906 -2.052 . . . . 0.0 116.504 -175.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -76.0 120.9 83.74 Favored Pre-proline 0 N--CA 1.445 -0.722 0 O-C-N 125.135 1.138 . . . . 0.0 111.776 162.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -81.9 174.21 10.42 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 CA-C-N 121.661 1.629 . . . . 0.0 110.275 178.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . 0.261 27.8 pt -138.99 174.32 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 O-C-N 125.921 2.013 . . . . 0.0 113.949 -164.311 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 18.7 ptpt -72.28 166.68 21.97 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 127.895 2.478 . . . . 0.0 113.067 172.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 25.9 m120 50.59 32.23 6.56 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 123.173 1.464 . . . . 0.0 107.71 -179.089 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 14.6 mmt -143.31 134.11 12.43 Favored Pre-proline 0 N--CA 1.448 -0.557 1 O-C-N 115.029 -4.794 . . . . 0.0 107.661 176.42 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -86.02 171.88 39.61 Favored 'Cis proline' 0 N--CA 1.449 -1.117 0 CA-C-N 121.563 1.594 . . . . 0.0 109.853 13.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . 0.442 HG21 HD13 ' A' ' 107' ' ' ILE . 19.3 pt -144.33 164.69 13.78 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-O 115.055 -2.402 . . . . 0.0 115.272 -178.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -126.7 136.04 51.92 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 124.659 3.39 . . . . 0.0 113.61 -166.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 3.3 t -128.57 140.73 48.43 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 C-N-CA 129.151 2.98 . . . . 0.0 114.682 -173.545 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 13.2 tppt? -74.74 142.64 44.34 Favored 'General case' 0 N--CA 1.445 -0.722 0 O-C-N 123.588 0.555 . . . . 0.0 111.191 178.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 69.4 m -132.06 140.77 48.98 Favored 'General case' 0 N--CA 1.452 -0.331 0 N-CA-C 115.178 1.547 . . . . 0.0 115.178 177.577 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.416 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 10.4 tp -149.08 135.85 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 CA-C-O 117.33 -1.319 . . . . 0.0 112.421 170.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.45 39.59 0.88 Allowed 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 123.009 2.64 . . . . 0.0 116.176 -164.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.341 0.85 0 O-C-N 126.056 2.097 . . . . 0.0 113.468 162.486 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo . . . . . 0 N--CA 1.453 -0.912 0 N-CA-C 117.296 1.998 . . . . 0.0 117.296 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -97.17 143.07 25.5 Favored Pre-proline 0 CA--C 1.519 -0.221 0 N-CA-C 118.308 2.707 . . . . 0.0 118.308 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -71.43 143.18 42.43 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 124.182 3.254 . . . . 0.0 109.839 166.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.6 m -123.25 168.76 12.04 Favored 'General case' 0 CA--C 1.516 -0.344 0 O-C-N 127.321 2.888 . . . . 0.0 111.774 -165.2 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.02 -41.09 82.68 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 115.874 1.805 . . . . 0.0 115.874 -174.185 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 56.4 mp0 -68.2 -16.94 64.18 Favored 'General case' 0 C--O 1.22 -0.453 0 C-N-CA 127.39 2.276 . . . . 0.0 112.873 173.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 86.1 m-70 -127.7 13.29 6.92 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 120.91 -1.119 . . . . 0.0 110.898 -154.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 9.1 t -135.45 122.82 21.85 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-O 122.913 1.339 . . . . 0.0 111.391 169.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.443 ' HB2' ' CE1' ' A' ' 39' ' ' PHE . 60.8 m-85 -152.39 154.79 36.3 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 128.792 2.837 . . . . 0.0 112.032 -172.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -138.51 162.42 34.55 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 120.066 1.303 . . . . 0.0 108.415 -164.01 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -146.76 132.0 18.45 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 127.316 2.247 . . . . 0.0 108.202 -170.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 139.17 -157.36 24.9 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 117.196 1.639 . . . . 0.0 117.196 145.091 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . 0.258 39.1 mt-10 -55.87 -41.72 74.82 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 119.375 3.102 . . . . 0.0 119.375 -175.642 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -67.7 2.82 5.66 Favored Glycine 0 CA--C 1.523 0.578 0 C-N-CA 127.829 2.633 . . . . 0.0 113.944 168.617 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.499 HD21 ' CE1' ' A' ' 36' ' ' PHE 0.334 20.9 mt -108.11 1.04 22.0 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 117.45 2.389 . . . . 0.0 117.45 155.988 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 72.9 t -119.8 -45.82 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 O-C-N 119.393 -2.067 . . . . 0.0 113.517 -174.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.262 31.5 ttmt -159.15 134.7 8.56 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 115.843 1.794 . . . . 0.0 115.843 175.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.7 t -135.65 139.62 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 106.715 -1.587 . . . . 0.0 106.715 -173.204 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 -121.25 176.64 5.52 Favored 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 128.964 2.906 . . . . 0.0 116.262 -169.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -80.25 -54.3 5.86 Favored 'General case' 0 N--CA 1.441 -0.894 0 O-C-N 120.011 -1.681 . . . . 0.0 113.058 178.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 -103.72 4.71 35.61 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 129.59 3.156 . . . . 0.0 114.478 177.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . 0.304 . . -110.39 84.07 3.63 Favored Pre-proline 0 N--CA 1.448 -0.537 0 CA-C-O 113.328 -3.225 . . . . 0.0 106.262 159.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -59.04 120.79 8.87 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 CA-C-N 123.816 2.399 . . . . 0.0 110.525 164.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -91.13 154.76 19.13 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 112.506 -2.133 . . . . 0.0 108.22 -175.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.437 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 45.8 mt-10 -120.36 165.98 14.16 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 109.712 -3.404 . . . . 0.0 112.49 175.364 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.499 ' CE1' HD21 ' A' ' 25' ' ' LEU . 10.7 p90 -162.16 173.5 14.22 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 128.566 2.746 . . . . 0.0 110.704 163.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 98.8 m -130.28 126.47 37.32 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 126.927 2.091 . . . . 0.0 115.652 -163.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 6.5 mt -92.34 105.14 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 C-N-CA 125.837 1.655 . . . . 0.0 108.018 178.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.443 ' CE1' ' HB2' ' A' ' 19' ' ' TYR 0.26 1.3 p90 -72.59 132.12 43.35 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.348 1.459 . . . . 0.0 112.04 167.055 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -130.98 134.7 46.96 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 118.272 -2.767 . . . . 0.0 113.133 -170.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.417 HG22 ' HA ' ' A' ' 47' ' ' ALA . 5.2 t -131.45 150.82 34.63 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.396 0 CA-C-O 125.882 2.753 . . . . 0.0 103.78 169.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.0 p30 -69.73 -70.8 0.26 Allowed 'General case' 0 N--CA 1.443 -0.806 1 O-C-N 115.935 -4.228 . . . . 0.0 112.517 169.063 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 24.3 p -162.68 -9.82 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.418 1 C-N-CA 135.045 5.338 . . . . 0.0 114.707 -179.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 26.5 mtpp -122.18 34.54 5.14 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 122.393 2.36 . . . . 0.0 111.328 -163.036 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.82 -58.13 5.03 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 118.853 2.301 . . . . 0.0 118.853 160.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 62.1 t -57.85 132.33 22.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 O-C-N 126.271 1.806 . . . . 0.0 111.007 163.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.417 ' HA ' HG22 ' A' ' 41' ' ' VAL . . . -45.59 161.8 0.04 OUTLIER 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 125.276 2.465 . . . . 0.0 116.849 170.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 9.5 mmm180 -55.37 110.38 0.68 Allowed 'General case' 0 CA--C 1.518 -0.263 0 O-C-N 117.069 -3.519 . . . . 0.0 110.467 174.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.1 p -76.07 5.47 6.66 Favored 'General case' 0 N--CA 1.449 -0.519 1 C-N-CA 136.483 5.913 . . . . 0.0 117.092 -179.085 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -170.14 168.19 8.42 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 123.797 1.761 . . . . 0.0 107.85 169.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -123.86 -162.86 11.57 Favored Glycine 0 C--N 1.344 1.002 0 O-C-N 117.829 -3.044 . . . . 0.0 111.632 -146.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.66 21.21 74.65 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 122.059 3.584 . . . . 0.0 122.059 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 41.9 m-20 -73.39 152.79 90.04 Favored Pre-proline 0 C--O 1.223 -0.31 0 CA-C-N 118.59 1.195 . . . . 0.0 111.925 174.073 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -101.29 131.55 0.14 Allowed 'Trans proline' 0 N--CA 1.457 -0.66 0 CA-C-O 126.001 2.417 . . . . 0.0 112.313 -174.423 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -136.7 155.68 49.55 Favored 'General case' 0 N--CA 1.444 -0.769 0 CA-C-N 111.478 -2.601 . . . . 0.0 110.262 -172.4 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.405 ' O ' ' HA ' ' A' ' 95' ' ' VAL . 34.5 tt0 -139.39 141.43 37.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 125.203 2.43 . . . . 0.0 111.425 175.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 46.6 t -133.98 76.86 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.693 0 C-N-CA 128.195 2.598 . . . . 0.0 104.916 -175.553 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -99.04 141.44 31.79 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 125.872 2.749 . . . . 0.0 107.812 -170.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.426 ' HA ' ' O ' ' A' ' 92' ' ' ASN . 54.5 mt -137.04 139.96 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-N 111.046 -2.797 . . . . 0.0 114.965 -159.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 12.2 m120 -124.59 117.09 23.54 Favored 'General case' 0 C--O 1.223 -0.312 0 C-N-CA 126.983 2.113 . . . . 0.0 106.471 176.02 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -78.98 -159.19 14.28 Favored Glycine 0 N--CA 1.445 -0.766 0 CA-C-O 114.571 -3.35 . . . . 0.0 115.845 161.499 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_endo . . . . . 0 N--CA 1.446 -1.298 1 C-N-CA 127.282 5.321 . . . . 0.0 110.63 162.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 51.8 t . . . . . 0 C--O 1.234 0.271 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 68.2 t -133.29 159.87 42.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 CA-C-N 113.162 -1.835 . . . . 0.0 109.456 -165.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.264 1.1 p30 -133.59 142.95 48.37 Favored 'General case' 0 N--CA 1.448 -0.55 0 O-C-N 120.24 -1.537 . . . . 0.0 109.875 157.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.3 147.08 24.96 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 125.519 1.762 . . . . 0.0 113.632 162.402 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -99.16 113.89 26.37 Favored 'General case' 0 CA--C 1.511 -0.525 0 C-N-CA 127.599 2.36 . . . . 0.0 108.36 -158.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.6 t -91.83 129.49 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 O-C-N 124.42 1.075 . . . . 0.0 111.079 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.7 m -136.87 140.67 42.54 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 102.34 -3.207 . . . . 0.0 102.34 -178.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 57.9 t0 -72.31 124.2 24.6 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 129.199 3.0 . . . . 0.0 107.603 -172.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -82.14 -1.5 49.06 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 116.343 -1.789 . . . . 0.0 115.331 169.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.395 1.5 m120 60.57 32.58 20.44 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-N 121.449 1.931 . . . . 0.0 115.691 176.748 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 25.7 p30 -144.5 6.1 1.25 Allowed 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 113.032 -1.894 . . . . 0.0 112.409 -172.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 89.8 7.27 68.84 Favored Glycine 0 C--N 1.333 0.414 0 CA-C-N 122.58 2.445 . . . . 0.0 115.653 -166.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.9 p -141.16 158.31 44.08 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 129.25 3.02 . . . . 0.0 114.208 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 23.2 m-85 -132.04 126.65 34.4 Favored 'General case' 0 N--CA 1.449 -0.501 0 O-C-N 120.215 -1.553 . . . . 0.0 107.478 -169.351 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -89.17 147.82 19.82 Favored Glycine 0 C--N 1.335 0.5 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 35' ' ' GLU . 2.3 t -131.54 133.83 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 CA-C-N 110.235 -2.982 . . . . 0.0 114.088 -174.027 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 13.7 p -137.54 131.39 43.93 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 CA-C-N 120.781 1.628 . . . . 0.0 110.359 -169.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -161.86 151.67 16.58 Favored 'General case' 0 N--CA 1.452 -0.353 1 O-C-N 115.95 -4.219 . . . . 0.0 111.582 176.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 26.0 p30 -116.93 151.66 36.17 Favored 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 130.92 3.688 . . . . 0.0 111.182 -172.412 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . 0.312 . . -130.44 104.91 16.04 Favored Pre-proline 0 N--CA 1.441 -0.876 0 N-CA-C 118.87 2.915 . . . . 0.0 118.87 -170.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -93.21 24.44 0.45 Allowed 'Trans proline' 0 N--CA 1.45 -1.044 0 C-N-CA 124.488 3.459 . . . . 0.0 112.76 -174.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.5 m -140.04 134.87 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 117.145 2.276 . . . . 0.0 117.145 -179.148 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . 0.284 38.5 tt0 -56.43 105.15 0.18 Allowed 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.705 144.016 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 162.41 -139.99 6.28 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 117.97 -1.461 . . . . 0.0 110.876 176.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 85.0 m-20 -143.24 137.97 29.3 Favored 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 105.848 -1.908 . . . . 0.0 105.848 -170.816 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -90.04 145.91 24.73 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 111.435 -2.62 . . . . 0.0 113.143 156.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.426 ' O ' ' HA ' ' A' ' 59' ' ' ILE . 26.1 t-20 -113.0 116.97 30.78 Favored 'General case' 0 N--CA 1.442 -0.828 0 O-C-N 128.566 3.666 . . . . 0.0 112.232 172.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 43.5 t -111.91 131.18 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 CA-C-O 126.102 2.858 . . . . 0.0 113.105 -168.448 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 21.5 t-20 -131.96 131.68 42.83 Favored 'General case' 0 N--CA 1.445 -0.694 0 O-C-N 119.157 -2.214 . . . . 0.0 111.302 176.309 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 56' ' ' GLU . 57.7 t -118.52 129.95 74.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 O-C-N 124.159 0.912 . . . . 0.0 112.718 -174.44 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.418 ' HB ' ' O ' ' A' ' 100' ' ' ASN . 46.9 p -139.6 153.19 47.31 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -172.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 3.2 mp -126.16 105.84 9.14 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 105.043 -2.206 . . . . 0.0 105.043 -142.149 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 44.4 ttm-85 46.93 42.22 11.95 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 125.997 2.808 . . . . 0.0 108.937 -153.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 57.93 14.22 16.16 Favored Glycine 0 CA--C 1.528 0.882 0 O-C-N 116.765 -3.71 . . . . 0.0 115.798 -177.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.418 ' O ' ' HB ' ' A' ' 96' ' ' THR . 76.8 m-20 -95.32 157.37 36.43 Favored Pre-proline 0 N--CA 1.449 -0.485 0 C-N-CA 117.6 -1.64 . . . . 0.0 115.325 168.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -79.91 168.38 19.18 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 CA-C-O 125.82 2.342 . . . . 0.0 111.836 -174.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 43.5 pt -147.02 -177.52 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-O 126.038 2.828 . . . . 0.0 113.733 -178.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 17.2 ptmt -84.71 168.51 15.17 Favored 'General case' 0 N--CA 1.446 -0.669 0 O-C-N 116.405 -3.934 . . . . 0.0 110.936 -176.337 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 17.4 m120 54.77 29.46 11.85 Favored 'General case' 0 N--CA 1.446 -0.674 0 O-C-N 120.386 -1.446 . . . . 0.0 114.536 175.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 11.1 mmt -143.18 150.55 52.66 Favored Pre-proline 0 CA--C 1.518 -0.28 0 CA-C-O 113.351 -3.214 . . . . 0.0 111.73 177.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.43 175.82 34.03 Favored 'Cis proline' 0 N--CA 1.446 -1.316 0 CA-C-N 123.809 2.396 . . . . 0.0 113.199 -0.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 14.0 pt -144.56 -176.04 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 170.272 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -135.12 148.52 49.81 Favored 'General case' 0 N--CA 1.45 -0.463 1 O-C-N 114.745 -4.972 . . . . 0.0 112.294 -172.862 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 99.5 t -143.66 128.81 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.909 0 N-CA-C 105.478 -2.045 . . . . 0.0 105.478 -171.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 69.5 tttt -70.63 132.19 45.07 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 112.669 -2.059 . . . . 0.0 112.221 -176.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 81.6 m -113.08 126.82 55.89 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.208 1.403 . . . . 0.0 109.548 -178.257 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.8 tp -135.36 132.14 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 O-C-N 119.86 -1.775 . . . . 0.0 108.897 155.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -72.75 55.23 0.38 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 130.377 3.471 . . . . 0.0 114.028 -163.036 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.452 0 C-N-CA 128.021 2.724 . . . . 0.0 115.692 176.338 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo . . . . . 0 N--CA 1.453 -0.907 0 CA-C-O 122.382 0.909 . . . . 0.0 111.586 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.406 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . . . -82.08 134.12 49.98 Favored Pre-proline 0 N--CA 1.445 -0.686 0 C-N-CA 127.135 2.174 . . . . 0.0 113.725 175.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 12' ' ' ALA . 24.1 Cg_exo -63.86 158.8 45.05 Favored 'Trans proline' 0 N--CA 1.443 -1.476 1 C-N-CA 127.015 5.143 . . . . 0.0 111.394 172.584 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -135.97 155.97 49.46 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 125.283 1.433 . . . . 0.0 111.791 -163.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -75.33 -33.58 61.15 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 117.191 2.293 . . . . 0.0 117.191 -172.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -57.77 -14.39 5.75 Favored 'General case' 0 N--CA 1.44 -0.932 1 O-C-N 114.574 -5.079 . . . . 0.0 116.756 153.475 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 48.1 m-70 -135.14 18.64 3.43 Favored 'General case' 0 N--CA 1.444 -0.733 0 O-C-N 125.956 2.035 . . . . 0.0 114.679 -159.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.9 t -138.3 120.16 15.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 O-C-N 117.152 -3.468 . . . . 0.0 107.697 171.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.442 ' O ' ' CD2' ' A' ' 39' ' ' PHE . 23.8 m-85 -153.78 150.64 28.68 Favored 'General case' 0 N--CA 1.455 -0.213 0 CA-C-O 114.441 -2.695 . . . . 0.0 111.569 -170.244 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.515 ' HB2' ' HA ' ' A' ' 38' ' ' ILE . . . -141.28 158.37 43.98 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 118.195 2.665 . . . . 0.0 118.195 -161.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -153.62 141.37 20.03 Favored 'General case' 0 CA--C 1.518 -0.269 0 C-N-CA 126.411 1.884 . . . . 0.0 112.356 -159.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 132.66 157.35 8.49 Favored Glycine 0 N--CA 1.447 -0.614 1 C-N-CA 130.874 4.083 . . . . 0.0 116.282 -174.272 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -63.46 -20.18 65.36 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 118.661 2.837 . . . . 0.0 118.661 -173.264 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.79 8.39 0.55 Allowed Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 128.821 3.105 . . . . 0.0 117.088 162.015 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 75.9 mt -108.75 10.25 26.8 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-O 116.294 -1.812 . . . . 0.0 109.747 160.317 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 91.7 t -139.47 -29.96 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 CA-C-N 121.959 2.163 . . . . 0.0 113.213 -174.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 26.9 ttmt -164.5 138.21 5.17 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 119.508 -1.995 . . . . 0.0 107.508 171.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 t -132.33 136.22 56.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.458 0 O-C-N 126.387 2.305 . . . . 0.0 109.699 -174.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.434 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 66.9 m-85 -127.86 -172.24 2.63 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 122.148 2.249 . . . . 0.0 112.592 -163.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -88.01 -54.74 4.07 Favored 'General case' 0 N--CA 1.448 -0.569 0 O-C-N 117.832 -3.042 . . . . 0.0 115.928 177.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 69.0 m-80 -97.91 8.28 44.99 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 115.64 1.718 . . . . 0.0 115.64 174.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . 0.259 . . -126.27 80.96 68.0 Favored Pre-proline 0 CA--C 1.516 -0.334 0 C-N-CA 125.614 1.566 . . . . 0.0 111.468 174.325 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -61.61 123.63 13.08 Favored 'Trans proline' 0 N--CA 1.445 -1.334 0 CA-C-O 122.903 1.126 . . . . 0.0 111.649 176.257 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.63 150.72 23.71 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 112.689 -2.05 . . . . 0.0 111.483 -164.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -129.66 153.89 47.67 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 127.514 2.325 . . . . 0.0 114.536 -162.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -164.48 158.84 18.75 Favored 'General case' 0 N--CA 1.446 -0.66 0 O-C-N 121.09 -1.006 . . . . 0.0 111.491 172.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 7.2 m -129.56 115.11 16.93 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 113.36 -1.745 . . . . 0.0 110.529 -154.349 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.515 ' HA ' ' HB2' ' A' ' 20' ' ' ALA . 15.5 mt -82.2 98.77 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 O-C-N 128.553 3.658 . . . . 0.0 108.979 178.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.442 ' CD2' ' O ' ' A' ' 19' ' ' TYR 0.328 47.3 p90 -76.94 105.12 7.81 Favored 'General case' 0 N--CA 1.451 -0.424 0 O-C-N 118.339 -2.726 . . . . 0.0 113.327 170.915 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . 0.264 . . -90.03 134.27 34.34 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 127.339 2.256 . . . . 0.0 116.674 -176.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 46.3 t -133.27 143.34 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 C-N-CA 126.776 2.03 . . . . 0.0 106.673 160.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.09 -81.22 0.02 OUTLIER 'General case' 0 N--CA 1.443 -0.795 0 O-C-N 117.846 -3.034 . . . . 0.0 114.476 161.611 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 19.1 p -161.32 -41.12 0.04 OUTLIER 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 128.436 2.695 . . . . 0.0 111.393 -169.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -90.62 52.16 2.14 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 121.927 2.149 . . . . 0.0 113.254 -167.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 71.81 -66.2 1.12 Allowed Glycine 0 C--N 1.341 0.848 0 CA-C-O 118.249 -1.306 . . . . 0.0 115.782 174.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 70.8 t -56.38 129.51 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 O-C-N 125.54 1.377 . . . . 0.0 111.974 178.303 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -36.91 164.83 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 130.284 3.434 . . . . 0.0 116.192 163.378 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . 0.254 7.3 mmm180 -66.16 101.67 0.74 Allowed 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 114.611 1.337 . . . . 0.0 114.611 175.232 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 61.8 p -79.37 2.76 20.48 Favored 'General case' 0 N--CA 1.449 -0.515 1 C-N-CA 133.464 4.705 . . . . 0.0 114.741 178.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -155.83 -174.72 5.08 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 130.014 3.326 . . . . 0.0 113.721 158.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -154.04 -176.45 26.41 Favored Glycine 0 CA--C 1.521 0.425 0 CA-C-O 124.741 2.301 . . . . 0.0 115.797 -141.68 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.71 14.35 67.31 Favored Glycine 0 C--N 1.336 0.549 0 O-C-N 117.462 -3.375 . . . . 0.0 112.789 -170.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -60.69 123.55 74.95 Favored Pre-proline 0 N--CA 1.446 -0.672 0 CA-C-N 123.7 3.75 . . . . 0.0 106.98 175.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -83.85 153.77 13.17 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 CA-C-N 122.468 1.917 . . . . 0.0 116.294 -162.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -142.95 156.29 44.86 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-O 126.35 2.976 . . . . 0.0 110.14 -157.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -144.11 153.25 41.96 Favored 'General case' 0 N--CA 1.448 -0.53 0 O-C-N 118.671 -2.518 . . . . 0.0 109.989 161.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.413 HG22 HG22 ' A' ' 95' ' ' VAL . 92.0 t -133.81 108.54 11.86 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.96 0 C-N-CA 129.789 3.235 . . . . 0.0 104.052 169.545 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -117.12 133.87 55.47 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 126.833 2.053 . . . . 0.0 112.287 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . 0.275 3.4 mp -124.06 144.9 32.24 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 C-N-CA 125.848 1.659 . . . . 0.0 113.94 -167.405 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 53.0 m-80 -118.23 140.41 49.84 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 114.217 -2.802 . . . . 0.0 110.061 174.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.47 -169.51 14.31 Favored Glycine 0 CA--C 1.526 0.774 0 CA-C-N 121.558 1.981 . . . . 0.0 111.68 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . 0.304 19.2 Cg_endo . . . . . 0 N--CA 1.451 -1.027 0 N-CA-C 114.96 1.1 . . . . 0.0 114.96 -179.107 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 51.5 t . . . . . 0 N--CA 1.445 -0.718 0 N-CA-C 105.432 -2.062 . . . . 0.0 105.432 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 9.5 t -133.51 150.7 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.155 0 CA-C-N 113.193 -1.821 . . . . 0.0 106.843 -165.287 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.269 2.4 p30 -117.74 137.8 52.46 Favored 'General case' 0 N--CA 1.439 -0.985 0 O-C-N 118.979 -2.326 . . . . 0.0 112.717 148.492 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.21 158.97 22.09 Favored 'General case' 0 N--CA 1.444 -0.738 0 O-C-N 126.277 2.235 . . . . 0.0 112.439 -174.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 38.9 mmtm -90.33 103.13 15.84 Favored 'General case' 0 N--CA 1.447 -0.609 0 O-C-N 120.265 -1.522 . . . . 0.0 112.719 -172.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 54.9 t -71.27 135.48 27.9 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.662 172.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 54.6 m -123.91 137.87 54.56 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 124.735 1.214 . . . . 0.0 112.033 162.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 48.5 t0 -78.02 121.38 24.15 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 124.161 1.934 . . . . 0.0 111.94 169.255 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 -76.2 -7.5 54.98 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 112.228 -2.26 . . . . 0.0 115.088 -177.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 4.7 m120 59.85 25.95 15.1 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 129.655 3.182 . . . . 0.0 114.248 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 42.7 p30 -134.25 -6.84 2.63 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 129.194 2.998 . . . . 0.0 112.903 -175.257 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 103.29 15.6 22.96 Favored Glycine 0 C--N 1.336 0.555 1 C-N-CA 133.41 5.291 . . . . 0.0 114.288 -172.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 27.1 p -140.69 165.24 28.03 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 122.505 3.152 . . . . 0.0 108.791 177.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 67.4 m-85 -135.88 125.12 24.62 Favored 'General case' 0 N--CA 1.447 -0.579 0 N-CA-C 104.823 -2.288 . . . . 0.0 104.823 -166.2 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -96.68 129.95 10.08 Favored Glycine 0 C--N 1.336 0.575 0 C-N-CA 129.597 3.475 . . . . 0.0 107.165 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.8 t -108.68 128.21 64.58 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 1 CA-C-O 110.811 -4.423 . . . . 0.0 112.892 172.253 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.2 p -127.54 142.27 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 123.915 3.052 . . . . 0.0 115.666 172.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -165.03 160.43 18.93 Favored 'General case' 0 N--CA 1.449 -0.491 0 O-C-N 117.096 -3.502 . . . . 0.0 112.947 -173.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.465 42.5 p30 -137.77 148.32 45.45 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 128.437 2.695 . . . . 0.0 114.347 -168.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -125.28 113.08 26.01 Favored Pre-proline 0 N--CA 1.445 -0.708 0 C-N-CA 128.26 2.624 . . . . 0.0 112.025 -171.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.258 59.0 Cg_endo -76.04 12.91 1.37 Allowed 'Trans proline' 0 N--CA 1.441 -1.611 0 O-C-N 125.186 2.15 . . . . 0.0 113.359 177.778 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.8 m -140.62 141.28 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 115.579 1.696 . . . . 0.0 115.579 -151.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -63.96 114.17 3.94 Favored 'General case' 0 N--CA 1.447 -0.625 0 O-C-N 117.329 -3.357 . . . . 0.0 110.119 144.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 163.07 -155.43 26.77 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 125.317 2.621 . . . . 0.0 117.561 -169.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 5.0 t30 -135.81 121.88 20.14 Favored 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 127.278 2.231 . . . . 0.0 107.432 -167.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . 0.25 7.3 m-85 -87.48 143.09 27.39 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 123.298 0.639 . . . . 0.0 112.65 158.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -127.55 123.65 36.3 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 124.376 2.036 . . . . 0.0 107.999 -175.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . 0.344 3.3 t -109.46 135.14 49.31 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 N-CA-C 117.519 2.414 . . . . 0.0 117.519 -164.81 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -136.57 128.51 29.36 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 131.494 3.917 . . . . 0.0 108.373 179.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.413 HG22 HG22 ' A' ' 57' ' ' VAL . 58.2 t -118.12 152.59 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 CA-C-O 123.677 1.703 . . . . 0.0 108.374 -173.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.7 p -151.15 152.0 32.74 Favored 'General case' 0 N--CA 1.441 -0.915 0 O-C-N 120.411 -1.431 . . . . 0.0 112.952 -177.085 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 9.4 mp -137.3 94.9 2.99 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 104.351 -2.463 . . . . 0.0 104.351 -153.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . 0.277 25.3 ttm-85 49.2 43.8 22.87 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 112.571 -2.104 . . . . 0.0 110.691 -162.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 74.31 -13.29 4.85 Favored Glycine 0 CA--C 1.522 0.489 0 CA-C-O 114.681 -3.288 . . . . 0.0 116.132 -168.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 72.6 m-20 -74.25 126.83 88.68 Favored Pre-proline 0 N--CA 1.451 -0.398 0 CA-C-N 122.534 3.167 . . . . 0.0 119.072 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.457 ' C ' HG23 ' A' ' 102' ' ' ILE . 61.4 Cg_endo -74.29 172.11 16.7 Favored 'Trans proline' 0 N--CA 1.453 -0.885 1 C-N-CA 127.451 5.434 . . . . 0.0 106.863 -177.468 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.572 HG13 ' HG3' ' A' ' 105' ' ' MET . 27.4 pt -143.87 177.61 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 O-C-N 118.346 -2.721 . . . . 0.0 107.705 -164.388 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 38.4 mttm -80.71 159.81 25.15 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 128.678 2.791 . . . . 0.0 111.191 -169.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 15.2 m120 54.2 43.89 29.93 Favored 'General case' 0 C--O 1.224 -0.285 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 176.25 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' MET . . . . . 0.572 ' HG3' HG13 ' A' ' 102' ' ' ILE . 6.9 mmt -138.55 139.52 24.91 Favored Pre-proline 0 N--CA 1.444 -0.728 0 C-N-CA 129.812 3.245 . . . . 0.0 107.956 -163.138 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -79.06 165.05 82.37 Favored 'Cis proline' 0 N--CA 1.447 -1.215 0 CA-C-N 122.78 2.029 . . . . 0.0 109.328 1.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . 0.276 2.2 pp -114.46 159.36 14.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 C-N-CA 125.366 1.466 . . . . 0.0 114.081 171.227 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -122.59 134.44 54.52 Favored 'General case' 0 N--CA 1.449 -0.502 0 O-C-N 118.588 -2.57 . . . . 0.0 111.899 -167.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 1.7 t -129.53 121.36 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-O 125.695 2.664 . . . . 0.0 112.615 -177.252 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -55.72 130.29 42.67 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 112.222 -2.263 . . . . 0.0 114.155 170.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 48.7 m -121.82 153.82 37.85 Favored 'General case' 0 N--CA 1.445 -0.699 0 O-C-N 123.994 0.809 . . . . 0.0 110.461 176.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.434 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 10.4 tp -150.52 138.06 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.773 0 C-N-CA 127.602 2.361 . . . . 0.0 113.486 165.367 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -68.84 43.29 0.04 OUTLIER 'General case' 0 N--CA 1.444 -0.768 1 CA-C-O 129.778 4.609 . . . . 0.0 115.584 -166.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.616 1 O-C-N 114.68 -5.013 . . . . 0.0 112.116 -175.359 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . 0.29 40.3 Cg_endo . . . . . 0 N--CA 1.453 -0.862 0 N-CA-C 118.429 2.434 . . . . 0.0 118.429 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.479 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . . . -77.85 129.22 76.93 Favored Pre-proline 0 CA--C 1.516 -0.347 0 N-CA-C 118.433 2.753 . . . . 0.0 118.433 -178.136 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.479 ' HD3' ' HA ' ' A' ' 12' ' ' ALA . 65.8 Cg_exo -62.81 150.6 87.73 Favored 'Trans proline' 0 N--CA 1.448 -1.162 1 C-N-CA 126.027 4.485 . . . . 0.0 110.775 169.84 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.8 t -129.64 152.13 49.49 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 117.159 2.281 . . . . 0.0 117.159 -170.03 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.33 -36.18 79.43 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 120.379 -1.451 . . . . 0.0 113.337 179.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 59.7 mm-40 -54.93 -31.01 59.95 Favored 'General case' 0 C--N 1.349 0.554 0 CA-C-N 124.32 3.236 . . . . 0.0 112.554 163.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . 0.446 ' CD2' ' HA ' ' A' ' 43' ' ' THR . 55.0 m-70 -125.23 19.37 8.25 Favored 'General case' 0 N--CA 1.445 -0.688 0 CA-C-O 125.627 2.632 . . . . 0.0 113.711 -154.153 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 7.1 t -147.38 122.69 10.28 Favored 'General case' 0 C--N 1.347 0.48 1 O-C-N 113.615 -5.678 . . . . 0.0 113.474 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 37.1 m-85 -160.36 151.13 18.7 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-O 116.185 -1.865 . . . . 0.0 110.235 -164.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.408 ' HA ' ' O ' ' A' ' 37' ' ' THR . . . -131.52 153.23 50.03 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-O 122.565 1.174 . . . . 0.0 109.78 -167.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -159.12 147.96 18.32 Favored 'General case' 0 N--CA 1.447 -0.609 0 C-N-CA 125.93 1.692 . . . . 0.0 110.348 -168.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.84 -179.87 16.02 Favored Glycine 0 C--N 1.338 0.666 0 C-N-CA 129.668 3.509 . . . . 0.0 117.339 175.097 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . 0.588 1.9 tt0 -62.23 -27.57 69.09 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 120.15 3.389 . . . . 0.0 120.15 -168.397 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.406 ' HA2' ' HB1' ' A' ' 34' ' ' ALA . . . -61.03 0.13 1.29 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 118.827 2.291 . . . . 0.0 118.827 160.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 49.2 mt -113.85 13.78 18.46 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.493 1.117 . . . . 0.0 111.463 168.205 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.9 t -129.47 -55.47 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 CA-C-O 115.839 -2.029 . . . . 0.0 113.334 178.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -150.16 128.25 11.94 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 116.638 -1.649 . . . . 0.0 111.777 -177.274 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 52.0 t -137.58 132.24 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 O-C-N 127.855 3.222 . . . . 0.0 113.255 -162.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.467 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 5.9 m-85 -126.63 -168.42 1.86 Allowed 'General case' 0 C--N 1.334 -0.065 0 CA-C-O 123.694 1.711 . . . . 0.0 112.453 -164.595 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -100.46 -56.32 2.38 Favored 'General case' 0 N--CA 1.449 -0.514 0 O-C-N 119.133 -2.229 . . . . 0.0 111.358 -166.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 40.0 m-80 -100.08 8.09 44.19 Favored 'General case' 0 N--CA 1.451 -0.403 0 O-C-N 119.027 -2.295 . . . . 0.0 111.678 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -121.22 93.14 48.81 Favored Pre-proline 0 N--CA 1.448 -0.57 0 O-C-N 119.423 -2.048 . . . . 0.0 108.197 167.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.11 128.02 22.87 Favored 'Trans proline' 0 N--CA 1.453 -0.901 1 C-N-CA 127.393 5.395 . . . . 0.0 113.465 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.406 ' HB1' ' HA2' ' A' ' 24' ' ' GLY . . . -92.47 152.47 19.66 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 128.257 2.623 . . . . 0.0 117.232 177.409 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 29.1 mt-10 -143.32 148.92 37.05 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 128.942 3.901 . . . . 0.0 110.265 -161.166 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 20.7 p90 -168.77 165.75 11.77 Favored 'General case' 0 CA--C 1.518 -0.284 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 -178.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 20' ' ' ALA . 57.7 m -133.63 122.55 23.63 Favored 'General case' 0 N--CA 1.448 -0.548 0 O-C-N 127.887 3.242 . . . . 0.0 114.173 -155.262 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.4 ' HB ' ' HB2' ' A' ' 79' ' ' TYR . 4.0 mt -86.03 101.17 10.0 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-O 114.866 -2.493 . . . . 0.0 105.638 177.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.484 ' HA ' HG22 ' A' ' 78' ' ' THR . 12.7 p90 -74.58 112.23 10.56 Favored 'General case' 0 N--CA 1.446 -0.634 0 O-C-N 124.917 1.386 . . . . 0.0 112.656 162.086 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . 0.252 . . -102.3 135.13 44.46 Favored 'General case' 0 C--O 1.222 -0.395 0 C-N-CA 126.151 1.78 . . . . 0.0 115.266 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.6 t -125.29 149.17 29.79 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 130.661 3.584 . . . . 0.0 108.961 162.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -74.96 -62.41 1.56 Allowed 'General case' 0 N--CA 1.441 -0.903 0 O-C-N 119.498 -2.001 . . . . 0.0 112.007 173.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.446 ' HA ' ' CD2' ' A' ' 17' ' ' HIS . 8.2 p -173.99 -25.83 0.01 OUTLIER 'General case' 0 C--O 1.218 -0.574 1 C-N-CA 133.158 4.583 . . . . 0.0 110.349 -173.857 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 71.4 mmtt -93.67 27.43 2.68 Favored 'General case' 0 N--CA 1.445 -0.691 0 O-C-N 118.529 -2.607 . . . . 0.0 112.311 -167.085 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 62.95 -32.3 0.07 OUTLIER Glycine 0 N--CA 1.444 -0.802 1 N-CA-C 123.404 4.122 . . . . 0.0 123.404 178.428 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 90.2 t -78.4 138.67 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.845 0 CA-C-N 119.196 1.498 . . . . 0.0 111.881 167.232 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -50.83 166.77 0.08 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.901 1.376 . . . . 0.0 113.397 -177.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 11.1 mmm180 -62.29 122.66 16.19 Favored 'General case' 0 C--O 1.22 -0.468 0 CA-C-N 121.947 2.158 . . . . 0.0 113.096 -172.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 72.9 p -100.38 13.49 34.28 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-O 126.756 3.17 . . . . 0.0 113.193 -161.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.8 p30 -159.66 175.14 13.55 Favored 'General case' 0 N--CA 1.45 -0.454 2 C-N-CA 131.861 4.064 . . . . 0.0 109.534 160.021 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -127.5 -178.34 15.28 Favored Glycine 0 C--N 1.343 0.94 0 N-CA-C 118.871 2.308 . . . . 0.0 118.871 -159.093 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.45 20.74 68.46 Favored Glycine 0 C--N 1.346 1.134 0 CA-C-O 114.094 -3.614 . . . . 0.0 110.597 172.349 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -70.21 145.94 94.11 Favored Pre-proline 0 N--CA 1.445 -0.695 0 CA-C-N 123.807 3.804 . . . . 0.0 112.858 170.357 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -76.08 119.26 5.27 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 N-CA-C 117.307 2.003 . . . . 0.0 117.307 -178.172 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -131.25 165.43 23.4 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-O 124.04 1.876 . . . . 0.0 115.891 168.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -160.64 147.06 15.25 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 113.51 -1.677 . . . . 0.0 110.233 -171.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 2.4 t -131.04 123.48 53.95 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.754 0 C-N-CA 127.984 2.514 . . . . 0.0 106.769 176.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -121.44 131.63 54.27 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 113.927 -1.488 . . . . 0.0 109.023 -170.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.6 mp -132.4 132.86 60.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 -163.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 24.8 m120 -113.78 129.73 56.54 Favored 'General case' 0 N--CA 1.442 -0.841 0 O-C-N 125.396 1.685 . . . . 0.0 108.287 151.451 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -96.75 -164.18 32.77 Favored Glycine 0 C--N 1.345 1.045 0 CA-C-O 123.379 1.544 . . . . 0.0 111.273 151.524 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . 0.282 84.2 Cg_endo . . . . . 0 N--CA 1.448 -1.171 0 C-N-CA 123.514 2.809 . . . . 0.0 118.379 176.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 87.1 t . . . . . 0 N--CA 1.45 -0.473 0 CA-C-O 116.662 -1.637 . . . . 0.0 107.61 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 87.9 t -135.54 143.84 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 125.922 1.689 . . . . 0.0 108.977 -173.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.319 35.5 t0 -129.52 125.99 37.58 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-O 115.337 -2.268 . . . . 0.0 110.435 175.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.25 162.23 19.24 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 125.453 1.72 . . . . 0.0 114.644 176.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -103.22 123.2 46.28 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 -177.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.5 t -100.68 137.05 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 O-C-N 128.595 3.684 . . . . 0.0 109.905 -175.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . 0.25 53.1 m -134.92 136.54 42.39 Favored 'General case' 0 N--CA 1.445 -0.676 0 O-C-N 117.912 -2.993 . . . . 0.0 109.371 -179.425 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 59.7 t0 -62.66 123.98 19.8 Favored 'General case' 0 N--CA 1.448 -0.559 0 O-C-N 120.497 -1.377 . . . . 0.0 112.004 164.255 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -84.83 -10.41 57.19 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-O 116.377 -1.773 . . . . 0.0 115.264 174.069 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.374 1.4 m120 74.21 36.95 0.63 Allowed 'General case' 0 C--O 1.219 -0.515 0 CA-C-O 115.988 -1.958 . . . . 0.0 113.768 172.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 20.0 p30 -154.58 -10.98 0.13 Allowed 'General case' 0 N--CA 1.449 -0.476 0 O-C-N 126.042 2.089 . . . . 0.0 114.676 -167.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 130.85 -25.72 4.13 Favored Glycine 0 CA--C 1.522 0.511 0 CA-C-N 122.852 2.569 . . . . 0.0 113.63 -158.153 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.484 HG22 ' HA ' ' A' ' 39' ' ' PHE . 2.8 p -136.81 171.77 14.0 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 118.252 2.686 . . . . 0.0 118.252 -157.361 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.4 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 34.6 m-85 -135.94 113.61 10.98 Favored 'General case' 0 N--CA 1.433 -1.282 0 C-N-CA 126.032 1.733 . . . . 0.0 109.487 -172.035 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -86.16 146.48 21.13 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-O 124.146 1.97 . . . . 0.0 112.723 176.282 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 35' ' ' GLU . 41.0 t -136.4 130.0 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 C-N-CA 128.113 2.565 . . . . 0.0 109.032 -167.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 14.7 p -134.34 122.09 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.429 0 C-N-CA 125.836 1.654 . . . . 0.0 110.401 -168.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.435 ' HE2' ' CD2' ' A' ' 91' ' ' TYR 0.257 0.1 OUTLIER -154.44 175.38 13.65 Favored 'General case' 0 N--CA 1.447 -0.597 0 O-C-N 118.975 -2.328 . . . . 0.0 111.91 -177.4 . . . . . . . . 4 4 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 5.2 p30 -151.76 162.96 40.17 Favored 'General case' 0 N--CA 1.448 -0.556 1 O-C-N 116.268 -4.02 . . . . 0.0 109.708 -174.107 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.62 ' HB2' ' CE2' ' A' ' 91' ' ' TYR . . . -134.46 110.89 11.53 Favored Pre-proline 0 N--CA 1.446 -0.637 1 C-N-CA 133.924 4.89 . . . . 0.0 113.103 -172.406 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -75.77 8.57 2.65 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 123.822 3.015 . . . . 0.0 114.132 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.5 m -134.03 138.15 50.83 Favored 'Isoleucine or valine' 0 C--O 1.238 0.46 0 C-N-CA 129.551 3.14 . . . . 0.0 115.855 -160.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 17.3 tt0 -59.81 109.31 0.9 Allowed 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 139.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 176.71 -157.21 22.34 Favored Glycine 0 C--N 1.344 0.975 0 CA-C-O 117.675 -1.625 . . . . 0.0 116.184 -173.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -133.12 139.21 46.98 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 127.623 2.369 . . . . 0.0 108.688 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . 0.62 ' CE2' ' HB2' ' A' ' 85' ' ' ALA . 3.0 m-30 -105.96 145.19 31.65 Favored 'General case' 0 N--CA 1.446 -0.642 0 O-C-N 119.747 -1.845 . . . . 0.0 110.627 161.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -126.55 116.96 21.87 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.843 -2.28 . . . . 0.0 104.843 -176.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 61.1 t -124.29 135.83 62.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 C-N-CA 125.417 1.487 . . . . 0.0 110.581 -149.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -136.32 133.68 37.13 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 105.447 -2.057 . . . . 0.0 105.447 -172.382 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 94.5 t -114.0 137.78 46.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 O-C-N 119.16 -2.212 . . . . 0.0 113.923 172.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 35.9 p -143.17 165.8 26.43 Favored 'General case' 0 CA--C 1.516 -0.349 0 O-C-N 120.614 -1.304 . . . . 0.0 113.609 -164.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . 0.26 7.4 tt -150.15 99.9 2.85 Favored 'General case' 0 C--N 1.344 0.368 0 N-CA-C 101.668 -3.456 . . . . 0.0 101.668 -146.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 8.7 ttm180 52.87 36.87 22.73 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 119.758 1.163 . . . . 0.0 111.471 -150.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.37 0.5 38.14 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-O 115.271 -2.96 . . . . 0.0 109.8 -178.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -94.81 142.93 25.35 Favored Pre-proline 0 N--CA 1.441 -0.877 0 CA-C-N 121.148 2.474 . . . . 0.0 109.868 -176.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -79.06 158.98 27.04 Favored 'Trans proline' 0 C--O 1.218 -0.499 0 CA-C-O 126.239 2.516 . . . . 0.0 113.459 -177.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 29.2 pt -142.92 -171.46 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 CA-C-N 109.386 -3.552 . . . . 0.0 113.32 -171.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -93.79 157.72 16.01 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 125.856 1.662 . . . . 0.0 112.341 -158.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.26 30.9 m120 50.19 34.1 8.15 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 129.793 3.237 . . . . 0.0 112.785 178.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 6.0 mmt -130.57 151.29 78.43 Favored Pre-proline 0 N--CA 1.444 -0.769 1 C-N-CA 134.551 5.141 . . . . 0.0 106.284 176.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -76.69 163.13 90.37 Favored 'Cis proline' 0 N--CA 1.45 -1.037 0 CA-C-N 126.432 3.333 . . . . 0.0 107.336 -2.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . 0.536 ' C ' HD12 ' A' ' 107' ' ' ILE 0.376 1.3 pp -127.04 167.54 21.66 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.409 0 N-CA-C 118.14 2.644 . . . . 0.0 118.14 163.743 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -106.57 142.13 36.72 Favored 'General case' 0 N--CA 1.449 -0.496 0 O-C-N 118.159 -2.838 . . . . 0.0 118.019 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 61.5 t -123.12 124.14 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 127.018 2.127 . . . . 0.0 109.977 -179.303 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -80.43 128.0 33.07 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-O 118.575 -0.726 . . . . 0.0 111.424 165.47 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 99.5 m -115.68 140.4 49.23 Favored 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 128.247 2.619 . . . . 0.0 112.819 -170.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.467 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 98.6 mt -133.85 145.73 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 CA-C-N 121.898 2.135 . . . . 0.0 106.795 177.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -82.19 48.1 1.22 Allowed 'General case' 0 N--CA 1.445 -0.698 0 O-C-N 116.76 -3.712 . . . . 0.0 113.692 -166.28 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.435 -1.391 0 O-C-N 120.575 -1.328 . . . . 0.0 116.111 174.493 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo . . . . . 0 N--CA 1.445 -1.348 0 N-CA-C 113.26 0.446 . . . . 0.0 113.26 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -119.17 138.41 26.25 Favored Pre-proline 0 CA--C 1.512 -0.491 0 C-N-CA 126.106 1.762 . . . . 0.0 110.474 -178.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_exo -65.47 169.49 12.54 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.155 1.903 . . . . 0.0 114.156 170.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -145.74 168.02 21.74 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 125.547 1.539 . . . . 0.0 113.131 -171.456 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.44 -43.78 72.62 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 117.593 2.442 . . . . 0.0 117.593 179.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 55.6 mm-40 -60.65 -20.42 60.79 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.5 1.52 . . . . 0.0 111.353 167.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . 0.444 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . 68.6 m-70 -126.48 18.54 7.5 Favored 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 129.322 3.049 . . . . 0.0 112.757 -158.682 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.9 t -141.56 126.3 18.02 Favored 'General case' 0 N--CA 1.444 -0.729 0 O-C-N 119.856 -1.777 . . . . 0.0 106.476 166.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -153.86 157.85 39.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 130.632 3.573 . . . . 0.0 110.679 -175.306 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -141.92 148.77 39.22 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 127.734 2.413 . . . . 0.0 116.718 -165.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -144.08 143.31 31.1 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 113.969 -1.469 . . . . 0.0 109.33 -171.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 138.98 173.4 12.98 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 118.625 2.21 . . . . 0.0 118.625 169.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -68.87 -24.82 64.38 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 120.202 -1.763 . . . . 0.0 111.973 -168.354 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.18 7.35 0.56 Allowed Glycine 0 C--N 1.339 0.697 0 C-N-CA 129.779 3.562 . . . . 0.0 116.954 171.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 96.6 mt -116.98 -2.59 11.72 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-O 114.185 -2.817 . . . . 0.0 110.221 172.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 t -129.8 -55.05 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 CA-C-N 122.832 2.56 . . . . 0.0 109.156 -168.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 23.8 pttt -145.36 120.62 10.21 Favored 'General case' 0 C--O 1.238 0.46 0 O-C-N 118.873 -2.392 . . . . 0.0 112.282 -172.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 93.9 t -125.85 139.54 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 119.348 -2.095 . . . . 0.0 105.466 -172.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.443 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 42.5 m-85 -127.79 -163.43 1.26 Allowed 'General case' 0 N--CA 1.447 -0.621 0 CA-C-O 115.099 -2.381 . . . . 0.0 110.215 -178.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -103.14 -50.52 3.47 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 120.803 1.638 . . . . 0.0 114.572 -170.072 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 19.1 m-80 -109.2 6.01 24.34 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 130.27 3.428 . . . . 0.0 111.028 -179.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -122.06 85.82 46.34 Favored Pre-proline 0 C--O 1.224 -0.252 0 C-N-CA 126.693 1.997 . . . . 0.0 111.73 165.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -55.93 146.56 67.62 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 C-N-CA 117.244 -1.37 . . . . 0.0 115.091 176.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -93.76 162.64 13.85 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 119.044 2.979 . . . . 0.0 119.044 170.3 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -136.85 147.77 46.71 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 117.612 2.449 . . . . 0.0 117.612 -174.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -157.98 160.81 37.92 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-N 122.182 2.265 . . . . 0.0 107.77 169.443 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 49.2 m -119.18 127.92 53.75 Favored 'General case' 0 N--CA 1.441 -0.909 0 CA-C-O 113.805 -2.997 . . . . 0.0 113.811 -166.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.0 mt -86.39 106.53 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 O-C-N 126.681 2.488 . . . . 0.0 105.548 179.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.474 55.5 p90 -85.34 114.25 22.27 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 117.874 2.546 . . . . 0.0 117.874 175.015 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -119.91 139.04 53.04 Favored 'General case' 0 CA--C 1.517 -0.325 0 CA-C-N 122.85 2.568 . . . . 0.0 113.106 -167.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.444 ' HB ' ' HB3' ' A' ' 17' ' ' HIS . 78.0 t -129.35 143.57 40.78 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 1 C-N-CA 132.236 4.214 . . . . 0.0 111.457 173.414 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -70.03 -82.93 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 126.941 3.258 . . . . 0.0 107.924 173.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 48.9 p -153.44 -21.3 0.14 Allowed 'General case' 0 C--N 1.328 -0.328 2 C-N-CA 134.773 5.229 . . . . 0.0 117.992 -179.394 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 18.4 mmtp -80.5 16.34 1.38 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 127.789 3.181 . . . . 0.0 116.33 -176.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.62 -56.65 5.03 Favored Glycine 0 C--N 1.345 1.034 0 N-CA-C 120.301 2.88 . . . . 0.0 120.301 -175.34 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 24.5 t -63.68 146.53 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 172.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.76 170.12 0.06 Allowed 'General case' 0 N--CA 1.438 -1.034 0 CA-C-O 121.589 0.709 . . . . 0.0 111.228 177.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.7 mmm180 -68.44 118.39 11.44 Favored 'General case' 0 C--N 1.351 0.659 0 O-C-N 118.261 -2.774 . . . . 0.0 113.564 -175.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 16.0 p -77.88 1.56 20.09 Favored 'General case' 0 N--CA 1.447 -0.591 1 C-N-CA 134.738 5.215 . . . . 0.0 117.733 -171.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 10.0 p30 -161.09 -174.5 4.39 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-N 111.171 -2.74 . . . . 0.0 104.801 163.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -144.2 -170.36 13.56 Favored Glycine 0 CA--C 1.524 0.641 0 C-N-CA 128.462 2.934 . . . . 0.0 117.321 -142.08 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 54.18 46.18 71.47 Favored Glycine 0 C--N 1.337 0.623 0 CA-C-O 123.629 1.683 . . . . 0.0 110.639 178.07 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -86.71 137.88 33.64 Favored Pre-proline 0 N--CA 1.45 -0.449 0 O-C-N 116.688 -3.831 . . . . 0.0 112.157 174.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -68.94 137.18 37.22 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.383 2.722 . . . . 0.0 113.756 -171.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -159.6 150.37 19.37 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 112.217 -2.265 . . . . 0.0 112.924 -165.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -152.34 134.92 15.32 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 118.106 -2.871 . . . . 0.0 113.977 -166.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 4.5 t -129.74 81.62 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 CA-C-N 113.325 -1.761 . . . . 0.0 113.643 -176.273 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -100.53 141.13 33.81 Favored 'General case' 0 CA--C 1.516 -0.354 0 O-C-N 126.023 2.077 . . . . 0.0 110.87 -174.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.5 mt -132.88 147.42 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 CA-C-O 125.01 2.338 . . . . 0.0 108.23 -163.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -116.5 118.83 33.73 Favored 'General case' 0 C--O 1.223 -0.33 0 O-C-N 119.3 -2.125 . . . . 0.0 109.166 166.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -111.31 -158.75 15.3 Favored Glycine 0 N--CA 1.442 -0.948 0 N-CA-C 121.797 3.479 . . . . 0.0 121.797 163.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo . . . . . 0 N--CA 1.434 -2.017 1 C-N-CA 125.834 4.356 . . . . 0.0 113.339 -177.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.44 -0.946 0 CA-C-O 118.009 -0.996 . . . . 0.0 112.757 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 72.8 t -132.63 145.34 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 CA-C-N 122.304 2.32 . . . . 0.0 106.465 -174.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -128.87 131.68 47.67 Favored 'General case' 0 N--CA 1.445 -0.69 0 O-C-N 119.122 -2.236 . . . . 0.0 110.332 172.186 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -102.63 137.37 40.95 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 126.476 1.91 . . . . 0.0 113.752 -165.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.271 37.1 ttpt -81.96 117.46 22.2 Favored 'General case' 0 C--O 1.218 -0.556 0 O-C-N 120.245 -1.535 . . . . 0.0 111.664 -160.05 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -88.48 131.6 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 175.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 67.2 m -131.84 125.96 33.09 Favored 'General case' 0 N--CA 1.452 -0.349 0 O-C-N 125.619 1.824 . . . . 0.0 110.934 172.321 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -66.29 118.52 10.09 Favored 'General case' 0 N--CA 1.44 -0.951 0 C-N-CA 128.153 2.581 . . . . 0.0 110.644 176.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.4 m-20 -79.63 -4.07 49.98 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 119.807 3.262 . . . . 0.0 119.807 175.653 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 68.56 25.66 6.6 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 131.595 3.958 . . . . 0.0 114.008 176.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 43.2 p30 -135.06 -4.69 2.41 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 114.053 -2.879 . . . . 0.0 110.946 -165.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 120.88 -14.34 9.71 Favored Glycine 0 C--N 1.337 0.624 0 C-N-CA 126.847 2.165 . . . . 0.0 111.223 -171.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 p -133.12 165.83 23.86 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 131.388 3.875 . . . . 0.0 113.56 -170.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 16.7 m-85 -131.57 137.57 48.51 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 128.704 2.802 . . . . 0.0 106.671 -174.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -92.21 139.41 14.67 Favored Glycine 0 C--O 1.226 -0.369 0 C-N-CA 128.159 2.79 . . . . 0.0 107.304 174.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 22.8 t -122.83 130.79 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-O 117.119 -1.419 . . . . 0.0 108.633 178.693 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.4 p -135.71 141.85 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 119.696 1.134 . . . . 0.0 112.527 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 7.5 p90 -161.11 169.61 22.05 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 115.902 1.816 . . . . 0.0 115.902 179.194 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 15.2 p30 -139.0 164.79 28.83 Favored 'General case' 0 N--CA 1.449 -0.508 0 O-C-N 118.756 -2.465 . . . . 0.0 117.532 177.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -123.53 112.57 29.35 Favored Pre-proline 0 N--CA 1.448 -0.568 0 O-C-N 125.305 1.628 . . . . 0.0 107.643 -174.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.336 14.9 Cg_endo -66.76 -8.52 21.56 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 N-CA-C 117.57 2.104 . . . . 0.0 117.57 170.382 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 28.4 m -148.08 134.51 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 O-C-N 120.369 -1.457 . . . . 0.0 110.606 -164.568 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -56.39 116.16 2.91 Favored 'General case' 0 N--CA 1.456 -0.169 0 O-C-N 126.195 2.185 . . . . 0.0 112.47 167.026 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 170.29 -166.7 39.89 Favored Glycine 0 CA--C 1.527 0.828 0 CA-C-O 122.306 0.948 . . . . 0.0 112.485 -172.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -106.42 137.75 43.84 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 114.37 1.248 . . . . 0.0 114.37 175.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -103.34 139.29 38.96 Favored 'General case' 0 N--CA 1.445 -0.713 0 C-N-CA 128.634 2.774 . . . . 0.0 110.418 168.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -114.53 119.55 37.21 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 117.164 2.283 . . . . 0.0 117.164 170.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . 0.275 65.2 t -118.1 133.64 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-N 112.795 -2.002 . . . . 0.0 111.863 -157.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -130.23 138.95 50.81 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 126.879 2.072 . . . . 0.0 109.087 171.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 85.8 t -114.79 126.48 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 C-N-CA 124.856 1.262 . . . . 0.0 113.312 168.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . 0.301 67.0 p -132.8 145.97 51.44 Favored 'General case' 0 N--CA 1.444 -0.767 0 O-C-N 125.423 1.702 . . . . 0.0 114.519 -168.561 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 8.4 tt -136.62 95.8 3.22 Favored 'General case' 0 N--CA 1.447 -0.58 1 O-C-N 116.182 -4.074 . . . . 0.0 107.796 -137.491 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . 0.316 51.4 ttt180 46.0 40.09 6.51 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 125.933 2.778 . . . . 0.0 115.858 -147.644 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 69.15 16.75 71.27 Favored Glycine 0 C--N 1.341 0.818 0 O-C-N 118.318 -2.739 . . . . 0.0 117.838 -175.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -106.57 153.51 40.56 Favored Pre-proline 0 N--CA 1.447 -0.6 0 O-C-N 116.508 -3.937 . . . . 0.0 111.678 165.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_endo -86.53 169.57 8.14 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 124.548 3.499 . . . . 0.0 114.166 -178.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.406 ' HB ' ' H ' ' A' ' 103' ' ' LYS . 11.2 pt -130.8 -173.22 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-N 113.975 -1.466 . . . . 0.0 109.13 176.218 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.406 ' H ' ' HB ' ' A' ' 102' ' ' ILE . 57.1 mttm -67.84 169.59 9.51 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 115.385 1.624 . . . . 0.0 115.385 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 33.3 m120 47.49 28.66 1.2 Allowed 'General case' 0 N--CA 1.447 -0.617 0 O-C-N 116.959 -3.588 . . . . 0.0 118.859 169.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 12.7 mmt -136.32 146.14 54.83 Favored Pre-proline 0 N--CA 1.444 -0.765 0 C-N-CA 129.128 2.971 . . . . 0.0 109.187 -177.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . 0.272 96.6 Cg_endo -68.07 169.24 55.87 Favored 'Cis proline' 0 N--CA 1.457 -0.63 0 CA-C-N 127.293 3.64 . . . . 0.0 116.232 -4.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 27.2 pt -146.77 161.25 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 O-C-N 126.9 2.625 . . . . 0.0 114.616 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -112.83 131.28 55.77 Favored 'General case' 0 N--CA 1.445 -0.71 0 C-N-CA 127.352 2.261 . . . . 0.0 112.875 -178.439 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 59.0 t -122.98 141.26 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 C-N-CA 126.681 1.992 . . . . 0.0 106.813 -175.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 39.8 mmtm -91.37 138.33 31.67 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 116.335 1.976 . . . . 0.0 116.335 176.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 21.8 m -115.96 126.51 53.95 Favored 'General case' 0 N--CA 1.441 -0.903 0 C-N-CA 129.504 3.122 . . . . 0.0 108.342 -174.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.443 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 15.2 mt -124.64 135.17 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 161.017 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -72.96 56.04 0.42 Allowed 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 118.699 2.851 . . . . 0.0 118.699 -176.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.4 0 O-C-N 117.388 -3.32 . . . . 0.0 117.14 165.975 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo . . . . . 0 N--CA 1.453 -0.887 0 CA-C-O 119.828 -0.155 . . . . 0.0 112.28 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -123.14 154.22 64.9 Favored Pre-proline 0 N--CA 1.446 -0.653 0 C-N-CA 128.059 2.543 . . . . 0.0 113.258 -166.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_exo -63.92 153.82 73.53 Favored 'Trans proline' 0 N--CA 1.444 -1.413 0 C-N-CA 124.162 3.241 . . . . 0.0 116.076 166.364 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.463 ' HB3' ' HB2' ' A' ' 17' ' ' HIS . 26.4 t -122.86 150.75 42.46 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.17 1.788 . . . . 0.0 106.259 178.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . 0.314 . . -51.19 -37.99 49.77 Favored 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 126.118 1.767 . . . . 0.0 114.632 163.067 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -58.61 -29.11 66.22 Favored 'General case' 0 N--CA 1.443 -0.809 0 C-N-CA 125.003 1.321 . . . . 0.0 110.192 170.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . 0.463 ' HB2' ' HB3' ' A' ' 14' ' ' SER . 86.6 m-70 -134.66 24.98 3.71 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 131.292 3.837 . . . . 0.0 112.556 -155.181 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 42.6 t -148.16 120.24 8.27 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 117.343 2.349 . . . . 0.0 117.343 166.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -146.48 142.49 28.15 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-O 113.482 -3.152 . . . . 0.0 113.832 -160.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -124.48 140.82 52.59 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 119.373 3.101 . . . . 0.0 119.373 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -136.44 147.57 47.3 Favored 'General case' 0 C--O 1.223 -0.317 0 CA-C-N 120.962 1.71 . . . . 0.0 112.19 -177.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.43 175.8 18.84 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 125.436 1.494 . . . . 0.0 114.575 167.403 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -55.93 -34.75 65.91 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-O 114.495 -2.669 . . . . 0.0 112.503 177.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -57.93 -3.0 1.02 Allowed Glycine 0 C--O 1.226 -0.355 0 CA-C-N 123.462 2.847 . . . . 0.0 116.138 165.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . 0.373 24.1 mt -109.29 29.26 7.7 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 120.544 2.172 . . . . 0.0 111.32 161.403 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 96.8 t -150.16 -42.0 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 CA-C-N 121.683 2.038 . . . . 0.0 114.584 -175.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.333 43.0 pttt -151.39 131.12 13.17 Favored 'General case' 0 C--N 1.326 -0.429 1 O-C-N 116.164 -4.085 . . . . 0.0 112.36 -179.425 . . . . . . . . 3 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 38.4 t -143.66 141.15 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 -166.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -136.08 172.31 13.19 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-N 120.181 1.355 . . . . 0.0 114.277 -169.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 46.8 t0 -78.55 -50.81 10.91 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-O 122.631 1.205 . . . . 0.0 112.519 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 70.4 m-80 -104.03 8.7 36.65 Favored 'General case' 0 N--CA 1.448 -0.545 0 O-C-N 118.427 -2.67 . . . . 0.0 111.636 -179.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -133.85 101.81 12.63 Favored Pre-proline 0 N--CA 1.447 -0.625 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 170.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -57.92 131.47 43.94 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 CA-C-O 125.552 2.23 . . . . 0.0 111.888 159.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -85.93 162.48 18.54 Favored 'General case' 0 N--CA 1.45 -0.459 0 O-C-N 117.008 -3.558 . . . . 0.0 113.539 165.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -133.22 154.6 50.51 Favored 'General case' 0 N--CA 1.448 -0.553 0 O-C-N 125.057 1.473 . . . . 0.0 110.508 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -157.48 171.45 20.34 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 117.662 -3.149 . . . . 0.0 105.403 167.176 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 91.1 m -133.35 130.47 38.86 Favored 'General case' 0 C--O 1.233 0.197 0 O-C-N 127.167 2.792 . . . . 0.0 113.737 -164.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.2 mt -84.77 104.06 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 123.929 0.892 . . . . 0.0 110.946 171.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 32.5 p90 -77.15 108.1 9.99 Favored 'General case' 0 N--CA 1.44 -0.973 0 N-CA-C 119.222 3.045 . . . . 0.0 119.222 163.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -117.78 150.22 39.49 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 121.288 1.858 . . . . 0.0 109.491 -163.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.2 t -137.79 159.19 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 105.718 -1.956 . . . . 0.0 105.718 174.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.0 p30 -78.36 -61.91 1.85 Allowed 'General case' 0 N--CA 1.452 -0.331 0 O-C-N 119.766 -1.834 . . . . 0.0 115.214 170.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 21.9 p -174.91 -35.63 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 131.64 3.976 . . . . 0.0 114.42 -161.034 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -107.69 40.92 1.61 Allowed 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 122.73 2.514 . . . . 0.0 112.665 -171.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 53.02 -25.39 0.01 OUTLIER Glycine 0 C--N 1.338 0.666 0 C-N-CA 130.129 3.728 . . . . 0.0 121.568 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.1 t -64.3 125.55 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 O-C-N 116.951 -3.676 . . . . 0.0 107.882 167.149 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -31.33 127.2 0.19 Allowed 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 117.36 2.356 . . . . 0.0 117.36 162.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 11.5 mmm180 -35.12 122.03 0.57 Allowed 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 118.672 2.841 . . . . 0.0 118.672 -177.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 8.5 p -78.79 -2.6 40.34 Favored 'General case' 0 N--CA 1.445 -0.696 0 C-N-CA 126.774 2.03 . . . . 0.0 111.576 -162.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.9 p30 -162.45 169.2 20.8 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 127.925 2.49 . . . . 0.0 109.199 178.055 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -123.91 -157.07 9.68 Favored Glycine 0 CA--C 1.522 0.502 0 C-N-CA 119.918 -1.134 . . . . 0.0 110.897 -160.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 61.01 41.05 99.31 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 178.286 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 58.4 m-20 -78.38 156.08 78.79 Favored Pre-proline 0 N--CA 1.448 -0.552 0 C-N-CA 126.982 2.113 . . . . 0.0 108.438 173.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -91.67 62.78 1.04 Allowed 'Trans proline' 0 N--CA 1.444 -1.395 0 C-N-CA 124.811 3.674 . . . . 0.0 117.284 -169.229 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -69.88 149.55 47.73 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 120.971 3.693 . . . . 0.0 120.971 173.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -150.49 128.36 11.74 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 127.22 2.208 . . . . 0.0 112.906 168.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.583 HG22 HG22 ' A' ' 95' ' ' VAL . 39.5 t -114.46 87.53 1.03 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.326 0 C-N-CA 129.99 3.316 . . . . 0.0 104.408 -174.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -104.66 142.29 34.94 Favored 'General case' 0 N--CA 1.444 -0.753 0 C-N-CA 127.14 2.176 . . . . 0.0 106.065 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 19.1 mt -130.86 155.38 41.87 Favored 'Isoleucine or valine' 0 C--O 1.238 0.463 0 C-N-CA 128.334 2.654 . . . . 0.0 113.492 -170.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 71.6 m-80 -125.01 126.25 45.14 Favored 'General case' 0 N--CA 1.446 -0.642 0 C-N-CA 131.426 3.89 . . . . 0.0 109.137 174.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -118.49 -177.87 16.92 Favored Glycine 0 CA--C 1.528 0.876 0 O-C-N 119.034 -2.291 . . . . 0.0 112.351 167.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo . . . . . 0 N--CA 1.441 -1.594 0 CA-C-N 118.741 1.27 . . . . 0.0 111.875 -174.739 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 26.2 t . . . . . 0 C--O 1.24 0.554 0 CA-C-O 122.063 0.935 . . . . 0.0 109.749 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 96.0 t -142.02 144.37 25.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 112.474 -2.148 . . . . 0.0 111.846 -177.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.301 3.6 p-10 -127.2 134.55 50.11 Favored 'General case' 0 N--CA 1.445 -0.695 0 O-C-N 117.953 -2.967 . . . . 0.0 111.285 168.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.75 155.57 19.49 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 126.927 3.251 . . . . 0.0 111.134 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.301 9.2 tmtt? -99.99 104.17 15.76 Favored 'General case' 0 N--CA 1.448 -0.553 1 O-C-N 113.235 -5.916 . . . . 0.0 111.216 -170.45 . . . . . . . . 3 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.0 t -76.38 138.64 20.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 O-C-N 127.17 2.794 . . . . 0.0 117.644 169.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 10.0 m -144.15 128.86 18.24 Favored 'General case' 0 C--O 1.237 0.443 0 O-C-N 126.725 2.516 . . . . 0.0 111.091 173.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -79.16 136.07 37.0 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 125.237 2.446 . . . . 0.0 110.226 -169.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . 0.266 8.0 m-20 -96.61 0.56 50.1 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 116.534 -3.854 . . . . 0.0 118.551 -175.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 6.5 m120 68.68 27.62 5.88 Favored 'General case' 0 C--O 1.215 -0.733 0 O-C-N 128.731 3.769 . . . . 0.0 114.512 176.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 26.7 p30 -134.66 -8.24 2.46 Favored 'General case' 0 N--CA 1.445 -0.706 0 CA-C-O 117.227 -1.368 . . . . 0.0 112.153 -176.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 109.02 5.88 30.41 Favored Glycine 0 C--N 1.35 1.313 0 CA-C-O 113.492 -3.949 . . . . 0.0 108.21 -170.141 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.7 p -130.09 158.07 40.64 Favored 'General case' 0 N--CA 1.442 -0.83 1 CA-C-N 126.491 5.146 . . . . 0.0 111.391 -175.065 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -135.93 113.01 10.42 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 120.633 1.561 . . . . 0.0 110.543 -174.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -63.33 136.91 42.63 Favored Glycine 0 N--CA 1.452 -0.268 0 N-CA-C 116.539 1.376 . . . . 0.0 116.539 167.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.9 t -131.64 134.41 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 126.713 2.005 . . . . 0.0 112.155 -178.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -132.5 141.56 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-N 122.912 2.596 . . . . 0.0 109.82 -175.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 1.8 p90 -166.32 170.81 12.73 Favored 'General case' 0 N--CA 1.446 -0.637 0 O-C-N 125.512 1.758 . . . . 0.0 115.185 170.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 27.2 p30 -142.41 141.87 32.3 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 129.077 2.951 . . . . 0.0 109.916 -158.01 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -112.91 125.61 29.57 Favored Pre-proline 0 C--N 1.344 0.365 0 CA-C-O 117.399 -1.286 . . . . 0.0 113.201 -176.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -84.01 -1.09 9.83 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 123.387 2.724 . . . . 0.0 112.54 178.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.4 m -128.24 148.93 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 O-C-N 118.783 -2.448 . . . . 0.0 113.532 -164.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -63.4 111.39 2.28 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-O 124.814 2.245 . . . . 0.0 109.235 139.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 169.26 -162.52 36.18 Favored Glycine 0 C--O 1.221 -0.657 0 O-C-N 118.583 -2.573 . . . . 0.0 118.015 -173.114 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 27.3 t30 -117.68 132.58 56.47 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 127.435 2.294 . . . . 0.0 111.83 177.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -90.73 153.28 20.39 Favored 'General case' 0 C--O 1.221 -0.416 0 O-C-N 118.423 -2.673 . . . . 0.0 113.086 158.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -128.37 113.28 15.39 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 113.186 -1.825 . . . . 0.0 113.699 176.05 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.6 t -115.07 120.37 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 CA-C-N 113.887 -1.506 . . . . 0.0 114.204 -154.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.6 t30 -129.65 111.16 12.41 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 126.301 1.84 . . . . 0.0 108.379 -167.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.583 HG22 HG22 ' A' ' 57' ' ' VAL . 84.2 t -98.03 134.89 34.66 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.525 0 C-N-CA 126.72 2.008 . . . . 0.0 109.971 177.047 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 17.0 p -144.01 157.42 44.34 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 126.497 3.046 . . . . 0.0 115.911 -173.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 49.3 tp -129.03 104.97 7.88 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 101.763 -3.421 . . . . 0.0 101.763 -149.039 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 67.6 ttp85 45.74 42.79 9.01 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 104.91 -2.256 . . . . 0.0 104.91 -162.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.63 -1.06 31.55 Favored Glycine 0 CA--C 1.52 0.378 0 N-CA-C 119.932 2.733 . . . . 0.0 119.932 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -85.96 148.76 48.92 Favored Pre-proline 0 N--CA 1.445 -0.677 0 C-N-CA 129.246 3.019 . . . . 0.0 112.225 174.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_endo -76.73 170.8 19.19 Favored 'Trans proline' 0 N--CA 1.444 -1.423 0 O-C-N 124.769 1.931 . . . . 0.0 112.383 -175.248 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . 0.284 4.3 pt -136.37 -163.15 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 C-N-CA 128.399 2.679 . . . . 0.0 112.438 -179.124 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 32.1 mttt -100.88 159.81 14.89 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 125.337 3.699 . . . . 0.0 109.19 -173.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 33.4 m120 54.31 31.51 14.48 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 128.36 2.664 . . . . 0.0 113.351 173.066 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' MET . . . . . . . . . . . . 0.263 7.2 mmt -132.49 150.37 75.68 Favored Pre-proline 0 N--CA 1.454 -0.248 0 O-C-N 118.082 -2.886 . . . . 0.0 105.594 -173.205 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -66.15 174.84 25.54 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 CA-C-N 125.47 2.989 . . . . 0.0 112.735 -5.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 12.4 pt -143.32 169.81 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 O-C-N 126.083 2.114 . . . . 0.0 109.1 170.323 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -125.7 141.39 52.04 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 122.482 2.401 . . . . 0.0 114.437 -167.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 58.5 t -132.81 120.57 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 123.337 0.655 . . . . 0.0 109.421 -170.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 62.5 mttm -65.67 132.21 48.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 126.94 2.096 . . . . 0.0 108.183 173.318 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 20.1 m -126.28 138.27 53.59 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 127.422 2.289 . . . . 0.0 115.885 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 83.7 mt -130.63 152.06 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 O-C-N 118.709 -2.494 . . . . 0.0 110.437 167.003 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -84.91 45.48 1.17 Allowed 'General case' 0 N--CA 1.453 -0.32 0 O-C-N 120.41 -1.431 . . . . 0.0 113.828 -165.29 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.93 0 N-CA-C 116.431 1.332 . . . . 0.0 116.431 -174.41 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.0 tpt . . . . . 0 N--CA 1.479 0.994 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . 0.404 ' CE1' HG22 ' A' ' 49' ' ' THR . 49.6 t-80 -78.15 -50.58 11.7 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 117.678 -1.609 . . . . 0.0 109.635 -177.066 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 8.9 t60 -78.66 114.13 17.31 Favored 'General case' 0 C--N 1.319 -0.726 0 O-C-N 117.304 -3.372 . . . . 0.0 107.151 175.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 85.8 t60 -159.46 140.99 13.04 Favored 'General case' 0 N--CA 1.446 -0.655 0 O-C-N 118.87 -2.394 . . . . 0.0 110.154 -175.221 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.4 m-70 -87.73 98.24 11.34 Favored 'General case' 0 N--CA 1.446 -0.664 0 O-C-N 119.689 -1.882 . . . . 0.0 115.696 167.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 15.5 t60 -81.73 -36.63 28.39 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 110.718 -2.946 . . . . 0.0 109.754 -178.174 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 47.0 t-80 -147.99 169.25 20.31 Favored 'General case' 0 N--CA 1.449 -0.495 0 O-C-N 118.373 -2.705 . . . . 0.0 111.692 -167.668 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -88.98 30.23 0.96 Allowed 'General case' 0 N--CA 1.438 -1.068 0 C-N-CA 127.45 2.3 . . . . 0.0 116.809 -178.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.6 p -140.65 160.2 40.55 Favored 'General case' 0 C--O 1.234 0.281 0 C-N-CA 126.109 1.764 . . . . 0.0 112.145 169.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 35.0 mtmt -143.86 133.17 11.5 Favored Pre-proline 0 N--CA 1.446 -0.63 1 CA-C-O 110.997 -4.335 . . . . 0.0 112.785 -171.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -71.79 168.55 23.48 Favored 'Trans proline' 0 N--CA 1.449 -1.129 0 O-C-N 126.05 2.605 . . . . 0.0 109.002 175.554 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -101.5 135.7 19.77 Favored Pre-proline 0 C--O 1.238 0.475 0 CA-C-O 115.816 -2.04 . . . . 0.0 113.868 -177.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -53.42 149.14 31.16 Favored 'Trans proline' 0 N--CA 1.44 -1.624 1 C-N-CA 132.061 8.507 . . . . 0.0 113.622 157.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.3 m -145.7 161.17 40.5 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 123.342 1.544 . . . . 0.0 107.45 -166.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.29 -44.04 89.23 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 108.825 -3.807 . . . . 0.0 114.601 -172.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . 0.288 68.1 mm-40 -64.88 -20.72 66.58 Favored 'General case' 0 N--CA 1.442 -0.83 0 C-N-CA 129.296 3.038 . . . . 0.0 112.763 167.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 9.2 m-70 -121.28 16.52 11.45 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 130.499 3.52 . . . . 0.0 117.733 -163.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 t -142.84 135.05 27.36 Favored 'General case' 0 N--CA 1.445 -0.684 0 O-C-N 118.374 -2.704 . . . . 0.0 110.661 166.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . 0.356 49.6 m-85 -154.41 147.27 24.43 Favored 'General case' 0 N--CA 1.446 -0.673 0 C-N-CA 127.646 2.378 . . . . 0.0 107.415 -167.052 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -136.69 150.08 48.27 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 118.377 2.732 . . . . 0.0 118.377 -172.319 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -156.61 145.63 20.28 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 119.324 3.083 . . . . 0.0 119.324 -165.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.8 -170.33 21.22 Favored Glycine 0 C--N 1.341 0.833 0 C-N-CA 127.521 2.486 . . . . 0.0 115.578 174.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -58.18 -38.66 77.11 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 125.813 1.645 . . . . 0.0 110.256 -170.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -68.33 -1.84 23.4 Favored Glycine 0 CA--C 1.527 0.835 0 O-C-N 117.814 -3.054 . . . . 0.0 113.366 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.5 mt -120.27 21.75 11.61 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 122.095 2.948 . . . . 0.0 107.289 169.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.0 t -124.43 -50.85 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-O 116.309 -1.805 . . . . 0.0 112.669 165.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.4 pttt -155.63 136.3 13.42 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 122.419 2.372 . . . . 0.0 110.505 -165.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 46.2 t -144.73 141.03 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 CA-C-O 115.303 -2.284 . . . . 0.0 109.049 -170.284 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -137.43 -171.47 2.98 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 120.36 3.467 . . . . 0.0 120.36 -172.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 48.4 t0 -94.03 -57.55 2.5 Favored 'General case' 0 N--CA 1.447 -0.587 1 O-C-N 115.101 -4.75 . . . . 0.0 109.294 -162.188 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 66.6 m-80 -97.97 -2.8 39.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 118.841 2.904 . . . . 0.0 118.841 172.093 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -114.47 88.85 16.54 Favored Pre-proline 0 N--CA 1.445 -0.719 0 CA-C-O 122.58 1.181 . . . . 0.0 110.248 160.106 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -43.77 135.63 7.26 Favored 'Trans proline' 0 N--CA 1.445 -1.325 0 N-CA-C 116.997 1.884 . . . . 0.0 116.997 156.381 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.44 153.95 22.58 Favored 'General case' 0 N--CA 1.448 -0.559 0 C-N-CA 127.238 2.215 . . . . 0.0 113.418 -174.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -138.11 147.92 44.46 Favored 'General case' 0 N--CA 1.442 -0.851 0 C-N-CA 128.494 2.717 . . . . 0.0 112.626 -171.051 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -155.02 175.14 14.21 Favored 'General case' 0 CA--C 1.514 -0.429 0 C-N-CA 130.111 3.365 . . . . 0.0 112.868 166.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.415 ' CG2' ' HB ' ' A' ' 78' ' ' THR . 86.9 m -123.36 125.7 45.48 Favored 'General case' 0 C--N 1.344 0.364 0 N-CA-C 117.23 2.307 . . . . 0.0 117.23 -164.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . 0.273 2.3 mt -78.31 123.25 34.85 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.717 0 CA-C-O 114.001 -2.904 . . . . 0.0 115.791 167.59 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.312 22.7 p90 -111.05 91.96 3.86 Favored 'General case' 0 N--CA 1.433 -1.287 0 C-N-CA 129.843 3.257 . . . . 0.0 115.262 177.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -97.74 138.14 35.57 Favored 'General case' 0 N--CA 1.445 -0.706 0 C-N-CA 130.529 3.531 . . . . 0.0 114.379 -166.266 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.1 t -131.58 135.73 58.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 CA-C-N 112.078 -2.328 . . . . 0.0 107.948 170.126 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -61.55 -61.26 2.65 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 117.029 2.233 . . . . 0.0 117.029 166.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 21.1 p -164.03 -26.67 0.04 OUTLIER 'General case' 0 N--CA 1.443 -0.795 0 C-N-CA 130.354 3.462 . . . . 0.0 110.648 169.196 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 34.6 mtmm -76.4 19.22 0.26 Allowed 'General case' 0 CA--C 1.515 -0.386 0 O-C-N 127.006 2.691 . . . . 0.0 114.166 -163.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 62.6 -46.38 0.07 OUTLIER Glycine 0 C--N 1.347 1.19 0 C-N-CA 127.067 2.27 . . . . 0.0 118.049 177.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 57.9 t -52.27 140.34 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 CA-C-N 121.881 2.841 . . . . 0.0 112.398 159.136 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -32.44 153.05 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 117.351 2.352 . . . . 0.0 117.351 165.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 8.0 mmm180 -59.7 128.13 35.41 Favored 'General case' 0 N--CA 1.452 -0.355 0 O-C-N 118.01 -2.931 . . . . 0.0 113.408 173.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.404 HG22 ' CE1' ' A' ' 2' ' ' HIS . 59.9 p -88.82 1.53 55.12 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 127.806 2.442 . . . . 0.0 112.877 -169.34 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -163.82 156.74 18.1 Favored 'General case' 0 N--CA 1.448 -0.526 1 O-C-N 115.786 -4.321 . . . . 0.0 112.922 176.4 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -99.81 -173.92 30.63 Favored Glycine 0 N--CA 1.466 0.684 0 O-C-N 125.591 1.807 . . . . 0.0 108.98 -155.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.23 32.36 83.89 Favored Glycine 0 C--O 1.236 0.224 0 C-N-CA 127.672 2.558 . . . . 0.0 114.076 171.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -60.71 145.17 88.48 Favored Pre-proline 0 CA--C 1.514 -0.418 0 O-C-N 117.743 -3.21 . . . . 0.0 106.763 160.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -84.09 135.97 6.68 Favored 'Trans proline' 0 CA--C 1.509 -0.735 0 C-N-CA 124.734 3.623 . . . . 0.0 115.952 170.304 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -135.2 163.96 28.77 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 129.62 3.168 . . . . 0.0 111.2 -172.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.439 ' O ' ' HA ' ' A' ' 95' ' ' VAL 0.275 21.5 tt0 -145.64 141.56 28.25 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 127.919 2.488 . . . . 0.0 113.472 164.667 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 4.3 t -129.9 61.49 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 129.487 3.115 . . . . 0.0 105.335 -173.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -83.81 132.04 34.85 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 112.839 -1.982 . . . . 0.0 113.958 -175.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.437 HD13 ' CE2' ' A' ' 83' ' ' TYR . 61.3 mt -138.77 145.59 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 CA-C-O 124.34 2.019 . . . . 0.0 108.486 -158.277 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 24.3 m120 -113.18 129.69 56.44 Favored 'General case' 0 N--CA 1.45 -0.455 0 O-C-N 116.587 -3.821 . . . . 0.0 108.993 167.206 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -92.22 -172.61 41.79 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 126.205 1.86 . . . . 0.0 114.042 157.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -63.78 124.89 14.36 Favored 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 122.94 2.427 . . . . 0.0 112.937 -178.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 55.61 -114.17 0.83 Allowed 'General case' 0 N--CA 1.441 -0.898 0 O-C-N 125.301 1.625 . . . . 0.0 111.1 -178.073 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -78.45 3.74 62.04 Favored Glycine 0 C--N 1.332 0.332 0 CA-C-O 125.677 2.821 . . . . 0.0 113.829 -161.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 33.9 mt -89.64 72.38 7.77 Favored 'General case' 0 C--O 1.219 -0.504 1 O-C-N 115.788 -4.36 . . . . 0.0 114.57 -172.032 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . 0.265 56.7 t -88.45 112.28 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 109.42 -3.536 . . . . 0.0 107.924 179.433 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 2.3 t -127.8 151.57 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.662 0 O-C-N 120.904 -1.123 . . . . 0.0 108.477 -168.136 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -121.76 139.75 53.2 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 126.411 3.005 . . . . 0.0 110.816 153.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -87.16 125.84 34.41 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 112.172 -2.285 . . . . 0.0 106.716 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 30.3 mmtm -81.17 133.64 35.49 Favored 'General case' 0 N--CA 1.449 -0.481 0 O-C-N 118.848 -2.407 . . . . 0.0 111.285 -167.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 72.2 t -107.97 139.96 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.685 0 CA-C-O 126.072 2.844 . . . . 0.0 106.842 -168.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 28.4 m -144.5 127.18 16.15 Favored 'General case' 0 C--N 1.345 0.37 0 CA-C-N 111.606 -2.543 . . . . 0.0 109.611 173.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 62.3 t0 -63.05 129.67 41.35 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 125.459 1.503 . . . . 0.0 111.752 177.279 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 -82.84 -11.37 58.29 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 115.954 1.835 . . . . 0.0 115.954 173.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.39 2.5 m120 63.66 48.5 3.31 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.294 2.238 . . . . 0.0 116.181 -172.697 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 44.0 p-10 -156.75 8.35 0.2 Allowed 'General case' 0 C--N 1.345 0.388 0 CA-C-O 126.376 2.988 . . . . 0.0 117.726 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 95.16 17.52 36.97 Favored Glycine 0 CA--C 1.526 0.742 0 O-C-N 117.588 -3.195 . . . . 0.0 108.441 -178.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.415 ' HB ' ' CG2' ' A' ' 37' ' ' THR . 31.1 p -136.76 166.58 23.26 Favored 'General case' 0 C--N 1.331 -0.226 0 O-C-N 124.728 0.899 . . . . 0.0 111.947 173.41 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -137.28 121.61 18.14 Favored 'General case' 0 N--CA 1.441 -0.888 0 O-C-N 125.674 1.859 . . . . 0.0 108.359 -172.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -76.18 134.24 15.45 Favored Glycine 0 N--CA 1.466 0.636 0 CA-C-O 124.221 2.012 . . . . 0.0 113.399 163.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 89.7 t -117.29 146.48 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 C-N-CA 129.575 3.15 . . . . 0.0 113.329 171.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -134.36 141.6 43.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 O-C-N 125.816 1.947 . . . . 0.0 113.285 175.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.437 ' CE2' HD13 ' A' ' 59' ' ' ILE . 1.3 p90 -162.15 167.38 24.27 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 116.275 -1.821 . . . . 0.0 112.051 168.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 40.7 p30 -144.99 154.64 42.76 Favored 'General case' 0 C--N 1.348 0.535 0 C-N-CA 126.096 1.758 . . . . 0.0 109.02 -166.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -124.42 118.25 26.37 Favored Pre-proline 0 N--CA 1.446 -0.647 0 C-N-CA 128.03 2.532 . . . . 0.0 114.514 -166.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.263 45.7 Cg_endo -71.87 -14.51 29.61 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.608 2.205 . . . . 0.0 111.803 -175.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.9 m -137.77 132.74 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.853 0 C-N-CA 128.139 2.576 . . . . 0.0 114.242 -139.387 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -54.45 112.17 0.94 Allowed 'General case' 0 N--CA 1.447 -0.618 0 O-C-N 118.045 -2.909 . . . . 0.0 115.255 144.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 168.69 -145.5 9.58 Favored Glycine 0 CA--C 1.529 0.922 1 O-C-N 114.453 -5.154 . . . . 0.0 114.818 -173.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . 0.559 HD21 ' HB3' ' A' ' 108' ' ' ASP . 5.4 t30 -145.49 133.39 21.26 Favored 'General case' 0 N--CA 1.448 -0.525 0 O-C-N 117.431 -3.394 . . . . 0.0 115.152 -176.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 17.7 m-85 -102.34 148.68 25.18 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 104.669 -2.345 . . . . 0.0 104.669 174.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -126.39 106.59 9.59 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 128.347 3.53 . . . . 0.0 112.51 -177.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 42.6 t -111.81 131.44 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 O-C-N 119.612 -1.93 . . . . 0.0 108.571 -158.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 -126.74 120.24 28.89 Favored 'General case' 0 CA--C 1.513 -0.473 0 C-N-CA 129.746 3.218 . . . . 0.0 110.158 174.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.439 ' HA ' ' O ' ' A' ' 56' ' ' GLU . 77.1 t -99.92 148.21 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 115.534 1.679 . . . . 0.0 115.534 170.467 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.48 HG22 ' HA ' ' A' ' 101' ' ' PRO . 4.7 p -150.41 148.83 29.24 Favored 'General case' 0 N--CA 1.445 -0.675 0 O-C-N 117.385 -3.322 . . . . 0.0 113.025 -177.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.449 HD13 HG21 ' A' ' 102' ' ' ILE . 8.0 mp -128.8 106.65 9.06 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 127.971 2.508 . . . . 0.0 110.184 -158.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.7 tmt_? 51.56 44.32 29.17 Favored 'General case' 0 N--CA 1.445 -0.675 0 C-N-CA 126.212 1.805 . . . . 0.0 108.295 -160.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 58.59 26.56 59.99 Favored Glycine 0 N--CA 1.439 -1.103 0 N-CA-C 118.429 2.131 . . . . 0.0 118.429 -177.146 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 73.5 m-20 -122.06 143.53 39.12 Favored Pre-proline 0 CA--C 1.516 -0.362 0 C-N-CA 125.088 1.355 . . . . 0.0 108.887 174.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.48 ' HA ' HG22 ' A' ' 96' ' ' THR 0.282 24.4 Cg_endo -82.88 175.83 8.25 Favored 'Trans proline' 0 N--CA 1.446 -1.293 0 CA-C-O 125.948 2.395 . . . . 0.0 108.318 -168.63 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.449 HG21 HD13 ' A' ' 97' ' ' LEU . 25.7 pt -149.7 -176.11 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 C-N-CA 127.961 2.505 . . . . 0.0 109.865 -167.575 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 41.1 mtpt -81.28 163.56 22.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 123.14 1.447 . . . . 0.0 113.314 -176.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.295 23.2 m120 58.39 54.49 5.57 Favored 'General case' 0 C--O 1.222 -0.386 0 N-CA-C 117.125 2.269 . . . . 0.0 117.125 168.115 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 9.7 mmt -164.3 146.98 7.39 Favored Pre-proline 0 CA--C 1.507 -0.686 0 C-N-CA 128.079 2.552 . . . . 0.0 105.449 -162.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -70.58 164.81 80.65 Favored 'Cis proline' 0 N--CA 1.445 -1.352 0 C-N-CA 130.836 1.598 . . . . 0.0 109.979 -5.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . 0.404 HD13 HG21 ' A' ' 107' ' ' ILE . 31.4 pt -130.43 174.04 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 C-N-CA 126.202 1.801 . . . . 0.0 108.043 174.336 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . 0.559 ' HB3' HD21 ' A' ' 90' ' ' ASN . 6.4 m-20 -125.44 139.31 53.76 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 117.49 2.404 . . . . 0.0 117.49 -168.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 2.4 t -147.39 125.67 3.76 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-O 124.005 1.86 . . . . 0.0 114.323 -175.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . 0.271 46.1 pttt -66.44 129.04 38.51 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 127.057 2.143 . . . . 0.0 108.818 -173.121 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . 0.383 72.5 m -107.71 141.95 38.45 Favored 'General case' 0 N--CA 1.448 -0.531 0 O-C-N 126.72 2.512 . . . . 0.0 104.528 178.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 21.9 mt -144.52 143.65 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 O-C-N 117.281 -3.387 . . . . 0.0 111.977 173.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . 0.298 12.0 pt-20 -93.56 53.1 1.81 Allowed 'General case' 0 N--CA 1.449 -0.507 1 O-C-N 114.427 -5.171 . . . . 0.0 110.741 -157.05 . . . . . . . . 3 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 0.338 0 C-N-CA 128.453 2.93 . . . . 0.0 113.671 -176.289 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.2 tpt . . . . . 0 N--CA 1.472 0.656 0 CA-C-O 123.44 1.591 . . . . 0.0 110.181 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 44.1 m80 -115.48 40.21 2.78 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 130.826 3.65 . . . . 0.0 113.827 177.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.6 m-70 -83.68 171.41 13.26 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 119.478 -2.013 . . . . 0.0 112.304 170.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 28.3 p80 -151.77 123.32 7.87 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 125.26 1.424 . . . . 0.0 112.935 176.061 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 9.7 m-70 -108.06 134.85 50.35 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 115.462 -2.209 . . . . 0.0 115.769 -168.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -135.85 -35.97 0.77 Allowed 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 116.31 1.967 . . . . 0.0 116.31 -166.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -140.44 155.17 46.8 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 103.201 -2.889 . . . . 0.0 103.201 -165.019 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -58.15 -61.94 2.19 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-N 115.523 -0.762 . . . . 0.0 112.981 176.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 71.6 m -52.33 152.49 3.4 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 126.581 1.953 . . . . 0.0 114.098 175.355 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 57.6 mttp -104.87 99.14 17.45 Favored Pre-proline 0 N--CA 1.447 -0.594 0 C-N-CA 127.724 2.409 . . . . 0.0 104.8 167.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -74.78 152.16 41.62 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 124.108 3.205 . . . . 0.0 110.556 169.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -99.55 161.65 23.81 Favored Pre-proline 0 N--CA 1.45 -0.432 0 N-CA-C 117.244 2.313 . . . . 0.0 117.244 -173.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -74.17 170.2 20.71 Favored 'Trans proline' 0 N--CA 1.445 -1.348 0 C-N-CA 123.927 3.084 . . . . 0.0 111.276 -178.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.5 t -152.22 173.99 14.31 Favored 'General case' 0 N--CA 1.452 -0.341 0 O-C-N 124.348 1.03 . . . . 0.0 111.716 174.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.83 -39.97 79.69 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-N 115.125 -0.943 . . . . 0.0 113.374 -170.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 72.5 mm-40 -53.0 -35.76 59.73 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 129.547 3.139 . . . . 0.0 113.596 168.186 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -120.5 19.76 11.94 Favored 'General case' 0 N--CA 1.438 -1.026 0 CA-C-N 111.928 -2.397 . . . . 0.0 111.76 -161.546 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.4 t -137.45 138.28 39.61 Favored 'General case' 0 N--CA 1.45 -0.472 0 O-C-N 117.999 -2.938 . . . . 0.0 105.468 171.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -164.31 153.44 13.52 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 110.778 -2.919 . . . . 0.0 110.606 -170.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.462 ' HB2' ' HA ' ' A' ' 38' ' ' ILE . . . -140.11 150.0 43.76 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 119.621 3.193 . . . . 0.0 119.621 -171.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -157.47 134.31 10.04 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 127.563 2.345 . . . . 0.0 111.916 -165.347 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 148.46 166.5 12.91 Favored Glycine 0 C--N 1.336 0.56 0 C-N-CA 126.473 1.987 . . . . 0.0 112.292 176.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -65.34 -19.78 66.1 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 116.682 -1.628 . . . . 0.0 109.436 -169.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.536 ' HA3' ' CD2' ' A' ' 36' ' ' PHE . . . -64.29 0.3 3.84 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 124.58 3.355 . . . . 0.0 117.22 168.182 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . 0.27 56.9 mt -109.54 13.33 24.0 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 129.637 3.175 . . . . 0.0 111.854 167.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 t -131.52 -53.36 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 C-N-CA 130.69 3.596 . . . . 0.0 112.018 -178.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 46.7 pttt -161.85 125.64 3.2 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 -159.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.2 t -137.67 155.72 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 C-N-CA 129.303 3.041 . . . . 0.0 109.907 -177.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -131.78 -176.66 4.12 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-O 123.933 1.825 . . . . 0.0 111.856 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -88.05 -46.85 8.98 Favored 'General case' 0 N--CA 1.446 -0.629 0 O-C-N 119.489 -2.007 . . . . 0.0 109.462 -174.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -109.5 6.91 24.52 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-O 126.64 3.114 . . . . 0.0 117.304 176.555 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -122.46 100.36 41.67 Favored Pre-proline 0 N--CA 1.442 -0.858 1 O-C-N 116.202 -4.061 . . . . 0.0 101.784 167.162 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -62.42 157.62 45.03 Favored 'Trans proline' 0 N--CA 1.45 -1.031 0 C-N-CA 123.654 2.903 . . . . 0.0 113.595 166.123 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -123.89 153.03 41.71 Favored 'General case' 0 CA--C 1.511 -0.548 0 C-N-CA 127.136 2.175 . . . . 0.0 112.86 -176.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.496 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 33.6 mt-10 -127.4 155.42 43.67 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 124.067 0.947 . . . . 0.0 108.979 -175.655 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.536 ' CD2' ' HA3' ' A' ' 24' ' ' GLY . 5.2 p90 -161.65 155.38 21.67 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -179.3 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 86.4 m -124.21 119.75 30.27 Favored 'General case' 0 N--CA 1.452 -0.342 0 O-C-N 119.014 -2.303 . . . . 0.0 109.593 -161.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.462 ' HA ' ' HB2' ' A' ' 20' ' ' ALA 0.263 17.2 mt -79.74 102.96 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 124.994 1.318 . . . . 0.0 111.533 164.897 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.371 40.5 p90 -83.24 124.76 30.88 Favored 'General case' 0 N--CA 1.443 -0.805 0 C-N-CA 126.49 1.916 . . . . 0.0 113.797 165.637 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -110.45 146.61 35.6 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 179.701 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 9.7 t -129.99 139.11 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 O-C-N 126.757 2.536 . . . . 0.0 106.431 160.228 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -66.76 -50.32 63.1 Favored 'General case' 0 N--CA 1.452 -0.336 0 O-C-N 117.779 -3.076 . . . . 0.0 111.881 178.364 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 64.3 p -148.98 -60.23 0.22 Allowed 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 115.947 -1.978 . . . . 0.0 111.359 -166.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 12.7 ttmt -134.61 101.29 4.9 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 122.149 2.249 . . . . 0.0 114.543 -178.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 77.45 -65.56 3.08 Favored Glycine 0 N--CA 1.451 -0.306 0 O-C-N 120.372 -1.455 . . . . 0.0 114.375 162.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 46.3 t -61.01 124.71 15.93 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 C-N-CA 128.891 2.876 . . . . 0.0 108.717 179.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -50.91 168.2 0.06 Allowed 'General case' 0 N--CA 1.449 -0.486 0 CA-C-O 124.471 2.081 . . . . 0.0 112.982 178.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -53.75 125.85 19.9 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 108.719 -3.855 . . . . 0.0 107.631 163.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 17.5 p -79.08 -18.33 53.57 Favored 'General case' 0 N--CA 1.453 -0.297 1 C-N-CA 131.757 4.023 . . . . 0.0 111.486 -173.05 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -151.86 169.35 22.48 Favored 'General case' 0 CA--C 1.517 -0.297 0 O-C-N 127.551 3.032 . . . . 0.0 107.965 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -102.58 -142.75 12.53 Favored Glycine 0 CA--C 1.525 0.671 0 C-N-CA 124.763 1.173 . . . . 0.0 115.001 -167.423 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 71.65 5.34 60.32 Favored Glycine 0 C--N 1.334 0.455 0 CA-C-O 117.234 -1.87 . . . . 0.0 116.751 165.489 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 38.1 m-20 -77.01 143.54 70.61 Favored Pre-proline 0 N--CA 1.45 -0.455 0 CA-C-O 115.435 -2.221 . . . . 0.0 115.981 -178.261 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -83.02 127.71 4.79 Favored 'Trans proline' 0 N--CA 1.449 -1.09 0 CA-C-N 125.151 2.875 . . . . 0.0 115.998 -176.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -138.25 161.48 36.77 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 114.133 -1.394 . . . . 0.0 111.428 -171.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -153.39 151.72 30.24 Favored 'General case' 0 N--CA 1.447 -0.62 0 O-C-N 120.547 -1.346 . . . . 0.0 113.22 172.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 53.5 t -133.35 99.73 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 C-N-CA 130.054 3.342 . . . . 0.0 104.335 -172.072 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -125.07 138.87 54.18 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 113.577 -1.647 . . . . 0.0 112.663 -170.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.4 mt -138.78 115.45 10.58 Favored 'Isoleucine or valine' 0 C--O 1.238 0.482 0 O-C-N 119.715 -1.866 . . . . 0.0 107.978 -147.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -88.64 138.62 31.26 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 118.823 -2.423 . . . . 0.0 107.011 173.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -141.83 173.33 23.64 Favored Glycine 0 CA--C 1.523 0.539 0 C-N-CA 129.359 3.361 . . . . 0.0 112.475 -166.321 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -49.07 145.91 13.3 Favored 'Trans proline' 0 N--CA 1.46 -0.484 1 C-N-CA 125.921 4.414 . . . . 0.0 117.454 170.629 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.261 30.0 m-20 67.63 7.6 5.76 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 112.498 -2.137 . . . . 0.0 112.871 -167.481 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 76.95 33.69 44.97 Favored Glycine 0 CA--C 1.523 0.585 0 O-C-N 117.813 -3.054 . . . . 0.0 110.837 175.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 67.6 mt -80.29 138.31 36.74 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 126.521 1.928 . . . . 0.0 114.863 173.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 4.5 t -103.27 145.36 12.58 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 CA-C-O 126.064 2.84 . . . . 0.0 113.207 166.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 8.9 t -149.43 152.67 11.71 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 O-C-N 116.906 -3.621 . . . . 0.0 107.5 -176.185 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -131.21 138.24 49.29 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-O 123.413 1.578 . . . . 0.0 115.02 161.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -94.09 131.1 39.94 Favored 'General case' 0 N--CA 1.441 -0.917 1 C-N-CA 133.319 4.648 . . . . 0.0 112.585 -164.289 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.408 ' HE2' ' HB3' ' A' ' 70' ' ' LYS 0.258 28.5 ttpt -71.31 126.03 28.56 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 122.894 2.588 . . . . 0.0 112.506 -166.663 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.442 HG22 HG22 ' A' ' 81' ' ' VAL . 68.8 t -106.88 140.2 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 O-C-N 119.552 -1.968 . . . . 0.0 106.446 -179.409 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 90.4 m -144.76 127.97 16.71 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-O 124.868 2.27 . . . . 0.0 113.933 178.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -69.26 128.31 36.14 Favored 'General case' 0 N--CA 1.456 -0.155 0 C-N-CA 127.35 2.26 . . . . 0.0 109.895 -174.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 55.8 m-20 -91.11 5.47 48.82 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 118.458 2.762 . . . . 0.0 118.458 174.527 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 1.8 m120 55.17 43.23 29.73 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 120.057 1.299 . . . . 0.0 112.423 174.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 35.3 p-10 -155.57 3.29 0.18 Allowed 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 128.052 2.541 . . . . 0.0 116.565 -174.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 98.95 4.2 56.79 Favored Glycine 0 CA--C 1.524 0.641 0 O-C-N 118.515 -2.616 . . . . 0.0 112.33 -174.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 16.9 p -133.94 165.77 24.24 Favored 'General case' 0 CA--C 1.515 -0.387 0 N-CA-C 116.723 2.12 . . . . 0.0 116.723 177.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 45.2 m-85 -129.64 134.43 47.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.602 177.179 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -81.75 133.72 12.35 Favored Glycine 0 C--N 1.342 0.863 0 O-C-N 125.775 1.922 . . . . 0.0 108.325 172.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 35' ' ' GLU . 17.5 t -118.55 136.94 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 128.122 2.569 . . . . 0.0 109.433 175.454 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 p -134.84 135.05 53.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 CA-C-O 114.574 -2.631 . . . . 0.0 111.347 -178.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 80.2 t80 -156.17 144.39 19.85 Favored 'General case' 0 N--CA 1.445 -0.686 1 O-C-N 130.82 5.075 . . . . 0.0 113.084 -174.794 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.9 p30 -130.0 149.0 51.91 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 126.473 1.909 . . . . 0.0 107.999 -177.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -115.25 112.27 44.1 Favored Pre-proline 0 CA--C 1.511 -0.532 0 C-N-CA 125.731 1.612 . . . . 0.0 112.016 -171.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -71.41 -14.55 31.01 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 C-N-CA 124.032 3.155 . . . . 0.0 117.321 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.8 m -143.57 143.59 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 O-C-N 119.824 -1.797 . . . . 0.0 109.853 -174.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 -49.47 121.48 5.11 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 162.306 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -179.92 171.57 43.06 Favored Glycine 0 C--N 1.339 0.711 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.394 -175.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -98.86 133.22 43.46 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 128.886 2.874 . . . . 0.0 112.504 158.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 -126.94 150.03 49.54 Favored 'General case' 0 C--O 1.22 -0.464 0 N-CA-C 106.363 -1.717 . . . . 0.0 106.363 -173.513 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -119.18 111.28 18.04 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-N 114.214 -1.357 . . . . 0.0 114.632 -170.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.6 t -102.35 132.82 47.6 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.43 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 -166.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -122.6 128.09 50.24 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 131.169 3.788 . . . . 0.0 112.243 166.113 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 62.0 t -117.36 143.65 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 CA-C-N 114.481 -1.236 . . . . 0.0 109.682 -177.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.5 p -140.31 160.55 39.72 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 117.971 -1.014 . . . . 0.0 111.888 -171.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . 0.257 8.2 tt -135.65 94.08 3.04 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 103.152 -2.907 . . . . 0.0 103.152 -152.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 26.4 ttp-105 52.96 37.42 24.46 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 120.975 1.716 . . . . 0.0 112.019 -170.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 65.07 35.95 92.41 Favored Glycine 0 C--N 1.338 0.679 0 N-CA-C 116.65 1.42 . . . . 0.0 116.65 -176.26 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 71.3 m-80 -115.38 141.19 26.83 Favored Pre-proline 0 N--CA 1.447 -0.588 0 CA-C-O 117.353 -1.308 . . . . 0.0 110.009 166.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -71.69 165.98 30.86 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 CA-C-O 124.988 1.995 . . . . 0.0 112.095 166.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 11.6 pt -137.62 179.55 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 C-N-CA 127.234 2.214 . . . . 0.0 112.788 -173.055 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.403 ' C ' ' H ' ' A' ' 105' ' ' MET . 56.3 mtpt -74.71 165.91 24.45 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-O 115.529 -2.177 . . . . 0.0 111.025 -173.084 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.421 15.1 m120 66.93 -20.58 0.11 Allowed 'General case' 0 C--N 1.33 -0.268 0 O-C-N 125.59 1.806 . . . . 0.0 114.019 172.737 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' MET . . . . . 0.403 ' H ' ' C ' ' A' ' 103' ' ' LYS . 12.9 mmt -67.17 158.65 80.77 Favored Pre-proline 0 N--CA 1.446 -0.644 0 C-N-CA 127.268 2.227 . . . . 0.0 116.575 -178.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -73.51 159.68 97.06 Favored 'Cis proline' 0 N--CA 1.442 -1.517 0 O-C-N 125.089 2.099 . . . . 0.0 107.932 -20.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 8.2 pt -131.23 161.96 40.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 C-N-CA 126.828 2.051 . . . . 0.0 108.736 -174.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 69.8 m-20 -117.27 147.9 42.14 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 126.481 1.912 . . . . 0.0 111.28 -159.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 42.7 t -139.66 117.29 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 C-N-CA 126.344 1.857 . . . . 0.0 111.889 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 65.4 tttt -81.9 136.14 35.35 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 115.524 1.675 . . . . 0.0 115.524 168.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 98.1 m -126.77 133.39 50.85 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 125.766 1.626 . . . . 0.0 107.622 -170.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 48.9 mm -121.82 141.78 40.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 O-C-N 120.156 -1.59 . . . . 0.0 107.65 177.272 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -82.75 41.23 0.72 Allowed 'General case' 0 N--CA 1.454 -0.246 1 O-C-N 114.941 -4.85 . . . . 0.0 116.548 -155.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.651 0 O-C-N 119.493 -2.004 . . . . 0.0 113.449 -175.685 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.6 mmt . . . . . 0 N--CA 1.472 0.664 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 46.3 t60 -151.48 148.75 28.44 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 126.429 3.014 . . . . 0.0 114.461 -164.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 8.1 m-70 -48.37 134.33 15.09 Favored 'General case' 0 N--CA 1.445 -0.701 0 C-N-CA 128.592 2.757 . . . . 0.0 115.272 165.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . 0.487 ' CD2' HG22 ' A' ' 49' ' ' THR . 3.6 p-80 -135.49 62.38 1.63 Allowed 'General case' 0 C--O 1.234 0.284 0 C-N-CA 127.832 2.453 . . . . 0.0 109.933 -171.632 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.8 p80 -85.43 155.74 21.14 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 129.984 3.314 . . . . 0.0 107.331 170.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 61.8 m80 -137.43 -30.31 0.85 Allowed 'General case' 0 N--CA 1.445 -0.69 0 C-N-CA 128.863 2.865 . . . . 0.0 114.768 177.197 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 16.9 p80 -126.71 144.9 50.79 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 129.181 2.993 . . . . 0.0 113.861 179.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -66.31 -28.77 68.94 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 120.723 3.601 . . . . 0.0 120.723 -175.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.4 p -66.46 132.7 48.85 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 122.187 2.267 . . . . 0.0 114.974 166.7 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 55.5 pttt -124.21 144.28 45.09 Favored Pre-proline 0 N--CA 1.451 -0.409 0 C-N-CA 126.955 2.102 . . . . 0.0 111.721 -176.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -92.53 176.26 1.73 Allowed 'Trans proline' 0 N--CA 1.447 -1.255 0 C-N-CA 123.72 2.947 . . . . 0.0 108.986 168.633 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -114.59 161.97 26.0 Favored Pre-proline 0 N--CA 1.447 -0.578 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_exo -52.06 166.78 0.59 Allowed 'Trans proline' 0 N--CA 1.444 -1.394 0 N-CA-C 115.806 1.425 . . . . 0.0 115.806 170.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.7 t -133.95 149.75 51.27 Favored 'General case' 0 N--CA 1.447 -0.59 0 O-C-N 120.306 -1.496 . . . . 0.0 107.971 160.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -47.99 -33.1 7.36 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 130.477 3.511 . . . . 0.0 111.406 164.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -67.43 -19.8 65.42 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 75.0 m-70 -141.32 14.91 2.21 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 117.321 2.341 . . . . 0.0 117.321 -159.25 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 43.1 t -141.49 126.31 18.11 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 176.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 65.4 m-85 -150.88 158.0 43.6 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 130.01 3.324 . . . . 0.0 108.882 -161.205 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -133.32 148.68 51.91 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 118.343 2.72 . . . . 0.0 118.343 -175.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -145.27 146.13 31.54 Favored 'General case' 0 C--O 1.221 -0.408 0 N-CA-C 119.917 3.302 . . . . 0.0 119.917 171.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.44 178.83 28.37 Favored Glycine 0 C--N 1.342 0.863 0 C-N-CA 125.457 1.503 . . . . 0.0 114.899 173.207 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -59.28 -32.33 69.92 Favored 'General case' 0 C--O 1.239 0.552 0 O-C-N 117.994 -3.063 . . . . 0.0 117.296 176.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.39 10.06 2.94 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 125.342 1.449 . . . . 0.0 115.795 170.187 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.424 ' HG ' ' CG ' ' A' ' 36' ' ' PHE . 89.6 mt -124.38 30.52 6.01 Favored 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 118.829 -2.571 . . . . 0.0 112.754 154.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 95.4 t -138.86 -63.05 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 O-C-N 120.111 -1.618 . . . . 0.0 109.683 175.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.292 37.2 pttt -144.65 131.83 20.57 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 123.122 2.692 . . . . 0.0 115.128 -173.111 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 t -130.78 146.76 33.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 1 O-C-N 129.176 4.048 . . . . 0.0 112.386 -174.366 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.492 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 3.9 m-85 -140.1 179.77 6.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 116.84 2.163 . . . . 0.0 116.84 177.137 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -82.36 -39.93 22.07 Favored 'General case' 0 C--O 1.235 0.341 0 O-C-N 116.818 -3.676 . . . . 0.0 113.538 -168.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 15.6 m-80 -105.81 3.42 28.72 Favored 'General case' 0 N--CA 1.449 -0.522 0 O-C-N 126.379 2.3 . . . . 0.0 112.907 178.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -128.77 89.64 48.49 Favored Pre-proline 0 N--CA 1.447 -0.599 0 O-C-N 121.693 -0.629 . . . . 0.0 110.731 175.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_endo -65.97 147.59 84.87 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 O-C-N 125.843 2.496 . . . . 0.0 110.576 -178.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.21 164.77 12.01 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 126.426 1.89 . . . . 0.0 111.305 -177.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.405 ' HG2' HG22 ' A' ' 82' ' ' VAL . 19.3 mt-10 -140.34 146.0 37.89 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 115.616 -2.135 . . . . 0.0 112.748 -175.097 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.424 ' CG ' ' HG ' ' A' ' 25' ' ' LEU . 24.6 p90 -153.52 167.39 29.64 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 122.858 2.572 . . . . 0.0 107.49 171.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 94.7 m -127.46 115.6 19.14 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.262 1.425 . . . . 0.0 109.012 -156.005 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . 0.405 8.4 mt -67.06 96.91 0.29 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.22 0 C-N-CA 125.529 1.532 . . . . 0.0 112.044 162.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -83.49 112.43 19.96 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-O 125.086 2.374 . . . . 0.0 111.942 166.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -114.97 126.94 55.35 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 116.496 -3.878 . . . . 0.0 110.259 -167.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.416 HG22 ' HA ' ' A' ' 47' ' ' ALA . 54.4 t -127.62 149.43 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 CA-C-O 123.967 1.841 . . . . 0.0 106.894 173.563 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -80.86 -37.57 29.67 Favored 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 117.162 2.282 . . . . 0.0 117.162 169.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 82.7 p -160.0 -69.94 0.07 Allowed 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 127.048 2.717 . . . . 0.0 116.907 -170.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 50.6 mttm -127.98 99.13 5.38 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 122.282 2.31 . . . . 0.0 113.253 -174.01 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 76.37 -75.32 1.6 Allowed Glycine 0 CA--C 1.525 0.661 0 CA-C-N 121.995 2.18 . . . . 0.0 114.915 159.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 65.5 t -46.66 129.03 2.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 C-N-CA 126.624 1.97 . . . . 0.0 107.005 171.157 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.416 ' HA ' HG22 ' A' ' 41' ' ' VAL . . . -58.81 171.23 0.68 Allowed 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 116.661 2.097 . . . . 0.0 116.661 177.088 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.3 mmm180 -64.22 116.06 5.63 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 115.598 -2.144 . . . . 0.0 106.28 165.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.487 HG22 ' CD2' ' A' ' 4' ' ' HIS . 23.7 p -76.63 4.6 9.07 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 127.762 3.164 . . . . 0.0 116.604 -160.45 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -168.4 163.06 12.69 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-O 125.338 2.494 . . . . 0.0 108.314 -173.697 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -103.17 -169.5 25.98 Favored Glycine 0 CA--C 1.524 0.646 0 O-C-N 118.064 -2.898 . . . . 0.0 113.61 -150.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 62.24 22.08 62.67 Favored Glycine 0 C--N 1.335 0.475 0 CA-C-O 113.854 -3.748 . . . . 0.0 117.952 169.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -69.09 153.59 95.89 Favored Pre-proline 0 N--CA 1.452 -0.363 0 CA-C-N 124.15 3.975 . . . . 0.0 110.253 173.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -88.03 133.08 2.87 Favored 'Trans proline' 0 N--CA 1.447 -1.264 1 C-N-CA 127.091 5.194 . . . . 0.0 118.388 -172.366 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -148.8 167.12 26.47 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 113.174 -1.83 . . . . 0.0 110.37 -156.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -161.96 141.76 10.01 Favored 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 129.021 2.928 . . . . 0.0 107.241 174.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 20.2 t -132.14 96.04 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 C-N-CA 130.769 3.628 . . . . 0.0 103.917 -178.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -116.16 140.36 49.38 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 112.236 -2.257 . . . . 0.0 110.016 -168.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 58.5 mt -134.82 148.84 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 CA-C-N 113.754 -1.567 . . . . 0.0 110.041 -159.229 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 54.2 m-80 -126.67 151.5 47.99 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 104.693 -2.336 . . . . 0.0 104.693 165.05 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.0 -145.72 4.72 Favored Glycine 0 C--O 1.219 -0.819 0 N-CA-C 107.613 -2.195 . . . . 0.0 107.613 173.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -75.02 133.65 16.82 Favored 'Trans proline' 0 N--CA 1.45 -1.029 0 CA-C-O 124.496 1.79 . . . . 0.0 111.746 -172.316 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.31 15.1 t70 48.74 -125.31 1.95 Allowed 'General case' 0 N--CA 1.45 -0.444 0 O-C-N 117.608 -3.182 . . . . 0.0 113.669 -172.068 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -80.93 4.76 68.62 Favored Glycine 0 CA--C 1.532 1.105 0 C-N-CA 127.021 2.248 . . . . 0.0 115.086 -170.465 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . 0.273 19.9 tp -72.93 104.34 4.04 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 114.792 1.404 . . . . 0.0 114.792 -177.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 99.0 t -116.3 135.01 57.91 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-O 123.295 1.521 . . . . 0.0 107.023 175.108 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 24.4 t -140.36 151.53 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.993 0 C-N-CA 125.21 1.404 . . . . 0.0 111.735 -168.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.256 8.3 p-10 -135.72 122.55 21.15 Favored 'General case' 0 C--N 1.326 -0.429 0 O-C-N 127.532 3.02 . . . . 0.0 109.791 167.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -74.75 151.08 39.19 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 128.586 2.754 . . . . 0.0 114.828 -178.173 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 66.3 tttt -93.73 98.75 11.31 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 114.369 -1.287 . . . . 0.0 111.376 -160.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.1 t -88.64 133.24 31.49 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.117 0 O-C-N 125.678 1.861 . . . . 0.0 106.451 -170.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 26.3 m -144.4 126.48 15.53 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 118.574 -1.25 . . . . 0.0 109.353 172.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -48.56 120.84 3.99 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 128.534 2.734 . . . . 0.0 118.283 166.589 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 -84.55 1.16 47.13 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 114.256 -2.783 . . . . 0.0 112.613 178.747 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 9.3 m120 61.29 24.24 14.37 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 117.556 2.428 . . . . 0.0 117.556 -177.267 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 19.8 p30 -134.55 -6.28 2.53 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 115.487 1.662 . . . . 0.0 115.487 -177.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 112.61 0.79 26.08 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 114.836 -3.202 . . . . 0.0 114.586 -166.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 66.0 p -131.74 160.46 35.47 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 120.407 2.103 . . . . 0.0 113.529 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -123.79 127.63 48.38 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 117.866 -3.021 . . . . 0.0 110.362 173.746 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -80.6 116.35 4.22 Favored Glycine 0 CA--C 1.526 0.755 0 C-N-CA 129.246 3.308 . . . . 0.0 106.103 171.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.7 t -102.14 125.34 56.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 117.194 2.294 . . . . 0.0 117.194 165.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.405 HG22 ' HG2' ' A' ' 35' ' ' GLU . 87.6 t -125.79 145.79 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-N 121.906 2.139 . . . . 0.0 111.762 -173.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . 0.343 1.2 p90 -165.93 172.63 11.33 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 122.849 2.568 . . . . 0.0 114.524 179.513 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 19.8 p30 -135.33 169.48 17.41 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -177.037 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -132.88 109.64 13.02 Favored Pre-proline 0 N--CA 1.447 -0.604 0 N-CA-C 114.752 1.389 . . . . 0.0 114.752 179.184 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.288 68.8 Cg_endo -71.88 -2.63 11.78 Favored 'Trans proline' 0 N--CA 1.449 -1.14 0 C-N-CA 124.702 3.601 . . . . 0.0 111.366 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 34.8 m -138.66 144.71 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.634 0 CA-C-O 121.653 0.739 . . . . 0.0 111.961 -163.05 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -63.29 127.52 31.66 Favored 'General case' 0 N--CA 1.451 -0.423 0 O-C-N 119.361 -2.087 . . . . 0.0 109.956 153.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 167.39 -166.37 39.24 Favored Glycine 0 CA--C 1.521 0.444 0 CA-C-O 123.756 1.753 . . . . 0.0 116.289 -172.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 11.1 t30 -114.48 139.71 49.32 Favored 'General case' 0 C--O 1.22 -0.487 0 CA-C-N 111.295 -2.452 . . . . 0.0 111.908 164.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . 0.415 ' CD2' ' SG ' ' A' ' 111' ' ' CYS . 10.1 m-85 -98.57 152.04 20.01 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-O 127.518 3.532 . . . . 0.0 112.494 152.269 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -129.08 109.07 10.88 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 109.806 -3.361 . . . . 0.0 108.164 -174.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 87.0 t -101.32 129.08 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 113.155 -1.839 . . . . 0.0 108.403 -163.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -131.15 130.52 43.16 Favored 'General case' 0 N--CA 1.449 -0.509 0 O-C-N 126.445 2.341 . . . . 0.0 110.889 176.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 99.6 t -112.74 147.13 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.741 0 N-CA-C 114.67 1.359 . . . . 0.0 114.67 -177.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 31.4 p -142.89 162.54 35.19 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 120.792 1.633 . . . . 0.0 111.597 175.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 3.0 tt -144.51 101.26 3.66 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 -147.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 28.8 ttm-85 47.51 42.01 13.92 Favored 'General case' 0 N--CA 1.445 -0.684 0 O-C-N 124.625 1.203 . . . . 0.0 108.324 -163.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 85.48 2.75 87.11 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 128.791 3.091 . . . . 0.0 120.077 177.129 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.409 ' HA ' ' HD3' ' A' ' 101' ' ' PRO . 84.2 m-20 -115.58 147.84 39.72 Favored Pre-proline 0 CA--C 1.514 -0.425 0 C-N-CA 125.881 1.672 . . . . 0.0 113.243 -176.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 100' ' ' ASN . 58.4 Cg_endo -74.15 163.04 37.52 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 124.755 3.637 . . . . 0.0 111.138 -177.485 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 10.7 pt -140.82 175.09 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 126.219 1.807 . . . . 0.0 112.699 -165.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -82.28 164.08 21.39 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 120.832 1.651 . . . . 0.0 113.915 -170.331 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 29.7 m120 53.97 40.15 31.28 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 127.403 2.281 . . . . 0.0 116.772 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 8.7 mmt -126.25 168.96 12.71 Favored Pre-proline 0 N--CA 1.45 -0.462 0 C-N-CA 126.993 2.117 . . . . 0.0 107.376 -170.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -65.67 168.66 14.47 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 N-CA-C 117.453 2.059 . . . . 0.0 117.453 -33.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . 0.372 17.1 pt -138.54 140.05 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-O 122.71 1.243 . . . . 0.0 109.202 -168.631 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -107.93 139.16 42.97 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 117.526 2.417 . . . . 0.0 117.526 -168.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 66.1 t -146.53 114.88 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.762 0 O-C-N 119.783 -1.823 . . . . 0.0 109.395 -161.442 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 68.2 tttt -80.51 144.26 32.65 Favored 'General case' 0 CA--C 1.523 -0.093 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.415 ' SG ' ' CD2' ' A' ' 91' ' ' TYR . 87.7 m -117.14 139.08 51.19 Favored 'General case' 0 N--CA 1.451 -0.42 2 O-C-N 131.991 5.807 . . . . 0.0 110.233 -179.984 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.492 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 90.9 mt -135.04 123.37 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 CA-C-N 108.469 -3.969 . . . . 0.0 113.361 171.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . 0.413 ' HG2' ' H ' ' A' ' 113' ' ' GLU 0.3 7.5 pt-20 -76.23 39.97 0.2 Allowed 'General case' 0 N--CA 1.451 -0.395 0 O-C-N 116.947 -3.595 . . . . 0.0 115.332 -164.646 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.626 0 CA-C-N 121.457 1.935 . . . . 0.0 115.585 169.728 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 tmt? . . . . . 0 CA--C 1.511 -0.553 0 CA-C-O 114.64 -2.6 . . . . 0.0 110.155 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 77.6 t60 -136.88 132.9 35.17 Favored 'General case' 0 C--N 1.34 0.185 0 CA-C-N 122.358 2.344 . . . . 0.0 106.355 175.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -80.15 113.27 18.2 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 126.273 2.939 . . . . 0.0 110.208 165.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 56.6 t-80 -157.99 129.17 6.57 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 112.196 -2.275 . . . . 0.0 116.255 177.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.4 m-70 -73.28 114.3 11.32 Favored 'General case' 0 N--CA 1.433 -1.314 0 O-C-N 118.981 -2.324 . . . . 0.0 114.964 178.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 28.2 t-80 -80.08 -47.6 14.57 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-O 116.012 -1.946 . . . . 0.0 112.86 174.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 72.5 m-70 -122.51 173.87 7.4 Favored 'General case' 0 N--CA 1.453 -0.288 0 O-C-N 127.741 3.15 . . . . 0.0 115.031 177.655 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -68.1 -33.55 74.74 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 116.815 2.154 . . . . 0.0 116.815 158.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.2 p -68.54 149.36 49.3 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 115.772 1.767 . . . . 0.0 115.772 160.195 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 31.9 pttt -161.18 154.49 18.05 Favored Pre-proline 0 N--CA 1.443 -0.819 0 C-N-CA 126.772 2.029 . . . . 0.0 115.756 179.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -69.3 168.6 20.48 Favored 'Trans proline' 0 N--CA 1.439 -1.703 0 C-N-CA 124.394 3.396 . . . . 0.0 111.313 176.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -111.53 136.83 21.03 Favored Pre-proline 0 C--O 1.239 0.538 0 C-N-CA 131.116 3.767 . . . . 0.0 114.187 -176.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . 0.252 23.3 Cg_exo -65.58 168.78 14.04 Favored 'Trans proline' 0 CA--C 1.514 -0.49 0 N-CA-C 117.498 2.076 . . . . 0.0 117.498 170.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.6 m -142.88 160.85 39.55 Favored 'General case' 0 N--CA 1.44 -0.958 0 CA-C-N 123.317 2.78 . . . . 0.0 110.937 -174.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.44 -48.43 81.68 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 113.597 -3.097 . . . . 0.0 113.861 174.638 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -52.64 -28.32 20.95 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 123.06 2.663 . . . . 0.0 106.773 173.005 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 74.4 m-70 -117.37 5.86 12.61 Favored 'General case' 0 C--O 1.218 -0.603 0 N-CA-C 116.525 2.046 . . . . 0.0 116.525 -156.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.8 t -135.14 121.86 20.88 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 116.816 2.154 . . . . 0.0 116.816 173.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 26.6 m-85 -153.31 155.19 36.02 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -161.109 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . 0.462 . . -132.01 147.92 52.48 Favored 'General case' 0 C--O 1.217 -0.61 0 N-CA-C 117.85 2.537 . . . . 0.0 117.85 -167.36 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -160.96 145.95 14.08 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 130.125 3.37 . . . . 0.0 108.736 -164.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.1 175.21 13.94 Favored Glycine 0 N--CA 1.446 -0.696 0 O-C-N 126.99 2.681 . . . . 0.0 117.505 -173.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -74.03 -30.21 62.31 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 112.652 -3.547 . . . . 0.0 113.715 -176.139 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -62.23 9.82 0.12 Allowed Glycine 0 CA--C 1.531 1.047 0 CA-C-N 124.945 3.52 . . . . 0.0 115.371 161.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 17.0 mt -113.9 19.85 16.25 Favored 'General case' 0 C--O 1.223 -0.312 0 CA-C-N 122.023 2.911 . . . . 0.0 109.799 167.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 1.7 t -137.97 -41.75 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 CA-C-O 115.313 -2.28 . . . . 0.0 110.312 174.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 42.4 mtmt -155.74 118.09 4.14 Favored 'General case' 0 C--N 1.328 -0.367 0 O-C-N 124.685 1.241 . . . . 0.0 114.096 -163.051 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 t -124.7 138.69 53.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 C-N-CA 130.853 3.661 . . . . 0.0 116.188 177.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 27.3 m-85 -128.78 -169.82 2.15 Favored 'General case' 0 N--CA 1.452 -0.358 0 O-C-N 126.552 2.408 . . . . 0.0 115.434 -174.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 17.7 t0 -105.17 -33.29 8.31 Favored 'General case' 0 CA--C 1.511 -0.541 0 O-C-N 118.278 -2.764 . . . . 0.0 114.212 -167.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 53.8 m-80 -101.83 8.73 41.22 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 120.511 3.523 . . . . 0.0 120.511 162.096 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -137.57 96.15 10.95 Favored Pre-proline 0 N--CA 1.445 -0.676 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.263 178.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_exo -62.83 128.29 22.79 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 121.883 1.722 . . . . 0.0 111.7 171.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -92.35 156.41 17.26 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 123.05 1.405 . . . . 0.0 109.71 -177.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -133.97 149.77 51.25 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 -169.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -161.64 173.27 14.95 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 104.194 -2.521 . . . . 0.0 104.194 168.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 26.1 m -127.02 118.17 23.93 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 131.53 3.932 . . . . 0.0 114.811 -158.268 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.415 ' HB ' ' HB2' ' A' ' 79' ' ' TYR . 44.7 mm -76.19 96.31 1.32 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.483 0 C-N-CA 127.012 2.125 . . . . 0.0 106.213 173.571 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -81.83 99.87 9.26 Favored 'General case' 0 C--O 1.214 -0.8 0 O-C-N 119.114 -2.241 . . . . 0.0 114.87 171.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -100.12 137.14 38.97 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 117.807 2.521 . . . . 0.0 117.807 -167.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 71.7 t -134.94 156.45 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 C-N-CA 128.449 2.7 . . . . 0.0 113.858 169.612 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.7 p30 -76.71 -71.65 0.38 Allowed 'General case' 0 N--CA 1.448 -0.555 0 O-C-N 118.741 -2.474 . . . . 0.0 109.882 174.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 77.8 p -156.18 -39.67 0.08 Allowed 'General case' 0 C--O 1.238 0.481 1 C-N-CA 133.57 4.748 . . . . 0.0 106.86 -175.705 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 46.6 mtmt -87.65 28.43 1.0 Allowed 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 123.237 2.744 . . . . 0.0 110.755 -154.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 78.28 -41.56 2.05 Favored Glycine 0 N--CA 1.444 -0.807 0 O-C-N 118.27 -2.769 . . . . 0.0 115.675 169.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.6 t -71.21 145.11 12.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 126.178 1.791 . . . . 0.0 114.667 168.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -47.12 162.19 0.06 Allowed 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 114.306 -1.316 . . . . 0.0 113.882 177.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -64.82 113.04 3.54 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.369 174.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.5 p -89.11 4.86 47.04 Favored 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 131.232 3.813 . . . . 0.0 113.142 -163.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.9 p30 -152.49 172.69 16.17 Favored 'General case' 0 N--CA 1.446 -0.657 1 C-N-CA 133.697 4.799 . . . . 0.0 108.521 162.737 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -138.03 -175.64 14.03 Favored Glycine 0 N--CA 1.443 -0.844 0 O-C-N 118.322 -2.736 . . . . 0.0 109.797 -149.523 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.93 41.5 98.67 Favored Glycine 0 CA--C 1.522 0.529 0 C-N-CA 127.213 2.339 . . . . 0.0 111.503 -178.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -74.51 156.61 86.9 Favored Pre-proline 0 C--O 1.221 -0.405 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 167.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -87.83 135.64 3.49 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 CA-C-O 127.298 2.958 . . . . 0.0 113.632 174.349 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -147.49 151.94 37.22 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 117.994 -2.941 . . . . 0.0 110.436 -173.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -140.59 142.8 35.05 Favored 'General case' 0 N--CA 1.446 -0.643 0 O-C-N 118.94 -2.35 . . . . 0.0 109.924 178.649 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.522 HG22 HG22 ' A' ' 95' ' ' VAL . 19.9 t -129.58 81.79 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 C-N-CA 129.876 3.27 . . . . 0.0 106.047 178.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -94.65 131.9 39.95 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 113.142 -1.844 . . . . 0.0 114.793 176.249 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.7 mt -124.13 156.95 31.58 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.581 0 C-N-CA 125.782 1.633 . . . . 0.0 108.116 -163.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -115.28 132.85 56.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 115.508 -2.187 . . . . 0.0 114.426 144.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -80.52 -152.42 8.23 Favored Glycine 0 CA--C 1.532 1.118 0 O-C-N 125.709 1.881 . . . . 0.0 110.611 160.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_exo -82.66 122.69 3.57 Favored 'Trans proline' 0 N--CA 1.442 -1.529 0 C-N-CA 124.773 3.648 . . . . 0.0 110.806 -170.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 25.5 t0 30.15 -92.81 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.408 0 O-C-N 126.775 2.547 . . . . 0.0 112.632 -156.027 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -76.21 2.86 55.21 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 118.533 2.173 . . . . 0.0 118.533 -167.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . 0.264 53.4 tp -86.51 90.01 8.09 Favored 'General case' 0 C--O 1.238 0.455 0 O-C-N 119.646 -2.091 . . . . 0.0 109.02 -174.172 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 96.4 t -77.24 114.48 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 CA-C-N 110.856 -2.884 . . . . 0.0 115.422 169.11 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 20.0 t -130.34 153.21 38.66 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.797 0 O-C-N 117.895 -3.003 . . . . 0.0 115.191 -173.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.2 p-10 -130.04 138.45 50.77 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 160.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -90.97 149.47 21.85 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-O 125.011 2.339 . . . . 0.0 111.926 177.11 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 52.6 mmtt -93.0 115.37 28.06 Favored 'General case' 0 N--CA 1.445 -0.681 0 O-C-N 118.612 -2.555 . . . . 0.0 108.62 -163.311 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 36.3 t -97.1 139.26 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 CA-C-N 114.051 -1.431 . . . . 0.0 109.813 -176.09 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 59.9 m -138.97 137.34 36.3 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 127.586 2.354 . . . . 0.0 113.056 174.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -73.05 128.68 36.19 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 126.132 1.773 . . . . 0.0 109.924 177.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 67.5 m-20 -90.16 -1.38 57.93 Favored 'General case' 0 C--O 1.221 -0.401 0 CA-C-O 115.722 -2.085 . . . . 0.0 115.3 175.034 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 1.7 m120 70.6 24.52 4.4 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 123.797 2.998 . . . . 0.0 111.553 167.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 38.0 p30 -139.27 -7.17 1.35 Allowed 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 121.582 3.919 . . . . 0.0 121.582 179.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 130.89 -13.2 5.56 Favored Glycine 0 C--O 1.242 0.628 0 CA-C-O 123.228 1.46 . . . . 0.0 112.967 -177.216 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.6 p -128.22 164.64 22.09 Favored 'General case' 0 C--O 1.24 0.586 0 C-N-CA 127.696 2.398 . . . . 0.0 113.472 -171.053 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.415 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 11.7 m-85 -128.49 147.76 50.7 Favored 'General case' 0 C--N 1.329 -0.291 0 O-C-N 125.308 1.63 . . . . 0.0 107.641 174.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -94.38 132.18 11.05 Favored Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 128.761 3.077 . . . . 0.0 111.183 173.201 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.9 t -128.07 138.62 54.17 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 CA-C-O 117.401 -1.285 . . . . 0.0 113.036 178.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.9 t -141.91 130.94 22.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 O-C-N 124.783 1.302 . . . . 0.0 112.695 -167.555 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -161.15 138.14 8.79 Favored 'General case' 0 CA--C 1.517 -0.313 0 CA-C-O 124.35 2.024 . . . . 0.0 111.859 -174.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.267 57.4 p-10 -109.88 160.9 15.98 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 129.227 3.011 . . . . 0.0 112.829 175.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -130.15 109.87 16.67 Favored Pre-proline 0 N--CA 1.443 -0.776 0 C-N-CA 126.508 1.923 . . . . 0.0 109.754 -167.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -70.5 -6.41 18.91 Favored 'Trans proline' 0 N--CA 1.445 -1.341 0 C-N-CA 122.072 1.848 . . . . 0.0 114.906 -179.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 25.5 m -149.68 147.14 16.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 O-C-N 118.126 -2.859 . . . . 0.0 114.737 -151.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 112' ' ' ILE . 28.7 tt0 -62.95 102.95 0.4 Allowed 'General case' 0 C--O 1.241 0.607 0 CA-C-O 123.35 1.548 . . . . 0.0 108.848 167.071 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -177.91 -136.62 2.55 Favored Glycine 0 N--CA 1.434 -1.488 1 O-C-N 116.288 -4.007 . . . . 0.0 122.784 178.098 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 25.8 t30 -132.36 137.04 47.23 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 130.18 3.392 . . . . 0.0 110.552 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 13.6 m-85 -106.75 151.9 24.53 Favored 'General case' 0 N--CA 1.446 -0.671 0 O-C-N 124.502 1.126 . . . . 0.0 112.75 151.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -119.77 116.52 26.08 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 110.894 -2.866 . . . . 0.0 112.213 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 3.3 t -112.33 126.02 69.67 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.966 0 N-CA-C 115.507 1.669 . . . . 0.0 115.507 -162.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -136.53 118.96 15.76 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 115.452 -2.213 . . . . 0.0 110.312 -168.183 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.522 HG22 HG22 ' A' ' 57' ' ' VAL . 67.3 t -119.24 144.41 27.71 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.473 0 CA-C-N 120.515 1.507 . . . . 0.0 108.625 -174.453 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 33.0 p -135.36 153.06 51.96 Favored 'General case' 0 N--CA 1.439 -0.984 0 C-N-CA 127.086 2.154 . . . . 0.0 110.619 -177.274 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.5 mp -126.14 91.65 3.42 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-O 112.702 -3.523 . . . . 0.0 112.673 -161.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.1 ttm180 55.92 35.27 25.17 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 124.744 2.211 . . . . 0.0 110.307 -159.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 75.32 0.91 63.05 Favored Glycine 0 CA--C 1.533 1.195 0 O-C-N 117.793 -3.067 . . . . 0.0 117.918 -177.441 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 63.8 m-80 -78.51 134.14 62.33 Favored Pre-proline 0 N--CA 1.448 -0.539 0 O-C-N 120.525 -1.573 . . . . 0.0 112.013 168.434 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -87.76 178.52 3.22 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 123.904 3.07 . . . . 0.0 104.968 -177.456 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 19.2 pt -152.82 177.32 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 O-C-N 120.169 -1.582 . . . . 0.0 112.761 -172.424 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 13.3 ptmt -86.86 170.97 11.19 Favored 'General case' 0 N--CA 1.442 -0.874 0 C-N-CA 128.28 2.632 . . . . 0.0 117.91 -168.161 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 10.3 m120 53.43 32.89 14.76 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 129.512 3.125 . . . . 0.0 113.878 -177.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' MET . . . . . 0.571 ' HG3' ' HA ' ' A' ' 106' ' ' PRO . 2.9 ttm -146.34 145.54 24.3 Favored Pre-proline 0 C--O 1.246 0.897 0 O-C-N 116.69 -3.757 . . . . 0.0 111.486 -158.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.571 ' HA ' ' HG3' ' A' ' 105' ' ' MET 0.3 10.1 Cg_endo -54.45 159.14 15.31 Favored 'Cis proline' 0 N--CA 1.443 -1.462 0 CA-C-N 125.002 2.822 . . . . 0.0 116.343 -13.625 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 13.4 pt -126.76 158.19 37.43 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 C-N-CA 130.38 3.472 . . . . 0.0 110.058 175.27 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -114.52 143.92 44.19 Favored 'General case' 0 CA--C 1.503 -0.833 0 N-CA-C 117.033 2.234 . . . . 0.0 117.033 -176.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 60.8 t -139.24 117.64 12.38 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 CA-C-O 117.087 -1.435 . . . . 0.0 110.318 -174.276 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . 0.25 32.6 ttpt -64.62 133.49 52.36 Favored 'General case' 0 N--CA 1.443 -0.797 0 C-N-CA 127.813 2.445 . . . . 0.0 113.66 -179.026 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 72.2 m -117.95 156.47 28.44 Favored 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 127.929 2.491 . . . . 0.0 112.492 -177.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 7.7 tt -155.27 156.64 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 114.776 1.399 . . . . 0.0 114.776 158.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . 0.316 5.0 pt-20 -62.51 43.44 0.01 OUTLIER 'General case' 0 N--CA 1.444 -0.769 0 C-N-CA 127.149 2.18 . . . . 0.0 116.879 173.372 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.676 0 N-CA-C 118.634 2.214 . . . . 0.0 118.634 179.939 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.1 tmt? . . . . . 0 N--CA 1.474 0.756 0 CA-C-O 117.066 -1.445 . . . . 0.0 108.599 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 72.9 t60 -116.33 130.95 57.04 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-N 120.819 1.645 . . . . 0.0 112.262 -170.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 9.4 t60 -97.85 119.51 36.58 Favored 'General case' 0 C--N 1.333 -0.133 0 N-CA-C 105.908 -1.886 . . . . 0.0 105.908 174.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 38.1 t-80 -160.44 135.58 7.88 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 127.325 2.25 . . . . 0.0 110.415 173.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.557 ' CE1' ' H ' ' A' ' 51' ' ' GLY . 92.1 m-70 -71.07 95.82 1.26 Allowed 'General case' 0 N--CA 1.453 -0.301 0 CA-C-O 125.946 2.784 . . . . 0.0 112.846 165.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 69.7 m80 -85.35 -22.38 28.48 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 119.231 -2.168 . . . . 0.0 114.65 172.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 67.3 m80 -141.34 166.3 25.14 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -162.434 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -74.97 -54.18 7.66 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 115.116 1.524 . . . . 0.0 115.116 164.212 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 65.8 m -68.37 135.07 51.22 Favored 'General case' 0 N--CA 1.455 -0.206 0 O-C-N 118.04 -2.912 . . . . 0.0 113.234 171.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . 0.429 ' HB2' ' HE3' ' A' ' 10' ' ' LYS . 28.8 mtmt -127.88 149.23 70.15 Favored Pre-proline 0 N--CA 1.45 -0.46 0 O-C-N 118.326 -2.734 . . . . 0.0 108.986 179.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -70.1 156.85 61.48 Favored 'Trans proline' 0 N--CA 1.451 -0.98 0 N-CA-C 118.05 2.288 . . . . 0.0 118.05 156.371 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -93.21 147.53 33.95 Favored Pre-proline 0 N--CA 1.45 -0.467 0 O-C-N 125.645 1.84 . . . . 0.0 114.414 -178.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -57.43 154.15 37.16 Favored 'Trans proline' 0 N--CA 1.449 -1.145 1 C-N-CA 127.224 5.283 . . . . 0.0 114.584 152.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 34.2 t -140.28 176.57 8.66 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 121.765 2.075 . . . . 0.0 113.579 -178.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . 0.296 . . -65.88 -48.23 72.21 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 129.935 3.294 . . . . 0.0 115.959 -173.223 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.0 mp0 -54.71 -28.18 46.12 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 111.231 -2.713 . . . . 0.0 113.458 166.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 31.4 m-70 -133.2 7.48 3.94 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-O 125.518 2.58 . . . . 0.0 112.928 -148.003 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . 0.268 29.2 t -125.46 114.04 18.29 Favored 'General case' 0 N--CA 1.45 -0.468 0 O-C-N 116.35 -3.969 . . . . 0.0 107.478 169.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . 0.265 75.6 m-85 -130.62 160.98 32.61 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 129.192 2.997 . . . . 0.0 108.195 174.449 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -137.85 151.16 47.79 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 127.63 2.372 . . . . 0.0 115.344 -169.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -154.39 137.14 15.26 Favored 'General case' 0 N--CA 1.452 -0.363 1 O-C-N 116.023 -4.173 . . . . 0.0 114.787 -165.589 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.36 -175.09 19.76 Favored Glycine 0 C--O 1.222 -0.636 0 C-N-CA 126.412 1.958 . . . . 0.0 108.514 160.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.2 tt0 -68.6 -22.78 64.43 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-O 114.725 -2.559 . . . . 0.0 113.714 -158.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -56.25 -0.14 0.17 Allowed Glycine 0 N--CA 1.443 -0.841 0 CA-C-O 115.247 -2.974 . . . . 0.0 117.829 161.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 23.8 mt -121.72 24.27 9.8 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 127.658 2.383 . . . . 0.0 114.729 168.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.8 t -142.96 -47.03 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 CA-C-O 114.976 -2.44 . . . . 0.0 107.7 -172.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 28.4 ttmt -172.47 139.54 0.99 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 115.36 -2.257 . . . . 0.0 112.279 -177.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 34.2 t -144.97 142.45 22.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 115.168 -2.348 . . . . 0.0 113.938 -166.384 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.427 ' HB2' ' HB3' ' A' ' 32' ' ' ALA 0.278 1.2 m-85 -129.6 177.53 7.15 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 125.381 1.676 . . . . 0.0 114.413 -166.283 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -94.86 -37.89 10.99 Favored 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 116.515 2.043 . . . . 0.0 116.515 -178.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 55.9 m-80 -102.52 19.48 18.9 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 115.975 1.843 . . . . 0.0 115.975 165.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.427 ' HB3' ' HB2' ' A' ' 29' ' ' PHE . . . -139.3 92.72 10.42 Favored Pre-proline 0 N--CA 1.455 -0.19 0 C-N-CA 126.1 1.76 . . . . 0.0 106.57 171.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . 0.324 74.9 Cg_exo -43.71 119.84 2.04 Favored 'Trans proline' 0 N--CA 1.449 -1.134 1 C-N-CA 129.854 7.036 . . . . 0.0 112.019 148.309 . . . . . . . . 3 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.418 ' O ' ' HA ' ' A' ' 82' ' ' VAL . . . -96.81 150.81 20.3 Favored 'General case' 0 N--CA 1.45 -0.457 0 C-N-CA 128.504 2.722 . . . . 0.0 111.116 -178.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -121.54 137.73 54.61 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-O 115.119 -2.372 . . . . 0.0 114.363 -173.109 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -154.53 172.17 18.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 CA-C-N 125.202 3.637 . . . . 0.0 107.723 164.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 55.5 m -138.0 129.6 28.09 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-O 115.947 -1.977 . . . . 0.0 111.533 -157.044 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 16.1 mt -89.57 124.01 42.07 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 O-C-N 125.928 2.018 . . . . 0.0 107.114 171.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.277 39.2 p90 -99.26 115.95 30.32 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 128.471 2.709 . . . . 0.0 112.232 170.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -116.46 129.74 56.38 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-O 123.716 1.722 . . . . 0.0 110.112 -161.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.6 t -125.03 151.41 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 C-N-CA 126.934 2.094 . . . . 0.0 113.816 163.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.9 p30 -77.05 -72.56 0.34 Allowed 'General case' 0 N--CA 1.443 -0.784 0 CA-C-O 125.193 2.425 . . . . 0.0 116.464 170.607 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 16.0 p -159.54 -28.24 0.07 Allowed 'General case' 0 CA--C 1.517 -0.293 1 C-N-CA 133.774 4.829 . . . . 0.0 112.239 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . 0.393 84.3 mttt -94.4 13.92 22.22 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 123.015 2.643 . . . . 0.0 115.89 -170.414 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 79.8 -33.72 2.13 Favored Glycine 0 CA--C 1.523 0.556 0 O-C-N 118.164 -2.835 . . . . 0.0 112.542 164.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 71.1 t -54.99 133.41 18.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 1 CA-C-N 125.402 4.601 . . . . 0.0 112.22 155.541 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.53 166.74 0.05 OUTLIER 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 117.399 2.37 . . . . 0.0 117.399 169.43 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 8.4 mmm180 -53.86 120.03 5.77 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 116.054 1.872 . . . . 0.0 116.054 176.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 34.8 p -88.19 -4.82 58.67 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 125.077 1.351 . . . . 0.0 110.914 -160.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -165.19 160.47 18.59 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 127.83 2.452 . . . . 0.0 108.998 -169.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.557 ' H ' ' CE1' ' A' ' 5' ' ' HIS . . . -106.59 -162.38 22.38 Favored Glycine 0 N--CA 1.444 -0.826 0 O-C-N 126.839 2.587 . . . . 0.0 116.641 -158.253 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 48.91 44.07 31.36 Favored Glycine 0 C--O 1.222 -0.616 0 C-N-CA 128.359 2.885 . . . . 0.0 113.957 174.764 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -78.02 141.06 62.6 Favored Pre-proline 0 N--CA 1.451 -0.395 0 O-C-N 119.347 -2.266 . . . . 0.0 109.538 159.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -90.92 132.24 1.57 Allowed 'Trans proline' 0 N--CA 1.442 -1.55 0 N-CA-C 121.234 3.513 . . . . 0.0 121.234 -171.675 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -136.68 149.72 48.08 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 113.053 0.76 . . . . 0.0 113.053 -151.083 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -134.4 145.23 48.73 Favored 'General case' 0 N--CA 1.442 -0.836 0 O-C-N 127.73 3.144 . . . . 0.0 106.457 168.265 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 40.6 t -126.46 99.47 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 102.598 -3.112 . . . . 0.0 102.598 163.46 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -109.57 137.0 48.04 Favored 'General case' 0 N--CA 1.442 -0.842 0 O-C-N 126.253 2.22 . . . . 0.0 113.662 -171.247 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 84.2 mt -140.21 148.33 22.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 114.996 1.48 . . . . 0.0 114.996 -157.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.6 m120 -122.26 144.4 49.01 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 127.257 2.223 . . . . 0.0 107.512 166.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -124.59 -163.92 11.79 Favored Glycine 0 C--N 1.337 0.632 0 C-N-CA 127.272 2.368 . . . . 0.0 109.302 161.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -56.59 133.17 56.28 Favored 'Trans proline' 0 N--CA 1.448 -1.147 1 C-N-CA 129.824 7.016 . . . . 0.0 116.322 178.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.271 42.1 t0 58.14 -112.24 0.63 Allowed 'General case' 0 N--CA 1.443 -0.806 1 O-C-N 116.136 -4.102 . . . . 0.0 110.665 179.622 . . . . . . . . 3 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -91.9 -5.92 65.82 Favored Glycine 0 CA--C 1.518 0.239 0 O-C-N 119.358 -2.089 . . . . 0.0 116.761 -174.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 31.6 tp -67.69 100.97 0.96 Allowed 'General case' 0 N--CA 1.448 -0.547 0 O-C-N 117.442 -3.387 . . . . 0.0 114.144 -176.621 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.8 t -106.07 134.16 48.43 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 CA-C-N 110.867 -2.878 . . . . 0.0 110.422 169.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 55.8 t -132.6 155.57 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 N-CA-C 115.515 1.672 . . . . 0.0 115.515 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.254 6.4 p-10 -129.87 123.38 30.67 Favored 'General case' 0 N--CA 1.44 -0.944 1 CA-C-O 128.993 4.235 . . . . 0.0 108.7 168.582 . . . . . . . . 3 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.21 131.17 34.3 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-O 127.459 3.504 . . . . 0.0 110.486 -178.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 14.5 mptt -91.13 119.91 31.64 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 112.696 -2.047 . . . . 0.0 114.196 -166.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.0 t -100.29 144.92 11.8 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.371 0 C-N-CA 130.421 3.488 . . . . 0.0 112.098 -169.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . 0.26 42.3 m -154.3 136.87 15.11 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 127.233 3.397 . . . . 0.0 111.465 170.027 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.436 ' HA ' ' CD1' ' A' ' 79' ' ' TYR . 39.7 t0 -62.04 118.23 7.03 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 131.076 3.75 . . . . 0.0 109.164 179.101 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 73.2 m-20 -80.04 -6.34 57.44 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-O 116.434 -1.746 . . . . 0.0 115.207 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.258 10.8 t-20 60.29 30.51 19.9 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 127.653 3.597 . . . . 0.0 114.693 -176.043 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 18.1 p30 -138.28 -1.18 1.95 Allowed 'General case' 0 C--O 1.238 0.46 0 O-C-N 117.084 -3.51 . . . . 0.0 119.116 174.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 104.92 1.51 42.31 Favored Glycine 0 CA--C 1.521 0.449 0 CA-C-O 116.482 -2.288 . . . . 0.0 118.44 -163.286 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 44.1 p -126.32 171.64 10.79 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 127.543 2.337 . . . . 0.0 111.635 177.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.436 ' CD1' ' HA ' ' A' ' 73' ' ' ASP . 46.3 m-85 -144.95 118.84 9.3 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-O 115.605 -2.141 . . . . 0.0 109.267 178.221 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.71 136.75 24.83 Favored Glycine 0 CA--C 1.524 0.629 1 C-N-CA 130.991 4.139 . . . . 0.0 111.239 175.302 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.0 t -135.29 126.63 45.76 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 CA-C-O 128.131 3.824 . . . . 0.0 107.85 -177.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.418 ' HA ' ' O ' ' A' ' 34' ' ' ALA . 3.7 p -122.11 132.15 71.62 Favored 'Isoleucine or valine' 0 C--O 1.236 0.37 0 O-C-N 118.772 -2.455 . . . . 0.0 114.021 178.149 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -158.15 168.65 26.47 Favored 'General case' 0 C--O 1.221 -0.414 0 N-CA-C 117.76 2.504 . . . . 0.0 117.76 173.084 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.427 31.9 p30 -133.7 151.82 51.73 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 123.673 1.701 . . . . 0.0 114.236 -173.187 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -119.92 118.41 31.74 Favored Pre-proline 0 N--CA 1.445 -0.682 0 O-C-N 119.867 -1.771 . . . . 0.0 109.204 -173.117 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.262 29.0 Cg_endo -83.01 4.71 6.91 Favored 'Trans proline' 0 N--CA 1.447 -1.232 1 C-N-CA 128.225 5.95 . . . . 0.0 108.756 -178.793 . . . . . . . . 3 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 14.9 m -132.05 138.55 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 N-CA-C 120.399 3.481 . . . . 0.0 120.399 -167.281 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -54.15 118.87 4.4 Favored 'General case' 0 N--CA 1.449 -0.512 0 O-C-N 120.157 -1.589 . . . . 0.0 107.246 137.252 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 159.96 -135.39 4.07 Favored Glycine 0 C--N 1.331 0.296 0 CA-C-N 120.334 1.425 . . . . 0.0 115.038 172.485 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 -141.36 138.87 33.35 Favored 'General case' 0 N--CA 1.445 -0.677 0 C-N-CA 127.579 2.351 . . . . 0.0 113.767 177.149 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 -99.61 149.12 23.6 Favored 'General case' 0 C--O 1.222 -0.376 0 C-N-CA 126.479 1.912 . . . . 0.0 112.52 168.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -137.1 114.99 11.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 103.713 -2.699 . . . . 0.0 103.713 -164.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.2 t -114.56 126.01 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 CA-C-N 111.186 -2.734 . . . . 0.0 109.71 -153.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.0 t30 -138.69 118.34 13.08 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 123.874 1.797 . . . . 0.0 106.651 -172.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 54.6 t -116.74 142.77 29.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 O-C-N 118.079 -2.888 . . . . 0.0 112.386 -178.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.4 ' C ' HD12 ' A' ' 97' ' ' LEU . 16.1 p -150.1 151.83 33.8 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 117.175 2.287 . . . . 0.0 117.175 -169.314 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.4 HD12 ' C ' ' A' ' 96' ' ' THR . 11.2 mp -135.08 87.53 2.34 Favored 'General case' 0 N--CA 1.442 -0.846 0 N-CA-C 102.861 -3.015 . . . . 0.0 102.861 -137.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 18.6 ttm-85 59.41 25.01 13.68 Favored 'General case' 0 N--CA 1.45 -0.466 0 O-C-N 117.322 -3.361 . . . . 0.0 108.737 -158.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 81.51 6.28 89.3 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-O 116.906 -2.052 . . . . 0.0 116.504 -175.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -76.0 120.9 83.74 Favored Pre-proline 0 N--CA 1.445 -0.722 0 O-C-N 125.135 1.138 . . . . 0.0 111.776 162.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -81.9 174.21 10.42 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 CA-C-N 121.661 1.629 . . . . 0.0 110.275 178.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . 0.261 27.8 pt -138.99 174.32 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 O-C-N 125.921 2.013 . . . . 0.0 113.949 -164.311 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 18.7 ptpt -72.28 166.68 21.97 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 127.895 2.478 . . . . 0.0 113.067 172.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 25.9 m120 50.59 32.23 6.56 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 123.173 1.464 . . . . 0.0 107.71 -179.089 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 14.6 mmt -143.31 134.11 12.43 Favored Pre-proline 0 N--CA 1.448 -0.557 1 O-C-N 115.029 -4.794 . . . . 0.0 107.661 176.42 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -86.02 171.88 39.61 Favored 'Cis proline' 0 N--CA 1.449 -1.117 0 CA-C-N 121.563 1.594 . . . . 0.0 109.853 13.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . 0.442 HG21 HD13 ' A' ' 107' ' ' ILE . 19.3 pt -144.33 164.69 13.78 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-O 115.055 -2.402 . . . . 0.0 115.272 -178.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -126.7 136.04 51.92 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 124.659 3.39 . . . . 0.0 113.61 -166.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 3.3 t -128.57 140.73 48.43 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 C-N-CA 129.151 2.98 . . . . 0.0 114.682 -173.545 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 13.2 tppt? -74.74 142.64 44.34 Favored 'General case' 0 N--CA 1.445 -0.722 0 O-C-N 123.588 0.555 . . . . 0.0 111.191 178.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 69.4 m -132.06 140.77 48.98 Favored 'General case' 0 N--CA 1.452 -0.331 0 N-CA-C 115.178 1.547 . . . . 0.0 115.178 177.577 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.416 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 10.4 tp -149.08 135.85 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 CA-C-O 117.33 -1.319 . . . . 0.0 112.421 170.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.45 39.59 0.88 Allowed 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 123.009 2.64 . . . . 0.0 116.176 -164.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.341 0.85 0 O-C-N 126.056 2.097 . . . . 0.0 113.468 162.486 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.1 tmm? . . . . . 0 N--CA 1.476 0.867 0 CA-C-O 117.476 -1.249 . . . . 0.0 110.514 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 78.3 t60 -93.87 98.66 11.21 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 117.581 -1.2 . . . . 0.0 111.528 -175.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 9.2 t60 -98.35 104.89 16.97 Favored 'General case' 0 N--CA 1.441 -0.896 0 CA-C-O 117.759 -1.115 . . . . 0.0 110.077 179.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 55.2 t60 -154.38 141.41 19.32 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-N 122.633 2.47 . . . . 0.0 109.747 -174.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.4 ' CE1' ' HB2' ' A' ' 50' ' ' ASP . 69.0 m-70 -79.17 106.5 11.25 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 117.993 -1.003 . . . . 0.0 112.064 -176.703 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 67.4 m80 -104.37 -47.78 4.02 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 124.51 1.124 . . . . 0.0 112.155 -176.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 54.2 m80 -94.25 159.48 15.11 Favored 'General case' 0 C--O 1.221 -0.438 0 C-N-CA 126.192 1.797 . . . . 0.0 113.241 -160.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -57.7 -45.03 86.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 116.37 -1.776 . . . . 0.0 113.939 172.292 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 69.0 m -129.94 154.92 46.86 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 122.797 2.544 . . . . 0.0 117.094 174.139 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 38.6 mtmt -95.88 146.86 32.06 Favored Pre-proline 0 N--CA 1.443 -0.803 0 O-C-N 118.617 -2.552 . . . . 0.0 111.309 -174.519 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -73.24 166.59 29.56 Favored 'Trans proline' 0 N--CA 1.453 -0.912 0 N-CA-C 117.296 1.998 . . . . 0.0 117.296 160.597 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -97.17 143.07 25.5 Favored Pre-proline 0 CA--C 1.519 -0.221 0 N-CA-C 118.308 2.707 . . . . 0.0 118.308 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -71.43 143.18 42.43 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 124.182 3.254 . . . . 0.0 109.839 166.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.6 m -123.25 168.76 12.04 Favored 'General case' 0 CA--C 1.516 -0.344 0 O-C-N 127.321 2.888 . . . . 0.0 111.774 -165.2 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.02 -41.09 82.68 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 115.874 1.805 . . . . 0.0 115.874 -174.185 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 56.4 mp0 -68.2 -16.94 64.18 Favored 'General case' 0 C--O 1.22 -0.453 0 C-N-CA 127.39 2.276 . . . . 0.0 112.873 173.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 86.1 m-70 -127.7 13.29 6.92 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 120.91 -1.119 . . . . 0.0 110.898 -154.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 9.1 t -135.45 122.82 21.85 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-O 122.913 1.339 . . . . 0.0 111.391 169.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.443 ' HB2' ' CE1' ' A' ' 39' ' ' PHE . 60.8 m-85 -152.39 154.79 36.3 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 128.792 2.837 . . . . 0.0 112.032 -172.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -138.51 162.42 34.55 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 120.066 1.303 . . . . 0.0 108.415 -164.01 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -146.76 132.0 18.45 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 127.316 2.247 . . . . 0.0 108.202 -170.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 139.17 -157.36 24.9 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 117.196 1.639 . . . . 0.0 117.196 145.091 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . 0.258 39.1 mt-10 -55.87 -41.72 74.82 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 119.375 3.102 . . . . 0.0 119.375 -175.642 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -67.7 2.82 5.66 Favored Glycine 0 CA--C 1.523 0.578 0 C-N-CA 127.829 2.633 . . . . 0.0 113.944 168.617 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.499 HD21 ' CE1' ' A' ' 36' ' ' PHE 0.334 20.9 mt -108.11 1.04 22.0 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 117.45 2.389 . . . . 0.0 117.45 155.988 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 72.9 t -119.8 -45.82 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 O-C-N 119.393 -2.067 . . . . 0.0 113.517 -174.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.262 31.5 ttmt -159.15 134.7 8.56 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 115.843 1.794 . . . . 0.0 115.843 175.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.7 t -135.65 139.62 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 106.715 -1.587 . . . . 0.0 106.715 -173.204 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 -121.25 176.64 5.52 Favored 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 128.964 2.906 . . . . 0.0 116.262 -169.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -80.25 -54.3 5.86 Favored 'General case' 0 N--CA 1.441 -0.894 0 O-C-N 120.011 -1.681 . . . . 0.0 113.058 178.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 -103.72 4.71 35.61 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 129.59 3.156 . . . . 0.0 114.478 177.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . 0.304 . . -110.39 84.07 3.63 Favored Pre-proline 0 N--CA 1.448 -0.537 0 CA-C-O 113.328 -3.225 . . . . 0.0 106.262 159.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -59.04 120.79 8.87 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 CA-C-N 123.816 2.399 . . . . 0.0 110.525 164.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -91.13 154.76 19.13 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 112.506 -2.133 . . . . 0.0 108.22 -175.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.437 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 45.8 mt-10 -120.36 165.98 14.16 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 109.712 -3.404 . . . . 0.0 112.49 175.364 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.499 ' CE1' HD21 ' A' ' 25' ' ' LEU . 10.7 p90 -162.16 173.5 14.22 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 128.566 2.746 . . . . 0.0 110.704 163.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 98.8 m -130.28 126.47 37.32 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 126.927 2.091 . . . . 0.0 115.652 -163.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 6.5 mt -92.34 105.14 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 C-N-CA 125.837 1.655 . . . . 0.0 108.018 178.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.443 ' CE1' ' HB2' ' A' ' 19' ' ' TYR 0.26 1.3 p90 -72.59 132.12 43.35 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.348 1.459 . . . . 0.0 112.04 167.055 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -130.98 134.7 46.96 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 118.272 -2.767 . . . . 0.0 113.133 -170.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.417 HG22 ' HA ' ' A' ' 47' ' ' ALA . 5.2 t -131.45 150.82 34.63 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.396 0 CA-C-O 125.882 2.753 . . . . 0.0 103.78 169.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 10.0 p30 -69.73 -70.8 0.26 Allowed 'General case' 0 N--CA 1.443 -0.806 1 O-C-N 115.935 -4.228 . . . . 0.0 112.517 169.063 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 24.3 p -162.68 -9.82 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.418 1 C-N-CA 135.045 5.338 . . . . 0.0 114.707 -179.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 26.5 mtpp -122.18 34.54 5.14 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 122.393 2.36 . . . . 0.0 111.328 -163.036 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.82 -58.13 5.03 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 118.853 2.301 . . . . 0.0 118.853 160.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 62.1 t -57.85 132.33 22.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 O-C-N 126.271 1.806 . . . . 0.0 111.007 163.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.417 ' HA ' HG22 ' A' ' 41' ' ' VAL . . . -45.59 161.8 0.04 OUTLIER 'General case' 0 N--CA 1.447 -0.58 0 CA-C-O 125.276 2.465 . . . . 0.0 116.849 170.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 9.5 mmm180 -55.37 110.38 0.68 Allowed 'General case' 0 CA--C 1.518 -0.263 0 O-C-N 117.069 -3.519 . . . . 0.0 110.467 174.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.1 p -76.07 5.47 6.66 Favored 'General case' 0 N--CA 1.449 -0.519 1 C-N-CA 136.483 5.913 . . . . 0.0 117.092 -179.085 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.4 ' HB2' ' CE1' ' A' ' 5' ' ' HIS . 1.2 p30 -170.14 168.19 8.42 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 123.797 1.761 . . . . 0.0 107.85 169.582 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -123.86 -162.86 11.57 Favored Glycine 0 C--N 1.344 1.002 0 O-C-N 117.829 -3.044 . . . . 0.0 111.632 -146.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.66 21.21 74.65 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 122.059 3.584 . . . . 0.0 122.059 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 41.9 m-20 -73.39 152.79 90.04 Favored Pre-proline 0 C--O 1.223 -0.31 0 CA-C-N 118.59 1.195 . . . . 0.0 111.925 174.073 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -101.29 131.55 0.14 Allowed 'Trans proline' 0 N--CA 1.457 -0.66 0 CA-C-O 126.001 2.417 . . . . 0.0 112.313 -174.423 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -136.7 155.68 49.55 Favored 'General case' 0 N--CA 1.444 -0.769 0 CA-C-N 111.478 -2.601 . . . . 0.0 110.262 -172.4 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.405 ' O ' ' HA ' ' A' ' 95' ' ' VAL . 34.5 tt0 -139.39 141.43 37.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 125.203 2.43 . . . . 0.0 111.425 175.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 46.6 t -133.98 76.86 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.693 0 C-N-CA 128.195 2.598 . . . . 0.0 104.916 -175.553 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -99.04 141.44 31.79 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 125.872 2.749 . . . . 0.0 107.812 -170.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.426 ' HA ' ' O ' ' A' ' 92' ' ' ASN . 54.5 mt -137.04 139.96 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-N 111.046 -2.797 . . . . 0.0 114.965 -159.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 12.2 m120 -124.59 117.09 23.54 Favored 'General case' 0 C--O 1.223 -0.312 0 C-N-CA 126.983 2.113 . . . . 0.0 106.471 176.02 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.44 ' HA3' ' HB3' ' A' ' 65' ' ' LEU . . . -78.98 -159.19 14.28 Favored Glycine 0 N--CA 1.445 -0.766 0 CA-C-O 114.571 -3.35 . . . . 0.0 115.845 161.499 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_endo -63.28 116.52 3.65 Favored 'Trans proline' 0 N--CA 1.446 -1.298 1 C-N-CA 127.282 5.321 . . . . 0.0 110.63 162.551 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 23.4 t70 51.46 -100.49 0.09 Allowed 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 117.051 2.241 . . . . 0.0 117.051 177.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -74.55 -6.63 77.25 Favored Glycine 0 N--CA 1.438 -1.194 0 O-C-N 121.157 -0.964 . . . . 0.0 115.363 -172.314 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.44 ' HB3' ' HA3' ' A' ' 61' ' ' GLY 0.328 14.6 tp -77.95 73.97 4.51 Favored 'General case' 0 N--CA 1.442 -0.837 0 O-C-N 118.975 -2.485 . . . . 0.0 114.615 -168.63 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 51.8 t -87.91 110.14 20.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 C-N-CA 127.599 2.36 . . . . 0.0 113.794 175.049 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 68.2 t -133.29 159.87 42.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 CA-C-N 113.162 -1.835 . . . . 0.0 109.456 -165.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.264 1.1 p30 -133.59 142.95 48.37 Favored 'General case' 0 N--CA 1.448 -0.55 0 O-C-N 120.24 -1.537 . . . . 0.0 109.875 157.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.3 147.08 24.96 Favored 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 125.519 1.762 . . . . 0.0 113.632 162.402 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -99.16 113.89 26.37 Favored 'General case' 0 CA--C 1.511 -0.525 0 C-N-CA 127.599 2.36 . . . . 0.0 108.36 -158.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.6 t -91.83 129.49 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 O-C-N 124.42 1.075 . . . . 0.0 111.079 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.7 m -136.87 140.67 42.54 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 102.34 -3.207 . . . . 0.0 102.34 -178.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 57.9 t0 -72.31 124.2 24.6 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 129.199 3.0 . . . . 0.0 107.603 -172.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -82.14 -1.5 49.06 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 116.343 -1.789 . . . . 0.0 115.331 169.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.395 1.5 m120 60.57 32.58 20.44 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-N 121.449 1.931 . . . . 0.0 115.691 176.748 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 25.7 p30 -144.5 6.1 1.25 Allowed 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 113.032 -1.894 . . . . 0.0 112.409 -172.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 89.8 7.27 68.84 Favored Glycine 0 C--N 1.333 0.414 0 CA-C-N 122.58 2.445 . . . . 0.0 115.653 -166.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.9 p -141.16 158.31 44.08 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 129.25 3.02 . . . . 0.0 114.208 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 23.2 m-85 -132.04 126.65 34.4 Favored 'General case' 0 N--CA 1.449 -0.501 0 O-C-N 120.215 -1.553 . . . . 0.0 107.478 -169.351 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -89.17 147.82 19.82 Favored Glycine 0 C--N 1.335 0.5 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 35' ' ' GLU . 2.3 t -131.54 133.83 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 CA-C-N 110.235 -2.982 . . . . 0.0 114.088 -174.027 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 13.7 p -137.54 131.39 43.93 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 CA-C-N 120.781 1.628 . . . . 0.0 110.359 -169.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -161.86 151.67 16.58 Favored 'General case' 0 N--CA 1.452 -0.353 1 O-C-N 115.95 -4.219 . . . . 0.0 111.582 176.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 26.0 p30 -116.93 151.66 36.17 Favored 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 130.92 3.688 . . . . 0.0 111.182 -172.412 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . 0.312 . . -130.44 104.91 16.04 Favored Pre-proline 0 N--CA 1.441 -0.876 0 N-CA-C 118.87 2.915 . . . . 0.0 118.87 -170.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -93.21 24.44 0.45 Allowed 'Trans proline' 0 N--CA 1.45 -1.044 0 C-N-CA 124.488 3.459 . . . . 0.0 112.76 -174.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.5 m -140.04 134.87 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 117.145 2.276 . . . . 0.0 117.145 -179.148 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . 0.284 38.5 tt0 -56.43 105.15 0.18 Allowed 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.705 144.016 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 162.41 -139.99 6.28 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-O 117.97 -1.461 . . . . 0.0 110.876 176.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 85.0 m-20 -143.24 137.97 29.3 Favored 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 105.848 -1.908 . . . . 0.0 105.848 -170.816 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -90.04 145.91 24.73 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 111.435 -2.62 . . . . 0.0 113.143 156.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.426 ' O ' ' HA ' ' A' ' 59' ' ' ILE . 26.1 t-20 -113.0 116.97 30.78 Favored 'General case' 0 N--CA 1.442 -0.828 0 O-C-N 128.566 3.666 . . . . 0.0 112.232 172.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 43.5 t -111.91 131.18 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 CA-C-O 126.102 2.858 . . . . 0.0 113.105 -168.448 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 21.5 t-20 -131.96 131.68 42.83 Favored 'General case' 0 N--CA 1.445 -0.694 0 O-C-N 119.157 -2.214 . . . . 0.0 111.302 176.309 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 56' ' ' GLU . 57.7 t -118.52 129.95 74.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 O-C-N 124.159 0.912 . . . . 0.0 112.718 -174.44 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.418 ' HB ' ' O ' ' A' ' 100' ' ' ASN . 46.9 p -139.6 153.19 47.31 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -172.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 3.2 mp -126.16 105.84 9.14 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 105.043 -2.206 . . . . 0.0 105.043 -142.149 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 44.4 ttm-85 46.93 42.22 11.95 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 125.997 2.808 . . . . 0.0 108.937 -153.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 57.93 14.22 16.16 Favored Glycine 0 CA--C 1.528 0.882 0 O-C-N 116.765 -3.71 . . . . 0.0 115.798 -177.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.418 ' O ' ' HB ' ' A' ' 96' ' ' THR . 76.8 m-20 -95.32 157.37 36.43 Favored Pre-proline 0 N--CA 1.449 -0.485 0 C-N-CA 117.6 -1.64 . . . . 0.0 115.325 168.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -79.91 168.38 19.18 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 CA-C-O 125.82 2.342 . . . . 0.0 111.836 -174.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 43.5 pt -147.02 -177.52 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-O 126.038 2.828 . . . . 0.0 113.733 -178.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 17.2 ptmt -84.71 168.51 15.17 Favored 'General case' 0 N--CA 1.446 -0.669 0 O-C-N 116.405 -3.934 . . . . 0.0 110.936 -176.337 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 17.4 m120 54.77 29.46 11.85 Favored 'General case' 0 N--CA 1.446 -0.674 0 O-C-N 120.386 -1.446 . . . . 0.0 114.536 175.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 11.1 mmt -143.18 150.55 52.66 Favored Pre-proline 0 CA--C 1.518 -0.28 0 CA-C-O 113.351 -3.214 . . . . 0.0 111.73 177.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.43 175.82 34.03 Favored 'Cis proline' 0 N--CA 1.446 -1.316 0 CA-C-N 123.809 2.396 . . . . 0.0 113.199 -0.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 14.0 pt -144.56 -176.04 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.283 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 170.272 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -135.12 148.52 49.81 Favored 'General case' 0 N--CA 1.45 -0.463 1 O-C-N 114.745 -4.972 . . . . 0.0 112.294 -172.862 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 99.5 t -143.66 128.81 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.909 0 N-CA-C 105.478 -2.045 . . . . 0.0 105.478 -171.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 69.5 tttt -70.63 132.19 45.07 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 112.669 -2.059 . . . . 0.0 112.221 -176.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 81.6 m -113.08 126.82 55.89 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.208 1.403 . . . . 0.0 109.548 -178.257 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.8 tp -135.36 132.14 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 O-C-N 119.86 -1.775 . . . . 0.0 108.897 155.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -72.75 55.23 0.38 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 130.377 3.471 . . . . 0.0 114.028 -163.036 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.452 0 C-N-CA 128.021 2.724 . . . . 0.0 115.692 176.338 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.9 tpt . . . . . 0 C--O 1.236 0.352 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 43.0 t-80 -163.14 140.23 7.53 Favored 'General case' 0 N--CA 1.443 -0.776 0 O-C-N 125.666 1.854 . . . . 0.0 112.419 173.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . 0.304 8.3 t60 -91.84 100.66 13.3 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 129.497 3.119 . . . . 0.0 112.209 -170.027 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 60.0 t-80 -147.25 150.63 35.21 Favored 'General case' 0 N--CA 1.445 -0.683 0 O-C-N 119.395 -2.066 . . . . 0.0 112.63 178.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -90.92 125.93 35.91 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-O 115.868 -2.015 . . . . 0.0 113.65 177.741 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 36.8 m80 -120.55 -26.97 5.23 Favored 'General case' 0 C--O 1.219 -0.533 0 C-N-CA 128.268 2.627 . . . . 0.0 112.36 -177.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 40.1 m80 -142.58 160.33 40.51 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-O 123.975 1.845 . . . . 0.0 112.89 -161.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -76.94 -22.68 52.91 Favored 'General case' 0 N--CA 1.454 -0.245 0 O-C-N 117.609 -3.182 . . . . 0.0 117.863 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 79.6 p -109.85 147.41 33.38 Favored 'General case' 0 N--CA 1.447 -0.621 0 O-C-N 128.393 3.558 . . . . 0.0 117.032 170.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . 0.294 20.0 mtmt -125.73 151.8 71.37 Favored Pre-proline 0 N--CA 1.455 -0.197 0 CA-C-O 114.745 -2.55 . . . . 0.0 112.715 173.405 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -70.99 150.7 61.19 Favored 'Trans proline' 0 N--CA 1.453 -0.907 1 O-C-N 128.964 4.139 . . . . 0.0 111.586 165.14 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.406 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . . . -82.08 134.12 49.98 Favored Pre-proline 0 N--CA 1.445 -0.686 0 C-N-CA 127.135 2.174 . . . . 0.0 113.725 175.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 12' ' ' ALA . 24.1 Cg_exo -63.86 158.8 45.05 Favored 'Trans proline' 0 N--CA 1.443 -1.476 1 C-N-CA 127.015 5.143 . . . . 0.0 111.394 172.584 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 m -135.97 155.97 49.46 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 125.283 1.433 . . . . 0.0 111.791 -163.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -75.33 -33.58 61.15 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 117.191 2.293 . . . . 0.0 117.191 -172.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -57.77 -14.39 5.75 Favored 'General case' 0 N--CA 1.44 -0.932 1 O-C-N 114.574 -5.079 . . . . 0.0 116.756 153.475 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 48.1 m-70 -135.14 18.64 3.43 Favored 'General case' 0 N--CA 1.444 -0.733 0 O-C-N 125.956 2.035 . . . . 0.0 114.679 -159.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.9 t -138.3 120.16 15.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 O-C-N 117.152 -3.468 . . . . 0.0 107.697 171.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.442 ' O ' ' CD2' ' A' ' 39' ' ' PHE . 23.8 m-85 -153.78 150.64 28.68 Favored 'General case' 0 N--CA 1.455 -0.213 0 CA-C-O 114.441 -2.695 . . . . 0.0 111.569 -170.244 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.515 ' HB2' ' HA ' ' A' ' 38' ' ' ILE . . . -141.28 158.37 43.98 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 118.195 2.665 . . . . 0.0 118.195 -161.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -153.62 141.37 20.03 Favored 'General case' 0 CA--C 1.518 -0.269 0 C-N-CA 126.411 1.884 . . . . 0.0 112.356 -159.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 132.66 157.35 8.49 Favored Glycine 0 N--CA 1.447 -0.614 1 C-N-CA 130.874 4.083 . . . . 0.0 116.282 -174.272 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -63.46 -20.18 65.36 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 118.661 2.837 . . . . 0.0 118.661 -173.264 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.79 8.39 0.55 Allowed Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 128.821 3.105 . . . . 0.0 117.088 162.015 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 75.9 mt -108.75 10.25 26.8 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-O 116.294 -1.812 . . . . 0.0 109.747 160.317 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 91.7 t -139.47 -29.96 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 CA-C-N 121.959 2.163 . . . . 0.0 113.213 -174.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 26.9 ttmt -164.5 138.21 5.17 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 119.508 -1.995 . . . . 0.0 107.508 171.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 t -132.33 136.22 56.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.458 0 O-C-N 126.387 2.305 . . . . 0.0 109.699 -174.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.434 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 66.9 m-85 -127.86 -172.24 2.63 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 122.148 2.249 . . . . 0.0 112.592 -163.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -88.01 -54.74 4.07 Favored 'General case' 0 N--CA 1.448 -0.569 0 O-C-N 117.832 -3.042 . . . . 0.0 115.928 177.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 69.0 m-80 -97.91 8.28 44.99 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 115.64 1.718 . . . . 0.0 115.64 174.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . 0.259 . . -126.27 80.96 68.0 Favored Pre-proline 0 CA--C 1.516 -0.334 0 C-N-CA 125.614 1.566 . . . . 0.0 111.468 174.325 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -61.61 123.63 13.08 Favored 'Trans proline' 0 N--CA 1.445 -1.334 0 CA-C-O 122.903 1.126 . . . . 0.0 111.649 176.257 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.63 150.72 23.71 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 112.689 -2.05 . . . . 0.0 111.483 -164.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -129.66 153.89 47.67 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 127.514 2.325 . . . . 0.0 114.536 -162.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -164.48 158.84 18.75 Favored 'General case' 0 N--CA 1.446 -0.66 0 O-C-N 121.09 -1.006 . . . . 0.0 111.491 172.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 7.2 m -129.56 115.11 16.93 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 113.36 -1.745 . . . . 0.0 110.529 -154.349 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.515 ' HA ' ' HB2' ' A' ' 20' ' ' ALA . 15.5 mt -82.2 98.77 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 O-C-N 128.553 3.658 . . . . 0.0 108.979 178.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.442 ' CD2' ' O ' ' A' ' 19' ' ' TYR 0.328 47.3 p90 -76.94 105.12 7.81 Favored 'General case' 0 N--CA 1.451 -0.424 0 O-C-N 118.339 -2.726 . . . . 0.0 113.327 170.915 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . 0.264 . . -90.03 134.27 34.34 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 127.339 2.256 . . . . 0.0 116.674 -176.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 46.3 t -133.27 143.34 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 C-N-CA 126.776 2.03 . . . . 0.0 106.673 160.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.09 -81.22 0.02 OUTLIER 'General case' 0 N--CA 1.443 -0.795 0 O-C-N 117.846 -3.034 . . . . 0.0 114.476 161.611 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 19.1 p -161.32 -41.12 0.04 OUTLIER 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 128.436 2.695 . . . . 0.0 111.393 -169.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -90.62 52.16 2.14 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 121.927 2.149 . . . . 0.0 113.254 -167.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 71.81 -66.2 1.12 Allowed Glycine 0 C--N 1.341 0.848 0 CA-C-O 118.249 -1.306 . . . . 0.0 115.782 174.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 70.8 t -56.38 129.51 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 O-C-N 125.54 1.377 . . . . 0.0 111.974 178.303 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -36.91 164.83 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 130.284 3.434 . . . . 0.0 116.192 163.378 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . 0.254 7.3 mmm180 -66.16 101.67 0.74 Allowed 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 114.611 1.337 . . . . 0.0 114.611 175.232 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 61.8 p -79.37 2.76 20.48 Favored 'General case' 0 N--CA 1.449 -0.515 1 C-N-CA 133.464 4.705 . . . . 0.0 114.741 178.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -155.83 -174.72 5.08 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 130.014 3.326 . . . . 0.0 113.721 158.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -154.04 -176.45 26.41 Favored Glycine 0 CA--C 1.521 0.425 0 CA-C-O 124.741 2.301 . . . . 0.0 115.797 -141.68 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.71 14.35 67.31 Favored Glycine 0 C--N 1.336 0.549 0 O-C-N 117.462 -3.375 . . . . 0.0 112.789 -170.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -60.69 123.55 74.95 Favored Pre-proline 0 N--CA 1.446 -0.672 0 CA-C-N 123.7 3.75 . . . . 0.0 106.98 175.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -83.85 153.77 13.17 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 CA-C-N 122.468 1.917 . . . . 0.0 116.294 -162.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -142.95 156.29 44.86 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-O 126.35 2.976 . . . . 0.0 110.14 -157.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -144.11 153.25 41.96 Favored 'General case' 0 N--CA 1.448 -0.53 0 O-C-N 118.671 -2.518 . . . . 0.0 109.989 161.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.413 HG22 HG22 ' A' ' 95' ' ' VAL . 92.0 t -133.81 108.54 11.86 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.96 0 C-N-CA 129.789 3.235 . . . . 0.0 104.052 169.545 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -117.12 133.87 55.47 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 126.833 2.053 . . . . 0.0 112.287 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . 0.275 3.4 mp -124.06 144.9 32.24 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 C-N-CA 125.848 1.659 . . . . 0.0 113.94 -167.405 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 53.0 m-80 -118.23 140.41 49.84 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 114.217 -2.802 . . . . 0.0 110.061 174.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.47 -169.51 14.31 Favored Glycine 0 CA--C 1.526 0.774 0 CA-C-N 121.558 1.981 . . . . 0.0 111.68 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . 0.304 19.2 Cg_endo -60.18 130.28 33.6 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 N-CA-C 114.96 1.1 . . . . 0.0 114.96 -179.107 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.27 8.7 t0 52.79 -109.29 0.46 Allowed 'General case' 0 N--CA 1.453 -0.287 0 CA-C-O 114.908 -2.472 . . . . 0.0 113.275 177.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.11 -10.12 77.58 Favored Glycine 0 CA--C 1.523 0.569 0 O-C-N 126.273 2.233 . . . . 0.0 115.341 -176.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 88.0 mt -71.87 100.97 2.53 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 124.161 0.984 . . . . 0.0 110.213 -170.078 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 51.5 t -133.56 126.57 51.93 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 O-C-N 119.347 -2.096 . . . . 0.0 105.432 164.228 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 9.5 t -133.51 150.7 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.155 0 CA-C-N 113.193 -1.821 . . . . 0.0 106.843 -165.287 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.269 2.4 p30 -117.74 137.8 52.46 Favored 'General case' 0 N--CA 1.439 -0.985 0 O-C-N 118.979 -2.326 . . . . 0.0 112.717 148.492 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.21 158.97 22.09 Favored 'General case' 0 N--CA 1.444 -0.738 0 O-C-N 126.277 2.235 . . . . 0.0 112.439 -174.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 38.9 mmtm -90.33 103.13 15.84 Favored 'General case' 0 N--CA 1.447 -0.609 0 O-C-N 120.265 -1.522 . . . . 0.0 112.719 -172.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 54.9 t -71.27 135.48 27.9 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.662 172.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 54.6 m -123.91 137.87 54.56 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 124.735 1.214 . . . . 0.0 112.033 162.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 48.5 t0 -78.02 121.38 24.15 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 124.161 1.934 . . . . 0.0 111.94 169.255 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 -76.2 -7.5 54.98 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 112.228 -2.26 . . . . 0.0 115.088 -177.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 4.7 m120 59.85 25.95 15.1 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 129.655 3.182 . . . . 0.0 114.248 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 42.7 p30 -134.25 -6.84 2.63 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 129.194 2.998 . . . . 0.0 112.903 -175.257 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 103.29 15.6 22.96 Favored Glycine 0 C--N 1.336 0.555 1 C-N-CA 133.41 5.291 . . . . 0.0 114.288 -172.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 27.1 p -140.69 165.24 28.03 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 122.505 3.152 . . . . 0.0 108.791 177.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 67.4 m-85 -135.88 125.12 24.62 Favored 'General case' 0 N--CA 1.447 -0.579 0 N-CA-C 104.823 -2.288 . . . . 0.0 104.823 -166.2 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -96.68 129.95 10.08 Favored Glycine 0 C--N 1.336 0.575 0 C-N-CA 129.597 3.475 . . . . 0.0 107.165 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.8 t -108.68 128.21 64.58 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 1 CA-C-O 110.811 -4.423 . . . . 0.0 112.892 172.253 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.2 p -127.54 142.27 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 123.915 3.052 . . . . 0.0 115.666 172.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -165.03 160.43 18.93 Favored 'General case' 0 N--CA 1.449 -0.491 0 O-C-N 117.096 -3.502 . . . . 0.0 112.947 -173.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . 0.465 42.5 p30 -137.77 148.32 45.45 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 128.437 2.695 . . . . 0.0 114.347 -168.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -125.28 113.08 26.01 Favored Pre-proline 0 N--CA 1.445 -0.708 0 C-N-CA 128.26 2.624 . . . . 0.0 112.025 -171.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.258 59.0 Cg_endo -76.04 12.91 1.37 Allowed 'Trans proline' 0 N--CA 1.441 -1.611 0 O-C-N 125.186 2.15 . . . . 0.0 113.359 177.778 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.8 m -140.62 141.28 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 115.579 1.696 . . . . 0.0 115.579 -151.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -63.96 114.17 3.94 Favored 'General case' 0 N--CA 1.447 -0.625 0 O-C-N 117.329 -3.357 . . . . 0.0 110.119 144.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 163.07 -155.43 26.77 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 125.317 2.621 . . . . 0.0 117.561 -169.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 5.0 t30 -135.81 121.88 20.14 Favored 'General case' 0 N--CA 1.444 -0.766 0 C-N-CA 127.278 2.231 . . . . 0.0 107.432 -167.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . 0.25 7.3 m-85 -87.48 143.09 27.39 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 123.298 0.639 . . . . 0.0 112.65 158.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -127.55 123.65 36.3 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-O 124.376 2.036 . . . . 0.0 107.999 -175.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . 0.344 3.3 t -109.46 135.14 49.31 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 N-CA-C 117.519 2.414 . . . . 0.0 117.519 -164.81 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -136.57 128.51 29.36 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 131.494 3.917 . . . . 0.0 108.373 179.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.413 HG22 HG22 ' A' ' 57' ' ' VAL . 58.2 t -118.12 152.59 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 CA-C-O 123.677 1.703 . . . . 0.0 108.374 -173.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.7 p -151.15 152.0 32.74 Favored 'General case' 0 N--CA 1.441 -0.915 0 O-C-N 120.411 -1.431 . . . . 0.0 112.952 -177.085 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 9.4 mp -137.3 94.9 2.99 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 104.351 -2.463 . . . . 0.0 104.351 -153.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . 0.277 25.3 ttm-85 49.2 43.8 22.87 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 112.571 -2.104 . . . . 0.0 110.691 -162.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 74.31 -13.29 4.85 Favored Glycine 0 CA--C 1.522 0.489 0 CA-C-O 114.681 -3.288 . . . . 0.0 116.132 -168.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 72.6 m-20 -74.25 126.83 88.68 Favored Pre-proline 0 N--CA 1.451 -0.398 0 CA-C-N 122.534 3.167 . . . . 0.0 119.072 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.457 ' C ' HG23 ' A' ' 102' ' ' ILE . 61.4 Cg_endo -74.29 172.11 16.7 Favored 'Trans proline' 0 N--CA 1.453 -0.885 1 C-N-CA 127.451 5.434 . . . . 0.0 106.863 -177.468 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.572 HG13 ' HG3' ' A' ' 105' ' ' MET . 27.4 pt -143.87 177.61 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 O-C-N 118.346 -2.721 . . . . 0.0 107.705 -164.388 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 38.4 mttm -80.71 159.81 25.15 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 128.678 2.791 . . . . 0.0 111.191 -169.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 15.2 m120 54.2 43.89 29.93 Favored 'General case' 0 C--O 1.224 -0.285 0 N-CA-C 117.57 2.433 . . . . 0.0 117.57 176.25 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' MET . . . . . 0.572 ' HG3' HG13 ' A' ' 102' ' ' ILE . 6.9 mmt -138.55 139.52 24.91 Favored Pre-proline 0 N--CA 1.444 -0.728 0 C-N-CA 129.812 3.245 . . . . 0.0 107.956 -163.138 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -79.06 165.05 82.37 Favored 'Cis proline' 0 N--CA 1.447 -1.215 0 CA-C-N 122.78 2.029 . . . . 0.0 109.328 1.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . 0.276 2.2 pp -114.46 159.36 14.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 C-N-CA 125.366 1.466 . . . . 0.0 114.081 171.227 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -122.59 134.44 54.52 Favored 'General case' 0 N--CA 1.449 -0.502 0 O-C-N 118.588 -2.57 . . . . 0.0 111.899 -167.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 1.7 t -129.53 121.36 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-O 125.695 2.664 . . . . 0.0 112.615 -177.252 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -55.72 130.29 42.67 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 112.222 -2.263 . . . . 0.0 114.155 170.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 48.7 m -121.82 153.82 37.85 Favored 'General case' 0 N--CA 1.445 -0.699 0 O-C-N 123.994 0.809 . . . . 0.0 110.461 176.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.434 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 10.4 tp -150.52 138.06 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.773 0 C-N-CA 127.602 2.361 . . . . 0.0 113.486 165.367 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -68.84 43.29 0.04 OUTLIER 'General case' 0 N--CA 1.444 -0.768 1 CA-C-O 129.778 4.609 . . . . 0.0 115.584 -166.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.616 1 O-C-N 114.68 -5.013 . . . . 0.0 112.116 -175.359 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 42.2 tpp . . . . . 0 N--CA 1.473 0.683 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -79.05 -19.48 51.28 Favored 'General case' 0 N--CA 1.44 -0.932 0 CA-C-O 117.113 -1.423 . . . . 0.0 111.758 -177.68 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 8.8 t60 -79.23 106.98 11.65 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 122.086 2.221 . . . . 0.0 108.132 -174.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 9.7 t-160 -161.37 109.86 1.53 Allowed 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 123.513 1.625 . . . . 0.0 108.42 -167.323 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.581 ' CE1' ' H ' ' A' ' 51' ' ' GLY 0.279 81.0 m-70 -60.77 127.41 31.51 Favored 'General case' 0 C--N 1.329 -0.288 0 O-C-N 120.764 -1.21 . . . . 0.0 113.995 172.906 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 15.6 t60 -139.73 -10.95 1.18 Allowed 'General case' 0 N--CA 1.452 -0.327 0 O-C-N 118.972 -2.33 . . . . 0.0 107.9 -175.268 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . 0.252 32.4 m170 -147.78 168.19 22.78 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.702 -164.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -69.5 -45.02 69.89 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 117.377 -1.297 . . . . 0.0 113.054 163.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.7 m -103.33 144.33 31.5 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 119.702 1.137 . . . . 0.0 111.396 -166.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 49.9 mtmt -127.99 161.63 54.72 Favored Pre-proline 0 N--CA 1.454 -0.266 0 C-N-CA 125.024 1.33 . . . . 0.0 113.236 -177.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . 0.29 40.3 Cg_endo -83.1 147.13 12.95 Favored 'Trans proline' 0 N--CA 1.453 -0.862 1 C-N-CA 126.729 4.953 . . . . 0.0 118.429 166.666 . . . . . . . . 3 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.479 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . . . -77.85 129.22 76.93 Favored Pre-proline 0 CA--C 1.516 -0.347 0 N-CA-C 118.433 2.753 . . . . 0.0 118.433 -178.136 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.479 ' HD3' ' HA ' ' A' ' 12' ' ' ALA . 65.8 Cg_exo -62.81 150.6 87.73 Favored 'Trans proline' 0 N--CA 1.448 -1.162 1 C-N-CA 126.027 4.485 . . . . 0.0 110.775 169.84 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.8 t -129.64 152.13 49.49 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 117.159 2.281 . . . . 0.0 117.159 -170.03 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.33 -36.18 79.43 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 120.379 -1.451 . . . . 0.0 113.337 179.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 59.7 mm-40 -54.93 -31.01 59.95 Favored 'General case' 0 C--N 1.349 0.554 0 CA-C-N 124.32 3.236 . . . . 0.0 112.554 163.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . 0.446 ' CD2' ' HA ' ' A' ' 43' ' ' THR . 55.0 m-70 -125.23 19.37 8.25 Favored 'General case' 0 N--CA 1.445 -0.688 0 CA-C-O 125.627 2.632 . . . . 0.0 113.711 -154.153 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 7.1 t -147.38 122.69 10.28 Favored 'General case' 0 C--N 1.347 0.48 1 O-C-N 113.615 -5.678 . . . . 0.0 113.474 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 37.1 m-85 -160.36 151.13 18.7 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-O 116.185 -1.865 . . . . 0.0 110.235 -164.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.408 ' HA ' ' O ' ' A' ' 37' ' ' THR . . . -131.52 153.23 50.03 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-O 122.565 1.174 . . . . 0.0 109.78 -167.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -159.12 147.96 18.32 Favored 'General case' 0 N--CA 1.447 -0.609 0 C-N-CA 125.93 1.692 . . . . 0.0 110.348 -168.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.84 -179.87 16.02 Favored Glycine 0 C--N 1.338 0.666 0 C-N-CA 129.668 3.509 . . . . 0.0 117.339 175.097 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . 0.588 1.9 tt0 -62.23 -27.57 69.09 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 120.15 3.389 . . . . 0.0 120.15 -168.397 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.406 ' HA2' ' HB1' ' A' ' 34' ' ' ALA . . . -61.03 0.13 1.29 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 118.827 2.291 . . . . 0.0 118.827 160.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 49.2 mt -113.85 13.78 18.46 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.493 1.117 . . . . 0.0 111.463 168.205 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.9 t -129.47 -55.47 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 CA-C-O 115.839 -2.029 . . . . 0.0 113.334 178.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -150.16 128.25 11.94 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 116.638 -1.649 . . . . 0.0 111.777 -177.274 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 52.0 t -137.58 132.24 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 O-C-N 127.855 3.222 . . . . 0.0 113.255 -162.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.467 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 5.9 m-85 -126.63 -168.42 1.86 Allowed 'General case' 0 C--N 1.334 -0.065 0 CA-C-O 123.694 1.711 . . . . 0.0 112.453 -164.595 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -100.46 -56.32 2.38 Favored 'General case' 0 N--CA 1.449 -0.514 0 O-C-N 119.133 -2.229 . . . . 0.0 111.358 -166.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 40.0 m-80 -100.08 8.09 44.19 Favored 'General case' 0 N--CA 1.451 -0.403 0 O-C-N 119.027 -2.295 . . . . 0.0 111.678 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -121.22 93.14 48.81 Favored Pre-proline 0 N--CA 1.448 -0.57 0 O-C-N 119.423 -2.048 . . . . 0.0 108.197 167.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -62.11 128.02 22.87 Favored 'Trans proline' 0 N--CA 1.453 -0.901 1 C-N-CA 127.393 5.395 . . . . 0.0 113.465 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.406 ' HB1' ' HA2' ' A' ' 24' ' ' GLY . . . -92.47 152.47 19.66 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 128.257 2.623 . . . . 0.0 117.232 177.409 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 29.1 mt-10 -143.32 148.92 37.05 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 128.942 3.901 . . . . 0.0 110.265 -161.166 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 20.7 p90 -168.77 165.75 11.77 Favored 'General case' 0 CA--C 1.518 -0.284 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 -178.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 20' ' ' ALA . 57.7 m -133.63 122.55 23.63 Favored 'General case' 0 N--CA 1.448 -0.548 0 O-C-N 127.887 3.242 . . . . 0.0 114.173 -155.262 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.4 ' HB ' ' HB2' ' A' ' 79' ' ' TYR . 4.0 mt -86.03 101.17 10.0 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-O 114.866 -2.493 . . . . 0.0 105.638 177.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.484 ' HA ' HG22 ' A' ' 78' ' ' THR . 12.7 p90 -74.58 112.23 10.56 Favored 'General case' 0 N--CA 1.446 -0.634 0 O-C-N 124.917 1.386 . . . . 0.0 112.656 162.086 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . 0.252 . . -102.3 135.13 44.46 Favored 'General case' 0 C--O 1.222 -0.395 0 C-N-CA 126.151 1.78 . . . . 0.0 115.266 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.6 t -125.29 149.17 29.79 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 130.661 3.584 . . . . 0.0 108.961 162.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -74.96 -62.41 1.56 Allowed 'General case' 0 N--CA 1.441 -0.903 0 O-C-N 119.498 -2.001 . . . . 0.0 112.007 173.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.446 ' HA ' ' CD2' ' A' ' 17' ' ' HIS . 8.2 p -173.99 -25.83 0.01 OUTLIER 'General case' 0 C--O 1.218 -0.574 1 C-N-CA 133.158 4.583 . . . . 0.0 110.349 -173.857 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 71.4 mmtt -93.67 27.43 2.68 Favored 'General case' 0 N--CA 1.445 -0.691 0 O-C-N 118.529 -2.607 . . . . 0.0 112.311 -167.085 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 62.95 -32.3 0.07 OUTLIER Glycine 0 N--CA 1.444 -0.802 1 N-CA-C 123.404 4.122 . . . . 0.0 123.404 178.428 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 90.2 t -78.4 138.67 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.845 0 CA-C-N 119.196 1.498 . . . . 0.0 111.881 167.232 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -50.83 166.77 0.08 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.901 1.376 . . . . 0.0 113.397 -177.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 11.1 mmm180 -62.29 122.66 16.19 Favored 'General case' 0 C--O 1.22 -0.468 0 CA-C-N 121.947 2.158 . . . . 0.0 113.096 -172.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 72.9 p -100.38 13.49 34.28 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-O 126.756 3.17 . . . . 0.0 113.193 -161.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.8 p30 -159.66 175.14 13.55 Favored 'General case' 0 N--CA 1.45 -0.454 2 C-N-CA 131.861 4.064 . . . . 0.0 109.534 160.021 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.581 ' H ' ' CE1' ' A' ' 5' ' ' HIS . . . -127.5 -178.34 15.28 Favored Glycine 0 C--N 1.343 0.94 0 N-CA-C 118.871 2.308 . . . . 0.0 118.871 -159.093 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.45 20.74 68.46 Favored Glycine 0 C--N 1.346 1.134 0 CA-C-O 114.094 -3.614 . . . . 0.0 110.597 172.349 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -70.21 145.94 94.11 Favored Pre-proline 0 N--CA 1.445 -0.695 0 CA-C-N 123.807 3.804 . . . . 0.0 112.858 170.357 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -76.08 119.26 5.27 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 N-CA-C 117.307 2.003 . . . . 0.0 117.307 -178.172 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -131.25 165.43 23.4 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-O 124.04 1.876 . . . . 0.0 115.891 168.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -160.64 147.06 15.25 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 113.51 -1.677 . . . . 0.0 110.233 -171.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 2.4 t -131.04 123.48 53.95 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.754 0 C-N-CA 127.984 2.514 . . . . 0.0 106.769 176.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -121.44 131.63 54.27 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 113.927 -1.488 . . . . 0.0 109.023 -170.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.6 mp -132.4 132.86 60.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 -163.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 24.8 m120 -113.78 129.73 56.54 Favored 'General case' 0 N--CA 1.442 -0.841 0 O-C-N 125.396 1.685 . . . . 0.0 108.287 151.451 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -96.75 -164.18 32.77 Favored Glycine 0 C--N 1.345 1.045 0 CA-C-O 123.379 1.544 . . . . 0.0 111.273 151.524 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . 0.282 84.2 Cg_endo -64.28 124.05 12.78 Favored 'Trans proline' 0 N--CA 1.448 -1.171 0 C-N-CA 123.514 2.809 . . . . 0.0 118.379 176.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 38.13 -101.93 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.533 1 C-N-CA 132.217 4.207 . . . . 0.0 115.298 -174.425 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -53.36 -23.29 18.06 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 125.459 1.504 . . . . 0.0 113.988 -172.258 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . 0.311 95.5 mt -76.54 64.38 2.2 Favored 'General case' 0 N--CA 1.44 -0.933 0 C-N-CA 130.182 3.393 . . . . 0.0 118.316 -179.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 87.1 t -72.08 128.02 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 CA-C-N 113.515 -1.675 . . . . 0.0 107.61 151.172 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 87.9 t -135.54 143.84 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 125.922 1.689 . . . . 0.0 108.977 -173.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.319 35.5 t0 -129.52 125.99 37.58 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-O 115.337 -2.268 . . . . 0.0 110.435 175.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.25 162.23 19.24 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 125.453 1.72 . . . . 0.0 114.644 176.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -103.22 123.2 46.28 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 -177.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.5 t -100.68 137.05 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 O-C-N 128.595 3.684 . . . . 0.0 109.905 -175.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . 0.25 53.1 m -134.92 136.54 42.39 Favored 'General case' 0 N--CA 1.445 -0.676 0 O-C-N 117.912 -2.993 . . . . 0.0 109.371 -179.425 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 59.7 t0 -62.66 123.98 19.8 Favored 'General case' 0 N--CA 1.448 -0.559 0 O-C-N 120.497 -1.377 . . . . 0.0 112.004 164.255 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -84.83 -10.41 57.19 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-O 116.377 -1.773 . . . . 0.0 115.264 174.069 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . 0.374 1.4 m120 74.21 36.95 0.63 Allowed 'General case' 0 C--O 1.219 -0.515 0 CA-C-O 115.988 -1.958 . . . . 0.0 113.768 172.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 20.0 p30 -154.58 -10.98 0.13 Allowed 'General case' 0 N--CA 1.449 -0.476 0 O-C-N 126.042 2.089 . . . . 0.0 114.676 -167.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 130.85 -25.72 4.13 Favored Glycine 0 CA--C 1.522 0.511 0 CA-C-N 122.852 2.569 . . . . 0.0 113.63 -158.153 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.484 HG22 ' HA ' ' A' ' 39' ' ' PHE . 2.8 p -136.81 171.77 14.0 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 118.252 2.686 . . . . 0.0 118.252 -157.361 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.4 ' HB2' ' HB ' ' A' ' 38' ' ' ILE . 34.6 m-85 -135.94 113.61 10.98 Favored 'General case' 0 N--CA 1.433 -1.282 0 C-N-CA 126.032 1.733 . . . . 0.0 109.487 -172.035 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -86.16 146.48 21.13 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-O 124.146 1.97 . . . . 0.0 112.723 176.282 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 35' ' ' GLU . 41.0 t -136.4 130.0 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 C-N-CA 128.113 2.565 . . . . 0.0 109.032 -167.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 14.7 p -134.34 122.09 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.429 0 C-N-CA 125.836 1.654 . . . . 0.0 110.401 -168.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.435 ' HE2' ' CD2' ' A' ' 91' ' ' TYR 0.257 0.1 OUTLIER -154.44 175.38 13.65 Favored 'General case' 0 N--CA 1.447 -0.597 0 O-C-N 118.975 -2.328 . . . . 0.0 111.91 -177.4 . . . . . . . . 4 4 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 5.2 p30 -151.76 162.96 40.17 Favored 'General case' 0 N--CA 1.448 -0.556 1 O-C-N 116.268 -4.02 . . . . 0.0 109.708 -174.107 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.62 ' HB2' ' CE2' ' A' ' 91' ' ' TYR . . . -134.46 110.89 11.53 Favored Pre-proline 0 N--CA 1.446 -0.637 1 C-N-CA 133.924 4.89 . . . . 0.0 113.103 -172.406 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -75.77 8.57 2.65 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 123.822 3.015 . . . . 0.0 114.132 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 2.5 m -134.03 138.15 50.83 Favored 'Isoleucine or valine' 0 C--O 1.238 0.46 0 C-N-CA 129.551 3.14 . . . . 0.0 115.855 -160.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 17.3 tt0 -59.81 109.31 0.9 Allowed 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 139.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 176.71 -157.21 22.34 Favored Glycine 0 C--N 1.344 0.975 0 CA-C-O 117.675 -1.625 . . . . 0.0 116.184 -173.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -133.12 139.21 46.98 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 127.623 2.369 . . . . 0.0 108.688 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . 0.62 ' CE2' ' HB2' ' A' ' 85' ' ' ALA . 3.0 m-30 -105.96 145.19 31.65 Favored 'General case' 0 N--CA 1.446 -0.642 0 O-C-N 119.747 -1.845 . . . . 0.0 110.627 161.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -126.55 116.96 21.87 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.843 -2.28 . . . . 0.0 104.843 -176.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 61.1 t -124.29 135.83 62.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 C-N-CA 125.417 1.487 . . . . 0.0 110.581 -149.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -136.32 133.68 37.13 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 105.447 -2.057 . . . . 0.0 105.447 -172.382 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 94.5 t -114.0 137.78 46.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 O-C-N 119.16 -2.212 . . . . 0.0 113.923 172.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 35.9 p -143.17 165.8 26.43 Favored 'General case' 0 CA--C 1.516 -0.349 0 O-C-N 120.614 -1.304 . . . . 0.0 113.609 -164.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . 0.26 7.4 tt -150.15 99.9 2.85 Favored 'General case' 0 C--N 1.344 0.368 0 N-CA-C 101.668 -3.456 . . . . 0.0 101.668 -146.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 8.7 ttm180 52.87 36.87 22.73 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 119.758 1.163 . . . . 0.0 111.471 -150.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.37 0.5 38.14 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-O 115.271 -2.96 . . . . 0.0 109.8 -178.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -94.81 142.93 25.35 Favored Pre-proline 0 N--CA 1.441 -0.877 0 CA-C-N 121.148 2.474 . . . . 0.0 109.868 -176.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -79.06 158.98 27.04 Favored 'Trans proline' 0 C--O 1.218 -0.499 0 CA-C-O 126.239 2.516 . . . . 0.0 113.459 -177.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 29.2 pt -142.92 -171.46 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 CA-C-N 109.386 -3.552 . . . . 0.0 113.32 -171.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 31.0 mtpt -93.79 157.72 16.01 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 125.856 1.662 . . . . 0.0 112.341 -158.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . 0.26 30.9 m120 50.19 34.1 8.15 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 129.793 3.237 . . . . 0.0 112.785 178.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 6.0 mmt -130.57 151.29 78.43 Favored Pre-proline 0 N--CA 1.444 -0.769 1 C-N-CA 134.551 5.141 . . . . 0.0 106.284 176.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -76.69 163.13 90.37 Favored 'Cis proline' 0 N--CA 1.45 -1.037 0 CA-C-N 126.432 3.333 . . . . 0.0 107.336 -2.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . 0.536 ' C ' HD12 ' A' ' 107' ' ' ILE 0.376 1.3 pp -127.04 167.54 21.66 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.409 0 N-CA-C 118.14 2.644 . . . . 0.0 118.14 163.743 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -106.57 142.13 36.72 Favored 'General case' 0 N--CA 1.449 -0.496 0 O-C-N 118.159 -2.838 . . . . 0.0 118.019 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 61.5 t -123.12 124.14 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 127.018 2.127 . . . . 0.0 109.977 -179.303 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -80.43 128.0 33.07 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-O 118.575 -0.726 . . . . 0.0 111.424 165.47 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 99.5 m -115.68 140.4 49.23 Favored 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 128.247 2.619 . . . . 0.0 112.819 -170.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.467 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 98.6 mt -133.85 145.73 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 CA-C-N 121.898 2.135 . . . . 0.0 106.795 177.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -82.19 48.1 1.22 Allowed 'General case' 0 N--CA 1.445 -0.698 0 O-C-N 116.76 -3.712 . . . . 0.0 113.692 -166.28 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.435 -1.391 0 O-C-N 120.575 -1.328 . . . . 0.0 116.111 174.493 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 17.2 tpt . . . . . 0 CA--C 1.531 0.226 0 CA-C-O 120.733 0.301 . . . . 0.0 111.208 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 91.9 m-70 -117.4 2.17 12.44 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 118.248 2.685 . . . . 0.0 118.248 -176.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -74.48 119.41 18.64 Favored 'General case' 0 N--CA 1.431 -1.376 0 O-C-N 118.964 -2.335 . . . . 0.0 115.502 -174.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 28.1 t-80 -166.12 123.88 1.45 Allowed 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 113.506 0.928 . . . . 0.0 113.506 -176.196 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 9.9 m-70 -82.56 131.64 35.21 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-O 118.016 -0.993 . . . . 0.0 112.921 -172.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 -142.49 -31.68 0.52 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 124.236 3.198 . . . . 0.0 112.555 -170.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 32.8 m170 -130.94 155.4 46.85 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 125.869 1.668 . . . . 0.0 114.193 -173.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.72 -48.43 54.6 Favored 'General case' 0 N--CA 1.442 -0.863 0 O-C-N 119.332 -2.105 . . . . 0.0 112.924 178.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 66.8 p -68.67 137.13 53.92 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 122.257 2.299 . . . . 0.0 113.301 166.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 32.3 mtmt -127.85 156.1 76.42 Favored Pre-proline 0 N--CA 1.448 -0.57 0 CA-C-O 115.983 -1.96 . . . . 0.0 114.564 176.09 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo -57.37 164.07 7.5 Favored 'Trans proline' 0 N--CA 1.445 -1.348 0 C-N-CA 124.582 3.521 . . . . 0.0 113.26 160.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -119.17 138.41 26.25 Favored Pre-proline 0 CA--C 1.512 -0.491 0 C-N-CA 126.106 1.762 . . . . 0.0 110.474 -178.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_exo -65.47 169.49 12.54 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.155 1.903 . . . . 0.0 114.156 170.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -145.74 168.02 21.74 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 125.547 1.539 . . . . 0.0 113.131 -171.456 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.44 -43.78 72.62 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 117.593 2.442 . . . . 0.0 117.593 179.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 55.6 mm-40 -60.65 -20.42 60.79 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.5 1.52 . . . . 0.0 111.353 167.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . 0.444 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . 68.6 m-70 -126.48 18.54 7.5 Favored 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 129.322 3.049 . . . . 0.0 112.757 -158.682 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.9 t -141.56 126.3 18.02 Favored 'General case' 0 N--CA 1.444 -0.729 0 O-C-N 119.856 -1.777 . . . . 0.0 106.476 166.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -153.86 157.85 39.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 130.632 3.573 . . . . 0.0 110.679 -175.306 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -141.92 148.77 39.22 Favored 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 127.734 2.413 . . . . 0.0 116.718 -165.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -144.08 143.31 31.1 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 113.969 -1.469 . . . . 0.0 109.33 -171.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 138.98 173.4 12.98 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 118.625 2.21 . . . . 0.0 118.625 169.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -68.87 -24.82 64.38 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 120.202 -1.763 . . . . 0.0 111.973 -168.354 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.18 7.35 0.56 Allowed Glycine 0 C--N 1.339 0.697 0 C-N-CA 129.779 3.562 . . . . 0.0 116.954 171.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 96.6 mt -116.98 -2.59 11.72 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-O 114.185 -2.817 . . . . 0.0 110.221 172.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 t -129.8 -55.05 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 CA-C-N 122.832 2.56 . . . . 0.0 109.156 -168.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 23.8 pttt -145.36 120.62 10.21 Favored 'General case' 0 C--O 1.238 0.46 0 O-C-N 118.873 -2.392 . . . . 0.0 112.282 -172.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 93.9 t -125.85 139.54 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 119.348 -2.095 . . . . 0.0 105.466 -172.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.443 ' HA ' ' O ' ' A' ' 112' ' ' ILE . 42.5 m-85 -127.79 -163.43 1.26 Allowed 'General case' 0 N--CA 1.447 -0.621 0 CA-C-O 115.099 -2.381 . . . . 0.0 110.215 -178.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -103.14 -50.52 3.47 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 120.803 1.638 . . . . 0.0 114.572 -170.072 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 19.1 m-80 -109.2 6.01 24.34 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 130.27 3.428 . . . . 0.0 111.028 -179.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -122.06 85.82 46.34 Favored Pre-proline 0 C--O 1.224 -0.252 0 C-N-CA 126.693 1.997 . . . . 0.0 111.73 165.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -55.93 146.56 67.62 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 C-N-CA 117.244 -1.37 . . . . 0.0 115.091 176.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -93.76 162.64 13.85 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 119.044 2.979 . . . . 0.0 119.044 170.3 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -136.85 147.77 46.71 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 117.612 2.449 . . . . 0.0 117.612 -174.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -157.98 160.81 37.92 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-N 122.182 2.265 . . . . 0.0 107.77 169.443 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 49.2 m -119.18 127.92 53.75 Favored 'General case' 0 N--CA 1.441 -0.909 0 CA-C-O 113.805 -2.997 . . . . 0.0 113.811 -166.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.0 mt -86.39 106.53 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 O-C-N 126.681 2.488 . . . . 0.0 105.548 179.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . 0.474 55.5 p90 -85.34 114.25 22.27 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 117.874 2.546 . . . . 0.0 117.874 175.015 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -119.91 139.04 53.04 Favored 'General case' 0 CA--C 1.517 -0.325 0 CA-C-N 122.85 2.568 . . . . 0.0 113.106 -167.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.444 ' HB ' ' HB3' ' A' ' 17' ' ' HIS . 78.0 t -129.35 143.57 40.78 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 1 C-N-CA 132.236 4.214 . . . . 0.0 111.457 173.414 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -70.03 -82.93 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 126.941 3.258 . . . . 0.0 107.924 173.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 48.9 p -153.44 -21.3 0.14 Allowed 'General case' 0 C--N 1.328 -0.328 2 C-N-CA 134.773 5.229 . . . . 0.0 117.992 -179.394 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 18.4 mmtp -80.5 16.34 1.38 Allowed 'General case' 0 C--N 1.325 -0.49 0 O-C-N 127.789 3.181 . . . . 0.0 116.33 -176.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.62 -56.65 5.03 Favored Glycine 0 C--N 1.345 1.034 0 N-CA-C 120.301 2.88 . . . . 0.0 120.301 -175.34 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 24.5 t -63.68 146.53 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 172.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.76 170.12 0.06 Allowed 'General case' 0 N--CA 1.438 -1.034 0 CA-C-O 121.589 0.709 . . . . 0.0 111.228 177.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.7 mmm180 -68.44 118.39 11.44 Favored 'General case' 0 C--N 1.351 0.659 0 O-C-N 118.261 -2.774 . . . . 0.0 113.564 -175.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 16.0 p -77.88 1.56 20.09 Favored 'General case' 0 N--CA 1.447 -0.591 1 C-N-CA 134.738 5.215 . . . . 0.0 117.733 -171.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 10.0 p30 -161.09 -174.5 4.39 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-N 111.171 -2.74 . . . . 0.0 104.801 163.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -144.2 -170.36 13.56 Favored Glycine 0 CA--C 1.524 0.641 0 C-N-CA 128.462 2.934 . . . . 0.0 117.321 -142.08 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 54.18 46.18 71.47 Favored Glycine 0 C--N 1.337 0.623 0 CA-C-O 123.629 1.683 . . . . 0.0 110.639 178.07 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -86.71 137.88 33.64 Favored Pre-proline 0 N--CA 1.45 -0.449 0 O-C-N 116.688 -3.831 . . . . 0.0 112.157 174.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -68.94 137.18 37.22 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.383 2.722 . . . . 0.0 113.756 -171.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -159.6 150.37 19.37 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 112.217 -2.265 . . . . 0.0 112.924 -165.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -152.34 134.92 15.32 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 118.106 -2.871 . . . . 0.0 113.977 -166.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 4.5 t -129.74 81.62 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 CA-C-N 113.325 -1.761 . . . . 0.0 113.643 -176.273 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -100.53 141.13 33.81 Favored 'General case' 0 CA--C 1.516 -0.354 0 O-C-N 126.023 2.077 . . . . 0.0 110.87 -174.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.5 mt -132.88 147.42 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 CA-C-O 125.01 2.338 . . . . 0.0 108.23 -163.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -116.5 118.83 33.73 Favored 'General case' 0 C--O 1.223 -0.33 0 O-C-N 119.3 -2.125 . . . . 0.0 109.166 166.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -111.31 -158.75 15.3 Favored Glycine 0 N--CA 1.442 -0.948 0 N-CA-C 121.797 3.479 . . . . 0.0 121.797 163.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo -68.52 141.34 50.35 Favored 'Trans proline' 0 N--CA 1.434 -2.017 1 C-N-CA 125.834 4.356 . . . . 0.0 113.339 -177.213 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.368 60.3 m-20 55.79 -125.33 2.06 Favored 'General case' 0 N--CA 1.446 -0.673 0 C-N-CA 126.834 2.054 . . . . 0.0 111.138 -176.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -82.6 8.61 61.55 Favored Glycine 0 CA--C 1.53 1.003 1 O-C-N 114.502 -5.124 . . . . 0.0 119.728 179.144 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.6 mt -76.57 75.96 3.27 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-N 117.882 0.841 . . . . 0.0 110.162 -176.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 1.4 m -58.04 123.31 9.51 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 O-C-N 120.186 -1.571 . . . . 0.0 112.757 134.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 72.8 t -132.63 145.34 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 CA-C-N 122.304 2.32 . . . . 0.0 106.465 -174.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -128.87 131.68 47.67 Favored 'General case' 0 N--CA 1.445 -0.69 0 O-C-N 119.122 -2.236 . . . . 0.0 110.332 172.186 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -102.63 137.37 40.95 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 126.476 1.91 . . . . 0.0 113.752 -165.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.271 37.1 ttpt -81.96 117.46 22.2 Favored 'General case' 0 C--O 1.218 -0.556 0 O-C-N 120.245 -1.535 . . . . 0.0 111.664 -160.05 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -88.48 131.6 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 175.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 67.2 m -131.84 125.96 33.09 Favored 'General case' 0 N--CA 1.452 -0.349 0 O-C-N 125.619 1.824 . . . . 0.0 110.934 172.321 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -66.29 118.52 10.09 Favored 'General case' 0 N--CA 1.44 -0.951 0 C-N-CA 128.153 2.581 . . . . 0.0 110.644 176.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.4 m-20 -79.63 -4.07 49.98 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 119.807 3.262 . . . . 0.0 119.807 175.653 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 68.56 25.66 6.6 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 131.595 3.958 . . . . 0.0 114.008 176.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 43.2 p30 -135.06 -4.69 2.41 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 114.053 -2.879 . . . . 0.0 110.946 -165.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 120.88 -14.34 9.71 Favored Glycine 0 C--N 1.337 0.624 0 C-N-CA 126.847 2.165 . . . . 0.0 111.223 -171.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 p -133.12 165.83 23.86 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 131.388 3.875 . . . . 0.0 113.56 -170.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 16.7 m-85 -131.57 137.57 48.51 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 128.704 2.802 . . . . 0.0 106.671 -174.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -92.21 139.41 14.67 Favored Glycine 0 C--O 1.226 -0.369 0 C-N-CA 128.159 2.79 . . . . 0.0 107.304 174.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 22.8 t -122.83 130.79 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-O 117.119 -1.419 . . . . 0.0 108.633 178.693 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.4 p -135.71 141.85 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 119.696 1.134 . . . . 0.0 112.527 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 7.5 p90 -161.11 169.61 22.05 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 115.902 1.816 . . . . 0.0 115.902 179.194 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 15.2 p30 -139.0 164.79 28.83 Favored 'General case' 0 N--CA 1.449 -0.508 0 O-C-N 118.756 -2.465 . . . . 0.0 117.532 177.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -123.53 112.57 29.35 Favored Pre-proline 0 N--CA 1.448 -0.568 0 O-C-N 125.305 1.628 . . . . 0.0 107.643 -174.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . 0.336 14.9 Cg_endo -66.76 -8.52 21.56 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 N-CA-C 117.57 2.104 . . . . 0.0 117.57 170.382 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 28.4 m -148.08 134.51 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 O-C-N 120.369 -1.457 . . . . 0.0 110.606 -164.568 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -56.39 116.16 2.91 Favored 'General case' 0 N--CA 1.456 -0.169 0 O-C-N 126.195 2.185 . . . . 0.0 112.47 167.026 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 170.29 -166.7 39.89 Favored Glycine 0 CA--C 1.527 0.828 0 CA-C-O 122.306 0.948 . . . . 0.0 112.485 -172.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -106.42 137.75 43.84 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 114.37 1.248 . . . . 0.0 114.37 175.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -103.34 139.29 38.96 Favored 'General case' 0 N--CA 1.445 -0.713 0 C-N-CA 128.634 2.774 . . . . 0.0 110.418 168.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -114.53 119.55 37.21 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 117.164 2.283 . . . . 0.0 117.164 170.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . 0.275 65.2 t -118.1 133.64 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 CA-C-N 112.795 -2.002 . . . . 0.0 111.863 -157.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -130.23 138.95 50.81 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 126.879 2.072 . . . . 0.0 109.087 171.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 85.8 t -114.79 126.48 72.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 C-N-CA 124.856 1.262 . . . . 0.0 113.312 168.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . 0.301 67.0 p -132.8 145.97 51.44 Favored 'General case' 0 N--CA 1.444 -0.767 0 O-C-N 125.423 1.702 . . . . 0.0 114.519 -168.561 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 8.4 tt -136.62 95.8 3.22 Favored 'General case' 0 N--CA 1.447 -0.58 1 O-C-N 116.182 -4.074 . . . . 0.0 107.796 -137.491 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . 0.316 51.4 ttt180 46.0 40.09 6.51 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 125.933 2.778 . . . . 0.0 115.858 -147.644 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 69.15 16.75 71.27 Favored Glycine 0 C--N 1.341 0.818 0 O-C-N 118.318 -2.739 . . . . 0.0 117.838 -175.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -106.57 153.51 40.56 Favored Pre-proline 0 N--CA 1.447 -0.6 0 O-C-N 116.508 -3.937 . . . . 0.0 111.678 165.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_endo -86.53 169.57 8.14 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 124.548 3.499 . . . . 0.0 114.166 -178.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.406 ' HB ' ' H ' ' A' ' 103' ' ' LYS . 11.2 pt -130.8 -173.22 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-N 113.975 -1.466 . . . . 0.0 109.13 176.218 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.406 ' H ' ' HB ' ' A' ' 102' ' ' ILE . 57.1 mttm -67.84 169.59 9.51 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 115.385 1.624 . . . . 0.0 115.385 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 33.3 m120 47.49 28.66 1.2 Allowed 'General case' 0 N--CA 1.447 -0.617 0 O-C-N 116.959 -3.588 . . . . 0.0 118.859 169.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' MET . . . . . . . . . . . . . 12.7 mmt -136.32 146.14 54.83 Favored Pre-proline 0 N--CA 1.444 -0.765 0 C-N-CA 129.128 2.971 . . . . 0.0 109.187 -177.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . 0.272 96.6 Cg_endo -68.07 169.24 55.87 Favored 'Cis proline' 0 N--CA 1.457 -0.63 0 CA-C-N 127.293 3.64 . . . . 0.0 116.232 -4.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 27.2 pt -146.77 161.25 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 O-C-N 126.9 2.625 . . . . 0.0 114.616 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -112.83 131.28 55.77 Favored 'General case' 0 N--CA 1.445 -0.71 0 C-N-CA 127.352 2.261 . . . . 0.0 112.875 -178.439 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 59.0 t -122.98 141.26 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 C-N-CA 126.681 1.992 . . . . 0.0 106.813 -175.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 39.8 mmtm -91.37 138.33 31.67 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 116.335 1.976 . . . . 0.0 116.335 176.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 21.8 m -115.96 126.51 53.95 Favored 'General case' 0 N--CA 1.441 -0.903 0 C-N-CA 129.504 3.122 . . . . 0.0 108.342 -174.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.443 ' O ' ' HA ' ' A' ' 29' ' ' PHE . 15.2 mt -124.64 135.17 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 161.017 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -72.96 56.04 0.42 Allowed 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 118.699 2.851 . . . . 0.0 118.699 -176.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.4 0 O-C-N 117.388 -3.32 . . . . 0.0 117.14 165.975 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 41.3 tpp . . . . . 0 CA--C 1.514 -0.428 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 68.5 m-70 -87.36 4.43 43.05 Favored 'General case' 0 CA--C 1.508 -0.636 0 C-N-CA 125.913 1.685 . . . . 0.0 112.059 173.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 5.3 t60 -88.22 124.43 33.84 Favored 'General case' 0 N--CA 1.445 -0.687 0 O-C-N 116.674 -3.766 . . . . 0.0 113.336 175.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . 0.267 11.5 t60 -172.13 130.95 0.62 Allowed 'General case' 0 N--CA 1.442 -0.861 0 C-N-CA 128.548 2.739 . . . . 0.0 115.177 -168.059 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 77.3 m-70 -95.68 88.12 4.9 Favored 'General case' 0 N--CA 1.438 -1.044 1 C-N-CA 131.747 4.019 . . . . 0.0 107.413 -179.032 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 3.2 t-80 -125.04 0.72 7.93 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 126.52 1.928 . . . . 0.0 115.272 -179.151 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -137.23 153.93 50.27 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-O 114.853 -2.499 . . . . 0.0 108.704 -172.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -90.17 -27.69 19.41 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 124.194 3.179 . . . . 0.0 117.614 177.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 11.3 m -85.12 149.63 25.4 Favored 'General case' 0 C--O 1.245 0.84 0 C-N-CA 129.411 3.085 . . . . 0.0 113.394 165.463 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 54.3 mtmt -119.36 152.09 52.16 Favored Pre-proline 0 N--CA 1.448 -0.555 0 N-CA-C 117.446 2.387 . . . . 0.0 117.446 170.22 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -70.85 164.76 34.47 Favored 'Trans proline' 0 N--CA 1.453 -0.887 0 CA-C-N 121.261 1.486 . . . . 0.0 112.28 146.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -123.14 154.22 64.9 Favored Pre-proline 0 N--CA 1.446 -0.653 0 C-N-CA 128.059 2.543 . . . . 0.0 113.258 -166.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_exo -63.92 153.82 73.53 Favored 'Trans proline' 0 N--CA 1.444 -1.413 0 C-N-CA 124.162 3.241 . . . . 0.0 116.076 166.364 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.463 ' HB3' ' HB2' ' A' ' 17' ' ' HIS . 26.4 t -122.86 150.75 42.46 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.17 1.788 . . . . 0.0 106.259 178.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . 0.314 . . -51.19 -37.99 49.77 Favored 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 126.118 1.767 . . . . 0.0 114.632 163.067 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -58.61 -29.11 66.22 Favored 'General case' 0 N--CA 1.443 -0.809 0 C-N-CA 125.003 1.321 . . . . 0.0 110.192 170.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . 0.463 ' HB2' ' HB3' ' A' ' 14' ' ' SER . 86.6 m-70 -134.66 24.98 3.71 Favored 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 131.292 3.837 . . . . 0.0 112.556 -155.181 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 42.6 t -148.16 120.24 8.27 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 117.343 2.349 . . . . 0.0 117.343 166.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -146.48 142.49 28.15 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-O 113.482 -3.152 . . . . 0.0 113.832 -160.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -124.48 140.82 52.59 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 119.373 3.101 . . . . 0.0 119.373 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -136.44 147.57 47.3 Favored 'General case' 0 C--O 1.223 -0.317 0 CA-C-N 120.962 1.71 . . . . 0.0 112.19 -177.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 145.43 175.8 18.84 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 125.436 1.494 . . . . 0.0 114.575 167.403 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -55.93 -34.75 65.91 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-O 114.495 -2.669 . . . . 0.0 112.503 177.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -57.93 -3.0 1.02 Allowed Glycine 0 C--O 1.226 -0.355 0 CA-C-N 123.462 2.847 . . . . 0.0 116.138 165.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . 0.373 24.1 mt -109.29 29.26 7.7 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 120.544 2.172 . . . . 0.0 111.32 161.403 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 96.8 t -150.16 -42.0 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 CA-C-N 121.683 2.038 . . . . 0.0 114.584 -175.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . 0.333 43.0 pttt -151.39 131.12 13.17 Favored 'General case' 0 C--N 1.326 -0.429 1 O-C-N 116.164 -4.085 . . . . 0.0 112.36 -179.425 . . . . . . . . 3 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 38.4 t -143.66 141.15 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 -166.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -136.08 172.31 13.19 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-N 120.181 1.355 . . . . 0.0 114.277 -169.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 46.8 t0 -78.55 -50.81 10.91 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-O 122.631 1.205 . . . . 0.0 112.519 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 70.4 m-80 -104.03 8.7 36.65 Favored 'General case' 0 N--CA 1.448 -0.545 0 O-C-N 118.427 -2.67 . . . . 0.0 111.636 -179.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -133.85 101.81 12.63 Favored Pre-proline 0 N--CA 1.447 -0.625 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 170.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -57.92 131.47 43.94 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 CA-C-O 125.552 2.23 . . . . 0.0 111.888 159.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -85.93 162.48 18.54 Favored 'General case' 0 N--CA 1.45 -0.459 0 O-C-N 117.008 -3.558 . . . . 0.0 113.539 165.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -133.22 154.6 50.51 Favored 'General case' 0 N--CA 1.448 -0.553 0 O-C-N 125.057 1.473 . . . . 0.0 110.508 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -157.48 171.45 20.34 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 117.662 -3.149 . . . . 0.0 105.403 167.176 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 91.1 m -133.35 130.47 38.86 Favored 'General case' 0 C--O 1.233 0.197 0 O-C-N 127.167 2.792 . . . . 0.0 113.737 -164.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 24.2 mt -84.77 104.06 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 C-N-CA 123.929 0.892 . . . . 0.0 110.946 171.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 32.5 p90 -77.15 108.1 9.99 Favored 'General case' 0 N--CA 1.44 -0.973 0 N-CA-C 119.222 3.045 . . . . 0.0 119.222 163.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -117.78 150.22 39.49 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 121.288 1.858 . . . . 0.0 109.491 -163.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.2 t -137.79 159.19 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 105.718 -1.956 . . . . 0.0 105.718 174.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.0 p30 -78.36 -61.91 1.85 Allowed 'General case' 0 N--CA 1.452 -0.331 0 O-C-N 119.766 -1.834 . . . . 0.0 115.214 170.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 21.9 p -174.91 -35.63 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 131.64 3.976 . . . . 0.0 114.42 -161.034 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -107.69 40.92 1.61 Allowed 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 122.73 2.514 . . . . 0.0 112.665 -171.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 53.02 -25.39 0.01 OUTLIER Glycine 0 C--N 1.338 0.666 0 C-N-CA 130.129 3.728 . . . . 0.0 121.568 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.1 t -64.3 125.55 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 O-C-N 116.951 -3.676 . . . . 0.0 107.882 167.149 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -31.33 127.2 0.19 Allowed 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 117.36 2.356 . . . . 0.0 117.36 162.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 11.5 mmm180 -35.12 122.03 0.57 Allowed 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 118.672 2.841 . . . . 0.0 118.672 -177.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 8.5 p -78.79 -2.6 40.34 Favored 'General case' 0 N--CA 1.445 -0.696 0 C-N-CA 126.774 2.03 . . . . 0.0 111.576 -162.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.9 p30 -162.45 169.2 20.8 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 127.925 2.49 . . . . 0.0 109.199 178.055 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -123.91 -157.07 9.68 Favored Glycine 0 CA--C 1.522 0.502 0 C-N-CA 119.918 -1.134 . . . . 0.0 110.897 -160.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 61.01 41.05 99.31 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 178.286 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 58.4 m-20 -78.38 156.08 78.79 Favored Pre-proline 0 N--CA 1.448 -0.552 0 C-N-CA 126.982 2.113 . . . . 0.0 108.438 173.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -91.67 62.78 1.04 Allowed 'Trans proline' 0 N--CA 1.444 -1.395 0 C-N-CA 124.811 3.674 . . . . 0.0 117.284 -169.229 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -69.88 149.55 47.73 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 120.971 3.693 . . . . 0.0 120.971 173.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -150.49 128.36 11.74 Favored 'General case' 0 N--CA 1.443 -0.786 0 C-N-CA 127.22 2.208 . . . . 0.0 112.906 168.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.583 HG22 HG22 ' A' ' 95' ' ' VAL . 39.5 t -114.46 87.53 1.03 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.326 0 C-N-CA 129.99 3.316 . . . . 0.0 104.408 -174.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -104.66 142.29 34.94 Favored 'General case' 0 N--CA 1.444 -0.753 0 C-N-CA 127.14 2.176 . . . . 0.0 106.065 179.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 19.1 mt -130.86 155.38 41.87 Favored 'Isoleucine or valine' 0 C--O 1.238 0.463 0 C-N-CA 128.334 2.654 . . . . 0.0 113.492 -170.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 71.6 m-80 -125.01 126.25 45.14 Favored 'General case' 0 N--CA 1.446 -0.642 0 C-N-CA 131.426 3.89 . . . . 0.0 109.137 174.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -118.49 -177.87 16.92 Favored Glycine 0 CA--C 1.528 0.876 0 O-C-N 119.034 -2.291 . . . . 0.0 112.351 167.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo -56.26 125.49 19.24 Favored 'Trans proline' 0 N--CA 1.441 -1.594 0 CA-C-N 118.741 1.27 . . . . 0.0 111.875 -174.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 58.0 m-20 63.26 -118.61 0.53 Allowed 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 126.17 1.788 . . . . 0.0 110.905 173.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -73.92 -7.89 76.75 Favored Glycine 0 N--CA 1.441 -0.981 0 O-C-N 126.357 2.286 . . . . 0.0 114.468 -166.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 93.2 mt -76.02 77.74 2.88 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 127.472 3.511 . . . . 0.0 119.058 176.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 26.2 t -64.0 131.65 29.69 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 CA-C-N 112.589 -2.096 . . . . 0.0 109.749 143.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 96.0 t -142.02 144.37 25.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 112.474 -2.148 . . . . 0.0 111.846 -177.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.301 3.6 p-10 -127.2 134.55 50.11 Favored 'General case' 0 N--CA 1.445 -0.695 0 O-C-N 117.953 -2.967 . . . . 0.0 111.285 168.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.75 155.57 19.49 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 126.927 3.251 . . . . 0.0 111.134 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.301 9.2 tmtt? -99.99 104.17 15.76 Favored 'General case' 0 N--CA 1.448 -0.553 1 O-C-N 113.235 -5.916 . . . . 0.0 111.216 -170.45 . . . . . . . . 3 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.0 t -76.38 138.64 20.29 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 O-C-N 127.17 2.794 . . . . 0.0 117.644 169.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 10.0 m -144.15 128.86 18.24 Favored 'General case' 0 C--O 1.237 0.443 0 O-C-N 126.725 2.516 . . . . 0.0 111.091 173.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -79.16 136.07 37.0 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 125.237 2.446 . . . . 0.0 110.226 -169.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . 0.266 8.0 m-20 -96.61 0.56 50.1 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 116.534 -3.854 . . . . 0.0 118.551 -175.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 6.5 m120 68.68 27.62 5.88 Favored 'General case' 0 C--O 1.215 -0.733 0 O-C-N 128.731 3.769 . . . . 0.0 114.512 176.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 26.7 p30 -134.66 -8.24 2.46 Favored 'General case' 0 N--CA 1.445 -0.706 0 CA-C-O 117.227 -1.368 . . . . 0.0 112.153 -176.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 109.02 5.88 30.41 Favored Glycine 0 C--N 1.35 1.313 0 CA-C-O 113.492 -3.949 . . . . 0.0 108.21 -170.141 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.7 p -130.09 158.07 40.64 Favored 'General case' 0 N--CA 1.442 -0.83 1 CA-C-N 126.491 5.146 . . . . 0.0 111.391 -175.065 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -135.93 113.01 10.42 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 120.633 1.561 . . . . 0.0 110.543 -174.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -63.33 136.91 42.63 Favored Glycine 0 N--CA 1.452 -0.268 0 N-CA-C 116.539 1.376 . . . . 0.0 116.539 167.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 10.9 t -131.64 134.41 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 126.713 2.005 . . . . 0.0 112.155 -178.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -132.5 141.56 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-N 122.912 2.596 . . . . 0.0 109.82 -175.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 1.8 p90 -166.32 170.81 12.73 Favored 'General case' 0 N--CA 1.446 -0.637 0 O-C-N 125.512 1.758 . . . . 0.0 115.185 170.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 27.2 p30 -142.41 141.87 32.3 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 129.077 2.951 . . . . 0.0 109.916 -158.01 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -112.91 125.61 29.57 Favored Pre-proline 0 C--N 1.344 0.365 0 CA-C-O 117.399 -1.286 . . . . 0.0 113.201 -176.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -84.01 -1.09 9.83 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 123.387 2.724 . . . . 0.0 112.54 178.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 1.4 m -128.24 148.93 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 O-C-N 118.783 -2.448 . . . . 0.0 113.532 -164.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -63.4 111.39 2.28 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-O 124.814 2.245 . . . . 0.0 109.235 139.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 169.26 -162.52 36.18 Favored Glycine 0 C--O 1.221 -0.657 0 O-C-N 118.583 -2.573 . . . . 0.0 118.015 -173.114 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 27.3 t30 -117.68 132.58 56.47 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 127.435 2.294 . . . . 0.0 111.83 177.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -90.73 153.28 20.39 Favored 'General case' 0 C--O 1.221 -0.416 0 O-C-N 118.423 -2.673 . . . . 0.0 113.086 158.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -128.37 113.28 15.39 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 113.186 -1.825 . . . . 0.0 113.699 176.05 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.6 t -115.07 120.37 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 CA-C-N 113.887 -1.506 . . . . 0.0 114.204 -154.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.6 t30 -129.65 111.16 12.41 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 126.301 1.84 . . . . 0.0 108.379 -167.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.583 HG22 HG22 ' A' ' 57' ' ' VAL . 84.2 t -98.03 134.89 34.66 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.525 0 C-N-CA 126.72 2.008 . . . . 0.0 109.971 177.047 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 17.0 p -144.01 157.42 44.34 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 126.497 3.046 . . . . 0.0 115.911 -173.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 49.3 tp -129.03 104.97 7.88 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 101.763 -3.421 . . . . 0.0 101.763 -149.039 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 67.6 ttp85 45.74 42.79 9.01 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 104.91 -2.256 . . . . 0.0 104.91 -162.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.63 -1.06 31.55 Favored Glycine 0 CA--C 1.52 0.378 0 N-CA-C 119.932 2.733 . . . . 0.0 119.932 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -85.96 148.76 48.92 Favored Pre-proline 0 N--CA 1.445 -0.677 0 C-N-CA 129.246 3.019 . . . . 0.0 112.225 174.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_endo -76.73 170.8 19.19 Favored 'Trans proline' 0 N--CA 1.444 -1.423 0 O-C-N 124.769 1.931 . . . . 0.0 112.383 -175.248 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . 0.284 4.3 pt -136.37 -163.15 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 C-N-CA 128.399 2.679 . . . . 0.0 112.438 -179.124 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 32.1 mttt -100.88 159.81 14.89 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 125.337 3.699 . . . . 0.0 109.19 -173.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 33.4 m120 54.31 31.51 14.48 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 128.36 2.664 . . . . 0.0 113.351 173.066 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' MET . . . . . . . . . . . . 0.263 7.2 mmt -132.49 150.37 75.68 Favored Pre-proline 0 N--CA 1.454 -0.248 0 O-C-N 118.082 -2.886 . . . . 0.0 105.594 -173.205 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -66.15 174.84 25.54 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 CA-C-N 125.47 2.989 . . . . 0.0 112.735 -5.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 12.4 pt -143.32 169.81 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 O-C-N 126.083 2.114 . . . . 0.0 109.1 170.323 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -125.7 141.39 52.04 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 122.482 2.401 . . . . 0.0 114.437 -167.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 58.5 t -132.81 120.57 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 123.337 0.655 . . . . 0.0 109.421 -170.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 62.5 mttm -65.67 132.21 48.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 126.94 2.096 . . . . 0.0 108.183 173.318 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 20.1 m -126.28 138.27 53.59 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 127.422 2.289 . . . . 0.0 115.885 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 83.7 mt -130.63 152.06 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.578 0 O-C-N 118.709 -2.494 . . . . 0.0 110.437 167.003 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -84.91 45.48 1.17 Allowed 'General case' 0 N--CA 1.453 -0.32 0 O-C-N 120.41 -1.431 . . . . 0.0 113.828 -165.29 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.93 0 N-CA-C 116.431 1.332 . . . . 0.0 116.431 -174.41 . . . . . . . . 0 0 . 1 stop_ save_